<SEC-DOCUMENT>0001171843-16-011576.txt : 20160808
<SEC-HEADER>0001171843-16-011576.hdr.sgml : 20160808
<ACCEPTANCE-DATETIME>20160808154019
ACCESSION NUMBER:		0001171843-16-011576
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		51
CONFORMED PERIOD OF REPORT:	20160630
FILED AS OF DATE:		20160808
DATE AS OF CHANGE:		20160808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOCRYST PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000882796
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				621413174
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23186
		FILM NUMBER:		161813997

	BUSINESS ADDRESS:	
		STREET 1:		4505 EMPEROR BOULEVARD
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
		BUSINESS PHONE:		919-859-1302

	MAIL ADDRESS:	
		STREET 1:		4505 EMPEROR BOULEVARD
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>f10q_080816p.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML><HEAD>
     <TITLE></TITLE>
</HEAD><BODY STYLE="font: 10pt Times New Roman, Times, Serif">





<p style="margin: 0"></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<!-- Field: Rule-Page --><div align="LEFT" style="margin-top: 1pt; margin-bottom: 1pt"><div style="font-size: 1pt; border-top: black 1.5pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 18pt; text-align: center; margin: 0pt 0"><b>UNITED STATES</b></p>

<p style="font-size: 18pt; text-align: center; margin: 0pt 0"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Washington, D.C. 20549</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">_____________</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><font style="font-size: 18pt"><b>FORM 10-Q</b></font><font style="font-size: 10pt">
</font></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">_____________</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Quarterly Report Pursuant to Section&nbsp;13 or 15(d)</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>of the Securities Exchange Act of 1934</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>For the quarterly period ended June&nbsp;30, 2016</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Commission File Number 000-23186</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">_____________</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 24pt; text-align: center; margin: 0pt 0"><b>BIOCRYST PHARMACEUTICALS, INC.</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(Exact name of registrant as specified in its charter)</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">_____________</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 55%; text-align: center"><font style="font-size: 10pt"><b>DELAWARE</b></font></td>
    <td style="width: 45%; text-align: center"><font style="font-size: 10pt"><b>62-1413174</b></font></td></tr>
<tr>
    <td style="text-align: center"><font style="font-size: 10pt"><b>(State of other jurisdiction of</b></font></td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>(I.R.S. Employer</b></font></td></tr>
<tr>
    <td style="text-align: center"><font style="font-size: 10pt"><b>incorporation or organization)</b></font></td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Identification No.)</b></font></td></tr>
<tr>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr>
    <td style="text-align: center"><font style="font-size: 10pt"><b>4505 Emperor Blvd., Suite&nbsp;200</b></font></td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Durham, North Carolina</b></font></td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>27703</b></font></td></tr>
<tr>
    <td style="text-align: center"><font style="font-size: 10pt"><b>(Address of principal executive offices)</b></font></td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>(Zip Code)</b></font></td></tr>
</table>
<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(919) 859-1302</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(Registrant&#8217;s telephone number, including area code)</b>
&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">_____________</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required
to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&nbsp;months (or for such
shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements
for the past 90&nbsp;days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp; &#9746;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp; &#9744;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">Indicate by check mark whether the registrant has submitted electronically and posted
on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&nbsp;405 of
Regulation&nbsp;S-T during the preceding 12&nbsp;months (or for such shorter period that the registrant was required to submit
and post such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp; &#9746;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp; &#9744;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated
filer, or a non- accelerated filer or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221;
&#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule&nbsp;12b-2 of the Exchange Act.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: bottom">
    <td style="width: 22%"><font style="font-size: 10pt">Large&nbsp;accelerated&nbsp;filer</font></td>
    <td style="width: 43%">&#9746;</td>
    <td style="width: 28%"><font style="font-size: 10pt">Accelerated&nbsp;filer</font></td>
    <td style="width: 7%">&#9744;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 10pt">Non-accelerated filer</font></td>
    <td>&#9744;<font style="font-size: 10pt">&nbsp;&nbsp;(Do not check if a smaller reporting company)</font></td>
    <td><font style="font-size: 10pt">Smaller&nbsp;reporting&nbsp;company</font></td>
    <td>&#9744;</td></tr>
</table>
<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">Indicate by check mark whether the registrant is a shell company (as defined in Rule&nbsp;12b-2
of the Exchange Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp; &#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp; &#9746;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">The number of shares of Common Stock, par value $0.01, of the Registrant outstanding
as of July&nbsp;31, 2016 was 73,700,542.&nbsp;&nbsp;&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><br clear="ALL">
</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><p style="margin: 0pt">&nbsp;</p></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>BIOCRYST PHARMACEUTICALS, INC.</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>INDEX</b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 90%">&nbsp;</td>
    <td style="width: 10%; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Page&nbsp;No.</b></font></td></tr>
<tr>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Part I. Financial Information</font></td></tr>
<tr>
    <td style="text-decoration: underline"><a href="#a_001"><font style="font-size: 10pt"><u>Item&nbsp;1. Financial Statements:</u></font></a></td>
    <td style="text-decoration: underline; text-align: center"><a href="#a_001"><font style="font-size: 10pt"><u>3</u></font></a></td></tr><tr>
    <td style="text-decoration: underline; text-indent: 20pt"><a href="#a_002"><font style="font-size: 10pt"><u>Consolidated Balance Sheets &#8212; June&nbsp;30, 2016 and December&nbsp;31, 2015</u></font></a></td>
    <td style="text-decoration: underline; text-align: center"><a href="#a_002"><font style="font-size: 10pt"><u>3</u></font></a></td></tr>
<tr>
    <td style="text-decoration: underline; text-indent: 20pt"><a href="#a_003"><font style="font-size: 10pt"><u>Consolidated Statements of Comprehensive Loss &#8212; Three and Six Months Ended June&nbsp;30, 2016 and 2015</u></font></a></td>
    <td style="text-decoration: underline; text-align: center"><a href="#a_003"><font style="font-size: 10pt"><u>4</u></font></a></td></tr>
<tr>
    <td style="text-decoration: underline; text-indent: 20pt"><a href="#a_004"><font style="font-size: 10pt"><u>Consolidated Statements of Cash Flows &#8212; Six Months Ended June&nbsp;30, 2016 and 2015</u></font></a></td>
    <td style="text-decoration: underline; text-align: center"><a href="#a_004"><font style="font-size: 10pt"><u>5</u></font></a></td></tr>
<tr>
    <td style="text-decoration: underline; text-indent: 20pt"><a href="#a_005"><font style="font-size: 10pt"><u>Notes to Consolidated Financial Statements</u></font></a></td>
    <td style="text-decoration: underline; text-align: center"><a href="#a_005"><font style="font-size: 10pt"><u>6</u></font></a></td></tr>
<tr>
    <td style="text-decoration: underline"><a href="#a_006"><font style="font-size: 10pt"><u>Item&nbsp;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</u></font></a></td>
    <td style="text-decoration: underline; text-align: center"><a href="#a_006"><font style="font-size: 10pt"><u>20</u></font></a></td></tr>
<tr>
    <td style="text-decoration: underline"><a href="#a_007"><font style="font-size: 10pt"><u>Item&nbsp;3. Quantitative and Qualitative Disclosures About Market Risk</u></font></a></td>
    <td style="text-decoration: underline; text-align: center"><a href="#a_007"><font style="font-size: 10pt"><u>32</u></font></a></td></tr>
<tr>
    <td style="text-decoration: underline"><a href="#a_008"><font style="font-size: 10pt"><u>Item&nbsp;4. Controls and Procedures</u></font></a></td>
    <td style="text-decoration: underline; text-align: center"><a href="#a_008"><font style="font-size: 10pt"><u>33</u></font></a></td></tr>
<tr>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Part II. Other Information</font></td></tr>
<tr>
    <td style="text-decoration: underline"><a href="#a_009"><font style="font-size: 10pt"><u>Item&nbsp;1A. Risk Factors</u></font></a></td>
    <td style="text-decoration: underline; text-align: center"><a href="#a_009"><font style="font-size: 10pt"><u>34</u></font></a></td></tr>
<tr>
    <td style="text-decoration: underline"><a href="#a_010"><font style="font-size: 10pt"><u>Item&nbsp;6. Exhibits</u></font></a></td>
    <td style="text-decoration: underline; text-align: center"><a href="#a_010"><font style="font-size: 10pt"><u>49</u></font></a></td></tr>
<tr>
    <td style="text-decoration: underline; text-indent: 20pt"><a href="#a_011"><font style="font-size: 10pt"><u>Signatures</u></font></a></td>
    <td style="text-decoration: underline; text-align: center"><a href="#a_011"><font style="font-size: 10pt"><u>50</u></font></a></td></tr>
<tr>
    <td style="text-indent: 20pt"><font style="font-size: 10pt">EX-10.1</font></td>
    <td style="text-align: center">&nbsp;</td></tr>
<TR>
    <TD STYLE="text-indent: 20pt">EX-10.2</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-indent: 20pt">EX-10.3</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<tr>
    <td style="text-indent: 20pt"><font style="font-size: 10pt">EX-31.1</font></td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr>
    <td style="text-indent: 20pt"><font style="font-size: 10pt">EX-31.2</font></td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr>
    <td style="text-indent: 20pt"><font style="font-size: 10pt">EX-32.1</font></td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr>
    <td style="text-indent: 20pt"><font style="font-size: 10pt">EX-32.2</font></td>
    <td style="text-align: center">&nbsp;</td></tr>
</table>
<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><p style="margin: 0pt">&nbsp;</p></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>PART I. FINANCIAL INFORMATION</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><a name="a_001"></a><b>Item&nbsp;1. &nbsp;&nbsp;&nbsp;Financial Statements</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b> BIOCRYST PHARMACEUTICALS, INC.</b></p>

<p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><a name="a_002"></a><b>CONSOLIDATED BALANCE SHEETS</b></p>

<p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>June&nbsp;30, 2016 and December&nbsp;31, 2015</b></p>

<p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>(In thousands, except per share data)</b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table="" data-td-statement-type="balance-sheet"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016<br> (Unaudited)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015<br> (Note 1)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Assets</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 74%; font-size: 10pt; text-align: left">Cash and cash equivalents</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">8,661</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">28,899</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Restricted cash</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,426</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,612</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Investments</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">27,079</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">22,664</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Receivables from collaborations</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,234</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,243</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Inventory</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,949</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,612</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Prepaid expenses and other current assets</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,674</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,674</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Deferred collaboration expense</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">89</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">90</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Total current assets</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">46,112</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">63,794</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Investments</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">24,154</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">47,683</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Property and equipment, net</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">10,112</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,149</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Deferred collaboration expense</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">229</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">265</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Other assets</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,610</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5,468</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; text-indent: 20pt">Total assets</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">82,217</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">122,359</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Liabilities and Stockholders&#8217; Equity</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Accounts payable</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">5,051</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">9,307</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Accrued expenses</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">11,783</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">16,237</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Interest payable</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">9,203</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,746</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Deferred collaboration revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,134</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,163</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Non-recourse notes payable</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">28,023</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">27,804</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; text-indent: 20pt">Total current liabilities</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">56,194</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">62,257</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Deferred collaboration revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">8,776</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">9,674</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Deferred rent</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">297</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">329</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Foreign currency derivative</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">974</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Lease financing obligation</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,589</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,375</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Stockholders&#8217; equity:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 30pt; text-indent: -10pt">Preferred stock, $0.001 par value; shares authorized &#8212; 5,000; no shares issued and outstanding</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 30pt; text-indent: -10pt">Common stock, $0.01 par value: shares authorized &#8212; 200,000; shares issued and outstanding &#8212; 73,701 in 2016 and 73,355 in 2015</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">737</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">734</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Additional paid-in capital</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">562,634</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">558,113</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Accumulated other comprehensive income (loss)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">46</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(206</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Accumulated deficit</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(550,030</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(510,917</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; text-indent: 20pt">Total stockholders&#8217; equity</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">13,387</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">47,724</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; text-indent: 20pt">Total liabilities and stockholders&#8217; equity</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">82,217</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">122,359</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">See accompanying notes to consolidated financial statements.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>BIOCRYST PHARMACEUTICALS, INC.</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b><a name="a_003"></a>CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Three and Six Months Ended June&nbsp;30, 2016 and 2015</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(In thousands, except per share data-Unaudited)</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>&nbsp;</b></p>

<div data-td-taggable-table="" data-td-statement-type="comprehensive-income"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center">Three Months</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center">Six Months</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Revenues</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 48%; font-size: 10pt; text-align: left">Product sales, net</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">537</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Royalty revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">629</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">132</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,519</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,650</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Collaborative and other research and development</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,158</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">25,710</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7,088</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">30,481</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 30pt; text-indent: -10pt">Total revenues</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,787</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">25,842</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">9,607</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">32,668</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Expenses</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Cost of products sold</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">15</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Research and development</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">14,166</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">16,524</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">34,745</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">33,644</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">General and administrative</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,724</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,534</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,936</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">7,595</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1pt">Royalty</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">27</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">442</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">104</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">502</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 30pt; text-indent: -10pt">Total operating expenses</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">16,917</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">20,500</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">40,785</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">41,756</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">(Loss) income from operations</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(12,130</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,342</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(31,178</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(9,088</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Interest and other income</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">147</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">116</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">586</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">233</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Interest expense</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1,421</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1,306</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(2,891</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(2,621</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">(Loss) gain on foreign currency derivative</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,877</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">749</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(5,630</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,213</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Net (loss) income</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(16,281</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">4,901</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(39,113</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(10,263</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Basic net (loss) income per common share</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">(0.22</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">0.07</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">(0.53</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">(0.14</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Diluted net (loss) income per common share</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">(0.22</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">0.06</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">(0.53</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">(0.14</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Weighted average shares outstanding, basic</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">73,695</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">72,642</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">73,648</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">72,492</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Weighted average shares outstanding, diluted</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">73,695</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">76,760</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">73,648</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">72,492</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Unrealized (loss) gain on available for sale investments</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(2</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(102</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">252</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">38</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Comprehensive (loss) income</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(16,283</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">4,799</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(38,861</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(10,225</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td></tr>
</table></div>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">See accompanying notes to consolidated financial statements.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 4; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>BIOCRYST PHARMACEUTICALS, INC.</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><a name="a_004"></a><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Six Months Ended June&nbsp;30, 2016 and 2015</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(In thousands-Unaudited)</b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table="" data-td-statement-type="cash-flows"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Operating activities</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="width: 74%; font-size: 10pt; text-align: left">Net loss</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">(39,113</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">(10,263</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Depreciation and amortization</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">136</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">94</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Stock-based compensation expense</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,491</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,934</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Amortization of debt issuance costs<BR>
</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">220</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">220</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 20pt">Amortization of premium/discount on investments</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><P STYLE="margin: 0pt 0">302</P>


</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><P STYLE="margin: 0pt 0">266</P>


</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Change in fair value of foreign currency derivative</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,441</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">332</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Changes in operating assets and liabilities:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Receivables</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,009</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,194</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Inventory</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(337</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(625</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Prepaid expenses and other assets</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,000</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">503</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Deferred collaboration expense</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">37</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(136</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Accounts payable and accrued expenses</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(8,742</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">8,612</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Interest payable</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,457</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1,579</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Deferred revenue</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(927</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5,820</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 20pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: 10pt">Net cash (used in) provided by operating activities</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(30,026</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">14,372</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Investing activities</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Acquisitions of property and equipment</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(5,099</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(934</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Change in restricted cash</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(2,814</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1,419</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Purchases of investments</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(19,407</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Sales and maturities of investments</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">19,064</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">24,884</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: 10pt">Net cash provided by investing activities</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">11,151</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">3,124</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Financing activities</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Sale of common stock, net</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,175</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Net proceeds from common stock issued under stock-based compensation plans</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">33</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,570</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Payment of foreign currency derivative collateral</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1,610</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Increase in lease financing obligation</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">214</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#8212;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: 10pt">Net cash (used in) provided by financing activities</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(1,363</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">4,745</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">(Decrease) increase in cash and cash equivalents</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(20,238</td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">22,241</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Cash and cash equivalents at beginning of period</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">28,899</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">54,540</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.25pt">Cash and cash equivalents at end of period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">8,661</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">76,781</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">See accompanying notes to consolidated financial statements.</p>

<p style="font-size: 10pt; text-align: right; text-indent: 0.5in; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 5; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: right; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>BIOCRYST PHARMACEUTICALS, INC.</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0; text-indent: 0.5in"><b><a name="a_005"></a>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(In thousands, except per share amounts)</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>Note 1 &#8212; Significant Accounting Policies</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>The Company</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">BioCryst Pharmaceuticals, Inc. (the &#8220;Company&#8221;) is a biotechnology
company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of
diseases. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and align with its
capabilities and expertise. The Company was incorporated in Delaware in 1986 and its headquarters is located in Durham, North Carolina.
The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop
small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred losses and negative
cash flows from operations since inception.&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Based on its current operating plans, the Company expects it has sufficient
liquidity, with its existing cash, restricted cash and investments of $64,320, to continue its planned operations through mid-2017.
The Company&#8217;s liquidity needs, and ability to address those needs, will largely be determined by the success of its product
candidates and key development and regulatory events in the future. In order to continue its operations substantially beyond mid-2017
it will need to: (1)&nbsp;successfully secure or increase U.S. Government funding of its programs, including procurement contracts;
(2)&nbsp;out-license rights to certain of its products or product candidates, pursuant to which the Company would receive cash
milestones; (3)&nbsp;raise additional capital through equity or debt financings or from other sources; (4)&nbsp;obtain additional
product candidate regulatory approvals, which would generate revenue and cash flow; (5)&nbsp;reduce spending on one or more research
and development programs; and/or (6)&nbsp;restructure operations. The Company may issue securities, including common stock, preferred
stock, depositary shares, stock purchase contracts, warrants and units, through private placement transactions or registered public
offerings pursuant to its registration statements on Form S-3 initially filed with the Securities and Exchange Commission (&#8220;SEC&#8221;)
on March 3, 2015 and November&nbsp;6, 2013. The Company will continue to incur operating losses and negative cash flows until revenues
reach a level sufficient to support ongoing operations.&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Basis of Presentation</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The consolidated financial statements include the accounts of the
Company and its wholly-owned subsidiary, JPR Royalty Sub LLC (&#8220;Royalty Sub&#8221;). Royalty Sub was formed in connection
with a $30,000&nbsp;financing transaction the Company completed on March&nbsp;9, 2011. See Note 4, Royalty Monetization, for a
further description of this transaction. All intercompany transactions and balances have been eliminated.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#8217;s consolidated financial statements have been prepared
in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim financial
reporting and the instructions to Form 10-Q and do not include all of the information and footnotes required by U.S. GAAP for complete
financial statements. Such financial statements reflect all adjustments that are, in management&#8217;s opinion, necessary to present
fairly, in all material respects, the Company&#8217;s consolidated financial position, results of operations, and cash flows. There
were no adjustments other than normal recurring adjustments.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">These financial statements should be read in conjunction with the
financial statements for the year ended December&nbsp;31, 2015 and the notes thereto included in the Company&#8217;s 2015 Annual
Report on Form 10-K. Interim operating results are not necessarily indicative of operating results for the full year. The balance
sheet as of December&nbsp;31, 2015 has been derived from the audited consolidated financial statements included in the Company&#8217;s
most recent Annual Report on Form 10-K.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Reclassifications</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">During the first quarter of 2016, the Company adopted Accounting Standards
Update No. 2015-03, <I>Interest &ndash; Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance
Costs</I>. Accordingly, debt issuance costs of $2,196 classified as other current assets as of December 31, 2015 have been reclassified
and netted against non-recourse notes payable to conform to the 2016 presentation.</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Cash and Cash Equivalents</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company generally considers cash equivalents to be all cash held
in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities
of three months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to
the short-term nature of these items.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 6; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Restricted Cash</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Restricted cash as of June&nbsp;30, 2016 reflects $3,022 in royalty
revenue paid by Shionogi&nbsp;&amp; Co., Ltd. (&#8220;Shionogi&#8221;) designated for interest on the PhaRMA Notes (defined in
Note 4) and $1,404 the Company is required to maintain as collateral for a letter of credit associated with the lease execution
and build-out of its new Birmingham research facilities.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Investments</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company invests in high credit quality investments in accordance
with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#8217;s investment
policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow
requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government
agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable
debt securities that may consist of U.S. Government and government agency securities, money market and mutual fund investments,
municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&#8217;s
investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of three years
and requires an average portfolio maturity of no more than 18 months. Some of the securities the Company invests in may have market
risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize
this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the
need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to
interest rate risk arising from its investments. Generally, the Company&#8217;s investments are not collateralized. The Company
has not realized any significant losses from its investments.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company classifies all of its investments as available-for-sale.
Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be
other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments
for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that
the carrying amount of an asset may not be recoverable. The Company believes the individual unrealized losses represent temporary
declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in
the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions
recorded on a settlement date basis. Investments with original maturities at date of purchase beyond three months and which mature
at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from
the balance sheet date are classified as long-term. At June 30, 2016, the Company believes that the costs of its investments are
recoverable in all material respects.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The following tables summarize the fair value of the Company&#8217;s
investments by type. The estimated fair value of the Company&#8217;s fixed income investments are classified as Level 2 in the
fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted
prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets
that are not active. These fair values are obtained from independent pricing services which utilize Level 2 inputs.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June&nbsp;30, 2016</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amortized<br> Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accrued<br> Interest</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br> Unrealized<br> Gains</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br> Unrealized<br> Losses</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Estimated<br> Fair&nbsp;Value</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt">Obligations of the U.S. Government and its agencies</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">14,081</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">38</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">8</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">14,127</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Corporate debt securities</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">16,641</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">147</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">23</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">16,810</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">Certificates of deposit</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">20,258</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">22</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">23</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(7</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">20,296</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">50,980</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">207</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">54</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(8</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">51,233</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31, 2015</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amortized<br> Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accrued<br> Interest</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br> Unrealized<br> Gains</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br> Unrealized<br> Losses</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Estimated<br> Fair&nbsp;Value</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt; width: 35%">Obligations of the U.S. Government and its agencies</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">26,557</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">88</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">(99</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">26,546</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Corporate debt securities</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">21,820</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">184</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(41</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">21,963</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">Certificates of deposit</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21,884</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(72</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21,838</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">70,261</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">293</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(212</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">70,347</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 7; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0">The following table summarizes the scheduled
maturity for the Company&#8217;s investments at June&nbsp;30, 2016 and December&nbsp;31, 2015.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; font-size: 10pt; text-align: left">Maturing in one year or less</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">27,079</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">22,664</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Maturing after one year through two years</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">18,164</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">28,395</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Maturing after two years</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5,990</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">19,288</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">51,233</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">70,347</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Receivables from Collaborations</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Receivables from collaborations are recorded for amounts due to the
Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables
from Shionogi and Seqirus UK Limited (&#8220;SUL&#8221;), and product sales to SUL. These receivables are evaluated to determine
if any reserve or allowance should be established at each reporting date. At June 30, 2016 and December&nbsp;31, 2015, the Company
had the following receivables.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June&nbsp;30, 2016</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Billed</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Unbilled</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 61%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">723</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">1,273</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">1,996</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Shionogi&nbsp;&amp; Co. Ltd.</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">145</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">145</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Seqirus UK Limited</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">37</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">56</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">93</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total receivables</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">905</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">1,329</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">2,234</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31, 2015</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Billed</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Unbilled</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 61%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">5,536</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">5,536</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Shionogi&nbsp;&amp; Co. Ltd.</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">469</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">469</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Seqirus UK Limited</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">210</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">28</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">238</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total receivables</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">679</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5,564</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">6,243</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Monthly invoices are submitted to the U.S. Department of Health and
Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of
indirect costs based on rates stipulated in the underlying contract. The Company&#8217;s calculations of its indirect cost rates
are subject to audit by the U.S. Government.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Receivables from Product Sales</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Receivables from product sales are recorded for amounts due to the
Company related to sales of RAPIVAB. These receivables are evaluated to determine if any reserve or allowance should be established
at each reporting date.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Inventory</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">At June 30, 2016 and December 31, 2015, the Company&#8217;s inventory
consisted of RAPIVAB work in process. Inventory is stated at the lower of cost, determined under the first-in, first-out (&#8220;FIFO&#8221;)
method, or market. The Company expenses costs related to the production of inventories as research and development expenses in
the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is
reliant upon receipt of regulatory approval. Upon regulatory approval, the Company will capitalize subsequent costs related to
the production of inventories.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">During 2014, in connection with the U.S. Food and Drug Administration
(&#8220;FDA&#8221;) approval of RAPIVAB, the Company began capitalizing costs associated with the production of RAPIVAB inventories.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 8; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#8217;s inventory consisted of the following at June&nbsp;30,
2016 and December&nbsp;31, 2015:</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; font-size: 10pt; text-align: left; padding-bottom: 1pt">Work in process</td><td style="width: 1%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,949</td><td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,612</td><td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.25pt">Inventories</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">1,949</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">1,612</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Property and Equipment</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Property and equipment are recorded at cost. Depreciation is computed
using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of
three years. Laboratory equipment, office equipment, and software are depreciated over a life of five years. Furniture and fixtures
are depreciated over a life of seven years. Leasehold improvements are amortized over their estimated useful lives or the expected
lease term, whichever is less. Property consists of a leased building which did not meet the sale-leaseback criteria and is recorded
at its fair value, less depreciation. The building is being depreciated over a period equal to the expected term of the related
lease.</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In accordance with U.S. GAAP, the Company periodically reviews its
property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets
may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from
the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover
the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed
of are reported at the lower of carrying amount or fair value less cost to sell.</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Patents and Licenses</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company seeks patent protection on all internally developed processes
and products. All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability
of such expenditures is uncertain.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Accrued Expenses</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company generally enters into contractual agreements with third-party
vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these
contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records
liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of
the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel
to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost
incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service
providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of
each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the
accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses
include:</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%">&nbsp;</td>
    <td style="vertical-align: top; width: 2%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 92%"><font style="font-size: 10pt">fees paid to Clinical Research Organizations (&#8220;CROs&#8221;) in connection with preclinical and toxicology studies and clinical trials;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">fees paid to investigative sites in connection with clinical trials;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">fees paid to contract manufacturers in connection with the production of our raw materials, drug substance and drug products;&nbsp;and</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">professional fees.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company bases its expenses related to clinical trials on its estimates
of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and
manage clinical trials on the Company&#8217;s behalf. The financial terms of these agreements are subject to negotiation, vary
from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such
as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company
estimates the time period over which services will be performed and the level of effort expended in each period. If the actual
timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.
As of June 30, 2016 and December 31, 2015, the carrying value of accrued expenses approximates their fair value due to their short-term
settlement.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Income Taxes</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The liability method is used in the Company&#8217;s accounting for
income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting
and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect
when the differences are expected to reverse.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 9; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Accumulated Other Comprehensive Income (Loss)</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Accumulated other comprehensive income (loss) is comprised of unrealized
gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&rsquo; equity. Amounts
reclassified from accumulated other comprehensive income (loss) are recorded as interest and other income on the Consolidated Statements
of Comprehensive Loss. During the six months ended June 30, 2016, realized gains of $10 were reclassified out of accumulated other
comprehensive income (loss). During the six months ended June 30, 2015, realized gains of $12 were reclassified out of accumulated
other comprehensive income (loss).</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Revenue Recognition</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recognizes revenues from collaborative and other research
and development arrangements, royalties and product sales when realized or realizable and earned. Revenue is realized or realizable
and earned when all of the following criteria are met: (i)&nbsp;persuasive evidence of an arrangement exists; (ii)&nbsp;delivery
has occurred or services have been rendered; (iii)&nbsp;the seller&#8217;s price to the buyer is fixed or determinable; and (iv)&nbsp;collectability
is reasonably assured.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><i>Collaborative and Other Research and Development Arrangements and Royalties</i></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Revenue from license fees, royalty payments, event payments, and
research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing
performance obligations or the Company has completed the performance obligations under the terms of the agreement. Fees received
under licensing agreements that are related to future performance are deferred and recognized over an estimated period determined
by management based on the terms of the agreement and the products licensed. Revisions to revenue or profit estimates as a result
of changes in the estimated revenue period are recognized prospectively.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Under certain of the Company&#8217;s license agreements, the Company
receives royalty payments based upon its licensees&#8217; net sales of covered products. The Company recognizes royalty revenues
when it can reliably estimate such amounts and collectability is reasonably assured.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">For arrangements that involve the delivery of more than one element,
each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting.
This determination is based on whether the deliverable has &#8220;stand-alone value&#8221; to the customer. The consideration that
is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable.
The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective
evidence of fair value, (ii) third-party evidence of selling price (&#8220;TPE&#8221;) and (iii) best estimate of selling price
(&#8220;BESP&#8221;). The BESP reflects our best estimate of what the selling price would be if the deliverable was regularly sold
by the Company on a stand-alone basis. In most cases the Company expects to use TPE or BESP for allocating consideration to each
deliverable. The consideration allocated to each unit of accounting is recognized as the related goods or services are delivered,
limited to the consideration that is not contingent upon future deliverables. Analyzing the arrangement to identify deliverables
requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset,
or another performance obligation.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In June 2015, the Company entered into a License Agreement (the &#8220;SUL
Agreement&#8221;) granting SUL and its affiliates worldwide rights, excluding Israel, Japan, Korea and Taiwan, to develop, manufacture
and commercialize RAPIVAB. The SUL Agreement provides for various types of payments, including a non-refundable upfront fee, milestone
payments, and future royalties. Analysis of the SUL Agreement identified three deliverables: (i) license rights, (ii) inventory
and (iii) regulatory support to obtain Canadian and European Union (&#8220;EU&#8221;) marketing approvals. The Company received
an upfront payment of $33,740 from SUL, of which $7,000 was determined to be contingent upon EU marketing approval and will be
deferred until that time. Approximately $21,777 of the upfront payment was allocated to the license rights and recognized as revenue
in the second quarter. Approximately $3,740 of the upfront payment was allocated to the pending sale of inventory and was recognized
during the third quarter, when the inventory transfer was completed. Approximately $1,223 of the revenue from the SUL Agreement
will be recognized over the expected period of involvement in these regulatory support activities.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Milestone payments are recognized as licensing revenue upon the achievement
of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not reasonably assured
at the inception of the agreement; and (ii) the fees are non-refundable. Any milestone payments received prior to satisfying these
revenue recognition criteria are recorded as deferred revenue.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 10; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Under the terms of the SUL Agreement, the Company may receive up to
$12,000 in additional payments related to the successful achievement of regulatory milestones, including marketing approval (i)
by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Products and Food
Branch of Health Canada (&#8220;Health Canada&#8221;) for an adult indication in Canada. The Company evaluated each event based
payment under the provisions of ASU 2010-17, <i>Milestone Method of Revenue Recognition</i>, and determined that each event based
payment met the criteria to be considered substantive and represents a milestone under the milestone method of accounting. No event
based payments were achieved during the periods presented.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Reimbursements received for direct out-of-pocket expenses related
to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a
reduction in expenses. Under the Company&#8217;s contracts with the Biomedical Advanced Research and Development Authority within
the United States Department of Health and Human Services (&#8221;BARDA/HHS&#8221;) and the National Institute of Allergy and Infectious
Diseases (&#8220;NIAID/HHS&#8221;), revenue is recognized as reimbursable direct and indirect costs are incurred.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><i>Product Sales</i></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recognizes revenue for sales of RAPIVAB when title and
substantially all the risks and rewards of ownership have transferred to the customer, which generally occurs on the date of shipment
from our specialty distributors, utilizing the Sell-Through revenue recognition methodology. Product sales are recognized when
there is persuasive evidence that an arrangement exists, title has passed, the price is fixed and determinable, and collectability
is reasonably assured. Product sales are recognized net of estimated allowances, discounts, sales returns, chargebacks and rebates.
In the United States, and prior to the SUL Agreement, the Company sold RAPIVAB to specialty distributors, who in turn, sell to
physician offices, hospitals and federal, state and commercial health care organizations.&nbsp;With the completion of the SUL worldwide
license of RAPIVAB, SUL will be responsible for sales of RAPIVAB, other than U.S. Government stockpiling sales. With the completion
of the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&#8217;s partners,
except for U.S. Government stockpiling sales, and the Company will be reliant on these partners to generate sales.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Sales deductions consist of statutory rebates to state Medicaid, Medicare
and other government agencies and sales discounts (including trade discounts and distribution service fees). These deductions are
recorded as reductions from revenue from RAPIVAB in the same period as the related sales with estimates of future utilization derived
from historical experience adjusted to reflect known changes in the factors that impact such reserves.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company utilizes data from external sources to help it estimate
gross-to-net sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. Externally sourced data includes,
but is not limited to, information obtained from specialty distributors with respect to their inventory levels and their sell-through
to customers, as well as information from third-party suppliers of market research data to the pharmaceutical industry.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company accounts for these sales deductions in accordance with
authoritative guidance on revenue recognition when consideration is given by a vendor to a customer.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company has categorized and described more fully the following
significant sales deductions, all of which involve estimates and judgments, which the Company considers to be critical accounting
estimates, and require it to use information from external sources.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 13.5pt"><i>Rebates and Chargebacks</i></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 13.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Statutory rebates to state Medicaid agencies and Medicare are based
on statutory discounts to RAPIVAB&#8217;s selling price.&nbsp;As it can take up to nine months or more for information to be received
on actual usage of RAPIVAB in Medicaid and other governmental programs, the Company maintains reserves for amounts payable under
these programs relating to RAPIVAB sales.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Chargebacks claimed by specialty distributors are based on the
differentials between product acquisition prices paid by the specialty distributors and lower government contract pricing paid
by eligible customers covered under federally qualified programs.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">The amount of the reserve for rebates and chargebacks is based
on multiple qualitative and quantitative factors, including the historical and projected utilization levels, historical payment
experience, changes in statutory laws and interpretations as well as contractual terms, product pricing (both normal selling prices
and statutory or negotiated prices), changes in prescription demand patterns and utilization of the Company&#8217;s product through
public benefit plans, and the levels of RAPIVAB inventory in the distribution channel. The Company acquires prescription utilization
data from third-party suppliers of market research data to the pharmaceutical industry. The Company updates its estimates and assumptions
each period and records any necessary adjustments to its reserves. Settlements of rebates and chargebacks typically occur within
nine months from point of sale. To the extent actual rebates and chargebacks differ from the Company&#8217;s estimates, additional
reserves may be required or reserves may need to be reversed, either of which would impact current period product revenue.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i></i></p>

<!-- Field: Page; Sequence: 11; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Discounts and Sales Incentives</i></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Discounts and other sales incentives primarily consist of Inventory
Management Agreement (&#8220;IMA&#8221;) Fees. Per contractual agreements with the Company&#8217;s specialty distributors, the
Company provides an IMA fee based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth in individual
contracts. The Company tracks sales to these distributors each period and accrues a liability relating to the unpaid portion of
these fees by applying the contractual rates to such product sales.&nbsp;With the completion of the SUL collaboration, all peramivir
sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&#8217;s partners, except for U.S. Government stockpiling
sales, and the Company will be reliant on these partners to generate sales and to provide for discounts and sales incentives.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Product Returns</i></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company does not record a product return allowance as it does
not offer the ability to return goods once a bonafide shipment has been accepted by a specialty distributor.&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recorded the following revenues for the three and six
months ended June&nbsp;30, 2016 and 2015:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%; font-size: 10pt; text-align: left">Product sales, net</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">537</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Royalty revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">629</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">132</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,519</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,650</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Collaborative and other research and development revenues:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 20pt">U.S. Department of Health and Human Services</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,709</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,731</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,033</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">8,206</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Shionogi (Japan)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">296</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">296</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">592</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">592</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Seqirus UK Limited</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">153</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21,683</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">463</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21,683</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total collaborative and other research and development revenues</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,158</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">25,710</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7,088</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">30,481</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total revenues</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">4,787</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">25,842</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">9,607</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">32,668</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Advertising</i></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company engages in very limited distribution and direct-response
advertising when promoting RAPIVAB. Advertising and promotional costs are expensed as the costs are incurred.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Research and Development Expenses</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#8217;s research and development costs are charged to
expense when incurred. Research and development expenses include all direct and indirect development costs related to the development
of the Company&#8217;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for
future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related
goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel
costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials
and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&#8217;s
manufacturing and clinical and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued
by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&#8217;s
on-going review of the level of services actually performed.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Additionally, the Company has license agreements with third parties,
such as Albert Einstein College of Medicine of Yeshiva University (&#8220;AECOM&#8221;), Industrial Research, Ltd. (&#8220;IRL&#8221;),
and the University of Alabama at Birmingham (&#8220;UAB&#8221;), which require fees related to sublicense agreements or maintenance
fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which
case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments
as incurred.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Deferred collaboration expenses represent sub-license payments, paid
to the Company&#8217;s academic partners upon receipt of consideration from various commercial partners, and other consideration
paid to our academic partners for modification to existing license agreements. These deferred expenses would not have been incurred
without receipt of such payments or modifications from the Company&#8217;s commercial partners and are being expensed in proportion
to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with
the associated revenue.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 12; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Stock-Based Compensation</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">All share-based payments, including grants of stock option awards
and restricted stock unit awards, are recognized in the Company&#8217;s Consolidated Statements of Comprehensive Loss based on
their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value
of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is
recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding
performance-based stock options for which no compensation expense is recognized until &#8220;performance&#8221; is deemed to have
occurred.</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Interest Expense and Deferred Financing Costs</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Interest expense for the three months ended June&nbsp;30, 2016 and
2015 was $1,338 and $1,306, respectively, and for the six months ended June 30, 2016 and 2015 was $2,677 and $2,621, respectively,
and relates to the issuance of the PhaRMA Notes (defined in Note 4). Costs directly associated with the issuance of the PhaRMA
Notes have been capitalized and are netted against the non-recourse notes payable on the Consolidated Balance Sheets. These costs
are being amortized to interest expense over the term of the PhaRMA Notes using the effective interest rate method. Amortization
of deferred financing costs included in interest expense was $110 for each of the three months ended June&nbsp;30, 2016 and 2015,
and $220 for each of the six months ended June 30, 2016 and 2015.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Lease Financing Obligation</i></b></p>

<p style="font-size: 10pt; text-indent: 0.25in; margin: 0pt 0 0pt 12pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Based on the terms of the lease agreement for the new research facility
in Birmingham, Alabama, the Company had construction period risks during the construction period and the Company was deemed the
owner of the building (for accounting purposes only) during the construction period. Accordingly, the Company recorded an asset
of $1,589, representing the Company&rsquo;s leased portion of the building and recorded a corresponding liability. Upon completion
of leasehold improvement construction, the Company did not meet the sale-leaseback criteria for de-recognition of the building
asset and liability. Therefore, the lease is accounted for as a financing obligation. The asset will be depreciated over the expected
duration of the lease of 20.5 years, and rental payments will be treated as principal and interest payments on the lease financing
obligation liability. The underlying accounting for this transaction has no impact on cash flows associated with the underlying
lease or construction in process. Interest expense for the three and six months ended June 30, 2016 includes $83 and $214, respectively,
related to the lease financing obligation.</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">At June 30, 2016, the lease financing obligation balance was $2,589
and was recorded as a long term liability on the consolidated balance sheets. The remaining future minimum payments under the lease
financing obligation are $4,839.</p>

<p style="font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0 0pt 12pt">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Currency Hedge Agreement</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In connection with the issuance by Royalty Sub of the PhaRMA Notes,
the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese
yen relative to the U.S. dollar. The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore, mark-to-market
adjustments are recognized in the Company&rsquo;s Consolidated Statements of Comprehensive Loss. Cumulative mark-to-market adjustments
for the six months ended June&nbsp;30, 2016 and 2015 resulted in losses of $6,441 and $332, respectively. Mark-to-market adjustments
are determined by a third party pricing model that uses quoted prices in markets that are not actively traded and for which significant
inputs are observable directly or indirectly, representing Level 2 in the fair value hierarchy as defined by U.S. GAAP. The Company
is also required to post collateral in connection with the mark-to-market adjustments based on thresholds defined in the Currency
Hedge Agreement. In addition, the Company realized currency exchange gains of $811 and $1,545 during the first six months of 2016
and 2015, respectively, associated with the exercise of a U.S. dollar/Japanese yen currency option under the Currency Hedge Agreement.
As of June&nbsp;30, 2016, $1,610 of hedge collateral was posted under the agreement. No hedge collateral was posted as of December
31, 2015.</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Net Loss Per Share</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Net loss per share is based upon the weighted average number of common
shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented
herein, except for the three months ended June 30, 2015 for which diluted income per share is $0.06 and basic income per share
is $0.07 per share, because common equivalent shares from unexercised stock options and common shares expected to be issued under
the Company&rsquo;s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the three
months ended June&nbsp;30, 2016 does not include 885 of such potential common shares, as their impact would be anti-dilutive. The
calculation of diluted earnings per share for the six months ended June&nbsp;30, 2016 and 2015 does not include 1,091 and 4,038,
respectively, of such potential common shares, as their impact would be anti-dilutive.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Use of Estimates</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The preparation of financial statements in conformity with U.S. GAAP
requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results
could differ from those estimates.</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i></i></b></p>

<!-- Field: Page; Sequence: 13; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Significant Customers and Other Risks</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><i>Significant Customers</i></p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Prior to the SUL Agreement, the Company relied primarily on three
specialty distributors to purchase and supply the majority of RAPIVAB. These three pharmaceutical specialty distributors accounted
for greater than 90% of all RAPIVAB product sales to date and accounted for predominantly all of the Company&#8217;s outstanding
receivables from product sales. The loss of one or more of these specialty distributors as a customer could negatively impact the
commercialization of RAPIVAB. However, the Company will utilize these specialty distributors on a limited basis subsequent to the
SUL collaboration as SUL, and other peramivir collaboration partners, will be responsible for commercial sales on a worldwide basis.
In addition, in connection with the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made
by the Company&#8217;s partners and the Company will be reliant on these partners to generate sales and remit cash to satisfy receivables.</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">The Company&rsquo;s primary source of revenue that has an underlying
cash flow stream is the reimbursement of RAPIVAB and BCX4430 development expenses earned under cost-plus-fixed-fee contracts with
BARDA/HHS and NIAID/HHS. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs
for its RAPIVAB and BCX4430 programs. Accordingly, reimbursement of these expenses represents a significant portion of the Company&rsquo;s
collaborative and other research and development revenues. The completion (as with the June 30, 2014 BARDA/HHS peramivir development
contract) or termination of the NIAID/HHS and BARDA/HHS BCX4430 contracts could negatively impact the Company&rsquo;s future Consolidated
Statements of Comprehensive Loss and Cash Flows. In addition, the Company also recognizes royalty revenue from the net sales of
RAPIACTA by Shionogi; however, the underlying cash flow from these royalty payments goes directly to pay the interest, and then
the principal, on the Company&rsquo;s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal
of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. Further, the Company&rsquo;s
drug development activities are performed by a limited group of third party vendors. If any of these vendors were unable to perform
their services, this could significantly impact the Company&rsquo;s ability to complete its drug development activities.</P>



<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><i>Risks from Third Party Manufacturing and Distribution Concentration</i></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 22.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">The Company relies on single source manufacturers for active pharmaceutical
ingredient and finished drug product manufacturing of RAPIVAB, as well as for its other product candidates in development. Delays
in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling
of RAPIVAB or the Company&#8217;s product candidates in development.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><i>Credit Risk</i></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 22.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Cash equivalents and investments are financial instruments which potentially
subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess
cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits.
The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities
that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio
of investments with an average maturity of approximately 18 months or less. Other than product sale and collaborative partner receivables
discussed above, the majority of the Company&#8217;s receivables from collaborations are due from the U.S. Government, for which
there is no assumed credit risk.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Recent Accounting Pronouncements</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In March 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;)
issued Accounting Standards Update No. 2016-09: <i>Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based
Payment Accounting</i> (&#8220;ASU 2016-09&#8221;). The amendments in this update simplify several aspects of the accounting for
employee share-based payment transactions, including the accounting for income taxes, forfeitures and statutory tax withholding
requirements, as well as classification in the statement of cash flows. ASU 2016-09 will be effective for the Company in fiscal
year 2017, but early adoption is permitted. The Company is currently evaluating the impact of this update on its consolidated financial
statements.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In February 2016, the FASB issued Accounting Standards Update No.
2016-02: <i>Leases (Topic 842)</i> (&#8220;ASU 2016-02&#8221;). The amendments in this update require lessees, among other things,
to recognize lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous
authoritative guidance. This update also introduces new disclosure requirements for leasing arrangements. ASU 2016-02 will be effective
for the Company in fiscal year 2019, but early adoption is permitted. The Company is currently evaluating the impact of this update
on its consolidated financial statements.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In January 2016, the FASB issued Accounting Standards Update No. 2016-01:
<i>Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</i>
(&#8220;ASU 2016-01&#8221;). The amendments in this update address certain aspects of recognition, measurement, presentation and
disclosure of financial instruments. In particular, the amendments in this update supersede, for public business entities, the
requirement to disclose the methods and significant assumptions used in calculating the fair value of financial instruments required
to be disclosed for financial instruments measured at amortized cost on the balance sheet. ASU 2016-01 will be effective for the
Company in fiscal year 2018, but early adoption is permitted. The Company does not expect this standard to have a material impact
on its consolidated financial statements.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 14; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 22.3pt; margin: 0pt 0">In November 2015, the FASB issued Accounting Standards Update No.
2015-17, <I>Balance Sheet Classification of Deferred Taxes</I>, requiring all deferred tax assets and liabilities, and any related
valuation allowance, to be classified as noncurrent on the balance sheet. The classification change for all deferred taxes as noncurrent
simplifies entities&rsquo; processes as it eliminates the need to separately identify the net current and net noncurrent deferred
tax asset or liability in each jurisdiction and allocate valuation allowances. We elected to prospectively adopt the accounting
standard in the beginning of our fourth quarter of fiscal 2015. Adoption of this standard had no impact on the Company&rsquo;s
consolidated financial statements.</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In July 2015, the FASB issued Accounting Standards Update No. 2015-11:
<i>Inventory (Topic 330): Simplifying the Measurement of Inventory</i> (&#8220;ASU 2015-11&#8221;), which changes the measurement
principle for inventory from the lower of cost or market to the lower of cost and net realizable value. ASU 2015-11 defines net
realizable value as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion,
disposal, and transportation. The update does not apply to inventory that is measured using last-in, first-out or the retail inventory
method. The update applies to all other inventory, which includes inventory that is measured using first-in, first-out or average
cost methods. The amendments in ASU 2015-11 will be effective for the Company for fiscal years, and the interim periods within
those years, beginning after December 15, 2016. The amendments must be applied prospectively and early adoption is permitted. The
Company does not expect this standard to have a material impact on its consolidated financial statements.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In April 2015, the FASB issued Accounting Standards Update No. 2015-03:
<i>Interest &#8211; Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs</i> (&#8220;ASU
2015-03&#8221;). This standard amends existing guidance to require the presentation of debt issuance costs in the balance sheet
as a deduction from the carrying amount of the related debt liability instead of a deferred charge. It is effective for annual
reporting periods beginning after December 15, 2015 and requires retrospective application for all periods presented. The Company
adopted ASU 2015-03 in the first quarter of 2016. Adoption did not have a material impact on its consolidated financial statements.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In August 2014, the FASB issued Accounting Standards Update No. 2014-15:
<i>Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#8217;s
Ability to Continue as a Going Concern</i> (&#8220;ASU 2014-15&#8221;) <i>,</i> which defines management&#8217;s responsibility
to evaluate, at each annual and interim reporting period, whether there are conditions or events that raise substantial doubt about
an entity&#8217;s ability to continue as a going concern within one year after the date the financial statements are issued and
to provide related footnote disclosures in certain circumstances. In connection with each annual and interim period, management
must assess if there is substantial doubt about the company&#8217;s ability to continue as a going concern within one year after
the issuance date.&nbsp;Disclosures are required if conditions give rise to substantial doubt.&nbsp;ASU 2014-15 is effective for
all companies in the first annual period ending after December 15, 2016, and interim periods thereafter, with early adoption permitted.
The Company is currently evaluating the impact this standard will have on its financial statements and disclosures.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In May 2014, the FASB issued Standards Update No. 2014-09: <i>Revenue
from Contracts with Customers (Topic 606) </i>(&#8220;ASU 2014-09&#8221;), which provides a single, comprehensive revenue recognition
model for all contracts with customers. The core principal of this ASU is that an entity should recognize revenue when it transfers
promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled
in exchange for those goods or services. ASU 2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty
of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets
recognized from costs incurred to obtain or fulfill a contract. In July 2015, the FASB finalized a one year delay in the effective
date of this standard, which will now be effective January 1, 2018; however, early adoption is permitted any time after the original
effective date, January 1, 2017. Companies can transition to the new standard under the full retrospective method or the modified
retrospective method. The Company is currently evaluating the impact this standard will have on its consolidated financial statements.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p></div><p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>Note 2 &#8212; Stock-Based Compensation</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As of June&nbsp;30, 2016, the Company had two stock-based employee
compensation plans, the Stock Incentive Plan (&ldquo;Incentive Plan&rdquo;) and the Employee Stock Purchase Plan (&ldquo;ESPP&rdquo;).
The Incentive Plan was amended and restated in April 2016 and approved by the Company&rsquo;s stockholders in May 2016. The ESPP
was amended and restated in March 2014 and approved by the Company&rsquo;s stockholders in May 2014. Stock-based compensation expense
of $4,491 ($4,402 of expense related to the Incentive Plan and $89 of expense related to the ESPP) was recognized during the first
six months of 2016, while $5,934 ($5,840 of expense related to the Incentive Plan and $94 of expense related to the ESPP) was recognized
during the first six months of 2015.</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">There was approximately $18,417 of total unrecognized compensation
cost related to non-vested stock option awards and restricted stock unit awards granted by the Company as of June&nbsp;30, 2016.
That cost is expected to be recognized as follows: $3,782 during the remainder of 2016, $6,966 in 2017, $4,703 in 2018, $2,586
in 2019 and $380 in 2020. In addition, the Company has outstanding performance-based stock options for which no compensation expense
is recognized until &#8220;performance&#8221; has occurred and the award vests. At the time of vesting, compensation expense will
be recognized.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i></i></b></p>

<!-- Field: Page; Sequence: 15; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Stock Incentive Plan</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company grants stock option awards and restricted stock unit awards
to its employees, directors, and consultants under the Incentive Plan. Under the Incentive Plan, stock option awards are granted
with an exercise price equal to the market price of the Company&#8217;s stock at the date of grant. Since March&nbsp;1, 2011, stock
option awards granted to employees generally vest 25% each year until fully vested after four years. In January 2013, the Company
made retention grants of stock option awards and restricted stock units. These awards vest 50% each year until fully vested after
two years. In August 2013 and December 2014, the Company issued 1,032 and 1,250 performance-based stock options, respectively.
These awards vest upon successful completion of specific development milestones. As of June 30, 2016, 75% of the August 2013 grants
have vested based upon achievement of three milestones: (1) successful completion of the OPuS-1 clinical trial, for which vesting
occurred in the second quarter of 2014, (2) FDA approval of RAPIVAB for which vesting occurred in the fourth quarter of 2014, and
(3) initiation of a Phase 1 clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally-administered
BCX7353 in healthy volunteers, for which vesting occurred in the second quarter of 2015. Thus, as of June 30, 2016, 25% of the
August 2013 performance-based grants and 100% of the December 2014 performance-based grants remain unvested and no compensation
expense has been recognized for these portions of the previously issued performance-based grants. Stock option awards granted to
non-employee directors of the Company generally vest monthly over one year. All stock option awards have contractual terms of 5
to 10&nbsp;years. The vesting exercise provisions of all awards granted under the Incentive Plan are subject to acceleration in
the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Incentive
Plan.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Related activity under the Incentive Plan is as follows:</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Awards<br> Available</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options<br> Outstanding</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted<br> Average<br> Exercise<br> Price</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 61%; font-size: 10pt">Balance December&nbsp;31, 2015</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 10%; font-size: 10pt; text-align: right">16</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 10%; font-size: 10pt; text-align: right">10,671</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">7.50</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Plan amendment</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,800</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Restricted stock unit awards granted</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(21</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Restricted stock unit awards cancelled</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">15</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Stock option awards granted</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(2,120</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,120</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3.21</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Stock option awards exercised</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(79</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2.32</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Stock option awards cancelled</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">499</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(499</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">11.24</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.25pt">Balance June&nbsp;30, 2016</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">2,189</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">12,213</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">$</td><td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: right">6.63</td><td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">For stock option awards granted under the Incentive Plan during the
first six months of 2016 and 2015, the fair value was estimated on the date of grant using a Black-Scholes option pricing model
and the assumptions noted in the table below. The weighted average grant date fair value per share of the awards granted during
the first six months of 2016 and 2015 was $2.18 and $8.21, respectively. The fair value of the stock option awards is amortized
to expense over the vesting periods using a straight-line expense attribution method. The following table summarizes the key assumptions
used by the Company to value the stock option awards granted during the first six months of 2016 and 2015. The expected life is
based on the average of the assumption that all outstanding stock option awards will be exercised at full vesting and the assumption
that all outstanding stock option awards will be exercised at the midpoint of the current date (if already vested) or at full vesting
(if not yet vested) and the full contractual term. The expected volatility represents the historical volatility on the Company&#8217;s
publicly traded common stock. The Company has assumed no expected dividend yield, as dividends have never been paid to stock or
option holders and will not be paid for the foreseeable future. The weighted average risk-free interest rate is the implied yield
currently available on zero-coupon government issues with a remaining term equal to the expected term.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Weighted Average Assumptions for Stock Option Awards Granted to</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Employees and Directors under the Incentive Plan</b></p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; font-size: 10pt; text-align: left">Expected Life in Years</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 10%; font-size: 10pt; text-align: right">5.6</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 10%; font-size: 10pt; text-align: right">5.5</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Expected Volatility</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">82</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">83</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Expected Dividend Yield</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.0</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">0.0</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Risk-Free Interest Rate</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1.4</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1.5</td><td style="font-size: 10pt; text-align: left">%</td></tr>
</table></div>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Employee Stock Purchase Plan</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company has reserved a total of 1,475 shares of common stock to
be purchased under the ESPP, of which 463 shares remain available for purchase at June&nbsp;30, 2016. Eligible employees may authorize
up to 15% of their salary to purchase common stock at the lower of 85% of the beginning or 85% of the ending price during six-month
purchase intervals. No more than 3 shares may be purchased by any one employee at the six-month purchase dates and no employee
may purchase stock having a fair market value at the commencement date of $25 or more in any one calendar year. The Company issued
34 shares during the first six months of 2016 under the ESPP. Compensation expense for shares purchased under the ESPP related
to the purchase discount and the &#8220;look-back&#8221; option were determined using a Black-Scholes option pricing model.</p></div><p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 16; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>Note 3 &#8212; Collaborative and Other Research and Development Contracts</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>U.S.&nbsp;Department of Health and Human Services (&#8220;BARDA/HHS&#8221;).</i>
On March 31, 2015, the Company announced that BARDA/HHS had awarded the Company a contract for the continued development of BCX4430
as a potential treatment for diseases caused by RNA pathogens, including filoviruses.&nbsp;This BARDA/HHS contract includes a base
contract of $16,265 to support BCX4430 drug manufacturing, as well as $22,855 in additional development options that can be exercised
by the government, bringing the potential value of the contract to $39,120. As of June 30, 2016, a total of $20,574 has been awarded
under exercised options within this contract.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><I>National Institute of Allergy and Infectious Diseases (&ldquo;NIAID/HHS&rdquo;).</I>
In September 2013, NIAID/HHS contracted with the Company for the development of BCX4430 as a treatment for Marburg virus disease.
NIAID/HHS, part of the National Institutes of Health, made an initial award of $5,000 to the Company. The goals of this contract,
including amendments, are to file IND applications for intravenous (&ldquo;i.v.&rdquo;) and intramuscular (&ldquo;i.m.&rdquo;)
BCX4430 for the treatment of Marburg virus disease and other hemorrhagic fever virus diseases, to study BCX4430 as a treatment
for Ebola virus disease and to conduct an initial Phase 1 human clinical trial. BCX4430 is the lead compound in the Company&rsquo;s
BSAV research program. On June 30, 2016, NIAID/HHS granted an additional $5,475 to BioCryst for the development of BCX4430 as a
treatment for hemorrhagic fever viruses. As of June 30, 2016, the total NIAID/HHS contract amount to advance the program through
the completion of the Phase I clinical program could be up to $39,477, if all contract options are exercised. As of June 30, 2016,
a total of $35,350 has been awarded under the exercised options within this contract.</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The contracts with BARDA/HHS and NIAID/HHS are cost-plus-fixed-fee
contracts. That is, the Company is entitled to receive reimbursement for all costs incurred in accordance with the contract provisions
that are related to the development of BCX4430 plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make periodic assessments
of progress and the continuation of the contract is based on the Company&rsquo;s performance, the timeliness and quality of deliverables,
and other factors. The government has rights under certain contract clauses to terminate these contracts. These contracts are terminable
by the government at any time for breach or without cause.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"><I>Seqirus UK Limited (&ldquo;SUL&rdquo;).</I> On June 16, 2015,
the Company and Seqirus UK Limited (&ldquo;SUL&rdquo;), a limited company organized under the laws of the United Kingdom and a
subsidiary of CSL Limited, a company organized under the laws of Australia, entered into a License Agreement (the &ldquo;SUL Agreement&rdquo;)
granting SUL and its affiliates worldwide rights to develop, manufacture and commercialize RAPIVAB (peramivir injection) for the
treatment of influenza except for the rights to conduct such activities in Israel, Japan, Korea and Taiwan (the permitted geographies
together constituting the &ldquo;Territory&rdquo;). RAPIVAB is an intravenous treatment for acute uncomplicated influenza and is
currently licensed for use in the United States, Japan and Korea. RAPIVAB is the first and only intravenous influenza treatment
in the world and was approved by the FDA in December 2014 for the treatment of acute uncomplicated influenza in patients 18 years
and older who have been symptomatic for no more than two days. The Company retains all rights and associated economics to procure
pandemic stockpiling orders for RAPIVAB from the U.S. Government, while SUL has the right to pursue government stockpiling outside
the U.S.</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Pursuant to the SUL Agreement, RAPIVAB will be commercialized by CSL's
subsidiary, SUL, which specializes in influenza prevention through the supply of seasonal and pandemic vaccine to global markets.
SUL will manufacture, commercialize and exercise decision-making authority with respect to the development and commercialization
of RAPIVAB within the Territory and be responsible for all related costs, including sales and promotion.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In December 2013, the Company submitted an NDA for RAPIVAB to the
FDA. Under the terms of the SUL Agreement, the Company is responsible for fulfilling all post-marketing approval commitments in
connection with the FDA's approval of the NDA, and upon fulfillment will transfer ownership of and financial responsibility for
the NDA to SUL. Pursuant to potential rights to sell RAPIVAB in Canada and the EU, the Company is also responsible for regulatory
filings and interactions with the Health Canada and the European Medicines Agency ("EMA") until marketing approval for
RAPIVAB is obtained and assigned to SUL. In January 2016, the Company submitted a New Drug Submission (&#8220;NDS&#8221;) for RAPIVAB
in Canada, seeking approval for treatment of acute uncomplicated influenza in adult patients. In accordance with the SUL Agreement,
the Company and SUL formed a joint steering committee, composed of an equal number of representatives from each party, to oversee,
review and coordinate the conduct and progress of the commercialization of RAPIVAB in the Territory and any additional development.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Under the terms of the SUL Agreement, the Company received an upfront
payment of $33,740, and may receive up to $12,000 in additional milestone payments related to the successful achievement of regulatory
milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in
the EU and (iii) by Health Canada for an adult indication in Canada. The Company is also entitled under the SUL Agreement to receive
tiered royalties at a percentage rate beginning in the mid-teens contingent upon meeting minimum thresholds of net sales, as well
as a low-thirties percentage of the gross profit from government stockpiling purchases made outside the U.S. Specifically, the
Company receives tiered royalties at a percentage rate in the mid-teens to low-forties on net sales in the U.S. during a Contract
Year (defined as July 1 - June 30) and tiered royalties at a percentage rate in the mid-teens to mid-twenties on net sales in the
Territory, other than in the U.S., during a Calendar Year, each subject to certain downward adjustments for circumstance or events
impacting the overall market opportunity. SUL's royalty payment obligations commence on the date of the SUL Agreement and expire,
on a country-by-country basis, upon the later of (i) the expiration of legal exclusivity in such country and (ii) ten years from
the date of the SUL Agreement. The Company developed RAPIVAB under a license from UAB and will owe sublicense payments to them
on any future milestone payments and/or royalties received by the Company from SUL.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 17; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>Shionogi&nbsp;&amp; Co., Ltd. (&#8220;Shionogi&#8221;).</i> In
February 2007, the Company entered into an exclusive license agreement with Shionogi to develop and commercialize peramivir in
Japan for the treatment of seasonal and potentially life-threatening human influenza. Under the terms of the agreement, Shionogi
obtained rights to injectable formulations of peramivir in Japan. The Company developed peramivir under a license from UAB and
will owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from Shionogi. In
October 2008, the Company and Shionogi amended the license agreement to expand the territory covered by the agreement to include
Taiwan. Shionogi has commercially launched peramivir under the commercial name RAPIACTA in Japan. Shionogi submitted an NDA to
the Taiwan FDA in late 2013.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>Green Cross Corporation (&#8220;Green Cross&#8221;).</i> In June
2006, the Company entered into an agreement with Green Cross to develop and commercialize peramivir in Korea. Under the terms of
the agreement, Green Cross will be responsible for all development, regulatory, and commercialization costs in Korea. The Company
received a one-time license fee of $250. The license also provides that the Company will share in profits resulting from the sale
of peramivir in Korea, including the sale of peramivir to the Korean government for stockpiling purposes. Furthermore, Green Cross
will pay the Company a premium over its cost to supply peramivir for development and any future marketing of peramivir products
in Korea.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>&nbsp;</i></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>Mundipharma International Holdings Limited (&#8220;Mundipharma&#8221;).</i>
In February 2006, the Company entered into an exclusive, royalty bearing right and license agreement with Mundipharma for the development
and commercialization of forodesine, a Purine Nucleoside Phosphorylase (&#8220;PNP&#8221;) inhibitor, for use in oncology. Under
the terms of the license agreement, as amended, Mundipharma obtained rights to forodesine in markets across Europe, Asia, and Australasia
in exchange for a $10,000 up-front payment.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>Albert Einstein College of Medicine of Yeshiva University and Industrial
Research, Ltd. (&#8220;AECOM&#8221; and &#8220;IRL&#8221; respectively).</i> In June 2000, the Company licensed a series of potent
inhibitors of PNP from AECOM and IRL, (collectively, the &#8220;Licensors&#8221;). The lead product candidates from this collaboration
are forodesine and ulodesine. The Company has obtained worldwide exclusive rights to develop and ultimately distribute these, or
any other, product candidates that might arise from research on these inhibitors. The Company has the option to expand the Agreement
to include other inventions in the field made by the investigators or employees of the Licensors. The Company agreed to use commercially
reasonable efforts to develop these drugs. In addition, the Company has agreed to pay certain milestone payments for each licensed
product (which range in the aggregate from $1,400 to almost $4,000&nbsp;per indication) for future development of these inhibitors,
single digit royalties on net sales of any resulting product made by the Company, and to share approximately one quarter of future
payments received from other third-party partners, if any. In addition, the Company has agreed to pay annual license fees, which
can range from $150 to $500, that are creditable against actual royalties and other payments due to the Licensors. This agreement
may be terminated by the Company at any time by giving 60&nbsp;days advance notice or in the event of material uncured breach by
the Licensors.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In May 2010, the Company amended the licensee agreement through which
the Company obtained worldwide exclusive rights to develop and ultimately distribute any product candidates that might arise from
research on a series of PNP inhibitors, including forodesine and ulodesine. Under the terms of the amendment, the Licensors agreed
to accept a reduction of one-half in the percentage of future payments received from third-party sub licensees of the licensed
PNP inhibitors that must be paid to the Licensors. This reduction does not apply to (i)&nbsp;any milestone payments the Company
may receive in the future under its license agreement dated February&nbsp;1, 2006 with Mundipharma and (ii)&nbsp;royalties received
from its sub licensees in connection with the sale of licensed products, for which the original payment rate will remain in effect.
The rate of royalty payments to the Licensors based on net sales of any resulting product made by the Company remains unchanged.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On November&nbsp;17, 2011, the Company further amended its agreements
with the Licensors whereby the Licensors agreed to accept a reduction of one-half in the percentage of Net Proceeds (as defined)
received by the Company under its Amended and Restated Agreement with Mundipharma that will be paid to AECOM/IRL.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On June 19, 2012, the Company further amended its agreements
with AECOM/IRL whereby the parties clarified the definition of the field with respect to PNP inhibition and AECOM/IRL agreed to
exclusive worldwide license of BCX4430 to BioCryst for any antiviral use.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">At its sole option and subject to certain agreed upon conditions,
any future non-royalty payments due to be paid by the Company to AECOM/IRL under the license agreement may be made either in cash,
in shares of the Company&#8217;s common stock, or in a combination of cash and shares.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 18; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On January 6, 2014, the Carbohydrate Chemistry Research Team from
Callaghan Innovation Research Limited, formerly Industrial Research Limited, transferred to Victoria University of Wellington (&#8220;VUW&#8221;)
to establish the Ferrier Research Institute. The intellectual property rights relating to this research team, and the contracts
relating to that intellectual property were transferred to a wholly owned subsidiary of VUW, including the contracts to which BioCryst
is a party. The parties executed novation agreements in order to effectuate the transfer. Except for a substitution of parties,
the terms and conditions of the contracts are substantially the same.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>The University of Alabama at Birmingham (&#8220;UAB&#8221;).</i>
The Company currently has agreements with UAB for influenza neuraminidase and complement inhibitors. Under the terms of these agreements,
UAB performed specific research for the Company in return for research payments and license fees. UAB has granted the Company certain
rights to any discoveries in these areas resulting from research developed by UAB or jointly developed with the Company. The Company
has agreed to pay single digit royalties on sales of any resulting product and to share in future payments received from other
third-party partners. The Company has completed the research under the UAB agreements. These two agreements have initial 25-year
terms, are automatically renewable for five-year terms throughout the life of the last patent and are terminable by the Company
upon three months&#8217; notice and by UAB under certain circumstances. Upon termination both parties shall cease using the other
parties&#8217; proprietary and confidential information and materials, the parties shall jointly own joint inventions and UAB shall
resume full ownership of all UAB licensed products. There is currently no activity between the Company and UAB on these agreements,
but when the Company licenses this technology, such as in the case of the Shionogi, Green Cross and SUL agreements, or commercializes
products related to these programs, the Company will owe sublicense fees or royalties on amounts it receives.</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>&nbsp;</b></p></div><p style="font-size: 10pt; margin: 0pt 0"><b></b></p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>Note 4 &#8212; Royalty Monetization</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Overview</i></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On March&nbsp;9, 2011, the Company completed a $30,000&nbsp;financing
transaction to monetize certain future royalty and milestone payments under the Shionogi Agreement, pursuant to which Shionogi
licensed from the Company the rights to market RAPIACTA in Japan and, if approved for commercial sale, Taiwan. The Company received
net proceeds of $22,691&nbsp;from the transaction after transaction costs of $4,309&nbsp;and the establishment of a $3,000&nbsp;interest
reserve account by Royalty Sub, available to help cover interest shortfalls in the future. All of the interest reserve account
has been fully utilized with the September 2012 interest payment.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As part of the transaction, the Company entered into a purchase and
sale agreement dated as of March&nbsp;9, 2011 with Royalty Sub, whereby the Company transferred to Royalty Sub, among other things,
(i)&nbsp;its rights to receive certain royalty and milestone payments from Shionogi arising under the Shionogi Agreement, and (ii)&nbsp;the
right to receive payments under a Japanese yen/US dollar foreign currency hedge arrangement (as further described below, the &#8220;Currency
Hedge Agreement&#8221;) put into place by the Company in connection with the transaction. Royalty payments will be paid by Shionogi
in Japanese yen and milestone payments will paid in U.S. dollars. The Company&#8217;s collaboration with Shionogi was not impacted
as a result of this transaction.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Non-Recourse Notes Payable</i></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On March&nbsp;9, 2011, Royalty Sub completed a private placement to
institutional investors of $30,000 in aggregate principal amount of its PhaRMA Senior Secured 14.0% Notes due 2020 (the &#8220;PhaRMA
Notes&#8221;). The PhaRMA Notes were issued by Royalty Sub under an Indenture, dated as of March&nbsp;9, 2011 (the &#8220;Indenture&#8221;),
by and between Royalty Sub and U.S. Bank National Association, as Trustee. Principal and interest on the PhaRMA Notes issued are
payable from, and are secured by, the rights to royalty and milestone payments under the Shionogi Agreement transferred by the
Company to Royalty Sub and payments, if any, made to Royalty Sub under the Currency Hedge Agreement. The PhaRMA Notes bear interest
at 14%&nbsp;per annum, payable annually in arrears on September&nbsp;1st of each year. The Company remains entitled to receive
any royalties and milestone payments related to sales of peramivir by Shionogi following repayment of the PhaRMA Notes.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Royalty Sub&#8217;s obligations to pay principal and interest on the
PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person, including the Company, except
to the extent of the Company&#8217;s pledge of its equity interests in Royalty Sub in support of the PhaRMA Notes. The Company
may, but is not obligated to, make capital contributions to a capital account that may be used to redeem, or on up to one occasion
pay any interest shortfall on, the PhaRMA Notes.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On September 1, 2014, Royalty Sub was unable to pay the full amount
of interest payable to avoid an event of default. Accordingly, the PhaRMA Notes and related accrued interest have been classified
as current liabilities on the balance sheet. As a result of the event of default under the PhaRMA Notes, the holders of the PhaRMA
Notes may pursue acceleration of the PhaRMA Notes, may foreclose on the collateral securing the PhaRMA Notes and the equity interest
in Royalty Sub and exercise other remedies available to them under the Indenture in respect of the PhaRMA Notes. In such event,
the Company may not realize the benefit of future royalty payments that might otherwise accrue to it following repayment of the
PhaRMA Notes and it might otherwise be adversely affected. Due to the non-recourse nature of the PhaRMA Notes, in the event of
any potential acceleration or foreclosure, the primary impact to the Company would be the loss of future royalty payments from
Shionogi and legal costs associated with retiring the PhaRMA Notes. In addition, the Company may incur costs associated with liquidating
the related Currency Hedge Agreement, which would no longer be required in the event of foreclosure, or if the PhaRMA Notes cease
to be outstanding. As the PhaRMA Notes are the obligation of Royalty Sub and non-recourse to the Company, the event of default
of the PhaRMA Notes is not expected to have a significant impact on the Company&#8217;s future results of operations or cash flows.
As of June 30, 2016, the PhaRMA Notes remain in default.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 19; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As of June 30, 2016, the aggregate fair value of the PhaRMA Notes
was estimated to be approximately 50% of its carrying value of $30,000. The estimated fair value of the PhaRMA Notes is classified
as Level 2 in the fair value hierarchy as defined in U.S. GAAP.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The PhaRMA Notes are redeemable at the option of Royalty Sub at any
time at a redemption price equal to the outstanding principal balance of the PhaRMA Notes being redeemed plus accrued and unpaid
interest through the redemption date on the PhaRMA Notes being redeemed.</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>&nbsp;</i></p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Foreign Currency Hedge</i></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In connection with the issuance by Royalty Sub of the PhaRMA Notes,
the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese
yen relative to the U.S. dollar. Under the Currency Hedge Agreement, the Company has the right to purchase dollars and sell yen
at a rate of 100 yen per dollar for which the Company may be required to pay a premium in each year from 2017 through 2020, provided
the Currency Hedge Agreement remains in effect. A payment of $1,950&nbsp;will be required if, on May&nbsp;18 of the relevant year,
the U.S. dollar is worth 100 yen or less as determined in accordance with the Currency Hedge Agreement.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Currency Hedge Agreement does not qualify for hedge accounting
treatment; therefore, mark-to-market adjustments are recognized in the Company&#8217;s Consolidated Statement of Comprehensive
Loss. Cumulative mark-to-market adjustments for the six months ended June&nbsp;30, 2016 and 2015 resulted in losses of $6,441 and
$332, respectively. The Company is also required to post collateral in connection with the mark-to-market adjustments based on
defined thresholds. As of June 30, 2016, $1,610 of hedge collateral was posted under the Currency Hedge Agreement. The Company
will not be required to post collateral exceeding the maximum premium payments remaining payable under the Currency Hedge Agreement.
As of June 30, 2016, the maximum amount of hedge collateral the Company may be required to post is $7,800.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p></div><p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p><div data-td-statement-type="note"><p style="font-size: 10pt; margin: 0pt 0"><b>Note 5 &#8212; Stockholders&#8217; Equity</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On March 3, 2015, the Company filed a $150,000 shelf registration
statement on Form S-3 with the SEC. This shelf registration statement, as amended by a post-effective amendment filed on February
26, 2016 and declared effective on April 18, 2016, allows the Company to sell securities, including common stock, preferred stock,
depository shares, stock purchase contracts, warrants and units, from time to time at prices and on terms to be determined at the
time of sale.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On November&nbsp;6, 2013, the Company filed a $125,000 shelf registration
statement on Form S-3 with the SEC. This shelf registration statement was declared effective in November 2013 and allows the Company
to sell securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants and units, from
time to time at prices and on terms to be determined at the time of sale. The Company has $10,000 remaining under this shelf registration
statement.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p></div><p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0"><b><a name="a_006"></a>Item&nbsp;2. &nbsp;&nbsp;&nbsp;&nbsp;Management&#8217;s Discussion
and Analysis of Financial Condition and Results of Operations</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>This Quarterly Report on Form 10-Q contains statements of a forward-looking
nature relating to future events or the future financial performance of BioCryst. Such statements are only predictions and the
actual events or results may differ materially from the results discussed in the forward-looking statements. Factors that could
cause or contribute to such differences include those discussed below and elsewhere in this report, as well as those discussed
in other filings made by the Company with the Securities and Exchange Commission, including the Company&#8217;s Annual Report on
Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. See &#8220;Information Regarding Forward-Looking Statements.&#8221;</i></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Cautionary Statement</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The discussion herein contains forward-looking statements within the
meaning of Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, which are subject to the &#8220;safe harbor&#8221;
created in Section&nbsp;21E. Forward looking statements regarding our financial condition and our results of operations that are
based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted
within the United States (&#8220;U.S. GAAP&#8221;), as well as projections for the future. The preparation of these financial statements
requires our management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses,
and related disclosure of contingent assets and liabilities. We evaluate our estimates on an ongoing basis. Our estimates are based
on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. The results
of our estimates form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent
from other sources.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 20; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We operate in a highly competitive environment that involves a number
of risks, some of which are beyond our control. We are subject to risks common to biotechnology and biopharmaceutical companies,
including risks inherent in our drug discovery, drug development and commercialization efforts, clinical trials, uncertainty of
regulatory actions and marketing approvals, reliance on collaborative partners, enforcement of patent and proprietary rights, the
need for future capital, competition associated with products, potential competition associated with our product candidates and
retention of key employees. In order for any of our product candidates to be commercialized, it will be necessary for us, or our
collaborative partners, to conduct clinical trials, demonstrate efficacy and safety of the product candidate to the satisfaction
of regulatory authorities, obtain marketing approval, enter into manufacturing, distribution and marketing arrangements, and obtain
market acceptance and adequate reimbursement from government and private insurers. We cannot provide assurance that we will generate
significant revenues or achieve and sustain profitability in the future. In addition, we can provide no assurance that we will
have sufficient funding to meet our future capital requirements. Statements contained in Management&#8217;s Discussion and Analysis
of Financial Condition and Results of Operations and elsewhere in this report which are not historical facts are, or may constitute,
forward-looking statements. Forward-looking statements involve known and unknown risks that could cause our actual results to differ
materially from expected results. The most significant known risks are discussed in the section entitled &#8220;Risk Factors.&#8221;
Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results,
levels of activity, performance or achievements.&nbsp;We caution you not to place undue reliance on any forward-looking statements.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our revenues are difficult to predict and depend on numerous factors,
including the prevalence and severity of influenza in regions for which peramivir has received regulatory approval, seasonality
of influenza, ongoing discussions with government agencies regarding future RAPIVAB and/or BCX4430 development and stockpiling
procurement, as well as entering into, or modifying, licensing agreements for our product candidates. Furthermore, revenues related
to our collaborative development activities are dependent upon the progress toward and the achievement of developmental milestones
by us or our collaborative partners.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our operating expenses are also difficult to predict and depend on
several factors, including research and development expenses (and whether these expenses are reimbursable under government contracts),
drug manufacturing, and clinical research activities, the ongoing requirements of our development programs, and the availability
of capital and direction from regulatory agencies, which are difficult to predict. Management may be able to control the timing
and level of research and development and general and administrative expenses, but many of these expenditures will occur irrespective
of our actions due to contractually committed activities and/or payments.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As a result of these factors, we believe that period to period comparisons
are not necessarily meaningful and you should not rely on them as an indication of future performance. Due to all of the foregoing
factors, it is possible that our operating results will be below the expectations of market analysts and investors. In such event,
the prevailing market price of our common stock could be materially adversely affected.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><u>Overview</u></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We are a biotechnology company that designs, optimizes and develops
novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. We focus on the treatment of rare diseases
in which significant unmet medical needs exist and align with our capabilities and expertise. We integrate the disciplines of biology,
crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process
known as structure-guided drug design.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Critical Accounting Policies and Estimates</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The accompanying discussion and analysis of our financial condition
and results of operations are based upon our consolidated financial statements and the related disclosures, which have been prepared
in accordance with U.S. GAAP. The preparation of these consolidated financial statements requires us to make estimates and judgments
that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities.
We evaluate our estimates, judgments and the policies underlying these estimates on a periodic basis, as situations change, and
regularly discuss financial events, policies, and issues with members of our audit committee and our independent registered public
accounting firm. We routinely evaluate our estimates and policies regarding revenue recognition, administration, inventory and
manufacturing, taxes, stock-based compensation, research and development, consulting and other expenses and any associated liabilities.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Recent Corporate Highlights</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 9pt"><b><i>RAPIVAB (peramivir injection)</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">RAPIVAB was approved by the FDA on December 19, 2014 and on June 16,
2015 we entered into a license agreement granting SUL and its affiliates worldwide rights to develop, manufacture and commercialize
RAPIVAB (peramivir injection) for the treatment of influenza on a worldwide basis except in Israel, Japan, Korea and Taiwan. With
the approval, commercial availability and out-licensing collaboration of RAPIVAB, we have moved our focus to: (1) obtaining a stockpiling
procurement contract with the U.S. Government to realize the strategic value of this program; (2) fulfilling our post-approval
development requirements, including conducting a pediatric trial and a trial in elderly/high risk influenza patients; and (3) submitting
a Marketing Authorization Application (&ldquo;MAA&rdquo;) and New Drug Submission (&ldquo;NDS&rdquo;) in the European Union (&ldquo;EU&rdquo;)
and Canada, respectively, to allow SUL the ability to commercialize the drug in those regions. In January 2016, we submitted a
NDS for RAPIVAB in Canada, seeking approval for the treatment of acute uncomplicated influenza in adult patients.</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 9pt"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 9pt"><b><i></i></b></p>

<!-- Field: Page; Sequence: 21; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0 0pt 9pt"><b><i>HAE Program</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>Avoralstat</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 20pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.35pt">On December 18, 2014, we announced the
dosing of the first patient in OPuS-2 (<B>O</B>ral <B>P</B>rophylaxi<B>S-2</B>), a blinded, randomized, placebo-controlled clinical
trial of orally-administered avoralstat in patients with hereditary angioedema (&ldquo;HAE&rdquo;). OPuS-2 was a 12-week, three-arm,
parallel cohort design trial to evaluate the efficacy and safety of two doses of avoralstat, 300 mg and 500 mg, administered three-times
daily compared with placebo. This trial was conducted in the U.S. and select European countries. The primary efficacy endpoint
for the trial was the mean angioedema attack rate for each avoralstat dose group compared to placebo. On February 8, 2016, we announced
results from OPuS-2. In the OPuS-2 study, HAE patients with a historical attack frequency of greater than 0.45 attacks per week
were randomized to treatment with either 500 mg or 300 mg of avoralstat, or placebo, administered three times daily for 12 weeks.
Thirty-eight subjects received avoralstat 500 mg, 36 subjects received avoralstat 300 mg, and 36 subjects received placebo. Treatment
with 500 mg and 300 mg of avoralstat three times daily failed to demonstrate a statistically significantly lower mean attack rate
versus placebo. The mean (standard deviation) attack rates per week were 0.63 (0.57) on avoralstat 500mg and 0.71 (0.66) on avoralstat
300mg, compared to 0.61 (0.41) on placebo. Statistically significant improvements in duration of attacks and in the Angioedema
Quality of Life total score were observed comparing the 500 mg three times a day avoralstat arm to placebo. Following the analysis
of OPuS-2 results, the decision was made to discontinue further development of the softgel avoralstat formulation in order to focus
development efforts on novel dosage forms of avoralstat to achieve meaningfully better drug exposure.</P>



<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 31.7pt; margin: 0pt 0">In August 2016, we reported a clinical pharmacology study of several
avoralstat dosage formulations was nearing completion. Cohorts of healthy volunteers have received single doses ranging from 200
mg to 2000 mg of avoralstat in tablet or suspension formulations, with no clinically significant adverse events reported. While
these dosing formulations have improved total avoralstat exposure (AUC) up to approximately five-fold compared to a 500 mg dose
given as soft gel capsules, the plasma concentration-time profile has not met our objectives of twice-daily dosing with drug levels
at or above the target range. For that reason, we have decided to stop further development of avoralstat.</P>



<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></P>



<P STYLE="font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>BCX7353</i></b> &nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">In January 2015, we selected BCX7353 to advance
into Phase 1 development as a once-daily, oral prophylactic HAE treatment. In October 2015, we successfully completed a Phase 1
clinical trial of BCX7353 in Western and Japanese healthy volunteers. In the Western portion of this trial, we studied BCX7353
single doses of up to 1000mg, once-daily doses of up to 500mg for seven days, and once-daily doses of 350mg for 14 days in healthy
Western volunteers. Plasma levels increased in approximate proportion to dose, and drug exposure was not affected by dosing with
food. The half-life of BCX7353 was estimated at 50-60 hours. After daily dosing, blood levels met or exceeded a predicted target
therapeutic range throughout the 24 hour dosing interval. Inhibition of the target enzyme, plasma kallikrein, was measured in a
sensitive and specific bioassay. Daily dosing with BCX7353 strongly inhibited plasma kallikrein at all four dose levels; the degree
of inhibition was dose-related (p &lt; 0.0001) and inhibition was sustained throughout the 24 hour dosing interval. This pharmacodynamic
effect correlated strongly to the achieved drug concentration (r = 0.91, p &lt; 0.0001).</P>



<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">In the Japanese portion of this trial, we
enrolled cohorts of healthy Japanese volunteers and gave single oral doses of BCX7353 of 100mg and 500mg, and daily doses of 250mg
of BCX7353 for seven days. Compared to Western subjects administered the same dose level, plasma drug levels in Japanese subjects
were moderately higher. Kallikrein inhibition on day seven of daily dosing with 250mg in Japanese subjects was similar to that
seen at the 350mg daily and 500mg daily dose levels in Western subjects.</P>




<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The combined data from all Phase 1 clinical
trials completed as of July 2016 indicates that oral BCX7353 has been generally safe and well tolerated in a total of 117 healthy
volunteers, 46 receiving single doses of up to 1000 mg, and 71 receiving once-daily doses of up to 500 mg for 7 days and 350 mg
for 14 days. In our Phase 1 trials, we have observed an approximate 5% rate of drug-related rash in healthy volunteers administered
daily doses of BCX7353 for at least 7 days. This drug-related rash appears within the first 14 days of drug administration and
resolves within a few days after discontinuing drug. No serious adverse events have been seen and no dose-limiting toxicity has
been identified. There have been no clinically significant laboratory abnormalities, ECG changes, or vital sign changes observed.</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">The safety, tolerability, drug exposure and on-target plasma kallikrein
inhibition results strongly support advancing the development program into a Phase 2 study in HAE patients. A Phase 2 trial (&ldquo;APeX-1&rdquo;)
to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of BCX7353 for prophylaxis of angioedema
attacks in patients with HAE has received regulatory approval in Canada and several European countries, and patient screening has
commenced.</P>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 22; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">APeX-1 is a two-part, Phase 2, randomized, double-blind, placebo-controlled
proof of concept and dose ranging trial studying BCX7353 as a preventative treatment to eliminate or reduce the frequency of angioedema
attacks in HAE patients. Up to a total of approximately 50 eligible subjects with HAE will be enrolled in the trial.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">In part 1 of APeX-1, up to 36 subjects with HAE will be randomized in a 1:1 ratio to
receive an oral dose of either 350 mg of BCX7353 once daily or placebo once daily for four weeks. An interim analysis will be conducted
after the first 24 subjects have completed treatment through study day 28. If a robust treatment effect is observed at the interim
analysis, Part 2 of the study will be initiated. In the event the treatment effect is not well characterized with 24 subjects,
a total of up to approximately 36 subjects may be enrolled in part 1 under the existing protocol. The sample size in Part 1 was
kept flexible to cover a range of response options. To characterize dose-response in part 2 of APeX-1, 14 additional subjects with
HAE will be randomized to 250mg of BCX7353 once daily (n=6), 125mg of BCX7353 once daily (n=6) or placebo (n=2).</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.35pt">The primary efficacy endpoint of APeX-1
is the number of angioedema attacks; attack rate per week, counts of attacks, proportion of subjects with no attacks, and number
of attack-free days. Secondary efficacy endpoints include severity and duration of angioedema attacks, and measures of health-related
quality of life. Safety will be characterized through evaluation of adverse events and laboratory testing.</P>




<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In October 2015 the Japanese Ministry of Health Labor &amp; Welfare
(&#8220;MHLW&#8221;) announced that BioCryst&#8217;s BCX7353 was one of six products designated under MHLW&#8217;s new Sakigake
fast track review system. The Sakigake Designation System promotes R&amp;D in Japan and provides for additional interactions with
the regulatory agency in Japan from early development through filing, and prioritized development and review, with the aim of introduction
of the product as soon as possible to address a serious unmet medical need.</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0.5in"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 20pt"><B><I>Other 2<SUP>nd</SUP> generation&nbsp;kallikrein inhibitors</I></B></P>



<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 20pt"></p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In addition to BCX7353, we have succeeded in inventing several uniquely
different plasma kallikrein inhibitor molecules from distinct structural classes. Accordingly, we have selected additional drug
candidates that have suitable pharmacologic properties to advance into preclinical development. Additional disclosure on these
compounds will occur as we near IND filings for any of these compounds.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>BCX4430</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23pt">In December 2014, we began dosing subjects
in a randomized, placebo-controlled Phase 1 clinical trial to evaluate i.m. administration of BCX4430 in healthy volunteers. The
main goals of this first-in-human study are to evaluate the safety, tolerability and pharmacokinetics of escalating doses of BCX4430
administered via i.m. injection in healthy subjects. In May 2016, we completed the Phase I trial. Single doses of BCX4430 ranging
from 0.3 to 10 mg/kg were administered, and daily doses of 2.5 mg/kg to 10 mg/kg were administered for 7 days. Exposure to BCX4430
was dose-proportional. BCX4430 dosing was generally safe and well-tolerated, and there were no grade 3 or 4 adverse events.</P>




<P STYLE="font-size: 10pt; text-indent: 23pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On March 7, 2016, results from a preclinical study of our antiviral
BCX4430 in interferon-receptor-deficient mice infected with Zika virus were presented at a World Health Organization (WHO) conference
in Geneva, Switzerland. The primary goal of the study was to assess the effect of BCX4430 treatment on survival through Day 28
in interferon-receptor-deficient mice infected with the Zika virus. BCX4430 was administered by i.m. injection twice a day beginning
four hours prior to virus challenge and continuing for eight days; two dose levels were tested. In the standard dose BCX4430 group,
7 of 8 mice survived through Day 28. In the low dose BCX4430 group (n=8), and in control groups administered vehicle placebo (n=8)
or ribavirin at two dose levels (n=16); no animals survived to Day 28. Overall survival for the standard dose level of BCX4430
was superior to both the placebo and the ribavirin treatment control groups (p &lt; 0.0001). For both dose levels of BCX4430, median
survival was superior to both control groups (&gt;28 days for BCX4430 standard dose and 23 days for low dose) compared to 14 to
17 days for controls.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Additional studies of BCX4430 in the same mouse model were conducted
at Utah State University. In one study, surviving mice that were previously treated with the standard dose of BCX4430 after initial
Zika virus challenge, were re-challenged with the Zika virus on Day 28, without additional BCX4430 treatment. All the re-challenged
mice survived through day 56 with no disease signs observed, indicating the development of effective immune responses. A further
experiment using the same AG129 mouse model tested the delayed treatment with BCX4430 after viral challenge. Groups of mice received
BCX4430 150 mg/kg twice-daily by i.m. injection starting on days 1, 3, 5, or 7 post infection, or vehicle (control group). All
BCX4430 treated groups showed a statistically significant survival benefit compared to vehicle controls.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Results of Operations (three months ended June 30, 2016 compared to the three months
ended June 30, 2015)</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">For the three months ended June 30, 2016, total revenues were $4.8
million as compared to $25.8 million for the three months ended June 30, 2015. The decrease in revenue in the second quarter of
2016, as compared to 2015, resulted primarily from lower collaborative revenue associated with the SUL agreement due to the partial
recognition of a one-time large upfront payment recognized in the second quarter of 2015 as well as lower collaborative revenue
associated with BCX4430 development in the second quarter of 2016. Revenues in the second quarter of 2016 included $0.6 million
of royalty revenue from SUL, Shionogi and Green Cross associated with sales of peramivir in the United States, Japan and Korea,
$0.8 million of reimbursement of collaborative expenses from NIAID/HHS and BARDA/HHS related to the development of BCX4430, $2.9
million of reimbursement of collaborative expenses from BARDA/HHS related to the development of RAPIVAB and $0.5 million associated
with collaborative revenue amortization from other corporate partnerships. Revenues in the second quarter of 2015 included $21.7
million of collaborative revenue related to recognizing revenue on a portion of the upfront payment from the SUL out-licensing
transaction, $0.1 million of royalty revenue from Shionogi and Green Cross associated with sales of peramivir in Japan and Korea,
$3.7 million of reimbursement of collaborative expenses from NIAID/HHS and BARDA/HHS related to the development of BCX4430 and
$0.3 million associated with collaborative revenue amortization from other corporate partnerships.</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 23; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Research and development (&ldquo;R&amp;D&rdquo;) expenses decreased
to $14.2 million for the second quarter of 2016 from $16.5 million in 2015. The decrease in 2016 R&amp;D expenses, as compared
to 2015, was primarily due to lower development costs associated with our BCX4430 program.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">General and administrative (&ldquo;G&amp;A&rdquo;) expenses decreased
to $2.7 million for the second quarter of 2016 as compared to $3.5&nbsp;million in 2015. The decrease reflects a general reduction
of administrative expenses throughout the Company in the second quarter of 2016, as compared to the second quarter of 2015. With
the completion of the SUL transaction we do not anticipate incurring substantial commercial expenses to promote RAPIVAB in the
future.</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Interest expense, which is primarily related
to the non-recourse notes issued in conjunction with the non-dilutive RAPIACTA royalty monetization transaction in March 2011,
was $1.4&nbsp;million in the second quarter of 2016, compared to $1.3 million in the second quarter of 2015.</P>



<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">A mark-to-market loss of $3.7 million was also recognized in the second
quarter of 2016 related to our foreign currency hedge, compared to a mark-to-market loss of $0.8 million in the same quarter in
the prior year, both resulting from changes in the U.S. dollar/Japanese yen exchange rate in the related time periods. In addition,
we realized a currency exchange gain of $0.8 million and $1.5 million, respectively, in the second quarter of 2016 and 2015 related
to the exercise of a U.S. dollar/Japanese yen currency option under our foreign currency hedge.</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Results of Operations (six months ended June 30, 2016 compared to the six months ended
June 30, 2015)</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">For the six months ended June 30, 2016, total revenues were $9.6 million
as compared to $32.7 million for the six months ended June 30, 2015. The decrease in 2016 revenue was primarily due to recognizing
$21.7 million of revenue on a portion of the upfront payment from the SUL transaction in the first six months of 2015. Revenues
in the first six months of 2016 included $2.5 million of royalty revenue from SUL, Shionogi and Green Cross associated with sales
of peramivir in the United States, Japan and Korea, $3.1 million of reimbursement of collaborative expenses from NIAID/HHS and
BARDA/HHS related to the development of BCX4430, $2.9 million of reimbursement of collaborative expenses from BARDA/HHS related
to the development of RAPIVAB and $0.6 million associated with collaborative revenue amortization from other corporate partnerships.
Revenues in the first six months of 2015 included $21.7 million of collaborative revenue related to the SUL Agreement, $1.7 million
of royalty revenue from Shionogi and Green Cross associated with sales of peramivir in Japan and Korea, $8.2 million of reimbursement
of collaborative expenses from NIAID/HHS and BARDA/HHS related to the development of BCX4430 and $0.6 million associated with collaborative
revenue amortization from other corporate partnerships. In addition, we recorded approximately $0.5 million of RAPIVAB revenue
under the &ldquo;Sell-Through&rdquo; revenue recognition methodology.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">R&amp;D expenses increased to $34.7 million for the first six months
of 2016 from $33.6 million in 2015. The increase in 2016 R&amp;D expenses, as compared to 2015, reflects increased spending on
our RAPIVAB program, somewhat offset by decreased development activity in our BCX4430 program.</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 24; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The following table summarizes our R&amp;D expenses for the periods
indicated (amounts are in thousands).</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp; &nbsp;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended<br> June 30,</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center">Six Months Ended<br> June&nbsp;30,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">R&amp;D expenses by program:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 48%; font-size: 10pt; text-indent: 10pt">Avoralstat</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">3,270</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">5,848</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">11,634</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">12,094</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-indent: 10pt">BCX7353</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,881</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,044</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">9,497</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,044</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-indent: 10pt">BCX4430</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,452</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,678</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,751</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,352</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-indent: 10pt"><P STYLE="font-size: 10pt; text-indent: 10pt">2nd generation kallikrein inhibitors</P>


</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">885</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,181</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,030</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">8,062</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-indent: 10pt">RAPIVAB
</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,397</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">892</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,662</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,038</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-indent: 10pt">Other research, preclinical and development costs</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,281</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,881</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5,171</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,054</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total R&amp;D expenses</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">14,166</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">16,524</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">34,745</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">33,644</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">G&amp;A expenses decreased to $5.9 million for the first six months
of 2016 as compared to $7.6&nbsp;million in 2015. The decrease of $1.7 million was primarily due to lower unrestricted grants awarded
to HAE patient advocacy groups, as well as a general reduction of administrative expenses in 2016.&nbsp;</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Interest expense, which is primarily related
to the non-recourse notes issued in conjunction with the non-dilutive RAPIACTA royalty monetization transaction in March 2011,
was $2.9&nbsp;million in the first six months of 2016, compared to $2.6 million in the first six months of 2015.</P>



<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">A mark-to-market loss of $6.4 million was recognized in the first
six months of 2016 related to our foreign currency hedge, compared to a mark-to-market loss of $0.3 million in the same period
in the prior year, both resulting from changes in the U.S. dollar/Japanese yen exchange rate in the related time periods. In addition,
we realized a currency exchange gain of $0.8 million and $1.5 million, respectively, in the second quarter of 2016 and 2015 related
to the exercise of a U.S. dollar/Japanese yen currency option under our foreign currency hedge.</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Liquidity and Capital Resources</b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Cash expenditures have exceeded revenues
since our inception and we expect our 2016 operating expenses to exceed our 2016 revenues. Our operations have principally been
funded through public offerings and private placements of equity securities; cash from collaborative and other research and development
agreements, including U.S. Government contracts for RAPIVAB and BCX4430; and to a lesser extent, the PhaRMA Notes financing. To
date, we have been awarded a BARDA/HHS RAPIVAB development contract totaling $234.8 million, which expired on June 30, 2014, a
NIAID/HHS BCX4430 development contract totaling $39.5 million, which is ongoing, and a BARDA/HHS BCX4430 development contract totaling
$39.1 million, which is also ongoing. The total amount of NIAID/HHS and BARDA/HHS funding obligated under awarded options in the
active contracts is $35.4&nbsp;million and $20.6 million, respectively. Most recently, we completed a successful public offering
in June 2014 of 11.5 million shares of common stock at a price of $10.00 per share, which provided net proceeds to us of approximately
$107.8 million. This financing and the recently completed SUL out-licensing transaction provide us liquidity through mid-2017.
We may issue securities through private placement transactions or registered public offerings pursuant to a registration statement
filed with the SEC. In addition to the above, we have received funding from other sources, including other collaborative and other
research and development agreements; government grants; equipment lease financing; facility leases; research grants; and interest
income on our investments.</P>



<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As of June 30, 2016, we had a net working capital deficit of $10.1
million, a decrease of approximately $11.6 million from the working capital surplus of $1.5 million at December&nbsp;31, 2015.
The decrease in working capital was principally due to our normal operating expenses associated with the development of our product
candidates. Our principal sources of liquidity at June&nbsp;30, 2016 were approximately $8.7 million in cash and cash equivalents;
approximately $51.2 million in investments considered available-for-sale; and approximately $2.0 million in U.S. Government receivables.
We anticipate our cash and investments will fund our operations through mid-2017.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We intend to contain costs and cash flow requirements by closely managing
our third party costs and headcount, leasing scientific equipment and facilities, contracting with other parties to conduct certain
research and development projects and using consultants. We expect to incur additional expenses, potentially resulting in significant
losses, as we continue to pursue our research and development activities and begin to build a commercial infrastructure. We may
incur additional expenses related to the filing, prosecution, maintenance, defense and enforcement of patent and other intellectual
property claims and additional regulatory costs as our clinical programs advance through later stages of development. The objective
of our investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient
to meet cash flow requirements. We place our excess cash with high credit quality financial institutions, commercial companies,
and government agencies in order to limit the amount of our credit exposure. We have not realized any significant losses on our
investments.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 25; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We extended and executed additional lease obligations in 2015 for
our Birmingham, Alabama operations, which increased the obligations by $5.6 million and extended the new obligations out to 2027.
These operating lease obligations encompass future rental obligations of our Birmingham operating facilities.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We plan to finance our needs principally from the following:</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%">&nbsp;</td>
    <td style="vertical-align: top; width: 2%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 92%"><font style="font-size: 10pt">lease or loan financing and future public or private equity financing;</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%">&nbsp;</td>
    <td style="vertical-align: top; width: 2%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 92%"><font style="font-size: 10pt">our existing capital resources and interest earned on that capital;</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%">&nbsp;</td>
    <td style="vertical-align: top; width: 2%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 92%"><font style="font-size: 10pt">payments under existing and executing new contracts with the U.S. Government; and</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%">&nbsp;</td>
    <td style="vertical-align: top; width: 2%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 92%"><font style="font-size: 10pt">payments under collaborative and licensing agreements with corporate partners.</font></td></tr>
</table>
<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As our programs continue to advance, our costs will increase. Our
current and planned clinical trials, plus the related development, manufacturing, regulatory approval process requirements and
additional personnel resources and testing required for the continuing development of our product candidates will consume significant
capital resources and will increase our expenses. Our expenses, revenues and cash utilization rate could vary significantly depending
on many factors, including our ability to raise additional capital, the development progress of our collaborative agreements for
our product candidates, the amount and timing of funding we receive from existing U.S. Government contracts for BCX4430, the amount
of funding or assistance, if any, we receive from new U.S. Government contracts or other new partnerships with third parties for
the development and or commercialization of our product candidates, the progress and results of our current and proposed clinical
trials for our most advanced product candidates, the progress made in the manufacturing of our lead product candidates and the
progression of our other programs.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">With the funds available at June 30, 2016, we believe these resources
will be sufficient to fund our operations through mid-2017. Our future liquidity needs, and ability to address those needs, will
largely be determined by the success of our product candidates and key development and regulatory events in the future. In order
to continue our operations substantially beyond mid-2017, we will need to: (1)&nbsp;successfully secure or increase U.S. Government
funding of our programs, including procurement contracts; (2)&nbsp;out-license rights to certain of our products or product candidates,
pursuant to which we would receive cash milestones; (3)&nbsp;raise additional capital through equity or debt financings or from
other sources; (4)&nbsp;obtain additional product candidate regulatory approvals, which would generate revenue and cash flow; (5)&nbsp;reduce
spending on one or more research and development programs; and/or (6)&nbsp;restructure operations. We may issue securities through
private placement transactions or registered public offerings pursuant to a registration statement filed with the SEC.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our long-term capital requirements and the adequacy of our available
funds will depend upon many factors, including:</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%">&nbsp;</td>
    <td style="vertical-align: top; width: 2%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 92%"><font style="font-size: 10pt">our ability to perform under our government contracts and receive reimbursement, and receive stockpiling procurement contracts;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">the magnitude of work under our government contracts;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">the progress and magnitude of our research, drug discovery and development programs;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">changes in existing collaborative relationships or government contracts;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">our ability to establish additional collaborative relationships with academic institutions, biotechnology or pharmaceutical companies and governmental agencies or other third parties;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">the extent to which our partners, including governmental agencies, will share in the costs associated with the development of our programs or run the development programs themselves;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">our ability to negotiate favorable development and marketing strategic alliances for certain product candidates or a decision to build or expand internal development and commercial capabilities;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">successful commercialization of marketed products by either us or a partner;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">the scope and results of preclinical studies and clinical trials to identify and develop product candidates;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td></td></tr></table>

<!-- Field: Page; Sequence: 26; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->


<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%">&nbsp;</td>
    <td style="vertical-align: top; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 92%">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">our ability to engage sites and enroll subjects in our clinical trials;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">the scope of manufacturing of our product candidates to support our preclinical research and clinical trials;</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"></p>



<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%">&nbsp;</td>
    <td style="vertical-align: top; width: 2%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 92%"><font style="font-size: 10pt">increases in personnel and related costs to support the development and commercialization of our product candidates;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">the scope of manufacturing of our drug substance and product candidates required for future NDA filings;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">competitive and technological advances;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">the time and costs involved in obtaining regulatory approvals;&nbsp;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">post-approval commitments for RAPIVAB and other products that receive regulatory approval; and</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">the costs involved in all aspects of intellectual property strategy and protection including the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We expect that we will be required to raise additional capital to
complete the development and commercialization of our current product candidates and we may seek to raise capital in the future.
Additional funding, whether through additional sales of equity or debt securities, collaborative or other arrangements with corporate
partners or from other sources, including governmental agencies in general and existing government contracts specifically, may
not be available when needed or on terms acceptable to us. The issuance of preferred or common stock or convertible securities,
with terms and prices significantly more favorable than those of the currently outstanding common stock, could have the effect
of diluting or adversely affecting the holdings or rights of our existing stockholders. In addition, collaborative arrangements
may require us to transfer certain material rights to such corporate partners. Insufficient funds may require us to delay, scale
back or eliminate certain of our research and development programs. Our future working capital requirements, including the need
for additional working capital, will be largely determined by the advancement of our portfolio of product candidates as well as
rate of reimbursement by U.S. Government agencies of our BCX4430 expenses and any future decisions regarding the future of the
RAPIVAB and BCX4430 programs, including those relating to stockpiling procurement. More specifically, our working capital requirements
will be dependent on the number, magnitude, scope and timing of our development programs; regulatory approval of our product candidates;
obtaining funding from collaborative partners; the cost, timing and outcome of regulatory reviews, regulatory investigations, and
changes in regulatory requirements; the costs of obtaining patent protection for our product candidates; the timing and terms of
business development activities; the rate of technological advances relevant to our operations; the efficiency of manufacturing
processes developed on our behalf by third parties; and the level of required administrative support for our daily operations.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Financial Outlook for 2016</b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Based upon our development plans, expected operations and our awarded
government contracts, we expect 2016 operating cash usage to be in the range of $55 to $75 million, and expect our total 2016 operating
expenses to be in the range of $78 to $98 million. Our operating expense range excludes equity-based compensation expense due to
the difficulty in accurately projecting this expense as it is significantly impacted by the volatility and price of the Company&#8217;s
stock, as well as vesting of the Company&#8217;s outstanding performance-based stock options. Our operating cash forecast excludes
any impact of our royalty monetization, hedge collateral posted or returned, and any other non-routine cash outflows or inflows.
Our ability to remain within our operating expense and operating cash target ranges is subject to multiple factors, including unanticipated
or additional general development and administrative costs and other factors described under the Risk Factors located elsewhere
in this report.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Off-Balance Sheet Arrangements</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As of June 30, 2016, we do not have any unconsolidated entities or
off&#8211;balance sheet arrangements.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Critical Accounting Policies</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We have established various accounting policies that govern the application
of U.S. GAAP, which were utilized in the preparation of our consolidated financial statements. Certain accounting policies involve
significant judgments and assumptions by management that have a material impact on the carrying value of certain assets and liabilities.
Management considers such accounting policies to be critical accounting policies. The judgments and assumptions used by management
are based on historical experience and other factors, which are believed to be reasonable under the circumstances. Because of the
nature of the judgments and assumptions made by management, actual results could differ from these judgments and estimates, which
could have a material impact on the carrying values of assets and liabilities and the results of operations.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 27; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">While our significant accounting policies are more fully described
in Note&nbsp;1 to our consolidated financial statements included in our 2015 Annual Report on Form&nbsp;10-K for the year ended
December&nbsp;31, 2015, we believe that the following accounting policies are the most critical to aid you in fully understanding
and evaluating our reported financial results and affect the more significant judgments and estimates that we use in the preparation
of our financial statements.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Inventory</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our inventories consist of RAPIVAB finished goods and work in process,
which are valued at the lower of cost or market using the first-in, first-out (i.e., FIFO) method. Cost includes materials, labor,
overhead, shipping and handling costs. Our inventories are subject to expiration dating. We regularly evaluate the carrying value
of our inventories and provide valuation reserves for any estimated obsolete, short-dated or unmarketable inventories. In addition,
we may experience spoilage of our raw materials and supplies. Our determination that a valuation reserve might be required, in
addition to the quantification of such reserve, requires us to utilize significant judgment. In connection with the FDA approval
of RAPIVAB in December 2014, we began capitalizing costs associated with the production of RAPIVAB commercial inventories.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Accrued Expenses</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We enter into contractual agreements with third-party vendors who
provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts
are subject to milestone-based invoicing and services are completed over an extended period of time. We record liabilities under
these contractual commitments when an obligation has been incurred. This accrual process involves reviewing open contracts and
purchase orders, communicating with our applicable personnel to identify services that have been performed and estimating the level
of service performed and the associated cost when we have not yet been invoiced or otherwise notified of actual cost. The majority
of our service providers invoice us monthly in arrears for services performed. We make estimates of our accrued expenses as of
each balance sheet date based on the facts and circumstances known to us. We periodically confirm the accuracy of our estimates
with the service providers and make adjustments if necessary. Examples of estimated accrued expenses include:</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%">&nbsp;</td>
    <td style="vertical-align: top; width: 2%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 92%"><font style="font-size: 10pt">fees paid to Clinical Research Organizations (&#8220;CROs&#8221;) in connection with preclinical and toxicology studies and clinical trials;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">fees paid to investigative sites in connection with clinical trials;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">fees paid to contract manufacturers in connection with the production of our raw materials, drug substance and product candidates;&nbsp;and</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">professional fees.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We base our expenses related to clinical trials on our estimates of
the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and
manage clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to
contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful
enrollment of patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over
which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services
or the level of effort varies from our estimate, we will adjust the accrual accordingly. If we do not identify costs that we have
begun to incur or if we underestimate or overestimate the level of these costs, our actual expenses could differ from our estimates.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Revenue Recognition</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We recognize revenues from collaborative and other research and development
arrangements and product sales. Revenue is realized or realizable and earned when all of the following criteria are met: (i)&nbsp;persuasive
evidence of an arrangement exists; (ii)&nbsp;delivery has occurred or services have been rendered; (iii)&nbsp;the seller&#8217;s
price to the buyer is fixed or determinable; and (iv)&nbsp;collectability is reasonably assured.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Collaborative and Other Research and Development Arrangements and Royalties</i></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 23pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Revenue from license fees, royalty payments, event payments, and
research and development fees are recognized as revenue when the earnings process is complete and we have no further continuing
performance obligations or we have completed the performance obligations under the terms of the agreement. Fees received under
licensing agreements that are related to future performance are deferred and recognized over an estimated period determined by
management based on the terms of the agreement and the products licensed. In the event a license agreement contains multiple deliverables,
we evaluate whether the deliverables are separate or combined units of accounting. Revisions to revenue or profit estimates as
a result of changes in the estimated revenue period are recognized prospectively.&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 28; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Under certain of our license agreements, we receive royalty payments
based upon our licensees&#8217; net sales of covered products. We recognize royalty revenues when we can reliably estimate such
amounts and collectability is reasonably assured. Royalty revenue paid by Shionogi on their product sales is subject to returns.</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">For arrangements that involve the delivery of more than one element,
each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting.
This determination is based on whether the deliverable has &#8220;stand-alone value&#8221; to the customer. The consideration that
is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable.
The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective
evidence of fair value, (ii) third-party evidence of selling price (&#8220;TPE&#8221;) and (iii) best estimate of selling price
(&#8220;BESP&#8221;). The BESP reflects our best estimate of what the selling price would be if the deliverable was regularly sold
by us on a stand-alone basis. In most cases we expect to use TPE or BESP for allocating consideration to each deliverable. The
consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the
consideration that is not contingent upon future deliverables. Analyzing the arrangement to identify deliverables requires the
use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another
performance obligation.</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In June 2015, we entered into a License Agreement (the "SUL Agreement")
granting SUL and its affiliates worldwide rights, excluding Israel, Japan, Korea and Taiwan, to develop, manufacture and commercialize
RAPIVAB. The SUL Agreement provides for various types of payments, including a non-refundable upfront fee, milestone payments,
and future royalties. Analysis of the SUL Agreement identified three deliverables: (i) license rights, (ii) inventory and (iii)
regulatory support to obtain Canadian and EU marketing approvals. We received an upfront payment of $33.7 million from SUL of which
$7.0 million was determined to be contingent upon EU marketing approval and will be deferred until that time. Approximately $21.7
million of the upfront payment was allocated to the license rights and recognized as revenue in the second quarter. Approximately
$3.7 million of the upfront payment was allocated to the sale of inventory and was recognized in the third quarter when the inventory
transfer was completed. Approximately $1.2 million of the revenue from the SUL Agreement will be recognized ratably over the expected
period of involvement in these regulatory support activities.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Milestone payments are recognized as licensing revenue upon the achievement
of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not reasonably assured
at the inception of the SUL Agreement; and (ii) the fees are non-refundable. Any milestone payments received prior to satisfying
these revenue recognition criteria are recorded as deferred revenue.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Under the terms of the SUL Agreement, we may receive up to $12.0 million
in additional payments related to the successful achievement of regulatory milestones, including marketing approval (i) by the
FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Canada for an adult indication
in Canada. We evaluated each event based payment under the provisions of ASU 2010-17, <i>Milestone Method of Revenue Recognition</i>,
and determined that each event based payment met the criteria to be considered substantive and represents a milestone under the
milestone method of accounting. No event based payments were achieved during the periods presented.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Reimbursements received for direct out-of-pocket expenses related
to research and development costs are recorded as revenue in the income statement rather than as a reduction in expenses. Under
our contracts with BARDA/HHS and NIAID/HHS, revenue is recognized as reimbursable direct and indirect costs are incurred.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Product Sales</i></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">We recognize revenue for sales of RAPIVAB when title and substantially
all the risks and rewards of ownership have transferred to the customer, which generally occurs on the date of shipment from our
specialty distributors, utilizing the Sell-Through revenue recognition methodology. Product sales are recognized when there is
persuasive evidence that an arrangement exists, title has passed, the price was fixed and determinable, and collectability is reasonably
assured. Product sales are recognized net of estimated allowances, discounts, sales returns, chargebacks and rebates. In the United
States, prior to completion of the SUL transaction, we sold RAPIVAB to specialty distributors, who, in turn, sell to physician
offices, hospitals and federal, state and commercial health care organizations. With the completion of the SUL worldwide license
of RAPIVAB, SUL will be responsible for sales of RAPIVAB, other than U.S. Government stockpiling sales. With the completion of
the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&#8217;s partners,
except for U.S. Government stockpiling sales, and the Company will be reliant on these partners to generate sales and provide for
sales discounts and rebates.</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Sales deductions consist of statutory rebates to state Medicaid, Medicare
and other government agencies and sales discounts (including trade discounts and distribution service fees). These deductions are
recorded as reductions to revenue from RAPIVAB in the same period as the related sales with estimates of future utilization derived
from historical experience adjusted to reflect known changes in the factors that impact such reserves.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 29; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We utilize data from external sources to help estimate gross-to-net
sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. External sourced data includes, but is not limited
to, information obtained from specialty distributors with respect to their inventory levels and sell-through to customers, and
information from third-party suppliers of market research data to the pharmaceutical industry.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">We have categorized and described more fully the following significant
sales deductions, all of which involve estimates and judgments, which we consider to be critical accounting estimates, and requires
us to use information from external sources.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Rebates and Chargebacks</i></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Statutory rebates to state Medicaid agencies and Medicare are based
on statutory discounts to RAPIVAB&#8217;s selling price.&nbsp;As it can take up to nine months or more for information to be received
on actual usage of RAPIVAB in Medicaid and other governmental programs, we maintain reserves for amounts payable under these programs
relating to RAPIVAB sales.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Chargebacks claimed by specialty distributors are based on the differentials
between product acquisition prices paid by the specialty distributors and lower government contract pricing paid by eligible customers
covered under federally qualified programs.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The amount of the reserve for rebates and chargebacks is based on
multiple qualitative and quantitative factors, including the historical and projected utilization levels, historical payment experience,
changes in statutory laws and interpretations as well as contractual terms, product pricing (both normal selling prices and statutory
or negotiated prices), changes in prescription demand patterns and utilization of our product through public benefit plans, and
the levels of RAPIVAB inventory in the distribution channel. We acquire prescription utilization data from third-party suppliers
of market research data to the pharmaceutical industry. We update our estimates and assumptions each period and record any necessary
adjustments to reserves. Settlements of rebates and chargebacks typically occur within nine months from point of sale. To the extent
actual rebates and chargebacks differ from our estimates, additional reserves may be required or reserves may need to be reversed,
either of which would impact current period product revenue.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Discounts and Sales Incentives</i></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 22.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Discounts and other sales incentives primarily consist of Inventory
Management Agreement (&#8220;IMA&#8221;) Fees. Per contractual agreements with our specialty distributors, we provide an IMA fee
based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth in our individual contracts. We track sales
to our specialty distributors each period and accrue a liability relating to the unpaid portion of these fees by applying contractual
rates to such sales.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Product Returns</i></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 22.5pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We do not record a product return allowance as we do not offer the
ability to return goods once a bona fide shipment has been accepted by a specialty distributor.</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Research and Development Expenses</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our research and development costs are charged to expense when incurred.
Advance payments for goods or services that will be used or rendered for future research and development activities are deferred
and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed.
Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs,
clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of
various administrative and facilities related costs. Most of our manufacturing and clinical and preclinical studies are performed
by third-party CROs. Costs for studies performed by CROs are accrued by us over the service periods specified in the contracts
and estimates are adjusted, if required, based upon our on-going review of the level of services actually performed.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Additionally, we have license agreements with third parties, such
as AECOM, IRL, and UAB, which require fees related to sublicense agreements or maintenance fees. We expense sublicense payments
as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized
over the related revenue recognition period. We expense maintenance payments as incurred.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Deferred collaboration expenses represent sub-license payments paid
to our academic partners upon receipt of consideration from various commercial partners, and other consideration to our academic
partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt
of such payments or modifications from our commercial partners and are being expensed in proportion to the related revenue being
recognized. We believe that this accounting treatment appropriately matches expenses with the associated revenue.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 30; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We group our R&amp;D expenses into two major categories: direct external
expenses and indirect expenses. Direct expenses consist of compensation for R&amp;D personnel and costs of outside parties to conduct
laboratory studies, develop manufacturing processes and manufacture the product candidate, conduct and manage clinical trials,
as well as other costs related to our clinical and preclinical studies. These costs are accumulated and tracked by program. Indirect
expenses consist of lab supplies and services, facility expenses, depreciation of development equipment and other overhead of our
research and development efforts. These costs apply to work on our clinical and preclinical candidates as well as our discovery
research efforts.</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Stock-Based Compensation</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">All share-based payments, including grants of stock option awards
and restricted stock unit awards, are recognized in our Consolidated Statements of Comprehensive Loss based on their fair values.
Stock-based compensation cost is estimated at the grant date based on the fair value of the award and is recognized as expense
on a straight-line basis over the requisite service period of the award. Determining the appropriate fair value model and the related
assumptions for the model requires judgment, including estimating the life of an award, the stock price volatility, and the expected
term. We utilize the Black-Scholes option-pricing model to value our awards and recognize compensation expense on a straight-line
basis over the vesting periods. The estimation of share-based payment awards that will ultimately vest requires judgment, and to
the extent actual results or updated estimates differ from our current estimates, such amounts will be recorded as a cumulative
adjustment in the period estimates are revised. In addition, we have outstanding performance-based stock options for which no compensation
expense is recognized until &#8220;performance&#8221; has occurred. Significant management judgment is also required in determining
estimates of future stock price volatility and forfeitures to be used in the valuation of the options. Actual results, and future
changes in estimates, may differ substantially from our current estimates.</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Currency Hedge Agreement</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In connection with our issuance of the PhaRMA Notes, we entered into
a foreign Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to
the U.S.&nbsp;dollar. Under the Currency Hedge Agreement, we have the right to purchase dollars and sell yen at a rate of 100 yen
per dollar for which we may be required to pay a premium in each year from 2017 through 2020, provided the Currency Hedge Agreement
remains in effect. A payment of $2.0&nbsp;million will be required if, on May&nbsp;18 of the relevant year, the U.S. dollar is
worth 100 yen or less as determined in accordance with the Currency Hedge Agreement. In conjunction with establishing the Currency
Hedge Agreement, we will be required to post collateral to the counterparty, which may cause us to experience additional quarterly
volatility in our financial results. We will not be required at any time to post collateral exceeding the maximum premium payments
remaining payable under the Currency Hedge Agreement. In establishing the hedge, we provided initial funds of approximately $2.0&nbsp;million
to support our potential hedge obligations. As of June 30, 2016, the maximum amount of hedge collateral we may be required to post
is $7.8 million.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Currency Hedge Agreement does not qualify for hedge accounting
treatment and therefore mark to market adjustments will be recognized in our Consolidated Statements of Comprehensive Loss. Mark
to market adjustments are determined by quoted prices in markets that are not actively traded and for which significant inputs
are observable directly or indirectly, representing the Level 2 in the fair value hierarchy as defined by generally accepted accounting
principles (&#8220;U.S. GAAP&#8221;). The Company is also required to post collateral in connection with the mark to market adjustments
based on defined thresholds. As of June 30, 2016, $1.6 million of collateral was posted under the agreement.</p>

<p style="font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Tax</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We account for uncertain tax positions in accordance with U.S. GAAP.
Significant management judgment is required in determining our provision for income taxes, deferred tax assets and liabilities
and any valuation allowance recorded against net deferred tax assets. We have recorded a valuation allowance against all potential
tax assets, due to uncertainties in our ability to utilize deferred tax assets, primarily consisting of certain net operating losses
carried forward, before they expire. The valuation allowance is based on estimates of taxable income in each of the jurisdictions
in which we operate and the period over which our deferred tax assets will be recoverable.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Information Regarding Forward-Looking Statements</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">This filing contains forward-looking statements within the meaning
of Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, which are subject to the &#8220;safe harbor&#8221; created
in Section&nbsp;21E. All statements other than statements of historical facts contained in this filing are forward-looking statements.
These forward-looking statements can generally be identified by the use of words such as &#8220;may,&#8221; &#8220;will,&#8221;
&#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;estimates,&#8221;
&#8220;predicts,&#8221; &#8220;potential,&#8221; the negative of these words or similar expressions. Statements that describe our
future plans, strategies, intentions, expectations, objectives, goals or prospects are also forward-looking statements. Discussions
containing these forward-looking statements are principally contained in &#8220;Business,&#8221; &#8220;Risk Factors&#8221; and
&#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; as well as any amendments
we make to those sections in filings with the SEC. These forward-looking statements include, but are not limited to, statements
about:&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 31; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%">&nbsp;</td>
    <td style="vertical-align: top; width: 2%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 92%"><font style="font-size: 10pt">the preclinical development, clinical development, commercialization, or post-marketing studies of our
product candidates and products, including our HAE program, RAPIVAB, BCX4430, and early stage discovery programs;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">the potential funding from our contracts with NIAID/HHS and BARDA/HHS for the development of BCX4430;</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 5%">&nbsp;</td>
    <td style="vertical-align: top; width: 2%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 92%"><font style="font-size: 10pt">the potential for government stockpiling orders of RAPIVAB, additional regulatory approvals of RAPIVAB or milestones royalties or profit from commercial sales of RAPIVAB by us or our partners;</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top"><font style="font-size: 10pt">the potential use of RAPIVAB as a treatment for H1N1, H5N1, and H7N9 or other strains of influenza;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td style="width: 5%">&nbsp;</td>
    <td style="vertical-align: top; width: 2%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: top; width: 87%"><font style="font-size: 10pt">the implementation of our business model, strategic plans for our business, products, product candidates and technology;</font></td>
    <td style="width: 5%">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top"><font style="font-size: 10pt">our ability to establish and maintain collaborations or out-license rights to our drug candidates;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">plans, programs, progress and potential success of our collaborations, including SUL for RAPIVAB, Mundipharma for forodesine and Shionogi and Green Cross for peramivir in their territories;</font></td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">Royalty Sub&#8217;s ability to service its payment obligations in respect of the PhaRMA Notes, and our ability to benefit from our equity interest in Royalty Sub;</font></td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">the foreign currency hedge agreement entered into by us in connection with the issuance by Royalty Sub of the PhaRMA Notes;</font></td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;</font></td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top"><font style="font-size: 10pt">our ability to operate our business without infringing the intellectual property rights of others;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top"><font style="font-size: 10pt">estimates of our expenses, revenues, capital requirements, annual cash utilization, and our needs for additional financing;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top"><font style="font-size: 10pt">the timing or likelihood of regulatory filings or regulatory agreements, deferrals, and approvals;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top"><font style="font-size: 10pt">our ability to raise additional capital to fund our operations;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top"><font style="font-size: 10pt">our financial performance;&nbsp;and</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top"><font style="font-size: 10pt">competitive companies, technologies and our industry.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">These statements relate to future events or to our future financial
performance and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance
or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking
statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those
listed under &#8220;Risk Factors.&#8221; Any forward-looking statement reflects our current views with respect to future events
and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, industry
and future growth. Except as required by law, we assume no obligation to update or revise these forward-looking statements for
any reason, even if new information becomes available in the future.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><a name="a_007"></a><b>Item 3. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Quantitative and Qualitative
Disclosures about Market Risk</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Interest Rate Risk</i></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We are subject to interest rate risk on our investment portfolio and
borrowings under our PhaRMA Notes.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We invest in marketable securities in accordance with our investment
policy. The primary objectives of our investment policy are to preserve capital, maintain proper liquidity to meet operating needs
and maximize yields. Our investment policy specifies credit quality standards for our investments and limits the amount of credit
exposure to any single issue, issuer or type of investment. We place our excess cash with high credit quality financial institutions,
commercial companies, and government agencies in order to limit the amount of credit exposure. Some of the securities we invest
in may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment
to fluctuate.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 32; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our investment exposure to market risk for changes in interest rates
relates to the increase or decrease in the amount of interest income we can earn on our portfolio, changes in the market value
due to changes in interest rates and other market factors as well as the increase or decrease in any realized gains and losses.
Our investment portfolio includes only marketable securities and instruments with active secondary or resale markets to help ensure
portfolio liquidity. A hypothetical 100 basis point drop in interest rates along the entire interest rate yield curve would not
significantly affect the fair value of our interest sensitive financial instruments. We generally have the ability to hold our
fixed-income investments to maturity and therefore do not expect that our operating results, financial position or cash flows will
be materially impacted due to a sudden change in interest rates. However, our future investment income may fall short of expectations
due to changes in interest rates, or we may suffer losses in principal if forced to sell securities which have declined in market
value due to changes in interest rates or other factors, such as changes in credit risk related to the securities&#8217; issuers.
To minimize this risk, we schedule our investments to have maturities that coincide with our expected cash flow needs, thus avoiding
the need to redeem an investment prior to its maturity date. Accordingly, we do not believe that we have material exposure to interest
rate risk arising from our investments. Generally, our investments are not collateralized. We have not realized any significant
losses from our investments.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We do not use interest rate derivative instruments to manage exposure
to interest rate changes. We ensure the safety and preservation of invested principal funds by limiting default risk, market risk
and reinvestment risk. We reduce default risk by investing in investment grade securities.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><i>Foreign Currency Risk</i></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The majority of our transactions occur in U.S. dollars and we do not
have operating subsidiaries or investments in foreign countries. Therefore, we are not subject to significant foreign currency
exchange risk in our normal operations.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In connection with the issuance by Royalty Sub of the PhaRMA Notes,
we entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative
to the U.S. dollar. Under the Currency Hedge Agreement, we are required to post collateral based on our potential obligations under
the Currency Hedge Agreement as determined by periodic mark-to-market adjustments. Provided the Currency Hedge Agreement remains
in effect, we may be required to pay an annual premium in the amount of $2.0&nbsp;million from May&nbsp;2017 through May&nbsp;2020.
Such payment will be required if, in May of the relevant year, the spot rate of exchange for Japanese yen-U.S. dollars (determined
in accordance with the Currency Hedge Agreement) is such that the U.S. dollar is worth 100 yen or less.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><b><a name="a_008"></a>Item&nbsp;4. &nbsp;&nbsp;&nbsp;&nbsp;Controls and Procedures</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We maintain a set of disclosure controls and procedures that are designed
to ensure that information relating to BioCryst Pharmaceuticals, Inc. required to be disclosed in our periodic filings under the
Exchange Act is recorded, processed, summarized and reported in a timely manner under the Exchange Act. We carried out an evaluation,
under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer,
of the effectiveness of the design and operation of our disclosure controls and procedures. Based upon that evaluation, the Chief
Executive Officer and Chief Financial Officer concluded that, as of June&nbsp;30, 2016, the Company&#8217;s disclosure controls
and procedures are effective to ensure that information required to be disclosed by the Company in the reports filed or submitted
by it under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s
rules and forms, and include controls and procedures designed to ensure that information required to be disclosed by the Company
in such reports is accumulated and communicated to the Company&#8217;s management, including the Chief Executive Officer and Chief
Financial Officer of the Company, as appropriate to allow timely decisions regarding required disclosure.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">There have been no changes in our internal control over financial
reporting that occurred during the quarter ended June&nbsp;30, 2016 that have materially affected, or are reasonably likely to
materially affect, the Company&#8217;s internal control over financial reporting.&nbsp;</p>

<p style="font-size: 10pt; text-align: right; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 33; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>PART II. OTHER INFORMATION</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><b><a name="a_009"></a>ITEM&nbsp;1A.</b> <b><i>&nbsp;&nbsp;&nbsp;&nbsp;RISK FACTORS</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><i>An investment in our stock involves risks. You should carefully
read this entire report and consider the following uncertainties and risks, which may adversely affect our business, financial
condition or results of operations, along with all of the other information included in our other filings with the Securities and
Exchange Commission, before deciding to buy our common stock.</i></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Risks Relating to Our Business</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>We have incurred losses since our inception, expect to continue to incur
such losses, and may never be profitable.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Since our inception, we have not achieved sustained profitability.
We expect to incur additional losses for the foreseeable future, and our losses could increase as our research and development
efforts progress. We expect that such losses will fluctuate from quarter to quarter and losses and fluctuations may be substantial.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">To become profitable, we, or our collaborative partners, must successfully
manufacture and develop product candidates, receive regulatory approval, and successfully commercialize and/or enter into profitable
agreements with other parties. It could be several years, if ever, before we receive significant revenue from any current or future
license agreements or revenues directly from product sales.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Because of the numerous risks and uncertainties associated with developing
our product candidates and their potential for commercialization, we are unable to predict the extent of any future losses. Even
if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. If we are
unable to achieve and sustain profitability, the market value of our common stock will likely decline.&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Our success depends upon our ability to advance our products through
the various stages of development, especially through the clinical trial process.</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">To receive the regulatory approvals necessary for the sale of
our product candidates, we or our partners must demonstrate through preclinical studies and clinical trials that each product candidate
is safe and effective. The development process and related regulatory process are complex and uncertain. Because of the cost and
duration of clinical trials, we may decide to discontinue development of product candidates that are unlikely to show good results
in the clinical trials, unlikely to help advance a product to the point of a meaningful collaboration, or unlikely to have reasonable
commercial potential. We may suffer significant setbacks in pivotal pre-clinical studies and clinical trials (e.g. BCX4430, BCX7353,
other kallikrein inhibitors and our other rare disease product candidates), even after earlier clinical trials show promising results.
The development of our product candidates, including our clinical trials, may not be adequately designed or executed, which could
affect the potential outcome and analysis of study results. Any of our product candidates may produce undesirable side effects
in humans. The pre-clinical and clinical data from our product candidates could cause us or regulatory authorities to interrupt,
delay, modify or halt preclinical or clinical trials of a product candidate. Undesirable or inconclusive data or side effects in
humans could also result in the FDA or foreign regulatory authorities refusing to approve the product candidate for any targeted
indications. In addition, the FDA or other regulatory agencies may determine that study data from our product candidates necessitates
additional studies or study designs which differ from our planned development strategy, and regulatory agencies may also require
patient monitoring and testing or may implement restrictions or other conditions on our development activities, any of which could
materially impact the cost and timing of our planned development strategy. We, our partners, the FDA or foreign regulatory authorities
may suspend or terminate clinical trials at any time if we or they believe the trial participants face unacceptable health risks.
Clinical trials may fail to demonstrate that our product candidates are safe or effective and have acceptable commercial viability.
Regulatory authorities may interrupt, delay or halt clinical trials for a product candidate for any number of reasons.</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our ability to successfully complete clinical trials is dependent
upon many factors, including but not limited to:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom; width: 95%"><font style="font-size: 10pt">our ability to find suitable clinical sites and investigators to enroll patients;</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom; width: 95%"><font style="font-size: 10pt">the ability to maintain contact with patients to provide complete data after treatment;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom"><font style="font-size: 10pt">our product candidates may not prove to be either safe or effective;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom"><font style="font-size: 10pt">clinical protocols or study procedures may not be adequately designed or followed by the investigators;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom"><font style="font-size: 10pt">formulation improvements may not work as expected, which could negatively impact commercial demand for our product candidates;</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom; width: 95%"><font style="font-size: 10pt">manufacturing or quality control problems could affect the supply of product candidates for our trials; and</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="vertical-align: bottom"><font style="font-size: 10pt">delays or changes in our planned development strategy, the regulations or guidelines, or other unexpected conditions or requirements by governmental agencies.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 34; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Clinical trials are lengthy and expensive. We or our partners incur
substantial expense for, and devote significant time to, preclinical testing and clinical trials, yet we cannot be certain that
the tests and trials will ever result in the commercial sale of a product. For example, clinical trials require adequate supplies
of drug and sufficient patient enrollment. Lack of adequate drug supply or delays in patient enrollment can result in increased
costs and longer development times. Even if we or our partners successfully complete clinical trials for our product candidates,
we or our partners might not file the required regulatory submissions in a timely manner and may not receive regulatory approval
for the product candidates.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 20pt">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>We focus on rare diseases, which may create additional risks and challenges.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Because we focus on developing drugs as treatments for rare diseases,
we may seek orphan drug, breakthrough therapy or fast track designations for our product candidates in the United States or the
equivalent designations elsewhere in the world. Often, regulatory agencies have broad discretion in determining whether or not
to grant such designations. We cannot guarantee that we will be able to receive orphan drug status from the FDA or equivalent regulatory
designations elsewhere. We also cannot guarantee that we will obtain breakthrough therapy or fast track designation, which may
provide certain potential benefits such as more frequent meetings with the FDA to discuss the development plan, intensive guidance
on an efficient drug development program, and potential eligibility for rolling review or priority review. Even if we are successful
in obtaining any such designation by the FDA or other regulatory agency for our product candidates, such designations may not lead
to faster development or regulatory review or approval, and it does not increase the likelihood that our product candidates will
receive marketing approval. We may not be able to obtain or maintain such designations for our product candidates, and our competitors
may obtain these designations for their product candidates, which could impact our ability to develop and commercialize our product
candidates or compete with such competitors, which may adversely impact our business, financial condition or results of operations.</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Although we have received Sakigake designation
for BCX7353 in Japan, we may not experience a faster development, review or approval process compared to the conventional process.</P>


<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Our clinical trials may not adequately show that our product candidates
are safe or effective.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0">Progression of our product candidates through
the clinical development process is dependent upon our trials indicating our product candidates have adequate safety and efficacy
in the patients being treated by achieving pre-determined safety and efficacy endpoints according to the clinical trial protocols.
Failure to achieve any of these endpoints in any of our programs, including BCX7353, and our other rare disease product candidates,
could result in delays in our trials or require the performance of additional unplanned trials. This could result in delays in
the development of our product candidates and could result in significant unexpected costs or the termination of programs.</P>



<P STYLE="font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>If our development collaborations with third parties, such as our development
partners and contract research organizations, fail, the development of our product candidates will be delayed or stopped.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We rely heavily upon third parties for many important stages
of our product candidate development, including but not limited to:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">discovery of compounds that cause or enable biological reactions necessary for the progression of the disease or disorder, called enzyme targets;</font></td></tr>
<tr style="vertical-align: top">
    <td colspan="3">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">licensing or designing of enzyme inhibitors for development as product candidates;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">execution of certain preclinical studies and late-stage development for our compounds and product candidates;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">management of our clinical trials, including medical monitoring and data management;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">execution of additional toxicology studies that may be required to obtain approval for our product candidates;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">formulation improvement strategies and methods; and</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">manufacturing the starting materials and drug substance required to formulate our products and the product candidates to be used in our clinical trials, toxicology studies and any potential commercial product.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 35; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our failure to engage in successful collaborations at any one of these
stages would greatly impact our business. If we do not license enzyme targets or inhibitors from academic institutions or from
other biotechnology companies on acceptable terms, our drug development efforts would suffer. Similarly, if the contract research
organizations that conduct our initial or late-stage clinical trials, conduct our toxicology studies, manufacture our starting
materials, drug substance and product candidates or manage our regulatory function breached their obligations to us or perform
their services inconsistent with industry standards and not in accordance with the required regulations, this would delay or prevent
both the development of our product candidates and the availability of any potential commercial product.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If we lose our relationship with any one or more of these parties,
we could experience a significant delay in both identifying another comparable provider and then contracting for its services.
We may be unable to retain an alternative provider on reasonable terms, if at all. Even if we locate an alternative provider, it
is likely that this provider may need additional time to respond to our needs and may not provide the same type or level of service
as the original provider. In addition, any provider that we retain will be subject to applicable FDA current Good Laboratory Practices
(&#8220;cGLP&#8221;), current Good Manufacturing Practices (&#8220;cGMP&#8221;) and current Good Clinical Practices (&#8220;cGCP&#8221;),
and comparable foreign standards. We do not have control over compliance with these regulations by these providers. Consequently,
if these practices and standards are not adhered to by these providers, the development and commercialization of our product candidates
could be delayed. If any of the foregoing risks are realized, our business, financial condition and results of operations could
be materially adversely affected.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>Because we have limited manufacturing experience, we depend on third-party
manufacturers to manufacture our product, product candidates and the materials for our product candidates. Often, especially early
in the development and commercialization process, we have only one source for manufacturing. If we cannot rely on existing third-party
manufacturers, we will be required to incur significant costs and potential delays in finding new third-party manufacturers.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We have limited manufacturing experience and only a small scale manufacturing
facility. We currently rely upon a very limited number of third-party manufacturers to manufacture the materials required for our
product, product candidates and most of the preclinical and clinical quantities of our product candidates. We depend on these third-party
manufacturers to perform their obligations in a timely manner and in accordance with applicable governmental regulations. Our third-party
manufacturers, which may be the only manufacturer we have engaged for a particular product, may encounter difficulties with meeting
our requirements including but not limited to problems involving:</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">inconsistent production yields;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">product liability claims or recalls of commercial product;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">difficulties in scaling production to commercial and validation sizes;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">interruption of the delivery of materials required for the manufacturing process;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">scheduling of plant time with other vendors or unexpected equipment failure;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">potential catastrophes that could strike their facilities or have an effect on infrastructure;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">potential impurities in our drug substance or products that could affect availability of product for our clinical trials or future commercialization;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">poor quality control and assurance or inadequate process controls; and</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">lack of compliance or cooperation with regulations and specifications or requests set forth by the FDA
or other foreign regulatory agencies, particularly associated with RAPIVAB and planned studies for BCX7353, BCX4430 and our early
stage compounds.</font></td></tr>
</table>
<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">These contract manufacturers may not be able to manufacture the materials
required for our product candidates at a cost or in quantities necessary to make them commercially viable. We also have no control
over whether third-party manufacturers breach their agreements with us or whether they may terminate or decline to renew agreements
with us. To date, our third-party manufacturers have met our manufacturing requirements, but they may not continue to do so. Furthermore,
changes in the manufacturing process or procedure, including a change in the location where the drug is manufactured or a change
of a third-party manufacturer, may require prior review and approval in accordance with the FDA&#8217;s cGMP and comparable foreign
requirements. This review may be costly and time-consuming and could delay or prevent the launch of a product. The FDA or similar
foreign regulatory agencies may at any time implement new standards, or change their interpretation and enforcement of existing
standards for manufacture, packaging or testing of products. If we or our contract manufacturers are unable to comply, we or they
may be subject to regulatory action, civil actions or penalties any of which could be costly to the Company and could result in
a delay or shortage of product.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 36; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If we are unable to maintain current manufacturing or other contract
relationships, or enter into new agreements with additional manufacturers on commercially reasonable terms, or if there is poor
manufacturing performance or failure to comply with any regulatory agency on the part of any of our third-party manufacturers,
we may not be able to complete development of, seek timely approval of, or market, our product candidates.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our raw materials, drug substances, and product candidates are manufactured
by a limited group of suppliers, including some at a single facility. If any of these suppliers were unable to produce these items,
this could significantly impact our supply of product candidate material for further preclinical testing and clinical trials.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>We face intense competition, and if we are unable to compete effectively,
the demand for our products, if any, may be reduced.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The biotechnology and pharmaceutical industries are highly competitive
and subject to rapid and substantial technological change. There are many companies seeking to develop products for the same indications
that we currently target. Our competitors in the United States and elsewhere are numerous and include, among others, major multinational
pharmaceutical and chemical companies and specialized biotechnology firms. Most of these competitors have greater resources than
we do, including greater financial resources, larger research and development staffs and more experienced marketing and manufacturing
organizations. In addition, most of our competitors have greater experience than we do in conducting clinical trials and obtaining
FDA and other regulatory approvals. Accordingly, our competitors may succeed in obtaining FDA or other regulatory approvals of
product candidates more rapidly than we do. Companies that complete clinical trials, obtain required regulatory approvals, and
commence commercial sale of their drugs before we do may achieve a significant competitive advantage, including patent and FDA
exclusivity rights that would delay our ability to market products. We face, and will continue to face, competition in the licensing
of potential product candidates for desirable disease targets licensing of desirable product candidates, and development and marketing
of our product candidates from academic institutions, government agencies, research institutions and biotechnology and pharmaceutical
companies. Competition may also arise from, among other things:</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">other drug development technologies;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">methods of preventing or reducing the incidence of disease, including vaccines;&nbsp;and</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">new small molecule or other classes of therapeutic agents.</font></td></tr>
</table>
<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Developments by others may render our product candidates or technologies
obsolete or noncompetitive.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We and our partners are performing research on or developing products
for the treatment of several disorders including HAE and recurrent/refractory peripheral T-cell lymphoma, as well as broad spectrum
antivirals that may be developed as medical countermeasures. We expect to encounter significant competition for any of the pharmaceutical
products we plan to develop. Companies that complete clinical trials, obtain required funding or government support, obtain required
regulatory approvals and commence commercial sales or stockpiling orders of their products before their competitors may achieve
a significant competitive advantage. Such is the case with Eisai Co. Ltd.&#8217;s TARGRETIN <sup>&#174;</sup> for cutaneous T-lymphoma;
the current neuraminidase inhibitors marketed by GSK and Roche for influenza; CINRYZE <sup>&#174;</sup> , KALBITOR <sup>&#174;</sup>
and FIRAZYR <sup>&#174;</sup> , marketed by Shire Pharmaceuticals, Inc. for HAE; and BERINERT <sup>&#174;</sup> , marketed by CSL
for HAE. Therapeutic products with potentially promising data to treat Ebola include Mapp Biopharmaceutical, Inc.&#8217;s ZMapp
(antibody-based) and Gilead Sciences, Inc.&#8217;s product currently under development (small molecule), both of which have been
used in Ebola infected patients. Further, several pharmaceutical and biotechnology firms, including major pharmaceutical companies
and specialized structure-based drug design companies, have announced efforts in the field of structure-based drug design and molecules
in development in the fields of HAE and in other therapeutic areas where we have discovery and development efforts ongoing. If
one or more of our competitors&#8217; products or programs are successful, the market for our products may be reduced or eliminated.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Compared to us, many of our competitors and potential competitors
have substantially greater:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">capital resources;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">research and development resources, including personnel and technology;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td>
        <p style="font-size: 10pt; margin: 0pt 0.8pt 0pt 0">regulatory experience;</p>
        <p style="font-size: 10pt; margin: 0pt 0.8pt 0pt 0"></p></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">preclinical study and clinical testing experience;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">manufacturing and marketing experience;&nbsp;and</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">production facilities.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 37; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Any of these competitive factors could impede our funding efforts,
render technology and product candidates noncompetitive or eliminate or reduce demand for our product candidates.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>We face risks related to our government-funded programs; if BARDA/HHS
or NIAID/HHS were to eliminate, reduce or delay funding from our contracts, this would have a significant negative impact on the
programs associated with such funding and could have a significant negative impact on our revenues and cash flows.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our projections of revenues and incoming cash flows are substantially
dependent upon BARDA/HHS and NIAID/HHS reimbursement for the costs related to our BCX4430 program. If BARDA/HHS or NIAID/HHS were
to eliminate, reduce or delay the funding for these programs or disallow some of our incurred costs, we would have to obtain additional
funding for continued development or regulatory registration for these product candidates or significantly reduce or stop the development
effort.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In contracting with BARDA/HHS and NIAID/HHS, we are subject to various
U.S. Government contract requirements, including general clauses for a cost-reimbursement research and development contract, which
may limit our reimbursement or if we are found to be in violation could result in contract termination. If the U.S. Government
terminates any of its contracts with us for its convenience, or if we default by failing to perform in accordance with the contract
schedule and terms, significant negative impact on our cash flows and operations could result.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>Our government contracts with BARDA/HHS and NIAID/HHS have special contracting
requirements, which create additional risks of reduction or loss of funding.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 20pt">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">We have completed work under a contract with
BARDA/HHS for the development of our neuraminidase inhibitor, RAPIVAB. We also have entered into contracts with BARDA/HHS and NIAID/HHS
for the development of BCX4430 as a treatment for diseases caused by RNA pathogens, including Marburg virus disease and Ebola virus
disease. In contracting with these government agencies, we are subject to various U.S. Government contract requirements, including
general clauses for a cost-reimbursement research and development contract, which may limit our reimbursement or, if we are found
to be in violation, could result in contract termination.</P>



<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">U.S. Government contracts typically contain a number of extraordinary
provisions that would not typically be found in commercial contracts and which may create a disadvantage and additional risks to
us as compared to competitors that do not rely on U.S. Government contracts. These risks include the ability of the U.S. Government
to unilaterally:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">terminate or reduce the scope of our contract with or without cause;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">interpret relevant regulations (federal acquisition regulation clauses);</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">require performance under circumstances which may not be favorable to us;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">require an in process review where the U.S. Government will review the project and its options under the contract;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">control the timing and amount funding, which impacts the development progress of our programs; and</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">audit and object to our contract-related costs and fees, including allocated indirect costs.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>Our government contracts with BARDA/HHS and NIAID/HHS have termination
and audit provisions which create additional risks to us.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The U.S. Government may terminate its contracts with us either for
its convenience or if we default by failing to perform in accordance with the contract schedule and terms. Termination for convenience
provisions generally enable us to recover only our costs incurred or committed, and settlement expenses and profit on the work
completed prior to termination. Termination does not permit these recoveries under default provisions. In the event of termination
or upon expiration of a contract, the U.S. Government may dispute wind-down and termination costs and may question prior expenses
under the contract and deny payment of those expenses. Should we choose to challenge the U.S. Government for denying certain payments
under a contract, such a challenge could subject us to substantial additional expenses which we may or may not recover. Further,
if the U.S. Government terminates its contracts with us for its convenience, or if we default by failing to perform in accordance
with the contract schedule and terms, significant negative impact on our cash flows and operations could result.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 38; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As a U.S. Government contractor, we are required to comply with applicable
laws, regulations and standards relating to our accounting practices and are subject to periodic audits and reviews. As part of
any such audit or review, the U.S. Government may review the adequacy of, and our compliance with, our internal control systems
and policies, including those relating to our purchasing, property, estimating, compensation and management information systems.
Audits conducted by the U.S. Government for the completed BARDA/HHS contract have been performed and concluded through fiscal 2009;
all subsequent fiscal years are still open and auditable. Audits under the active BARDA/HHS and NIAID/HHS contracts may occur at
the election of the U.S. Government and have been concluded through fiscal 2013. Based on the results of its audits, the U.S. Government
may adjust our contract-related costs and fees, including allocated indirect costs. This adjustment could impact the amount of
revenues reported on a historic basis and could impact our cash flows under the contracts prospectively. In addition, in the event
BARDA/HHS or NIAID/HHS determines that certain costs and fees were unallowable or determines that the allocated indirect cost rate
was higher than the actual indirect cost rate, BARDA/HHS or NIAID/HHS would be entitled to recoup any overpayment from us as a
result. In addition, if an audit or review uncovers any improper or illegal activity, we may be subject to civil and criminal penalties
and administrative sanctions, including termination of our contracts, forfeiture of profits, suspension of payments, fines and
suspension or prohibition from doing business with the U.S. Government. We could also suffer serious harm to our reputation if
allegations of impropriety were made against us. In addition, under U.S. Government purchasing regulations, some of our costs may
not be reimbursable or allowed under our contracts. Further, as a U.S. Government contractor, we are subject to an increased risk
of investigations, criminal prosecution, civil fraud, whistleblower lawsuits and other legal actions and liabilities as compared
to private sector commercial companies.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>If we fail to reach milestones or to make annual minimum payments or
otherwise breach our obligations under our license agreements, our licensors may terminate our agreements with them and seek additional
remedies.</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If we are unable or fail to meet payment obligations, performance
milestones relating to the timing of regulatory filings, product supply obligations, post approval commitments for RAPIVAB, or
development and commercial diligence obligations; are unable or fail to make milestone payments or material data use payments in
accordance with applicable provisions; or fail to pay the minimum annual payments under our respective licenses, our licensors
may terminate the applicable license or seek other available remedies. As a result, our development of the respective product candidate
or commercialization of the product would cease.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>If we fail to obtain additional financing or acceptable partnership
arrangements, we may be unable to complete the development and commercialization of our product candidates or continue operations.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As our programs advance, our costs are likely to increase. Our current
and planned discovery activities, pre-clinical and clinical trials, the related development, manufacturing, regulatory approval
process requirements, and the additional personnel resources and testing required for supporting the development of our product
candidates will consume significant capital resources. Our expenses, revenues and cash utilization rate could vary significantly
depending on many factors, including: our ability to raise additional capital; the development progress of our collaborative agreements
for our product candidates; the amount of funding we receive from NIAID/HHS and BARDA/HHS for BCX4430 or from other new partnerships
with third parties for the development of our product candidates, including BCX7353 and our other rare disease product candidates;
the commercial success of peramivir achieved by our partners; the amount or profitability of any orders for RAPIVAB or BCX4430
by any government agency or other party; the progress and results of our current and proposed clinical trials for our most advanced
product candidates, including BCX7353 and our other rare disease product candidates; the progress made in the manufacture of our
lead products and the progression of our other programs.&nbsp;</P>



<P STYLE="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We expect that we will be required to raise additional capital to
complete the development and commercialization of our current product candidates and we may seek to raise capital at any time.
Additional funding, whether through additional sales of securities or collaborative arrangements with partners, including governmental
agencies in general and from any BARDA/HHS or NIAID/HHS contract specifically, may not be available when needed or on terms acceptable
to us. The issuance of preferred or common stock or convertible securities, with terms and prices significantly more favorable
than those of the currently outstanding common stock, could have the effect of diluting or adversely affecting the holdings or
rights of our existing stockholders. In addition, collaborative arrangements may require us to transfer certain material rights
to such corporate partners. Insufficient funds or lack of an acceptable partnership may require us to delay, scale-back or eliminate
certain of our research and development programs.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">In order to continue future operations and continue our drug development
programs, we will be required to raise additional capital. In addition to seeking strategic partnerships, transactions and government
funding, we may decide to access the equity or debt markets or seek other sources to meet liquidity needs. Our ability to raise
additional capital may be limited and may greatly depend upon the success of ongoing development related to our current drug development
programs, including post approval studies for RAPIVAB,&nbsp;the progress, timeline and ultimate outcome of&nbsp;our kallikrein
inhibitor, including the BCX7353 program (including, but not limited to, formulation progress, phase 3 trials, long-term human
safety studies, and the timing of carcinogenicity or other required studies), the progress our other rare disease product candidates,
funding for and continued successful development of BCX4430, and the progress of our early discovery programs. In addition, constriction
and volatility in the equity and debt markets may restrict our future flexibility to raise capital when such needs arise. Furthermore,
we have exposure to many different industries, financing partners and counterparties, including commercial banks, investment banks
and partners (which include investors, licensing partners, and the U.S. Government) which may be unstable or may become unstable
in the current economic and political environment. Any such instability may impact these parties&rsquo; ability to fulfill contractual
obligations to us or they might limit or place burdensome conditions upon future transactions with us. Also, it is possible that
suppliers may be negatively impacted. Any such unfavorable outcomes in our current programs or unfavorable economic conditions
could place severe downward pressure on the price of our common stock and may decrease opportunities to raise capital in the capital
or credit markets, and further could reduce the return available on invested corporate cash, which, if severe and sustained, could
have a material and adverse impact on our results of operations and cash flows and limit our ability to continue development of
our product candidates.</P>



<P STYLE="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i></i></b></p>

<!-- Field: Page; Sequence: 39; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>If we fail to successfully commercialize or establish collaborative
relationships to commercialize certain of our product candidates, or if any partner terminates or fails to perform its obligations
under agreements with us, potential revenues from commercialization of our product candidates could be reduced, delayed or eliminated.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our business strategy is to increase the asset value of our product
candidate portfolio. We believe this is best achieved by retaining full product rights or through collaborative arrangements with
third parties as appropriate. As needed, potential third-party relationships could include preclinical development, clinical development,
regulatory approval, marketing, sales and distribution of our product candidates.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Currently, we have established collaborative relationships with Mundipharma
for the development and commercialization of forodesine and with each of Shionogi and Green Cross for the development and commercialization
of peramivir, in Japan, Taiwan and South Korea. Most recently we have established a collaborative relationship with Seqirus UK
Limited for RAPIVAB in the United States and countries other than Israel, Japan, Korea and Taiwan. The process of establishing
and implementing collaborative relationships is difficult, time-consuming and involves significant uncertainty, including:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">our partners may seek to renegotiate or terminate their relationships with us due to unsatisfactory clinical results, including post approval clinical commitments, a change in business strategy, a change of control or other reasons;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">our contracts for collaborative arrangements may expire;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">our partners may choose to pursue alternative technologies, including those of our competitors;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">we may have disputes with a partner that could lead to litigation or arbitration;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">we do not have day to day control over the activities of our partners and have limited control over their decisions;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">our ability to generate future event payments and royalties from our partners depends upon their abilities to establish the safety and efficacy of our product candidates, obtain regulatory approvals and achieve market acceptance of products developed from our product candidates;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">we or our partners may fail to properly initiate, maintain or defend our intellectual property rights, where applicable, or a party may utilize our proprietary information in such a way as to invite litigation that could jeopardize or potentially invalidate our proprietary information or expose us to potential liability;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">we or our partners may not devote sufficient capital or resources towards our product candidates; and</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">we or our partners may not comply with applicable government regulatory requirements.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If we or our partners fail to fulfill our responsibilities in
a timely manner, or at all, our commercialization efforts related to that collaboration could be reduced, delayed or terminated,
or it may be necessary for us to assume responsibility for activities that would otherwise have been the responsibility of our
partner. If we are unable to establish and maintain collaborative relationships on acceptable terms, we may have to delay or discontinue
further development of one or more of our product candidates, undertake commercialization activities at our own expense or find
alternative sources of funding. Any delay in the development or commercialization of our product candidates would severely affect
our business, because if our product candidates do not progress through the development process or reach the market in a timely
manner, or at all, we may not receive additional future event payments and may never receive milestone, product sales or royalty
payments.&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>We do not have a great deal of experience in commercializing our products
or technologies, and our future revenue generation is uncertain.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We do not have a great deal of experience in commercializing
our products or technologies. We currently have limited marketing and commercial capability, no direct or third-party sales force
and limited distribution capabilities. We may be unable to establish or sufficiently increase these capabilities for products we
currently, or plan to, commercialize. In addition, our revenue from collaborative agreements may be dependent upon the status of
our preclinical and clinical programs. If we fail to advance these programs to the point of being able to enter into successful
collaborations, we will not receive any potential future event or other collaborative payments.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 40; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our ability to receive revenue from products we commercialize presents
several risks, including:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">we or our collaborators may fail to successfully complete clinical trials, or satisfy post-marketing commitments, sufficient to obtain and keep FDA marketing approval;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">many competitors are more experienced and have significantly more resources, and their products could reach the market faster, be more cost effective or have a better efficacy or tolerability profile than our product candidates;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">we may fail to employ a comprehensive and effective intellectual property strategy, which could result in decreased commercial value of our Company and our products;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">we may fail to employ a comprehensive and effective regulatory strategy, which could result in a delay or failure in commercialization of our products;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">our ability to successfully commercialize our products is affected by the competitive landscape, which cannot be fully known at this time;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">reimbursement is constantly changing, which could greatly affect usage of our products; and</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">future revenue from product sales would depend on our ability to successfully complete clinical studies, obtain regulatory approvals, and manufacture, market and commercialize our approved drugs.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Commercialization of RAPIVAB by our partners is subject to the potential
commercialization risks described herein and numerous additional risks. Any potential revenue benefits to us in the form of milestone
payments, royalties or other consideration are highly speculative.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Commercialization success of RAPIVAB is uncertain and is subject
to all the risks and uncertainties disclosed in our other risk factors relating to drug development and commercialization. In addition,
commercialization of RAPIVAB is subject to further risks and may be negatively impacted by a number of factors, including, but
not limited to, the following:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">RAPIVAB may not prove to be adequately safe and effective for market approval in markets other than the United States;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">necessary funding for post-marketing commitments and further development of RAPIVAB may not be available timely, at all, or in sufficient amounts;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">flu prevention or pandemic treatment concerns may not materialize at all, or in the near future;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">advances in flu vaccines or other antivirals, including competitive i.v. antivirals, could substantially replace potential demand for RAPIVAB;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">a limited number of governmental entities are expected to be the primary potential stockpiling customers for RAPIVAB and if we are not successful at marketing RAPIVAB to these entities for any reason, we will not receive substantial revenues from stockpiling orders;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">government and third party payors may not provide sufficient coverage or reimbursement which would negatively impact the demand for RAPIVAB;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">we may not be able to supply commercial material to our partners and our partners may not be able to maintain or establish sufficient and acceptable commercial manufacturing, either directly or through third-party manufacturers;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">the commercial demand and acceptance for RAPIVAB by healthcare providers and by patients may not be sufficient to result in substantial revenues of RAPIVAB to our partners and may result in little to no milestones or royalties to us;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">effectiveness of marketing efforts for RAPIVAB by our partners;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">market satisfaction with existing alternative therapies;</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">perceived efficacy relative to other available therapies;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">disease prevalence;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">cost of treatment;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom"></td></tr></table>

<!-- Field: Page; Sequence: 41; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->


<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%">&nbsp;</td>
    <td style="width: 95%">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">pricing and availability of alternative products;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">marketing and sales activities of competitors;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">shifts in the medical community to new treatment paradigms or standards of care; and</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">relative convenience and ease of administration.</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>We are subject to various federal and state laws related to RAPIVAB and
other products under development and, if we or our partners do not comply with these regulations, we could face substantial penalties.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our or our partners&#8217; activities related to RAPIVAB, or any of
our other products under development and following their regulatory approval, are subject to regulatory and law enforcement authorities
in addition to the FDA, including the Federal Trade Commission, the Department of Justice, and state and local governments. In
the case of our collaboration with SUL, although SUL is responsible for RAPIVAB marketing and commercialization efforts, we continue
to carry certain risks associated with RAPIVAB because we hold the RAPIVAB NDA. For example, we are responsible for reporting adverse
drug experiences, we have responsibility for certain post-approval studies, we may have responsibilities and costs related to a
recall or withdrawal of RAPIVAB from sale, we may incur liability associated with RAPIVAB manufacturing contracted by us or in
support of any of our partners, we are required to maintain records and provide data and reports to regulatory agencies related
to RAPIVAB (e.g. risk evaluation and mitigation strategies, track and trace requirements, adverse events), and we may incur certain
promotional regulatory and government pricing risks, all of which could have a material adverse impact on our operations and financial
condition. In addition, we are now subject to the federal physician sunshine act and certain similar legislation in various states.
We are subject to various federal and state laws pertaining to health care &#8220;fraud and abuse,&#8221; including both federal
and state anti-kickback laws. Although we seek to comply with these statutes, it is possible that our practices, or those of our
distributors, might be challenged under anti-kickback or similar laws. Violations of the physician sunshine act and similar state
legislation or the fraud and abuse laws may be punishable by civil or criminal sanctions, including fines and civil monetary penalties,
and future exclusion from participation in government healthcare programs.&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We have a number of outstanding post-marketing commitments to the
FDA that we retain, despite our partnership with SUL, which we may not complete successfully or on time for any number of reasons,
including but not limited to lack of funds to complete the studies and insufficient interest by appropriate sites, investigators
or study subjects. For example, as a condition of the approval of RAPIVAB, we are required to complete a pediatric patient study
of RAPIVAB and to submit the final results of this clinical trial to the FDA. Depending on the outcome of this clinical trial,
we may be unable to expand the indication for RAPIVAB or we may be required to include specific warnings or limitations on dosing
this product, which could negatively impact sales of RAPIVAB and negatively impact our relationship with our partner. We may be
subject to penalties if we fail to comply with post-approval legal and regulatory requirements and our products could be subject
to continual recordkeeping and reporting requirements, review and periodic inspections by the FDA and other regulatory bodies.
Regulatory approval of a product may be subject to limitations on the indicated uses for which the product may be marketed or to
the other restrictive conditions of approval that limit our ability to promote, sell or distribute a product. Furthermore, the
approval of RAPIVAB and any other future product candidates may be subject to requirements for costly post-marketing testing and
surveillance to monitor its safety or efficacy.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Advertising and promotion are subject to stringent FDA rules and oversight
and as the holder of the NDA we may be held responsible for any advertising and promotion conducted by our partner that is not
in compliance with the rules and regulations. In particular, the claims in all promotional materials and activities must be consistent
with the FDA approvals for approved products, and must be appropriately substantiated and fairly balanced with information on the
safety risks and limitations of the products. Adverse event information concerning approved products must be reviewed and as the
NDA holder of RAPIVAB we are required to make expedited and periodic adverse event reports to the FDA and other regulatory authorities.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In addition, the research, manufacturing, distribution, sale and promotion
of products are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including
the Centers for Medicare and Medicaid Services, other divisions of the U.S. Department of Health and Human Services, the U.S. Department
of Justice and individual U.S. Attorney offices within the Department of Justice, and state and local governments. Until we can
successfully transfer the pricing responsibilities to our partner, we remain responsible for pricing and rebate programs. Pricing
and rebate programs must comply with the Medicaid rebate requirements of the Omnibus Budget Reconciliation Act of 1990, as amended,
and the Veterans Health Care Act of 1992, as amended. If products are made available to authorized users of the Federal Supply
Schedule of the General Services Administration, additional laws and requirements apply. All of these activities are also potentially
subject to federal and state consumer protection and unfair competition laws.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>



<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If our operations with respect to RAPIVAB or our other products that
are subject to healthcare laws and regulations are found to be in violation of any of the healthcare fraud and abuse laws described
above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties,
damages, fines and the curtailment or restructuring of our operations. Any penalties, damages, fines, curtailment or restructuring
of our operations could adversely affect our ability to operate our business and our financial results. Although compliance programs
can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Any
action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal
expenses and divert our management's attention from the operation of our business. Moreover, achieving and sustaining compliance
with all applicable federal and state fraud and abuse laws may be costly.&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i></i></b></p>

<!-- Field: Page; Sequence: 42; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>We and our partners may be subject to new legislation, regulatory proposals
and healthcare payor initiatives that may increase our costs of compliance and adversely affect our or our partners&#8217; ability
to market our products, including RAPIVAB, obtain collaborators and raise capital.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Patient Protection and Affordable Care Act, or PPACA, made extensive
changes to the delivery of health care in the U.S. The PPACA includes numerous provisions that affect pharmaceutical companies,
some of which became effective immediately and others of which will be taking effect over the next several years. For example,
the PPACA seeks to expand health care coverage to the uninsured through private health insurance reforms and an expansion of Medicaid.
The PPACA will also impose substantial costs on pharmaceutical manufacturers, such as an increase in liability for rebates paid
to Medicaid, new drug discounts that must be offered to certain enrollees in the Medicare prescription drug benefit, an annual
fee imposed on all manufacturers of brand prescription drugs in the U.S., and an expansion of an existing program requiring pharmaceutical
discounts to certain types of hospitals and federally subsidized clinics. The PPACA also contains cost containment measures that
could reduce reimbursement levels for health care items and services generally, including pharmaceuticals. It also will require
reporting and public disclosure of payments and other transfers of value provided by pharmaceutical companies to physicians and
teaching hospitals. We cannot predict what effect the PPACA or other healthcare reform initiatives that may be adopted in the future
will have on our business. Further, it remains unclear whether there will be any changes made to provisions of the PPACA or other
health care laws through acts of Congress in the future. The continuing efforts of the government, insurance companies, managed
care organizations and other payors of health care services to contain or reduce costs of health care could result in decreased
net revenues from our pharmaceutical products and decrease potential returns from our development efforts. In addition, pharmaceutical
and device manufacturers will also be required to report and disclose investment interests held by physicians and their immediate
family members during the preceding calendar year. Failure to submit required information may result in civil monetary penalties
for payments, transfers of value or ownership or investment interests not reported in an annual submission. Compliance with the
PPACA and state laws with similar provisions is difficult and time consuming, and companies that do not comply with these state
laws face civil penalties. Because of the breadth of these laws and the narrowness of the safe harbors, it is possible that some
of our business activities could be subject to challenge under one or more of such laws. Such a challenge could have a material
adverse effect on our business, financial condition, results of operations and growth prospects.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In addition, there have been a number of other legislative and regulatory
proposals aimed at changing the pharmaceutical industry. In particular, legislation has been enacted in certain states and proposed
at a federal level that requires development of an electronic pedigree to track and trace each prescription drug at the saleable
unit level through the distribution system. Compliance with these electronic pedigree requirements may increase our operational
expenses and impose significant administrative burdens. In addition, our compliance may be deemed insufficient and we could face
a material adverse effect on our business, financial condition, results of operations and growth prospects.&nbsp;As a result of
these and other new proposals, we may determine to change our current manner of operation, provide additional benefits or change
our contract arrangements, any of which could have a material adverse effect on our business, financial condition and results of
operations.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Managed care organizations are increasingly challenging the prices
charged for medical products and services and, in some cases, imposing restrictions on the coverage of particular drugs. Many managed
care organizations negotiate the price of medical services and products and develop formularies which establish pricing and reimbursement
levels. Exclusion of a product from a formulary can lead to its sharply reduced usage in the managed care organization&#8217;s
patient population. The process for obtaining coverage can be lengthy and costly, and we expect that it could take several months
before a particular payor initially reviews our product and makes a decision with respect to coverage. For example, third-party
payors may require cost-benefit analysis data from us in order to demonstrate the cost-effectiveness of RAPIVAB or any other product
we might bring to market. For any individual third-party payor, we may not be able to provide data sufficient to gain reimbursement
on a similar or preferred basis to competitive products, or at all which may have a material adverse effect on our business, financial
condition and results of operations.&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>There are risks related to the potential government use or sale of peramivir
(RAPIVAB).</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">United States Government use or sale of RAPIVAB in emergency situations,
or otherwise, may result in the use of RAPIVAB outside of its approved use. To the extent that RAPIVAB is used as a treatment for
influenza by the U.S. Government or peramivir by any other government entity, there can be no assurance that it will prove to be
generally safe, well-tolerated and effective. Such government use of peramivir may create certain liabilities for us or our partners
in the case of government use outside of the U.S. There is no assurance that we or our manufacturers will be able to fully meet
the demand for peramivir in the event of additional orders. Further, we may not achieve a favorable price for additional orders
of RAPIVAB in the U.S. or peramivir in any other country. Our competitors may develop products that could compete with or replace
peramivir. We may face competition in markets where we have no existing intellectual property protection or are unable to successfully
enforce our intellectual property rights.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 43; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">There is no assurance that the non-U.S. partnerships that we have
entered into for peramivir will result in any order for peramivir in those countries. There is no assurance that peramivir will
be approved for any use or will achieve market approval in additional countries. In the event that any emergency use or market
approval is granted, there is no assurance that any government order or commercialization of peramivir in any countries will be
substantial or will be profitable to us. In addition, the sale of peramivir, emergency use or other use of peramivir in any country
may create certain liabilities for us and our partners.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>If we or our partners do not obtain and maintain governmental approvals
for our product candidates under development, we or our partners will not be able to sell these potential products, which would
significantly harm our business because we will receive no revenue.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We or our partners must obtain regulatory approval before marketing
or selling our future product candidates. If we or our partners are unable to receive regulatory approval and do not market or
sell our future product candidates, we will never receive any revenue from such product sales. In the United States, we or our
partners must obtain FDA approval for product candidates that we intend to commercialize. The process of preparing for and obtaining
FDA approval may be lengthy and expensive, and approval is never certain. Products distributed abroad are also subject to foreign
government regulation and export laws of the United States. Because of the risks and uncertainties in biopharmaceutical development,
our product candidates could take a significantly longer time to gain regulatory approval than we expect or may never gain approval.
If the FDA delays regulatory approval of our product candidates, our management&#8217;s credibility, our value and our operating
results may suffer. Even if the FDA or foreign regulatory agencies approve a product candidate, the approval may limit the indicated
uses for a product candidate and/or may require post-approval studies.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The FDA regulates, among other things, the record keeping and storage
of data pertaining to potential pharmaceutical products. We currently store most of our preclinical research data, our clinical
data and our manufacturing data at our facility. While we do store duplicate copies of most of our clinical data offsite and a
significant portion of our data is included in regular backups of our systems, we could lose important data if our facility incurs
damage, or if our vendor data systems fail, suffer damage or are destroyed. If we receive approval to market our potential products,
whether in the United States or internationally, we will continue to be subject to extensive regulatory requirements. These requirements
are wide ranging and govern, among other things:</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">adverse drug experience reporting regulations;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">product promotion;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">product manufacturing, including good manufacturing practice requirements;&nbsp;and</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">product changes or modifications.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our failure to comply with existing or future regulatory requirements,
or our loss of, or changes to, previously obtained approvals, could have a material adverse effect on our business because we will
not receive product or royalty revenues if we or our partners do not receive approval of our products for marketing.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Royalties and milestone payments from Shionogi under our license agreement
with Shionogi (the &#8220;Shionogi Agreement&#8221;) will be required to be used by Royalty Sub to service its obligations under
its PhaRMA Notes, and generally will not be available to us for other purposes until Royalty Sub has repaid in full its obligations
under the PhaRMA Notes.</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In March 2011, our wholly-owned subsidiary Royalty Sub issued $30.0
million in aggregate principal amount of PhaRMA Notes. The PhaRMA Notes are secured principally by (i) certain royalty and milestone
payments under the Shionogi Agreement, pursuant to which Shionogi licensed from us the rights to market peramivir in Japan and,
if approved for commercial sale, Taiwan, (ii) rights to certain payments under a Japanese yen/U.S. dollar foreign currency hedge
arrangement put into place by us in connection with the issuance of the PhaRMA Notes and (iii) the pledge by us of our equity interest
in Royalty Sub. Payments from Shionogi to us under the Shionogi Agreement will generally not be available to us for other purposes
until Royalty Sub has repaid in full its obligations under the PhaRMA Notes. Accordingly, these funds will be required to be dedicated
to Royalty Sub&#8217;s debt service and not available to us for product development or other purposes. As of September 1, 2014,
the payments from Shionogi were insufficient for Royalty Sub to service its obligations under the PhaRMA Notes, resulting in an
event of default with respect to the PhaRMA Notes. As a result of this event of default, the holders of the PhaRMA Notes may be
able to pursue acceleration of the PhaRMA Notes and foreclose on the collateral securing the PhaRMA Notes and our equity interest
in Royalty Sub and may&nbsp;exercise other remedies available to them under the indenture or other documents related to&nbsp;the
PhaRMA Notes. In such event, we may not realize the benefit of future royalty payments that might otherwise accrue to us following
repayment of the PhaRMA Notes, we may incur legal costs&nbsp;and we might otherwise be adversely affected.</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i></i></b></p>

<!-- Field: Page; Sequence: 44; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Because an event of default has occurred under the PhaRMA Notes, the
holders of the PhaRMA Notes may be able to pursue acceleration of the PhaRMA Notes and foreclose on the collateral securing the
PhaRMA Notes and our equity interest in Royalty Sub, in which case we may not realize the benefit of future royalty payments that
might otherwise accrue to us following repayment of the PhaRMA Notes and we could otherwise be adversely affected.</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Royalty Sub&#8217;s ability to service its payment obligations
in respect of the PhaRMA Notes, and our ability to benefit from our equity interest in Royalty Sub, is subject to numerous risks.
Royalty Sub&#8217;s ability to service the PhaRMA Notes may be adversely affected by, among other things, changes in or any termination
of our relationship with Shionogi, reimbursement, regulatory, manufacturing and/or intellectual property issues, product returns,
product recalls, product liability claims and allegations of safety issues, as well as other factors. As Royalty Sub has been unable
to service its obligations under the PhaRMA Notes and an event of default has occurred under the PhaRMA Notes, the holders of the
PhaRMA Notes may be able to pursue acceleration of the PhaRMA Notes and foreclose on the collateral securing the PhaRMA Notes and
our equity interest in Royalty Sub and may&nbsp;exercise other remedies available to them under the indenture&nbsp;or other documents
related to&nbsp;the PhaRMA Notes. In such event, we may not realize the benefit of future royalty payments that might otherwise
accrue to us following repayment of the PhaRMA Notes, we may incur legal costs&nbsp;and we might otherwise be adversely affected.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>We may be required to pay significant premiums under the foreign currency
hedge arrangement entered into by us in connection with the issuance of the PhaRMA Notes. In addition, because our potential obligations
under the foreign currency hedge are marked to market, we may experience additional quarterly volatility in our operating results
and cash flows attributable to the foreign currency hedge arrangement.&nbsp;</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In connection with the issuance by Royalty Sub of the PhaRMA Notes,
we entered into a foreign currency hedge arrangement to hedge certain risks associated with changes in the value of the Japanese
yen relative to the U.S. dollar. Under the foreign currency hedge agreement, we may be required to pay an annual premium in the
amount of $2.0 million in each May continuing through May 2020. Such payment will be required if, in May of the relevant year,
the spot rate of exchange for Japanese yen-U.S. dollars (determined in accordance with the foreign currency hedge arrangement)
is such that the U.S. dollar is worth 100 yen or less. We will be required to mark-to-market our potential obligations under the
currency hedge and post cash collateral, which may cause us to experience additional quarterly volatility in our operating results
and cash flows as a result. Additionally, we may be required to pay significant premiums or a termination fee under the foreign
currency hedge agreement entered into by us in connection with the issuance of the PhaRMA Notes. We are required to maintain a
foreign currency hedge at 100 yen per dollar under the agreements governing the PhaRMA Notes.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>If we fail to adequately protect or enforce our intellectual property
rights or secure rights to patents of others, the value of those rights would diminish.</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our success will depend in part on our ability and the abilities
of our partners to obtain, protect and enforce viable intellectual property rights including but not limited to trade name, trademark
and patent protection for our Company and its products, methods, processes and other technologies we may license or develop, to
preserve our trade secrets, and to operate without infringing the proprietary rights of third parties both domestically and abroad.
The patent position of biotechnology and pharmaceutical companies is generally highly uncertain, involves complex legal and factual
questions and has recently been the subject of much litigation. Neither the United States Patent and Trademark Office (&#8220;USPTO&#8221;),
the Patent Cooperation Treaty offices, nor the courts of the United States and other jurisdictions have consistent policies nor
predictable rulings regarding the breadth of claims allowed or the degree of protection afforded under many biotechnology and pharmaceutical
patents. Further, we may not have worldwide patent protection for all of our product candidates and our intellectual property rights
may not be legally protected or enforceable in all countries throughout the world. In some jurisdictions, some of our product candidates
in certain programs, including our HAE program, may have short or no composition of matter patent life and we may therefore rely
on orphan drug exclusivity or data exclusivity. There can be no assurance that we will obtain orphan drug exclusivity or data exclusivity
in every jurisdiction. Further, in some jurisdictions, we may rely on formulation patents or method of use patents. Both the ability
to achieve issuance and the enforcement of formulation and method of use patents can be highly uncertain and can vary from jurisdiction
to jurisdiction, and such patents may therefore not adequately prevent competitors and potential infringers in some jurisdictions.
The validity, scope, enforceability and commercial value of the rights protected by such patents, therefore, is highly uncertain.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We also rely on trade secrets to protect technology in cases when
we believe patent protection is not appropriate or obtainable. However, trade secrets are difficult to protect. If we cannot maintain
the confidentiality of our technology and other confidential information in connection with our collaborators and advisors, our
ability to receive patent protection or protect our proprietary information may be imperiled.</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b>&nbsp;</b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 20pt"><b><i>We may be involved in lawsuits to protect or enforce our patents, the
patents of our partners or our other intellectual property rights, which could be expensive, time consuming and unsuccessful</i></b>.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 45; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Competitors may infringe or otherwise violate our patents, the patents
of our licensors or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to
file legal claims, which can be expensive and time-consuming and unsuccessful. An adverse result in any litigation or defense proceeding
could put one or more of our patents at risk. Our success depends in part on avoiding the infringement of other parties&#8217;
patents and other intellectual property rights as well as avoiding the breach of any licenses relating to our technologies and
products. In the United States, patent applications filed in recent years are confidential for 18 months, while older applications
are not published until the patent issues. As a result, avoiding patent infringement may be difficult and we may inadvertently
infringe third-party patents or proprietary rights. These third parties could bring claims against us, our partners or our licensors
that even if resolved in our favor, could cause us to incur substantial expenses and, if resolved against us, could additionally
cause us to pay substantial damages. Further, if a patent infringement suit were brought against us, our partners or our licensors,
we or they could be forced to stop or delay research, development, manufacturing or sales of any infringing product in the country
or countries covered by the patent we infringe, unless we can obtain a license from the patent holder. Such a license may not be
available on acceptable terms, or at all, particularly if the third party is developing or marketing a product competitive with
the infringing product. Even if we, our partners or our licensors were able to obtain a license, the rights may be nonexclusive,
which would give our competitors access to the same intellectual property.&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If we or our partners are unable or fail to adequately initiate, protect,
defend or enforce our intellectual property rights in any area of commercial interest or in any part of the world where we wish
to seek regulatory approval for our products, methods, processes and other technologies, the value of the product candidates to
produce revenue would diminish. Additionally, if our products, methods, processes, and other technologies or our commercial use
of such products, processes, and other technologies, including but not limited to any trade name, trademark or commercial strategy
infringe the proprietary rights of other parties, we could incur substantial costs. The USPTO and the patent offices of other jurisdictions
have issued to us a number of patents for our various inventions and we have in-licensed several patents from various institutions.
We have filed additional patent applications and provisional patent applications with the USPTO. We have filed a number of corresponding
foreign patent applications and intend to file additional foreign and U.S. patent applications, as appropriate. We have also filed
certain trademark and trade name applications worldwide. We cannot assure you as to:</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">the degree and range of protection any patents will afford against competitors with similar products;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">if and when patents will issue;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">if patents do issue we cannot be sure that we will be able to adequately defend such patents and whether or not we will be able to adequately enforce such patents;&nbsp;or</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">whether or not others will obtain patents claiming aspects similar to those covered by our patent applications.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">If the USPTO or other foreign patent office upholds patents issued
to others or if the USPTO grants patent applications filed by others, we may have to:</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">obtain licenses or redesign our products or processes to avoid infringement;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">stop using the subject matter claimed in those patents;&nbsp;or</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">pay damages.</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">We may initiate, or others may bring against us, litigation or
administrative proceedings related to intellectual property rights, including proceedings before the USPTO or other foreign patent
office. Any judgment adverse to us in any litigation or other proceeding arising in connection with a patent or patent application
could materially and adversely affect our business, financial condition and results of operations. In addition, the costs of any
such proceeding may be substantial whether or not we are successful.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our success is also dependent upon the skills, knowledge and experience,
none of which is patentable, of our scientific and technical personnel. To help protect our rights, we require all employees, consultants,
advisors and partners to enter into confidentiality agreements that prohibit the disclosure of confidential information to anyone
outside of our company and require disclosure and assignment to us of their ideas, developments, discoveries and inventions. These
agreements may not provide adequate protection for our trade secrets, know-how or other proprietary information in the event of
any unauthorized use or disclosure or the lawful development by others of such information, and if any of our proprietary information
is disclosed, our business will suffer because our revenues depend upon our ability to license or commercialize our product candidates
and any such events would significantly impair the value of such product candidates.</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>We face an inherent risk of liability in the event that the use or misuse
of our products results in personal injury or death and our product liability insurance coverage may be insufficient.</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If the use or misuse of peramivir or any other regulatory body-approved
products we or a partner may sell in the future harms people, we may be subject to costly and damaging product liability claims
brought against us by consumers, healthcare providers, pharmaceutical companies, third-party payors or others. The use of our product
candidates in clinical trials, including post marketing clinical studies, could also expose us to product liability claims. We
cannot predict all of the possible harms or side effects that may result from the use of our products or the testing of product
candidates and, therefore, the amount of insurance coverage we currently may not be adequate to cover all liabilities or defense
costs we might incur. A product liability claim or series of claims brought against us could give rise to a substantial liability
that could exceed our resources. Even if claims are not successful, the costs of defending such claims and potential adverse publicity
could be harmful to our business.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 46; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We face an inherent risk of product liability exposure related to
the testing of our product candidates in human clinical trials and will face even greater risks upon any commercialization by us
of our product candidates. We have product liability insurance covering our commercial sale of RAPIVAB and our clinical trials.
Clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient
insurance or increase our existing coverage at a reasonable cost to protect us against losses that could have a material adverse
effect on our business. An individual may bring a product liability claim against us if one of our products or product candidates
causes, or is claimed to have caused, an injury or is found to be unsuitable for consumer use. Any product liability claim brought
against us, with or without merit, could result in:</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">liabilities that substantially exceed our product liability insurance, which we would then be required to pay from other sources, if available;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">an increase of our product liability insurance rates or the inability to maintain insurance coverage in the future on acceptable terms, or at all;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">withdrawal of clinical trial volunteers or patients;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">damage to our reputation and the reputation of our products, resulting in lower sales;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">regulatory investigations that could require costly recalls or product modifications;</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">litigation costs;&nbsp;and</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">the diversion of management&#8217;s attention from managing our business.</font></td></tr>
</table>
<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Insurance coverage is increasingly more costly and difficult to obtain
or maintain.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">While we currently have insurance for our business, property,
directors and officers, and our products insurance is increasingly more costly and narrower in scope, and we may be required to
assume more risk in the future. If we are subject to claims or suffer a loss or damage in excess of our insurance coverage, we
will be required to bear any loss in excess of our insurance limits. If we are subject to claims or suffer a loss or damage that
is outside of our insurance coverage, we may incur significant uninsured costs associated with loss or damage that could have an
adverse effect on our operations and financial position. Furthermore, any claims made on our insurance policies may impact our
ability to obtain or maintain insurance coverage at reasonable costs or at all.&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>If our facility incurs damage or power is
lost for a significant length of time, or if we incur significant cost overruns or delays in the construction of our new research
facility in Birmingham, Alabama, our business will suffer.</i></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We store clinical and stability samples at our facility that could
be damaged if our facility incurs physical damage or in the event of an extended power failure. We have backup power systems in
addition to backup generators to maintain power to all critical functions, but any loss of these samples could result in significant
delays in our drug development process.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In addition, we store most of our preclinical and clinical data at
our facilities. Duplicate copies of most critical data are secured off-site. Any significant degradation or failure of our computer
systems could cause us to inaccurately calculate or lose our data. Loss of data could result in significant delays in our drug
development process and any system failure could harm our business and operations.&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0">We also face the risk that the costs and time
required in connection with the construction of our new research facility in Birmingham, Alabama could exceed our current expectations.
If there is a significant cost overrun or significant delay in the completion of the construction, our business, financial condition,
and results of operations could be adversely affected.</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>A significant disruption in our information technology systems or a
cyber-security breach could adversely affect our business.</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We are increasingly dependent on information technology systems
to operate our business. Like other companies in our industry, our networks and infrastructure may be vulnerable to cyber-attacks
or intrusions, including by computer hackers, foreign governments, foreign companies or competitors, or may be breached by employee
error, malfeasance or other disruption. A breakdown, invasion, corruption, destruction or interruption of critical information
technology systems could negatively impact operations.&nbsp;If our systems are damaged, fail to function properly or otherwise
become unavailable, we may incur substantial costs to repair or replace them, and we may experience loss of critical data and interruptions
or delays in our ability to perform critical functions, which could adversely affect our business, financial condition or results
of operations. Any compromise of our data security could also result in a violation of applicable privacy and other laws, significant
legal and financial exposure, damage to our reputation, loss or misuse of the information and a loss of confidence in our data
security measures, which could harm our business. There can be no assurance that our efforts to protect our data and information
technology systems will prevent breakdowns or breaches in our systems, or those of third parties with which we do business, and
any such events could adversely affect our business.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i></i></b></p>

<!-- Field: Page; Sequence: 47; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>If we fail to retain our existing key personnel or fail to attract and
retain additional key personnel, the development of our product candidates and commercialization of our products and the related
expansion of our business will be delayed or stopped.</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We are highly dependent upon our senior management and scientific
team, the unexpected loss of whose services might impede the achievement of our development and commercial objectives. Competition
for key personnel with the experience that we require is intense and is expected to continue to increase. Our inability to attract
and retain the required number of skilled and experienced management, commercial, operational and scientific personnel will harm
our business because we rely upon these personnel for many critical functions of our business.&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>If because of our use of hazardous materials, we violate any environmental
controls or regulations that apply to such materials, we may incur substantial costs and expenses in our remediation efforts.</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our research and development involves the controlled use of hazardous
materials, chemicals and various radioactive compounds. We are subject to federal, state and local laws and regulations governing
the use, storage, handling and disposal of these materials and some waste products. Accidental contamination or injury from these
materials could occur. In the event of an accident, we could be liable for any damages that result and any liabilities could exceed
our resources. Compliance with environmental laws and regulations or a violation of such environmental laws and regulations could
require us to incur substantial unexpected costs, which would materially and adversely affect our results of operations.&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Risks relating to investing in our common stock</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Our existing principal stockholders hold a substantial amount of our
common stock and may be able to influence significant corporate decisions, which may conflict with the interest of other stockholders.</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Several of our stockholders own greater than 5% of our outstanding
common stock. Our top ten stockholders own more than 50% of BioCryst and can individually, and as a group, influence our operations
based upon their concentrated ownership. These stockholders, if they act together, may be able to influence the outcome of matters
requiring approval of the stockholders, including the election of our directors and other corporate actions.&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Our stock price has been, and is likely to continue to be, highly volatile,
which could cause the value of an investment in our common stock to decline significantly.</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The market prices for securities of biotechnology companies in general
have been highly volatile and may continue to be highly volatile in the future. Moreover, our stock price has fluctuated frequently,
and these fluctuations are often not related to our financial results. For the twelve months ended June 30, 2016, the 52-week range
of the market price of our stock was from $1.63 to $16.83 per share. The following factors, in addition to other risk factors described
in this section, may have a significant impact on the market price of our common stock:</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">announcements of technological innovations or new products by us or our competitors;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">developments or disputes concerning patents or proprietary rights;</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">additional dilution through sales of our common stock or other derivative securities;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">status of new or existing licensing or collaborative agreements and government contracts;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">announcements relating to the status of our programs;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">developments and announcements regarding new and virulent strains of influenza;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">we or our partners achieving or failing to achieve development milestones;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">publicity regarding actual or potential medical results relating to products under development by us or our competitors;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">publicity regarding certain public health concerns for which we are or may be developing treatments;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom"></td></tr></table>

<!-- Field: Page; Sequence: 48; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->


<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%">&nbsp;</td>
    <td style="width: 95%">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">regulatory developments in both the United States and foreign countries;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
</table>




<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 3%"><font style="font-size: 10pt">&#8226;</font></td>
    <td style="width: 95%"><font style="font-size: 10pt">public concern as to the safety of pharmaceutical products;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">actual or anticipated fluctuations in our operating results;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">changes in financial estimates or recommendations by securities analysts;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">changes in the structure of healthcare payment systems, including developments in price control legislation;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">additions or departures of key personnel or members of our board of directors;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">purchases or sales of substantial amounts of our stock by existing stockholders, including officers or directors;</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">economic and other external factors or other disasters or crises; and</font></td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8226;</font></td>
    <td><font style="font-size: 10pt">period-to-period fluctuations in our financial results.</font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>Future sales and issuances of securities may dilute the ownership interests
of our current stockholders and cause our stock price to decline.</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Future sales of our common stock by current stockholders into the
public market could cause the market price of our stock to fall. As of July 31, 2016, there were 73,700,542 shares of our common
stock outstanding. We may from time to time issue securities in relation to a license arrangement, collaboration, merger or acquisition.
We may also sell, for our own account, shares of common stock or other equity securities, from time to time at prices and on terms
to be determined at the time of sale.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As of July 31, 2016, there were 12,771,523 stock options and restricted
stock units outstanding, 2,071,866 shares available for issuance under our Amended and Restated Stock Incentive Plan, and 463,227
shares available for issuance under our Employee Stock Purchase Plan. In addition, we could also make equity compensation grants
outside of our Stock Incentive Plan. The shares underlying existing stock options, restricted stock units and possible future stock
options, stock appreciation rights and stock awards have been registered pursuant to registration statements on Form S-8.</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">If some or all of such shares are sold or otherwise issued into the
public market over a short period of time, our current stockholders&#8217; ownership interests may be diluted and the value of
all publicly traded shares is likely to decline, as the market may not be able to absorb those shares at then-current market prices.
Additionally, such sales and issuances may make it more difficult for us to sell equity securities or equity-related securities
in the future at a time and price that our management deems acceptable, or at all.&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>We have anti-takeover provisions in our corporate charter documents
that may result in outcomes with which you do not agree.</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Our board of directors has the authority to issue up to 4,800,000
shares of undesignated preferred stock and to determine the rights, preferences, privileges and restrictions of those shares without
further vote or action by our stockholders. The rights of the holders of any preferred stock that may be issued in the future may
adversely affect the rights of the holders of common stock. The issuance of preferred stock could make it more difficult for third
parties to acquire a majority of our outstanding voting stock.&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In addition, our certificate of incorporation provides for staggered
terms for the members of the board of directors and supermajority approval of the removal of any member of the board of directors
and prevents our stockholders from acting by written consent. Our certificate also requires supermajority approval of any amendment
of these provisions. These provisions and other provisions of our by-laws and of Delaware law applicable to us could delay or make
more difficult a merger, tender offer or proxy contest involving us.&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.25in"><b><i>We have never paid dividends on our common stock and do not anticipate
doing so in the foreseeable future.</i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 27pt; margin: 0pt 0">We have never paid cash dividends on our stock. We currently
intend to retain all future earnings, if any, for use in the operation of our business. Accordingly, we do not anticipate paying
cash dividends on our common stock in the foreseeable future.&nbsp;<b>&nbsp;</b></p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"><b>&nbsp;</b></p>

<p style="font-size: 10pt; margin: 0pt 0"><a name="a_010"></a><b>Item&nbsp;6. &nbsp;&nbsp;&nbsp;&nbsp;Exhibits</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">See the Exhibit&nbsp;Index attached to this quarterly report and incorporated herein
by reference.</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 49; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b><a name="a_011"></a>SIGNATURES</b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 8th day of August, 2016.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 50%">&nbsp;</td>
    <td style="width: 30%">&nbsp;</td>
    <td style="width: 20%">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">BIOCRYST PHARMACEUTICALS, INC.</font></td>
    <td>&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 10pt">/s/ Jon P. Stonehouse</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Jon P. Stonehouse</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td colspan="2">
        <p style="font-size: 10pt; margin: 0pt 3.4pt 0pt 0"><i>President and Chief Executive Officer</i></p>
        <p style="font-size: 10pt; margin: 0pt 3.4pt 0pt 0"><i>(Principal Executive Officer)</i></p></td></tr>
<tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 10pt">/s/ Thomas R. Staab, II</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">Thomas R. Staab, II</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td>&nbsp;</td>
    <td colspan="2"><font style="font-size: 10pt"><i>Senior Vice President, Chief Financial Officer and Treasurer</i></font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td colspan="2"><font style="font-size: 10pt"><i>(Principal Financial and Principal Accounting Officer)</i></font></td></tr>
</table>
<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: right; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 50; Value: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: right; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>INDEX TO EXHIBITS</b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="width: 7%; text-align: center">&nbsp;</td>
    <td style="width: 93%">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><font style="font-size: 10pt"><b>Number</b></font></td>
    <td style="text-align: center"><font style="font-size: 10pt"><b>Description</b></font></td></tr>
<tr>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><font style="font-size: 10pt">3.1</font></td>
    <td><font style="font-size: 10pt">Third Restated Certificate of Incorporation of Registrant. Incorporated by reference to Exhibit&nbsp;3.1 to the Company&#8217;s Form&nbsp;8-K filed December&nbsp;22, 2006.</font></td></tr>
<tr>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><font style="font-size: 10pt">3.2</font></td>
    <td><font style="font-size: 10pt">Certificate of Amendment to the Third Restated Certificate of Incorporation of Registrant. Incorporated by reference to Exhibit&nbsp;3.1 to the Company&#8217;s Form&nbsp;8-K filed July&nbsp;24, 2007.</font></td></tr>
<tr>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><font style="font-size: 10pt">3.3</font></td>
    <td><font style="font-size: 10pt">Certificate of Increase of Authorized Number of Shares of Series&nbsp;B Junior Participating Preferred Stock. Incorporated by reference to Exhibit&nbsp;3.1 to the Company&#8217;s Form&nbsp;8-K filed November&nbsp;4, 2008.</font></td></tr>
<tr>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><font style="font-size: 10pt">3.4</font></td>
    <td><font style="font-size: 10pt">Certificate of Amendment to the Third Restated Certificate of Incorporation of Registrant. Incorporated by reference to Exhibit&nbsp;3.1 to the Company&#8217;s Form&nbsp;8-K filed May&nbsp;8, 2014.</font></td></tr>
<tr>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><font style="font-size: 10pt">3.5</font></td>
    <td><font style="font-size: 10pt">Certificate of Increase of Authorized Number of Shares of Series&nbsp;B Junior Participating Preferred Stock. Incorporated by reference to Exhibit&nbsp;3.2 to the Company&#8217;s Form&nbsp;8-K filed May&nbsp;8, 2014.</font></td></tr>
<tr>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><font style="font-size: 10pt">3.6</font></td>
    <td><font style="font-size: 10pt">Amended and Restated Bylaws of Registrant effective October&nbsp;29, 2008. Incorporated by reference to Exhibit&nbsp;3.2 to the Company&#8217;s Form&nbsp;8-K filed November&nbsp;4, 2008.</font></td></tr>
<tr>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td></tr>
<TR>
    <TD STYLE="text-align: center; vertical-align: top">(10.1)&dagger;</TD>
    <TD>Amendment #5 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Biomedical Advanced Research
and Development Authority within the U.S. Department of Health and Human Services&rsquo; Office of the Assistant Secretary for
Preparedness and Response, dated April 11, 2016. (Portions omitted pursuant to request for confidential treatment.)</TD></TR>
<TR>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: center; vertical-align: top">(10.2)&dagger;</TD>
    <TD>Amendment #6 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Biomedical Advanced Research
and Development Authority within the U.S. Department of Health and Human Services&rsquo; Office of the Assistant Secretary for
Preparedness and Response, dated May 20, 2016. (Portions omitted pursuant to request for confidential treatment.)</TD></TR>
<TR>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td style="text-align: center"><P STYLE="margin: 0pt 0">(10.3)&dagger;</P>


</td>
    <td><font style="font-size: 10pt">Amendment #18 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated June 30, 2016. (Portions omitted pursuant to request for confidential treatment.)</font></td></tr>
<tr>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td></tr>
<TR>
    <TD STYLE="text-align: center; vertical-align: top">10.4</TD>
    <TD>Amended and Restated Stock Incentive Plan. Incorporated by reference to Exhibit 10.1 to the Company&rsquo;s
Registration Statement on Form S-8 filed May 23, 2016</TD></TR>
<TR>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td style="text-align: center"><font style="font-size: 10pt">(31.1)</font></td>
    <td><font style="font-size: 10pt">Certification of the Chief Executive Officer Pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002.</font></td></tr>
<tr>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><font style="font-size: 10pt">(31.2)</font></td>
    <td><font style="font-size: 10pt">Certification of the Chief Financial Officer Pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002.</font></td></tr>
<tr>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><font style="font-size: 10pt">(32.1)</font></td>
    <td><font style="font-size: 10pt">Certification pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002.</font></td></tr>
<tr>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><font style="font-size: 10pt">(32.2)</font></td>
    <td><font style="font-size: 10pt">Certification pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002.</font></td></tr>
<tr>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><font style="font-size: 10pt">(101)</font></td>
    <td><font style="font-size: 10pt">Financial statements from the Quarterly Report on Form 10-Q of BioCryst Pharmaceuticals, Inc. for the three months ended June 30, 2016, formatted in XBRL: (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Comprehensive Loss, (iii) Consolidated Statements of Cash Flows, and (iv) Notes to Consolidated Financial Statements.</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<!-- Field: Rule-Page --><div align="LEFT" style="margin: 1pt 547pt 1pt 0in"><div style="font-size: 1pt; border-top: black 1pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: top; width: 4%"><font style="font-size: 10pt">(&nbsp;&nbsp;)</font></td>
    <td style="width: 96%"><font style="font-size: 10pt">Filed or furnished herewith.</font></td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#8224;</font></td>
    <td><font style="font-size: 10pt">Confidential treatment requested.</font></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">51</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div align="CENTER" style="margin-top: 3pt; margin-bottom: 3pt"><div style="font-size: 1pt; border-top: Black 4pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: right; margin: 0pt 0"></p>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exh_101.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right">EXHIBIT 10.1</P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="exh101_1.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;<IMG SRC="exh101_2.jpg" ALT=""></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>exh_102.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right">EXHIBIT 10.2</P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="exh102_1.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="exh102_2.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="font-size: 10pt; margin: 0pt 0">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked &quot;***&quot; and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Request with the Commission.</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>



<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Statement of Work</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>BioCryst Pharmaceuticals Contract HHSO100201500007C</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>BCX4430 NDA Enabling CMC and Non-Clinical Toxicology Studies</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>PREAMBLE</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Independently and not as an agent of the Government, the Contractor shall furnish all
the necessary services, qualified personnel, material, equipment, and facilities, not otherwise provided by the Government as needed
to perform the Statement of Work submitted in response to the BARDA Broad Agency Announcement (BAA) CBRN-BAA-10-100-SOL-00013.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The Government reserves the right to modify the milestones, progress, schedule, budget,
or deliverables to add or delete deliverables, process, or schedules if the need arises. Because of the nature of this research
and development (R&amp;D) contract and the complexities inherent in this and prior programs, at designated milestones the Government
will evaluate whether work should be redirected, removed, or whether schedule or budget adjustments should be made.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Overall Objectives and Scope</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The overall objective of this contract is to advance the development of BCX4430, a novel
small molecule nucleoside with broad spectrum antiviral activity being developed for diseases caused by RNA pathogens. BCX4430,
an inhibitor of viral RNA &ndash; dependent RNA polymerase (RdRp), is the lead compound in our broad-spectrum antiviral program
to meet the need for a parenteral, direct-acting antiviral medical countermeasure (MCM) having efficacy across multiple viruses.
The scope of work for this contract includes preclinical and manufacturing development activities that fall into the following
areas: manufacturing of clinical trial material, manufacturing process improvements and development, non-clinical toxicology studies;
and all associated regulatory, quality assurance, management, and administrative activities. The proposed activities take into
account the Ebola virus disease (EVD) outbreak in West Africa. The R&amp;D effort will contribute toward an NDA filing for BCX4430.
Overall, this Statement of Work (SOW) focuses on:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>Drug substance (DS) and drug product (DP) manufacturing process development activities that will be conducted at US based facilities,
which will result in the ability to consistently produce high quality, GMP compliant material and deliver drug supply that could
be available for deployment as a medical countermeasure during the Ebola crisis and support future clinical and non-clinical studies</TD></TR>                                                                                                                                              <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>Nonclinical development activities to advance the intramuscular (IM) and intravenous (IV) formulation through NDA-enabling
toxicology including <B>* * * </B> and <B>* * * </B> studies in the <B>* * * </B>and <B>*&nbsp;*&nbsp;* </B></TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt">BioCryst Pharmaceuticals</FONT></TD><TD STYLE="width: 50%; text-align: right; font-size: 10pt"><FONT STYLE="font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> of 17</FONT></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">May 18, 2016</FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right"></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="font-size: 10pt; margin: 0pt 0">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked &quot;***&quot; and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Request with the Commission.</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1</FONT></TD><TD STYLE="text-align: justify">BASE: MANUFACTURE OF CLINICAL TRIAL MATERIAL</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Duration: 43 months</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Drug Substance and Drug Product GMP manufacturing by US suppliers to support non-clinical
and clinical activities. Drug Substance will be produced following an <B>*&nbsp;*&nbsp;* </B>starting with <B>*&nbsp;*&nbsp;* </B>,
which will be used as the starting material to produce GMP BCX4430. Previous campaigns of GMP BCX4430 have produced between <B>*&nbsp;*&nbsp;*
</B>to <B>*&nbsp;*&nbsp;* </B>per batch. The scope of work under this option will target up to a 5-fold increase in the GMP BCX4430
batch size.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The primary objectives will be to:</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>Produce a total of <B>*&nbsp;*&nbsp;* </B>batches of GMP BCX4430 drug substance following the <B>*&nbsp;*&nbsp;* </B>).</TD></TR>                                                                                                                                                                                                                                                    <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>Conduct drug product process improvements that will be focused on validation of analytical methods, stress testing, stability
studies, and process design space optimization</TD></TR>                                                        <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.1.</FONT></TD><TD STYLE="text-align: justify">Procurement of Starting Materials</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall procure enough starting materials to produce up to a total of <B>*&nbsp;*&nbsp;*
</B> of the current manufacturing process of BCX4430. The key starting materials to be procured are <B>*&nbsp;*&nbsp;* </B> and
<B>*&nbsp;*&nbsp;* </B>.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.1.1.</FONT></TD><TD STYLE="text-align: justify">Procurement of Starting Materials to produce <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;*
</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall procure <B>*&nbsp;*&nbsp;* </B>and <B>*&nbsp;*&nbsp;* </B>for the
manufacture of <B>*&nbsp;*&nbsp;* </B>to support an initial campaign (WBS 1.4.1 and 1.4.2) of manufacturing <B>*&nbsp;*&nbsp;*
</B>batches of BCX4430 followed by an additional <B>*&nbsp;*&nbsp;* </B>batches of BCX4430 (Clinical Trial Material Batch <B>*&nbsp;*&nbsp;*
</B> WBS1.7.1) using the <B>*&nbsp;*&nbsp;* </B>.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.2.</FONT></TD><TD STYLE="text-align: justify">Further Process Improvements of <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;* </FONT>Route</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall conduct further process improvements that may be identified focused
on improving the existing plant-scale processes following generally the same <B>*&nbsp;*&nbsp;* </B>.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.2.1.</FONT></TD><TD STYLE="text-align: justify">Conduct Process Improvements</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall conduct the process improvements with existing plant-scale processes.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.2.2.</FONT></TD><TD STYLE="text-align: justify">Determination that Process is Sufficient to move to Commercial Scale up</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall evaluate the processes developed and provide sufficient information
through a deliverable that will enable BARDA to determine that the <B>*&nbsp;*&nbsp;* </B> processes ( <B>*&nbsp;*&nbsp;* </B>and
<B>*&nbsp;*&nbsp;* </B> BCX4430) are sufficient to move to commercial scale<FONT STYLE="font-family: Symbol">-</FONT>up activities.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.3.</FONT></TD><TD STYLE="text-align: justify">Manufacture of <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;* </FONT>at <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;*
</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>*&nbsp;*&nbsp;* </B>will be utilized as the starting material
for the manufacture of BCX4430 in accordance with GMP guidance.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.3.1.</FONT></TD><TD STYLE="text-align: justify">Manufacture of the <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;* </FONT>batch of <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;*
</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall target producing between a <B>*&nbsp;*&nbsp;* </B>batch using the
<B>*&nbsp;*&nbsp;* </B>.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt">BioCryst Pharmaceuticals</FONT></TD><TD STYLE="width: 50%; text-align: right; font-size: 10pt"><FONT STYLE="font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> of 17</FONT></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">May 18, 2016</FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right"></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="font-size: 10pt; margin: 0pt 0">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked &quot;***&quot; and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Request with the Commission.</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.3.2.</FONT></TD><TD STYLE="text-align: justify">Manufacture of <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;* </FONT>Batches <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;*
</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Based on the performance of the <B>*&nbsp;*&nbsp;* </B>batch of <B>*&nbsp;*&nbsp;* </B>,
additional lab-scale studies and a qualification run will be conducted to improve the <B>*&nbsp;*&nbsp;* </B>. This process will
then be incrementally scaled-up in the plant.</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><BR>
</TD><TD STYLE="width: 1in"><FONT STYLE="color: #010000">1.3.2.1.</FONT></TD><TD STYLE="text-align: justify">Manufacture of the <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;* </FONT>batch of <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;*
</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall produce approximately <B>*&nbsp;*&nbsp;* </B>per batch using the
<B>*&nbsp;*&nbsp;* </B>.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 1in"><FONT STYLE="color: #010000">1.3.2.2.</FONT></TD><TD STYLE="text-align: justify">Manufacture of the <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;* </FONT>batch of <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;*
</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall target produce approximately <B>*&nbsp;*&nbsp;* </B>per batch using
the <B>*&nbsp;*&nbsp;* </B>.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.4.</FONT></TD><TD STYLE="text-align: justify">Manufacturing Campaign of GMP BCX4430</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall produce <B>*&nbsp;*&nbsp;* </B>batches of BCX4430 at <B>*&nbsp;*&nbsp;*
</B>in compliance with GMP.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.4.1.</FONT></TD><TD STYLE="text-align: justify">Manufacturing of the <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;* </FONT>batch of GMP BCX4430</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall produce and release approximately <B>*&nbsp;*&nbsp;* </B>of GMP
BCX430 utilizing the <B>*&nbsp;*&nbsp;* </B> for making BCX4430 starting with the <B>*&nbsp;*&nbsp;* </B>batch ( <B>*&nbsp;*&nbsp;*
</B>) of <B>*&nbsp;*&nbsp;* </B>.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.4.2.</FONT></TD><TD STYLE="text-align: justify">Manufacturing of the <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;* </FONT>batch of GMP BGX4430</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall produce and release approximately <B>*&nbsp;*&nbsp;* </B>of GMP
BCX4430 utilizing the <B>*&nbsp;*&nbsp;* </B> for making BCX4430 starting with the recovered portion of the <B>*&nbsp;*&nbsp;*
</B>batch ( <B>*&nbsp;*&nbsp;* </B>) of <B>*&nbsp;*&nbsp;* </B>. NOTE: This quantity is dependent on the amount and quality of
<B>*&nbsp;*&nbsp;* </B>isolated during the recovery of <B>*&nbsp;*&nbsp;* </B>.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.4.3.</FONT></TD><TD STYLE="text-align: justify">Prepare a Campaign Summary Report</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall prepare a campaign summary report of the manufacture and release
of DS batches.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.4.4.</FONT></TD><TD STYLE="text-align: justify">Drug Substance Stability Studies</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall place samples from DS batches of BCX4430 on a <B>*&nbsp;*&nbsp;*
</B>stability program at <B>*&nbsp;*&nbsp;* </B> and a <B>*&nbsp;*&nbsp;* </B>accelerated stability study at <B>*&nbsp;*&nbsp;*
</B>.</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt">BioCryst Pharmaceuticals</FONT></TD><TD STYLE="width: 50%; text-align: right; font-size: 10pt"><FONT STYLE="font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> of 17</FONT></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">May 18, 2016</FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right"></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="font-size: 10pt; margin: 0pt 0">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked &quot;***&quot; and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Request with the Commission.</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Table 1:&#9;BCX4430 Drug Substance Stability Study Sampling Points</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="background-color: black">
    <TD STYLE="border: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; color: white">Test</FONT></TD>
    <TD COLSPAN="10" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; color: white">Months</FONT></TD></TR>
<TR>
    <TD STYLE="width: 10%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; background-color: black; text-align: center"><FONT STYLE="font-size: 10pt; color: white">ID</FONT></TD>
    <TD STYLE="width: 9%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD STYLE="width: 9%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1</FONT></TD>
    <TD STYLE="width: 9%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">3</FONT></TD>
    <TD STYLE="width: 9%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">6</FONT></TD>
    <TD STYLE="width: 9%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">9</FONT></TD>
    <TD STYLE="width: 9%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">12</FONT></TD>
    <TD STYLE="width: 9%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">18</FONT></TD>
    <TD STYLE="width: 9%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">24</FONT></TD>
    <TD STYLE="vertical-align: top; width: 9%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">48</FONT></TD>
    <TD STYLE="vertical-align: top; width: 9%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">60</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">X</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">B</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">X</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">C</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">X</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">D</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">X</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">E</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">X</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">F</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">X</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">G</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">X</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">X</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; background-color: lightgrey">X</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>NOTE: BARDA will only cover stability activities for&nbsp;<B>*&nbsp;*&nbsp;* </B>.</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Table 2:&#9;BCX4430 Drug Substance Stability Tests</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 16%; border: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Test ID</B></FONT></TD>
    <TD STYLE="width: 84%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; background-color: black; text-align: center"><FONT STYLE="font-size: 10pt; color: white">Test</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">A</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">B</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">C</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">D</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">E</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">F</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">G</FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.5.</FONT></TD><TD STYLE="text-align: justify">Drug Product Development</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall conduct drug product process improvements that will be focused on
validation of analytical methods, stress testing, stability studies, and process design space optimization for an IM formulation.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall conduct formulation development activities and produce a sterile,
parenteral formulation containing <B>*&nbsp;*&nbsp;* </B>of the active compound per unit in compliance with GMP guidance. Initial
development efforts will be focused on delivering <B>*&nbsp;*&nbsp;* </B>that tolerates terminal sterilization and provides an
acceptable stability profile. Additionally, studies to include: <B>*&nbsp;*&nbsp;* </B>will be conducted to evaluate the feasibility
of <B>*&nbsp;*&nbsp;* </B>.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.5.1.</FONT></TD><TD STYLE="text-align: justify">Stress Conditions Studies</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall conduct a series of experiments under conditions outlined in ICH
guidance to evaluate the stability of the drug product made from available drug substance.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.5.2.</FONT></TD><TD STYLE="text-align: justify">Design Space Studies</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall conduct studies to evaluate and define the design space of the formulation
process.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.5.3.</FONT></TD><TD STYLE="text-align: justify">Analytical Method Validation</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall conduct analytical methods validation or qualification as listed
in the table below.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt">BioCryst Pharmaceuticals</FONT></TD><TD STYLE="width: 50%; text-align: right; font-size: 10pt"><FONT STYLE="font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> of 17</FONT></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">May 18, 2016</FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right"></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="font-size: 10pt; margin: 0pt 0">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked &quot;***&quot; and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Request with the Commission.</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0"><B></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Table 3:&#9;BCX4430 Drug Product Methods that will be Validated or Qualified</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="background-color: black">
    <TD STYLE="width: 42%; border: Black 1pt solid"><FONT STYLE="font-size: 10pt; color: White">Test</FONT></TD>
    <TD STYLE="width: 58%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt; color: White">Method
    and Objective</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 1.5in">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.5.4.</FONT></TD><TD STYLE="text-align: justify">Prepare Process Development Report for DP</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall prepare a process development report summarizing the experiments
and results of the studies conducted to define the process and evaluate the formulation.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.5.5.</FONT></TD><TD STYLE="text-align: justify">Pre-formulation and Physicochemical Properties Studies</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall conduct studies to determine the physicochemical properties of the
drug substance and identify potential formulations and primary packaging for an IM injection based on stability and ability to
be produced on manufacturing lines.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.5.6.</FONT></TD><TD STYLE="text-align: justify">Feasibility Runs</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall conduct small-scale, nonGMP manufacturing runs of potential formulations
and formats.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.5.7.</FONT></TD><TD STYLE="text-align: justify">Extractable/Leachable Study</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall conduct studies to determine drug product stability in primary packaging
and of syringe types that will be used for delivery.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.5.8.</FONT></TD><TD STYLE="text-align: justify">Excipient Compatibility Studies for IV Formulation from lM</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall conduct studies to evaluate the compatibility of the IM formulation
added to various standard IV fluids.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.6.</FONT></TD><TD STYLE="text-align: justify">Manufacturing of Drug Product to Support Clinical Trials</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall produce <B>*&nbsp;*&nbsp;* </B>batches of approximately <B>*&nbsp;*&nbsp;*
</B>of drug product suitable for clinical trial use. The drug product will produced from the <B>*&nbsp;*&nbsp;* </B>GMP BCX4430
DS Batches (WBS 1.4.1 and 1.4.2)</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 1.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt">BioCryst Pharmaceuticals</FONT></TD><TD STYLE="width: 50%; text-align: right; font-size: 10pt"><FONT STYLE="font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> of 17</FONT></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">May 18, 2016</FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right"></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="font-size: 10pt; margin: 0pt 0">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked &quot;***&quot; and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Request with the Commission.</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.6.1.</FONT></TD><TD STYLE="text-align: justify">Manufacture of Clinical Trial Material (DP Batch <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;*
</FONT>)</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall produce approximately <B>*&nbsp;*&nbsp;* </B>, assuming <B>*&nbsp;*&nbsp;*
</B>of BCX4430 is delivered from the DS Batch <B>*&nbsp;*&nbsp;* </B> of BCX4430, per GMP for use in clinical trials which will
include active drug and placebo batches to support the future clinical safety study.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.6.2.</FONT></TD><TD STYLE="text-align: justify">Manufacture of Clinical Trial Material (DP Batch <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;*
</FONT>)</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall produce approximately <B>*&nbsp;*&nbsp;* </B>, assuming <B>*&nbsp;*&nbsp;*
</B>of BCX4430 is delivered from the DS Batch <B>*&nbsp;*&nbsp;* </B> of BCX4430, per GMP for use in clinical trials which will
include active drug and placebo batches to support the future clinical safety study.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.6.3.</FONT></TD><TD STYLE="text-align: justify">Prepare a Campaign Summary Reports</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall prepare a campaign summary report of the manufacture and release
of CTM Batches.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.6.4.</FONT></TD><TD STYLE="text-align: justify">Drug Product Stability Studies - Active</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall place drug product on stability based on the following conditions:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Table 4:&#9;BCX4430 Drug Product Stability Testing Conditions and Sampling</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="background-color: black">
    <TD STYLE="width: 27%; border: Black 1pt solid"><FONT STYLE="font-size: 10pt; color: White">Stability Conditions</FONT></TD>
    <TD STYLE="width: 23%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt; color: White">Configuration</FONT></TD>
    <TD STYLE="vertical-align: top; width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt; color: White">Test
    Points</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0; color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; color: white"><FONT STYLE="background-color: black"></FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>NOTE: BARDA will only cover stability activities for </B> <B>*&nbsp;*&nbsp;* </B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Testing at each interval, unless otherwise specified, below, will include:</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD><B>*&nbsp;*&nbsp;* </B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD><B>*&nbsp;*&nbsp;* </B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD><B>*&nbsp;*&nbsp;* </B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD><B>*&nbsp;*&nbsp;* </B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD><B>*&nbsp;*&nbsp;* </B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD><B>*&nbsp;*&nbsp;* </B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD><B>*&nbsp;*&nbsp;* </B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD><B>*&nbsp;*&nbsp;* </B></TD></TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.6.5.</FONT></TD><TD STYLE="text-align: justify">Drug Product Stability Studies - Placebo</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall place drug product on stability based on the following conditions:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 1.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt">BioCryst Pharmaceuticals</FONT></TD><TD STYLE="width: 50%; text-align: right; font-size: 10pt"><FONT STYLE="font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> of 17</FONT></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">May 18, 2016</FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right"></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="font-size: 10pt; margin: 0pt 0">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked &quot;***&quot; and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Request with the Commission.</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Table 5:&#9;BCX4430 Drug Product Stability Testing Conditions and Sampling</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="background-color: black">
    <TD STYLE="width: 27%; border: Black 1pt solid"><FONT STYLE="font-size: 10pt; color: White">Stability Conditions</FONT></TD>
    <TD STYLE="width: 23%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt; color: White">Configuration</FONT></TD>
    <TD STYLE="vertical-align: top; width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt; color: White">Test
    Points</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Testing at each interval, unless otherwise specified below, will include:</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD><B>*&nbsp;*&nbsp;* </B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD><B>*&nbsp;*&nbsp;* </B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD><B>*&nbsp;*&nbsp;* </B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD><B>*&nbsp;*&nbsp;* </B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD><B>*&nbsp;*&nbsp;* </B></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>NOTE: BARDA will only cover stability activities for </B> <B>*&nbsp;*&nbsp;* </B></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.6.6.</FONT></TD><TD STYLE="text-align: justify">Comparibility Study</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall conduct comparability studies evaluating drug substance produced
by <B>*&nbsp;*&nbsp;* </B>and <B>*&nbsp;*&nbsp;* </B>, and the subsequently produced drug product, will be conduct per FDA Guidance.
These studies will evaluate: in-process checks, impurity profiles, release testing results, and stability profiles at standard
and accelerated conditions to ensure the material produced by both manufacturers is substantially comparable.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.7.</FONT></TD><TD STYLE="text-align: justify">Manufacture of Additional Supply</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">That contractor shall produce approximately <B>*&nbsp;*&nbsp;* </B>batches of BCX4430
utilizing the <B>*&nbsp;*&nbsp;* </B>for both <B>*&nbsp;*&nbsp;* </B>and BCX4430 from the <B>*&nbsp;*&nbsp;* </B>facility and subsequently
produce approximately <B>*&nbsp;*&nbsp;* </B>of drug product at <B>*&nbsp;*&nbsp;* </B>suitable for clinical trial use.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.7.1.</FONT></TD><TD STYLE="text-align: justify">Manufacturing of approximately <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;* </FONT>GMP BCX4430</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall produce approximately <B>*&nbsp;*&nbsp;* </B>of GMP BCX4430 (DS
Batch <B>*&nbsp;*&nbsp;* </B>) from <B>*&nbsp;*&nbsp;* </B>following the <B>*&nbsp;*&nbsp;* </B></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.7.2.</FONT></TD><TD STYLE="text-align: justify">Manufacturing of approximately <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;* </FONT>GMP BCX4430</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall produce approximately <B>*&nbsp;*&nbsp;* </B>of GMP BCX4430 (DS
Batch <B>*&nbsp;*&nbsp;* </B>) from <B>*&nbsp;*&nbsp;* </B>following the <B>*&nbsp;*&nbsp;* </B></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.7.3.</FONT></TD><TD STYLE="text-align: justify">Prepare a Campaign Summary Report</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall prepare a campaign summary report of the manufacture and release
of DS.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt">BioCryst Pharmaceuticals</FONT></TD><TD STYLE="width: 50%; text-align: right; font-size: 10pt"><FONT STYLE="font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> of 17</FONT></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">May 18, 2016</FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right"></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="font-size: 10pt; margin: 0pt 0">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked &quot;***&quot; and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Request with the Commission.</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.7.4.</FONT></TD><TD STYLE="text-align: justify">Manufacturing of approximately <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;* </FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall produce approximately <B>*&nbsp;*&nbsp;* </B>of GMP BCX4430 drug
product using drug substance from the <B>*&nbsp;*&nbsp;* </B>GMP BCX4430 batches produced (&nbsp;WBS 1.7.1 and WBS 1.7.2).</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.7.5.</FONT></TD><TD STYLE="text-align: justify">Prepare a Campaign Summary Report</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall prepare a campaign summary report of the manufacture and release
of CTM Batches.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.7.6.</FONT></TD><TD STYLE="text-align: justify">Stability Studies for DS and DP</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall conduct drug substance and drug product stabilities for the DS and
DP manufactured from the <B>*&nbsp;*&nbsp;* </B>batches of GMP BCX4430 drug substance based on <B>*&nbsp;*&nbsp;* </B>and BCX4430
(WBS 1.7.1, 1.7.2, 1.7.4).</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>NOTE: BARDA will only cover stability activities for </B> <B>*&nbsp;*&nbsp;* </B></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.7.7.</FONT></TD><TD STYLE="text-align: justify">Comparability Studies</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall conduct comparability studies evaluating drug substance produced
by <B>*&nbsp;*&nbsp;* </B>and both process at <B>*&nbsp;*&nbsp;* </B>, and the subsequently produced drug product, will be conduct
per FDA Guidance. These studies will evaluate: in-process checks, impurity profiles, release testing results, and stability profiles
at standard and accelerated conditions to ensure the material produced by both manufacturers and both <B>*&nbsp;*&nbsp;* </B>process
are substantially comparable.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.7.8.</FONT></TD><TD STYLE="text-align: justify">Drug Product <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;* </FONT>Formulation Development</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>*&nbsp;*&nbsp;* </B>has been identified
as a potential product presentation that will provide a stable formulation suitable for IV administration at potentially higher
doses than are feasible <B>*&nbsp;*&nbsp;*</B>.</P>



<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.8.</FONT></TD><TD STYLE="text-align: justify">Analytical Method Development</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Confirmation that the <B>*&nbsp;*&nbsp;* </B>is suitable for a <B>*&nbsp;*&nbsp;* </B>product
and qualification of a <B>*&nbsp;*&nbsp;* </B>.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.9.</FONT></TD><TD STYLE="text-align: justify">Formulation Development</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Develop a <B>*&nbsp;*&nbsp;* </B>process that can be scaled to the manufacturing facility</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.9.1.</FONT></TD><TD STYLE="text-align: justify">Pre-formulation Studies</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Evaluate the current IM formulation and bulking agents to produce a prototype <B>*&nbsp;*&nbsp;*
</B>product.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.9.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;* </FONT>Cycle Development</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Evaluate <B>*&nbsp;*&nbsp;* </B>process cycles capable of producing the final product
to specifications utilizing a design of experiments of known critical process parameters. The critical parameters will be confirmed
and ranges established in subsequent small-scale runs.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 1.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt">BioCryst Pharmaceuticals</FONT></TD><TD STYLE="width: 50%; text-align: right; font-size: 10pt"><FONT STYLE="font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> of 17</FONT></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">May 18, 2016</FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right"></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="font-size: 10pt; margin: 0pt 0">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked &quot;***&quot; and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Request with the Commission.</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.9.3.</FONT></TD><TD STYLE="text-align: justify">Stability Study</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Evaluate the stability of the product produced during cycle development. Two fill volumes
will be placed on accelerated and real-time studies. <B>*&nbsp;*&nbsp;* </B>will be run for <B>*&nbsp;*&nbsp;* </B>with <B>*&nbsp;*&nbsp;*
</B>and <B>*&nbsp;*&nbsp;* </B>run for <B>*&nbsp;*&nbsp;* </B>.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.9.4.</FONT></TD><TD STYLE="text-align: justify">Terminal Sterilization</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Product produced during cycle development will be subjected to terminal sterilization
by gamma irradiation. The irradiated product will be tested for changes in chemical and physical characteristics.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.9.5.</FONT></TD><TD STYLE="text-align: justify">Pre-manufacturing Studies</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">A material comparability study examining processing and packaging components will be
performed. Additionally, a microbial retention filter validation study will be performed using the <B>*&nbsp;*&nbsp;* </B>, identified
during cycle development.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">2</FONT></TD><TD STYLE="text-align: justify">OPTION 1: COMMERCIAL SCALE UP AND NDA REGISTRATION BATCHES</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Duration: <B>*&nbsp;*&nbsp;* </B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Go/No Go Criteria to Initiate: WBS 1.2.2 BARDA approval of process developed<BR>
Through optimization of manufacturing processes, BARDA will evaluate and determine what process should be sufficient to initiate
commercial scale up activities in this Option. This Option will add value to the project through conducting manufacturing regulatory
activities that will be needed for future product approval with the FDA.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Decision Criteria:</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD><B>*&nbsp;*&nbsp;* </B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD><B>*&nbsp;*&nbsp;* </B></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The objective is to produce DS registration batches from the qualified process, <B>*&nbsp;*&nbsp;*
</B>. This will be determined upon the conclusion of the DS development effort being undertaken by BioCryst and funded by NIAID
that is scheduled to conclude in December 2015. Additionally during this stage, the DP manufacturing process would be finalized
for the commercial presentation and registration batches produced.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">2.1.</FONT></TD><TD STYLE="text-align: justify">Procurement</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall procure the <B>*&nbsp;*&nbsp;* </B>starting materials needed to
produce BCX4430.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">2.1.1.</FONT></TD><TD STYLE="text-align: justify">Procurement of <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;* </FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall qualify a vendor(s) to produce the <B>*&nbsp;*&nbsp;* </B>starting
material and procure enough material to support the manufacture of <B>*&nbsp;*&nbsp;* </B>batches of BCX4430 drug substance.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">2.1.2.</FONT></TD><TD STYLE="text-align: justify">Procurement of <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;* </FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall qualify a vendor(s) to produce the <B>*&nbsp;*&nbsp;* </B>starting
material and procure enough material to support the manufacture of <B>*&nbsp;*&nbsp;* </B>batches of BCX4430 drug substance.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 1.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt">BioCryst Pharmaceuticals</FONT></TD><TD STYLE="width: 50%; text-align: right; font-size: 10pt"><FONT STYLE="font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> of 17</FONT></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">May 18, 2016</FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right"></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="font-size: 10pt; margin: 0pt 0">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked &quot;***&quot; and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Request with the Commission.</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">2.2.</FONT></TD><TD STYLE="text-align: justify">Drug Substance Process Scale-up</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall conduct process development work targeting a <B>*&nbsp;*&nbsp;*
</B>that can be scaled to plant equipment. This work will include: development of a <B>*&nbsp;*&nbsp;* </B>through lab scale studies,
process hazard evaluation including RC-1 and digital scanning calorimetry, lab scale qualification runs, pilot plant scale-up technical
batches, necessary modifications to analytical methods based on the <B>*&nbsp;*&nbsp;* </B>, and plant-scale registration runs.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">2.2.1.</FONT></TD><TD STYLE="text-align: justify">Further Process Improvements of Final Route</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall conduct further process improvements that may be identified focused
on improving the <B>*&nbsp;*&nbsp;* </B>to be scaled up. The <B>*&nbsp;*&nbsp;* </B>will be based either <B>*&nbsp;*&nbsp;* .</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">2.2.2.</FONT></TD><TD STYLE="text-align: justify">Process Hazard Evaluation</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall conduct process hazard evaluation studies needed for the scale-up
of the optimized process into the plant.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">2.2.3.</FONT></TD><TD STYLE="text-align: justify">Scale-up Technical Run</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall conduct a nonGMP manufacturing run at plant-scale to ensure the
safety and output of the optimized process.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">2.2.4.</FONT></TD><TD STYLE="text-align: justify">Analytical Method Development and Qualification</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall modify, add to, revalidate, or requalify the analytical methods.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">2.2.5.</FONT></TD><TD STYLE="text-align: justify">Prepare Process Development Report</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall prepare a process development report describing the experiments
and results leading to the selection of the optimized manufacturing process</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">2.3.</FONT></TD><TD STYLE="text-align: justify">Manufacture of GMP Drug Substance Registration Batches</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall produce <B>*&nbsp;*&nbsp;* </B>GMP batches of BCX4430 following
the <B>*&nbsp;*&nbsp;* </B>at a scale comparable to the estimated commercial scale.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">2.3.1.</FONT></TD><TD STYLE="text-align: justify">Manufacture of DS Batch (DS Registration Batch <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;*
</FONT>)</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall manufacture a batch of GMP BCX4430 at plant scale.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">2.3.2.</FONT></TD><TD STYLE="text-align: justify">Manufacture of DS Batch (DS Registration Batch <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;*
</FONT>)</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall manufacture a batch of GMP BCX4430 at plant scale.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">2.3.3.</FONT></TD><TD STYLE="text-align: justify">Manufacture of DS Batch (DS Registration Batch <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;*
</FONT>)</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall manufacture a batch of GMP BCX4430 at plant scale.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">2.3.4.</FONT></TD><TD STYLE="text-align: justify">Prepare Campaign Summary Report</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall prepare a report summarizing the conduct, observations, and results
of the manufacturing of DS Registration Batches <B>*&nbsp;*&nbsp;* </B>.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 1.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt">BioCryst Pharmaceuticals</FONT></TD><TD STYLE="width: 50%; text-align: right; font-size: 10pt"><FONT STYLE="font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> of 17</FONT></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">May 18, 2016</FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right"></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="font-size: 10pt; margin: 0pt 0">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked &quot;***&quot; and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Request with the Commission.</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">2.4.</FONT></TD><TD STYLE="text-align: justify">Drug Product Registration Batches</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall produce <B>*&nbsp;*&nbsp;* </B>drug product lots at a qualified
CMO that will be used as the NDA registration batches.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">2.4.1.</FONT></TD><TD STYLE="text-align: justify">Manufacture of DP Registration (DP Registration Batch <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;*
</FONT>)</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall manufacture a NDA registration batch of GMP BCX4430 drug product
at a representative fraction of the estimated commercial scale.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">2.4.2.</FONT></TD><TD STYLE="text-align: justify">Manufacture of DP Registration (DP Registration Batch <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;*
</FONT>)</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall manufacture a NDA registration batch of GMP BCX4430 drug product
at a representative fraction of the estimated commercial scale.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">2.4.3.</FONT></TD><TD STYLE="text-align: justify">Manufacture of DP Registration (DP Registration Batch <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;*
</FONT>)</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall manufacture a NDA registration batch of GMP BCX4430 drug product
at at a representative fraction of the estimated commercial scale.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">2.4.4.</FONT></TD><TD STYLE="text-align: justify">Prepare campaign summary report</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall prepare a report summarizing the conduct, observations, and results
of the manufacturing of DPR Batches <B>*&nbsp;*&nbsp;* </B>.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">2.5.</FONT></TD><TD STYLE="text-align: justify">Stability studies for DS and DP</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall conduct drug substance and drug product stabilities as described
in Table 9, Table 10, Table 11, Table 12 and Table 13.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>NOTE: BARDA will only cover stability activities for </B> <B>*&nbsp;*&nbsp;* </B></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">2.6.</FONT></TD><TD STYLE="text-align: justify">Comparability study</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall conduct comparability studies evaluating drug substance produced
for clinical trials in the base period versus the NDA registration batches manufactured via <B>*&nbsp;*&nbsp;* </B>, and the subsequently
produced drug product, will be conduct per FDA Guidance. These studies will evaluate: in-process checks, impurity profiles, release
testing results, and stability profiles at standard and accelerated conditions to ensure the material produced by both processes
is substantially comparable.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">3</FONT></TD><TD STYLE="text-align: justify">OPTION 2: NONCLINICAL NDA-ENABLING TOXICOLOGY</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Duration: <B>*&nbsp;*&nbsp;* </B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Go/No Go Criteria to Initiate: Availability of GMP BCX4430 <B>*&nbsp;*&nbsp;* </B>DS
batch manufactured under NIAID contract HHSO100201500007C</P>
<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt">BioCryst Pharmaceuticals</FONT></TD><TD STYLE="width: 50%; text-align: right; font-size: 10pt"><FONT STYLE="font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> of 17</FONT></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">May 18, 2016</FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right"></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="font-size: 10pt; margin: 0pt 0">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked &quot;***&quot; and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Request with the Commission.</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>


<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Through completion of manufacturing of Drug substance there will be material to conduct
further regulatory activities such as the non-clinical NDA-enabling toxicology studies in this option. This Option will add value
to the project through conducting additional non-clinical activities that will support a potential future NDA.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Decision Criterion:</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD><B>*&nbsp;*&nbsp;* </B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD><B>*&nbsp;*&nbsp;* </B></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall perform nonclinical GLP studies of BCX4430 to characterize &nbsp;<B>*&nbsp;*&nbsp;*</B>.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">3.1.</FONT></TD><TD STYLE="text-align: justify">GLP <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;* </FONT>Toxicology</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall for each toxicology study develop the protocol, select and qualify
the vendor, conduct in life and recovery phases and analyze study data resulting in a final study report.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Studies include:</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">3.1.1.</FONT></TD><TD STYLE="text-align: justify">Conduct GLP <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;* </FONT>toxicology study - <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;*
</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">3.1.2.</FONT></TD><TD STYLE="text-align: justify">Conduct GLP <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;* </FONT>general toxicology study -
<FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;* </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">3.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;* </FONT>toxicology</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall for each <B>*&nbsp;*&nbsp;* </B>study segment develop the protocol,
select and qualify the vendor, conduct in life and recovery phases and analyze study data resulting in a final study report.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Studies include:</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">3.2.1.</FONT></TD><TD STYLE="text-align: justify">Conduct <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;* </FONT>assessment in <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;*
</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">3.2.2.</FONT></TD><TD STYLE="text-align: justify">Conduct <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;* </FONT>Dose Range Finding Studies in
<FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;* </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">3.2.3.</FONT></TD><TD STYLE="text-align: justify">Conduct Definitive <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;* </FONT>toxicology in <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;*
</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">3.2.4.</FONT></TD><TD STYLE="text-align: justify">Conduct <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;* </FONT>toxicology <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;*
</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">3.3.</FONT></TD><TD STYLE="text-align: justify">Nonclinical ADME</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall procure radiolabeled BCX4430. In addition for each ADME study, the
contractor shall develop the protocol, select and qualify the vendor, conduct the study and analyze study data resulting in a final
study report. Studies include:</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">3.3.1.</FONT></TD><TD STYLE="text-align: justify">Conduct Radiolabeled ADME study &ndash; <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;* </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">3.3.2.</FONT></TD><TD STYLE="text-align: justify">Conduct Radiolabeled ADME &ndash; <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;* </FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">A listing of the proposed studies for the nonclinical NDA-enabling toxicology studies
is provided.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt">BioCryst Pharmaceuticals</FONT></TD><TD STYLE="width: 50%; text-align: right; font-size: 10pt"><FONT STYLE="font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> of 17</FONT></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">May 18, 2016</FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right"></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="font-size: 10pt; margin: 0pt 0">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked &quot;***&quot; and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Request with the Commission.</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Table 6: Nonclinical NDA-enabling Toxicology Studies</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top; background-color: black">
    <TD STYLE="width: 9%; border: Black 1pt solid"><FONT STYLE="font-size: 10pt; color: white">Study #</FONT></TD>
    <TD STYLE="width: 23%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt; color: white">Description</FONT></TD>
    <TD STYLE="width: 55%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt; color: white">Objective(s)</FONT></TD>
    <TD STYLE="width: 13%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt; color: white">Species</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">GLP &nbsp;<B>*&nbsp;*&nbsp;* </B>general toxicology</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"><B>*&nbsp;*&nbsp;* </B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">GLP &nbsp;<B>*&nbsp;*&nbsp;* </B>general toxicology</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"><B>*&nbsp;*&nbsp;* </B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B>assessment</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"><B>*&nbsp;*&nbsp;* </B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B>Dose Range Finding</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"><B>*&nbsp;*&nbsp;* </B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B>Dose Range Finding</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"><B>*&nbsp;*&nbsp;* </B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Definitive &nbsp;<B>*&nbsp;*&nbsp;* </B>toxicology</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"><B>*&nbsp;*&nbsp;* </B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Definitive &nbsp;<B>*&nbsp;*&nbsp;* </B>toxicology</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"><B>*&nbsp;*&nbsp;* </B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B>toxicology</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"><B>*&nbsp;*&nbsp;* </B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Radiolabeled ADME</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Determine the absorption, distribution, metabolism and excretion of the test article following IM dosing</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Radiolabeled ADME</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Determine the absorption, metabolism and excretion of the test article following IM dosing</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">4</FONT></TD><TD STYLE="text-align: justify">OPTION 3: <I>IN VITRO</I> EXPERIMENTS &ndash; IV</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Duration: <B>*&nbsp;*&nbsp;* </B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Go/No Go to Initiate: Selection of a preliminary IV formulation (LRI) based on initial
studies</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Through completion of earlier studies, it will be determined what is an
appropriate IV formulation to continue with toxicology studies of the IV formulation under this Option. This Option will add
value to determine if there is any identified toxicology in <I>in vitro </I>assays before moving to animal studies in Option
4.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt">BioCryst Pharmaceuticals</FONT></TD><TD STYLE="width: 50%; text-align: right; font-size: 10pt"><FONT STYLE="font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> of 17</FONT></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">May 18, 2016</FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right"></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="font-size: 10pt; margin: 0pt 0">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked &quot;***&quot; and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Request with the Commission.</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Decision Criterion:</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD><B>*&nbsp;*&nbsp;* </B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">4.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;* </FONT>&ndash; IV</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall develop the protocol, select and qualify the vendor, conduct the
experiments and analyze the data resulting in a study report.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">4.2.</FONT></TD><TD STYLE="text-align: justify">Conduct <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;* </FONT>Test &ndash; IV</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall develop the protocol, select and qualify the vendor, conduct the
experiment and analyze the data resulting in a study report.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">A listing of the proposed experiments for the <I>in vitro</I> experiments to be conducted
in advance of the noncIinicaI NDA-enabling toxicology studies for the IV formulation is provided in Table 15 .</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Table 7:&#9;In vitro Experiments - IV</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top; background-color: black">
    <TD STYLE="width: 10%; border: Black 1pt solid"><FONT STYLE="font-size: 10pt; color: White">Study #</FONT></TD>
    <TD STYLE="width: 23%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt; color: White">Description</FONT></TD>
    <TD STYLE="width: 53%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; color: White">Objectives</FONT></TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="color: White">Species</FONT></P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="color: White">(N)</FONT></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0"><FONT STYLE="color: White">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"><B>*&nbsp;*&nbsp;* </B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"><B>*&nbsp;*&nbsp;* </B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">4.3.</FONT></TD><TD STYLE="text-align: justify">Study Report on all in vitro assays</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall submit a summarized study report with data and conclusions from
all in vitro experiments conducted in table 7 to determine whether there is any toxicology before advancing into non-clinical NDA
enabling toxicology studies (Option 5).</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">5</FONT></TD><TD STYLE="text-align: justify">OPTION 4: NONCLINICAL NDA-ENABLING TOXICOLOGY</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Duration: <B>*&nbsp;*&nbsp;* </B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Go/No Go Criteria to Initiate: WBS 4.3 Study Report on all <I>in vitro</I> assays</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Through completion of the IV <I>in vitro</I> toxicology studies with the IV formulation
conducted in Option 3 and summarized in WBS 4.3, it will be determined if the IV formulation is safe to move into non-clinical
toxicology animal studies in this Option. This Option will add value to the project through conducting additional non-clinical
activities that will support a potential future NDA.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt">BioCryst Pharmaceuticals</FONT></TD><TD STYLE="width: 50%; text-align: right; font-size: 10pt"><FONT STYLE="font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> of 17</FONT></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">May 18, 2016</FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right"></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="font-size: 10pt; margin: 0pt 0">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked &quot;***&quot; and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Request with the Commission.</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Decision Criterion:</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD><B>*&nbsp;*&nbsp;* </B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD><B>*&nbsp;*&nbsp;* </B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">5.1.</FONT></TD><TD STYLE="text-align: justify">GLP <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;* </FONT>Toxicology</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall for each toxicology study develop the protocol, select and qualify
the vendor, conduct in life and recovery phases and analyze study data resulting in a final study report. Studies include:</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">5.1.1.</FONT></TD><TD STYLE="text-align: justify">Conduct GLP <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;* </FONT>general toxicology study -
<FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;* </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">5.1.2.</FONT></TD><TD STYLE="text-align: justify">Conduct GLP <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;* </FONT>toxicology study - <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;*
</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">5.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;* </FONT>toxicology</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall for each <B>*&nbsp;*&nbsp;* </B>study segment develop the protocol,
select and qualify the vendor, conduct in life and recovery phases and analyze study data resulting in a final study report. Studies
include:</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">5.2.1.</FONT></TD><TD STYLE="text-align: justify">Conduct <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;* </FONT>assessment in <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;*
</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">5.2.2.</FONT></TD><TD STYLE="text-align: justify">Conduct <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;* </FONT>Dose Range Finding Studies in
<FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;* </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">5.2.3.</FONT></TD><TD STYLE="text-align: justify">Conduct Definitive <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;* </FONT>toxicology in <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;*
</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">5.2.4.</FONT></TD><TD STYLE="text-align: justify">Conduct <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;* </FONT>toxicology <FONT STYLE="font-weight: normal">*&nbsp;*&nbsp;*
</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">A listing of the proposed studies for the nonclinical NDA-enabling toxicology studies
for the IV formulation is provided in Table 16.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Table 8:&#9;Nonclinical NDA-enabling Toxicology Studies</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top; background-color: black">
    <TD STYLE="width: 10%; border: Black 1pt solid"><FONT STYLE="font-size: 10pt; color: white">Study #</FONT></TD>
    <TD STYLE="width: 24%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt; color: white">Description</FONT></TD>
    <TD STYLE="width: 52%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; color: white">Objective(s)</FONT></TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt; color: white">Species</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">GLP &nbsp;<B>*&nbsp;*&nbsp;* </B>&nbsp;general toxicology</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"><B>*&nbsp;*&nbsp;* </B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">GLP &nbsp;<B>*&nbsp;*&nbsp;* </B>general toxicology</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"><B>*&nbsp;*&nbsp;* </B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B>assessment</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"><B>*&nbsp;*&nbsp;* </B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B>Dose Range Finding</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"><B>*&nbsp;*&nbsp;* </B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt">BioCryst Pharmaceuticals</FONT></TD><TD STYLE="width: 50%; text-align: right; font-size: 10pt"><FONT STYLE="font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> of 17</FONT></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">May 18, 2016</FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right"></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="font-size: 10pt; margin: 0pt 0">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked &quot;***&quot; and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Request with the Commission.</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; border: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 24%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B>Dose Range Finding</FONT></TD>
    <TD STYLE="width: 52%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"><B>*&nbsp;*&nbsp;* </B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Definitive &nbsp;<B>*&nbsp;*&nbsp;* </B>toxicology</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"><B>*&nbsp;*&nbsp;* </B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Definitive &nbsp;<B>*&nbsp;*&nbsp;* </B>toxicology</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"><B>*&nbsp;*&nbsp;* </B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B>toxicology</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"><B>*&nbsp;*&nbsp;* </B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B></B></P>



<P STYLE="font-size: 10pt; margin: 0pt 0"><B></B></P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">6</FONT></TD><TD STYLE="text-align: justify">PROGRAM MANAGEMENT</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall provide all expertise needed for the implementation of the activities
to be performed under this contract, including: research, manufacturing, regulatory, clinical, statistical analyses, management
and administrative activities.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">6.1.</FONT></TD><TD STYLE="text-align: justify">Technical and Project Management Support</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall appoint a Principal Investigator (PI) who will be responsible for
all aspects of project performance and communication with the BARDA.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall provide project management that will ensure day-to-day monitoring
and tracking of progress and timelines, the coordination of project activities and costs incurred.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall provide all managerial and administrative functions necessary for
overall planning, monitoring, and implementing activities for the completion of the strategic product development plan.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall provide for all necessary legal affairs required to ensure the timely
acquisition of all proprietary rights, including intellectual property rights and all materials needed to perform the project,
as well as reporting to the Government all inventions made in the performance of the project.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">6.2.</FONT></TD><TD STYLE="text-align: justify">Subcontractor Management</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall provide for tracking, coordination and oversight of subcontractor
efforts and manage communications with subcontractors.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">6.3.</FONT></TD><TD STYLE="text-align: justify">Risk Management</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall identify project risks, develop risk management strategies and implement
mitigation actions.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">6.4.</FONT></TD><TD STYLE="text-align: justify">Earned Value Management (EVM)</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall provide EVM information.<BR CLEAR="ALL"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt">BioCryst Pharmaceuticals</FONT></TD><TD STYLE="width: 50%; text-align: right; font-size: 10pt"><FONT STYLE="font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --> of 17</FONT></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">May 18, 2016</FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right"></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="font-size: 10pt; margin: 0pt 0">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked &quot;***&quot; and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Request with the Commission.</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">6.5.</FONT></TD><TD STYLE="text-align: justify">Project Communications</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall provide for project communications including communications with
BARDA and external experts.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall provide planning and steps required for the conduct of contract
review meetings.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">7</FONT></TD><TD STYLE="text-align: justify">REGULATORY</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall ensure adherence to FDA regulations and guidance, including requirements
for the conduct of animal studies and assays under GLP, the manufacturing of the therapeutic product under GMP, and the conduct
of clinical trials under GCP standards.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">7.1.</FONT></TD><TD STYLE="text-align: justify">Regulatory Authority Interactions</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall prepare and submit documentation and correspondence to regulatory
authorities as required. The contractor shall request and conduct meetings with regulatory authorities to ensure the development
program is conducted in accordance with regulatory guidelines and expectations.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">7.2.</FONT></TD><TD STYLE="text-align: justify">Quality Assurance</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall maintain quality assurance documentation. The contractor shall arrange
for audits of subcontractor facilities to ensure all planned procedures comply with the FDA regulations and guidance that are required
to meet GLP, GMP and GCP standards. In addition, the contractor shall ensure that all contractor and/or subcontractor records and
staff are available for site visits or audits.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">7.3.</FONT></TD><TD STYLE="text-align: justify">Expert Collaborations</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The contractor shall collaborate with experts in the field in the design of experiments
and studies that support the advancement of the development program.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt">BioCryst Pharmaceuticals</FONT></TD><TD STYLE="width: 50%; text-align: right; font-size: 10pt"><FONT STYLE="font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --> of 17</FONT></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">May 18, 2016</FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right"></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="font-size: 10pt; margin: 0pt 0">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked &quot;***&quot; and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Request with the Commission.</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>MILESTONE AND DELIVERABLES CHART<BR>
BioCryst Pharmaceuticals Contract HHSO100201500007C</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top; background-color: #A6A6A6">
    <TD STYLE="width: 8%; border: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; color: white"><B>WBS</B></FONT></TD>
    <TD STYLE="width: 21%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; color: white"><B>Milestone</B></FONT></TD>
    <TD STYLE="width: 30%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; color: white"><B>Deliverable</B></FONT></TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0; color: white"><B>Success </B></P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0; color: white"><B>Criteria</B></P></TD>
    <TD STYLE="width: 12%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; color: white"><B>Timing</B></FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; color: white"><B>Go/No-Go for initiation</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="6" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>CLIN 0001 &ndash; MANUFACTURE OF CLINICAL TRIAL MATERIAL</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.2.1</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Process Improvements Report</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Report on Process Development</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Process Developed</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.2.2</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Determination of Sufficient Process for Commercial Scale up</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Evaluation report</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">BARDA approval of developed process</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.3.1</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Manufacture &nbsp;<B>*&nbsp;*&nbsp;* </B>(Batch &nbsp;<B>*&nbsp;*&nbsp;* </B>)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Acceptable quality and yield</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.3.2</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Manufacture &nbsp;<B>*&nbsp;*&nbsp;* </B>(Batch &nbsp;<B>*&nbsp;*&nbsp;* </B>)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Acceptable quality and yield</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.3.3</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Manufacture &nbsp;<B>*&nbsp;*&nbsp;* </B>(Batch &nbsp;<B>*&nbsp;*&nbsp;* </B>)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Acceptable quality and yield</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.4.1</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Manufacture GMP BCX4430 (DS Batch &nbsp;<B>*&nbsp;*&nbsp;* </B>)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">BCX4430 DS</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CofA,</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Acceptable quality and yield</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.4.2</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Manufacture
    GMP BCX4430 (DS Batch &nbsp;<B>*&nbsp;*&nbsp;* </B>)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">BCX4430 DS</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CofA,</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Acceptable quality and yield</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.4.3</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Prepare a Campaign Summary Reports</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Campaign Reports (DS Batches &nbsp;<B>*&nbsp;*&nbsp;* </B>)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Completion of DS Campaigns</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.4.4</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Drug substance stability study</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Report on stability activities</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Stability data</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.5</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Drug Product Development</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">DP Process Development Report (WBS 1.5.4)</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Pre-formulation and Physicochemical Report (WBS 1.5.5)</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Extractable/Leachable Report (WBS 1.5.7)</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Completion of Studies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.5.8</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Excipient Compatibility Report for IV Formulation</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Compatibility Report</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">IV formulation completed</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.6.1</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Manufacture GMP DP (DP Batch &nbsp;<B>*&nbsp;*&nbsp;* </B>)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">BCX4430 DP</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CofA,</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Acceptable quality and yield</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Accepted GMP DS</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.6.2</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Manufacture GMP DP (DP Batch &nbsp;<B>*&nbsp;*&nbsp;* </B>)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">BCX4430 DP</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CofA,</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Acceptable quality and yield</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Accepted GMP DS</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><P STYLE="font-size: 10pt; margin: 0pt 0">BioCryst Pharmaceuticals</P><P STYLE="font-size: 10pt; margin: 0pt 0">May 18, 2016</P><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="font-size: 10pt; margin: 0pt 0">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked &quot;***&quot; and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Request with the Commission.</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; border: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.6.3</FONT></TD>
    <TD STYLE="width: 21%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Prepare a Campaign Summary Reports</FONT></TD>
    <TD STYLE="width: 30%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Campaign Reports (DP Batches &nbsp;<B>*&nbsp;*&nbsp;* </B>)</FONT></TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Completion of DP Campaigns</FONT></TD>
    <TD STYLE="width: 12%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.6.4</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Drug Product stability study &ndash; Active</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Report on stability activities</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Stability Data</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.6.5</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Drug Product stability study &ndash; Placebo</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Report on stability activities</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Stability Data</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.6.6</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Comparability Study</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Comparability Protocol and Report</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Completion of DS and DP Campaigns</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.7.1</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Manufacture GMP BCX4340 (DS Batch &nbsp;<B>*&nbsp;*&nbsp;* </B>)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">BCX4430 DS</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CofA</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Acceptable DS process</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.7.2</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Manufacture GMP BCX4340 (DS Batch &nbsp;<B>*&nbsp;*&nbsp;* </B>)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">BCX4430 DS</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CofA</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Acceptable DS process</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.7.3</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Prepare a Campaign Summary Report</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Campaign Reports (DS Batch &nbsp;<B>*&nbsp;*&nbsp;* </B>)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Completion of DS Campaign</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.7.4</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Manufacture GMP DP (<B>*&nbsp;*&nbsp;* </B>)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">BCX4430 DP</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CofA,</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Acceptable quality and yield</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Accepted GMP DS</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.7.5</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Prepare a Campaign Summary Report</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Campaign Report (CTM Batches &nbsp;<B>*&nbsp;*&nbsp;* </B>)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Completion of DS Campaigns</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.7.6</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Drug Substance and Drug Product stability study</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">report on stability activities</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Stability Data</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Manufacture of 1.7.1 &amp; 1.7.2 drug substance and 1.7.4 drug product</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.7.7</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Comparability Study</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Comparability Protocol and Report</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Comparable DS and DP profiles</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1.7.8</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Drug Product &nbsp;<B>*&nbsp;*&nbsp;* </B>formulation Development</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B>Process that can be sealed to a manufacturing facility</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Suitable &nbsp;<B>*&nbsp;*&nbsp;* </B>/Finalized process</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="6" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>CLIN 0002 &ndash; COMMERCIAL SCALE UP AND NDA REGISTRATION BATCHES</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Go/No Go Criteria to Initiate: WBS 1.2.2 BARDA approval of process developed</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">2.2</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Drug Substance Process Scale-up</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Process Development Report (WBS 2.2.4)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Selection of the optimized manufacturing process</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">2.3.1</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Manufacture BCX4340 DS (DS Registration Batch &nbsp;<B>*&nbsp;*&nbsp;* </B>)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">BCX4430 Registration DS</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CofA</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Acceptable quality and yield</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">2.3.2</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Manufacture BCX4340 DS (DS Registration Batch &nbsp;<B>*&nbsp;*&nbsp;* </B>)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">BCX4430 Registration DS</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CofA,</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Acceptable quality and yield</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">2.3.3</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Manufacture BCX4340 DS (DS Registration Batch &nbsp;<B>*&nbsp;*&nbsp;* </B>)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">BCX4430 Registration DS</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CofA,</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Acceptable quality and yield</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"></TD></TR></TABLE>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><P STYLE="font-size: 10pt; margin: 0pt 0">BioCryst Pharmaceuticals</P><P STYLE="font-size: 10pt; margin: 0pt 0">May 18, 2016</P><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="font-size: 10pt; margin: 0pt 0">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked &quot;***&quot; and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Request with the Commission.</P></DIV>
    <!-- Field: /Page -->


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 8%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 21%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 30%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 14%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 12%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 15%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">2.3.4</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Prepare a Campaign Summary Report</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Campaign Reports (DS Batches &nbsp;<B>*&nbsp;*&nbsp;* </B>)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Completion of DS Campaign</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">2.4.1</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Manufacture BCX4430 DP (DP Registration Batch &nbsp;<B>*&nbsp;*&nbsp;* </B>)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">BCX4430 DP</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CofA,</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Acceptable quality and yield</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Accepted GMP DS</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">2.4.2</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Manufacture BCX4430 DP (DP Registration Batch &nbsp;<B>*&nbsp;*&nbsp;* </B>)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">BCX4430 DP</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CofA,</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Acceptable quality and yield</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Accepted GMP DS</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">2.4.3</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Manufacture BCX4430 DP (DP Registration Batch &nbsp;<B>*&nbsp;*&nbsp;* </B>)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">BCX4430 DP</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CofA,</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Acceptable quality and yield</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Accepted GMP DS</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">2.4.4</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Prepare a Campaign Summary Report</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Campaign Report (CTM Registration Batches &nbsp;<B>*&nbsp;*&nbsp;* </B>)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Completion of DS Campaigns</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">2.5</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Drug substance and Drug Product stability study</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Report on stability activities</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Stability Data</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">2.6</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Comparability Study</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;Comparability Protocol and Report</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Comparable DS and DP profiles</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Accepted GMP DS</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="6" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>CLIN 0003 &ndash; NONCLINICAL NDA-ENABLING TOXICOLOGY</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Go/No Go Criteria to Initiate: /availability of </B>&nbsp;<B>*&nbsp;*&nbsp;* GMP batch of DS manufactured under NIAID contract</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>HHSO100201500007C</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">3.1.1</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Complete GLP &nbsp;<B>*&nbsp;*&nbsp;* </B>Tox Study &ndash; &nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Study Report</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Established NOAEL</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Drug Substance confirming to release criteria</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">3.1.2</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Complete GLP &nbsp;<B>*&nbsp;*&nbsp;* </B>Tox Study &ndash; &nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Study Report</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Established NOAEL</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Drug Substance confirming to release criteria</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">3.2.1</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Conduct &nbsp;<B>*&nbsp;*&nbsp;* </B>assessment in &nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Study Report</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">No significant findings</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">3.2.2</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Conduct &nbsp;<B>*&nbsp;*&nbsp;* </B>Dose Range Finding Studies in &nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Study Report</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">No significant findings</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">3.2.3</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Conduct Definitive &nbsp;<B>*&nbsp;*&nbsp;* </B>toxicology in &nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Study Report</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">No significant findings</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">3.2.4</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Conduct &nbsp;<B>*&nbsp;*&nbsp;* </B>&nbsp;toxicology &nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Study Report</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">No significant findings</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><P STYLE="font-size: 10pt; margin: 0pt 0">BioCryst Pharmaceuticals</P><P STYLE="font-size: 10pt; margin: 0pt 0">May 18, 2016</P><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="font-size: 10pt; margin: 0pt 0">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked &quot;***&quot; and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Request with the Commission.</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; border: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">3.3.1</FONT></TD>
    <TD STYLE="width: 21%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Conduct Radiolabeled ADME study &ndash; &nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="width: 30%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Study Report</FONT></TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Characterize drug disposition</FONT></TD>
    <TD STYLE="width: 12%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Acceptable Radiolabel Material</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">3.3.2</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Conduct Radiolabeled ADME &ndash; &nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Study Report</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Characterize drug disposition</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Acceptable Radiolabel Material</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="6" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>CLIN 0004 &ndash; IN VITRO EXPERIMENTS &ndash; IV</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Go/No Go to Initiate: selection of an appropriate preliminary IV formulation</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">4.1.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Conduct &nbsp;<B>*&nbsp;*&nbsp;* </B>Test &ndash; IV</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Study Report</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">No effect on human, rat and non-human erythrocytes ex vivo</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">IV formulation WBS 1.5.8</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">4.2.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Conduct &nbsp;<B>*&nbsp;*&nbsp;* </B>Test &ndash; IV</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Study Report</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">No effect on mitotic apparatus</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">4.3</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">In Vitro IV experiments</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Study report on all In Vitro assays with recommendation to proceed CLIN0005</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">No toxicology <I>in vitro</I></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="6" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>CLIN 0005 &ndash; NONCLINICAL NDA-ENABLING TOXICOLOGY</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Go/No Go to Initiate: WBS 4.3 Completion of </B>&nbsp;<B>*&nbsp;*&nbsp;* IV toxicology studies</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">5.1.1</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Complete GLP &nbsp;<B>*&nbsp;*&nbsp;* </B>Tox Study &ndash; &nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Study Report</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Established NOAEL</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Drug Substance confirming to release criteria</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">5.1.2</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Complete GLP &nbsp;<B>*&nbsp;*&nbsp;* </B>Tox Study &ndash; &nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Study Report</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Established NOAEL</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Drug Substance confirming to release criteria</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">5.2.1</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Conduct &nbsp;<B>*&nbsp;*&nbsp;* </B>assessment in &nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Study Report</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">No significant findings</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">5.2.2</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Conduct &nbsp;<B>*&nbsp;*&nbsp;* </B>Dose Range Finding Studies in &nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Study Report</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">No significant findings</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">5.2.3</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Conduct Definitive &nbsp;<B>*&nbsp;*&nbsp;* </B>toxicology in &nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Study Report</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">No significant findings</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">5.2.4</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Conduct &nbsp;<B>*&nbsp;*&nbsp;* </B>&nbsp;toxicology &nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Study Report</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">No significant findings</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;<B>*&nbsp;*&nbsp;* </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>


<P STYLE="margin-top: 0; margin-bottom: 0; text-align: left"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">BioCryst Pharmaceuticals</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">May 18, 2016</P>



<P STYLE="margin-top: 0; margin-bottom: 0; text-align: left"></P>


<P STYLE="margin-top: 0; margin-bottom: 0; text-align: left"></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>exh_103.htm
<DESCRIPTION>EXHIBIT 10.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right">EXHIBIT 10.3</P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;<IMG SRC="exh103_1.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="exh103_2.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;<IMG SRC="exh103_3.jpg" ALT=""></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>exh_311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0"><B>Exhibit 31.1</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>CERTIFICATIONS</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">I, Jon P. Stonehouse, certify that:</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 4%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%; font-size: 10pt"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%; font-size: 10pt"><FONT STYLE="font-size: 10pt">I have reviewed this quarterly report on Form 10-Q of BioCryst Pharmaceuticals, Inc.;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 87%"><FONT STYLE="font-size: 10pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 87%"><FONT STYLE="font-size: 10pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">c.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 87%"><FONT STYLE="font-size: 10pt">evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">d.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 87%"><FONT STYLE="font-size: 10pt">disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 87%"><FONT STYLE="font-size: 10pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 87%"><FONT STYLE="font-size: 10pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 30%">&nbsp;</TD>
    <TD STYLE="width: 20%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">Date: August 8, 2016</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Jon P. Stonehouse</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Jon P. Stonehouse</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: right; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>exh_312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0"><B>Exhibit 31.2</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>CERTIFICATIONS</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">I, Thomas R. Staab, II, certify that:</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 4%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%; font-size: 10pt"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%; font-size: 10pt"><FONT STYLE="font-size: 10pt">I have reviewed this quarterly report on Form 10-Q of BioCryst Pharmaceuticals, Inc.;&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 87%"><FONT STYLE="font-size: 10pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 87%"><FONT STYLE="font-size: 10pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">c.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 87%"><FONT STYLE="font-size: 10pt">evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">d.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 87%"><FONT STYLE="font-size: 10pt">disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 87%"><FONT STYLE="font-size: 10pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="vertical-align: top; width: 87%"><FONT STYLE="font-size: 10pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">Date: August 8, 2016</FONT></TD>
    <TD STYLE="width: 30%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Thomas R. Staab, II</FONT></TD>
    <TD STYLE="width: 20%">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Thomas R. Staab, II</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Senior Vice President, Chief Financial Officer and Treasurer</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>exh_321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0"><B>Exhibit 32.1</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">In connection with the Quarterly Report of BioCryst Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;)
on Form 10-Q for the period ending June 30, 2016 as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;),
I, Jon P. Stonehouse, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &sect; 1350, as adopted pursuant to
&sect; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top">
        <P STYLE="font-size: 10pt; margin: 0pt 4.4pt 0pt 0">The Report fully complies with the requirements of section 13(a) or 15(d) of
        the Securities Exchange Act of 1934; and</P>
        <P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 4.4pt 0pt 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.&nbsp;&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3">
        <P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0.05in 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0.05in 0pt 0; text-indent: 0.5in">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Jon P. Stonehouse</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Jon P. Stonehouse</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="4" STYLE="vertical-align: top">
        <P STYLE="font-size: 10pt; text-indent: -0.25in; margin: 0pt 7.4pt 0pt 0.25in">President and Chief Executive Officer</P>
        <P STYLE="font-size: 10pt; text-indent: -0.25in; margin: 0pt 7.4pt 0pt 0.25in">Date: August 8, 2016</P></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 25%">&nbsp;</TD>
    <TD STYLE="width: 66%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>exh_322.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0"><B>Exhibit&nbsp;32.2</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">In connection with the Quarterly Report of BioCryst Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;)
on Form 10-Q for the period ending June&nbsp;30, 2016 as filed with the Securities and Exchange Commission on the date hereof (the
&ldquo;Report&rdquo;), I, Thomas R. Staab, II, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &sect; 1350,
as adopted pursuant to &sect; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 4%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%; font-size: 10pt"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%; font-size: 10pt"><FONT STYLE="font-size: 10pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="vertical-align: top; width: 92%"><FONT STYLE="font-size: 10pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 30%">&nbsp;</TD>
    <TD STYLE="width: 70%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Thomas R. Staab, II</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Thomas R. Staab, II</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">
        <P STYLE="font-size: 10pt; margin: 0pt 4.4pt 0pt 0">Senior Vice President, Chief Financial Officer and Treasurer</P>
        <P STYLE="font-size: 10pt; margin: 0pt 4.4pt 0pt 0">Date: August&nbsp;8, 2016</P></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>9
<FILENAME>bcrx-20160630.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 10:21PM UTC 2016-08-06--><xbrli:xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:bcrx="http://www.biocryst.com/20160630" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:href="bcrx-20160630.xsd" xlink:type="simple"/>
  <bcrx:AccruedExpensesPolicyTextBlock contextRef="d_2016-01-01_2016-06-30" id="c8267412">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Accrued Expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company generally enters into contractual agreements with third-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include:&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; width: 700px;"&gt; &lt;tr&gt; &lt;td style="width: 5%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; width: 2%"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;#x2022;&lt;/div&gt;&lt;/td&gt; &lt;td style="vertical-align: top; width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; width: 92%"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;fees paid to Clinical Research Organizations (&amp;#x201c;CROs&amp;#x201d;) in connection with preclinical and toxicology studies and clinical trials;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;#x2022;&lt;/div&gt;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;fees paid to investigative sites in connection with clinical trials;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;#x2022;&lt;/div&gt;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;fees paid to contract manufacturers in connection with the production of our raw materials, drug substance and drug products;&amp;nbsp;and&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;#x2022;&lt;/div&gt;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;professional fees.&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&amp;#x2019;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of June 30, 2016 and December 31, 2015, the carrying value of accrued expenses approximates their fair value due to their short-term settlement.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</bcrx:AccruedExpensesPolicyTextBlock>
  <bcrx:AdvanceNoticePeriodForTerminationOfAgreement contextRef="d_2000-06-01_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember" id="c7789302">P60D</bcrx:AdvanceNoticePeriodForTerminationOfAgreement>
  <bcrx:AmortizationOfDiscountAndPremiumOnInvestments contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c8266783" unitRef="iso4217-usd">302000</bcrx:AmortizationOfDiscountAndPremiumOnInvestments>
  <bcrx:AmortizationOfDiscountAndPremiumOnInvestments contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c8266784" unitRef="iso4217-usd">266000</bcrx:AmortizationOfDiscountAndPremiumOnInvestments>
  <bcrx:AnnualLicenseFeeMaximum contextRef="i_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember" decimals="INF" id="c7789301" unitRef="iso4217-usd">500000</bcrx:AnnualLicenseFeeMaximum>
  <bcrx:AnnualLicenseFeeMinimum contextRef="i_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember" decimals="INF" id="c7789300" unitRef="iso4217-usd">150000</bcrx:AnnualLicenseFeeMinimum>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2016-06-30_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c7788839" unitRef="iso4217-usd">38000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2016-06-30_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c7788844" unitRef="iso4217-usd">147000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2016-06-30_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c7788849" unitRef="iso4217-usd">22000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2016-06-30" decimals="-3" id="c7788854" unitRef="iso4217-usd">207000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2015-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c7788859" unitRef="iso4217-usd">88000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2015-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c7788864" unitRef="iso4217-usd">184000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2015-12-31_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c7788869" unitRef="iso4217-usd">21000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest contextRef="i_2015-12-31" decimals="-3" id="c7788874" unitRef="iso4217-usd">293000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <bcrx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue contextRef="i_2016-06-30" decimals="-3" id="c7788880" unitRef="iso4217-usd">18164000</bcrx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue>
  <bcrx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue contextRef="i_2015-12-31" decimals="-3" id="c7788881" unitRef="iso4217-usd">28395000</bcrx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue>
  <bcrx:AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock contextRef="d_2016-01-01_2016-06-30" id="c-17">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 74%; font-size: 10pt; text-align: left"&gt;Maturing in one year or less&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;27,079&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;22,664&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Maturing after one year through two years&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;18,164&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;28,395&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Maturing after two years&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;5,990&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;19,288&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;51,233&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;70,347&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</bcrx:AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock>
  <bcrx:AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears contextRef="i_2016-06-30" decimals="-3" id="c7788882" unitRef="iso4217-usd">5990000</bcrx:AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears>
  <bcrx:AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears contextRef="i_2015-12-31" decimals="-3" id="c7788883" unitRef="iso4217-usd">19288000</bcrx:AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears>
  <bcrx:AveragematurityForPortfolioInvestments contextRef="d_2016-01-01_2016-06-30_RangeAxis-MaximumMember" id="c7789111">P1Y180D</bcrx:AveragematurityForPortfolioInvestments>
  <bcrx:AveragematurityPeriodOfHighQualityMarketableSecurities contextRef="d_2016-01-01_2016-06-30_RangeAxis-MaximumMember" id="c7789011">P1Y180D</bcrx:AveragematurityPeriodOfHighQualityMarketableSecurities>
  <bcrx:CollaborationAgreementAdditionalPaymentsReceived contextRef="i_2016-06-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember" decimals="INF" id="c8267287" unitRef="iso4217-usd">35350</bcrx:CollaborationAgreementAdditionalPaymentsReceived>
  <bcrx:CollaborativeAndOtherResearchAndDevelopment contextRef="d_2016-04-01_2016-06-30" decimals="-3" id="c7788708" unitRef="iso4217-usd">4158000</bcrx:CollaborativeAndOtherResearchAndDevelopment>
  <bcrx:CollaborativeAndOtherResearchAndDevelopment contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c7788709" unitRef="iso4217-usd">25710000</bcrx:CollaborativeAndOtherResearchAndDevelopment>
  <bcrx:CollaborativeAndOtherResearchAndDevelopment contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7788710" unitRef="iso4217-usd">7088000</bcrx:CollaborativeAndOtherResearchAndDevelopment>
  <bcrx:CollaborativeAndOtherResearchAndDevelopment contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7788711" unitRef="iso4217-usd">30481000</bcrx:CollaborativeAndOtherResearchAndDevelopment>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2016-04-01_2016-06-30_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c7788923" unitRef="iso4217-usd">3709000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2015-04-01_2015-06-30_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c7788924" unitRef="iso4217-usd">3731000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2016-01-01_2016-06-30_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c7788925" unitRef="iso4217-usd">6033000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2015-01-01_2015-06-30_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c7788926" unitRef="iso4217-usd">8206000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2016-04-01_2016-06-30_CounterpartyNameAxis-ShionogiAndCoLtdMember" decimals="-3" id="c7788927" unitRef="iso4217-usd">296000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2015-04-01_2015-06-30_CounterpartyNameAxis-ShionogiAndCoLtdMember" decimals="-3" id="c7788928" unitRef="iso4217-usd">296000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2016-01-01_2016-06-30_CounterpartyNameAxis-ShionogiAndCoLtdMember" decimals="-3" id="c7788929" unitRef="iso4217-usd">592000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2015-01-01_2015-06-30_CounterpartyNameAxis-ShionogiAndCoLtdMember" decimals="-3" id="c7788930" unitRef="iso4217-usd">592000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2016-04-01_2016-06-30_CounterpartyNameAxis-SeqirusUKLimitedMember" decimals="-3" id="c7788931" unitRef="iso4217-usd">153000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2015-04-01_2015-06-30_CounterpartyNameAxis-SeqirusUKLimitedMember" decimals="-3" id="c7788932" unitRef="iso4217-usd">21683000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2016-01-01_2016-06-30_CounterpartyNameAxis-SeqirusUKLimitedMember" decimals="-3" id="c7788933" unitRef="iso4217-usd">463000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2015-01-01_2015-06-30_CounterpartyNameAxis-SeqirusUKLimitedMember" decimals="-3" id="c7788934" unitRef="iso4217-usd">21683000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2016-04-01_2016-06-30" decimals="-3" id="c7788935" unitRef="iso4217-usd">4158000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c7788936" unitRef="iso4217-usd">25710000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7788937" unitRef="iso4217-usd">7088000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7788938" unitRef="iso4217-usd">30481000</bcrx:CollaborativeAndOtherResearchAndDevelopmentRevenues>
  <bcrx:ConcentrationOfMarketRiskPolicyTextBlock contextRef="d_2016-01-01_2016-06-30" id="c8269842">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Significant Customers and Other Risks&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Significant Customers&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Prior to the SUL Agreement, the Company relied primarily on three specialty distributors to purchase and supply the majority of RAPIVAB. These three pharmaceutical specialty distributors accounted for greater than 90% of all RAPIVAB product sales to date and accounted for predominantly all of the Company&amp;#x2019;s outstanding receivables from product sales. The loss of one or more of these specialty distributors as a customer could negatively impact the commercialization of RAPIVAB. However, the Company will utilize these specialty distributors on a limited basis subsequent to the SUL collaboration as SUL, and other peramivir collaboration partners, will be responsible for commercial sales on a worldwide basis. In addition, in connection with the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&amp;#x2019;s partners and the Company will be reliant on these partners to generate sales and remit cash to satisfy receivables.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;The Company&amp;#x2019;s primary source of revenue that has an underlying cash flow stream is the reimbursement of RAPIVAB and BCX4430 development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its RAPIVAB and BCX4430 programs. Accordingly, reimbursement of these expenses represents a significant portion of the Company&amp;#x2019;s collaborative and other research and development revenues. The completion (as with the June 30, 2014 BARDA/HHS peramivir development contract) or termination of the NIAID/HHS and BARDA/HHS BCX4430 contracts could negatively impact the Company&amp;#x2019;s future Consolidated Statements of Comprehensive Loss and Cash Flows. In addition, the Company also recognizes royalty revenue from the net sales of RAPIACTA by Shionogi; however, the underlying cash flow from these royalty payments goes directly to pay the interest, and then the principal, on the Company&amp;#x2019;s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. Further, the Company&amp;#x2019;s drug development activities are performed by a limited group of third party vendors. If any of these vendors were unable to perform their services, this could significantly impact the Company&amp;#x2019;s ability to complete its drug development activities.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Risks from Third Party Manufacturing and Distribution Concentration&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 22.5pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;The Company relies on single source manufacturers for active pharmaceutical ingredient and finished drug product manufacturing of RAPIVAB, as well as for its other product candidates in development. Delays in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling of RAPIVAB or the Company&amp;#x2019;s product candidates in development.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Credit Risk&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 22.5pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately 18 months or less. Other than product sale and collaborative partner receivables discussed above, the majority of the Company&amp;#x2019;s receivables from collaborations are due from the U.S. Government, for which there is no assumed credit risk.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</bcrx:ConcentrationOfMarketRiskPolicyTextBlock>
  <bcrx:CurrencyHedgeAgreementPolicyTextBlock contextRef="d_2016-01-01_2016-06-30" id="c8267419">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Currency Hedge Agreement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore, mark-to-market adjustments are recognized in the Company&amp;#x2019;s Consolidated Statements of Comprehensive Loss. Cumulative mark-to-market adjustments for the six months ended June&amp;nbsp;30, 2016 and 2015 resulted in losses of $6,441 and $332, respectively. Mark-to-market adjustments are determined by a third party pricing model that uses quoted prices in markets that are not actively traded and for which significant inputs are observable directly or indirectly, representing Level 2 in the fair value hierarchy as defined by U.S. GAAP. The Company is also required to post collateral in connection with the mark-to-market adjustments based on thresholds defined in the Currency Hedge Agreement. In addition, the Company realized currency exchange gains of $811 and $1,545 during the first six months of 2016 and 2015, respectively, associated with the exercise of a U.S. dollar/Japanese yen currency option under the Currency Hedge Agreement. As of June&amp;nbsp;30, 2016, $1,610 of hedge collateral was posted under the agreement. No hedge collateral was posted as of December 31, 2015.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</bcrx:CurrencyHedgeAgreementPolicyTextBlock>
  <bcrx:DeferredCollaborationExpenseAssets contextRef="i_2016-06-30" decimals="-3" id="c7788657" unitRef="iso4217-usd">229000</bcrx:DeferredCollaborationExpenseAssets>
  <bcrx:DeferredCollaborationExpenseAssets contextRef="i_2015-12-31" decimals="-3" id="c7788658" unitRef="iso4217-usd">265000</bcrx:DeferredCollaborationExpenseAssets>
  <bcrx:DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7788800" unitRef="iso4217-usd">-37000</bcrx:DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities>
  <bcrx:DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7788801" unitRef="iso4217-usd">136000</bcrx:DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities>
  <bcrx:DescriptionOfCompanyPolicyTextBlock contextRef="d_2016-01-01_2016-06-30" id="c8267402">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;The Company&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;BioCryst Pharmaceuticals, Inc. (the &amp;#x201c;Company&amp;#x201d;) is a biotechnology company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and align with its capabilities and expertise. The Company was incorporated in Delaware in 1986 and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred losses and negative cash flows from operations since inception.&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Based on its current operating plans, the Company expects it has sufficient liquidity, with its existing cash, restricted cash and investments of $64,320, to continue its planned operations through mid-2017. The Company&amp;#x2019;s liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key development and regulatory events in the future. In order to continue its operations substantially beyond mid-2017 it will need to: (1)&amp;nbsp;successfully secure or increase U.S. Government funding of its programs, including procurement contracts; (2)&amp;nbsp;out-license rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; (3)&amp;nbsp;raise additional capital through equity or debt financings or from other sources; (4)&amp;nbsp;obtain additional product candidate regulatory approvals, which would generate revenue and cash flow; (5)&amp;nbsp;reduce spending on one or more research and development programs; and/or (6)&amp;nbsp;restructure operations. The Company may issue securities, including common stock, preferred stock, depositary shares, stock purchase contracts, warrants and units, through private placement transactions or registered public offerings pursuant to its registration statements on Form S-3 initially filed with the Securities and Exchange Commission (&amp;#x201c;SEC&amp;#x201d;) on March 3, 2015 and November&amp;nbsp;6, 2013. The Company will continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations.&amp;nbsp;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</bcrx:DescriptionOfCompanyPolicyTextBlock>
  <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7789197" unitRef="iso4217-usd">3782000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear>
  <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7789205" unitRef="iso4217-usd">380000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive>
  <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7789203" unitRef="iso4217-usd">2586000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour>
  <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7789201" unitRef="iso4217-usd">4703000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree>
  <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7789199" unitRef="iso4217-usd">6966000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo>
  <bcrx:ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts contextRef="d_2013-09-01_2016-06-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember" decimals="INF" id="c7789282" unitRef="iso4217-usd">39477000</bcrx:ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts>
  <bcrx:InterestExpenseAndDeferredFinancingCostsPolicyTextBlock contextRef="d_2016-01-01_2016-06-30" id="c8267417">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Interest Expense and Deferred Financing Costs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Interest expense for the three months ended June&amp;nbsp;30, 2016 and 2015 was $1,338 and $1,306, respectively, and for the six months ended June 30, 2016 and 2015 was $2,677 and $2,621, respectively, and relates to the issuance of the PhaRMA Notes (defined in Note 4). Costs directly associated with the issuance of the PhaRMA Notes have been capitalized and are netted against the non-recourse notes payable on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the term of the PhaRMA Notes using the effective interest rate method. Amortization of deferred financing costs included in interest expense was $110 for each of the three months ended June&amp;nbsp;30, 2016 and 2015, and $220 for each of the six months ended June 30, 2016 and 2015.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</bcrx:InterestExpenseAndDeferredFinancingCostsPolicyTextBlock>
  <bcrx:Interestreserve contextRef="d_2011-03-01_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember" decimals="-3" id="c7789318" unitRef="iso4217-usd">3000000</bcrx:Interestreserve>
  <bcrx:LeaseFinancingObligationNetOfCurrent contextRef="i_2016-06-30_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" decimals="INF" id="c7789079" unitRef="iso4217-usd">2589000</bcrx:LeaseFinancingObligationNetOfCurrent>
  <bcrx:LeaseFinancingObligationNetOfCurrent contextRef="i_2016-06-30" decimals="-3" id="c7788682" unitRef="iso4217-usd">2589000</bcrx:LeaseFinancingObligationNetOfCurrent>
  <bcrx:LeaseFinancingObligationNetOfCurrent contextRef="i_2015-12-31" decimals="-3" id="c7788683" unitRef="iso4217-usd">2375000</bcrx:LeaseFinancingObligationNetOfCurrent>
  <bcrx:LongtermInvestmentMaturityMinimum contextRef="d_2016-01-01_2016-06-30_RangeAxis-MinimumMember" id="c7789014">P1Y</bcrx:LongtermInvestmentMaturityMinimum>
  <bcrx:MaturityOfInvestments contextRef="d_2016-01-01_2016-03-31" id="c7789004">P3Y</bcrx:MaturityOfInvestments>
  <bcrx:MaturityPeriodOfHighQualityMarketablesecurities contextRef="d_2016-01-01_2016-06-30_RangeAxis-MaximumMember" id="c7789010">P3Y</bcrx:MaturityPeriodOfHighQualityMarketablesecurities>
  <bcrx:MaturityperiodOfShortTermInvestment contextRef="d_2016-01-01_2016-06-30_RangeAxis-MinimumMember" id="c7789012">P90D</bcrx:MaturityperiodOfShortTermInvestment>
  <bcrx:MaturityperiodOfShortTermInvestment contextRef="d_2016-01-01_2016-06-30_RangeAxis-MaximumMember" id="c7789013">P1Y</bcrx:MaturityperiodOfShortTermInvestment>
  <bcrx:MaximumAggregateOfferingPrice contextRef="i_2015-03-03" decimals="-6" id="c7789344" unitRef="iso4217-usd">150000000</bcrx:MaximumAggregateOfferingPrice>
  <bcrx:MaximumAggregateOfferingPrice contextRef="i_2013-11-06" decimals="-6" id="c7789347" unitRef="iso4217-usd">125000000</bcrx:MaximumAggregateOfferingPrice>
  <bcrx:MaximumAmountOfCollateralRequiredToPost contextRef="i_2016-06-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="-3" id="c7789342" unitRef="iso4217-usd">7800000</bcrx:MaximumAmountOfCollateralRequiredToPost>
  <bcrx:MilestonePaymentMaximum contextRef="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember" decimals="INF" id="c7789045" unitRef="iso4217-usd">12000000</bcrx:MilestonePaymentMaximum>
  <bcrx:MilestonePaymentMaximum contextRef="d_2015-06-16_2015-06-16_CounterpartyNameAxis-CSLLimitedMember" decimals="INF" id="c7789289" unitRef="iso4217-usd">12000000</bcrx:MilestonePaymentMaximum>
  <bcrx:MilestonePaymentMaximum contextRef="d_2000-06-01_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember" decimals="INF" id="c7789297" unitRef="iso4217-usd">4000000</bcrx:MilestonePaymentMaximum>
  <bcrx:MilestonePaymentMinimum contextRef="d_2000-06-01_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember" decimals="INF" id="c7789296" unitRef="iso4217-usd">1400000</bcrx:MilestonePaymentMinimum>
  <bcrx:NumberOfMajorCustomers contextRef="d_2016-01-01_2016-06-30_ConcentrationRiskByBenchmarkAxis-SalesRevenueProductLineMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_ProductOrServiceAxis-RAPIVABMember" decimals="INF" id="c7789372" unitRef="xbrli-pure">3</bcrx:NumberOfMajorCustomers>
  <bcrx:NumberOfMilestonesAchieved contextRef="d_2016-01-01_2016-06-30_AwardDateAxis-August2013Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" decimals="INF" id="c7789217" unitRef="xbrli-pure">3</bcrx:NumberOfMilestonesAchieved>
  <bcrx:NumberOfStockbasedCompensationPlans contextRef="d_2016-01-01_2016-06-30" decimals="INF" id="c7789181" unitRef="xbrli-pure">2</bcrx:NumberOfStockbasedCompensationPlans>
  <bcrx:PercentageOfCarryingAmountInExcessOfFairValue1 contextRef="i_2016-06-30_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember" decimals="INF" id="c7789329" unitRef="xbrli-pure">0.5</bcrx:PercentageOfCarryingAmountInExcessOfFairValue1>
  <bcrx:PercentageOfCommonStockSharesBeginning contextRef="d_2016-01-01_2016-06-30_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="INF" id="c7789255" unitRef="xbrli-pure">0.85</bcrx:PercentageOfCommonStockSharesBeginning>
  <bcrx:PercentageOfCommonStockSharesEnding contextRef="d_2016-01-01_2016-06-30_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="INF" id="c7789256" unitRef="xbrli-pure">0.85</bcrx:PercentageOfCommonStockSharesEnding>
  <bcrx:PercentageOfSalaryToPurchaseCommonStockMaximum contextRef="d_2016-01-01_2016-06-30_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="INF" id="c7789254" unitRef="xbrli-pure">0.15</bcrx:PercentageOfSalaryToPurchaseCommonStockMaximum>
  <bcrx:PeriodOfAgreement contextRef="d_2016-01-01_2016-06-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-UABMember" id="c7789311">P25Y</bcrx:PeriodOfAgreement>
  <bcrx:PrivatePlacementOfSeniorSecuredNotes contextRef="d_2011-03-01_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember" decimals="-3" id="c7789321" unitRef="iso4217-usd">30000000</bcrx:PrivatePlacementOfSeniorSecuredNotes>
  <bcrx:ProceedsFromAwardsForResearchAndDevelopmentContracts contextRef="d_2016-01-01_2016-06-30_TypeOfArrangementAxis-ASPRBARDAContractMember" decimals="INF" id="c7789273" unitRef="iso4217-usd">20574000</bcrx:ProceedsFromAwardsForResearchAndDevelopmentContracts>
  <bcrx:ProceedsFromAwardsForResearchAndDevelopmentContracts contextRef="d_2013-09-01_2013-09-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember" decimals="INF" id="c7789275" unitRef="iso4217-usd">5000000</bcrx:ProceedsFromAwardsForResearchAndDevelopmentContracts>
  <bcrx:ProceedsFromAwardsForResearchAndDevelopmentContracts contextRef="d_2016-01-01_2016-06-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember" decimals="INF" id="c7789280" unitRef="iso4217-usd">5475000</bcrx:ProceedsFromAwardsForResearchAndDevelopmentContracts>
  <bcrx:RemainingAggregateOfferingPrice contextRef="i_2013-11-06" decimals="-6" id="c7789350" unitRef="iso4217-usd">10000000</bcrx:RemainingAggregateOfferingPrice>
  <bcrx:RenewablePeriodOfAgreement contextRef="d_2016-01-01_2016-06-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-UABMember" id="c7789312">P5Y</bcrx:RenewablePeriodOfAgreement>
  <bcrx:RequiredForeignCurrencyHedgePerDollar contextRef="i_2016-05-18_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="INF" id="c7789336" unitRef="iso4217-jpy">100</bcrx:RequiredForeignCurrencyHedgePerDollar>
  <bcrx:RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet contextRef="d_2011-03-01_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember" decimals="-3" id="c7789316" unitRef="iso4217-usd">22691000</bcrx:RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet>
  <bcrx:RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized contextRef="i_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember" decimals="INF" id="c7788989" unitRef="iso4217-usd">30000000</bcrx:RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized>
  <bcrx:RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized contextRef="i_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember" decimals="-3" id="c7789315" unitRef="iso4217-usd">30000000</bcrx:RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized>
  <bcrx:RoyaltyMonetizationTextBlock contextRef="d_2016-01-01_2016-06-30" id="s265752">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note 4 &amp;#x2014; Royalty Monetization&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Overview&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;On March&amp;nbsp;9, 2011, the Company completed a $30,000&amp;nbsp;financing transaction to monetize certain future royalty and milestone payments under the Shionogi Agreement, pursuant to which Shionogi licensed from the Company the rights to market RAPIACTA in Japan and, if approved for commercial sale, Taiwan. The Company received net proceeds of $22,691&amp;nbsp;from the transaction after transaction costs of $4,309&amp;nbsp;and the establishment of a $3,000&amp;nbsp;interest reserve account by Royalty Sub, available to help cover interest shortfalls in the future. All of the interest reserve account has been fully utilized with the September 2012 interest payment.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;As part of the transaction, the Company entered into a purchase and sale agreement dated as of March&amp;nbsp;9, 2011 with Royalty Sub, whereby the Company transferred to Royalty Sub, among other things, (i)&amp;nbsp;its rights to receive certain royalty and milestone payments from Shionogi arising under the Shionogi Agreement, and (ii)&amp;nbsp;the right to receive payments under a Japanese yen/US dollar foreign currency hedge arrangement (as further described below, the &amp;#x201c;Currency Hedge Agreement&amp;#x201d;) put into place by the Company in connection with the transaction. Royalty payments will be paid by Shionogi in Japanese yen and milestone payments will paid in U.S. dollars. The Company&amp;#x2019;s collaboration with Shionogi was not impacted as a result of this transaction.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Non-Recourse Notes Payable&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;On March&amp;nbsp;9, 2011, Royalty Sub completed a private placement to institutional investors of $30,000 in aggregate principal amount of its PhaRMA Senior Secured 14.0% Notes due 2020 (the &amp;#x201c;PhaRMA Notes&amp;#x201d;). The PhaRMA Notes were issued by Royalty Sub under an Indenture, dated as of March&amp;nbsp;9, 2011 (the &amp;#x201c;Indenture&amp;#x201d;), by and between Royalty Sub and U.S. Bank National Association, as Trustee. Principal and interest on the PhaRMA Notes issued are payable from, and are secured by, the rights to royalty and milestone payments under the Shionogi Agreement transferred by the Company to Royalty Sub and payments, if any, made to Royalty Sub under the Currency Hedge Agreement. The PhaRMA Notes bear interest at 14%&amp;nbsp;per annum, payable annually in arrears on September&amp;nbsp;1st of each year. The Company remains entitled to receive any royalties and milestone payments related to sales of peramivir by Shionogi following repayment of the PhaRMA Notes.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Royalty Sub&amp;#x2019;s obligations to pay principal and interest on the PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person, including the Company, except to the extent of the Company&amp;#x2019;s pledge of its equity interests in Royalty Sub in support of the PhaRMA Notes. The Company may, but is not obligated to, make capital contributions to a capital account that may be used to redeem, or on up to one occasion pay any interest shortfall on, the PhaRMA Notes.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;On September 1, 2014, Royalty Sub was unable to pay the full amount of interest payable to avoid an event of default. Accordingly, the PhaRMA Notes and related accrued interest have been classified as current liabilities on the balance sheet. As a result of the event of default under the PhaRMA Notes, the holders of the PhaRMA Notes may pursue acceleration of the PhaRMA Notes, may foreclose on the collateral securing the PhaRMA Notes and the equity interest in Royalty Sub and exercise other remedies available to them under the Indenture in respect of the PhaRMA Notes. In such event, the Company may not realize the benefit of future royalty payments that might otherwise accrue to it following repayment of the PhaRMA Notes and it might otherwise be adversely affected. Due to the non-recourse nature of the PhaRMA Notes, in the event of any potential acceleration or foreclosure, the primary impact to the Company would be the loss of future royalty payments from Shionogi and legal costs associated with retiring the PhaRMA Notes. In addition, the Company may incur costs associated with liquidating the related Currency Hedge Agreement, which would no longer be required in the event of foreclosure, or if the PhaRMA Notes cease to be outstanding. As the PhaRMA Notes are the obligation of Royalty Sub and non-recourse to the Company, the event of default of the PhaRMA Notes is not expected to have a significant impact on the Company&amp;#x2019;s future results of operations or cash flows. As of June 30, 2016, the PhaRMA Notes remain in default.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;!-- Field: Page; Sequence: 19; Value: 3 --&gt; &lt;div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: left"&gt; &lt;td style="width: 100%; text-align: center"&gt; &lt;!-- Field: Sequence; Type: Arabic; Name: PageNo --&gt;19 &lt;!-- Field: /Sequence --&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style="page-break-before: always; margin-top: 6pt"&gt;  &amp;nbsp; &lt;/div&gt; &lt;!-- Field: /Page --&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;As of June 30, 2016, the aggregate fair value of the PhaRMA Notes was estimated to be approximately 50% of its carrying value of $30,000. The estimated fair value of the PhaRMA Notes is classified as Level 2 in the fair value hierarchy as defined in U.S. GAAP.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The PhaRMA Notes are redeemable at the option of Royalty Sub at any time at a redemption price equal to the outstanding principal balance of the PhaRMA Notes being redeemed plus accrued and unpaid interest through the redemption date on the PhaRMA Notes being redeemed.&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Foreign Currency Hedge&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. Under the Currency Hedge Agreement, the Company has the right to purchase dollars and sell yen at a rate of 100 yen per dollar for which the Company may be required to pay a premium in each year from 2017 through 2020, provided the Currency Hedge Agreement remains in effect. A payment of $1,950&amp;nbsp;will be required if, on May&amp;nbsp;18 of the relevant year, the U.S. dollar is worth 100 yen or less as determined in accordance with the Currency Hedge Agreement.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore, mark-to-market adjustments are recognized in the Company&amp;#x2019;s Consolidated Statement of Comprehensive Loss. Cumulative mark-to-market adjustments for the six months ended June&amp;nbsp;30, 2016 and 2015 resulted in losses of $6,441 and $332, respectively. The Company is also required to post collateral in connection with the mark-to-market adjustments based on defined thresholds. As of June 30, 2016, $1,610 of hedge collateral was posted under the Currency Hedge Agreement. The Company will not be required to post collateral exceeding the maximum premium payments remaining payable under the Currency Hedge Agreement. As of June 30, 2016, the maximum amount of hedge collateral the Company may be required to post is $7,800.&lt;/div&gt;&lt;/div&gt;</bcrx:RoyaltyMonetizationTextBlock>
  <bcrx:RoyaltyTerm contextRef="d_2015-06-16_2015-06-16_CounterpartyNameAxis-CSLLimitedMember" id="c7789290">P10Y</bcrx:RoyaltyTerm>
  <bcrx:ScheduleOfReceivablesFromCollaborationsTableTextBlock contextRef="d_2016-01-01_2016-06-30" id="c-18">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;June&amp;nbsp;30, 2016&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Billed&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Unbilled&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Total&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 61%; font-size: 10pt; text-align: left"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;723&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;1,273&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;1,996&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Shionogi&amp;nbsp;&amp;amp; Co. Ltd.&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;145&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;145&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Seqirus UK Limited&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;37&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;56&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;93&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total receivables&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;905&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;1,329&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;2,234&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&amp;nbsp;31, 2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Billed&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Unbilled&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Total&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 61%; font-size: 10pt; text-align: left"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;5,536&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;5,536&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Shionogi&amp;nbsp;&amp;amp; Co. Ltd.&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;469&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;469&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Seqirus UK Limited&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;210&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;28&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;238&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total receivables&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;679&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;5,564&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;6,243&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</bcrx:ScheduleOfReceivablesFromCollaborationsTableTextBlock>
  <bcrx:ScheduleOfRevenuesFromCollaborationsTableTextBlock contextRef="d_2016-01-01_2016-06-30" id="c-20">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Three Months&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Six Months&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 48%; font-size: 10pt; text-align: left"&gt;Product sales, net&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;537&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Royalty revenue&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;629&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;132&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;2,519&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,650&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Collaborative and other research and development revenues:&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 20pt"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;3,709&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;3,731&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;6,033&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;8,206&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 20pt"&gt;Shionogi (Japan)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;296&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;296&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;592&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;592&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 20pt"&gt;Seqirus UK Limited&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;153&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;21,683&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;463&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;21,683&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Total collaborative and other research and development revenues&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;4,158&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;25,710&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;7,088&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;30,481&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total revenues&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;4,787&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;25,842&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;9,607&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;32,668&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</bcrx:ScheduleOfRevenuesFromCollaborationsTableTextBlock>
  <bcrx:ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount contextRef="i_2016-06-30_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="-3" id="c7789261" unitRef="iso4217-usd">25000</bcrx:ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount>
  <bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate contextRef="d_2016-01-01_2016-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_TitleOfIndividualAxis-NonEmployeeDirectorsMember" id="c7789234">P1Y</bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate>
  <bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable contextRef="d_2016-01-01_2016-06-30_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c7788955" unitRef="xbrli-shares">2120000</bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable>
  <bcrx:SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage contextRef="d_2016-01-01_2016-06-30_AwardDateAxis-August2013Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" decimals="INF" id="c7789230" unitRef="xbrli-pure">0.25</bcrx:SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage>
  <bcrx:SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage contextRef="d_2016-01-01_2016-06-30_AwardDateAxis-December2014Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" decimals="INF" id="c7789232" unitRef="xbrli-pure">1</bcrx:SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage>
  <bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable contextRef="d_2016-01-01_2016-06-30_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c7788961" unitRef="xbrli-shares">499000</bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable>
  <bcrx:TransactionCosts contextRef="d_2011-03-01_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember" decimals="-3" id="c7789317" unitRef="iso4217-usd">4309000</bcrx:TransactionCosts>
  <bcrx:UpfrontPaymentsReceivableAmount contextRef="d_2006-02-01_2006-02-28_TypeOfArrangementAxis-MundipharmaMember" decimals="INF" id="c7789295" unitRef="iso4217-usd">10000000</bcrx:UpfrontPaymentsReceivableAmount>
  <dei:AmendmentFlag contextRef="d_2016-01-01_2016-06-30" id="c-14">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="d_2016-01-01_2016-06-30" id="c-4">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="d_2016-01-01_2016-06-30" id="c-13">Q2</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="d_2016-01-01_2016-06-30" id="c-12">2016</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="d_2016-01-01_2016-06-30" id="c-11">2016-06-30</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="d_2016-01-01_2016-06-30" id="c-10">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="d_2016-01-01_2016-06-30" id="c-2">0000882796</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding contextRef="i_2016-07-31" decimals="INF" id="c-9" unitRef="xbrli-shares">73700542</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCurrentReportingStatus contextRef="d_2016-01-01_2016-06-30" id="c-6">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory contextRef="d_2016-01-01_2016-06-30" id="c-5">Large Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityRegistrantName contextRef="d_2016-01-01_2016-06-30" id="c-1">BIOCRYST PHARMACEUTICALS INC</dei:EntityRegistrantName>
  <dei:EntityVoluntaryFilers contextRef="d_2016-01-01_2016-06-30" id="c-7">No</dei:EntityVoluntaryFilers>
  <dei:EntityWellKnownSeasonedIssuer contextRef="d_2016-01-01_2016-06-30" id="c-8">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:TradingSymbol contextRef="d_2016-01-01_2016-06-30" id="c-3">bcrx</dei:TradingSymbol>
  <us-gaap:AccountsPayableCurrent contextRef="i_2016-06-30" decimals="-3" id="c7788664" unitRef="iso4217-usd">5051000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="i_2015-12-31" decimals="-3" id="c7788665" unitRef="iso4217-usd">9307000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="i_2016-06-30" decimals="-3" id="c7788643" unitRef="iso4217-usd">2234000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="i_2015-12-31" decimals="-3" id="c7788644" unitRef="iso4217-usd">6243000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="i_2016-06-30" decimals="-3" id="c7788666" unitRef="iso4217-usd">11783000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="i_2015-12-31" decimals="-3" id="c7788667" unitRef="iso4217-usd">16237000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="i_2016-06-30" decimals="-3" id="c7788691" unitRef="iso4217-usd">46000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="i_2015-12-31" decimals="-3" id="c7788692" unitRef="iso4217-usd">-206000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AdditionalPaidInCapital contextRef="i_2016-06-30" decimals="-3" id="c7788689" unitRef="iso4217-usd">562634000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital contextRef="i_2015-12-31" decimals="-3" id="c7788690" unitRef="iso4217-usd">558113000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7789184" unitRef="iso4217-usd">4491000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2016-01-01_2016-06-30_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c7789185" unitRef="iso4217-usd">4402000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2016-01-01_2016-06-30_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="-3" id="c7789186" unitRef="iso4217-usd">89000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7789190" unitRef="iso4217-usd">5934000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2015-01-01_2015-06-30_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c7789191" unitRef="iso4217-usd">5840000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2015-01-01_2015-06-30_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="-3" id="c7789192" unitRef="iso4217-usd">94000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AmortizationOfFinancingCosts contextRef="d_2016-04-01_2016-06-30" decimals="INF" id="c7789369" unitRef="iso4217-usd">110000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:AmortizationOfFinancingCosts contextRef="d_2016-01-01_2016-06-30" decimals="INF" id="c7789370" unitRef="iso4217-usd">220000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:AmortizationOfFinancingCosts contextRef="d_2015-04-01_2015-06-30" decimals="INF" id="c7789068" unitRef="iso4217-usd">110000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:AmortizationOfFinancingCosts contextRef="d_2015-01-01_2015-06-30" decimals="INF" id="c7789071" unitRef="iso4217-usd">220000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2016-04-01_2016-06-30" decimals="-3" id="c7789095" unitRef="xbrli-shares">885000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7789098" unitRef="xbrli-shares">1091000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7789099" unitRef="xbrli-shares">4038000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:Assets contextRef="i_2016-06-30" decimals="-3" id="c7788661" unitRef="iso4217-usd">82217000</us-gaap:Assets>
  <us-gaap:Assets contextRef="i_2015-12-31" decimals="-3" id="c7788662" unitRef="iso4217-usd">122359000</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="i_2016-06-30" decimals="-3" id="c7788651" unitRef="iso4217-usd">46112000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="i_2015-12-31" decimals="-3" id="c7788652" unitRef="iso4217-usd">63794000</us-gaap:AssetsCurrent>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2016-06-30" decimals="-3" id="c7788884" unitRef="iso4217-usd">51233000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2015-12-31" decimals="-3" id="c7788885" unitRef="iso4217-usd">70347000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2016-06-30_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c7788842" unitRef="iso4217-usd">14127000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2016-06-30_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c7788847" unitRef="iso4217-usd">16810000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2016-06-30_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c7788852" unitRef="iso4217-usd">20296000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2015-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c7788862" unitRef="iso4217-usd">26546000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2015-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c7788867" unitRef="iso4217-usd">21963000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2015-12-31_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c7788872" unitRef="iso4217-usd">21838000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2016-06-30_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c7788840" unitRef="iso4217-usd">8000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2016-06-30_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c7788845" unitRef="iso4217-usd">23000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2016-06-30_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c7788850" unitRef="iso4217-usd">23000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2016-06-30" decimals="-3" id="c7788855" unitRef="iso4217-usd">54000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2015-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" id="c7788860" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2015-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" id="c7788865" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2015-12-31_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c7788870" unitRef="iso4217-usd">5000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="i_2015-12-31" decimals="-3" id="c7788875" unitRef="iso4217-usd">5000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2016-06-30_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" id="c7788841" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2016-06-30_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c7788846" unitRef="iso4217-usd">1000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2016-06-30_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c7788851" unitRef="iso4217-usd">7000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2016-06-30" decimals="-3" id="c7788856" unitRef="iso4217-usd">8000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2015-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c7788861" unitRef="iso4217-usd">99000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2015-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c7788866" unitRef="iso4217-usd">41000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2015-12-31_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c7788871" unitRef="iso4217-usd">72000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="i_2015-12-31" decimals="-3" id="c7788876" unitRef="iso4217-usd">212000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2016-06-30_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c7788838" unitRef="iso4217-usd">14081000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2016-06-30_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c7788843" unitRef="iso4217-usd">16641000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2016-06-30_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c7788848" unitRef="iso4217-usd">20258000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2016-06-30" decimals="-3" id="c7788853" unitRef="iso4217-usd">50980000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2015-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="c7788858" unitRef="iso4217-usd">26557000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2015-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c7788863" unitRef="iso4217-usd">21820000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2015-12-31_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="-3" id="c7788868" unitRef="iso4217-usd">21884000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="i_2015-12-31" decimals="-3" id="c7788873" unitRef="iso4217-usd">70261000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="i_2016-06-30" decimals="-3" id="c7788878" unitRef="iso4217-usd">27079000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="i_2015-12-31" decimals="-3" id="c7788879" unitRef="iso4217-usd">22664000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="i_2016-06-30" decimals="-3" id="c7788641" unitRef="iso4217-usd">27079000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="i_2015-12-31" decimals="-3" id="c7788642" unitRef="iso4217-usd">22664000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="i_2016-06-30" decimals="-3" id="c7788653" unitRef="iso4217-usd">24154000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="i_2015-12-31" decimals="-3" id="c7788654" unitRef="iso4217-usd">47683000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
  <us-gaap:AvailableForSaleSecuritiesTextBlock contextRef="d_2016-01-01_2016-06-30" id="c-16">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;June&amp;nbsp;30, 2016&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Amortized&lt;br /&gt; Cost&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Accrued&lt;br /&gt; Interest&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Gains&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Losses&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Estimated&lt;br /&gt; Fair&amp;nbsp;Value&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 35%; font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Obligations of the U.S. Government and its agencies&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;14,081&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;38&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;8&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;14,127&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Corporate debt securities&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;16,641&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;147&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;23&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(1&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;16,810&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Certificates of deposit&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;20,258&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;22&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;23&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(7&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;20,296&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;50,980&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;207&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;54&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;(8&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;51,233&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&amp;nbsp;31, 2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Amortized&lt;br /&gt; Cost&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Accrued&lt;br /&gt; Interest&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Gains&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Losses&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Estimated&lt;br /&gt; Fair&amp;nbsp;Value&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt; width: 35%"&gt;Obligations of the U.S. Government and its agencies&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;26,557&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;88&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;(99&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;26,546&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Corporate debt securities&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;21,820&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;184&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(41&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;21,963&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Certificates of deposit&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;21,884&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;21&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;5&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(72&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;21,838&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;70,261&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;293&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;5&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;(212&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;70,347&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="d_2016-01-01_2016-06-30" id="c8267403">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Basis of Presentation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, JPR Royalty Sub LLC (&amp;#x201c;Royalty Sub&amp;#x201d;). Royalty Sub was formed in connection with a $30,000&amp;nbsp;financing transaction the Company completed on March&amp;nbsp;9, 2011. See Note 4, Royalty Monetization, for a further description of this transaction. All intercompany transactions and balances have been eliminated.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company&amp;#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&amp;#x201c;U.S. GAAP&amp;#x201d;) for interim financial reporting and the instructions to Form 10-Q and do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management&amp;#x2019;s opinion, necessary to present fairly, in all material respects, the Company&amp;#x2019;s consolidated financial position, results of operations, and cash flows. There were no adjustments other than normal recurring adjustments.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;These financial statements should be read in conjunction with the financial statements for the year ended December&amp;nbsp;31, 2015 and the notes thereto included in the Company&amp;#x2019;s 2015 Annual Report on Form 10-K. Interim operating results are not necessarily indicative of operating results for the full year. The balance sheet as of December&amp;nbsp;31, 2015 has been derived from the audited consolidated financial statements included in the Company&amp;#x2019;s most recent Annual Report on Form 10-K.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:CapitalLeasesFutureMinimumPaymentsDue contextRef="i_2016-06-30_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember" decimals="INF" id="c7789080" unitRef="iso4217-usd">4839000</us-gaap:CapitalLeasesFutureMinimumPaymentsDue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2016-06-30" decimals="-3" id="c7788637" unitRef="iso4217-usd">8661000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2015-12-31" decimals="-3" id="c7788638" unitRef="iso4217-usd">28899000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2014-12-31" decimals="-3" id="c7788835" unitRef="iso4217-usd">54540000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2015-06-30" decimals="-3" id="c7788837" unitRef="iso4217-usd">76781000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7788832" unitRef="iso4217-usd">-20238000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7788833" unitRef="iso4217-usd">22241000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="d_2016-01-01_2016-06-30" id="c8267405">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Cash and Cash Equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of three months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="d_2016-01-01_2016-06-30" id="c8267406">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Restricted Cash&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Restricted cash as of June&amp;nbsp;30, 2016 reflects $3,022 in royalty revenue paid by Shionogi&amp;nbsp;&amp;amp; Co., Ltd. (&amp;#x201c;Shionogi&amp;#x201d;) designated for interest on the PhaRMA Notes (defined in Note 4) and $1,404 the Company is required to maintain as collateral for a letter of credit associated with the lease execution and build-out of its new Birmingham research facilities.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="d_2016-01-01_2016-06-30" id="s265751">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note 3 &amp;#x2014; Collaborative and Other Research and Development Contracts&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;U.S.&amp;nbsp;Department of Health and Human Services (&amp;#x201c;BARDA/HHS&amp;#x201d;).&lt;/div&gt; On March 31, 2015, the Company announced that BARDA/HHS had awarded the Company a contract for the continued development of BCX4430 as a potential treatment for diseases caused by RNA pathogens, including filoviruses.&amp;nbsp;This BARDA/HHS contract includes a base contract of $16,265 to support BCX4430 drug manufacturing, as well as $22,855 in additional development options that can be exercised by the government, bringing the potential value of the contract to $39,120. As of June 30, 2016, a total of $20,574 has been awarded under exercised options within this contract.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;National Institute of Allergy and Infectious Diseases (&amp;#x201c;NIAID/HHS&amp;#x201d;).&lt;/div&gt; In September 2013, NIAID/HHS contracted with the Company for the development of BCX4430 as a treatment for Marburg virus disease. NIAID/HHS, part of the National Institutes of Health, made an initial award of $5,000 to the Company. The goals of this contract, including amendments, are to file IND applications for intravenous (&amp;#x201c;i.v.&amp;#x201d;) and intramuscular (&amp;#x201c;i.m.&amp;#x201d;) BCX4430 for the treatment of Marburg virus disease and other hemorrhagic fever virus diseases, to study BCX4430 as a treatment for Ebola virus disease and to conduct an initial Phase 1 human clinical trial. BCX4430 is the lead compound in the Company&amp;#x2019;s BSAV research program. On June 30, 2016, NIAID/HHS granted an additional $5,475 to BioCryst for the development of BCX4430 as a treatment for hemorrhagic fever viruses. As of June 30, 2016, the total NIAID/HHS contract amount to advance the program through the completion of the Phase I clinical program could be up to $39,477, if all contract options are exercised. As of June 30, 2016, a total of $35,350 has been awarded under the exercised options within this contract.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The contracts with BARDA/HHS and NIAID/HHS are cost-plus-fixed-fee contracts. That is, the Company is entitled to receive reimbursement for all costs incurred in accordance with the contract provisions that are related to the development of BCX4430 plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make periodic assessments of progress and the continuation of the contract is based on the Company&amp;#x2019;s performance, the timeliness and quality of deliverables, and other factors. The government has rights under certain contract clauses to terminate these contracts. These contracts are terminable by the government at any time for breach or without cause.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Seqirus UK Limited (&amp;#x201c;SUL&amp;#x201d;).&lt;/div&gt; On June 16, 2015, the Company and Seqirus UK Limited (&amp;#x201c;SUL&amp;#x201d;), a limited company organized under the laws of the United Kingdom and a subsidiary of CSL Limited, a company organized under the laws of Australia, entered into a License Agreement (the &amp;#x201c;SUL Agreement&amp;#x201d;) granting SUL and its affiliates worldwide rights to develop, manufacture and commercialize RAPIVAB (peramivir injection) for the treatment of influenza except for the rights to conduct such activities in Israel, Japan, Korea and Taiwan (the permitted geographies together constituting the &amp;#x201c;Territory&amp;#x201d;). RAPIVAB is an intravenous treatment for acute uncomplicated influenza and is currently licensed for use in the United States, Japan and Korea. RAPIVAB is the first and only intravenous influenza treatment in the world and was approved by the FDA in December 2014 for the treatment of acute uncomplicated influenza in patients 18 years and older who have been symptomatic for no more than two days. The Company retains all rights and associated economics to procure pandemic stockpiling orders for RAPIVAB from the U.S. Government, while SUL has the right to pursue government stockpiling outside the U.S.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Pursuant to the SUL Agreement, RAPIVAB will be commercialized by CSL's subsidiary, SUL, which specializes in influenza prevention through the supply of seasonal and pandemic vaccine to global markets. SUL will manufacture, commercialize and exercise decision-making authority with respect to the development and commercialization of RAPIVAB within the Territory and be responsible for all related costs, including sales and promotion.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In December 2013, the Company submitted an NDA for RAPIVAB to the FDA. Under the terms of the SUL Agreement, the Company is responsible for fulfilling all post-marketing approval commitments in connection with the FDA's approval of the NDA, and upon fulfillment will transfer ownership of and financial responsibility for the NDA to SUL. Pursuant to potential rights to sell RAPIVAB in Canada and the EU, the Company is also responsible for regulatory filings and interactions with the Health Canada and the European Medicines Agency (&amp;quot;EMA&amp;quot;) until marketing approval for RAPIVAB is obtained and assigned to SUL. In January 2016, the Company submitted a New Drug Submission (&amp;#x201c;NDS&amp;#x201d;) for RAPIVAB in Canada, seeking approval for treatment of acute uncomplicated influenza in adult patients. In accordance with the SUL Agreement, the Company and SUL formed a joint steering committee, composed of an equal number of representatives from each party, to oversee, review and coordinate the conduct and progress of the commercialization of RAPIVAB in the Territory and any additional development.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Under the terms of the SUL Agreement, the Company received an upfront payment of $33,740, and may receive up to $12,000 in additional milestone payments related to the successful achievement of regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Canada for an adult indication in Canada. The Company is also entitled under the SUL Agreement to receive tiered royalties at a percentage rate beginning in the mid-teens contingent upon meeting minimum thresholds of net sales, as well as a low-thirties percentage of the gross profit from government stockpiling purchases made outside the U.S. Specifically, the Company receives tiered royalties at a percentage rate in the mid-teens to low-forties on net sales in the U.S. during a Contract Year (defined as July 1 - June 30) and tiered royalties at a percentage rate in the mid-teens to mid-twenties on net sales in the Territory, other than in the U.S., during a Calendar Year, each subject to certain downward adjustments for circumstance or events impacting the overall market opportunity. SUL's royalty payment obligations commence on the date of the SUL Agreement and expire, on a country-by-country basis, upon the later of (i) the expiration of legal exclusivity in such country and (ii) ten years from the date of the SUL Agreement. The Company developed RAPIVAB under a license from UAB and will owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from SUL.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;!-- Field: Page; Sequence: 17; Value: 3 --&gt;   &lt;!-- Field: /Page --&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Shionogi&amp;nbsp;&amp;amp; Co., Ltd. (&amp;#x201c;Shionogi&amp;#x201d;).&lt;/div&gt; In February 2007, the Company entered into an exclusive license agreement with Shionogi to develop and commercialize peramivir in Japan for the treatment of seasonal and potentially life-threatening human influenza. Under the terms of the agreement, Shionogi obtained rights to injectable formulations of peramivir in Japan. The Company developed peramivir under a license from UAB and will owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from Shionogi. In October 2008, the Company and Shionogi amended the license agreement to expand the territory covered by the agreement to include Taiwan. Shionogi has commercially launched peramivir under the commercial name RAPIACTA in Japan. Shionogi submitted an NDA to the Taiwan FDA in late 2013.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Green Cross Corporation (&amp;#x201c;Green Cross&amp;#x201d;).&lt;/div&gt; In June 2006, the Company entered into an agreement with Green Cross to develop and commercialize peramivir in Korea. Under the terms of the agreement, Green Cross will be responsible for all development, regulatory, and commercialization costs in Korea. The Company received a one-time license fee of $250. The license also provides that the Company will share in profits resulting from the sale of peramivir in Korea, including the sale of peramivir to the Korean government for stockpiling purposes. Furthermore, Green Cross will pay the Company a premium over its cost to supply peramivir for development and any future marketing of peramivir products in Korea.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Mundipharma International Holdings Limited (&amp;#x201c;Mundipharma&amp;#x201d;).&lt;/div&gt; In February 2006, the Company entered into an exclusive, royalty bearing right and license agreement with Mundipharma for the development and commercialization of forodesine, a Purine Nucleoside Phosphorylase (&amp;#x201c;PNP&amp;#x201d;) inhibitor, for use in oncology. Under the terms of the license agreement, as amended, Mundipharma obtained rights to forodesine in markets across Europe, Asia, and Australasia in exchange for a $10,000 up-front payment.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. (&amp;#x201c;AECOM&amp;#x201d; and &amp;#x201c;IRL&amp;#x201d; respectively).&lt;/div&gt; In June 2000, the Company licensed a series of potent inhibitors of PNP from AECOM and IRL, (collectively, the &amp;#x201c;Licensors&amp;#x201d;). The lead product candidates from this collaboration are forodesine and ulodesine. The Company has obtained worldwide exclusive rights to develop and ultimately distribute these, or any other, product candidates that might arise from research on these inhibitors. The Company has the option to expand the Agreement to include other inventions in the field made by the investigators or employees of the Licensors. The Company agreed to use commercially reasonable efforts to develop these drugs. In addition, the Company has agreed to pay certain milestone payments for each licensed product (which range in the aggregate from $1,400 to almost $4,000&amp;nbsp;per indication) for future development of these inhibitors, single digit royalties on net sales of any resulting product made by the Company, and to share approximately one quarter of future payments received from other third-party partners, if any. In addition, the Company has agreed to pay annual license fees, which can range from $150 to $500, that are creditable against actual royalties and other payments due to the Licensors. This agreement may be terminated by the Company at any time by giving 60&amp;nbsp;days advance notice or in the event of material uncured breach by the Licensors.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In May 2010, the Company amended the licensee agreement through which the Company obtained worldwide exclusive rights to develop and ultimately distribute any product candidates that might arise from research on a series of PNP inhibitors, including forodesine and ulodesine. Under the terms of the amendment, the Licensors agreed to accept a reduction of one-half in the percentage of future payments received from third-party sub licensees of the licensed PNP inhibitors that must be paid to the Licensors. This reduction does not apply to (i)&amp;nbsp;any milestone payments the Company may receive in the future under its license agreement dated February&amp;nbsp;1, 2006 with Mundipharma and (ii)&amp;nbsp;royalties received from its sub licensees in connection with the sale of licensed products, for which the original payment rate will remain in effect. The rate of royalty payments to the Licensors based on net sales of any resulting product made by the Company remains unchanged.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;On November&amp;nbsp;17, 2011, the Company further amended its agreements with the Licensors whereby the Licensors agreed to accept a reduction of one-half in the percentage of Net Proceeds (as defined) received by the Company under its Amended and Restated Agreement with Mundipharma that will be paid to AECOM/IRL.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;On June 19, 2012, the Company further amended its agreements with AECOM/IRL whereby the parties clarified the definition of the field with respect to PNP inhibition and AECOM/IRL agreed to exclusive worldwide license of BCX4430 to BioCryst for any antiviral use.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;At its sole option and subject to certain agreed upon conditions, any future non-royalty payments due to be paid by the Company to AECOM/IRL under the license agreement may be made either in cash, in shares of the Company&amp;#x2019;s common stock, or in a combination of cash and shares.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;!-- Field: Page; Sequence: 18; Value: 3 --&gt;   &lt;!-- Field: /Page --&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;On January 6, 2014, the Carbohydrate Chemistry Research Team from Callaghan Innovation Research Limited, formerly Industrial Research Limited, transferred to Victoria University of Wellington (&amp;#x201c;VUW&amp;#x201d;) to establish the Ferrier Research Institute. The intellectual property rights relating to this research team, and the contracts relating to that intellectual property were transferred to a wholly owned subsidiary of VUW, including the contracts to which BioCryst is a party. The parties executed novation agreements in order to effectuate the transfer. Except for a substitution of parties, the terms and conditions of the contracts are substantially the same.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;The University of Alabama at Birmingham (&amp;#x201c;UAB&amp;#x201d;).&lt;/div&gt; The Company currently has agreements with UAB for influenza neuraminidase and complement inhibitors. Under the terms of these agreements, UAB performed specific research for the Company in return for research payments and license fees. UAB has granted the Company certain rights to any discoveries in these areas resulting from research developed by UAB or jointly developed with the Company. The Company has agreed to pay single digit royalties on sales of any resulting product and to share in future payments received from other third-party partners. The Company has completed the research under the UAB agreements. These two agreements have initial 25-year terms, are automatically renewable for five-year terms throughout the life of the last patent and are terminable by the Company upon three months&amp;#x2019; notice and by UAB under certain circumstances. Upon termination both parties shall cease using the other parties&amp;#x2019; proprietary and confidential information and materials, the parties shall jointly own joint inventions and UAB shall resume full ownership of all UAB licensed products. There is currently no activity between the Company and UAB on these agreements, but when the Company licenses this technology, such as in the case of the Shionogi, Green Cross and SUL agreements, or commercializes products related to these programs, the Company will owe sublicense fees or royalties on amounts it receives.&lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:CollateralAlreadyPostedAggregateFairValue contextRef="i_2015-12-31_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="INF" id="c7789371" unitRef="iso4217-usd">0</us-gaap:CollateralAlreadyPostedAggregateFairValue>
  <us-gaap:CollateralAlreadyPostedAggregateFairValue contextRef="i_2016-06-30_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="INF" id="c7789093" unitRef="iso4217-usd">1610000</us-gaap:CollateralAlreadyPostedAggregateFairValue>
  <us-gaap:CollateralAlreadyPostedAggregateFairValue contextRef="i_2016-06-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="-3" id="c7789341" unitRef="iso4217-usd">1610000</us-gaap:CollateralAlreadyPostedAggregateFairValue>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="i_2016-06-30" decimals="INF" id="c7789359" unitRef="iso4217-usd-per-xbrli-shares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="i_2015-12-31" decimals="INF" id="c7789360" unitRef="iso4217-usd-per-xbrli-shares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="i_2016-06-30" decimals="0" id="c7789361" unitRef="xbrli-shares">200000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="i_2015-12-31" decimals="0" id="c7789362" unitRef="xbrli-shares">200000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued contextRef="i_2016-06-30" decimals="0" id="c7789363" unitRef="xbrli-shares">73701000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="i_2015-12-31" decimals="0" id="c7789364" unitRef="xbrli-shares">73355000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="i_2016-06-30" decimals="0" id="c7789365" unitRef="xbrli-shares">73701000</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="i_2015-12-31" decimals="0" id="c7789366" unitRef="xbrli-shares">73355000</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue contextRef="i_2016-06-30" decimals="-3" id="c7788687" unitRef="iso4217-usd">737000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue contextRef="i_2015-12-31" decimals="-3" id="c7788688" unitRef="iso4217-usd">734000</us-gaap:CommonStockValue>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="d_2016-04-01_2016-06-30" decimals="-3" id="c7788777" unitRef="iso4217-usd">-16283000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c7788778" unitRef="iso4217-usd">4799000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7788779" unitRef="iso4217-usd">-38861000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7788780" unitRef="iso4217-usd">-10225000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="d_2016-01-01_2016-06-30" id="c8267413">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Accumulated Other Comprehensive Income (Loss)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Accumulated other comprehensive income (loss) is comprised of unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&amp;#x2019; equity. Amounts reclassified from accumulated other comprehensive income (loss) are recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. During the six months ended June 30, 2016, realized gains of $10 were reclassified out of accumulated other comprehensive income (loss). During the six months ended June 30, 2015, realized gains of $12 were reclassified out of accumulated other comprehensive income (loss).&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="d_2016-01-01_2016-06-30_ConcentrationRiskByBenchmarkAxis-SalesRevenueProductLineMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-ThreeCustomersMember_ProductOrServiceAxis-RAPIVABMember" decimals="INF" id="c7789103" unitRef="xbrli-pure">0.9</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:CostOfGoodsSold contextRef="d_2016-04-01_2016-06-30" id="c7788717" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:CostOfGoodsSold contextRef="d_2015-04-01_2015-06-30" id="c7788718" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:CostOfGoodsSold contextRef="d_2016-01-01_2016-06-30" id="c7788719" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:CostOfGoodsSold contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7788720" unitRef="iso4217-usd">15000</us-gaap:CostOfGoodsSold>
  <us-gaap:CostsAndExpenses contextRef="d_2016-04-01_2016-06-30" decimals="-3" id="c7788733" unitRef="iso4217-usd">16917000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c7788734" unitRef="iso4217-usd">20500000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7788735" unitRef="iso4217-usd">40785000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7788736" unitRef="iso4217-usd">41756000</us-gaap:CostsAndExpenses>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="i_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember" decimals="INF" id="c7789322" unitRef="xbrli-pure">0.14</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DeferredCostsCurrent contextRef="i_2016-06-30" decimals="-3" id="c7788649" unitRef="iso4217-usd">89000</us-gaap:DeferredCostsCurrent>
  <us-gaap:DeferredCostsCurrent contextRef="i_2015-12-31" decimals="-3" id="c7788650" unitRef="iso4217-usd">90000</us-gaap:DeferredCostsCurrent>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="i_2016-06-30" decimals="-3" id="c7788678" unitRef="iso4217-usd">297000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="i_2015-12-31" decimals="-3" id="c7788679" unitRef="iso4217-usd">329000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DeferredRevenueAdditions contextRef="d_2015-06-01_2015-06-30_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember" decimals="INF" id="c7789041" unitRef="iso4217-usd">3740000</us-gaap:DeferredRevenueAdditions>
  <us-gaap:DeferredRevenueAdditions contextRef="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_DeferredRevenueArrangementTypeAxis-RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember" decimals="INF" id="c7789043" unitRef="iso4217-usd">1223000</us-gaap:DeferredRevenueAdditions>
  <us-gaap:DeferredRevenueCurrent contextRef="i_2016-06-30" decimals="-3" id="c7788670" unitRef="iso4217-usd">2134000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="i_2015-12-31" decimals="-3" id="c7788671" unitRef="iso4217-usd">2163000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="i_2016-06-30" decimals="-3" id="c7788676" unitRef="iso4217-usd">8776000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="i_2015-12-31" decimals="-3" id="c7788677" unitRef="iso4217-usd">9674000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7788785" unitRef="iso4217-usd">136000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7788786" unitRef="iso4217-usd">94000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DerivativeForwardExchangeRate1 contextRef="i_2015-09-30_CurrencyAxis-JapanYenMember_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="INF" id="c7789332" unitRef="xbrli-pure">100</us-gaap:DerivativeForwardExchangeRate1>
  <us-gaap:DerivativeGainOnDerivative contextRef="d_2016-01-01_2016-06-30_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember" decimals="INF" id="c7789087" unitRef="iso4217-usd">811000</us-gaap:DerivativeGainOnDerivative>
  <us-gaap:DerivativeGainOnDerivative contextRef="d_2015-01-01_2015-06-30_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember" decimals="INF" id="c7789088" unitRef="iso4217-usd">1545000</us-gaap:DerivativeGainOnDerivative>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="i_2016-06-30" decimals="-3" id="c7788680" unitRef="iso4217-usd">974000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="i_2015-12-31" id="c7788681" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:DerivativeLossOnDerivative contextRef="d_2016-01-01_2016-06-30_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember" decimals="INF" id="c7789083" unitRef="iso4217-usd">6441000</us-gaap:DerivativeLossOnDerivative>
  <us-gaap:DerivativeLossOnDerivative contextRef="d_2015-01-01_2015-06-30_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember" decimals="INF" id="c7789084" unitRef="iso4217-usd">332000</us-gaap:DerivativeLossOnDerivative>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="d_2016-01-01_2016-06-30" id="s265748">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note 2 &amp;#x2014; Stock-Based Compensation&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;   &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;As of June&amp;nbsp;30, 2016, the Company had two stock-based employee compensation plans, the Stock Incentive Plan (&amp;#x201c;Incentive Plan&amp;#x201d;) and the Employee Stock Purchase Plan (&amp;#x201c;ESPP&amp;#x201d;). The Incentive Plan was amended and restated in April 2016 and approved by the Company&amp;#x2019;s stockholders in May 2016. The ESPP was amended and restated in March 2014 and approved by the Company&amp;#x2019;s stockholders in May 2014. Stock-based compensation expense of $4,491 ($4,402 of expense related to the Incentive Plan and $89 of expense related to the ESPP) was recognized during the first six months of 2016, while $5,934 ($5,840 of expense related to the Incentive Plan and $94 of expense related to the ESPP) was recognized during the first six months of 2015.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;There was approximately $18,417 of total unrecognized compensation cost related to non-vested stock option awards and restricted stock unit awards granted by the Company as of June&amp;nbsp;30, 2016. That cost is expected to be recognized as follows: $3,782 during the remainder of 2016, $6,966 in 2017, $4,703 in 2018, $2,586 in 2019 and $380 in 2020. In addition, the Company has outstanding performance-based stock options for which no compensation expense is recognized until &amp;#x201c;performance&amp;#x201d; has occurred and the award vests. At the time of vesting, compensation expense will be recognized.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;!-- Field: Page; Sequence: 15; Value: 3 --&gt;   &lt;!-- Field: /Page --&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Stock Incentive Plan&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company grants stock option awards and restricted stock unit awards to its employees, directors, and consultants under the Incentive Plan. Under the Incentive Plan, stock option awards are granted with an exercise price equal to the market price of the Company&amp;#x2019;s stock at the date of grant. Since March&amp;nbsp;1, 2011, stock option awards granted to employees generally vest 25% each year until fully vested after four years. In January 2013, the Company made retention grants of stock option awards and restricted stock units. These awards vest 50% each year until fully vested after two years. In August 2013 and December 2014, the Company issued 1,032 and 1,250 performance-based stock options, respectively. These awards vest upon successful completion of specific development milestones. As of June 30, 2016, 75% of the August 2013 grants have vested based upon achievement of three milestones: (1) successful completion of the OPuS-1 clinical trial, for which vesting occurred in the second quarter of 2014, (2) FDA approval of RAPIVAB for which vesting occurred in the fourth quarter of 2014, and (3) initiation of a Phase 1 clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally-administered BCX7353 in healthy volunteers, for which vesting occurred in the second quarter of 2015. Thus, as of June 30, 2016, 25% of the August 2013 performance-based grants and 100% of the December 2014 performance-based grants remain unvested and no compensation expense has been recognized for these portions of the previously issued performance-based grants. Stock option awards granted to non-employee directors of the Company generally vest monthly over one year. All stock option awards have contractual terms of 5 to 10&amp;nbsp;years. The vesting exercise provisions of all awards granted under the Incentive Plan are subject to acceleration in the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Incentive Plan.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Related activity under the Incentive Plan is as follows:&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Awards&lt;br /&gt; Available&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Options&lt;br /&gt; Outstanding&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Weighted&lt;br /&gt; Average&lt;br /&gt; Exercise&lt;br /&gt; Price&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 61%; font-size: 10pt"&gt;Balance December&amp;nbsp;31, 2015&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;16&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;10,671&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;7.50&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 20pt"&gt;Plan amendment&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;3,800&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 20pt"&gt;Restricted stock unit awards granted&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(21&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 20pt"&gt;Restricted stock unit awards cancelled&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;15&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 20pt"&gt;Stock option awards granted&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(2,120&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;2,120&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;3.21&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 20pt"&gt;Stock option awards exercised&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(79&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;2.32&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 20pt"&gt;Stock option awards cancelled&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;499&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(499&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"&gt;11.24&lt;/td&gt; &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;Balance June&amp;nbsp;30, 2016&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;2,189&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;12,213&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: right"&gt;6.63&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;For stock option awards granted under the Incentive Plan during the first six months of 2016 and 2015, the fair value was estimated on the date of grant using a Black-Scholes option pricing model and the assumptions noted in the table below. The weighted average grant date fair value per share of the awards granted during the first six months of 2016 and 2015 was $2.18 and $8.21, respectively. The fair value of the stock option awards is amortized to expense over the vesting periods using a straight-line expense attribution method. The following table summarizes the key assumptions used by the Company to value the stock option awards granted during the first six months of 2016 and 2015. The expected life is based on the average of the assumption that all outstanding stock option awards will be exercised at full vesting and the assumption that all outstanding stock option awards will be exercised at the midpoint of the current date (if already vested) or at full vesting (if not yet vested) and the full contractual term. The expected volatility represents the historical volatility on the Company&amp;#x2019;s publicly traded common stock. The Company has assumed no expected dividend yield, as dividends have never been paid to stock or option holders and will not be paid for the foreseeable future. The weighted average risk-free interest rate is the implied yield currently available on zero-coupon government issues with a remaining term equal to the expected term.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Weighted Average Assumptions for Stock Option Awards Granted to&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Employees and Directors under the Incentive Plan&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 74%; font-size: 10pt; text-align: left"&gt;Expected Life in Years&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;5.6&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;5.5&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Expected Volatility&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;82&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;83&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Expected Dividend Yield&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;0.0&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;0.0&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Risk-Free Interest Rate&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1.4&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1.5&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Employee Stock Purchase Plan&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company has reserved a total of 1,475 shares of common stock to be purchased under the ESPP, of which 463 shares remain available for purchase at June&amp;nbsp;30, 2016. Eligible employees may authorize up to 15% of their salary to purchase common stock at the lower of 85% of the beginning or 85% of the ending price during six-month purchase intervals. No more than 3 shares may be purchased by any one employee at the six-month purchase dates and no employee may purchase stock having a fair market value at the commencement date of $25 or more in any one calendar year. The Company issued 34 shares during the first six months of 2016 under the ESPP. Compensation expense for shares purchased under the ESPP related to the purchase discount and the &amp;#x201c;look-back&amp;#x201d; option were determined using a Black-Scholes option pricing model.&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:EarningsPerShareBasic contextRef="d_2015-04-01_2015-06-30" decimals="INF" id="c8267093" unitRef="iso4217-usd-per-xbrli-shares">0.07</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic contextRef="d_2016-04-01_2016-06-30" decimals="INF" id="c7788757" unitRef="iso4217-usd-per-xbrli-shares">-0.22</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic contextRef="d_2016-01-01_2016-06-30" decimals="INF" id="c7788759" unitRef="iso4217-usd-per-xbrli-shares">-0.53</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic contextRef="d_2015-01-01_2015-06-30" decimals="INF" id="c7788760" unitRef="iso4217-usd-per-xbrli-shares">-0.14</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareDiluted contextRef="d_2015-04-01_2015-06-30" decimals="INF" id="c8267092" unitRef="iso4217-usd-per-xbrli-shares">0.06</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted contextRef="d_2016-04-01_2016-06-30" decimals="INF" id="c7788761" unitRef="iso4217-usd-per-xbrli-shares">-0.22</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted contextRef="d_2016-01-01_2016-06-30" decimals="INF" id="c7788763" unitRef="iso4217-usd-per-xbrli-shares">-0.53</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted contextRef="d_2015-01-01_2015-06-30" decimals="INF" id="c7788764" unitRef="iso4217-usd-per-xbrli-shares">-0.14</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="d_2016-01-01_2016-06-30" id="c8267420">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Net Loss Per Share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein, except for the three months ended June 30, 2015 for which diluted income per share is $0.06 and basic income per share is $0.07 per share, because common equivalent shares from unexercised stock options and common shares expected to be issued under the Company&amp;#x2019;s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the three months ended June&amp;nbsp;30, 2016 does not include 885 of such potential common shares, as their impact would be anti-dilutive. The calculation of diluted earnings per share for the six months ended June&amp;nbsp;30, 2016 and 2015 does not include 1,091 and 4,038, respectively, of such potential common shares, as their impact would be anti-dilutive.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="i_2016-06-30" decimals="-3" id="c7789196" unitRef="iso4217-usd">18417000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="d_2016-04-01_2016-06-30" decimals="-3" id="c7788749" unitRef="iso4217-usd">-2877000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
  <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c7788750" unitRef="iso4217-usd">749000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
  <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7788751" unitRef="iso4217-usd">-5630000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
  <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7788752" unitRef="iso4217-usd">1213000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
  <us-gaap:GovernmentContractReceivable contextRef="i_2015-03-31_TypeOfArrangementAxis-BaseContractMember" decimals="INF" id="c7789269" unitRef="iso4217-usd">16265000</us-gaap:GovernmentContractReceivable>
  <us-gaap:GovernmentContractReceivable contextRef="i_2015-03-31_TypeOfArrangementAxis-AdditionalDevelopmentOptionsMember" decimals="INF" id="c7789271" unitRef="iso4217-usd">22855000</us-gaap:GovernmentContractReceivable>
  <us-gaap:GovernmentContractReceivable contextRef="i_2015-03-31_TypeOfArrangementAxis-ASPRBARDAContractMember" decimals="INF" id="c7789272" unitRef="iso4217-usd">39120000</us-gaap:GovernmentContractReceivable>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="d_2016-01-01_2016-06-30" id="c8269880">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The liability method is used in the Company&amp;#x2019;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7788802" unitRef="iso4217-usd">-8742000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7788803" unitRef="iso4217-usd">8612000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7788806" unitRef="iso4217-usd">-927000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7788807" unitRef="iso4217-usd">5820000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDerivativeAssets contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7788791" unitRef="iso4217-usd">-6441000</us-gaap:IncreaseDecreaseInDerivativeAssets>
  <us-gaap:IncreaseDecreaseInDerivativeAssets contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7788792" unitRef="iso4217-usd">-332000</us-gaap:IncreaseDecreaseInDerivativeAssets>
  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7788804" unitRef="iso4217-usd">2457000</us-gaap:IncreaseDecreaseInInterestPayableNet>
  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7788805" unitRef="iso4217-usd">-1579000</us-gaap:IncreaseDecreaseInInterestPayableNet>
  <us-gaap:IncreaseDecreaseInInventories contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7788796" unitRef="iso4217-usd">337000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInInventories contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7788797" unitRef="iso4217-usd">625000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7788798" unitRef="iso4217-usd">-1000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7788799" unitRef="iso4217-usd">-503000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInReceivables contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7788794" unitRef="iso4217-usd">-4009000</us-gaap:IncreaseDecreaseInReceivables>
  <us-gaap:IncreaseDecreaseInReceivables contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7788795" unitRef="iso4217-usd">-5194000</us-gaap:IncreaseDecreaseInReceivables>
  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7788813" unitRef="iso4217-usd">2814000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7788814" unitRef="iso4217-usd">1419000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="d_2016-01-01_2016-06-30" id="c8267411">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Patents and Licenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
  <us-gaap:InterestAndOtherIncome contextRef="d_2016-04-01_2016-06-30" decimals="-3" id="c7788741" unitRef="iso4217-usd">147000</us-gaap:InterestAndOtherIncome>
  <us-gaap:InterestAndOtherIncome contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c7788742" unitRef="iso4217-usd">116000</us-gaap:InterestAndOtherIncome>
  <us-gaap:InterestAndOtherIncome contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7788743" unitRef="iso4217-usd">586000</us-gaap:InterestAndOtherIncome>
  <us-gaap:InterestAndOtherIncome contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7788744" unitRef="iso4217-usd">233000</us-gaap:InterestAndOtherIncome>
  <us-gaap:InterestExpense contextRef="d_2016-04-01_2016-06-30_LongtermDebtTypeAxis-PhaRMANotesMember" decimals="INF" id="c7789061" unitRef="iso4217-usd">1338000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="d_2015-04-01_2015-06-30_LongtermDebtTypeAxis-PhaRMANotesMember" decimals="INF" id="c7789062" unitRef="iso4217-usd">1306000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="d_2016-01-01_2016-06-30_LongtermDebtTypeAxis-PhaRMANotesMember" decimals="INF" id="c7789065" unitRef="iso4217-usd">2677000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="d_2015-01-01_2015-06-30_LongtermDebtTypeAxis-PhaRMANotesMember" decimals="INF" id="c7789066" unitRef="iso4217-usd">2621000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="d_2016-04-01_2016-06-30_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember" decimals="INF" id="c8267074" unitRef="iso4217-usd">83</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="d_2016-01-01_2016-06-30_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember" decimals="INF" id="c7789078" unitRef="iso4217-usd">214000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="d_2016-04-01_2016-06-30" decimals="-3" id="c7788745" unitRef="iso4217-usd">1421000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c7788746" unitRef="iso4217-usd">1306000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7788747" unitRef="iso4217-usd">2891000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7788748" unitRef="iso4217-usd">2621000</us-gaap:InterestExpense>
  <us-gaap:InterestPayableCurrent contextRef="i_2016-06-30" decimals="-3" id="c7788668" unitRef="iso4217-usd">9203000</us-gaap:InterestPayableCurrent>
  <us-gaap:InterestPayableCurrent contextRef="i_2015-12-31" decimals="-3" id="c7788669" unitRef="iso4217-usd">6746000</us-gaap:InterestPayableCurrent>
  <us-gaap:InventoryNet contextRef="i_2016-06-30" decimals="-3" id="c7788645" unitRef="iso4217-usd">1949000</us-gaap:InventoryNet>
  <us-gaap:InventoryNet contextRef="i_2015-12-31" decimals="-3" id="c7788646" unitRef="iso4217-usd">1612000</us-gaap:InventoryNet>
  <us-gaap:InventoryPolicyTextBlock contextRef="d_2016-01-01_2016-06-30" id="c8267409">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Inventory&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;At June 30, 2016 and December 31, 2015, the Company&amp;#x2019;s inventory consisted of RAPIVAB work in process. Inventory is stated at the lower of cost, determined under the first-in, first-out (&amp;#x201c;FIFO&amp;#x201d;) method, or market. The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company will capitalize subsequent costs related to the production of inventories.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;During 2014, in connection with the U.S. Food and Drug Administration (&amp;#x201c;FDA&amp;#x201d;) approval of RAPIVAB, the Company began capitalizing costs associated with the production of RAPIVAB inventories.&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company&amp;#x2019;s inventory consisted of the following at June&amp;nbsp;30, 2016 and December&amp;nbsp;31, 2015:&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 74%; font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Work in process&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,949&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,612&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;Inventories&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;1,949&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;1,612&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="i_2016-06-30" decimals="-3" id="c7788910" unitRef="iso4217-usd">1949000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="i_2015-12-31" decimals="-3" id="c7788911" unitRef="iso4217-usd">1612000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:InvestmentPolicyTextBlock contextRef="d_2016-01-01_2016-06-30" id="c8267407">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Investments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&amp;#x2019;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that may consist of U.S. Government and government agency securities, money market and mutual fund investments, municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&amp;#x2019;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of three years and requires an average portfolio maturity of no more than 18 months. Some of the securities the Company invests in may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&amp;#x2019;s investments are not collateralized. The Company has not realized any significant losses from its investments.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond three months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. At June 30, 2016, the Company believes that the costs of its investments are recoverable in all material respects.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The following tables summarize the fair value of the Company&amp;#x2019;s investments by type. The estimated fair value of the Company&amp;#x2019;s fixed income investments are classified as Level 2 in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. These fair values are obtained from independent pricing services which utilize Level 2 inputs.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;June&amp;nbsp;30, 2016&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Amortized&lt;br /&gt; Cost&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Accrued&lt;br /&gt; Interest&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Gains&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Losses&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Estimated&lt;br /&gt; Fair&amp;nbsp;Value&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 35%; font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Obligations of the U.S. Government and its agencies&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;14,081&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;38&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;8&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;14,127&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Corporate debt securities&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;16,641&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;147&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;23&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(1&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;16,810&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Certificates of deposit&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;20,258&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;22&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;23&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(7&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;20,296&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;50,980&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;207&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;54&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;(8&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;51,233&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&amp;nbsp;31, 2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Amortized&lt;br /&gt; Cost&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Accrued&lt;br /&gt; Interest&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Gains&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Losses&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Estimated&lt;br /&gt; Fair&amp;nbsp;Value&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt; width: 35%"&gt;Obligations of the U.S. Government and its agencies&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;26,557&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;88&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;(99&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;26,546&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Corporate debt securities&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;21,820&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;184&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(41&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;21,963&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Certificates of deposit&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;21,884&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;21&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;5&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(72&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;21,838&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;70,261&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;293&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;5&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;(212&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;70,347&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0"&gt;The following table summarizes the scheduled maturity for the Company&amp;#x2019;s investments at June&amp;nbsp;30, 2016 and December&amp;nbsp;31, 2015.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 74%; font-size: 10pt; text-align: left"&gt;Maturing in one year or less&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;27,079&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;22,664&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Maturing after one year through two years&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;18,164&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;28,395&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Maturing after two years&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;5,990&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;19,288&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;51,233&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;70,347&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
  <us-gaap:InvestmentsAndCash contextRef="i_2016-06-30" decimals="INF" id="c7788977" unitRef="iso4217-usd">64320000</us-gaap:InvestmentsAndCash>
  <us-gaap:LeasePolicyTextBlock contextRef="d_2016-01-01_2016-06-30" id="c8267418">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Lease Financing Obligation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 0.25in; margin: 0pt 0 0pt 12pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Based on the terms of the lease agreement for the new research facility in Birmingham, Alabama, the Company had construction period risks during the construction period and the Company was deemed the owner of the building (for accounting purposes only) during the construction period. Accordingly, the Company recorded an asset of $1,589, representing the Company&amp;#x2019;s leased portion of the building and recorded a corresponding liability. Upon completion of leasehold improvement construction, the Company did not meet the sale-leaseback criteria for de-recognition of the building asset and liability. Therefore, the lease is accounted for as a financing obligation. The asset will be depreciated over the expected duration of the lease of 20.5 years, and rental payments will be treated as principal and interest payments on the lease financing obligation liability. The underlying accounting for this transaction has no impact on cash flows associated with the underlying lease or construction in process. Interest expense for the three and six months ended June 30, 2016 includes $83 and $214, respectively, related to the lease financing obligation.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;At June 30, 2016, the lease financing obligation balance was $2,589 and was recorded as a long term liability on the consolidated balance sheets. The remaining future minimum payments under the lease financing obligation are $4,839.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LeasePolicyTextBlock>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="i_2016-06-30" decimals="-3" id="c7788697" unitRef="iso4217-usd">82217000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="i_2015-12-31" decimals="-3" id="c7788698" unitRef="iso4217-usd">122359000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="i_2016-06-30" decimals="-3" id="c7788674" unitRef="iso4217-usd">56194000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="i_2015-12-31" decimals="-3" id="c7788675" unitRef="iso4217-usd">62257000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LossOnSaleOfInvestments contextRef="d_2016-01-01_2016-06-30" decimals="INF" id="c7789368" unitRef="iso4217-usd">0</us-gaap:LossOnSaleOfInvestments>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7788830" unitRef="iso4217-usd">-1363000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7788831" unitRef="iso4217-usd">4745000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7788819" unitRef="iso4217-usd">11151000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7788820" unitRef="iso4217-usd">3124000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7788808" unitRef="iso4217-usd">-30026000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7788809" unitRef="iso4217-usd">14372000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetIncomeLoss contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7788782" unitRef="iso4217-usd">-39113000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7788783" unitRef="iso4217-usd">-10263000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2016-04-01_2016-06-30" decimals="-3" id="c7788753" unitRef="iso4217-usd">-16281000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c7788754" unitRef="iso4217-usd">4901000</us-gaap:NetIncomeLoss>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="d_2016-01-01_2016-06-30" id="c8269843">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Recent Accounting Pronouncements&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In March 2016, the Financial Accounting Standards Board (&amp;#x201c;FASB&amp;#x201d;) issued Accounting Standards Update No. 2016-09: &lt;div style="display: inline; font-style: italic;"&gt;Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting&lt;/div&gt; (&amp;#x201c;ASU 2016-09&amp;#x201d;). The amendments in this update simplify several aspects of the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures and statutory tax withholding requirements, as well as classification in the statement of cash flows. ASU 2016-09 will be effective for the Company in fiscal year 2017, but early adoption is permitted. The Company is currently evaluating the impact of this update on its consolidated financial statements.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In February 2016, the FASB issued Accounting Standards Update No. 2016-02: &lt;div style="display: inline; font-style: italic;"&gt;Leases (Topic 842)&lt;/div&gt; (&amp;#x201c;ASU 2016-02&amp;#x201d;). The amendments in this update require lessees, among other things, to recognize lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous authoritative guidance. This update also introduces new disclosure requirements for leasing arrangements. ASU 2016-02 will be effective for the Company in fiscal year 2019, but early adoption is permitted. The Company is currently evaluating the impact of this update on its consolidated financial statements.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In January 2016, the FASB issued Accounting Standards Update No. 2016-01: &lt;div style="display: inline; font-style: italic;"&gt;Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities&lt;/div&gt; (&amp;#x201c;ASU 2016-01&amp;#x201d;). The amendments in this update address certain aspects of recognition, measurement, presentation and disclosure of financial instruments. In particular, the amendments in this update supersede, for public business entities, the requirement to disclose the methods and significant assumptions used in calculating the fair value of financial instruments required to be disclosed for financial instruments measured at amortized cost on the balance sheet. ASU 2016-01 will be effective for the Company in fiscal year 2018, but early adoption is permitted. The Company does not expect this standard to have a material impact on its consolidated financial statements.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 22.3pt; margin: 0pt 0"&gt;In November 2015, the FASB issued Accounting Standards Update No. 2015-17, &lt;div style="display: inline; font-style: italic;"&gt;Balance Sheet Classification of Deferred Taxes&lt;/div&gt;, requiring all deferred tax assets and liabilities, and any related valuation allowance, to be classified as noncurrent on the balance sheet. The classification change for all deferred taxes as noncurrent simplifies entities&amp;#x2019; processes as it eliminates the need to separately identify the net current and net noncurrent deferred tax asset or liability in each jurisdiction and allocate valuation allowances. We elected to prospectively adopt the accounting standard in the beginning of our fourth quarter of fiscal 2015. Adoption of this standard had no impact on the Company&amp;#x2019;s consolidated financial statements.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In July 2015, the FASB issued Accounting Standards Update No. 2015-11: &lt;div style="display: inline; font-style: italic;"&gt;Inventory (Topic 330): Simplifying the Measurement of Inventory&lt;/div&gt; (&amp;#x201c;ASU 2015-11&amp;#x201d;), which changes the measurement principle for inventory from the lower of cost or market to the lower of cost and net realizable value. ASU 2015-11 defines net realizable value as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The update does not apply to inventory that is measured using last-in, first-out or the retail inventory method. The update applies to all other inventory, which includes inventory that is measured using first-in, first-out or average cost methods. The amendments in ASU 2015-11 will be effective for the Company for fiscal years, and the interim periods within those years, beginning after December 15, 2016. The amendments must be applied prospectively and early adoption is permitted. The Company does not expect this standard to have a material impact on its consolidated financial statements.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In April 2015, the FASB issued Accounting Standards Update No. 2015-03: &lt;div style="display: inline; font-style: italic;"&gt;Interest &amp;#x2013; Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs&lt;/div&gt; (&amp;#x201c;ASU 2015-03&amp;#x201d;). This standard amends existing guidance to require the presentation of debt issuance costs in the balance sheet as a deduction from the carrying amount of the related debt liability instead of a deferred charge. It is effective for annual reporting periods beginning after December 15, 2015 and requires retrospective application for all periods presented. The Company adopted ASU 2015-03 in the first quarter of 2016. Adoption did not have a material impact on its consolidated financial statements.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In August 2014, the FASB issued Accounting Standards Update No. 2014-15: &lt;div style="display: inline; font-style: italic;"&gt;Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&amp;#x2019;s Ability to Continue as a Going Concern&lt;/div&gt; (&amp;#x201c;ASU 2014-15&amp;#x201d;) &lt;div style="display: inline; font-style: italic;"&gt;,&lt;/div&gt; which defines management&amp;#x2019;s responsibility to evaluate, at each annual and interim reporting period, whether there are conditions or events that raise substantial doubt about an entity&amp;#x2019;s ability to continue as a going concern within one year after the date the financial statements are issued and to provide related footnote disclosures in certain circumstances. In connection with each annual and interim period, management must assess if there is substantial doubt about the company&amp;#x2019;s ability to continue as a going concern within one year after the issuance date.&amp;nbsp;Disclosures are required if conditions give rise to substantial doubt.&amp;nbsp;ASU 2014-15 is effective for all companies in the first annual period ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The Company is currently evaluating the impact this standard will have on its financial statements and disclosures.&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In May 2014, the FASB issued Standards Update No. 2014-09: &lt;div style="display: inline; font-style: italic;"&gt;Revenue from Contracts with Customers (Topic 606) &lt;/div&gt;(&amp;#x201c;ASU 2014-09&amp;#x201d;), which provides a single, comprehensive revenue recognition model for all contracts with customers. The core principal of this ASU is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. In July 2015, the FASB finalized a one year delay in the effective date of this standard, which will now be effective January 1, 2018; however, early adoption is permitted any time after the original effective date, January 1, 2017. Companies can transition to the new standard under the full retrospective method or the modified retrospective method. The Company is currently evaluating the impact this standard will have on its consolidated financial statements.&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:NotesPayableCurrent contextRef="i_2016-06-30" decimals="-3" id="c7788672" unitRef="iso4217-usd">28023000</us-gaap:NotesPayableCurrent>
  <us-gaap:NotesPayableCurrent contextRef="i_2015-12-31" decimals="-3" id="c7788673" unitRef="iso4217-usd">27804000</us-gaap:NotesPayableCurrent>
  <us-gaap:NotesPayableFairValueDisclosure contextRef="i_2016-06-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member" decimals="-3" id="c7789330" unitRef="iso4217-usd">30000000</us-gaap:NotesPayableFairValueDisclosure>
  <us-gaap:OperatingIncomeLoss contextRef="d_2016-04-01_2016-06-30" decimals="-3" id="c7788737" unitRef="iso4217-usd">-12130000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c7788738" unitRef="iso4217-usd">5342000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7788739" unitRef="iso4217-usd">-31178000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7788740" unitRef="iso4217-usd">-9088000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherAssetsNoncurrent contextRef="i_2016-06-30" decimals="-3" id="c7788659" unitRef="iso4217-usd">1610000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="i_2015-12-31" decimals="-3" id="c7788660" unitRef="iso4217-usd">5468000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="d_2016-04-01_2016-06-30" decimals="-3" id="c7788773" unitRef="iso4217-usd">-2000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c7788774" unitRef="iso4217-usd">-102000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7788775" unitRef="iso4217-usd">252000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7788776" unitRef="iso4217-usd">38000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:PaymentsForHedgeFinancingActivities contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7788826" unitRef="iso4217-usd">1610000</us-gaap:PaymentsForHedgeFinancingActivities>
  <us-gaap:PaymentsForHedgeFinancingActivities contextRef="d_2015-01-01_2015-06-30" id="c7788827" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:PaymentsForProceedsFromHedgeInvestingActivities contextRef="d_2016-05-18_2016-05-18_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" decimals="-3" id="c7789335" unitRef="iso4217-usd">1950000</us-gaap:PaymentsForProceedsFromHedgeInvestingActivities>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="d_2016-01-01_2016-06-30" id="c7788815" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7788816" unitRef="iso4217-usd">19407000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
  <us-gaap:PaymentsToAcquireProductiveAssets contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7788811" unitRef="iso4217-usd">5099000</us-gaap:PaymentsToAcquireProductiveAssets>
  <us-gaap:PaymentsToAcquireProductiveAssets contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7788812" unitRef="iso4217-usd">934000</us-gaap:PaymentsToAcquireProductiveAssets>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="i_2016-06-30" decimals="INF" id="c7789351" unitRef="iso4217-usd-per-xbrli-shares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="i_2015-12-31" decimals="INF" id="c7789352" unitRef="iso4217-usd-per-xbrli-shares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="i_2016-06-30" decimals="0" id="c7789353" unitRef="xbrli-shares">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="i_2015-12-31" decimals="0" id="c7789354" unitRef="xbrli-shares">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued contextRef="i_2016-06-30" decimals="0" id="c7789355" unitRef="xbrli-shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued contextRef="i_2015-12-31" decimals="0" id="c7789356" unitRef="xbrli-shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="i_2016-06-30" decimals="0" id="c7789357" unitRef="xbrli-shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding contextRef="i_2015-12-31" decimals="0" id="c7789358" unitRef="xbrli-shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockValue contextRef="i_2016-06-30" id="c7788685" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:PreferredStockValue contextRef="i_2015-12-31" id="c7788686" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="i_2016-06-30" decimals="-3" id="c7788647" unitRef="iso4217-usd">1674000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="i_2015-12-31" decimals="-3" id="c7788648" unitRef="iso4217-usd">2674000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PriorPeriodReclassificationAdjustment contextRef="d_2016-01-01_2016-03-31_CreationDateAxis-December312015Member_NewAccountingPronouncementEarlyAdoptionAxis-DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" decimals="INF" id="c7789001" unitRef="iso4217-usd">2196000</us-gaap:PriorPeriodReclassificationAdjustment>
  <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="d_2016-01-01_2016-06-30" id="c8267404">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Reclassifications&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;During the first quarter of 2016, the Company adopted Accounting Standards Update No. 2015-03, &lt;div style="display: inline; font-style: italic;"&gt;Interest &amp;#x2013; Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs&lt;/div&gt;. Accordingly, debt issuance costs of $2,196 classified as other current assets as of December 31, 2015 have been reclassified and netted against non-recourse notes payable to conform to the 2016 presentation.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="d_2016-01-01_2016-06-30" id="c7788822" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7788823" unitRef="iso4217-usd">1175000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromLicenseFeesReceived contextRef="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember" decimals="INF" id="c7789037" unitRef="iso4217-usd">33740000</us-gaap:ProceedsFromLicenseFeesReceived>
  <us-gaap:ProceedsFromLicenseFeesReceived contextRef="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_ProductOrServiceAxis-RAPIVABMember_StatementScenarioAxis-ContingentUponEuMarketingApprovalMember_TypeOfArrangementAxis-AgreementMember" decimals="INF" id="c7789038" unitRef="iso4217-usd">7000000</us-gaap:ProceedsFromLicenseFeesReceived>
  <us-gaap:ProceedsFromLicenseFeesReceived contextRef="d_2015-06-16_2015-06-16_CounterpartyNameAxis-CSLLimitedMember" decimals="INF" id="c7789288" unitRef="iso4217-usd">33740000</us-gaap:ProceedsFromLicenseFeesReceived>
  <us-gaap:ProceedsFromLicenseFeesReceived contextRef="d_2006-06-01_2006-06-30_TypeOfArrangementAxis-GreenCrossCorporationMember" decimals="INF" id="c7789294" unitRef="iso4217-usd">250000</us-gaap:ProceedsFromLicenseFeesReceived>
  <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7788817" unitRef="iso4217-usd">19064000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7788818" unitRef="iso4217-usd">24884000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7788824" unitRef="iso4217-usd">33000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7788825" unitRef="iso4217-usd">3570000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockPlans contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7788828" unitRef="iso4217-usd">214000</us-gaap:ProceedsFromStockPlans>
  <us-gaap:ProceedsFromStockPlans contextRef="d_2015-01-01_2015-06-30" id="c7788829" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2016-06-30_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" decimals="INF" id="c7789074" unitRef="iso4217-usd">1589000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="i_2016-06-30" decimals="-3" id="c7788655" unitRef="iso4217-usd">10112000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="i_2015-12-31" decimals="-3" id="c7788656" unitRef="iso4217-usd">5149000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="d_2016-01-01_2016-06-30" id="c8267410">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Property and Equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of three years. Laboratory equipment, office equipment, and software are depreciated over a life of five years. Furniture and fixtures are depreciated over a life of seven years. Leasehold improvements are amortized over their estimated useful lives or the expected lease term, whichever is less. Property consists of a leased building which did not meet the sale-leaseback criteria and is recorded at its fair value, less depreciation. The building is being depreciated over a period equal to the expected term of the related lease.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In accordance with U.S. GAAP, the Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="d_2016-01-01_2016-06-30_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember" id="c7789026">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="d_2016-01-01_2016-06-30_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" id="c7789027">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="d_2016-01-01_2016-06-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" id="c7789028">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="d_2016-01-01_2016-06-30_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" id="c7789075">P20Y182D</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c7788886" unitRef="iso4217-usd">723000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c7788887" unitRef="iso4217-usd">1273000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-06-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c7788888" unitRef="iso4217-usd">1996000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" decimals="-3" id="c7788889" unitRef="iso4217-usd">145000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" id="c7788890" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-06-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" decimals="-3" id="c7788891" unitRef="iso4217-usd">145000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember" decimals="-3" id="c7788892" unitRef="iso4217-usd">37000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember" decimals="-3" id="c7788893" unitRef="iso4217-usd">56000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-06-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember" decimals="-3" id="c7788894" unitRef="iso4217-usd">93000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember" decimals="-3" id="c7788895" unitRef="iso4217-usd">905000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember" decimals="-3" id="c7788896" unitRef="iso4217-usd">1329000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2016-06-30" decimals="-3" id="c7788897" unitRef="iso4217-usd">2234000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" id="c7788898" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c7788899" unitRef="iso4217-usd">5536000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" decimals="-3" id="c7788900" unitRef="iso4217-usd">5536000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" decimals="-3" id="c7788901" unitRef="iso4217-usd">469000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" id="c7788902" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" decimals="-3" id="c7788903" unitRef="iso4217-usd">469000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember" decimals="-3" id="c7788904" unitRef="iso4217-usd">210000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember" decimals="-3" id="c7788905" unitRef="iso4217-usd">28000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember" decimals="-3" id="c7788906" unitRef="iso4217-usd">238000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember" decimals="-3" id="c7788907" unitRef="iso4217-usd">679000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember" decimals="-3" id="c7788908" unitRef="iso4217-usd">5564000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="i_2015-12-31" decimals="-3" id="c7788909" unitRef="iso4217-usd">6243000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesPolicyTextBlock contextRef="d_2016-01-01_2016-06-30" id="c8267408">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Receivables from Collaborations&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables from Shionogi and Seqirus UK Limited (&amp;#x201c;SUL&amp;#x201d;), and product sales to SUL. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date. At June 30, 2016 and December&amp;nbsp;31, 2015, the Company had the following receivables.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;June&amp;nbsp;30, 2016&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Billed&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Unbilled&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Total&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 61%; font-size: 10pt; text-align: left"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;723&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;1,273&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;1,996&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Shionogi&amp;nbsp;&amp;amp; Co. Ltd.&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;145&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;145&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Seqirus UK Limited&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;37&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;56&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;93&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total receivables&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;905&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;1,329&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;2,234&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&amp;nbsp;31, 2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Billed&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Unbilled&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Total&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 61%; font-size: 10pt; text-align: left"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;5,536&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;5,536&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Shionogi&amp;nbsp;&amp;amp; Co. Ltd.&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;469&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;469&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Seqirus UK Limited&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;210&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;28&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;238&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total receivables&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;679&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;5,564&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;6,243&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Monthly invoices are submitted to the U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&amp;#x2019;s calculations of its indirect cost rates are subject to audit by the U.S. Government.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Receivables from Product Sales&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Receivables from product sales are recorded for amounts due to the Company related to sales of RAPIVAB. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
  <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax contextRef="d_2016-01-01_2016-06-30" decimals="INF" id="c7789032" unitRef="iso4217-usd">10000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
  <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax contextRef="d_2015-01-01_2015-06-30" decimals="INF" id="c7789033" unitRef="iso4217-usd">12000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2016-04-01_2016-06-30" decimals="-3" id="c7788721" unitRef="iso4217-usd">14166000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c7788722" unitRef="iso4217-usd">16524000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7788723" unitRef="iso4217-usd">34745000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7788724" unitRef="iso4217-usd">33644000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="d_2016-01-01_2016-06-30" id="c8267415">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Research and Development Expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company&amp;#x2019;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&amp;#x2019;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&amp;#x2019;s manufacturing and clinical and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&amp;#x2019;s on-going review of the level of services actually performed.&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Additionally, the Company has license agreements with third parties, such as Albert Einstein College of Medicine of Yeshiva University (&amp;#x201c;AECOM&amp;#x201d;), Industrial Research, Ltd. (&amp;#x201c;IRL&amp;#x201d;), and the University of Alabama at Birmingham (&amp;#x201c;UAB&amp;#x201d;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Deferred collaboration expenses represent sub-license payments, paid to the Company&amp;#x2019;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to our academic partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt of such payments or modifications from the Company&amp;#x2019;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="i_2016-06-30_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-RoyaltyReceivableMember" decimals="INF" id="c7789007" unitRef="iso4217-usd">3022000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="i_2016-06-30_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-CollateralForCreditMember" decimals="INF" id="c7789009" unitRef="iso4217-usd">1404000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="i_2016-06-30" decimals="-3" id="c7788639" unitRef="iso4217-usd">4426000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="i_2015-12-31" decimals="-3" id="c7788640" unitRef="iso4217-usd">1612000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="i_2016-06-30" decimals="-3" id="c7788693" unitRef="iso4217-usd">-550030000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="i_2015-12-31" decimals="-3" id="c7788694" unitRef="iso4217-usd">-510917000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="d_2016-01-01_2016-06-30" id="c8267414">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Revenue Recognition&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company recognizes revenues from collaborative and other research and development arrangements, royalties and product sales when realized or realizable and earned. Revenue is realized or realizable and earned when all of the following criteria are met: (i)&amp;nbsp;persuasive evidence of an arrangement exists; (ii)&amp;nbsp;delivery has occurred or services have been rendered; (iii)&amp;nbsp;the seller&amp;#x2019;s price to the buyer is fixed or determinable; and (iv)&amp;nbsp;collectability is reasonably assured.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Collaborative and Other Research and Development Arrangements and Royalties&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Revenue from license fees, royalty payments, event payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement. Fees received under licensing agreements that are related to future performance are deferred and recognized over an estimated period determined by management based on the terms of the agreement and the products licensed. Revisions to revenue or profit estimates as a result of changes in the estimated revenue period are recognized prospectively.&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Under certain of the Company&amp;#x2019;s license agreements, the Company receives royalty payments based upon its licensees&amp;#x2019; net sales of covered products. The Company recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured.&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;For arrangements that involve the delivery of more than one element, each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting. This determination is based on whether the deliverable has &amp;#x201c;stand-alone value&amp;#x201d; to the customer. The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective evidence of fair value, (ii) third-party evidence of selling price (&amp;#x201c;TPE&amp;#x201d;) and (iii) best estimate of selling price (&amp;#x201c;BESP&amp;#x201d;). The BESP reflects our best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis. In most cases the Company expects to use TPE or BESP for allocating consideration to each deliverable. The consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In June 2015, the Company entered into a License Agreement (the &amp;#x201c;SUL Agreement&amp;#x201d;) granting SUL and its affiliates worldwide rights, excluding Israel, Japan, Korea and Taiwan, to develop, manufacture and commercialize RAPIVAB. The SUL Agreement provides for various types of payments, including a non-refundable upfront fee, milestone payments, and future royalties. Analysis of the SUL Agreement identified three deliverables: (i) license rights, (ii) inventory and (iii) regulatory support to obtain Canadian and European Union (&amp;#x201c;EU&amp;#x201d;) marketing approvals. The Company received an upfront payment of $33,740 from SUL, of which $7,000 was determined to be contingent upon EU marketing approval and will be deferred until that time. Approximately $21,777 of the upfront payment was allocated to the license rights and recognized as revenue in the second quarter. Approximately $3,740 of the upfront payment was allocated to the pending sale of inventory and was recognized during the third quarter, when the inventory transfer was completed. Approximately $1,223 of the revenue from the SUL Agreement will be recognized over the expected period of involvement in these regulatory support activities.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not reasonably assured at the inception of the agreement; and (ii) the fees are non-refundable. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Under the terms of the SUL Agreement, the Company may receive up to $12,000 in additional payments related to the successful achievement of regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Products and Food Branch of Health Canada (&amp;#x201c;Health Canada&amp;#x201d;) for an adult indication in Canada. The Company evaluated each event based payment under the provisions of ASU 2010-17, &lt;div style="display: inline; font-style: italic;"&gt;Milestone Method of Revenue Recognition&lt;/div&gt;, and determined that each event based payment met the criteria to be considered substantive and represents a milestone under the milestone method of accounting. No event based payments were achieved during the periods presented.&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company&amp;#x2019;s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (&amp;#x201d;BARDA/HHS&amp;#x201d;) and the National Institute of Allergy and Infectious Diseases (&amp;#x201c;NIAID/HHS&amp;#x201d;), revenue is recognized as reimbursable direct and indirect costs are incurred.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Product Sales&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company recognizes revenue for sales of RAPIVAB when title and substantially all the risks and rewards of ownership have transferred to the customer, which generally occurs on the date of shipment from our specialty distributors, utilizing the Sell-Through revenue recognition methodology. Product sales are recognized when there is persuasive evidence that an arrangement exists, title has passed, the price is fixed and determinable, and collectability is reasonably assured. Product sales are recognized net of estimated allowances, discounts, sales returns, chargebacks and rebates. In the United States, and prior to the SUL Agreement, the Company sold RAPIVAB to specialty distributors, who in turn, sell to physician offices, hospitals and federal, state and commercial health care organizations.&amp;nbsp;With the completion of the SUL worldwide license of RAPIVAB, SUL will be responsible for sales of RAPIVAB, other than U.S. Government stockpiling sales. With the completion of the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&amp;#x2019;s partners, except for U.S. Government stockpiling sales, and the Company will be reliant on these partners to generate sales.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Sales deductions consist of statutory rebates to state Medicaid, Medicare and other government agencies and sales discounts (including trade discounts and distribution service fees). These deductions are recorded as reductions from revenue from RAPIVAB in the same period as the related sales with estimates of future utilization derived from historical experience adjusted to reflect known changes in the factors that impact such reserves.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company utilizes data from external sources to help it estimate gross-to-net sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. Externally sourced data includes, but is not limited to, information obtained from specialty distributors with respect to their inventory levels and their sell-through to customers, as well as information from third-party suppliers of market research data to the pharmaceutical industry.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company accounts for these sales deductions in accordance with authoritative guidance on revenue recognition when consideration is given by a vendor to a customer.&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company has categorized and described more fully the following significant sales deductions, all of which involve estimates and judgments, which the Company considers to be critical accounting estimates, and require it to use information from external sources.&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Rebates and Chargebacks&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 13.5pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Statutory rebates to state Medicaid agencies and Medicare are based on statutory discounts to RAPIVAB&amp;#x2019;s selling price.&amp;nbsp;As it can take up to nine months or more for information to be received on actual usage of RAPIVAB in Medicaid and other governmental programs, the Company maintains reserves for amounts payable under these programs relating to RAPIVAB sales.&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Chargebacks claimed by specialty distributors are based on the differentials between product acquisition prices paid by the specialty distributors and lower government contract pricing paid by eligible customers covered under federally qualified programs.&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;The amount of the reserve for rebates and chargebacks is based on multiple qualitative and quantitative factors, including the historical and projected utilization levels, historical payment experience, changes in statutory laws and interpretations as well as contractual terms, product pricing (both normal selling prices and statutory or negotiated prices), changes in prescription demand patterns and utilization of the Company&amp;#x2019;s product through public benefit plans, and the levels of RAPIVAB inventory in the distribution channel. The Company acquires prescription utilization data from third-party suppliers of market research data to the pharmaceutical industry. The Company updates its estimates and assumptions each period and records any necessary adjustments to its reserves. Settlements of rebates and chargebacks typically occur within nine months from point of sale. To the extent actual rebates and chargebacks differ from the Company&amp;#x2019;s estimates, additional reserves may be required or reserves may need to be reversed, either of which would impact current period product revenue.&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Discounts and Sales Incentives&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Discounts and other sales incentives primarily consist of Inventory Management Agreement (&amp;#x201c;IMA&amp;#x201d;) Fees. Per contractual agreements with the Company&amp;#x2019;s specialty distributors, the Company provides an IMA fee based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth in individual contracts. The Company tracks sales to these distributors each period and accrues a liability relating to the unpaid portion of these fees by applying the contractual rates to such product sales.&amp;nbsp;With the completion of the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&amp;#x2019;s partners, except for U.S. Government stockpiling sales, and the Company will be reliant on these partners to generate sales and to provide for discounts and sales incentives.&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Product Returns&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company does not record a product return allowance as it does not offer the ability to return goods once a bonafide shipment has been accepted by a specialty distributor.&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company recorded the following revenues for the three and six months ended June&amp;nbsp;30, 2016 and 2015:&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Three Months&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Six Months&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 48%; font-size: 10pt; text-align: left"&gt;Product sales, net&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;537&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Royalty revenue&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;629&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;132&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;2,519&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,650&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Collaborative and other research and development revenues:&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 20pt"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;3,709&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;3,731&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;6,033&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;8,206&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 20pt"&gt;Shionogi (Japan)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;296&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;296&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;592&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;592&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 20pt"&gt;Seqirus UK Limited&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;153&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;21,683&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;463&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;21,683&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Total collaborative and other research and development revenues&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;4,158&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;25,710&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;7,088&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;30,481&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total revenues&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;4,787&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;25,842&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;9,607&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;32,668&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Advertising&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company engages in very limited distribution and direct-response advertising when promoting RAPIVAB. Advertising and promotional costs are expensed as the costs are incurred.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:Revenues contextRef="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember" decimals="INF" id="c7789039" unitRef="iso4217-usd">21777000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="d_2016-04-01_2016-06-30" decimals="-3" id="c7788939" unitRef="iso4217-usd">4787000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c7788940" unitRef="iso4217-usd">25842000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7788941" unitRef="iso4217-usd">9607000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7788942" unitRef="iso4217-usd">32668000</us-gaap:Revenues>
  <us-gaap:RoyaltyExpense contextRef="d_2016-04-01_2016-06-30" decimals="-3" id="c7788729" unitRef="iso4217-usd">27000</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyExpense contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c7788730" unitRef="iso4217-usd">442000</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyExpense contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7788731" unitRef="iso4217-usd">104000</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyExpense contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7788732" unitRef="iso4217-usd">502000</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyRevenue contextRef="d_2016-04-01_2016-06-30" decimals="-3" id="c7788704" unitRef="iso4217-usd">629000</us-gaap:RoyaltyRevenue>
  <us-gaap:RoyaltyRevenue contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c7788705" unitRef="iso4217-usd">132000</us-gaap:RoyaltyRevenue>
  <us-gaap:RoyaltyRevenue contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7788706" unitRef="iso4217-usd">2519000</us-gaap:RoyaltyRevenue>
  <us-gaap:RoyaltyRevenue contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7788707" unitRef="iso4217-usd">1650000</us-gaap:RoyaltyRevenue>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2016-04-01_2016-06-30" id="c7788700" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2015-04-01_2015-06-30" id="c7788701" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2016-01-01_2016-06-30" id="c7788702" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7788703" unitRef="iso4217-usd">537000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueNet contextRef="d_2016-04-01_2016-06-30" decimals="-3" id="c7788712" unitRef="iso4217-usd">4787000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c7788713" unitRef="iso4217-usd">25842000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7788714" unitRef="iso4217-usd">9607000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7788715" unitRef="iso4217-usd">32668000</us-gaap:SalesRevenueNet>
  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="d_2016-01-01_2016-06-30" id="c-19">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 74%; font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Work in process&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,949&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,612&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;Inventories&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;1,949&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;1,612&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="d_2016-01-01_2016-06-30" id="c-21">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Awards&lt;br /&gt; Available&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Options&lt;br /&gt; Outstanding&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Weighted&lt;br /&gt; Average&lt;br /&gt; Exercise&lt;br /&gt; Price&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 61%; font-size: 10pt"&gt;Balance December&amp;nbsp;31, 2015&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;16&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;10,671&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;7.50&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 20pt"&gt;Plan amendment&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;3,800&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 20pt"&gt;Restricted stock unit awards granted&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(21&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 20pt"&gt;Restricted stock unit awards cancelled&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;15&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 20pt"&gt;Stock option awards granted&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(2,120&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;2,120&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;3.21&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 20pt"&gt;Stock option awards exercised&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(79&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;2.32&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 20pt"&gt;Stock option awards cancelled&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;499&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(499&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"&gt;11.24&lt;/td&gt; &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;Balance June&amp;nbsp;30, 2016&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;2,189&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;12,213&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: right"&gt;6.63&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="d_2016-01-01_2016-06-30" id="c-22">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 74%; font-size: 10pt; text-align: left"&gt;Expected Life in Years&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;5.6&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;5.5&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Expected Volatility&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;82&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;83&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Expected Dividend Yield&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;0.0&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;0.0&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Risk-Free Interest Rate&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1.4&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1.5&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="d_2016-04-01_2016-06-30" decimals="-3" id="c7788725" unitRef="iso4217-usd">2724000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c7788726" unitRef="iso4217-usd">3534000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7788727" unitRef="iso4217-usd">5936000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7788728" unitRef="iso4217-usd">7595000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:ShareBasedCompensation contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7788787" unitRef="iso4217-usd">4491000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7788788" unitRef="iso4217-usd">5934000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="d_2016-01-01_2016-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember" id="c7789209">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="d_2013-01-01_2013-01-31_AwardTypeAxis-StockOptionsAndRestrictedStockMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest50PercentEachYearUntilFullyVestedMember" id="c7789211">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="d_2016-01-01_2016-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c7788952" unitRef="xbrli-shares">15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="d_2016-01-01_2016-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c7788949" unitRef="xbrli-shares">21000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="d_2016-01-01_2016-06-30_PlanNameAxis-IncentivePlanMember" decimals="INF" id="c7789385" unitRef="xbrli-pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="d_2015-01-01_2015-06-30_PlanNameAxis-IncentivePlanMember" decimals="3" id="c7788972" unitRef="xbrli-pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="d_2016-01-01_2016-06-30_PlanNameAxis-IncentivePlanMember" decimals="3" id="c7788969" unitRef="xbrli-pure">0.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="d_2015-01-01_2015-06-30_PlanNameAxis-IncentivePlanMember" decimals="3" id="c7788970" unitRef="xbrli-pure">0.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2016-01-01_2016-06-30_PlanNameAxis-IncentivePlanMember" decimals="3" id="c7788973" unitRef="xbrli-pure">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2015-01-01_2015-06-30_PlanNameAxis-IncentivePlanMember" decimals="3" id="c7788974" unitRef="xbrli-pure">0.015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee contextRef="d_2016-01-01_2016-06-30_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="-3" id="c7789258" unitRef="xbrli-shares">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="d_2016-01-01_2016-06-30_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c7788946" unitRef="xbrli-shares">3800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="i_2016-06-30_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="-3" id="c7789252" unitRef="xbrli-shares">1475000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="i_2016-06-30_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="-3" id="c7789253" unitRef="xbrli-shares">463000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="i_2015-12-31_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c7788943" unitRef="xbrli-shares">16000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="i_2016-06-30_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c7788964" unitRef="xbrli-shares">2189000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="i_2016-06-30_PlanNameAxis-IncentivePlanMember" decimals="INF" id="c7788966" unitRef="iso4217-usd-per-xbrli-shares">6.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="d_2016-01-01_2016-06-30_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c7788962" unitRef="xbrli-shares">499000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="d_2016-01-01_2016-06-30_PlanNameAxis-IncentivePlanMember" decimals="INF" id="c7788963" unitRef="iso4217-usd-per-xbrli-shares">11.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="d_2016-01-01_2016-06-30_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c7788956" unitRef="xbrli-shares">2120000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2013-08-01_2013-08-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" decimals="-3" id="c7789213" unitRef="xbrli-shares">1032000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2014-12-01_2014-12-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" decimals="-3" id="c7789214" unitRef="xbrli-shares">1250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="d_2016-01-01_2016-06-30_PlanNameAxis-IncentivePlanMember" decimals="INF" id="c7789245" unitRef="iso4217-usd-per-xbrli-shares">2.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="d_2015-01-01_2015-06-30_PlanNameAxis-IncentivePlanMember" decimals="INF" id="c7789246" unitRef="iso4217-usd-per-xbrli-shares">8.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i_2015-12-31_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c7788944" unitRef="xbrli-shares">10671000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i_2016-06-30_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c7788965" unitRef="xbrli-shares">12213000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i_2015-12-31_PlanNameAxis-IncentivePlanMember" decimals="INF" id="c7788945" unitRef="iso4217-usd-per-xbrli-shares">7.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="d_2016-01-01_2016-06-30_PlanNameAxis-IncentivePlanMember" decimals="INF" id="c7788960" unitRef="iso4217-usd-per-xbrli-shares">2.32</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="d_2016-01-01_2016-06-30_PlanNameAxis-IncentivePlanMember" decimals="INF" id="c7788957" unitRef="iso4217-usd-per-xbrli-shares">3.21</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="d_2016-01-01_2016-06-30" id="c8267416">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Stock-Based Compensation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&amp;#x2019;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which no compensation expense is recognized until &amp;#x201c;performance&amp;#x201d; is deemed to have occurred.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="d_2016-01-01_2016-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember" decimals="INF" id="c7789208" unitRef="xbrli-pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="d_2013-01-01_2013-01-31_AwardTypeAxis-StockOptionsAndRestrictedStockMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest50PercentEachYearUntilFullyVestedMember" decimals="INF" id="c7789210" unitRef="xbrli-pure">0.5</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="d_2016-01-01_2016-06-30_AwardDateAxis-August2013Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" decimals="INF" id="c7789215" unitRef="xbrli-pure">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2016-01-01_2016-06-30_PlanNameAxis-IncentivePlanMember" id="c7788967">P5Y219D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2015-01-01_2015-06-30_PlanNameAxis-IncentivePlanMember" id="c7788968">P5Y182D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="d_2016-01-01_2016-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_RangeAxis-MinimumMember" id="c7789235">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="d_2016-01-01_2016-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_RangeAxis-MaximumMember" id="c7789236">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="d_2016-01-01_2016-06-30" id="s265740">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note 1 &amp;#x2014; Significant Accounting Policies&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;The Company&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;BioCryst Pharmaceuticals, Inc. (the &amp;#x201c;Company&amp;#x201d;) is a biotechnology company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and align with its capabilities and expertise. The Company was incorporated in Delaware in 1986 and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred losses and negative cash flows from operations since inception.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Based on its current operating plans, the Company expects it has sufficient liquidity, with its existing cash, restricted cash and investments of $64,320, to continue its planned operations through mid-2017. The Company&amp;#x2019;s liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key development and regulatory events in the future. In order to continue its operations substantially beyond mid-2017 it will need to: (1)&amp;nbsp;successfully secure or increase U.S. Government funding of its programs, including procurement contracts; (2)&amp;nbsp;out-license rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; (3)&amp;nbsp;raise additional capital through equity or debt financings or from other sources; (4)&amp;nbsp;obtain additional product candidate regulatory approvals, which would generate revenue and cash flow; (5)&amp;nbsp;reduce spending on one or more research and development programs; and/or (6)&amp;nbsp;restructure operations. The Company may issue securities, including common stock, preferred stock, depositary shares, stock purchase contracts, warrants and units, through private placement transactions or registered public offerings pursuant to its registration statements on Form S-3 initially filed with the Securities and Exchange Commission (&amp;#x201c;SEC&amp;#x201d;) on March 3, 2015 and November&amp;nbsp;6, 2013. The Company will continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations.&amp;nbsp;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Basis of Presentation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, JPR Royalty Sub LLC (&amp;#x201c;Royalty Sub&amp;#x201d;). Royalty Sub was formed in connection with a $30,000&amp;nbsp;financing transaction the Company completed on March&amp;nbsp;9, 2011. See Note 4, Royalty Monetization, for a further description of this transaction. All intercompany transactions and balances have been eliminated.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company&amp;#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&amp;#x201c;U.S. GAAP&amp;#x201d;) for interim financial reporting and the instructions to Form 10-Q and do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management&amp;#x2019;s opinion, necessary to present fairly, in all material respects, the Company&amp;#x2019;s consolidated financial position, results of operations, and cash flows. There were no adjustments other than normal recurring adjustments.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;These financial statements should be read in conjunction with the financial statements for the year ended December&amp;nbsp;31, 2015 and the notes thereto included in the Company&amp;#x2019;s 2015 Annual Report on Form 10-K. Interim operating results are not necessarily indicative of operating results for the full year. The balance sheet as of December&amp;nbsp;31, 2015 has been derived from the audited consolidated financial statements included in the Company&amp;#x2019;s most recent Annual Report on Form 10-K.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Reclassifications&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;   &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;During the first quarter of 2016, the Company adopted Accounting Standards Update No. 2015-03, &lt;div style="display: inline; font-style: italic;"&gt;Interest &amp;#x2013; Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs&lt;/div&gt;. Accordingly, debt issuance costs of $2,196 classified as other current assets as of December 31, 2015 have been reclassified and netted against non-recourse notes payable to conform to the 2016 presentation.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Cash and Cash Equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of three months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;!-- Field: Page; Sequence: 6; Value: 3 --&gt;   &lt;!-- Field: /Page --&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Restricted Cash&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Restricted cash as of June&amp;nbsp;30, 2016 reflects $3,022 in royalty revenue paid by Shionogi&amp;nbsp;&amp;amp; Co., Ltd. (&amp;#x201c;Shionogi&amp;#x201d;) designated for interest on the PhaRMA Notes (defined in Note 4) and $1,404 the Company is required to maintain as collateral for a letter of credit associated with the lease execution and build-out of its new Birmingham research facilities.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Investments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&amp;#x2019;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that may consist of U.S. Government and government agency securities, money market and mutual fund investments, municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&amp;#x2019;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of three years and requires an average portfolio maturity of no more than 18 months. Some of the securities the Company invests in may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&amp;#x2019;s investments are not collateralized. The Company has not realized any significant losses from its investments.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond three months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. At June 30, 2016, the Company believes that the costs of its investments are recoverable in all material respects.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The following tables summarize the fair value of the Company&amp;#x2019;s investments by type. The estimated fair value of the Company&amp;#x2019;s fixed income investments are classified as Level 2 in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. These fair values are obtained from independent pricing services which utilize Level 2 inputs.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;June&amp;nbsp;30, 2016&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Amortized&lt;br /&gt; Cost&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Accrued&lt;br /&gt; Interest&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Gains&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Losses&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Estimated&lt;br /&gt; Fair&amp;nbsp;Value&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 35%; font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Obligations of the U.S. Government and its agencies&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;14,081&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;38&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;8&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;14,127&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Corporate debt securities&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;16,641&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;147&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;23&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(1&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;16,810&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Certificates of deposit&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;20,258&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;22&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;23&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(7&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;20,296&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;50,980&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;207&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;54&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;(8&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;51,233&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&amp;nbsp;31, 2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Amortized&lt;br /&gt; Cost&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Accrued&lt;br /&gt; Interest&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Gains&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Gross&lt;br /&gt; Unrealized&lt;br /&gt; Losses&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Estimated&lt;br /&gt; Fair&amp;nbsp;Value&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt; width: 35%"&gt;Obligations of the U.S. Government and its agencies&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;26,557&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;88&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;(99&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;26,546&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Corporate debt securities&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;21,820&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;184&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(41&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;21,963&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Certificates of deposit&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;21,884&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;21&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;5&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(72&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;21,838&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;70,261&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;293&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;5&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;(212&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;70,347&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;   &lt;!-- Field: Page; Sequence: 7; Value: 3 --&gt;   &lt;!-- Field: /Page --&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0"&gt;The following table summarizes the scheduled maturity for the Company&amp;#x2019;s investments at June&amp;nbsp;30, 2016 and December&amp;nbsp;31, 2015.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 74%; font-size: 10pt; text-align: left"&gt;Maturing in one year or less&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;27,079&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;22,664&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Maturing after one year through two years&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;18,164&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;28,395&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Maturing after two years&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;5,990&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;19,288&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;51,233&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;70,347&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Receivables from Collaborations&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables from Shionogi and Seqirus UK Limited (&amp;#x201c;SUL&amp;#x201d;), and product sales to SUL. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date. At June 30, 2016 and December&amp;nbsp;31, 2015, the Company had the following receivables.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;June&amp;nbsp;30, 2016&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Billed&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Unbilled&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Total&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 61%; font-size: 10pt; text-align: left"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;723&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;1,273&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;1,996&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Shionogi&amp;nbsp;&amp;amp; Co. Ltd.&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;145&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;145&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Seqirus UK Limited&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;37&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;56&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;93&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total receivables&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;905&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;1,329&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;2,234&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&amp;nbsp;31, 2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Billed&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Unbilled&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Total&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 61%; font-size: 10pt; text-align: left"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;5,536&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;5,536&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Shionogi&amp;nbsp;&amp;amp; Co. Ltd.&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;469&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;469&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Seqirus UK Limited&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;210&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;28&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;238&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total receivables&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;679&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;5,564&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;6,243&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Monthly invoices are submitted to the U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&amp;#x2019;s calculations of its indirect cost rates are subject to audit by the U.S. Government.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Receivables from Product Sales&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Receivables from product sales are recorded for amounts due to the Company related to sales of RAPIVAB. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Inventory&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;At June 30, 2016 and December 31, 2015, the Company&amp;#x2019;s inventory consisted of RAPIVAB work in process. Inventory is stated at the lower of cost, determined under the first-in, first-out (&amp;#x201c;FIFO&amp;#x201d;) method, or market. The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company will capitalize subsequent costs related to the production of inventories.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;During 2014, in connection with the U.S. Food and Drug Administration (&amp;#x201c;FDA&amp;#x201d;) approval of RAPIVAB, the Company began capitalizing costs associated with the production of RAPIVAB inventories.&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;!-- Field: Page; Sequence: 8; Value: 3 --&gt;   &lt;!-- Field: /Page --&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company&amp;#x2019;s inventory consisted of the following at June&amp;nbsp;30, 2016 and December&amp;nbsp;31, 2015:&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 74%; font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Work in process&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,949&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,612&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;Inventories&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;1,949&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;1,612&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Property and Equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of three years. Laboratory equipment, office equipment, and software are depreciated over a life of five years. Furniture and fixtures are depreciated over a life of seven years. Leasehold improvements are amortized over their estimated useful lives or the expected lease term, whichever is less. Property consists of a leased building which did not meet the sale-leaseback criteria and is recorded at its fair value, less depreciation. The building is being depreciated over a period equal to the expected term of the related lease.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In accordance with U.S. GAAP, the Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Patents and Licenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Accrued Expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company generally enters into contractual agreements with third-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include:&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; width: 700px;"&gt;  &lt;tr&gt; &lt;td style="width: 5%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; width: 2%"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;#x2022;&lt;/div&gt;&lt;/td&gt; &lt;td style="vertical-align: top; width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top; width: 92%"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;fees paid to Clinical Research Organizations (&amp;#x201c;CROs&amp;#x201d;) in connection with preclinical and toxicology studies and clinical trials;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;#x2022;&lt;/div&gt;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;fees paid to investigative sites in connection with clinical trials;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;#x2022;&lt;/div&gt;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;fees paid to contract manufacturers in connection with the production of our raw materials, drug substance and drug products;&amp;nbsp;and&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;#x2022;&lt;/div&gt;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;professional fees.&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&amp;#x2019;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of June 30, 2016 and December 31, 2015, the carrying value of accrued expenses approximates their fair value due to their short-term settlement.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The liability method is used in the Company&amp;#x2019;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;!-- Field: Page; Sequence: 9; Value: 3 --&gt;   &lt;!-- Field: /Page --&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Accumulated Other Comprehensive Income (Loss)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;   &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Accumulated other comprehensive income (loss) is comprised of unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&amp;#x2019; equity. Amounts reclassified from accumulated other comprehensive income (loss) are recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. During the six months ended June 30, 2016, realized gains of $10 were reclassified out of accumulated other comprehensive income (loss). During the six months ended June 30, 2015, realized gains of $12 were reclassified out of accumulated other comprehensive income (loss).&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Revenue Recognition&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company recognizes revenues from collaborative and other research and development arrangements, royalties and product sales when realized or realizable and earned. Revenue is realized or realizable and earned when all of the following criteria are met: (i)&amp;nbsp;persuasive evidence of an arrangement exists; (ii)&amp;nbsp;delivery has occurred or services have been rendered; (iii)&amp;nbsp;the seller&amp;#x2019;s price to the buyer is fixed or determinable; and (iv)&amp;nbsp;collectability is reasonably assured.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Collaborative and Other Research and Development Arrangements and Royalties&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Revenue from license fees, royalty payments, event payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement. Fees received under licensing agreements that are related to future performance are deferred and recognized over an estimated period determined by management based on the terms of the agreement and the products licensed. Revisions to revenue or profit estimates as a result of changes in the estimated revenue period are recognized prospectively.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Under certain of the Company&amp;#x2019;s license agreements, the Company receives royalty payments based upon its licensees&amp;#x2019; net sales of covered products. The Company recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;For arrangements that involve the delivery of more than one element, each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting. This determination is based on whether the deliverable has &amp;#x201c;stand-alone value&amp;#x201d; to the customer. The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective evidence of fair value, (ii) third-party evidence of selling price (&amp;#x201c;TPE&amp;#x201d;) and (iii) best estimate of selling price (&amp;#x201c;BESP&amp;#x201d;). The BESP reflects our best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis. In most cases the Company expects to use TPE or BESP for allocating consideration to each deliverable. The consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In June 2015, the Company entered into a License Agreement (the &amp;#x201c;SUL Agreement&amp;#x201d;) granting SUL and its affiliates worldwide rights, excluding Israel, Japan, Korea and Taiwan, to develop, manufacture and commercialize RAPIVAB. The SUL Agreement provides for various types of payments, including a non-refundable upfront fee, milestone payments, and future royalties. Analysis of the SUL Agreement identified three deliverables: (i) license rights, (ii) inventory and (iii) regulatory support to obtain Canadian and European Union (&amp;#x201c;EU&amp;#x201d;) marketing approvals. The Company received an upfront payment of $33,740 from SUL, of which $7,000 was determined to be contingent upon EU marketing approval and will be deferred until that time. Approximately $21,777 of the upfront payment was allocated to the license rights and recognized as revenue in the second quarter. Approximately $3,740 of the upfront payment was allocated to the pending sale of inventory and was recognized during the third quarter, when the inventory transfer was completed. Approximately $1,223 of the revenue from the SUL Agreement will be recognized over the expected period of involvement in these regulatory support activities.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not reasonably assured at the inception of the agreement; and (ii) the fees are non-refundable. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;!-- Field: Page; Sequence: 10; Value: 3 --&gt;   &lt;!-- Field: /Page --&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Under the terms of the SUL Agreement, the Company may receive up to $12,000 in additional payments related to the successful achievement of regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Products and Food Branch of Health Canada (&amp;#x201c;Health Canada&amp;#x201d;) for an adult indication in Canada. The Company evaluated each event based payment under the provisions of ASU 2010-17, &lt;div style="display: inline; font-style: italic;"&gt;Milestone Method of Revenue Recognition&lt;/div&gt;, and determined that each event based payment met the criteria to be considered substantive and represents a milestone under the milestone method of accounting. No event based payments were achieved during the periods presented.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company&amp;#x2019;s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (&amp;#x201d;BARDA/HHS&amp;#x201d;) and the National Institute of Allergy and Infectious Diseases (&amp;#x201c;NIAID/HHS&amp;#x201d;), revenue is recognized as reimbursable direct and indirect costs are incurred.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Product Sales&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company recognizes revenue for sales of RAPIVAB when title and substantially all the risks and rewards of ownership have transferred to the customer, which generally occurs on the date of shipment from our specialty distributors, utilizing the Sell-Through revenue recognition methodology. Product sales are recognized when there is persuasive evidence that an arrangement exists, title has passed, the price is fixed and determinable, and collectability is reasonably assured. Product sales are recognized net of estimated allowances, discounts, sales returns, chargebacks and rebates. In the United States, and prior to the SUL Agreement, the Company sold RAPIVAB to specialty distributors, who in turn, sell to physician offices, hospitals and federal, state and commercial health care organizations.&amp;nbsp;With the completion of the SUL worldwide license of RAPIVAB, SUL will be responsible for sales of RAPIVAB, other than U.S. Government stockpiling sales. With the completion of the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&amp;#x2019;s partners, except for U.S. Government stockpiling sales, and the Company will be reliant on these partners to generate sales.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Sales deductions consist of statutory rebates to state Medicaid, Medicare and other government agencies and sales discounts (including trade discounts and distribution service fees). These deductions are recorded as reductions from revenue from RAPIVAB in the same period as the related sales with estimates of future utilization derived from historical experience adjusted to reflect known changes in the factors that impact such reserves.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company utilizes data from external sources to help it estimate gross-to-net sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. Externally sourced data includes, but is not limited to, information obtained from specialty distributors with respect to their inventory levels and their sell-through to customers, as well as information from third-party suppliers of market research data to the pharmaceutical industry.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company accounts for these sales deductions in accordance with authoritative guidance on revenue recognition when consideration is given by a vendor to a customer.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company has categorized and described more fully the following significant sales deductions, all of which involve estimates and judgments, which the Company considers to be critical accounting estimates, and require it to use information from external sources.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Rebates and Chargebacks&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 13.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Statutory rebates to state Medicaid agencies and Medicare are based on statutory discounts to RAPIVAB&amp;#x2019;s selling price.&amp;nbsp;As it can take up to nine months or more for information to be received on actual usage of RAPIVAB in Medicaid and other governmental programs, the Company maintains reserves for amounts payable under these programs relating to RAPIVAB sales.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Chargebacks claimed by specialty distributors are based on the differentials between product acquisition prices paid by the specialty distributors and lower government contract pricing paid by eligible customers covered under federally qualified programs.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;The amount of the reserve for rebates and chargebacks is based on multiple qualitative and quantitative factors, including the historical and projected utilization levels, historical payment experience, changes in statutory laws and interpretations as well as contractual terms, product pricing (both normal selling prices and statutory or negotiated prices), changes in prescription demand patterns and utilization of the Company&amp;#x2019;s product through public benefit plans, and the levels of RAPIVAB inventory in the distribution channel. The Company acquires prescription utilization data from third-party suppliers of market research data to the pharmaceutical industry. The Company updates its estimates and assumptions each period and records any necessary adjustments to its reserves. Settlements of rebates and chargebacks typically occur within nine months from point of sale. To the extent actual rebates and chargebacks differ from the Company&amp;#x2019;s estimates, additional reserves may be required or reserves may need to be reversed, either of which would impact current period product revenue.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;!-- Field: Page; Sequence: 11; Value: 3 --&gt;   &lt;!-- Field: /Page --&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Discounts and Sales Incentives&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Discounts and other sales incentives primarily consist of Inventory Management Agreement (&amp;#x201c;IMA&amp;#x201d;) Fees. Per contractual agreements with the Company&amp;#x2019;s specialty distributors, the Company provides an IMA fee based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth in individual contracts. The Company tracks sales to these distributors each period and accrues a liability relating to the unpaid portion of these fees by applying the contractual rates to such product sales.&amp;nbsp;With the completion of the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&amp;#x2019;s partners, except for U.S. Government stockpiling sales, and the Company will be reliant on these partners to generate sales and to provide for discounts and sales incentives.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Product Returns&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company does not record a product return allowance as it does not offer the ability to return goods once a bonafide shipment has been accepted by a specialty distributor.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company recorded the following revenues for the three and six months ended June&amp;nbsp;30, 2016 and 2015:&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Three Months&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Six Months&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 48%; font-size: 10pt; text-align: left"&gt;Product sales, net&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&amp;#x2014;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;537&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Royalty revenue&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;629&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;132&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;2,519&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,650&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Collaborative and other research and development revenues:&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 20pt"&gt;U.S. Department of Health and Human Services&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;3,709&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;3,731&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;6,033&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;8,206&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 20pt"&gt;Shionogi (Japan)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;296&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;296&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;592&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;592&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 20pt"&gt;Seqirus UK Limited&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;153&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;21,683&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;463&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;21,683&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Total collaborative and other research and development revenues&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;4,158&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;25,710&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;7,088&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;30,481&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total revenues&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;4,787&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;25,842&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;9,607&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;32,668&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Advertising&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company engages in very limited distribution and direct-response advertising when promoting RAPIVAB. Advertising and promotional costs are expensed as the costs are incurred.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Research and Development Expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The Company&amp;#x2019;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&amp;#x2019;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&amp;#x2019;s manufacturing and clinical and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&amp;#x2019;s on-going review of the level of services actually performed.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Additionally, the Company has license agreements with third parties, such as Albert Einstein College of Medicine of Yeshiva University (&amp;#x201c;AECOM&amp;#x201d;), Industrial Research, Ltd. (&amp;#x201c;IRL&amp;#x201d;), and the University of Alabama at Birmingham (&amp;#x201c;UAB&amp;#x201d;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Deferred collaboration expenses represent sub-license payments, paid to the Company&amp;#x2019;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to our academic partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt of such payments or modifications from the Company&amp;#x2019;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;!-- Field: Page; Sequence: 12; Value: 3 --&gt;   &lt;!-- Field: /Page --&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Stock-Based Compensation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&amp;#x2019;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which no compensation expense is recognized until &amp;#x201c;performance&amp;#x201d; is deemed to have occurred.&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Interest Expense and Deferred Financing Costs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Interest expense for the three months ended June&amp;nbsp;30, 2016 and 2015 was $1,338 and $1,306, respectively, and for the six months ended June 30, 2016 and 2015 was $2,677 and $2,621, respectively, and relates to the issuance of the PhaRMA Notes (defined in Note 4). Costs directly associated with the issuance of the PhaRMA Notes have been capitalized and are netted against the non-recourse notes payable on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the term of the PhaRMA Notes using the effective interest rate method. Amortization of deferred financing costs included in interest expense was $110 for each of the three months ended June&amp;nbsp;30, 2016 and 2015, and $220 for each of the six months ended June 30, 2016 and 2015.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Lease Financing Obligation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.25in; margin: 0pt 0 0pt 12pt"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Based on the terms of the lease agreement for the new research facility in Birmingham, Alabama, the Company had construction period risks during the construction period and the Company was deemed the owner of the building (for accounting purposes only) during the construction period. Accordingly, the Company recorded an asset of $1,589, representing the Company&amp;#x2019;s leased portion of the building and recorded a corresponding liability. Upon completion of leasehold improvement construction, the Company did not meet the sale-leaseback criteria for de-recognition of the building asset and liability. Therefore, the lease is accounted for as a financing obligation. The asset will be depreciated over the expected duration of the lease of 20.5 years, and rental payments will be treated as principal and interest payments on the lease financing obligation liability. The underlying accounting for this transaction has no impact on cash flows associated with the underlying lease or construction in process. Interest expense for the three and six months ended June 30, 2016 includes $83 and $214, respectively, related to the lease financing obligation.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;At June 30, 2016, the lease financing obligation balance was $2,589 and was recorded as a long term liability on the consolidated balance sheets. The remaining future minimum payments under the lease financing obligation are $4,839.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0 0pt 12pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Currency Hedge Agreement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore, mark-to-market adjustments are recognized in the Company&amp;#x2019;s Consolidated Statements of Comprehensive Loss. Cumulative mark-to-market adjustments for the six months ended June&amp;nbsp;30, 2016 and 2015 resulted in losses of $6,441 and $332, respectively. Mark-to-market adjustments are determined by a third party pricing model that uses quoted prices in markets that are not actively traded and for which significant inputs are observable directly or indirectly, representing Level 2 in the fair value hierarchy as defined by U.S. GAAP. The Company is also required to post collateral in connection with the mark-to-market adjustments based on thresholds defined in the Currency Hedge Agreement. In addition, the Company realized currency exchange gains of $811 and $1,545 during the first six months of 2016 and 2015, respectively, associated with the exercise of a U.S. dollar/Japanese yen currency option under the Currency Hedge Agreement. As of June&amp;nbsp;30, 2016, $1,610 of hedge collateral was posted under the agreement. No hedge collateral was posted as of December 31, 2015.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Net Loss Per Share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein, except for the three months ended June 30, 2015 for which diluted income per share is $0.06 and basic income per share is $0.07 per share, because common equivalent shares from unexercised stock options and common shares expected to be issued under the Company&amp;#x2019;s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the three months ended June&amp;nbsp;30, 2016 does not include 885 of such potential common shares, as their impact would be anti-dilutive. The calculation of diluted earnings per share for the six months ended June&amp;nbsp;30, 2016 and 2015 does not include 1,091 and 4,038, respectively, of such potential common shares, as their impact would be anti-dilutive.&lt;/div&gt;   &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Use of Estimates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt;  &lt;!-- Field: Page; Sequence: 13; Value: 3 --&gt;   &lt;!-- Field: /Page --&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Significant Customers and Other Risks&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Significant Customers&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;Prior to the SUL Agreement, the Company relied primarily on three specialty distributors to purchase and supply the majority of RAPIVAB. These three pharmaceutical specialty distributors accounted for greater than 90% of all RAPIVAB product sales to date and accounted for predominantly all of the Company&amp;#x2019;s outstanding receivables from product sales. The loss of one or more of these specialty distributors as a customer could negatively impact the commercialization of RAPIVAB. However, the Company will utilize these specialty distributors on a limited basis subsequent to the SUL collaboration as SUL, and other peramivir collaboration partners, will be responsible for commercial sales on a worldwide basis. In addition, in connection with the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&amp;#x2019;s partners and the Company will be reliant on these partners to generate sales and remit cash to satisfy receivables.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;The Company&amp;#x2019;s primary source of revenue that has an underlying cash flow stream is the reimbursement of RAPIVAB and BCX4430 development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its RAPIVAB and BCX4430 programs. Accordingly, reimbursement of these expenses represents a significant portion of the Company&amp;#x2019;s collaborative and other research and development revenues. The completion (as with the June 30, 2014 BARDA/HHS peramivir development contract) or termination of the NIAID/HHS and BARDA/HHS BCX4430 contracts could negatively impact the Company&amp;#x2019;s future Consolidated Statements of Comprehensive Loss and Cash Flows. In addition, the Company also recognizes royalty revenue from the net sales of RAPIACTA by Shionogi; however, the underlying cash flow from these royalty payments goes directly to pay the interest, and then the principal, on the Company&amp;#x2019;s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. Further, the Company&amp;#x2019;s drug development activities are performed by a limited group of third party vendors. If any of these vendors were unable to perform their services, this could significantly impact the Company&amp;#x2019;s ability to complete its drug development activities.&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Risks from Third Party Manufacturing and Distribution Concentration&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 22.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"&gt;The Company relies on single source manufacturers for active pharmaceutical ingredient and finished drug product manufacturing of RAPIVAB, as well as for its other product candidates in development. Delays in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling of RAPIVAB or the Company&amp;#x2019;s product candidates in development.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Credit Risk&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 22.5pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately 18 months or less. Other than product sale and collaborative partner receivables discussed above, the majority of the Company&amp;#x2019;s receivables from collaborations are due from the U.S. Government, for which there is no assumed credit risk.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Recent Accounting Pronouncements&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In March 2016, the Financial Accounting Standards Board (&amp;#x201c;FASB&amp;#x201d;) issued Accounting Standards Update No. 2016-09: &lt;div style="display: inline; font-style: italic;"&gt;Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting&lt;/div&gt; (&amp;#x201c;ASU 2016-09&amp;#x201d;). The amendments in this update simplify several aspects of the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures and statutory tax withholding requirements, as well as classification in the statement of cash flows. ASU 2016-09 will be effective for the Company in fiscal year 2017, but early adoption is permitted. The Company is currently evaluating the impact of this update on its consolidated financial statements.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In February 2016, the FASB issued Accounting Standards Update No. 2016-02: &lt;div style="display: inline; font-style: italic;"&gt;Leases (Topic 842)&lt;/div&gt; (&amp;#x201c;ASU 2016-02&amp;#x201d;). The amendments in this update require lessees, among other things, to recognize lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous authoritative guidance. This update also introduces new disclosure requirements for leasing arrangements. ASU 2016-02 will be effective for the Company in fiscal year 2019, but early adoption is permitted. The Company is currently evaluating the impact of this update on its consolidated financial statements.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In January 2016, the FASB issued Accounting Standards Update No. 2016-01: &lt;div style="display: inline; font-style: italic;"&gt;Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities&lt;/div&gt; (&amp;#x201c;ASU 2016-01&amp;#x201d;). The amendments in this update address certain aspects of recognition, measurement, presentation and disclosure of financial instruments. In particular, the amendments in this update supersede, for public business entities, the requirement to disclose the methods and significant assumptions used in calculating the fair value of financial instruments required to be disclosed for financial instruments measured at amortized cost on the balance sheet. ASU 2016-01 will be effective for the Company in fiscal year 2018, but early adoption is permitted. The Company does not expect this standard to have a material impact on its consolidated financial statements.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;!-- Field: Page; Sequence: 14; Value: 3 --&gt;   &lt;!-- Field: /Page --&gt;   &lt;div style=" font-size: 10pt; text-indent: 22.3pt; margin: 0pt 0"&gt;In November 2015, the FASB issued Accounting Standards Update No. 2015-17, &lt;div style="display: inline; font-style: italic;"&gt;Balance Sheet Classification of Deferred Taxes&lt;/div&gt;, requiring all deferred tax assets and liabilities, and any related valuation allowance, to be classified as noncurrent on the balance sheet. The classification change for all deferred taxes as noncurrent simplifies entities&amp;#x2019; processes as it eliminates the need to separately identify the net current and net noncurrent deferred tax asset or liability in each jurisdiction and allocate valuation allowances. We elected to prospectively adopt the accounting standard in the beginning of our fourth quarter of fiscal 2015. Adoption of this standard had no impact on the Company&amp;#x2019;s consolidated financial statements.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In July 2015, the FASB issued Accounting Standards Update No. 2015-11: &lt;div style="display: inline; font-style: italic;"&gt;Inventory (Topic 330): Simplifying the Measurement of Inventory&lt;/div&gt; (&amp;#x201c;ASU 2015-11&amp;#x201d;), which changes the measurement principle for inventory from the lower of cost or market to the lower of cost and net realizable value. ASU 2015-11 defines net realizable value as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The update does not apply to inventory that is measured using last-in, first-out or the retail inventory method. The update applies to all other inventory, which includes inventory that is measured using first-in, first-out or average cost methods. The amendments in ASU 2015-11 will be effective for the Company for fiscal years, and the interim periods within those years, beginning after December 15, 2016. The amendments must be applied prospectively and early adoption is permitted. The Company does not expect this standard to have a material impact on its consolidated financial statements.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In April 2015, the FASB issued Accounting Standards Update No. 2015-03: &lt;div style="display: inline; font-style: italic;"&gt;Interest &amp;#x2013; Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs&lt;/div&gt; (&amp;#x201c;ASU 2015-03&amp;#x201d;). This standard amends existing guidance to require the presentation of debt issuance costs in the balance sheet as a deduction from the carrying amount of the related debt liability instead of a deferred charge. It is effective for annual reporting periods beginning after December 15, 2015 and requires retrospective application for all periods presented. The Company adopted ASU 2015-03 in the first quarter of 2016. Adoption did not have a material impact on its consolidated financial statements.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In August 2014, the FASB issued Accounting Standards Update No. 2014-15: &lt;div style="display: inline; font-style: italic;"&gt;Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&amp;#x2019;s Ability to Continue as a Going Concern&lt;/div&gt; (&amp;#x201c;ASU 2014-15&amp;#x201d;) &lt;div style="display: inline; font-style: italic;"&gt;,&lt;/div&gt; which defines management&amp;#x2019;s responsibility to evaluate, at each annual and interim reporting period, whether there are conditions or events that raise substantial doubt about an entity&amp;#x2019;s ability to continue as a going concern within one year after the date the financial statements are issued and to provide related footnote disclosures in certain circumstances. In connection with each annual and interim period, management must assess if there is substantial doubt about the company&amp;#x2019;s ability to continue as a going concern within one year after the issuance date.&amp;nbsp;Disclosures are required if conditions give rise to substantial doubt.&amp;nbsp;ASU 2014-15 is effective for all companies in the first annual period ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The Company is currently evaluating the impact this standard will have on its financial statements and disclosures.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;In May 2014, the FASB issued Standards Update No. 2014-09: &lt;div style="display: inline; font-style: italic;"&gt;Revenue from Contracts with Customers (Topic 606) &lt;/div&gt;(&amp;#x201c;ASU 2014-09&amp;#x201d;), which provides a single, comprehensive revenue recognition model for all contracts with customers. The core principal of this ASU is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. In July 2015, the FASB finalized a one year delay in the effective date of this standard, which will now be effective January 1, 2018; however, early adoption is permitted any time after the original effective date, January 1, 2017. Companies can transition to the new standard under the full retrospective method or the modified retrospective method. The Company is currently evaluating the impact this standard will have on its consolidated financial statements.&amp;nbsp;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="d_2016-01-01_2016-06-30_PlanNameAxis-EmployeeStockPurchasePlanMember" decimals="-3" id="c7789263" unitRef="xbrli-shares">34000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="d_2016-01-01_2016-06-30_PlanNameAxis-IncentivePlanMember" decimals="-3" id="c7788959" unitRef="xbrli-shares">79000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockholdersEquity contextRef="i_2016-06-30" decimals="-3" id="c7788695" unitRef="iso4217-usd">13387000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2015-12-31" decimals="-3" id="c7788696" unitRef="iso4217-usd">47724000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="d_2016-01-01_2016-06-30" id="s265753">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Note 5 &amp;#x2014; Stockholders&amp;#x2019; Equity&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;On March 3, 2015, the Company filed a $150,000 shelf registration statement on Form S-3 with the SEC. This shelf registration statement, as amended by a post-effective amendment filed on February 26, 2016 and declared effective on April 18, 2016, allows the Company to sell securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants and units, from time to time at prices and on terms to be determined at the time of sale.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;On November&amp;nbsp;6, 2013, the Company filed a $125,000 shelf registration statement on Form S-3 with the SEC. This shelf registration statement was declared effective in November 2013 and allows the Company to sell securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants and units, from time to time at prices and on terms to be determined at the time of sale. The Company has $10,000 remaining under this shelf registration statement.&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:UseOfEstimates contextRef="d_2016-01-01_2016-06-30" id="c8267421">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Use of Estimates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="d_2016-04-01_2016-06-30" decimals="-3" id="c7788769" unitRef="xbrli-shares">73695000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c7788770" unitRef="xbrli-shares">76760000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7788771" unitRef="xbrli-shares">73648000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7788772" unitRef="xbrli-shares">72492000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="d_2016-04-01_2016-06-30" decimals="-3" id="c7788765" unitRef="xbrli-shares">73695000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c7788766" unitRef="xbrli-shares">72642000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7788767" unitRef="xbrli-shares">73648000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7788768" unitRef="xbrli-shares">72492000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended"/>
  <xbrli:unit id="iso4217-usd">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="xbrli-pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="xbrli-shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="iso4217-usd-per-xbrli-shares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="iso4217-jpy">
    <xbrli:measure>iso4217:JPY</xbrli:measure>
  </xbrli:unit>
  <xbrli:context id="d_2000-06-01_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AECOMAndIRLMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2000-06-01</xbrli:startDate>
      <xbrli:endDate>2000-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2006-02-01_2006-02-28_TypeOfArrangementAxis-MundipharmaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:MundipharmaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2006-02-01</xbrli:startDate>
      <xbrli:endDate>2006-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2006-06-01_2006-06-30_TypeOfArrangementAxis-GreenCrossCorporationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2006-06-01</xbrli:startDate>
      <xbrli:endDate>2006-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2011-03-01_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-03-01</xbrli:startDate>
      <xbrli:endDate>2011-03-09</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2011-03-01_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcrx:RoyaltyMonetizationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-03-01</xbrli:startDate>
      <xbrli:endDate>2011-03-09</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2013-01-01_2013-01-31_AwardTypeAxis-StockOptionsAndRestrictedStockMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest50PercentEachYearUntilFullyVestedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bcrx:StockOptionsAndRestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:Vest50PercentEachYearUntilFullyVestedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2013-08-01_2013-08-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-08-01</xbrli:startDate>
      <xbrli:endDate>2013-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2013-09-01_2013-09-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-09-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2013-09-01_2016-06-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-09-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-12-01_2014-12-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-12-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-06-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-06-30_CounterpartyNameAxis-SeqirusUKLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-06-30_CounterpartyNameAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-06-30_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-06-30_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-06-30_LongtermDebtTypeAxis-PhaRMANotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-06-30_PlanNameAxis-EmployeeStockPurchasePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-06-30_PlanNameAxis-IncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-04-01_2015-06-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-04-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-04-01_2015-06-30_CounterpartyNameAxis-SeqirusUKLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-04-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-04-01_2015-06-30_CounterpartyNameAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-04-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-04-01_2015-06-30_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-04-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-04-01_2015-06-30_LongtermDebtTypeAxis-PhaRMANotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-04-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_DeferredRevenueArrangementTypeAxis-RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:CSLMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">bcrx:RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-06-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_ProductOrServiceAxis-RAPIVABMember_StatementScenarioAxis-ContingentUponEuMarketingApprovalMember_TypeOfArrangementAxis-AgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:CSLMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">bcrx:ContingentUponEuMarketingApprovalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-06-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-06-01_2015-06-30_CounterpartyNameAxis-CSLMember_ProductOrServiceAxis-RAPIVABMember_TypeOfArrangementAxis-AgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:CSLMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-06-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-06-01_2015-06-30_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-06-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-06-16_2015-06-16_CounterpartyNameAxis-CSLLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:CSLLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-06-16</xbrli:startDate>
      <xbrli:endDate>2015-06-16</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-03-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-03-31_CreationDateAxis-December312015Member_NewAccountingPronouncementEarlyAdoptionAxis-DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CreationDateAxis">bcrx:December312015Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:NewAccountingPronouncementEarlyAdoptionAxis">bcrx:DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30_AwardDateAxis-August2013Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">bcrx:August2013Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30_AwardDateAxis-December2014Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">bcrx:December2014Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_TitleOfIndividualAxis-NonEmployeeDirectorsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcrx:NonEmployeeDirectorsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:Vest25PercentEachYearUntilFullyVestedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-IncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30_ConcentrationRiskByBenchmarkAxis-SalesRevenueProductLineMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-ThreeCustomersMember_ProductOrServiceAxis-RAPIVABMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">bcrx:ThreeCustomersMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30_ConcentrationRiskByBenchmarkAxis-SalesRevenueProductLineMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_ProductOrServiceAxis-RAPIVABMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30_CounterpartyNameAxis-SeqirusUKLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30_CounterpartyNameAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">bcrx:BirminghamResearchFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">bcrx:BirminghamResearchFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30_LongtermDebtTypeAxis-PhaRMANotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30_PlanNameAxis-EmployeeStockPurchasePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30_PlanNameAxis-IncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentOfficeEquipmentAndSoftwareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcrx:LaboratoryEquipmentOfficeEquipmentAndSoftwareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-UABMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:UABMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30_TypeOfArrangementAxis-ASPRBARDAContractMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:ASPRBARDAContractMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-04-01_2016-06-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-04-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-04-01_2016-06-30_CounterpartyNameAxis-SeqirusUKLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-04-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-04-01_2016-06-30_CounterpartyNameAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-04-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-04-01_2016-06-30_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-04-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-04-01_2016-06-30_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">bcrx:BirminghamResearchFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-04-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-04-01_2016-06-30_LongtermDebtTypeAxis-PhaRMANotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-04-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-05-18_2016-05-18_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-05-18</xbrli:startDate>
      <xbrli:endDate>2016-05-18</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AECOMAndIRLMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2000-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-03-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2011-03-09_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcrx:RoyaltyMonetizationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-03-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-03-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2013-11-06">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-11-06</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-03-03">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-03-31_TypeOfArrangementAxis-ASPRBARDAContractMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:ASPRBARDAContractMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-03-31_TypeOfArrangementAxis-AdditionalDevelopmentOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AdditionalDevelopmentOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-03-31_TypeOfArrangementAxis-BaseContractMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:BaseContractMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-06-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-09-30_CurrencyAxis-JapanYenMember_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">bcrx:JapanYenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_InvestmentTypeAxis-CertificatesOfDepositMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_PlanNameAxis-IncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-05-18_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-05-18</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-06-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-06-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-06-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-JPRRoyaltySubLLCMember_DebtInstrumentAxis-PhaRMANotesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-06-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-06-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-06-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-06-30_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-06-30_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-06-30_InvestmentTypeAxis-CertificatesOfDepositMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-06-30_InvestmentTypeAxis-CorporateDebtSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-06-30_InvestmentTypeAxis-USGovernmentAgenciesDebtSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-06-30_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">bcrx:BirminghamResearchFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-06-30_LeaseArrangementTypeAxis-BirminghamResearchFacilityMember_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">bcrx:BirminghamResearchFacilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-06-30_PlanNameAxis-EmployeeStockPurchasePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-06-30_PlanNameAxis-IncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-06-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-06-30_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-CollateralForCreditMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:CollateralForCreditMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-06-30_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-RoyaltyReceivableMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:RoyaltyReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-07-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>bcrx-20160630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 10:21PM UTC 2016-08-06--><xsd:schema xmlns:bcrx="http://www.biocryst.com/20160630" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:us-roles="http://fasb.org/us-roles/2016-01-31" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biocryst.com/20160630">
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2016-01-31" schemaLocation="http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2014-01-31" schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://fasb.org/us-roles/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-roles-2016-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcrx-20160630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcrx-20160630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcrx-20160630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcrx-20160630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://www.biocryst.com/20160630/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets-current-period-unaudited" roleURI="http://www.biocryst.com/20160630/role/statement-consolidated-balance-sheets-current-period-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Consolidated Balance Sheets (Current Period Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" roleURI="http://www.biocryst.com/20160630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-comprehensive-loss-income-unaudited" roleURI="http://www.biocryst.com/20160630/role/statement-consolidated-statements-of-comprehensive-loss-income-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Consolidated Statements of Comprehensive (Loss) Income (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-cash-flows-unaudited" roleURI="http://www.biocryst.com/20160630/role/statement-consolidated-statements-of-cash-flows-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-significant-accounting-policies" roleURI="http://www.biocryst.com/20160630/role/statement-note-1-significant-accounting-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Disclosure - Note 1 - Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-stockbased-compensation" roleURI="http://www.biocryst.com/20160630/role/statement-note-2-stockbased-compensation">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">006 - Disclosure - Note 2 - Stock-based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-collaborative-and-other-research-and-development-contracts" roleURI="http://www.biocryst.com/20160630/role/statement-note-3-collaborative-and-other-research-and-development-contracts">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">007 - Disclosure - Note 3 - Collaborative and Other Research and Development Contracts</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-royalty-monetization" roleURI="http://www.biocryst.com/20160630/role/statement-note-4-royalty-monetization">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">008 - Disclosure - Note 4 - Royalty Monetization</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-stockholders-equity" roleURI="http://www.biocryst.com/20160630/role/statement-note-5-stockholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">009 - Disclosure - Note 5 - Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://www.biocryst.com/20160630/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">010 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-significant-accounting-policies-tables" roleURI="http://www.biocryst.com/20160630/role/statement-note-1-significant-accounting-policies-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">011 - Disclosure - Note 1 - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-stockbased-compensation-tables" roleURI="http://www.biocryst.com/20160630/role/statement-note-2-stockbased-compensation-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">012 - Disclosure - Note 2 - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-significant-accounting-policies-details-textual" roleURI="http://www.biocryst.com/20160630/role/statement-note-1-significant-accounting-policies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">013 - Disclosure - Note 1 - Significant Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-fair-value-of-the-companys-investments-by-type-details" roleURI="http://www.biocryst.com/20160630/role/statement-note-1-fair-value-of-the-companys-investments-by-type-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">014 - Disclosure - Note 1 - Fair Value of the Company's Investments by Type (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-scheduled-maturity-for-the-companys-investments-details" roleURI="http://www.biocryst.com/20160630/role/statement-note-1-scheduled-maturity-for-the-companys-investments-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">015 - Disclosure - Note 1 - Scheduled Maturity for the Company's Investments (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-summary-of-receivables-details" roleURI="http://www.biocryst.com/20160630/role/statement-note-1-summary-of-receivables-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">016 - Disclosure - Note 1 - Summary of Receivables (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-inventory-details" roleURI="http://www.biocryst.com/20160630/role/statement-note-1-inventory-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">017 - Disclosure - Note 1 - Inventory (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-summary-of-revenues-details" roleURI="http://www.biocryst.com/20160630/role/statement-note-1-summary-of-revenues-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">018 - Disclosure - Note 1 - Summary of Revenues (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-stockbased-compensation-details-textual" roleURI="http://www.biocryst.com/20160630/role/statement-note-2-stockbased-compensation-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">019 - Disclosure - Note 2 - Stock-based Compensation (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-stock-incentive-plan-activities-details" roleURI="http://www.biocryst.com/20160630/role/statement-note-2-stock-incentive-plan-activities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">020 - Disclosure - Note 2 - Stock Incentive Plan Activities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-weighted-average-assumptions-details" roleURI="http://www.biocryst.com/20160630/role/statement-note-2-weighted-average-assumptions-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">021 - Disclosure - Note 2 - Weighted Average Assumptions (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-collaborative-and-other-research-and-development-contracts-details-textual" roleURI="http://www.biocryst.com/20160630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">022 - Disclosure - Note 3 - Collaborative and Other Research and Development Contracts (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-royalty-monetization-details-textual" roleURI="http://www.biocryst.com/20160630/role/statement-note-4-royalty-monetization-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">023 - Disclosure - Note 4 - Royalty Monetization (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-stockholders-equity-details-textual" roleURI="http://www.biocryst.com/20160630/role/statement-note-5-stockholders-equity-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">024 - Disclosure - Note 5 - Stockholders' Equity (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="bcrx_AECOMAndIRLMember" name="AECOMAndIRLMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ASPRBARDAContractMember" name="ASPRBARDAContractMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AccruedExpensesPolicyTextBlock" name="AccruedExpensesPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_AdditionalDevelopmentOptionsMember" name="AdditionalDevelopmentOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AdvanceNoticePeriodForTerminationOfAgreement" name="AdvanceNoticePeriodForTerminationOfAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_AgreementMember" name="AgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" name="AmortizationOfDiscountAndPremiumOnInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AnnualLicenseFeeMaximum" name="AnnualLicenseFeeMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_AnnualLicenseFeeMinimum" name="AnnualLicenseFeeMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_August2013Member" name="August2013Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AvailableForSaleSecuritiesAccruedInterest" name="AvailableForSaleSecuritiesAccruedInterest" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" name="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" name="AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" name="AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_AveragematurityForPortfolioInvestments" name="AveragematurityForPortfolioInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" name="AveragematurityPeriodOfHighQualityMarketableSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_BaseContractMember" name="BaseContractMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_BirminghamResearchFacilityMember" name="BirminghamResearchFacilityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_CSLLimitedMember" name="CSLLimitedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_CSLMember" name="CSLMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_CollaborationAgreementAdditionalPaymentsReceived" name="CollaborationAgreementAdditionalPaymentsReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_CollaborativeAndOtherResearchAndDevelopment" name="CollaborativeAndOtherResearchAndDevelopment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" name="CollaborativeAndOtherResearchAndDevelopmentRevenues" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_CollateralForCreditMember" name="CollateralForCreditMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" name="ConcentrationOfMarketRiskPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ContingentUponEuMarketingApprovalMember" name="ContingentUponEuMarketingApprovalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_CurrencyDomain" name="CurrencyDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_CurrencyHedgeAgreementMember" name="CurrencyHedgeAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_CurrencyHedgeAgreementPolicyTextBlock" name="CurrencyHedgeAgreementPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" name="DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_December2014Member" name="December2014Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_December312015Member" name="December312015Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_DeferredCollaborationExpenseAssets" name="DeferredCollaborationExpenseAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" name="DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_DescriptionOfCompanyPolicyTextBlock" name="DescriptionOfCompanyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" name="ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_GreenCrossCorporationMember" name="GreenCrossCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_IncentivePlanMember" name="IncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" name="InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_Interestreserve" name="Interestreserve" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_JPRRoyaltySubLLCMember" name="JPRRoyaltySubLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_JapanYenMember" name="JapanYenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" name="LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_LeaseFinancingObligationNetOfCurrent" name="LeaseFinancingObligationNetOfCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_LongtermInvestmentMaturityMinimum" name="LongtermInvestmentMaturityMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MaturityOfInvestments" name="MaturityOfInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" name="MaturityPeriodOfHighQualityMarketablesecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MaturityperiodOfShortTermInvestment" name="MaturityperiodOfShortTermInvestment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MaximumAggregateOfferingPrice" name="MaximumAggregateOfferingPrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_MaximumAmountOfCollateralRequiredToPost" name="MaximumAmountOfCollateralRequiredToPost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_MilestonePaymentMaximum" name="MilestonePaymentMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MilestonePaymentMinimum" name="MilestonePaymentMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_MundipharmaMember" name="MundipharmaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" name="NationalInstituteOfAllergyAndInfectiousDiseasesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_NonEmployeeDirectorsMember" name="NonEmployeeDirectorsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_NumberOfMajorCustomers" name="NumberOfMajorCustomers" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_NumberOfMilestonesAchieved" name="NumberOfMilestonesAchieved" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_NumberOfStockbasedCompensationPlans" name="NumberOfStockbasedCompensationPlans" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" name="PercentageOfCarryingAmountInExcessOfFairValue1" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_PercentageOfCommonStockSharesBeginning" name="PercentageOfCommonStockSharesBeginning" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PercentageOfCommonStockSharesEnding" name="PercentageOfCommonStockSharesEnding" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" name="PercentageOfSalaryToPurchaseCommonStockMaximum" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PeriodOfAgreement" name="PeriodOfAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_PhaRMANotesMember" name="PhaRMANotesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PrivatePlacementOfSeniorSecuredNotes" name="PrivatePlacementOfSeniorSecuredNotes" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" name="ProceedsFromAwardsForResearchAndDevelopmentContracts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_RAPIVABMember" name="RAPIVABMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" name="RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RemainingAggregateOfferingPrice" name="RemainingAggregateOfferingPrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_RenewablePeriodOfAgreement" name="RenewablePeriodOfAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RequiredForeignCurrencyHedgePerDollar" name="RequiredForeignCurrencyHedgePerDollar" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" name="RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" name="RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_RoyaltyMonetizationMember" name="RoyaltyMonetizationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RoyaltyMonetizationTextBlock" name="RoyaltyMonetizationTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_RoyaltyReceivableMember" name="RoyaltyReceivableMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RoyaltyTerm" name="RoyaltyTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" name="ScheduleOfReceivablesFromCollaborationsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" name="ScheduleOfRevenuesFromCollaborationsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_SeqirusUKLimitedMember" name="SeqirusUKLimitedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" name="ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" name="SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ShionogiAndCoLtdMember" name="ShionogiAndCoLtdMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_StockOptionsAndRestrictedStockMember" name="StockOptionsAndRestrictedStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ThreeCustomersMember" name="ThreeCustomersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_TransactionCosts" name="TransactionCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_UABMember" name="UABMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_USDepartmentOfHealthAndHumanServicesMember" name="USDepartmentOfHealthAndHumanServicesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_UpfrontPaymentsReceivableAmount" name="UpfrontPaymentsReceivableAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_Vest25PercentEachYearUntilFullyVestedMember" name="Vest25PercentEachYearUntilFullyVestedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_Vest50PercentEachYearUntilFullyVestedMember" name="Vest50PercentEachYearUntilFullyVestedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" name="VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-fair-value-of-the-companys-investments-by-type-details" name="statement-statement-note-1-fair-value-of-the-companys-investments-by-type-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-inventory-details" name="statement-statement-note-1-inventory-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-scheduled-maturity-for-the-companys-investments-details" name="statement-statement-note-1-scheduled-maturity-for-the-companys-investments-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-significant-accounting-policies-tables" name="statement-statement-note-1-significant-accounting-policies-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-summary-of-receivables-details" name="statement-statement-note-1-summary-of-receivables-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-summary-of-revenues-details" name="statement-statement-note-1-summary-of-revenues-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-2-stock-incentive-plan-activities-details" name="statement-statement-note-2-stock-incentive-plan-activities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-2-stockbased-compensation-tables" name="statement-statement-note-2-stockbased-compensation-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-2-weighted-average-assumptions-details" name="statement-statement-note-2-weighted-average-assumptions-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>bcrx-20160630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 10:22PM UTC 2016-08-06--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-consolidated-balance-sheets-current-period-unaudited" xlink:href="bcrx-20160630.xsd#statement-consolidated-balance-sheets-current-period-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20160630/role/statement-consolidated-balance-sheets-current-period-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_DeferredCollaborationExpenseAssets" xlink:label="bcrx_DeferredCollaborationExpenseAssets" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_LeaseFinancingObligationNetOfCurrent" xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DeferredCostsCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="bcrx_DeferredCollaborationExpenseAssets" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_InterestPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_NotesPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_DeferredRentCreditNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_DeferredRevenueNoncurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-consolidated-statements-of-cash-flows-unaudited" xlink:href="bcrx-20160630.xsd#statement-consolidated-statements-of-cash-flows-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20160630/role/statement-consolidated-statements-of-cash-flows-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:label="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForHedgeFinancingActivities" xlink:label="us-gaap_PaymentsForHedgeFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInInventories" xlink:type="arc"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:type="arc"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="arc"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_AmortizationOfFinancingCosts" xlink:type="arc"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:type="arc"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="arc"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsForHedgeFinancingActivities" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromStockPlans" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:href="bcrx-20160630.xsd#statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20160630/role/statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-note-1-inventory-details" xlink:href="bcrx-20160630.xsd#statement-note-1-inventory-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20160630/role/statement-note-1-inventory-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-consolidated-statements-of-comprehensive-loss-income-unaudited" xlink:href="bcrx-20160630.xsd#statement-consolidated-statements-of-comprehensive-loss-income-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20160630/role/statement-consolidated-statements-of-comprehensive-loss-income-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueGoodsNet" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_RoyaltyRevenue" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SalesRevenueNet" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_RoyaltyExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostOfGoodsSold" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_SalesRevenueNet" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_CostsAndExpenses" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestAndOtherIncome" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>bcrx-20160630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 10:22PM UTC 2016-08-06--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-document-and-entity-information" xlink:href="bcrx-20160630.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160630/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:href="bcrx-20160630.xsd#statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-note-1-significant-accounting-policies" xlink:href="bcrx-20160630.xsd#statement-note-1-significant-accounting-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160630/role/statement-note-1-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AgreementMember" xlink:label="bcrx_AgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_BirminghamResearchFacilityMember" xlink:label="bcrx_BirminghamResearchFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_CSLMember" xlink:label="bcrx_CSLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_ContingentUponEuMarketingApprovalMember" xlink:label="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:label="bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_December312015Member" xlink:label="bcrx_December312015Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:label="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_ThreeCustomersMember" xlink:label="bcrx_ThreeCustomersMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreationDateAxis" xlink:label="us-gaap_CreationDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefaultFinancialStatementsDateMember" xlink:label="us-gaap_DefaultFinancialStatementsDateMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefaultFinancialStatementsDateMember" xlink:label="us-gaap_DefaultFinancialStatementsDateMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:label="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:label="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:label="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueProductLineMember" xlink:label="us-gaap_SalesRevenueProductLineMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueProductLineMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="bcrx_RAPIVABMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:to="bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:to="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreationDateAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefaultFinancialStatementsDateMember" xlink:to="bcrx_December312015Member" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreationDateAxis" xlink:to="us-gaap_DefaultFinancialStatementsDateMember-default" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="bcrx_RoyaltyReceivableMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="bcrx_CollateralForCreditMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AgreementMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_CSLMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HedgingDesignationDomain" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="bcrx_BirminghamResearchFacilityMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MajorCustomersAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="bcrx_ThreeCustomersMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreationDateAxis" xlink:to="us-gaap_DefaultFinancialStatementsDateMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:to="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-note-2-stockbased-compensation" xlink:href="bcrx-20160630.xsd#statement-note-2-stockbased-compensation" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160630/role/statement-note-2-stockbased-compensation" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_August2013Member" xlink:label="bcrx_August2013Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_December2014Member" xlink:label="bcrx_December2014Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_NonEmployeeDirectorsMember" xlink:label="bcrx_NonEmployeeDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_StockOptionsAndRestrictedStockMember" xlink:label="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_EmployeeStockPurchasePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardDateAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="bcrx_August2013Member" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="bcrx_December2014Member" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bcrx_NonEmployeeDirectorsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-note-3-collaborative-and-other-research-and-development-contracts" xlink:href="bcrx-20160630.xsd#statement-note-3-collaborative-and-other-research-and-development-contracts" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160630/role/statement-note-3-collaborative-and-other-research-and-development-contracts" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_CSLLimitedMember" xlink:label="bcrx_CSLLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_MundipharmaMember" xlink:label="bcrx_MundipharmaMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_BaseContractMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_ASPRBARDAContractMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_CSLLimitedMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_MundipharmaMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AECOMAndIRLMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_UABMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-note-4-royalty-monetization" xlink:href="bcrx-20160630.xsd#statement-note-4-royalty-monetization" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160630/role/statement-note-4-royalty-monetization" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_CurrencyDomain" xlink:label="bcrx_CurrencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_CurrencyDomain" xlink:label="bcrx_CurrencyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_JapanYenMember" xlink:label="bcrx_JapanYenMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_RoyaltyMonetizationTextBlock" xlink:label="bcrx_RoyaltyMonetizationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="us-gaap_CurrencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="bcrx_RoyaltyMonetizationMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CurrencyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_CurrencyDomain" xlink:to="bcrx_JapanYenMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CurrencyAxis" xlink:to="bcrx_CurrencyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HedgingDesignationDomain" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CurrencyAxis" xlink:to="bcrx_CurrencyDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="bcrx_RoyaltyMonetizationTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-note-5-stockholders-equity" xlink:href="bcrx-20160630.xsd#statement-note-5-stockholders-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160630/role/statement-note-5-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-significant-accounting-policies-policies" xlink:href="bcrx-20160630.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160630/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AccruedExpensesPolicyTextBlock" xlink:label="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:label="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeasePolicyTextBlock" xlink:label="us-gaap_LeasePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LeasePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-note-1-significant-accounting-policies-tables" xlink:href="bcrx-20160630.xsd#statement-note-1-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160630/role/statement-note-1-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-note-2-stockbased-compensation-tables" xlink:href="bcrx-20160630.xsd#statement-note-2-stockbased-compensation-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160630/role/statement-note-2-stockbased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-note-1-significant-accounting-policies-details-textual" xlink:href="bcrx-20160630.xsd#statement-note-1-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160630/role/statement-note-1-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AgreementMember" xlink:label="bcrx_AgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AveragematurityForPortfolioInvestments" xlink:label="bcrx_AveragematurityForPortfolioInvestments" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" xlink:label="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_BirminghamResearchFacilityMember" xlink:label="bcrx_BirminghamResearchFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_CSLMember" xlink:label="bcrx_CSLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_ContingentUponEuMarketingApprovalMember" xlink:label="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:label="bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_December312015Member" xlink:label="bcrx_December312015Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_LeaseFinancingObligationNetOfCurrent" xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_LongtermInvestmentMaturityMinimum" xlink:label="bcrx_LongtermInvestmentMaturityMinimum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_MaturityOfInvestments" xlink:label="bcrx_MaturityOfInvestments" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_MaturityperiodOfShortTermInvestment" xlink:label="bcrx_MaturityperiodOfShortTermInvestment" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_MilestonePaymentMaximum" xlink:label="bcrx_MilestonePaymentMaximum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_NumberOfMajorCustomers" xlink:label="bcrx_NumberOfMajorCustomers" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:label="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_ThreeCustomersMember" xlink:label="bcrx_ThreeCustomersMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:label="us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreationDateAxis" xlink:label="us-gaap_CreationDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefaultFinancialStatementsDateMember" xlink:label="us-gaap_DefaultFinancialStatementsDateMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefaultFinancialStatementsDateMember" xlink:label="us-gaap_DefaultFinancialStatementsDateMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="us-gaap_DeferredRevenueAdditions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="us-gaap_DerivativeGainOnDerivative" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsAndCash" xlink:label="us-gaap_InvestmentsAndCash" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossOnSaleOfInvestments" xlink:label="us-gaap_LossOnSaleOfInvestments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:label="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:label="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:label="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustment" xlink:label="us-gaap_PriorPeriodReclassificationAdjustment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueProductLineMember" xlink:label="us-gaap_SalesRevenueProductLineMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueProductLineMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="bcrx_RAPIVABMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:to="bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:to="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreationDateAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefaultFinancialStatementsDateMember" xlink:to="bcrx_December312015Member" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreationDateAxis" xlink:to="us-gaap_DefaultFinancialStatementsDateMember-default" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="bcrx_RoyaltyReceivableMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="bcrx_CollateralForCreditMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AgreementMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_CSLMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HedgingDesignationDomain" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="bcrx_BirminghamResearchFacilityMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MajorCustomersAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="bcrx_ThreeCustomersMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreationDateAxis" xlink:to="us-gaap_DefaultFinancialStatementsDateMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:to="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossOnSaleOfInvestments" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentsAndCash" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_NumberOfMajorCustomers" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PriorPeriodReclassificationAdjustment" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaturityOfInvestments" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaturityperiodOfShortTermInvestment" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_LongtermInvestmentMaturityMinimum" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredRevenueAdditions" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMaximum" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLossOnDerivative" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeGainOnDerivative" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
    <link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" xlink:type="arc"/>
    <link:definitionArc order="30" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AveragematurityForPortfolioInvestments" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-note-2-stockbased-compensation-details-textual" xlink:href="bcrx-20160630.xsd#statement-note-2-stockbased-compensation-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160630/role/statement-note-2-stockbased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_August2013Member" xlink:label="bcrx_August2013Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_December2014Member" xlink:label="bcrx_December2014Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_NonEmployeeDirectorsMember" xlink:label="bcrx_NonEmployeeDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_NumberOfMilestonesAchieved" xlink:label="bcrx_NumberOfMilestonesAchieved" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_NumberOfStockbasedCompensationPlans" xlink:label="bcrx_NumberOfStockbasedCompensationPlans" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_PercentageOfCommonStockSharesBeginning" xlink:label="bcrx_PercentageOfCommonStockSharesBeginning" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_PercentageOfCommonStockSharesEnding" xlink:label="bcrx_PercentageOfCommonStockSharesEnding" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:label="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" xlink:label="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_StockOptionsAndRestrictedStockMember" xlink:label="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_EmployeeStockPurchasePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardDateAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="bcrx_August2013Member" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="bcrx_December2014Member" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bcrx_NonEmployeeDirectorsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_NumberOfStockbasedCompensationPlans" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_NumberOfMilestonesAchieved" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCommonStockSharesBeginning" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCommonStockSharesEnding" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-details-textual" xlink:href="bcrx-20160630.xsd#statement-note-3-collaborative-and-other-research-and-development-contracts-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AnnualLicenseFeeMaximum" xlink:label="bcrx_AnnualLicenseFeeMaximum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AnnualLicenseFeeMinimum" xlink:label="bcrx_AnnualLicenseFeeMinimum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_CSLLimitedMember" xlink:label="bcrx_CSLLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_CollaborationAgreementAdditionalPaymentsReceived" xlink:label="bcrx_CollaborationAgreementAdditionalPaymentsReceived" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_MilestonePaymentMaximum" xlink:label="bcrx_MilestonePaymentMaximum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_MilestonePaymentMinimum" xlink:label="bcrx_MilestonePaymentMinimum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_MundipharmaMember" xlink:label="bcrx_MundipharmaMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_PeriodOfAgreement" xlink:label="bcrx_PeriodOfAgreement" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_RenewablePeriodOfAgreement" xlink:label="bcrx_RenewablePeriodOfAgreement" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_RoyaltyTerm" xlink:label="bcrx_RoyaltyTerm" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_UpfrontPaymentsReceivableAmount" xlink:label="bcrx_UpfrontPaymentsReceivableAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GovernmentContractReceivable" xlink:label="us-gaap_GovernmentContractReceivable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_BaseContractMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_ASPRBARDAContractMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_CSLLimitedMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_MundipharmaMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AECOMAndIRLMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_UABMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GovernmentContractReceivable" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborationAgreementAdditionalPaymentsReceived" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMaximum" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyTerm" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_UpfrontPaymentsReceivableAmount" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMinimum" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AnnualLicenseFeeMinimum" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AnnualLicenseFeeMaximum" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PeriodOfAgreement" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RenewablePeriodOfAgreement" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-note-4-royalty-monetization-details-textual" xlink:href="bcrx-20160630.xsd#statement-note-4-royalty-monetization-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160630/role/statement-note-4-royalty-monetization-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_CurrencyDomain" xlink:label="bcrx_CurrencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_CurrencyDomain" xlink:label="bcrx_CurrencyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_Interestreserve" xlink:label="bcrx_Interestreserve" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_JapanYenMember" xlink:label="bcrx_JapanYenMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:label="bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:label="bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_TransactionCosts" xlink:label="bcrx_TransactionCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:label="us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="us-gaap_CurrencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeForwardExchangeRate1" xlink:label="us-gaap_DerivativeForwardExchangeRate1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="bcrx_RoyaltyMonetizationMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CurrencyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_CurrencyDomain" xlink:to="bcrx_JapanYenMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CurrencyAxis" xlink:to="bcrx_CurrencyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HedgingDesignationDomain" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CurrencyAxis" xlink:to="bcrx_CurrencyDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_TransactionCosts" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_Interestreserve" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NotesPayableFairValueDisclosure" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeForwardExchangeRate1" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLossOnDerivative" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-note-5-stockholders-equity-details-textual" xlink:href="bcrx-20160630.xsd#statement-note-5-stockholders-equity-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160630/role/statement-note-5-stockholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_MaximumAggregateOfferingPrice" xlink:label="bcrx_MaximumAggregateOfferingPrice" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_RemainingAggregateOfferingPrice" xlink:label="bcrx_RemainingAggregateOfferingPrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaximumAggregateOfferingPrice" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RemainingAggregateOfferingPrice" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-consolidated-balance-sheets-current-period-unaudited" xlink:href="bcrx-20160630.xsd#statement-consolidated-balance-sheets-current-period-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160630/role/statement-consolidated-balance-sheets-current-period-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_DeferredCollaborationExpenseAssets" xlink:label="bcrx_DeferredCollaborationExpenseAssets" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_LeaseFinancingObligationNetOfCurrent" xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredCostsCurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="bcrx_DeferredCollaborationExpenseAssets" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_InterestPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_NotesPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-consolidated-statements-of-cash-flows-unaudited" xlink:href="bcrx-20160630.xsd#statement-consolidated-statements-of-cash-flows-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160630/role/statement-consolidated-statements-of-cash-flows-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:label="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:label="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForHedgeFinancingActivities" xlink:label="us-gaap_PaymentsForHedgeFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForHedgeFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:href="bcrx-20160630.xsd#statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160630/role/statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-note-1-inventory-details" xlink:href="bcrx-20160630.xsd#statement-note-1-inventory-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160630/role/statement-note-1-inventory-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-note-2-stock-incentive-plan-activities-details" xlink:href="bcrx-20160630.xsd#statement-note-2-stock-incentive-plan-activities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160630/role/statement-note-2-stock-incentive-plan-activities-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-note-2-weighted-average-assumptions-details" xlink:href="bcrx-20160630.xsd#statement-note-2-weighted-average-assumptions-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160630/role/statement-note-2-weighted-average-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-consolidated-statements-of-comprehensive-loss-income-unaudited" xlink:href="bcrx-20160630.xsd#statement-consolidated-statements-of-comprehensive-loss-income-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160630/role/statement-consolidated-statements-of-comprehensive-loss-income-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_SalesRevenueGoodsNet" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RoyaltyRevenue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_SalesRevenueNet" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostOfGoodsSold" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_RoyaltyExpense" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_InterestAndOtherIncome" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:href="bcrx-20160630.xsd#statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160630/role/statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:label="bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_InvestmentTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-note-1-summary-of-receivables-details" xlink:href="bcrx-20160630.xsd#statement-note-1-summary-of-receivables-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160630/role/statement-note-1-summary-of-receivables-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_SeqirusUKLimitedMember" xlink:label="bcrx_SeqirusUKLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_ShionogiAndCoLtdMember" xlink:label="bcrx_ShionogiAndCoLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BilledRevenuesMember" xlink:label="us-gaap_BilledRevenuesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesBillingStatusDomain" xlink:label="us-gaap_ReceivablesBillingStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesBillingStatusDomain" xlink:label="us-gaap_ReceivablesBillingStatusDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnbilledRevenuesMember" xlink:label="us-gaap_UnbilledRevenuesMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesBillingStatusDomain" xlink:to="us-gaap_BilledRevenuesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_ReceivablesBillingStatusDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesBillingStatusDomain" xlink:to="us-gaap_UnbilledRevenuesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_ShionogiAndCoLtdMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_SeqirusUKLimitedMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_ReceivablesBillingStatusDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReceivablesNetCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-note-1-summary-of-revenues-details" xlink:href="bcrx-20160630.xsd#statement-note-1-summary-of-revenues-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20160630/role/statement-note-1-summary-of-revenues-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_SeqirusUKLimitedMember" xlink:label="bcrx_SeqirusUKLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_ShionogiAndCoLtdMember" xlink:label="bcrx_ShionogiAndCoLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_ShionogiAndCoLtdMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_SeqirusUKLimitedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueGoodsNet" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RoyaltyRevenue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>bcrx-20160630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 10:21PM UTC 2016-08-06--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AgreementMember" xlink:label="bcrx_AgreementMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement [Member]</link:label>
    <link:label xlink:label="bcrx_AgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents a License Agreement (the "Agreement") granting rights to develop, manufacture and commercialize RAPIVAB&#174;.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AgreementMember" xlink:to="bcrx_AgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_DocumentAndEntityInformation" xlink:label="bcrx_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DocumentAndEntityInformation" xlink:to="bcrx_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:label="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncement, Early Adoption [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:to="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="bcrx_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_statement-statement-significant-accounting-policies-policies" xlink:label="bcrx_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-significant-accounting-policies-policies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementsignificantaccountingpoliciespolicies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-significant-accounting-policies-policies" xlink:to="bcrx_statement-statement-significant-accounting-policies-policies-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-tables" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote1significantaccountingpoliciestables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-tables" xlink:to="bcrx_statement-statement-note-1-significant-accounting-policies-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_statement-statement-note-2-stockbased-compensation-tables" xlink:label="bcrx_statement-statement-note-2-stockbased-compensation-tables" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-2-stockbased-compensation-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote2stockbasedcompensationtables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-2-stockbased-compensation-tables" xlink:to="bcrx_statement-statement-note-2-stockbased-compensation-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_statement-statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:label="bcrx_statement-statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-fair-value-of-the-companys-investments-by-type-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote1fairvalueofthecompanysinvestmentsbytypedetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:to="bcrx_statement-statement-note-1-fair-value-of-the-companys-investments-by-type-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_MaturityperiodOfShortTermInvestment" xlink:label="bcrx_MaturityperiodOfShortTermInvestment" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MaturityperiodOfShortTermInvestment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MaturityperiodOfShortTermInvestment</link:label>
    <link:label xlink:label="bcrx_MaturityperiodOfShortTermInvestment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity Period of Short Term Investment</link:label>
    <link:label xlink:label="bcrx_MaturityperiodOfShortTermInvestment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maturity period of short term investment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaturityperiodOfShortTermInvestment" xlink:to="bcrx_MaturityperiodOfShortTermInvestment-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_statement-statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:label="bcrx_statement-statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-scheduled-maturity-for-the-companys-investments-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote1scheduledmaturityforthecompanysinvestmentsdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:to="bcrx_statement-statement-note-1-scheduled-maturity-for-the-companys-investments-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_statement-statement-note-1-summary-of-receivables-details" xlink:label="bcrx_statement-statement-note-1-summary-of-receivables-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-summary-of-receivables-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote1summaryofreceivablesdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-summary-of-receivables-details" xlink:to="bcrx_statement-statement-note-1-summary-of-receivables-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_LongtermInvestmentMaturityMinimum" xlink:label="bcrx_LongtermInvestmentMaturityMinimum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_LongtermInvestmentMaturityMinimum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_LongtermInvestmentMaturityMinimum</link:label>
    <link:label xlink:label="bcrx_LongtermInvestmentMaturityMinimum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Investment Maturity, Minimum</link:label>
    <link:label xlink:label="bcrx_LongtermInvestmentMaturityMinimum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents long term investment maturity minimum.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_LongtermInvestmentMaturityMinimum" xlink:to="bcrx_LongtermInvestmentMaturityMinimum-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_statement-statement-note-1-inventory-details" xlink:label="bcrx_statement-statement-note-1-inventory-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-inventory-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote1inventorydetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-inventory-details" xlink:to="bcrx_statement-statement-note-1-inventory-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_statement-statement-note-1-summary-of-revenues-details" xlink:label="bcrx_statement-statement-note-1-summary-of-revenues-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-summary-of-revenues-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote1summaryofrevenuesdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-summary-of-revenues-details" xlink:to="bcrx_statement-statement-note-1-summary-of-revenues-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_statement-statement-note-2-stock-incentive-plan-activities-details" xlink:label="bcrx_statement-statement-note-2-stock-incentive-plan-activities-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-2-stock-incentive-plan-activities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote2stockincentiveplanactivitiesdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-2-stock-incentive-plan-activities-details" xlink:to="bcrx_statement-statement-note-2-stock-incentive-plan-activities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:label="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Regulatory Support Revenue for Canadian and EU Marketing Approvals, Portion Recognized Ratably Over Expected Period of Involvement [Member]</link:label>
    <link:label xlink:label="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents deferred revenue from upfront payment allocated to the regulatory support for the Canadian and EU marketing approvals, portion to be recognized ratably over the expected period of involvement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:to="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_statement-statement-note-2-weighted-average-assumptions-details" xlink:label="bcrx_statement-statement-note-2-weighted-average-assumptions-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-2-weighted-average-assumptions-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote2weightedaverageassumptionsdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-2-weighted-average-assumptions-details" xlink:to="bcrx_statement-statement-note-2-weighted-average-assumptions-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_NotesToFinancialStatements" xlink:label="bcrx_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NotesToFinancialStatements" xlink:to="bcrx_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="bcrx_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:label="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Principles, Early Adoption [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:to="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_CSLMember" xlink:label="bcrx_CSLMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CSLMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CSL [Member]</link:label>
    <link:label xlink:label="bcrx_CSLMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents CSL Limited (&#8220;CSL&#8221;) and its affiliates.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CSLMember" xlink:to="bcrx_CSLMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" xlink:label="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities</link:label>
    <link:label xlink:label="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average Maturity Period of High Quality Marketable Securities</link:label>
    <link:label xlink:label="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average maturity period of high quality marketable securities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" xlink:to="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized</link:label>
    <link:label xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition Royalty and Milestone Revenue Recognized</link:label>
    <link:label xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue recognition royalty and milestone revenue recognized.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:to="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_UABMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UAB [Member]</link:label>
    <link:label xlink:label="bcrx_UABMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">UAB</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_UABMember" xlink:to="bcrx_UABMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AECOMAndIRLMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AECOM and IRL [Member]</link:label>
    <link:label xlink:label="bcrx_AECOMAndIRLMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AECOM and IRL</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AECOMAndIRLMember" xlink:to="bcrx_AECOMAndIRLMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentUsefulLife</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Department of Health and Human Services [Member]</link:label>
    <link:label xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">United States department of health and human services.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MaturityPeriodOfHighQualityMarketablesecurities</link:label>
    <link:label xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity Period of High Quality Marketable Securities</link:label>
    <link:label xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents maturity period of high quality marketable securities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:to="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts</link:label>
    <link:label xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from awards for Research and Development Contracts</link:label>
    <link:label xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents proceeds from awards for research and development contracts.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:to="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AveragematurityForPortfolioInvestments" xlink:label="bcrx_AveragematurityForPortfolioInvestments" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AveragematurityForPortfolioInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AveragematurityForPortfolioInvestments</link:label>
    <link:label xlink:label="bcrx_AveragematurityForPortfolioInvestments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average Maturity for Portfolio Investments</link:label>
    <link:label xlink:label="bcrx_AveragematurityForPortfolioInvestments-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average maturity for portfolio investments during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AveragematurityForPortfolioInvestments" xlink:to="bcrx_AveragematurityForPortfolioInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:label="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyReceivableMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Receivable [Member]</link:label>
    <link:label xlink:label="bcrx_RoyaltyReceivableMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents royalty receivable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyReceivableMember" xlink:to="bcrx_RoyaltyReceivableMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RAPIVABMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RAPIVAB [Member]</link:label>
    <link:label xlink:label="bcrx_RAPIVABMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents RAPIVAB product.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RAPIVABMember" xlink:to="bcrx_RAPIVABMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FurnitureAndFixturesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollateralForCreditMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collateral for Credit [Member]</link:label>
    <link:label xlink:label="bcrx_CollateralForCreditMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted cash and cash equivalents required to maintain as collateral for a letter of credit.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollateralForCreditMember" xlink:to="bcrx_CollateralForCreditMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherCommitmentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CertificatesOfDepositMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherCommitmentsDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="us-gaap_OtherCommitmentsDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInRestrictedCash</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in restricted cash</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:label="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AmortizationOfDiscountAndPremiumOnInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of premium/discount on investments</link:label>
    <link:label xlink:label="bcrx_AmortizationOfDiscountAndPremiumOnInvestments-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of amortization expense attributable to the discount and premium on investments.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:to="bcrx_AmortizationOfDiscountAndPremiumOnInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsForProceedsFromHedgeInvestingActivities</link:label>
    <link:label xlink:label="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Hedge, Investing Activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TypeOfArrangementAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_DeferredCollaborationExpenseAssets" xlink:label="bcrx_DeferredCollaborationExpenseAssets" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DeferredCollaborationExpenseAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_DeferredCollaborationExpenseAssets</link:label>
    <link:label xlink:label="bcrx_DeferredCollaborationExpenseAssets-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred collaboration expense</link:label>
    <link:label xlink:label="bcrx_DeferredCollaborationExpenseAssets-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents deferred collaboration expense.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DeferredCollaborationExpenseAssets" xlink:to="bcrx_DeferredCollaborationExpenseAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative and other research and development</link:label>
    <link:label xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative and other research and development during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRentCreditNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred rent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRevenueNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredRevenueNoncurrent</link:label>
    <link:label xlink:label="us-gaap_DeferredRevenueNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred collaboration revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diluted net (loss) income per common share (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_EarningsPerShareDiluted-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic net (loss) income per common share (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_EarningsPerShareBasic-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding, basic (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_RoyaltyTerm" xlink:label="bcrx_RoyaltyTerm" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RoyaltyTerm</link:label>
    <link:label xlink:label="bcrx_RoyaltyTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Term</link:label>
    <link:label xlink:label="bcrx_RoyaltyTerm-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period of time between the date of the Agreement and its expiration.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyTerm" xlink:to="bcrx_RoyaltyTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</link:label>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AdvanceNoticePeriodForTerminationOfAgreement</link:label>
    <link:label xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advance Notice Period for Termination of Agreement</link:label>
    <link:label xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents advance notice period for termination of agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:to="bcrx_AdvanceNoticePeriodForTerminationOfAgreement-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign currency derivative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding, diluted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MaximumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MinimumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MajorCustomersAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_MajorCustomersAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NameOfMajorCustomerDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="us-gaap_NameOfMajorCustomerDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_CSLLimitedMember" xlink:label="bcrx_CSLLimitedMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CSLLimitedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CSL Limited [Member</link:label>
    <link:label xlink:label="bcrx_CSLLimitedMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents CSL Limited which is a company organized under the laws of Australia.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CSLLimitedMember" xlink:to="bcrx_CSLLimitedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForHedgeFinancingActivities" xlink:label="us-gaap_PaymentsForHedgeFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsForHedgeFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsForHedgeFinancingActivities</link:label>
    <link:label xlink:label="us-gaap_PaymentsForHedgeFinancingActivities-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payment of foreign currency derivative collateral</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForHedgeFinancingActivities" xlink:to="us-gaap_PaymentsForHedgeFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ForeignExchangeContractMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignExchangeContractMember" xlink:to="us-gaap_ForeignExchangeContractMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RoyaltyExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel2Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_RoyaltyMonetizationTextBlock" xlink:label="bcrx_RoyaltyMonetizationTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyMonetizationTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Monetization [Text Block]</link:label>
    <link:label xlink:label="bcrx_RoyaltyMonetizationTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty monetization.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyMonetizationTextBlock" xlink:to="bcrx_RoyaltyMonetizationTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_PeriodOfAgreement" xlink:label="bcrx_PeriodOfAgreement" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PeriodOfAgreement</link:label>
    <link:label xlink:label="bcrx_PeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period of Agreement</link:label>
    <link:label xlink:label="bcrx_PeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents period of agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PeriodOfAgreement" xlink:to="bcrx_PeriodOfAgreement-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_RenewablePeriodOfAgreement" xlink:label="bcrx_RenewablePeriodOfAgreement" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RenewablePeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RenewablePeriodOfAgreement</link:label>
    <link:label xlink:label="bcrx_RenewablePeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Renewable Period of Agreement</link:label>
    <link:label xlink:label="bcrx_RenewablePeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents renewable period of agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RenewablePeriodOfAgreement" xlink:to="bcrx_RenewablePeriodOfAgreement-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProductOrServiceAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductOrServiceAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="us-gaap_DeferredRevenueAdditions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRevenueAdditions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredRevenueAdditions</link:label>
    <link:label xlink:label="us-gaap_DeferredRevenueAdditions-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Additions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueAdditions" xlink:to="us-gaap_DeferredRevenueAdditions-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProductsAndServicesDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="us-gaap_ProductsAndServicesDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_UpfrontPaymentsReceivableAmount" xlink:label="bcrx_UpfrontPaymentsReceivableAmount" xlink:type="locator"/>
    <link:label xlink:label="bcrx_UpfrontPaymentsReceivableAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_UpfrontPaymentsReceivableAmount</link:label>
    <link:label xlink:label="bcrx_UpfrontPaymentsReceivableAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront Payments Receivable Amount</link:label>
    <link:label xlink:label="bcrx_UpfrontPaymentsReceivableAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents upfront payments receivable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_UpfrontPaymentsReceivableAmount" xlink:to="bcrx_UpfrontPaymentsReceivableAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_MilestonePaymentMaximum" xlink:label="bcrx_MilestonePaymentMaximum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MilestonePaymentMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MilestonePaymentMaximum</link:label>
    <link:label xlink:label="bcrx_MilestonePaymentMaximum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payment Maximum</link:label>
    <link:label xlink:label="bcrx_MilestonePaymentMaximum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents milestone payment maximum.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MilestonePaymentMaximum" xlink:to="bcrx_MilestonePaymentMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossOnSaleOfInvestments" xlink:label="us-gaap_LossOnSaleOfInvestments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LossOnSaleOfInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LossOnSaleOfInvestments</link:label>
    <link:label xlink:label="us-gaap_LossOnSaleOfInvestments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on Sale of Investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossOnSaleOfInvestments" xlink:to="us-gaap_LossOnSaleOfInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseholdImprovementsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="us-gaap_CurrencyAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CurrencyAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrencyAxis" xlink:to="us-gaap_CurrencyAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">National Institute of Allergy and Infectious Diseases [Member]</link:label>
    <link:label xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents National Institute of Allergy and Infectious Diseases.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_MilestonePaymentMinimum" xlink:label="bcrx_MilestonePaymentMinimum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MilestonePaymentMinimum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MilestonePaymentMinimum</link:label>
    <link:label xlink:label="bcrx_MilestonePaymentMinimum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payment Minimum</link:label>
    <link:label xlink:label="bcrx_MilestonePaymentMinimum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents milestone payment minimum.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MilestonePaymentMinimum" xlink:to="bcrx_MilestonePaymentMinimum-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_CollaborationAgreementAdditionalPaymentsReceived" xlink:label="bcrx_CollaborationAgreementAdditionalPaymentsReceived" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollaborationAgreementAdditionalPaymentsReceived-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_CollaborationAgreementAdditionalPaymentsReceived</link:label>
    <link:label xlink:label="bcrx_CollaborationAgreementAdditionalPaymentsReceived-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreement Additional Payments Received</link:label>
    <link:label xlink:label="bcrx_CollaborationAgreementAdditionalPaymentsReceived-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents collaboration agreement additional payments received.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborationAgreementAdditionalPaymentsReceived" xlink:to="bcrx_CollaborationAgreementAdditionalPaymentsReceived-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts</link:label>
    <link:label xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected Receivable From Awards for Research and Development Contracts</link:label>
    <link:label xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents expected receivable from awards for research and development contracts.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:to="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestAndOtherIncome-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest and other income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:label="us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CollateralAlreadyPostedAggregateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CollateralAlreadyPostedAggregateFairValue</link:label>
    <link:label xlink:label="us-gaap_CollateralAlreadyPostedAggregateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collateral Already Posted, Aggregate Fair Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:to="us-gaap_CollateralAlreadyPostedAggregateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AnnualLicenseFeeMaximum" xlink:label="bcrx_AnnualLicenseFeeMaximum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AnnualLicenseFeeMaximum</link:label>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMaximum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual License Fee Maximum</link:label>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMaximum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents annual maximum license fee.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AnnualLicenseFeeMaximum" xlink:to="bcrx_AnnualLicenseFeeMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_BirminghamResearchFacilityMember" xlink:label="bcrx_BirminghamResearchFacilityMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_BirminghamResearchFacilityMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Birmingham Research Facility [Member]</link:label>
    <link:label xlink:label="bcrx_BirminghamResearchFacilityMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the Birmingham Research Facility.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_BirminghamResearchFacilityMember" xlink:to="bcrx_BirminghamResearchFacilityMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</link:label>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComputerEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AnnualLicenseFeeMinimum" xlink:label="bcrx_AnnualLicenseFeeMinimum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMinimum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AnnualLicenseFeeMinimum</link:label>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMinimum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual License Fee Minimum</link:label>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMinimum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represent minimum annual license fee.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AnnualLicenseFeeMinimum" xlink:to="bcrx_AnnualLicenseFeeMinimum-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment, Office Equipment and Software [Member]</link:label>
    <link:label xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to laboratory equipment, office equipment and software.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:to="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_CurrencyDomain" xlink:label="bcrx_CurrencyDomain" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CurrencyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CurrencyDomain" xlink:to="bcrx_CurrencyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">(Loss) gain on foreign currency derivative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustment" xlink:label="us-gaap_PriorPeriodReclassificationAdjustment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PriorPeriodReclassificationAdjustment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PriorPeriodReclassificationAdjustment</link:label>
    <link:label xlink:label="us-gaap_PriorPeriodReclassificationAdjustment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Period Reclassification Adjustment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustment" xlink:to="us-gaap_PriorPeriodReclassificationAdjustment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UseOfEstimates-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_December312015Member" xlink:label="bcrx_December312015Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_December312015Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">December 31, 2015 [Member]</link:label>
    <link:label xlink:label="bcrx_December312015Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period reclassified.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_December312015Member" xlink:to="bcrx_December312015Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NondesignatedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NondesignatedMember" xlink:to="us-gaap_NondesignatedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_HedgingDesignationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_HedgingDesignationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HedgingDesignationDomain" xlink:to="us-gaap_HedgingDesignationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:label="bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs Reclassifed from Other Current Assets [Member]</link:label>
    <link:label xlink:label="bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt issuance costs reclassified from other current assets to conform to the 2016 presentation as per the newly adopted Accounting Standards Update.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:to="bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AllocatedShareBasedCompensationExpense</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseArrangementTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseArrangementTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="us-gaap_LeaseArrangementTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeForwardExchangeRate1" xlink:label="us-gaap_DerivativeForwardExchangeRate1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeForwardExchangeRate1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DerivativeForwardExchangeRate1</link:label>
    <link:label xlink:label="us-gaap_DerivativeForwardExchangeRate1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, Forward Exchange Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeForwardExchangeRate1" xlink:to="us-gaap_DerivativeForwardExchangeRate1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueProductLineMember" xlink:label="us-gaap_SalesRevenueProductLineMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SalesRevenueProductLineMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Product Line [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueProductLineMember" xlink:to="us-gaap_SalesRevenueProductLineMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRevenueCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredRevenueCurrent</link:label>
    <link:label xlink:label="us-gaap_DeferredRevenueCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred collaboration revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScenarioUnspecifiedDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioUnspecifiedDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskPercentage1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ConcentrationRiskPercentage1</link:label>
    <link:label xlink:label="us-gaap_ConcentrationRiskPercentage1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementScenarioAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VestingDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VestingAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NotesPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NotesPayableCurrent</link:label>
    <link:label xlink:label="us-gaap_NotesPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-recourse notes payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales and maturities of investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan amendment (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentGross</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Awards Available (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Awards Available (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_MaturityOfInvestments" xlink:label="bcrx_MaturityOfInvestments" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MaturityOfInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MaturityOfInvestments</link:label>
    <link:label xlink:label="bcrx_MaturityOfInvestments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity of Investments</link:label>
    <link:label xlink:label="bcrx_MaturityOfInvestments-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents maturity of investments.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaturityOfInvestments" xlink:to="bcrx_MaturityOfInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="us-gaap_DerivativeGainOnDerivative" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeGainOnDerivative-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DerivativeGainOnDerivative</link:label>
    <link:label xlink:label="us-gaap_DerivativeGainOnDerivative-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, Gain on Derivative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainOnDerivative" xlink:to="us-gaap_DerivativeGainOnDerivative-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Stock option awards cancelled (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeLossOnDerivative-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DerivativeLossOnDerivative</link:label>
    <link:label xlink:label="us-gaap_DerivativeLossOnDerivative-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, Loss on Derivative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLossOnDerivative" xlink:to="us-gaap_DerivativeLossOnDerivative-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options Outstanding (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options Outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_ContingentUponEuMarketingApprovalMember" xlink:label="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ContingentUponEuMarketingApprovalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent upon EU Marketing Approval [Member]</link:label>
    <link:label xlink:label="bcrx_ContingentUponEuMarketingApprovalMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information about the contingent proceed which is upon EU marketing approval.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ContingentUponEuMarketingApprovalMember" xlink:to="bcrx_ContingentUponEuMarketingApprovalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option awards granted (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option awards exercised (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_MundipharmaMember" xlink:label="bcrx_MundipharmaMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MundipharmaMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mundipharma [Member]</link:label>
    <link:label xlink:label="bcrx_MundipharmaMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to Mundipharma.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MundipharmaMember" xlink:to="bcrx_MundipharmaMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option awards cancelled (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_JapanYenMember" xlink:label="bcrx_JapanYenMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_JapanYenMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Japan, Yen [Member]</link:label>
    <link:label xlink:label="bcrx_JapanYenMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Japanese Yen.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_JapanYenMember" xlink:to="bcrx_JapanYenMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PerformanceSharesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vest Upon Successful Completion of Specific Development Milestones [Member]</link:label>
    <link:label xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents vesting upon successful completion of specific development milestones.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedStockUnitsRSUMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GovernmentContractReceivable" xlink:label="us-gaap_GovernmentContractReceivable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GovernmentContractReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GovernmentContractReceivable</link:label>
    <link:label xlink:label="us-gaap_GovernmentContractReceivable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government Contract Receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentContractReceivable" xlink:to="us-gaap_GovernmentContractReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_December2014Member" xlink:label="bcrx_December2014Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_December2014Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">December 2014 [Member]</link:label>
    <link:label xlink:label="bcrx_December2014Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents award date of December 2014.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_December2014Member" xlink:to="bcrx_December2014Member-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_August2013Member" xlink:label="bcrx_August2013Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_August2013Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">August 2013 [Member]</link:label>
    <link:label xlink:label="bcrx_August2013Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents award date of August 2013.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_August2013Member" xlink:to="bcrx_August2013Member-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vest 25% Each Year Until Fully Vested [Member]</link:label>
    <link:label xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents vest 25% each year until fully vested.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_Vest50PercentEachYearUntilFullyVestedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vest 50% Each Year Until Fully Vested [Member]</link:label>
    <link:label xlink:label="bcrx_Vest50PercentEachYearUntilFullyVestedMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents vest 50% each year until fully vested.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:to="bcrx_Vest50PercentEachYearUntilFullyVestedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock unit awards cancelled (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock unit awards granted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CounterpartyNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_CounterpartyNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquireProductiveAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquireProductiveAssets</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquireProductiveAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PercentageOfCarryingAmountInExcessOfFairValue1</link:label>
    <link:label xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Carrying Amount in Excess of Fair Value</link:label>
    <link:label xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of carrying amount in excess of fair value.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:to="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk-Free Interest Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CustomerConcentrationRiskMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Volatility</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax</link:label>
    <link:label xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:to="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeasePolicyTextBlock" xlink:label="us-gaap_LeasePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeasePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasePolicyTextBlock" xlink:to="us-gaap_LeasePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Life in Years</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Revenues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Revenues</link:label>
    <link:label xlink:label="us-gaap_Revenues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized (loss) gain on available for sale investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityVoluntaryFilers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_SeqirusUKLimitedMember" xlink:label="bcrx_SeqirusUKLimitedMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_SeqirusUKLimitedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Seqirus UK Limited [Member]</link:label>
    <link:label xlink:label="bcrx_SeqirusUKLimitedMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to Seqirus UK Limited.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_SeqirusUKLimitedMember" xlink:to="bcrx_SeqirusUKLimitedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Dividend Yield</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InterestExpense</link:label>
    <link:label xlink:label="us-gaap_InterestExpense-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label xlink:label="us-gaap_InterestExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsAndCash" xlink:label="us-gaap_InvestmentsAndCash" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentsAndCash-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InvestmentsAndCash</link:label>
    <link:label xlink:label="us-gaap_InvestmentsAndCash-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments and Cash</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAndCash" xlink:to="us-gaap_InvestmentsAndCash-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AmortizationOfFinancingCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AmortizationOfFinancingCosts</link:label>
    <link:label xlink:label="us-gaap_AmortizationOfFinancingCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityWellKnownSeasonedIssuer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ComprehensiveIncomeNetOfTax</link:label>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive (loss) income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInventories-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInInventories</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInventories-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInReceivables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInReceivables</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInReceivables-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Receivables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongtermDebtTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongtermDebtTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInDerivativeAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of foreign currency derivative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Four</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee service share based compensation nonvested awards compensation cost expected to be recognized year four.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RoyaltyRevenue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty revenue</link:label>
    <link:label xlink:label="us-gaap_RoyaltyRevenue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyRevenue" xlink:to="us-gaap_RoyaltyRevenue-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Five</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee service share based compensation nonvested awards compensation cost expected to be recognized year five.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, First Vesting Period After Grant Date</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment award first vesting period after grant date.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_NumberOfMajorCustomers" xlink:label="bcrx_NumberOfMajorCustomers" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NumberOfMajorCustomers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_NumberOfMajorCustomers</link:label>
    <link:label xlink:label="bcrx_NumberOfMajorCustomers-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Major Customers</link:label>
    <link:label xlink:label="bcrx_NumberOfMajorCustomers-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of major customers accounting for 10% or more of the specified concentration risk benchmark, which includes, but not limited to, sales revenue, accounts receivable, etc.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NumberOfMajorCustomers" xlink:to="bcrx_NumberOfMajorCustomers-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_ThreeCustomersMember" xlink:label="bcrx_ThreeCustomersMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ThreeCustomersMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Three Customers [Member]</link:label>
    <link:label xlink:label="bcrx_ThreeCustomersMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the three specialty distributors as customers.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ThreeCustomersMember" xlink:to="bcrx_ThreeCustomersMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label xlink:label="us-gaap_AvailableForSaleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="us-gaap_AvailableForSaleSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Three</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee service share based compensation nonvested awards compensation cost expected to be recognized year three.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation Nonvested Awards Compensation Cost Expected to be Recognized For Remainder of Fiscal Year</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee service share based compensation nonvested awards compensation cost expected to be recognized for remainder of fiscal year.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Two</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee service share based compensation nonvested awards compensation cost expected to be recognized year two.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</link:label>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SalesRevenueNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SalesRevenueNet</link:label>
    <link:label xlink:label="us-gaap_SalesRevenueNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsPayable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option awards granted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Stock option awards exercised (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInDeferredRevenue</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInInterestPayableNet</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentTypeCategorizationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefaultFinancialStatementsDateMember" xlink:label="us-gaap_DefaultFinancialStatementsDateMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DefaultFinancialStatementsDateMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Statement Filing Date [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefaultFinancialStatementsDateMember" xlink:to="us-gaap_DefaultFinancialStatementsDateMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_ShionogiAndCoLtdMember" xlink:label="bcrx_ShionogiAndCoLtdMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ShionogiAndCoLtdMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shionogi and Co. Ltd [Member]</link:label>
    <link:label xlink:label="bcrx_ShionogiAndCoLtdMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shionogi &amp; Co. Ltd.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShionogiAndCoLtdMember" xlink:to="bcrx_ShionogiAndCoLtdMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreationDateAxis" xlink:label="us-gaap_CreationDateAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CreationDateAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Report Date [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreationDateAxis" xlink:to="us-gaap_CreationDateAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CapitalLeasesFutureMinimumPaymentsDue</link:label>
    <link:label xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments Due</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentInterestRateStatedPercentage</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">(Decrease) increase in cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues</link:label>
    <link:label xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative and other research and development revenues</link:label>
    <link:label xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents collaborative and other research and development.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturing in one year or less</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenues from Collaborations [Table Text Block]</link:label>
    <link:label xlink:label="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of schedule of revenues from collaborations.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:to="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsReceivableNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccountsReceivableNetCurrent</link:label>
    <link:label xlink:label="us-gaap_AccountsReceivableNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivables from collaborations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:label="bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesAccruedInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Interest</link:label>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesAccruedInterest-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents available for sale securities accrued interest.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:to="bcrx_AvailableForSaleSecuritiesAccruedInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity of Counterparty, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SalesRevenueGoodsNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product sales, net</link:label>
    <link:label xlink:label="us-gaap_SalesRevenueGoodsNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product sales, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueGoodsNet" xlink:to="us-gaap_SalesRevenueGoodsNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReceivablesNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ReceivablesNetCurrent</link:label>
    <link:label xlink:label="us-gaap_ReceivablesNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity Type of Counterparty [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Billing Status, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesBillingStatusDomain" xlink:label="us-gaap_ReceivablesBillingStatusDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReceivablesBillingStatusDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables Billing Status [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesBillingStatusDomain" xlink:to="us-gaap_ReceivablesBillingStatusDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnbilledRevenuesMember" xlink:label="us-gaap_UnbilledRevenuesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnbilledRevenuesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unbilled Revenues [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnbilledRevenuesMember" xlink:to="us-gaap_UnbilledRevenuesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BilledRevenuesMember" xlink:label="us-gaap_BilledRevenuesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BilledRevenuesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Billed Revenues [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BilledRevenuesMember" xlink:to="us-gaap_BilledRevenuesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.001 par value; shares authorized &#8212; 5,000; no shares issued and outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Debt Maturities Fair Value [Table Text Block]</link:label>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of available for sale securities debt maturities fair value.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturing after one year through two years</link:label>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents available for sale securities debt maturities after one through two years fair value.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Receivables from Collaborations [Table Text Block]</link:label>
    <link:label xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure representing receivables from collaborations.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:to="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of common stock, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PhaRMANotesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PhaRMA Notes Member]</link:label>
    <link:label xlink:label="bcrx_PhaRMANotesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents PhaRMA notes.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PhaRMANotesMember" xlink:to="bcrx_PhaRMANotesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_JPRRoyaltySubLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">JPR Royalty Sub LLC [Member]</link:label>
    <link:label xlink:label="bcrx_JPRRoyaltySubLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents JPR Royalty Sub LLC.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_JPRRoyaltySubLLCMember" xlink:to="bcrx_JPRRoyaltySubLLCMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:to="us-gaap_AvailableForSaleSecuritiesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">(Loss) income from operations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, $0.01 par value: shares authorized &#8212; 200,000; shares issued and outstanding &#8212; 73,701 in 2016 and 73,355 in 2015</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net proceeds from common stock issued under stock-based compensation plans</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromStockPlans-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase in lease financing obligation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CorporateDebtSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReceivablesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenuesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PrivatePlacementOfSeniorSecuredNotes</link:label>
    <link:label xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement of Senior Secured Notes</link:label>
    <link:label xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents private placement of senior secured notes.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:to="bcrx_PrivatePlacementOfSeniorSecuredNotes-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet</link:label>
    <link:label xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition Royalty And Milestone Revenue Recognized, Net</link:label>
    <link:label xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents revenue recognition royalty and milestone revenue recognized, net.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:to="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) provided by operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities</link:label>
    <link:label xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred collaboration expense</link:label>
    <link:label xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents deferred collaboration expense.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:to="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TitleOfIndividualAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromLicenseFeesReceived-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromLicenseFeesReceived</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromLicenseFeesReceived-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from License Fees Received</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:label="bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MaximumAmountOfCollateralRequiredToPost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MaximumAmountOfCollateralRequiredToPost</link:label>
    <link:label xlink:label="bcrx_MaximumAmountOfCollateralRequiredToPost-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum Amount of Collateral Required to Post</link:label>
    <link:label xlink:label="bcrx_MaximumAmountOfCollateralRequiredToPost-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents maximum amount of collateral required to post.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:to="bcrx_MaximumAmountOfCollateralRequiredToPost-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_RemainingAggregateOfferingPrice" xlink:label="bcrx_RemainingAggregateOfferingPrice" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RemainingAggregateOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RemainingAggregateOfferingPrice</link:label>
    <link:label xlink:label="bcrx_RemainingAggregateOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining Aggregate Offering Price</link:label>
    <link:label xlink:label="bcrx_RemainingAggregateOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the remaining aggregate offering price of common stock, preferred stock, depository shares, stock purchase contracts, warrants and units.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RemainingAggregateOfferingPrice" xlink:to="bcrx_RemainingAggregateOfferingPrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NotesPayableFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NotesPayableFairValueDisclosure</link:label>
    <link:label xlink:label="us-gaap_NotesPayableFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableFairValueDisclosure" xlink:to="us-gaap_NotesPayableFairValueDisclosure-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_MaximumAggregateOfferingPrice" xlink:label="bcrx_MaximumAggregateOfferingPrice" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MaximumAggregateOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MaximumAggregateOfferingPrice</link:label>
    <link:label xlink:label="bcrx_MaximumAggregateOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum Aggregate Offering Price</link:label>
    <link:label xlink:label="bcrx_MaximumAggregateOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the maximum aggregate offering price of common stock, preferred stock, depository shares, stock purchase contracts, warrants and units.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaximumAggregateOfferingPrice" xlink:to="bcrx_MaximumAggregateOfferingPrice-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CurrencyHedgeAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency Hedge Agreement [Member]</link:label>
    <link:label xlink:label="bcrx_CurrencyHedgeAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CurrencyHedgeAgreementMember" xlink:to="bcrx_CurrencyHedgeAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardDateDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateDomain" xlink:to="us-gaap_AwardDateDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:label="bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RequiredForeignCurrencyHedgePerDollar-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RequiredForeignCurrencyHedgePerDollar</link:label>
    <link:label xlink:label="bcrx_RequiredForeignCurrencyHedgePerDollar-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Required Foreign Currency Hedge Per Dollar</link:label>
    <link:label xlink:label="bcrx_RequiredForeignCurrencyHedgePerDollar-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The Company is required to maintain a foreign currency hedge per dollar under the agreements governing the PhaRMA Notes.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:to="bcrx_RequiredForeignCurrencyHedgePerDollar-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardDateAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_Interestreserve" xlink:label="bcrx_Interestreserve" xlink:type="locator"/>
    <link:label xlink:label="bcrx_Interestreserve-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_Interestreserve</link:label>
    <link:label xlink:label="bcrx_Interestreserve-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Reserve</link:label>
    <link:label xlink:label="bcrx_Interestreserve-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents interest reserve established as part of the royalty monetization.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_Interestreserve" xlink:to="bcrx_Interestreserve-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyMonetizationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Monetization [Member]</link:label>
    <link:label xlink:label="bcrx_RoyaltyMonetizationMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the royalty monetization transaction.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyMonetizationMember" xlink:to="bcrx_RoyaltyMonetizationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepreciationDepletionAndAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_GreenCrossCorporationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Green Cross Corporation [Member]</link:label>
    <link:label xlink:label="bcrx_GreenCrossCorporationMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Green Cross Corporation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_GreenCrossCorporationMember" xlink:to="bcrx_GreenCrossCorporationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_TransactionCosts" xlink:label="bcrx_TransactionCosts" xlink:type="locator"/>
    <link:label xlink:label="bcrx_TransactionCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_TransactionCosts</link:label>
    <link:label xlink:label="bcrx_TransactionCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction Costs</link:label>
    <link:label xlink:label="bcrx_TransactionCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents transaction costs associated with royalty monetization.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_TransactionCosts" xlink:to="bcrx_TransactionCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_BaseContractMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Base Contract [Member]</link:label>
    <link:label xlink:label="bcrx_BaseContractMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The base contract of ASPR/BARDA to support BCX4430 drug manufacturing.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_BaseContractMember" xlink:to="bcrx_BaseContractMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ASPRBARDAContractMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ASPRBARDA Contract [Member]</link:label>
    <link:label xlink:label="bcrx_ASPRBARDAContractMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The potential value of the ASPR/BARDA Contract.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ASPRBARDAContractMember" xlink:to="bcrx_ASPRBARDAContractMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AdditionalDevelopmentOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Development Options [Member]</link:label>
    <link:label xlink:label="bcrx_AdditionalDevelopmentOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The additional development options that can be exercised by the Government.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AdditionalDevelopmentOptionsMember" xlink:to="bcrx_AdditionalDevelopmentOptionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_IncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incentive Plan [Member]</link:label>
    <link:label xlink:label="bcrx_IncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Incentive Plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_IncentivePlanMember" xlink:to="bcrx_IncentivePlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeStockPurchasePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label xlink:label="bcrx_EmployeeStockPurchasePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan, (ESPP).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeStockPurchasePlanMember" xlink:to="bcrx_EmployeeStockPurchasePlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of Company [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The description of company policy.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:to="bcrx_DescriptionOfCompanyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label xlink:label="us-gaap_InventoryNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostOfGoodsSold-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of products sold</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsSold" xlink:to="us-gaap_CostOfGoodsSold-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_StockOptionsAndRestrictedStockMember" xlink:label="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_StockOptionsAndRestrictedStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Options and Restricted Stock [Member]</link:label>
    <link:label xlink:label="bcrx_StockOptionsAndRestrictedStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents stock options and restricted stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_StockOptionsAndRestrictedStockMember" xlink:to="bcrx_StockOptionsAndRestrictedStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration of Market Risk [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents concentration of market risk policy.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:to="bcrx_ConcentrationOfMarketRiskPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense and Deferred Financing Costs [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents interest expense and deferred financing costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:to="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensation</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:label="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CurrencyHedgeAgreementPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency Hedge Agreement [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_CurrencyHedgeAgreementPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents currency hedge agreement policy.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:to="bcrx_CurrencyHedgeAgreementPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:type="locator"/>
    <link:label xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable</link:label>
    <link:label xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option awards cancelled (in shares)</link:label>
    <link:label xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment award options forfeitures in period awards available.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:to="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostsAndExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CostsAndExpenses</link:label>
    <link:label xlink:label="us-gaap_CostsAndExpenses-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredCostsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred collaboration expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrent" xlink:to="us-gaap_DeferredCostsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturing after two years</link:label>
    <link:label xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents debt maturities after two years.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AccruedExpensesPolicyTextBlock" xlink:label="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AccruedExpensesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Expenses [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_AccruedExpensesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents accrued expenses policy.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AccruedExpensesPolicyTextBlock" xlink:to="bcrx_AccruedExpensesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostsAndExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_NonEmployeeDirectorsMember" xlink:label="bcrx_NonEmployeeDirectorsMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NonEmployeeDirectorsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-employee Directors [Member]</link:label>
    <link:label xlink:label="bcrx_NonEmployeeDirectorsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents non-employee directors of the company.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NonEmployeeDirectorsMember" xlink:to="bcrx_NonEmployeeDirectorsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapital-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Stock option awards granted (in shares)</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents share based compensation arrangement by share based payment award options grants in period awards available.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_NumberOfMilestonesAchieved" xlink:label="bcrx_NumberOfMilestonesAchieved" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NumberOfMilestonesAchieved-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_NumberOfMilestonesAchieved</link:label>
    <link:label xlink:label="bcrx_NumberOfMilestonesAchieved-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Milestones Achieved</link:label>
    <link:label xlink:label="bcrx_NumberOfMilestonesAchieved-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of milestones achieved.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NumberOfMilestonesAchieved" xlink:to="bcrx_NumberOfMilestonesAchieved-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" xlink:label="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" xlink:type="locator"/>
    <link:label xlink:label="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage</link:label>
    <link:label xlink:label="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Shar-based Payment Award, Awards Unvested, Percentage</link:label>
    <link:label xlink:label="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of performance awards that remain unvested.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" xlink:to="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum</link:label>
    <link:label xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Salary to Purchase Common Stock, Maximum</link:label>
    <link:label xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents percentage of salary to purchase common stock maximum.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:to="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_NumberOfStockbasedCompensationPlans" xlink:label="bcrx_NumberOfStockbasedCompensationPlans" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NumberOfStockbasedCompensationPlans-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_NumberOfStockbasedCompensationPlans</link:label>
    <link:label xlink:label="bcrx_NumberOfStockbasedCompensationPlans-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Stock-based Compensation Plans</link:label>
    <link:label xlink:label="bcrx_NumberOfStockbasedCompensationPlans-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents number of stock based compensation plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NumberOfStockbasedCompensationPlans" xlink:to="bcrx_NumberOfStockbasedCompensationPlans-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_LeaseFinancingObligationNetOfCurrent" xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:type="locator"/>
    <link:label xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease financing obligation</link:label>
    <link:label xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Financing Obligation, Net of Current</link:label>
    <link:label xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease Financing obligation as of the balance sheet date.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:to="bcrx_LeaseFinancingObligationNetOfCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeInstrumentRiskAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeContractTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsCurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_PercentageOfCommonStockSharesEnding" xlink:label="bcrx_PercentageOfCommonStockSharesEnding" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesEnding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PercentageOfCommonStockSharesEnding</link:label>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesEnding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Common Stock Shares, Ending</link:label>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesEnding-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents percentage of common stock shares ending.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PercentageOfCommonStockSharesEnding" xlink:to="bcrx_PercentageOfCommonStockSharesEnding-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_PercentageOfCommonStockSharesBeginning" xlink:label="bcrx_PercentageOfCommonStockSharesBeginning" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesBeginning-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PercentageOfCommonStockSharesBeginning</link:label>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesBeginning-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Common Stock Shares, Beginning</link:label>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesBeginning-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents percentage of common stock shares beginning.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PercentageOfCommonStockSharesBeginning" xlink:to="bcrx_PercentageOfCommonStockSharesBeginning-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:label="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shar-based Compensation Arrangement by Shar-based Payment Award, Maximum Number of Shares Per Employee, Amount</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents share-based compensation arrangement by share-based payment award maximum value per employee amount.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:to="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>bcrx-20160630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 10:21PM UTC 2016-08-06--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-document-and-entity-information" xlink:href="bcrx-20160630.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160630/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_DocumentAndEntityInformation" xlink:label="bcrx_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_DocumentAndEntityInformation" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:href="bcrx-20160630.xsd#statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-note-1-significant-accounting-policies" xlink:href="bcrx-20160630.xsd#statement-note-1-significant-accounting-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160630/role/statement-note-1-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AgreementMember" xlink:label="bcrx_AgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_BirminghamResearchFacilityMember" xlink:label="bcrx_BirminghamResearchFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_CSLMember" xlink:label="bcrx_CSLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_ContingentUponEuMarketingApprovalMember" xlink:label="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:label="bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_December312015Member" xlink:label="bcrx_December312015Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:label="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_ThreeCustomersMember" xlink:label="bcrx_ThreeCustomersMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreationDateAxis" xlink:label="us-gaap_CreationDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefaultFinancialStatementsDateMember" xlink:label="us-gaap_DefaultFinancialStatementsDateMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:label="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:label="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueProductLineMember" xlink:label="us-gaap_SalesRevenueProductLineMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueProductLineMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="bcrx_RAPIVABMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:to="bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreationDateAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreationDateAxis" xlink:to="bcrx_December312015Member" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="bcrx_RoyaltyReceivableMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="bcrx_CollateralForCreditMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AgreementMember" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_CSLMember" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="bcrx_BirminghamResearchFacilityMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MajorCustomersAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="bcrx_ThreeCustomersMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreationDateAxis" xlink:to="us-gaap_DefaultFinancialStatementsDateMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:to="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-note-2-stockbased-compensation" xlink:href="bcrx-20160630.xsd#statement-note-2-stockbased-compensation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160630/role/statement-note-2-stockbased-compensation" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_August2013Member" xlink:label="bcrx_August2013Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_December2014Member" xlink:label="bcrx_December2014Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_NonEmployeeDirectorsMember" xlink:label="bcrx_NonEmployeeDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_StockOptionsAndRestrictedStockMember" xlink:label="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_EmployeeStockPurchasePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardDateAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="bcrx_August2013Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="bcrx_December2014Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="bcrx_NonEmployeeDirectorsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-note-3-collaborative-and-other-research-and-development-contracts" xlink:href="bcrx-20160630.xsd#statement-note-3-collaborative-and-other-research-and-development-contracts" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160630/role/statement-note-3-collaborative-and-other-research-and-development-contracts" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_CSLLimitedMember" xlink:label="bcrx_CSLLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_MundipharmaMember" xlink:label="bcrx_MundipharmaMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_BaseContractMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_ASPRBARDAContractMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_CSLLimitedMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_MundipharmaMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AECOMAndIRLMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="bcrx_UABMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-note-4-royalty-monetization" xlink:href="bcrx-20160630.xsd#statement-note-4-royalty-monetization" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160630/role/statement-note-4-royalty-monetization" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_CurrencyDomain" xlink:label="bcrx_CurrencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_JapanYenMember" xlink:label="bcrx_JapanYenMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_RoyaltyMonetizationTextBlock" xlink:label="bcrx_RoyaltyMonetizationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="us-gaap_CurrencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="bcrx_RoyaltyMonetizationMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CurrencyAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrencyAxis" xlink:to="bcrx_JapanYenMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrencyAxis" xlink:to="bcrx_CurrencyDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="bcrx_RoyaltyMonetizationTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-note-5-stockholders-equity" xlink:href="bcrx-20160630.xsd#statement-note-5-stockholders-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160630/role/statement-note-5-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-significant-accounting-policies-policies" xlink:href="bcrx-20160630.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160630/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AccruedExpensesPolicyTextBlock" xlink:label="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:label="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_statement-statement-significant-accounting-policies-policies" xlink:label="bcrx_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeasePolicyTextBlock" xlink:label="us-gaap_LeasePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-significant-accounting-policies-policies" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LeasePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-note-1-significant-accounting-policies-tables" xlink:href="bcrx-20160630.xsd#statement-note-1-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160630/role/statement-note-1-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-tables" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-note-2-stockbased-compensation-tables" xlink:href="bcrx-20160630.xsd#statement-note-2-stockbased-compensation-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160630/role/statement-note-2-stockbased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_statement-statement-note-2-stockbased-compensation-tables" xlink:label="bcrx_statement-statement-note-2-stockbased-compensation-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-2-stockbased-compensation-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-note-1-significant-accounting-policies-details-textual" xlink:href="bcrx-20160630.xsd#statement-note-1-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160630/role/statement-note-1-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AgreementMember" xlink:label="bcrx_AgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AveragematurityForPortfolioInvestments" xlink:label="bcrx_AveragematurityForPortfolioInvestments-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities" xlink:label="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_BirminghamResearchFacilityMember" xlink:label="bcrx_BirminghamResearchFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_CSLMember" xlink:label="bcrx_CSLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_ContingentUponEuMarketingApprovalMember" xlink:label="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:label="bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_December312015Member" xlink:label="bcrx_December312015Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_LeaseFinancingObligationNetOfCurrent" xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_LongtermInvestmentMaturityMinimum" xlink:label="bcrx_LongtermInvestmentMaturityMinimum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_MaturityOfInvestments" xlink:label="bcrx_MaturityOfInvestments-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_MaturityperiodOfShortTermInvestment" xlink:label="bcrx_MaturityperiodOfShortTermInvestment-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_MilestonePaymentMaximum" xlink:label="bcrx_MilestonePaymentMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_NumberOfMajorCustomers" xlink:label="bcrx_NumberOfMajorCustomers-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:label="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_ThreeCustomersMember" xlink:label="bcrx_ThreeCustomersMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:label="us-gaap_CollateralAlreadyPostedAggregateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreationDateAxis" xlink:label="us-gaap_CreationDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefaultFinancialStatementsDateMember" xlink:label="us-gaap_DefaultFinancialStatementsDateMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="us-gaap_DeferredRevenueAdditions-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="us-gaap_DerivativeGainOnDerivative-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsAndCash" xlink:label="us-gaap_InvestmentsAndCash-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossOnSaleOfInvestments" xlink:label="us-gaap_LossOnSaleOfInvestments-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:label="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:label="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustment" xlink:label="us-gaap_PriorPeriodReclassificationAdjustment-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueProductLineMember" xlink:label="us-gaap_SalesRevenueProductLineMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueProductLineMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="bcrx_RAPIVABMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:to="bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreationDateAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreationDateAxis" xlink:to="bcrx_December312015Member" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="bcrx_RoyaltyReceivableMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="bcrx_CollateralForCreditMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AgreementMember" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_CSLMember" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="bcrx_ContingentUponEuMarketingApprovalMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="bcrx_BirminghamResearchFacilityMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MajorCustomersAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="bcrx_ThreeCustomersMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreationDateAxis" xlink:to="us-gaap_DefaultFinancialStatementsDateMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:to="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossOnSaleOfInvestments-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentsAndCash-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CollateralAlreadyPostedAggregateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_NumberOfMajorCustomers-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PriorPeriodReclassificationAdjustment-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaturityOfInvestments-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaturityperiodOfShortTermInvestment-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_LongtermInvestmentMaturityMinimum-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredRevenueAdditions-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpense-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_LeaseFinancingObligationNetOfCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDue-2" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLossOnDerivative-2" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeGainOnDerivative-2" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted-2" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic-2" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1-2" xlink:type="arc"/>
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AveragematurityForPortfolioInvestments-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-note-2-stockbased-compensation-details-textual" xlink:href="bcrx-20160630.xsd#statement-note-2-stockbased-compensation-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160630/role/statement-note-2-stockbased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_August2013Member" xlink:label="bcrx_August2013Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_December2014Member" xlink:label="bcrx_December2014Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_NonEmployeeDirectorsMember" xlink:label="bcrx_NonEmployeeDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_NumberOfMilestonesAchieved" xlink:label="bcrx_NumberOfMilestonesAchieved-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_NumberOfStockbasedCompensationPlans" xlink:label="bcrx_NumberOfStockbasedCompensationPlans-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_PercentageOfCommonStockSharesBeginning" xlink:label="bcrx_PercentageOfCommonStockSharesBeginning-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_PercentageOfCommonStockSharesEnding" xlink:label="bcrx_PercentageOfCommonStockSharesEnding-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:label="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage" xlink:label="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_StockOptionsAndRestrictedStockMember" xlink:label="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_EmployeeStockPurchasePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="bcrx_StockOptionsAndRestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_Vest50PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardDateAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="bcrx_August2013Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="bcrx_December2014Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="bcrx_NonEmployeeDirectorsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_NumberOfStockbasedCompensationPlans-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_NumberOfMilestonesAchieved-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCommonStockSharesBeginning-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCommonStockSharesEnding-2" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-2" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-2" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-details-textual" xlink:href="bcrx-20160630.xsd#statement-note-3-collaborative-and-other-research-and-development-contracts-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AnnualLicenseFeeMaximum" xlink:label="bcrx_AnnualLicenseFeeMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AnnualLicenseFeeMinimum" xlink:label="bcrx_AnnualLicenseFeeMinimum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_CSLLimitedMember" xlink:label="bcrx_CSLLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_CollaborationAgreementAdditionalPaymentsReceived" xlink:label="bcrx_CollaborationAgreementAdditionalPaymentsReceived-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_MilestonePaymentMaximum" xlink:label="bcrx_MilestonePaymentMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_MilestonePaymentMinimum" xlink:label="bcrx_MilestonePaymentMinimum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_MundipharmaMember" xlink:label="bcrx_MundipharmaMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_PeriodOfAgreement" xlink:label="bcrx_PeriodOfAgreement-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_RenewablePeriodOfAgreement" xlink:label="bcrx_RenewablePeriodOfAgreement-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_RoyaltyTerm" xlink:label="bcrx_RoyaltyTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_UpfrontPaymentsReceivableAmount" xlink:label="bcrx_UpfrontPaymentsReceivableAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GovernmentContractReceivable" xlink:label="us-gaap_GovernmentContractReceivable-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_BaseContractMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_ASPRBARDAContractMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_CSLLimitedMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_MundipharmaMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AECOMAndIRLMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="bcrx_UABMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GovernmentContractReceivable-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborationAgreementAdditionalPaymentsReceived-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyTerm-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_UpfrontPaymentsReceivableAmount-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMinimum-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AnnualLicenseFeeMinimum-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AnnualLicenseFeeMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AdvanceNoticePeriodForTerminationOfAgreement-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PeriodOfAgreement-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RenewablePeriodOfAgreement-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-note-4-royalty-monetization-details-textual" xlink:href="bcrx-20160630.xsd#statement-note-4-royalty-monetization-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160630/role/statement-note-4-royalty-monetization-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_CurrencyDomain" xlink:label="bcrx_CurrencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_Interestreserve" xlink:label="bcrx_Interestreserve-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_JapanYenMember" xlink:label="bcrx_JapanYenMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:label="bcrx_MaximumAmountOfCollateralRequiredToPost-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:label="bcrx_RequiredForeignCurrencyHedgePerDollar-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:label="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_TransactionCosts" xlink:label="bcrx_TransactionCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:label="us-gaap_CollateralAlreadyPostedAggregateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="us-gaap_CurrencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeForwardExchangeRate1" xlink:label="us-gaap_DerivativeForwardExchangeRate1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="bcrx_RoyaltyMonetizationMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CurrencyAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrencyAxis" xlink:to="bcrx_JapanYenMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrencyAxis" xlink:to="bcrx_CurrencyDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_TransactionCosts-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_Interestreserve-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PrivatePlacementOfSeniorSecuredNotes-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NotesPayableFairValueDisclosure-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeForwardExchangeRate1-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RequiredForeignCurrencyHedgePerDollar-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLossOnDerivative-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CollateralAlreadyPostedAggregateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaximumAmountOfCollateralRequiredToPost-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-note-5-stockholders-equity-details-textual" xlink:href="bcrx-20160630.xsd#statement-note-5-stockholders-equity-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160630/role/statement-note-5-stockholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_MaximumAggregateOfferingPrice" xlink:label="bcrx_MaximumAggregateOfferingPrice-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_RemainingAggregateOfferingPrice" xlink:label="bcrx_RemainingAggregateOfferingPrice-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaximumAggregateOfferingPrice-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RemainingAggregateOfferingPrice-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-consolidated-balance-sheets-current-period-unaudited" xlink:href="bcrx-20160630.xsd#statement-consolidated-balance-sheets-current-period-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160630/role/statement-consolidated-balance-sheets-current-period-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_DeferredCollaborationExpenseAssets" xlink:label="bcrx_DeferredCollaborationExpenseAssets-1" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_LeaseFinancingObligationNetOfCurrent" xlink:label="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredCostsCurrent" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent-1" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="bcrx_DeferredCollaborationExpenseAssets-1" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_InterestPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_NotesPayableCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="bcrx_LeaseFinancingObligationNetOfCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-consolidated-statements-of-cash-flows-unaudited" xlink:href="bcrx-20160630.xsd#statement-consolidated-statements-of-cash-flows-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160630/role/statement-consolidated-statements-of-cash-flows-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:label="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:label="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForHedgeFinancingActivities" xlink:label="us-gaap_PaymentsForHedgeFinancingActivities-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAttributableToReportingEntityAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue-1" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets-n7" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash-n7" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-n7" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForHedgeFinancingActivities-n7" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-4" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:href="bcrx-20160630.xsd#statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160630/role/statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_statement-statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:label="bcrx_statement-statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-scheduled-maturity-for-the-companys-investments-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecurities-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-note-1-inventory-details" xlink:href="bcrx-20160630.xsd#statement-note-1-inventory-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160630/role/statement-note-1-inventory-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_statement-statement-note-1-inventory-details" xlink:label="bcrx_statement-statement-note-1-inventory-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-inventory-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-note-2-stock-incentive-plan-activities-details" xlink:href="bcrx-20160630.xsd#statement-note-2-stock-incentive-plan-activities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160630/role/statement-note-2-stock-incentive-plan-activities-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-n8" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_statement-statement-note-2-stock-incentive-plan-activities-details" xlink:label="bcrx_statement-statement-note-2-stock-incentive-plan-activities-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n8" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-2-stock-incentive-plan-activities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n8" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-5" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-note-2-weighted-average-assumptions-details" xlink:href="bcrx-20160630.xsd#statement-note-2-weighted-average-assumptions-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160630/role/statement-note-2-weighted-average-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_statement-statement-note-2-weighted-average-assumptions-details" xlink:label="bcrx_statement-statement-note-2-weighted-average-assumptions-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-2-weighted-average-assumptions-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-consolidated-statements-of-comprehensive-loss-income-unaudited" xlink:href="bcrx-20160630.xsd#statement-consolidated-statements-of-comprehensive-loss-income-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160630/role/statement-consolidated-statements-of-comprehensive-loss-income-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_SalesRevenueGoodsNet" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RoyaltyRevenue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_SalesRevenueNet-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostOfGoodsSold" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_RoyaltyExpense" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_InterestAndOtherIncome" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_InterestExpense-n7" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:href="bcrx-20160630.xsd#statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160630/role/statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:label="bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_statement-statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:label="bcrx_statement-statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-fair-value-of-the-companys-investments-by-type-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_InvestmentTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-n7" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-note-1-summary-of-receivables-details" xlink:href="bcrx-20160630.xsd#statement-note-1-summary-of-receivables-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160630/role/statement-note-1-summary-of-receivables-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_SeqirusUKLimitedMember" xlink:label="bcrx_SeqirusUKLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_ShionogiAndCoLtdMember" xlink:label="bcrx_ShionogiAndCoLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_statement-statement-note-1-summary-of-receivables-details" xlink:label="bcrx_statement-statement-note-1-summary-of-receivables-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BilledRevenuesMember" xlink:label="us-gaap_BilledRevenuesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesBillingStatusDomain" xlink:label="us-gaap_ReceivablesBillingStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnbilledRevenuesMember" xlink:label="us-gaap_UnbilledRevenuesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-summary-of-receivables-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_BilledRevenuesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_UnbilledRevenuesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_ShionogiAndCoLtdMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_SeqirusUKLimitedMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_ReceivablesBillingStatusDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReceivablesNetCurrent-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20160630/role/statement-note-1-summary-of-revenues-details" xlink:href="bcrx-20160630.xsd#statement-note-1-summary-of-revenues-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20160630/role/statement-note-1-summary-of-revenues-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_SeqirusUKLimitedMember" xlink:label="bcrx_SeqirusUKLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_ShionogiAndCoLtdMember" xlink:label="bcrx_ShionogiAndCoLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20160630.xsd#bcrx_statement-statement-note-1-summary-of-revenues-details" xlink:label="bcrx_statement-statement-note-1-summary-of-revenues-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-summary-of-revenues-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_ShionogiAndCoLtdMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="bcrx_SeqirusUKLimitedMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueGoodsNet-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RoyaltyRevenue-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues-2" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>exh101_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh101_1.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_X1? 17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    <    <@$R  (    4    CH=I  0    !    I    -  +<;    G
M$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S #(P,38Z,#@Z
M,#,@,38Z,30Z,C0      Z !  ,    !__\  * "  0    !   "P* #  0
M   !   #CP         & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $  !:*
M     $@    !    2     '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 #_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ H !\ P$B  (1 0,1 ?_=  0
M"/_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M[OH42T^FR61M.T2(F-O^<Y$6&VK&--]GH7AS -/M&029=M]G^$9_-[OT3/\
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M6W^;^FW_ *:D.ET^H7FQ[@[1S"*R"WV^P_H]^US:ZV_3_P &J9S&E@<S.,,
M%CG%IW'Z6YVQE;:G.;^ZW9_(1&YE0&TV[WP-/5=N,_G;6UI*="O%QZG[ZZVL
M<&A@<!!VB-K/ZOM15DC.QB#^DF#K^GM[_P!5BSW7YGJ!M-N3D%^H].^L  _G
M,9=CM>YGJ_HO>DIZ99?5#>W(I=5:RDA[(-D!OT,K=[G-=])OM:J#>J9#:&DX
MUEA:!+G98#G#;+K'>GMK^E^ZUB'D9^1?[?L37ZM):<JI^US!8?\ M2RRO]__
M #$E-EMO4N_5\:.\>GR/I-^@B5'J#W V=6I#($BL5N,Q^\YH_P"I5*NVZRVL
M58+7O<'.:&68ID&!](XS?9Z?[BUL2_-;O8[IHQ&C:6;7M<'&-I_F6^STVLK:
MDI#@BYK:S;U;U6P!LV4LF6MV_1:?HJYZE/\ W-_&K_TFJM'5&UM;38UK;B&-
M]-SG;MQ;7#?YK^4C6=5;4XLM:UCQR"YVD_\ 6DE)/5H_[G?]*K_R"L5%IK!;
M9ZHU]^AG7^0&M5:O.NM8VRJD/K> YCVN,$'AP_1JS4][ZPY[=CC,MY[_  :D
MID9D1XZ_<G4'N(+ /SG0?N)4TE/_T_55%X)8X#D@@?ZZJ2%E,L?CV,K(:]S2
M&DDM$_UF^Y)3SU;GL8S<QVP-T#;&&(@#;^BJ9OWN_F_H)ZBY@#K*?;N(:U[V
MEDO&QK_:VE_YNUS$1_U?=6T&IK(&KF>L^#!]K6-V-_-]BK?L@-T&'D>V-^Q\
M20&[W,_2,^FWV_1_G$E)A9<YQ:^FD/8"3M:00(]AK_2V^]O_ !3U!YL (;6]
MQJT!FN=3[=H%?DICI.,'.9]@RR'!P)]5NV/Y/Z5O_2_<4\; Q&%SG=*R;7.(
M]]YJ<=!M]OZ;VM24ALJ(9O\ 3<Y@$[SM,@AS&N=^C;^8S>W=^^FNKM]1LLL,
M.#6 BLG> ]O^B'YE2NNQL4OW'HMA.I#IJF3#C_AMWYJJGI]  <>EW@BP;0XX
M\EKFO;Z-4/=^BKV,_GO^#24Q?+@\V->\UD%YVM.H/F/YWZ'YNS]&]_\ HDUE
M9,5[!N=I]!IU,5>_V'=LG_!?^"*[BMOQF[&8.4*Q.RKU*6-:?I^QN.^O^<WJ
MR<K)!;_D_),F-+6:>;OT_P!%)3C4%QQJWLD%A:T[6#:PFNO8=L?FV;58P< Y
M3O2>QS:F6.#R P%I:-VT[MOM?N_P==G^$1F6Y3JF%N'EQZ;06UW,;RRM^[WV
MCWMCT_I*1;F6.;^@SJP]NV3?7#""S]([WV/W_P!7U/\ "I*=M)4O1=,[&?\
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MSAU.%AV85C/;SD7/<WG\P/\ 7]_]A$QV.V-!QG_S=?#Q_*_X1%+#_P!QK/\
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M'4 VK?74?TH+FE]>NON^C@LW>JW;O_FUH5U]0<XM=8YC1!#W"LSKJ-C/H?\
M33WU9(K9NOW$'5VQO8E\_P#;?Z-)36%76!.W'Q6]X#WQ^%;4WV;K'Z-OL'IO
M +Q8-SV]W6>ICW?]#TU=?1GESBW*#6D^P>D# G@^[W)_0S9;^M" V"#6-723
MO^D/S?;M24Y6/B]7+:VAT--=8)%K"6B7^]H^R?FM6F,2T  O:XC\X[P3Y^VP
M-0ZZLHLJ%60&.]-NYQK#IX_E-_E_YZ,ZC,+GEN3M#IV#8T[9+?\ .VM:[_/2
M4P^QV3,CY.L'_HQ'HK-;-I\21JX_^?"YR:JO(:X&R[U&AL1M#27227R/Y/MV
M(R2D=H^AK'N$(B':)#?)P/XHB2G_UO54+)C[/9+VUC:9>^=HT^D[:ZO_ ,^,
M14.]SV4O>SZ36D@1/'\G=7_U:2G->UHMNWYV,TAS3D,][2(VQQF;:'.:_P#<
M]_L2C#>XG[=4:R Q@%KP0T.-AE[<KWV>F?YW;ZGY_P#P:,_*RR7160UQ K#J
MIVCZ+O5<,C;_ "O\&B3EENMF/NG26.C;&K?YS]XL24T;17/NZEBMW'> 38);
M8UK:^,YF[<QGL_,_T;$79B5Y+#]MJ::R!96ZRPDO!U^EE>S_ (M]=BLN;FG0
M/QR=@@%CN1]/_"?S>[Z"0KS20Z<<^XR=COHG;MCW_3^EN24UFX[ \!^95L8U
MS'M:ZUIBN=WN^V.VOJML_36;/4_P:A=Z+K6..718&$/V-<\'VA]MKM,ES?I>
M]GZ/]&S_ $BO/9F[@6>A$OF6NF"9J[_]NH.15EAK2UM$Q!]KN=CM_P#9^EM2
M4C;3@L#JK\I@9N)#6W65N$B6[W_:7.=^C/\ Z,5AS.GAQ#KRUQ'ID>N\&6;-
M/YS^<;[-[OYS_MQ.ZC*>Y_J,QWL+@&RTSL)]^^9W/]'_ *:;TLR!-6,7;W$G
MW#0Q[OH._2._/24BPZ,5P9Z3WN#J2TEMUCH'MW;?TKMCO=]/^<5JG$JI<',=
M82 1[[;+!!,_1M>] PV93&TCTJJV[3N:QQ CV^[^:9^D_D*9?U6!%-!/>;GC
M_P!UTE-M)0J-Q#O5:UI#B&[7%TM_,<[<UFU_[S/^FII*1V[8;N_>;'QG1$4'
M@';K$.!4TE/_U_54.\5NHL;:":RUP>!).V/=&SW?YJ(H6O+*WO:W<6M)#1W(
M'T= Y)3S3ZNA-M%>+1;>?:;&?I6[1&^8V[OS_4N9Z?O_ ..KV*#*^CWRRH/9
M[0<=[1D$EQ;+A;9M9C?2;]-EWZ7]]$RL_+OZ=8T5^E<[5M8W^U^YINQ:VUU4
M7_:=AL97^E_3V?I/YIZA9D=2ZE56YS\-SZK 'U;; TEH=+,M[G[WU;C[<;T/
MZ5Z?\_Z5B2DM6%C.MVG%=8YK@6-%M8<0#[F64O\ 3?L]KW?\3_VVK?V/#):X
M](!U >6AL@$:O9N]/?M=N_EJ6-?UV\ M;C-VRU[',M;M?\7EKW?]L_I?](M%
MAS0QH>RIUD#>0YS03^<6MV6;?\Y)3A7U]+9=MQFX;*O<"VRIP(=6W<&;=GYM
MSJGV6;_T=7T*?4_2J%S.D68E-C!46&[T][ &M<-KRREUGI'&]1^[9LV?X3]&
MM5N#FMWD7N;ZA9[6V>UH8 ',J:ZEVSU8<ZS^NF]'JA>[UO2],N<:H>XO&YKQ
M!_1-9^<DIR&8_1A2"^UK7LWN8/4I^E^C<SWLH8S_ %_2[U)N-TJZRNCU=I>=
M0RW'+I.[;^C%?J6?N,]-:%/3<S&:ZS#>7/MV[O5M!D#OZCL6ZW<I/PNI%Y?L
M8^QT!UAR7M= =OAFS$VL_-=M9_.;/?\ X7U$IJ4]%Z;MJ:V^_;M]OM;KM+=L
M;L?]W_KB,W!Z7C6U7/RW5.:X["_:PD<>CN<QCOH?N?I%7?3=CUXN1EASR1Z)
M;7>T@,(]0['VUX;M]^S])[]_\U^EM_FU9MZLW)+*Z:;V.>Q[:WUFAS@06>YK
M!=9^;_(^@DIL-R^D.>UC.H,+W_18,@$G^JW>5=H]/8?3L-HGZ1=N^4K';]HL
MM8*J,BE]H]1EUU5;B'@&O]/M>QK=K!^A8^S_ -%K;8YSA+F%AX@P?G[2Y)2U
M@:=NXQ[A'Q4U%Y:(W=R .^IX4DE/_]#U5),AG%QB[<:F%QU)VB4E,]C-^_:-
M\1NC6/BH6T"QS7A[JWLD!S8X/TA#VO9^:F.)C'FIOW!-]AP_]"S[DE,Z:&4@
M[9+G&7O<27$_$HBK_8</GTFI'!Q3_@_Q/]Z2FPH6<L_K?P<A?8<69V:]CN=W
M_M)?8<;P=_GO_P#))*2T_P RS^J/R*:K58=/ILW!P=M (WO\/ZRG]EI[;Q\'
MO'_?DE(K,6NVNBJYNX-\"6P0WZ7MVN2;TO"8\/:QP<'!P(>_EL1/O]WT5/['
M4-D&P!O %CXB"/WU+[-7XV?]N/\ _)I*3)(/V6K]ZS_MVS_R:0QJQPZS_MQY
M_*Y)24F.Q/;3S3J#*PR8+C/[Q+O^J4TE/__9_^T;WE!H;W1O<VAO<" S+C
M.$))300E       0                     #A"24T#[0      $ $L
M 0 ! 2P    !  $X0DE-!"8       X             /X   #A"24T$#0
M    !    !XX0DE-!!D       0    >.$))30/S       )           !
M #A"24T$"@       0  .$))32<0       *  $          CA"24T#]
M    $@ U     0 M    !@       3A"24T#]P      '   ____________
M_________________P/H   X0DE-! @      !     !   "0    D
M.$))300>       $     #A"24T$&@     #10    8              X\
M  +     " !E '@ :  Q #  ,0!? #$    !
M  $              L    ./                      $
M            $     $       !N=6QL     @    9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   ./     %)G:'1L;VYG   "P     9S;&EC97-6
M;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI
M8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI
M8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   #CP    !29VAT;&]N9P   L     #=7)L5$585     $       !N=6QL
M5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M 0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
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M971L;VYG       X0DE-!"@       P    !/_         X0DE-!!$
M  $! #A"24T$%       !     $X0DE-! P     %J8    !    ?    *
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MQ $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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MG2=(OF02&5\8WY^YJM8F1DM(JR+WV%P:&%F+<TR3MFVVSU&?^>]GT[%=#7@
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MBPQ/I:./M]VT?X./4_MI*:9Z7U &6UTR#O$.K^D/:WGI_P!+:W^=_EJ-F!U
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M$>^VRP03/T;7O0,-F4QM(]*JMNT[FL<0(]ON_FF?I/Y"F7]5@1303WFYX_\
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MG_/^E8DI+5A8SK=IQ76.:X%C1;6'$ ^YEE+_ $W[/:]W_$_]MJW]CPR6N/2
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M24E)CL3VT\TZ@RL,F"XS^\2[_JE-)3__V3A"24T$(0      50    $!
M#P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E
M "  4 !H &\ = !O ', : !O '  ( !# %, ,@    $ .$))300&       '
M  0    ! 0#_X3DA:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP
M86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y
M9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM
M<'1K/2(S+C$N,2TQ,3$B/@H@(" \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z
M+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(" @
M(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X
M;6QN<SIX87!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(^
M"B @(" @(" @(#QX87!-33I$;V-U;65N=$E$/G5U:60Z-D,X,S$Y1C=#1C4Y
M138Q,3@U.#,Y,S)!1C Y,#$Q-C \+WAA<$U-.D1O8W5M96YT240^"B @(" @
M(" @(#QX87!-33I);G-T86YC94E$/G5U:60Z-S X,S$Y1C=#1C4Y138Q,3@U
M.#,Y,S)!1C Y,#$Q-C \+WAA<$U-.DEN<W1A;F-E240^"B @(" @(#PO<F1F
M.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U
M=#TB(@H@(" @(" @(" @("!X;6QN<SIX87 ](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"\B/@H@(" @(" @(" \>&%P.D-R96%T941A=&4^,C Q-BTP
M."TP,U0Q-CHQ,CHP,BTP-SHP,#PO>&%P.D-R96%T941A=&4^"B @(" @(" @
M(#QX87 Z36]D:69Y1&%T93XR,#$V+3 X+3 S5#$V.C$T.C(T+3 W.C P/"]X
M87 Z36]D:69Y1&%T93X*(" @(" @(" @/'AA<#I-971A9&%T841A=&4^,C Q
M-BTP."TP,U0Q-CHQ-#HR-"TP-SHP,#PO>&%P.DUE=&%D871A1&%T93X*(" @
M(" @(" @/'AA<#I#<F5A=&]R5&]O;#Y!9&]B92!0:&]T;W-H;W @0U,R(%=I
M;F1O=W,\+WAA<#I#<F5A=&]R5&]O;#X*(" @(" @/"]R9&8Z1&5S8W)I<'1I
M;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @
M(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O
M,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^:6UA9V4O:G!E9SPO9&,Z9F]R
M;6%T/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C
M<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&AO=&]S
M:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q+C O(CX*(" @
M(" @(" @/'!H;W1O<VAO<#I#;VQO<DUO9&4^,3PO<&AO=&]S:&]P.D-O;&]R
M36]D93X*(" @(" @(" @/'!H;W1O<VAO<#I(:7-T;W)Y+SX*(" @(" @/"]R
M9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.G1I9F8](FAT=' Z+R]N<RYA9&]B
M92YC;VTO=&EF9B\Q+C O(CX*(" @(" @(" @/'1I9F8Z3W)I96YT871I;VX^
M,3PO=&EF9CI/<FEE;G1A=&EO;CX*(" @(" @(" @/'1I9F8Z6%)E<V]L=71I
M;VX^,S P,# P,"\Q,# P,#PO=&EF9CI84F5S;VQU=&EO;CX*(" @(" @(" @
M/'1I9F8Z65)E<V]L=71I;VX^,S P,# P,"\Q,# P,#PO=&EF9CI94F5S;VQU
M=&EO;CX*(" @(" @(" @/'1I9F8Z4F5S;VQU=&EO;E5N:70^,CPO=&EF9CI2
M97-O;'5T:6]N56YI=#X*(" @(" @(" @/'1I9F8Z3F%T:79E1&EG97-T/C(U
M-BPR-3<L,C4X+#(U.2PR-C(L,C<T+#(W-RPR.#0L-3,P+#4S,2PR.#(L,C@S
M+#(Y-BPS,#$L,S$X+#,Q.2PU,CDL-3,R+#,P-BPR-S L,C<Q+#(W,BPS,#4L
M,S$U+#,S-#,R.SDS,D9%,C-!,$1"1$)$,4-!,D$W,#)!13DR-D0R1C8U/"]T
M:69F.DYA=&EV941I9V5S=#X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @
M(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @
M('AM;&YS.F5X:68](FAT=' Z+R]N<RYA9&]B92YC;VTO97AI9B\Q+C O(CX*
M(" @(" @(" @/&5X:68Z4&EX96Q81&EM96YS:6]N/C<P-#PO97AI9CI0:7AE
M;%A$:6UE;G-I;VX^"B @(" @(" @(#QE>&EF.E!I>&5L641I;65N<VEO;CXY
M,3$\+V5X:68Z4&EX96Q91&EM96YS:6]N/@H@(" @(" @(" \97AI9CI#;VQO
M<E-P86-E/BTQ/"]E>&EF.D-O;&]R4W!A8V4^"B @(" @(" @(#QE>&EF.DYA
M=&EV941I9V5S=#XS-C@V-"PT,#DV,"PT,#DV,2PS-S$R,2PS-S$R,BPT,#DV
M,BPT,#DV,RPS-S4Q,"PT,#DV-"PS-C@V-RPS-C@V."PS,S0S-"PS,S0S-RPS
M-#@U,"PS-#@U,BPS-#@U-2PS-#@U-BPS-S,W-RPS-S,W."PS-S,W.2PS-S,X
M,"PS-S,X,2PS-S,X,BPS-S,X,RPS-S,X-"PS-S,X-2PS-S,X-BPS-S,Y-BPT
M,30X,RPT,30X-"PT,30X-BPT,30X-RPT,30X."PT,30Y,BPT,30Y,RPT,30Y
M-2PT,3<R."PT,3<R.2PT,3<S,"PT,3DX-2PT,3DX-BPT,3DX-RPT,3DX."PT
M,3DX.2PT,3DY,"PT,3DY,2PT,3DY,BPT,3DY,RPT,3DY-"PT,3DY-2PT,3DY
M-BPT,C Q-BPP+#(L-"PU+#8L-RPX+#DL,3 L,3$L,3(L,3,L,30L,34L,38L
M,3<L,3@L,C L,C(L,C,L,C0L,C4L,C8L,C<L,C@L,S [1$9".$8T-#A$03DS
M.3$X,T$Y-T0V-C,V13DQ,30W1$(\+V5X:68Z3F%T:79E1&EG97-T/@H@(" @
M(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T
M83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T
M(&5N9#TB=R(_/O_N  Y!9&]B90!D      #_VP!#  8$! 0%! 8%!08)!@4&
M"0L(!@8("PP*"@L*"@P0# P,# P,$ P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  +" ./ L ! 1$ _]T ! !8_\0 T@    <! 0$! 0
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M6#UK*VCN+:YY0O1V-K!':J"PXO\ %;Q"/X67^9^?V<$+^5NAIYNT_P SK<7
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M=K?G?RYHEI!>:C/)';W,#W4;QV\\]((@A>1Q"DAC1?5CW?C]K%+<Z!YB-KJ
MC>672KES;F9)K>2"X"&-ZQR"-P?3D(^-?B1_Y6PYJ,3@N;><.8)5E$;M%(4(
M;BZ&C*:=&7N,4KC7DCC1I)&"(@+,[&@ &Y))PKUCS1H^DZ?;:A=2.]G>20PV
M\T$;SAY+E@L 'I!C^]=E1&^SR9<"6'F*PUNZM)]/)DMX;JXMI6=71TFAB82(
M\; /'(CU1DE5?YOY<D/(5I7?*+*!4G;$;R^L[.WDN;N9(+>$<I99&"JHK2I)
MQ8LH[X&NM1AMIH(Y$D*SEP9E4F*(1H9"TK](UHM%9OVOAP/I?F'2]3N[NVLY
M#(]F(&D?B0C+<Q":)HV.SJR'JN,U3S/H^F3Q6]Q*6GEN+6U,42F1D>]<QP&0
M+_=H[JR\V^'#3FM0*BK?9'C\L*-4\U:;8:DFE^G/=ZB\/UE[6TB:9X[?EP]6
M2FRJ6!5!]N3B_I(_!L':9J=GJ>GVNH6CEK:\A2X@+ HQCD4,I*M1EV/1L$\T
MJ!45)H/GURO4CK3D*UI2N]3OB%I?I<1\FCDMF]66)8YP$=O2<IR45-4?CSC/
M[4?%L;+J,:75K;I%),+II%]>)0T49C4L?5:OP\J<5_R\7^LVWI^KZJ>F:T?D
M..W7?IVQ3&R1QRQM'(H>-P5=2*@@[$$8G965G8VD5G901VUI H2"WA4)&B#H
MJ*H"JH\!BV;$+NPL;Q8EN[>*X6&19X1*BN$E3=)%Y \77]EA\2XOFS9L)_,T
M)ECTX*RJRZA:N.;!*\9*L%J15N/+X?VL.,V;-FS_T/5.;-FS9LV;([YZ.NPZ
M1%?Z*9Y;BPN(IY]/MN/.[MN7": <ALW!_5C*\?WD:_L\LA=@WYB6^EV;ZQ+>
M37MGJVGZ9,$A65+F%+PO<WW$1/QAD@E1?4'I>G]7;[&1J.R\VZ>;>^A76(]8
MT_3-122X-M)/)+,-:CD6%G:*3U8Y8N<BJGVXOC7X<F/YKV.JW%V'AAO;O3Y=
M UNU:TM8WFB>[FCA^KK+$BM4NHE]/E^W_E84:A>>>[=&T^WNM8^H&\FBMM3B
ML6N+E)&M+6:U!0+ &M?K!O8S(X]!&X13LL>2/\QM/O+AM)O;6:ZL=6MH+H17
M<=HVH6A$JQ"6TO+:,.6BN>/PO&T;IZ7P2_%Q>/"^_,>&3T;6RO-.N[32X9-)
MTBVM_6T]E.G4>WDN9&$:307PHJO^_;C#PYPO-FUG4_-\>D27&C#S'-'>6&IK
M8)<6Y^LQW@BMYK0,G!9(PLJW4:27'V_BC^*+T,,(5\VF_-TUQJTJR^8H8!;3
M14CCTUH^;,%$8XQK(SIZX;]A/WG\Q%IK_F!I7EZRM;"TU9YK/1BMZDT;22?6
M(M2B%P8FDXF:X>T-PUO^]_>*J,GVN6'.EOYW_3>@#ZQJEYI3-RE%S ]E*L+S
M3LLDI/J*ZI'Z44MO>>E=>GZ$T;^LTZ,EYSNOS C\R:M^B5U069MKN* PQM)%
MR.E\[9X>(X*1>KQ'PR3>KR]5UA:*/$#)YU"R6-TNM7&DRSCZQ,J2?65:?2HV
M0*P57:W6^]82J@98I>"/^XY88ZSIFKR_EQY(MX[*[6]L;G19KN)(2\\"VG S
MNT=&WCXGX:?%]E<#:G%YK2*QETS],S_5KBYEUEQ$+-[ZSEN$),<2\ M['SXV
MY*Q\[:WG^QZENV,UNV\W:E8Z_;75IJS7HFD6(Q\#8R6K7\$MG);1MR_?Q6J_
M%\*\'^L?6.?[K&W7_*P8+J&&T@U>>VLM1GD@E:3D9+5=2@;@_-T:2MF;CTGN
M'D7T?W?I>K^\C+)[CS_I6AW-Q=W&JI++;7$9^LR;-/\ IM4LH8V)'IS7%C)Z
M2O'\?!N7][&F+6[^=K\6T%G<ZT;5;B[CE>W(]>TO/K*7%O%.]RZ\[5+)XX%E
M99XV_>^M#ZKKDTUZTU2R_,33/,GU*;4=)73;C3G2V4226D\LT<HF$9(9DG2/
MTI&C#.GIQ_L,V%&M6OG"?4V;2K"[TU9TM9]%,4@6""X-\[WYOHHW],^O;M'(
MPD]3X?5CCXW&$E[I'G1[.Z>V/F 7#V>M&W7ZS*"+F+4.>D@UD '[AG_R9(_@
MN.:JB8I?:'YXO-4NY>.L)9W-_K *K=RQ4LY+&-K,($E!C_TY/W'#C(GQ*W&!
MVS7=A^9=QIFHR%-2CNIETJ2WB>0O&94T]TNHF6&>*:*-KKCZDD#KPN.%S^^B
M23D_4]*_,8S:NUM#?GU%M'M^-PZS1O'=VIEAC<3"WN(GMX[AO5].WE1?4AF]
M7UER];T7\PY[;5C!%J7Z1$>JQSRV]UZ272RW"OI?U0>LJQ2014#-^YX*DT<O
M/U/C-[^'5]*\@?F!]8DO;..W;4+G1KB:Z8S+!]561'BG]1I$7ZP)>"N_P_ZF
M$\OEWSLLWZ1T]=2GTB:>;T--DO>=P$NM*:)Y7>2?CZ7U[TY$7U6]+XIH41<I
M?*_G>33;V6:+4X]4*Z7'"SW?UB*BVD/UP>A]91)8S<P\9PLD$K<GDAE^US5L
MM!_,2WODYV5T09K>Z/#4:PQJVAO:SP>I)(96_P!R"I(Q])OM+<KSDQ/3?*'G
M"6*VM-1M-1&G_79)[B%;X)6&?1Q"Z-PNF8@:@.5#(_QMZW[3X??ESY9\P:=K
M&I7VMVTBSZGIND)-</,LA-Q:VOH7,;A7;]YZ@Y^HHX,K?WG+ED8T/R)YYL='
MTW2ULYK22TM[*/3[F*[7A9W5M?.]Y+(!(WJ0WMNR4HLK,B^A)%%AW^:&D^<;
MK7+&]TF"4V-BUA-)<).H3A'?AKR-H6<?:M?Y(I/77]WS3T^$HGS=9ZKHFK^9
M_,*VCW^F:OH\5L9(9(DEM);(3FA$SQ#T)A<<N<;,R2(W*/XN6(7_ )8\V2ZO
M<2I:R0UF]6"XM;H+"+!M-,+Z>$YQ'D+SXXV]-$^-;GU4D3CA-IWD7S,NGV%O
MJ&DW-UZ=QY>N[A9[N*>ES:QE-2F!><]E56X_WO\ NM&QVN>4O/%]I%S8RZ7<
M7L$L6L16=NUY$K07$]^\UI.[--1XGM&6)?C>2#CZ7I<)'Q^I^3?.UW/JDDMM
M>R74EY&RW4>H110SVC:E%<J$B1HY5DM;19(&]:7X?L6_JI-^[9/Y"\T"WO\
MZOID@E-AYBT[2I/K48EMTO+@3:?1_5Y!67DJ_%RA_;XKFU3R?Y]N9]5,-A((
M[W2M0L-[N(K(UQIMO';!U=V^S<Q2KP^"&#FTD?/U9),FOFO1M7O/RRN](L[3
MUM6GTY;6.VYQI21D5"#(QX44]3RPL\V>5-=UGS!<7]E%):2G0Y(M/NVN.*0Z
MD78Q<HHW/QHCL/6X/Q_RLC%[Y%\Z2:;!^C-*DLI1++>PVTVH1226MP)[63BC
M*!!#'*L$Y3ZLC2?%\4D*W$ZY6I?EGYE>/4[>#3$*S2>8[BWFBN$C5I=3*36#
M%>2'E%+\/)O[IH^:XK??E_YO>*ZMULY)=*DO8+F?34O(HVN?6TU;>YD$CB55
MDBO T_Q_WO+UD_?*N+/^7&O27=PKV;,;FXNX9+V:[]8-97.B"SXN';FZO?*L
MCCAS;^^9>6'VK>5];NOR[T#1;?3TM[VSN=*EN[2"9(UB2RN8IIC'*.*\R(FX
M<?\ =C?[+(J?*?F"6TD\O6\":C!H6K7":D/K(MY=434;3U4N999$D'UZW%PK
M2\EXNRM+"\;^G&K]6\MZQ!Y@T_2M52V>75+J[@T[5GN'DE>"319X5MG5U,AC
MMY@M7=_WC>G-P]>5\N3R%YZGBN)KK3HIK>ZELS=Z/]>4&5$TPV,K>LT3QAXI
M@LZ<E^/[?))D3%-:_*OS%?+JT @AGBN+*.*,7<PF+30-9L@BG93<*D@M7$JW
M(FX2>G- W[V9,E_GKR1<>8;?36LQ#:W48DLKVI^$:?>1&*YCCH-Y(OW<UMMQ
M]6)?V6;"#_E7/F*;3-*AO4M[B^;Z]%J]P6 012Z<VGV]%X_O 46W:5?^,N(Z
M=^7OF&+4M-OY-,MK>XLI]'*O%< ^C!9VTD-VL9"I]OGQX<5]9?M_87#3S+Y&
MU.]\TWVH6]A:W%GJ4NB/<RO($E]/3KMI9T*\#S#1<.-7^/[&%6D_EUYF@U'0
M_KEI#+96(B$+)>R1-8&TO)Y4X*B5GCGMYHH_362)?W?I3>I#DJFT?7]+\[ZC
MK^FVD6HVFLV=K;7,33"":":R:7@REE97AE6?XARYQNG)5?G\)'>^1?,UWKLM
MW<I;N6O$OH[V.3XEMOT>;672PK*&^KR3_'_OMED:1T]5?B*-+_+'S#8MITR:
M7:QW-I_A]GE2XJPDL0Z:DX8K4M/"5AY?:N(_AE^%,0LORN\T6D5K+'IMH+JT
ML]*$7[\'C>6&IM/+*&XUY&R;T4E^WQ_<?W6&%O\ EWYH6ZTYOJULB6>IW]W1
MY5DB^KW.IM>(O IZD<JQ%?1FMY(WCF7TY/4@; D'Y5^;ETV*QA-O9GCJ<<-Z
M'47%NMWIT=K"9&ACC6X=9DX^J%23ZNL<DO.ZY-B]_P#E7J^HW<=W+IUC#:R&
MZ:31C)S@A:32OJ2^F/3X'UKCC(_PKQ1$D_O<Z/Y9AUBVTR"SU.*)&M8;>&.6
M.5I3(5@02L]43C2;U%7=^:*LGP\N"FV;-FS9LV;-B-S:I<>ES"DPR+*I90U"
MOA7[)W^T,6S9LV;/_]'U3FS9LV;-FS9LV;-FS9LV;-FS9LV;-B-Y96=[;/;7
MD$=S;2;203(LB, :_$K J=\NTL[2SMTMK2".WMXQ2.&)0B*/!54 #%<V;-FS
M9L9/!#/$T,\:RPN*/&X#*P\"#L<<B(B!$4*B@!5&P &P &7FS9LV%/FUBGEG
M5) .1BMI9 O6I12P'TTQOG&40^5-7E,*7"I:3%X)*\'7@>2MQ(-"OOAP!04&
M;-FS9LV;-FS9LV133KGAK>JJS*>6MQQQMQ.P.FPGC51NWVJ\OLY*R <V;-FS
M9LV;-FS9LV;-FS9LV;-FS9LV;-FS9L__TO5.;-FS9LV;-FS9LV;-FS9LV;-F
MS9LQ (H>AS  "@Z#-FS9LV;&ROZ<;OQ+\06X**L:"M /'' U /2O8YLV;-FS
M9L+/-#E/+FJ/2JI9W#%>YI$QI@/SI,A\D:O+(K&)K&4R*AHW!HSRXFJ[\>F^
M'XS9LV;-FS9LV;-FR*::]@=4UR-(QZD6M0>J-MI7L[8AQ3OQ89*\V;-FS9LV
M;-FS9LV;-FS9LV;-FS9L9(Y5HP/VFH?N)\1X8_-FS9L__]/U3FS9LQ (H14'
MJ#FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-@'7J?H/4:CD/JTU0
M:$']VWCMA;YBN(I/(E_<'X8GTYWW19*!HJ_8<A&_U6^')!FS9LV;-490=#6C
M TZ[],9]8AJZK(I=!5D#"HKTKOME?6[42>DTT8E_WWR'+[JURC>V88*9XPQ'
M(+S6I'6O7*;4+!/MW,2UK2KJ.FQ[XW]*:9Q1OK</&0<HV]1*,/$;[C(3;ZO8
M1:CK92XBY3>8;52>:$!5L[,,_P!JI'[)/[+-DLN/-'EFV%;G5[* 5*@R7$2#
MDIH1NPW!Q)/.7E!P"FN:>P) %+J U)- -G[DXZ7S?Y3B!,NM6$8 J>5U"NWC
MNV!O^5@>0B0/\2:54[C_ $VW[_[/*7\PO(+*&'F72B#T/UVW[;?SYO\ E8GY
M?U(_Q-I-1N1]>MMJ?[/ LWYK?EA#+Z4OFW1UEKQX&^MJUZ4ISS#\UORQ-*>;
M-(JS!0/KUO7D>@IS]\9)^;OY6QB0OYMTD>G]O_3("16G8-T^)<#O^=?Y2(_!
MO-VEU]KF,C?W!IC9/SI_*0,H/F_3!7H1<I0]NH-,<_YV?E&AHWF[2Z^US&1]
MX.4/SL_*,L%'F_2JML/])CIO[UH,0E_/G\GH@E?-=BWJ-P01NTAK6FX16(^G
M-_RO?\HJ@?XFMJL_I<>,M0WN.%5'^4?AQ4?GC^49!(\UZ?Q%:MZNPH:4)I2O
MM@:[_/\ _)ZT8K-YGMJA2W[M)I10'B:&.-@=^PR<:9J5EJ>G6NI6,GJV5Y$D
M]M+Q9.4<BAE;BX5EJIZ,O+!.;-FS9LV%VLL5^HD/P_TN(=Q6M13;#'-FS9B0
M!4F@S__4]4YLV;-FS9LV0:?S?^9D-L9?\!\W+*JQ+JMNQ^*14!:D9I0-S>G+
MBJMEIYG_ #69N/\ @>U3K\;:S'3:E/LVS'XOEC3YE_-TLI7R58A.'QAM96O,
M]*4M2.(_:S)YB_-]G3EY-TY$HW.NLU->BTI:??E7.N_G.'1;?RGI#!V(,C:O
M*0J@$U8?4U.Y_EY8@=7_ #WJ?^=;T"G;_<G<^/3_ 'EP5!?_ )UOZWK:/Y?A
M*\?0_P!R%XX;?XJTM!3X?L_Y6.N)_P Z?1'U>R\N"8\00]S?%5K]H[0#E3P^
M'$GG_/'T"R6?EKUV!(0W%_Q0T- 6]'X]Z=H\=:M^>#*K7*>6HB5^)$:_?B?F
M0O+%8X?SF,E9;ORZL9ZA;:^8C<[[SK7;CB,5K^=QGK+J/EP0ANB6=\2RT(WK
M<?":T_:P5:V?YN$.UUJNA*QIZ<<5A=LH^(\JLUVI/P\:;8G-IWYN&XB1-=T=
M8)&8S2KIDQ:-0H*@*U[\=6^&M5XK\6(2^7OSB:5F3SCIJ)Q'&,:.2.0&^YNR
M=_GE)Y=_.-F#2^<]-0!=TCT8D<O&K7=<67RW^:I4%_.EJLA;XE32$X!:_L\K
M@M]GQ.(-Y1_-=Y1R\_I'"%W]'1[4.6)-=Y'D VIQVQ.?R3^:[,IB_,=T KR!
MT>Q->E/#PR_\%?F4JA7_ #'N22QX-^B["M3O0T2E!1N/_&V-G\A?F:[DQ_F5
M>1J2#Q.F:<:$#<5],?"<4D_+WSO+:RP2_F+JO[V)HBZ6NFQD%EXA@1;\P?\
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MT5O#9-$Z#TH2SM)Z 9"SN_ _76;]CTN46= D_)?\IY&5G\IZ9R7C0BW0&B[
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M0\7C^M0\@=]B.5:[8E/Y[\D6\S0S^8=-BF2G.-[R!6%145!>O3 Y_,O\N@W
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MMV]I=6FE.\VG1:38O$=3M[M(1-&(XIV?UH"]RD4?J?97AS_N\Z;Y:\F^6Y-
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M/^F+X<2IKL!(%]OLXM+^6^FNU4UC78NFR:M>T^&E-FD;PQ*7\KM,E5UDUSS
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M&_Y77^5W!W_3T05#1ZQS@B@J30QUX_Y7V<(/*_YN?EG'K/FBY778#!>7T5S
MZB5^2"PM8F- I*T=&7A@;SA^:'D>:+7F768TM[G14BC]2.5 TCR2A0BO'\4E
M'IT_XBV3!_S<_+I$5CK4;*PY!ECF;8=:\4-,:/S?_+LQK(-6^!ZT/U:Z[-Q(
M/[K8U[',GYO?E\_V=2D(&Q/U2\H-J[_N=OIQC_G'^7:!V?49E2-2SR&QO@@4
M=^?H<:?3E_\ *W_R]2-V?4Y%2*OJO)9WB! !RY.6A 1:?M-\.*C\U_([>KQN
M[EA"%,A73[]@ WV2"(/BK_DXX?FEY+(<BXNR$^T1IVH4^SSV/H;_  BNV-3\
MU?)3FB3WC"A:HT[4/V1R;_='[*_$W\N+V_YB^5YXC+ ]]-'Q,A9=-U T7<?\
ML_ME3?F5Y3AVDDO1NP---U!J%#1OLVY[XW_E9WE 7,-JTMXES.XBAB?3M04L
MY%>(K!UIU_EQLGYG>5XVE#1ZG6&G.FE:D?M*&%*6_O@:7\WO)Z(_P:J70#G&
MFD:F76HKT%OVPJ\L?F1Y:CUCS)&ZWZM+JBLBC3-0)%;&U2DE(#Z<G-7^%^+?
MM?9PZT3S7I,,E]##:ZE()+NXE+)I]Z5#;,RDF+X78D_"<N3\S-.1@!H?F!P1
M6JZ/?4_&,8P?F?8<%8Z!YA!/5?T/>5'SHE,5_P"5DZ>5!71->8DTX_HB]!%/
M'E&!BC?F%:+*\;Z)KBE!4L-,N67I4 %%;E7I\/[67>^?K6TN3 VBZW+10XEA
MTVXEC(:NP95/Q;;JWQ8C'^9-@[JIT/7T#$ ,VDW@&_C1#2GOC#^9UC4!=!\P
M$L0%!TFZ6M1R/VU7[(K_ ,:Y:_F7:.\:)Y?\P$R&@/Z+N55:&AY,P"K]^+3?
MF'9Q\..B:Y*'-*IIESMN!5N2K0;XQOS&M!ZE-!UYC&G.@TNY^([? I*@,^^(
M2?F=$@4GRQYB(8D#CIDC=!W .U>W++D_-"S1:_X=\Q-0\6XZ3<[;5KN-Q_JX
MX?F7;%48>7?,%'[_ *+GV':HZ^^7+^95HA-/+WF!VI6BZ5<]/F0%^BN4/S,M
M22%\O>8#0\?^.7< <J5/4#I7[7V/\K*7\RXG^QY:\PL"G-#^CI%#"M*?$RT:
MGQ4;C_P?PX?^7]<.L6LEQ^C[W31'(8Q%J$/H2-0 \U7DWP&NQPSS9B0.N;-F
MS83>:%0P:<S&A34;,J:5%3,%WW'\V'.;-FS9_]3U3FS9LV;-FS9SS5=7T:\_
M,W_"]Y!>1<K9+H:C#J-U;Q_6-BL/H1/&HK&G+D#\?+CP^/(9K7G;0[;5-9M4
MT?6)[ZP^M1V=N-3U/A>R07D5I#]76)VY/+*\ZR@#G$MO_ON5'PLN_P R_+<D
MD\-AI=]<+#),D5])J.IM$UI'Z?H2BDJ^I)+)]9AX*_*.6TDY-DJU_6/*.G_X
M<2YL[FZ_3UNSZC<I?7S6]K!Z=$>9DFD0+)=M%;KRD_G^/ED7M_/=C=P6\\>A
M-9D1)<7>GW6H:@MU/*\=H\L%JHD =W^OJ]O)^]2=%^RG+]V<^9O,'ES2_,>H
MZ!96OU2*W^J0IK>HWNHQV NGF4W$+OZL<9:&"YCGXI/SY<^?[+9'/TYI7H--
M8Z/;/?32116]C!=:C/=Q>K]54L\2W$;3).;A_JV]MZG&/ ZZWIHLM8F?0+.!
M;33K.]MH)+Z;D\ETMOS,G/4$D"*MS+^[:**)75(GO/4PZ\BW'E+S!YNFTV70
M[<13:6FIP"![PW+GT8"S,3.[0AVFD58YH8>:^G)%-<\WQWE6UTW6O,FE6MMH
M>G7-K=))=:A<VQFF:*'A;ND9,UVG"6W-QZ5Q*BSOZG#_ $>+DW%;4[7RFE]J
M-M<6ND0QVEVED_UN.ZD.FVD<C0I=:@[7'I.EQZ8: 2-;?#)$[>K'\6$<$*ZA
M')Z7D?3[6:2TGNK/4OJD\R2FVL8KMH&C+HX:>:3]UR;D\$GP?OH&Q>Y@DTO4
M;JQ?R-8W<4%DRV$GZ/9A/J#6EI<) H69W?\ TF=O4B:)(_2B_=S^HLV&>DV^
MEZO/)$WE_3='U#ZB&M-+;1UED-TMH[RRF5_@ACANHY+;TY4]-_L\O5E1L+=6
MB^IV_P!7M] T:\UB2PBG@TQM(A^LW/JV)N&OD5!Q6&UN0EKZ7INGP,LDC3.N
M&EW8VVG^4K1-0\@:5?\ FF^O[FTMM-FT^!!2!2(3(8E:-FD"PGUH/]'5'9OA
M]-L-_(UYY0\PO/;ZOY L]%LG/^BO=Z?#%ZADF:**(H8R.3)0JX?X_C_=Q+PY
MEM_YBLHM>U/3])_*F"\M-/EGCEF>R-N;E(54B2 M:&)@W"<(H=^;1Q_9]5,6
MT#S=9:GJ=G9W?Y:Q:%:R"VGO+N^M%].-;J.:5P"L 42*D<6[M_>2^E(BMQY"
M-4\SV&F^:KO28/RW@N=-MII(3J<-N-RD22R?"+4Q@LC>HO[_ (O'&WQ>MZ<+
M =1\X6<-L-3M?RUM1HJ<KMM2NK=81Z,:&24\'MT9)Y4,*VH_W?.SP-Z;)\0[
MS]K5K:>7-&OM&\HVUU#?7,L.N6BZ;];DAA@1UGA/IB%8Y%D'IR2N_"-5FX>J
MRJKEA\\:U:V=\L?Y7*7M6ABDMX[*3A=\_0'JQN("#''(\W^_>2I&_)/B;)1Y
ME\YZ_I?F._T71O(CZG:65O;L+U8VCCEB=&>>"*D+1NZJJ1QIZGI^HW[SAQP+
M8^:/-LNDZ+=IH7Z,O=2U&X5+>+3IGB2P@7X!.6CCFMWG^Q&TD4?[Q^7PP)RQ
MMCJOYK0>6M3UK4K&*)KAX$TZ*&T]>]M%DN6BN+E[6%0TO" I,MORED:3ER?T
M\07S]^9$=O\ 5K3RA+).;B* ZC);26[2%80\TCP!71)):,8V]9K5/[MY_7_<
M9,?RX\P>8?,.G3WOF#1QH]RK0TLF4\XW>!'D4LP!8J7_ )?@_NF^),EL=M;Q
MLS1Q(C/NY50"3[TQX516@ KUH,N@S9"X]<T7R]YAU^6]81?I'4(>4@XT01Z;
M"SR2$D<8T2+XF_RLB/YFZ]8:CIFKWNFQM=QV,-G$H% )93=121F/D?C3A.7#
M?M<'P'Y$UW\WA?Z3>Z_8:DVBVLEU:Z@)U)N)$N6"PSM"L4,LWH30$J5MX_2M
M;G]O[>&_YC:C^;1UJ\B\LVLPTSC96UA*H%/KJ7,=U-,_$&3ZH]KZEK+(?W?/
MX./+(Y'J_P"==U-J<EWI]]9W,MO?3Z) GKLD<MQ',]M$YB3ZNSVX>*)OK,BI
MZL?[KXL'I>_G )9WN+74EUDS^E;Q1!'TTQQ\TN)6)-%22/A-:?M^KP3_ 'Y@
M*RO_ ,[[K4--36[:\L[*VFL(;ST$DD]<V\;BZN/]&(;TYY8_AC9EBX2KZO\
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MX;91</90QJI6LBR+,D<D<$9E2/C_ '?-4PMU_P S>6=2TN.35?+,VJW$%W-
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MOTOKPHI5$&L7X5:@<B*2\JM2M2V(0_DWY/ABABBN-72* $1QKK&I*N[%^@G
M^TS'_99$/.7Y>7^G:Q96OEV74&M7TW4YU:?5-7EI>0QQ_5_4X7(_=?%\"+^\
M>3_(QVM^2-0U+\NK*72FU>S\SNVG1WH>[U&0QR7/I+=E5DN"JI"LSRNZ<D5H
M?\AL@!T7\RH-,OO6T?4HYFBEDLG%WJ=Q-+Z2Z@5DFX2_!/(T5G\$;\&3@_\
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M9V7-/H'G:2#A%YM]*5=GE&GV[= /V2U :U;$#H7G1@UNGG7_ $D1AF/U"T)
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M')UIIT31]-M;2&[46@9+:U,LWJ;\*I$K,3_NM?A7^7+D\U>7([&:_.I6[64
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M1K6/.WYP"]GM].\M%TM7DECD$;QBX6*^>-8A(_J(H>U0,_PJ[<_5@^UQ4O\
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M+<I(>7HRLDC(;A5=5^+G_=,(\J>0O.MIY9U[].:PK^9]8/JQ7-FTRI!+"6:
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M<>:+81^7KZ\OH[.ZBMI7EC2V>188S'"9'/KJD;1R.G-W]1.'%HGQ"'\P//\
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M3_:PZT'R-^5&MS:E96_EQD.DW;VDTDRW*HSP-3]W*7HZ_P"2&^S^SPQ#S=Y
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MXPW@64']?OF-U:AN)F3EMMR%=Q4=_ 93WMG&:23QH32G)U'VMAU/?*&H6!(
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MTWO+=KTR&$R(TL9*E&(#QQR$+]CBOV<"7-UY)M]1O+>;SSJ<5Y920QW4#7I
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M[[6;6/-GEZPN[>UD\JZ)(MQI4%ZD@M;=E6ZE8DR2^B\OIV<0_?>HIFBX<O\
M2EF^!P]YYMM/KS6P\I:!J&FP0RUUBUM%DL#?1VUS,525N+T=[?TU_=<7Y/\
MZ3]GF9:7=W&IVUK-=>2-%LM(U#5X],0SV*5E@E:2-W0!JG@8-I9$C2=94XQI
MZ?[PGB\YZ!-:LP\F^7KR=8XX5T6"*+ZX6<6[+(P= %M;AYS!!(Z\?66)^;J[
M>F;7/F;RRVCZ'?0>5-$@M]52\=K.]@BCFECM+Z*UCMK=54JUW+&_J>F>?%H^
M/'%DO+!_)$_F"Y\DZ4^IR7$5CH%JVGIZ4_UB188B&B-U,\7&C,?1@?C'_<Y%
MIO._E*25Y[3\OM,^J1^L#<SV"@QB"%#);R*XB5+F&\:Z@=79(^,7/FD?QJ,U
M?SCH%G,D=MY(T>7E:6<UOJBVT$EK&L]M-+=12R1%H@T2QL5XW#Q21>K^]^''
M7_G?0+?5XHI?(VEWR->06NGZU:V:O;32->^E=SQN W&)8#%,AY\?6]2/U7XX
M7:=YRTR2WMKQO(&B7,-VL<QFM;:V;ZM<23VT,(F5))S'\=Q)U].5.4+/"B\\
M-+W6M%T=#/JWDO1]12VOKZ.\>RL%B,%A97C6YF5',OJ.RQ7=S3DGV/23^;$H
M==\MR:>EQ<>2]!M=1F@,@TMH@;Q_W=U*L\:A5_T>(PJMPRM\/^D?'_=\QCZ[
MI6I:M%80>3]%U=[R=8(=5MK&*6*X6LC230I))%ZB!8FCY?6/@EAF_>2? F.L
M=8\H_6;^34?+OEU!:Q3@6'U*NHW<L!E99(% DYPA[=8&JG]]R;UOL1,VUOK:
M5+>Z?R=H5M+'8F2^TZ33O])AU&WOH;*>/UN7'TN,_K0?N^?#A^S@>3S3H5JH
MNO\ !VA7T9=I)(;*V!N;.W2*[E>WN 5/*]@%KZCQ+Z?J+ZJ1QK\#R&NKW?DV
M&TTJ:3RIY?M9+BSTZ?4+Z_@CCM[.;52SHS-Q'[E/JUQRY21\YOJZ<UY,V!8?
M./Y?0C3+;4O(VG"6=0AN%BM1&SQ^DTYMHY%]>1$BGCN./'GZ//E]CXG:9Y[_
M "YU6QL[N#R1:(MT LQ:WMI5B=IY+>):<4+B7ZO+\:\?37CR7XL0T[\Q/RSU
M*!Y)/(VGQ@)+<R3 61AH\K0QS>JR1_NI2%]:9E7T/4_>?M\1,7F?R+&-+^O>
M2M+,%UI)U<B**$O&KK<21<8VC_>1M;6KR33 _N6:+E]M<&ZK>^1 +"*#R=I<
M<^H6,5QI-G>6\4=Q,\]X+>&-(PO+>%GN)*?O(4XM(OVL)K*XT'4FTYM,\H:!
MJM[J<ID>#3K03/::>D2AEN/5>VC^LQF6!)5$B\?4_N?A^(P\SZ[^4FD^8[W1
M+KR3:7MQIEW I:*"V8N;U1+)((Z;\"Z)Z1^.9VXQ)A9'YD_+[ZU;"+R+I":0
M\')9S):MP-P[)&L[K^[M:.D2W/JEF@=^'QX81WWY:W6FZG=Z=Y!LQ=V=A;W%
ML+B"#TGN;@BW6V/$,\?"218W?A\7%W5?@PHU+SG^4%M;7<EY^7D ^I0P3.OI
M6P!GN0C-$E>+!?29I(Y"B^LL;*B?9RD\T?EA-K%VMIY'L)[.SB]6/TE@DEG/
M,LKET8I%QA]2=X91ZRK_ *Z<C/2M5_)FZU^STF3R;I]JU]<W$"SR&V:-$@B6
M<R/2JQLQ*H\)/J1M\,GQ?#@[S!<_E-H&KWD2^3;:1+>46MU>QK#$OK,@:!:-
MQV:561Y6_=V_HO/(ZHF%L?F;\JHN3R>4[,7+3HMJ(YK<1F( QF>6=I%C]"*Y
MCDA^L+SA_N>+_%A%IFO>5U\@WKWGEB)+^3ZT\-Q')!'17N;@VB2L\BKQ5%;G
M+S]&'G'_ #9*_,WF;\KM(ETBVNO+"/>:OI\>I:?%-/!#$9;H>DEN\DDO%)"K
MOSE9?16)9.,C?8PO_P :?EM*)'G\MP#E-(-,5IEA:5!$BL6221&FD,\L=O\
M5XA+(_\ >\?3^+ \GG;R$\4]M!Y1MQKEM$L\UN)_W8Y.[<6=2KEO29)Z<>,O
MK/&O)E;!TWFO\JY;V!;CRU.)0RPV\T%U\$?+@]I_=SKZ<]S(ZQI'&&G1O@EP
M+HWFC\J)94BO?*DEI>,@FNWAO$N!#5'=?1*W'K>IZL4L;QPQK);LOJ3^DGQ9
M5SYM_*[3=,N;JZ\IW*VUHA,\*WA=D;]U&457F5>;3W20H4/QKZDO+TU^*0^7
MM2\A>8+^+3-/\OR/I,T%S<37;W^T4=ND?-7@]8R1R.\RKZ;<.4;>ORX/A.GG
M;\MFTY)+30+E-5G:,0Z=?WK)Q22[%N96<SR+  \<?[S_ 'XT2\OM,MGSA^6Y
MNM1A?1+U[>.,+%=&^FBA*3K (P\LEPL4579D>X]3TX/1X.ZOAC?7?D-=!74[
MKRO>7"W-[)IVGV=G?-+)+%"P224DW$421K/RBXB1_LI^P^1UO/'Y73K=P:=Y
M6U2XNH/JH2V>_FA65KJ,R.%<7+H5MBBI+3E]IO2Y9(_+<OY<>9-2EM;#0-6Y
M6JW3/,;VZ2-HK=8PLJ W2O*MSZW"']WS^WZO#(W!YB_*B;S/I^I:9::L=+@A
MG34[D7UVJV[-);&.4,;HM(@YHLL,'+FEPDG"3C\(W_'WY3M#IU\VB:^@U"X2
MS1?K-ZLD=PTS0QI)&+H4Y)%+-4<OW<7Q?O."8KYHU?R/IGGJ'1IM/U)(-/NN
M4VHI?WCQ.L=C)+."QG_<M"TUN :JTK<EY<$^)./SQ^6<^E0W%IHNKQ/)IYN(
MH+F_O(BR)<RH]NY2YD<3_NC+^\7CZ3HWJ<<6TWSC^6EUYCL=%DT[5X&U!D@B
MD34+]UBE"UG6Z9+GTUC@D:*-'1Y49G9_[OX\G?E7RSY4UK3EU%(;RWGBEN;*
M:)-4U!U5[:XDB=>0G4."ZEMU_:PS'Y;^5U^Q^D$ZU*ZIJ0)J2=_](WW8XG%^
M6'E6(?"VI$] S:MJ9(6H/$?Z1]G;ICO^5:^6_JX@];5/3!4C_<MJ5:* .-?K
M'V6"T89E_++RJLK2@ZB7;[-=5U(A*@_8'UCX>IR_^5:^60C*LFI+R%.2ZKJ0
M(-6/('ZQ]KXVWRA^6OEM>8$VJ!7%"HU;4Z"G<?Z1]K:F7'^6_E^.-T%UJS!Z
M[MJVI$@D<>2DSU#<13*/Y;Z+ZAD6_P!94DEN(U?4: DUJ 9STQO_ "K;1R_)
M]3UMS0#?6-1 J-J[3#<XHOY>:4KA_P!)ZT6"E23J]_N#3J/6IV[8Z7R!ITC*
MWZ5UI HH575;T [4W_>UVRQY$L@A0:MK-*L:_I*ZK\1)Z\^U=L2C_+NQ2+A^
MF=<9N)7U&U6[+4/?[=*^],E$,8BB2(%F"*%#.2S&@I5F.Y/OCLV;-FS93CDC
M"@-010]#A1Y.*?X2T8(K(BV5NJHX*L.,2BA!"^'AAQFS9L__U_5.;-FS9LV;
M-A%YQ\V1^6-,&H2Z?=ZA%R E%HL9]-20"\C2O&H7?L6=OV4RK;SIHTEYI^G7
M*SV&JZC;_68-/N89%D%%+-$74-#ZZJKDPK(S\49OLX(T/S/Y>\P+*=)NX[U8
M!$TQ0-1?67F@;D!1^/VD^W'_ +L56P-J'F*&V\PG1Y-+EF5=.FOOKJF Q^G&
MP1X0C.)>9)3_ '7Z?Q?:QGE/S5INMPBUBL)]-E2UM[M;*X2, VUT#Z3QM"TL
M+H>#*0K\D_;5<0N?S"T&'S#/H+PSM>6<\<5RXC'I1B2V-TLH:M63B/3/!6D6
M7@O#C(C,GJ7Y@?EWI)6^O;Z&!YV2V6<0R,[GTDN8XZHC,1Z4T;Q_L_O.*_'\
M.59_F+Y)O;R:RGN(H9[)WDA]9?@9([=;KUXI*%/]YG]:G+U?3Y-QP3_RL7R0
MNCQZLVI(FG/.;1)6CE4^NL9D]+TR@D60QCDB%/C^'ARY+AO9ZOI5W*L%K,LD
MDEO'>J@!!,$Y8))N!LY5L%K#"OV8U7Y #V_CD?'G"T.LZGHME:&XN=*CJ88Y
M8%>67TTD]*&)G5_@6:+U)'X1)ZB_%C=+\\^7Y],-YJ<D.B-]8N+5X+^:&/E+
M:2^DYC?EPE2H7BZ']I>7%_APPBUVS;5-3TZ:%K?]&P0W4EQ(8_2D@N!(?47B
MQ8!6AE5_45/L_P N$VE>=M)U73=.\P)I%S$M[=MI@EGBB2>W#3F%#*&?FL4T
M@2BIS;]XG-,&GS1:V_FA?+CV)BG-N9M/99+:LR1K5N$(D]:-%_NUDDC2+FK+
MR^SR+[OSG$OE^R\U6^AR3PM#(;@N]O'/:+R"O$U6;DYE7@R0LR\T_P!7#D>9
MK-O-I\M+%(URMF;Y[D!?1 $BQ^D37EZM'63CQ_NV7^;#5885+%452[<F( %6
M(I4^],2DT[3Y)9)9+:)Y)HUAE=D4EXT)9$8D?$JL[,J_L\L#7/EW1+K6++6;
MFSBFU334ECL+IQ5X5G $OI]EY@49OM<<&I:VR !(D0 !0%4 4&X%!X=LI[2U
MD1DDA1T=2CJR@AD;JI!&ZGPP)K'E_1=9L'T_4[..YLI4,4D#"BF,T)C/&GP-
MQ7DGV6XX,-O;EHF,:%H:^B2HJE1Q/'^7X=MLN*""$$11K&&8LP10M6;<DT[G
M,T$#$LT:LQ*L20":H:J?]C^SC#9V9B:$P1F)Z\X^"\6Y$L:BE#5B6Q1(XTKP
M4+7<T 'OB4^GV%QS]>VBE]0J7YHK<C&:H34;\/V?Y<46&)2Q1%4N:L5 !)/<
MT^6%%EY+\IV.G?HVTTBUBL>;2&W$2E2[LKNQJ"2SNB,Q/VN"X;O!!(K*\:NK
M@AU8 @@@@@UZUJ<2?3M/=.#6T3+P]+B8U(].M>%"/LU_9R$2:1H>H_ECI\=S
M9?6+*=K.>Y@FY.9#+<(9VFIQ]5G]25Y>7PLS<LFQTS36C2-K2%HXT$4:&-2%
MC6A" $;*.*_#CVL;)I$D-O&9(R6C<HO)6848J:;$C;$X](TJ-N4=E C$*I98
MD!XH*(*@=%'V?Y<R:5I:4X6<"T;U!2-!\8)/+8?:J2>65^B-*]99OJ<'K)ZG
M"3TDY#UC66AI4>H?[S^?]K+ETK2Y4D26S@D28@RJT:,'*TXE@1\7'BM*_P N
M.CT[3XI6ECMHDE>O-U10QY!0U2!4\@B _P"HO\N(C0=#$7I#3[98_3]'B(4
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M.(^5_)UCY=5A!=W=XWH06D3WDBR&.WM@PBB3@D8"KS;J.;?M-B5SY \NW7F
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MTDY)^[6)'P]ATCSO%Y_T347N)YTNHH7U6-FN%@MX4LGBG@XK_H;E[STKA/\
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MY]4NX[2*5_3B,AW9Z%N*@;M159S3[**S?9P5;W=K<1)+;RI-%*@DC=&#!D8
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MMV]:B\/WTGPX'A_**:+4K*Y$EHT.GRQFPC]-U-I$;PWLRVWVN'!UCM[=:_#
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M<&^2/+/F!/,-YK,EQ97.G1VEQI>FD"0SAX)8K8^N" C(18QEO39?CY_:^'@
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MZU]4]9/K7I^MZ'(<_3KQY\>O'EMRRK:^M+KUO0D#_5Y6@FI4<9$IR7?PKB^
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M93 +.\-I/ZL<END+._[YU^%/5MGDXJ9^<](U!/.<]EI/E>TO;#A:>C"^D0-
MW[^$R%[@Q-5.+3*W&7G'_P L\?'ZRT8GL_. %S<VODRRU.;ZO)-//<:-;PN9
M39+RCB+VT7)K6\Y>BC^K]8@3AZ\DCICK_1_.GU*1K#RM8SWZ3722Q?HBW"B"
MVCD>$@R6,2$22)\$4<DS3_#PG@=OBE^N:!!>:S/8Z%HECIPL9-)@]2#2[.5V
M34)0UQ<.DT1,44$240?[\5^?V<()?..@2R1M#^7NG:E=6EO<,2D"2,\$#20^
MJDD5L\(A>XMI#R?CSAXR0HW/AAAJ<OEGZKY;NYORVTYM2U6QN'@M&@4,)2.
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MC+Z4UPRV\HEXH&00QAZ'X%B]%69G]'DS<DU_([R4M32=BZ,DI=HV]0/&T1+
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MY2?E<6#?X3TD,*FHLX!]H$'HO^4<2F_)O\J9IC-)Y3TLR-(96(MHUJY!!J
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<S9LV;-FS9LV;-FS9LV;-E'C45I6OPU\:=L__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>exh101_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh101_2.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_X1$/17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    <    <@$R  (    4    CH=I  0    !    I    -  +<;    G
M$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S #(P,38Z,#@Z
M,#,@,38Z,30Z,34      Z !  ,    !__\  * "  0    !   "P* #  0
M   !   #CP         & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $   _9
M     $@    !    2     '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 #_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ H !\ P$B  (1 0,1 ?_=  0
M"/_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M[@[TVOK :QQ_,FFW\W_MS_2)*1,Z2'N+W8U3ZG >UMM@XC:6N]1S?S?W$:O
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M_P">[499EO6.G%]!]4@"W;JQX]Q:ZO;JS]^QC5=^UU?NV?\ ;5G_ )!)29)
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M 2P    !  $X0DE-!"8       X             /X   #A"24T$#0
M!    !XX0DE-!!D       0    >.$))30/S       )           ! #A"
M24T$"@       0  .$))32<0       *  $          CA"24T#]
M$@ U     0 M    !@       3A"24T#]P      '   ________________
M_____________P/H   X0DE-! @      !     !   "0    D      .$))
M300>       $     #A"24T$&@     #10    8              X\   +
M    " !E '@ :  Q #  ,0!? #(    !                          $
M             L    ./                      $
M        $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   ./     %)G:'1L;VYG   "P     9S;&EC97-6;$QS
M     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M      =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/
M<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54
M>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   #
MCP    !29VAT;&]N9P   L     #=7)L5$585     $       !N=6QL5$58
M5     $       !-<V=E5$585     $       9A;'1486=415A4     0
M    #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M    "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U
M;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F
M875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
M    3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N
M9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L
M;VYG       X0DE-!"@       P    !/_         X0DE-!!$       $!
M #A"24T$%       !     $X0DE-! P     #_4    !    ?    *    %T
M  #H@   #]D &  !_]C_X  02D9)1@ ! @  2 !(  #_[0 ,061O8F5?0TT
M __N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3
M$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+
M#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,
M# P,# P,# P,# P,# P,#/_  !$( *  ? ,!(@ "$0$#$0'_W0 $  C_Q $_
M   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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MUC6;UJH.3S2?"P?B'-24QM:&.Q6CAMD=AQ7:/S8:A90/KG3EM9G^K:"4>_\
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M &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %
M: !O '0 ;P!S &@ ;P!P "  0P!3 #(    ! #A"24T$!@      !P $
M 0$ _^$Y(6AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T
M(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX*
M/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB
M,RXQ+C$M,3$Q(CX*(" @/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W
M+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX*(" @(" @/')D
M9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z
M>&%P34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B/@H@(" @
M(" @(" \>&%P34TZ1&]C=6UE;G1)1#YU=6ED.C9$.#,Q.48W0T8U.44V,3$X
M-3@S.3,R048P.3 Q,38P/"]X87!-33I$;V-U;65N=$E$/@H@(" @(" @(" \
M>&%P34TZ26YS=&%N8V5)1#YU=6ED.C9%.#,Q.48W0T8U.44V,3$X-3@S.3,R
M048P.3 Q,38P/"]X87!-33I);G-T86YC94E$/@H@(" @(" \+W)D9CI$97-C
M<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*
M(" @(" @(" @(" @>&UL;G,Z>&%P/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O(CX*(" @(" @(" @/'AA<#I#<F5A=&5$871E/C(P,38M,#@M,#-4
M,38Z,3(Z,#(M,#<Z,# \+WAA<#I#<F5A=&5$871E/@H@(" @(" @(" \>&%P
M.DUO9&EF>41A=&4^,C Q-BTP."TP,U0Q-CHQ-#HQ-2TP-SHP,#PO>&%P.DUO
M9&EF>41A=&4^"B @(" @(" @(#QX87 Z365T861A=&%$871E/C(P,38M,#@M
M,#-4,38Z,30Z,34M,#<Z,# \+WAA<#I-971A9&%T841A=&4^"B @(" @(" @
M(#QX87 Z0W)E871O<E1O;VP^061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S
M/"]X87 Z0W)E871O<E1O;VP^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @
M("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B
M/@H@(" @(" @(" \9&,Z9F]R;6%T/FEM86=E+VIP96<\+V1C.F9O<FUA=#X*
M(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I
M;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!H;W1O<VAO<#TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(^"B @(" @(" @
M(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C$\+W!H;W1O<VAO<#I#;VQO<DUO9&4^
M"B @(" @(" @(#QP:&]T;W-H;W Z2&ES=&]R>2\^"B @(" @(#PO<F1F.D1E
M<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB
M(@H@(" @(" @(" @("!X;6QN<SIT:69F/2)H='1P.B\O;G,N861O8F4N8V]M
M+W1I9F8O,2XP+R(^"B @(" @(" @(#QT:69F.D]R:65N=&%T:6]N/C$\+W1I
M9F8Z3W)I96YT871I;VX^"B @(" @(" @(#QT:69F.EA297-O;'5T:6]N/C,P
M,# P,# O,3 P,# \+W1I9F8Z6%)E<V]L=71I;VX^"B @(" @(" @(#QT:69F
M.EE297-O;'5T:6]N/C,P,# P,# O,3 P,# \+W1I9F8Z65)E<V]L=71I;VX^
M"B @(" @(" @(#QT:69F.E)E<V]L=71I;VY5;FET/C(\+W1I9F8Z4F5S;VQU
M=&EO;E5N:70^"B @(" @(" @(#QT:69F.DYA=&EV941I9V5S=#XR-38L,C4W
M+#(U."PR-3DL,C8R+#(W-"PR-S<L,C@T+#4S,"PU,S$L,C@R+#(X,RPR.38L
M,S Q+#,Q."PS,3DL-3(Y+#4S,BPS,#8L,C<P+#(W,2PR-S(L,S U+#,Q-2PS
M,S0S,CM&,$1!-S8V.$(Y1C%"-C9!-$(P0D4Y,#=%038T.$4P1#PO=&EF9CI.
M871I=F5$:6=E<W0^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \
M<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN
M<SIE>&EF/2)H='1P.B\O;G,N861O8F4N8V]M+V5X:68O,2XP+R(^"B @(" @
M(" @(#QE>&EF.E!I>&5L6$1I;65N<VEO;CXW,#0\+V5X:68Z4&EX96Q81&EM
M96YS:6]N/@H@(" @(" @(" \97AI9CI0:7AE;%E$:6UE;G-I;VX^.3$Q/"]E
M>&EF.E!I>&5L641I;65N<VEO;CX*(" @(" @(" @/&5X:68Z0V]L;W)3<&%C
M93XM,3PO97AI9CI#;VQO<E-P86-E/@H@(" @(" @(" \97AI9CI.871I=F5$
M:6=E<W0^,S8X-C0L-# Y-C L-# Y-C$L,S<Q,C$L,S<Q,C(L-# Y-C(L-# Y
M-C,L,S<U,3 L-# Y-C0L,S8X-C<L,S8X-C@L,S,T,S0L,S,T,S<L,S0X-3 L
M,S0X-3(L,S0X-34L,S0X-38L,S<S-S<L,S<S-S@L,S<S-SDL,S<S.# L,S<S
M.#$L,S<S.#(L,S<S.#,L,S<S.#0L,S<S.#4L,S<S.#8L,S<S.38L-#$T.#,L
M-#$T.#0L-#$T.#8L-#$T.#<L-#$T.#@L-#$T.3(L-#$T.3,L-#$T.34L-#$W
M,C@L-#$W,CDL-#$W,S L-#$Y.#4L-#$Y.#8L-#$Y.#<L-#$Y.#@L-#$Y.#DL
M-#$Y.3 L-#$Y.3$L-#$Y.3(L-#$Y.3,L-#$Y.30L-#$Y.34L-#$Y.38L-#(P
M,38L,"PR+#0L-2PV+#<L."PY+#$P+#$Q+#$R+#$S+#$T+#$U+#$V+#$W+#$X
M+#(P+#(R+#(S+#(T+#(U+#(V+#(W+#(X+#,P.T1&0CA&-#0X1$$Y,SDQ.#-!
M.3=$-C8S-D4Y,3$T-T1"/"]E>&EF.DYA=&EV941I9V5S=#X*(" @(" @/"]R
M9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0]
M(G<B/S[_[@ .061O8F4 9       _]L 0P &! 0$!00&!04&"08%!@D+" 8&
M" L,"@H+"@H,$ P,# P,#! ,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  "P@#CP+  0$1 /_=  0 6/_$ -(    ' 0$! 0$           0% P(&
M 0 '" D*"Q   @$# P($ @8' P0"!@)S 0(#$00 !2$2,4%1!A-A(G&!%#*1
MH0<5L4(CP5+1X3,68O D<H+Q)4,T4Y*BLF-SPC5$)Y.CLS875&1TP]+B"":#
M"0H8&82414:DM%;352@:\N/SQ-3D]&5UA96EM<75Y?5F=H:6IK;&UN;V-T=7
M9W>'EZ>WQ]?G]SA(6&AXB)BHN,C8Z/@I.4E9:7F)F:FYR=GI^2HZ2EIJ>HJ:
MJKK*VNKZ_]H " $!   _ /5.;-FS9JYLV;,305QL;%E#[T8 J""" 1W!QV;-
MFS9LV;-FS9LV;-FS9LV-1B_Q"H4[ $$'8^^.S9LV;-FS9LV;-FS9LV;-FQB/
MSW%0 2I# @U!I7?MC\V;-FS9LV;-FS9LV;-FS9L:K<F-*@*2I!!%3XBO;'9L
MV;-FS9LV;-FS9LV;-G__T/5.;-FS93HCBC@, 0:'Q!J/QR\P !) W/4YLV;-
MFS9LV;-FS9LV;-FRF564JPJIZ@Y>:@K6F_2N;-FS9LV;-FS9LV;-FS9LJ1$D
M1HW')'!5@>X.QRP   .@V&:@K6F_2N;-FS9LV;-FS9LV;-FS9LIT61&1Q56!
M##Q!V.9$5$5%^RH 'R&705K3?I7-FS9LV;-FS9LV;-FS9LV8BHIXXR"&*"&.
M&)>,42A$7<T510#?'D D$C<=,__1]4YLV;-FS9LV;-FS9LV;-FS9LV;-FS9L
MV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV-66
M-G=%8%DH''A45'X8[-FS9LV;-FS9LQ8 @=STS__2]4YLV;-FS9LV;-FS9LV;
M-FS9LV;-FS9LV;-FS9LV;-FS9LV;-@/5M0&GV@N#'ZE9H(>(-/[^9(:]#]GU
M.6#,V;-FS9LV;-FS9LV)O.J3Q0D&LH;B>WP@&GXXIFS9LV;-FS9LV;-FS9LV
M;-FS9LV;-FS9LV;-G__3]4YLV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV
M;-E,Z( 78*"0 2:;DT ^DY>;-FS84^:IA#HKRD5"36S4'M<QX;9LV;-FS9LV
M4"2344H=CXC+S9LV!+KF+^R(^S60-L.Z5'ZL%YLV;-FS9LV;-FS9LV;-F!!%
M0:@]\V;-FS9LV;*9U6@)IR-![GKEYLV->2-./-@O(A5J:5)Z#/_4]4YLV;-F
MS9LHEJFBUVV/:OAD(T;\UM*O+R*WU*U?2$N!>_5[FXEB:)FTV[%E<*[*U8_W
MSIZ1<<9%;[7/X,D$WG+RE!,(9]9LHIC*\ B>>-6]6)UCD3B6KR1W1''[+,N-
M7SMY0:*24:S9^E%')-*YF0!8X6597:IV6,R1\V_9YI_-BD_F_P JP/<I/J]G
M$UF0+H//&OIEG$8#U/P_O&6/_7;CB-OYV\L76J:?IEI?1W-SJ<5Q/:>D>:,E
MHZQS?$-@R.W'C]KDK_RXU//7E-FU)7U*&']$W1L;YI6]-4G$0F*5:G+C&>3$
M?RO_ "XIYJ\SV_E_RY/KK0M>V\/I'A"RU99I%C#!F(7B.?+_ %?LX$U;S9JN
MGZ_9Z=^@YIK"]N8K./4Q/"JF21&D<B$GU62)$8LU/V6Q2_\ -5P/,$N@Z18?
MI&^M+9+N_=YA!#"DS,L*%^,C---Z<C(@3CP3E(Z<DY%-O^8FHSZFVGG15@ND
MCL)&M;B\CBN#]?#GTUB9*-+!Z4WJ)ZGQ*GP8KY=_,1M5UFUTNYTQK66]2_>W
MDCF6=1^C;GZK-ZPXQO%S<\H6XLK_ .2_PX-U?S?>:7Y@L;&XTB7]$WUPMDFK
M"1-KAX7F'[C[?H!8RKS<OA?_ '7P_>8SRIY[M=?N$@^K-:M=6,.K:>&8.9K&
MX=D1VXCX)!Q7G'5^/J1_&WQ<4]-\]3M>ZG::UI$VE26%O!>P_O$N/5@NI)(H
M5_=@<+II(F3ZO\?VDX2/@/2OS5TBXETX:HD>CPZE86]Y US.I(EN)W@^KM0!
M:JR+^\Y\69^/^L>^;=>U+1-,DOK'3#J7H1R7%RIF2W1(($YR'FP:LA']U'QX
MNWVY(E^+#2SO(KJQ@O$#)%/$LRB0<6"NH8<AV(!WPJC\\>5)8))HM1CD2)TC
M*H'9RTB&6/A&%+R+)$K2HT:LKQ*TB_ N(6?G;R>;Z.PAUJ*YNKQHI($Y\ZB[
MC:6 *RCB$EC1C#O\7^MA7H/YE0:E<&>Y6UL-&D@O;FUN)IY%N6AL)_0ED>!H
M518UV=I/7^'U$CX\N?$1I_YE:'(-7FU*6.PM=-OVL8IF,C%T2VAN6ED0QH\
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M &'#!OZ:_-L%*^5M*(_W8!J\E>WV:V0_RNN)MY@_-W:GD_3=S_U>6V6NX/\
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M#B/_ !9IQ<[@+,&_57&#\Z?R@G$=P?,NGLL;_NIG:@5V4CX68#BY3E_E<?\
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M45FJ?BD;XY6^.1F?#I=1T]F"K=0LQZ*)%)VW\<;^E=+,C1B\@]1:<D]1.0J
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M="U_RR_EN_A_W%ND4?IQA4*I"5*A#Q_=[+QY(%95_N^&,C\E:%'Y-_P@L?\
MN(^JFSXE8R_%@07W3TS+R/J<S'_>?'BOE'REHWE/0X=$T=&CL(&=HPY#/^\<
MM1GH&?C7@K/R?@J\G;#G >LW\VGZ1>WT-M)>S6L$DT5G"*R3.BEEC3K\3D<1
M@F!I6AC:9!'*5!DC!Y!6(W :@K0]\YV=&UQ=2_,*:#3-1@O-0A'Z&OUO5X3\
M;14C6W FY6TBW"M]I(^*_M?LX#N=(\_00Z,FF2:NQDM0S27-U$[PZFTB<Y-1
MY2,'M?1#_N;421I^\]*))/1=1ODS1?S L?,D=SJL]W/I<RWBW$5S=+,L;-,9
M(65.3&G'X% _NTX_Y6#/S8\LZCK]CI<%CIZ7\L%V).,YB:W2J%*SQ2@EHRK-
M^]@9+F!^$D7[62W6]/EU'1[RQAN'M)KB)HXKF)G1XW(^%PT;(_PMO\+KA1Y'
M\H3>6O*\>A7&HS:D8S(%NY"4?TVV15"FD7!*#]UP7E\:JO+ WY>>2=0\J6=_
M!>ZS/K+WEP;E))^0]/G\4BJ"SCXIFD?G_>/R7U6D9.6)^4?(-YH'F;6M9FUJ
MYU"#56Y16,S.4@^*@W9V]5O22&-7D#.G!UC9(G]/)CFS9RS2[7S9IOE.73(Y
M-<]>VU$QZC?.D$UR+-I96:33ZKQD7^ZK6.21(G_=QLZJN3KR<^MOY9L7USD=
M3*-ZS2(L<C+S;TVE1/@25HN#2JGPK)RR._E=IMW:2:_)/ITUAZ]\S,UV1]8F
MEJS2,_"6:&1!S58IXEA]5/MQ_N\&>=_*'F+7-5T6[TK7)=+M].G]:\MHR*3C
M9*"J/P?TGG'/^;A\/[2O_,;RIY@\R:9:VVB:R^C7$%PL\DJ@,KK%^\12I5O]
MW)%\7[*<_M_9Q;SQY7UC7?*3Z+I6K2Z9>OZ:?I#9V*#X9.8(_><D+?R?O.+8
M=:+:7EII-I;7MPUW>11(MS<L:F26GQMT78M7CM]G!F(75RUNC2>D\D:1O(YC
M')O@H>*H*LS,*\0HPJ\F%VT1F<,"U[J#!7%&"M?3%01M0\3T.'F;-FR#?F 8
MQYK_ "^C8&IUJ8H%X_LZ9=]:D;?+)R !4@;GKFH*U[YL0N;"QNH7@NK:*>&6
MGJ12HKJU#4<E8$'?(;^3L=N/*,P4*TD6L:TKD+QHPU2Y! '[.W\N3-+*S1BZ
M01JS'DS!%!+>)-.N<]_)?2M._P .ZK,UE")&U_6J.T:<RHU"914T[ <</;[2
M=)F\_P"GB6QADY:3?ABT*,I!N+04)(\&;;_6P5Y1TK3E\M00-;1.CJ\<U8U
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M^[;^\^SA)Z/G9?-UMJ=F;C]#RP:;!J%C<K$6DY"Y]:;9U2": O 9Q K+(O\
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M3#\\+.7E\+>6;I0M>A6_MS6GORR<YLV;-FS9LV;-FS9LV;-FPKU]'9+'C&)
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M]4YLV;-FS9LV;-FS9LB/FDA?//DH\*LT^H('WV!LG;;8]>&,T._\Q_XFU?\
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M$]/5%*?[LXKS_FXKBESY4\N7-Y<WMQIT$MW>0-:W4[("TD#KP:-C_*R#@?\
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M0*54<5:1W=S14CCC#222.=DCC5G;"2]_,+0H-5T#38!+>R>8N3V<]NC-"D2
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MX4U",-4T!4QR-2G0MR5:8=YLV;-G_]'U3FS9LV;-FS9LV;-FR'>:FB'Y@>2
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M/@3DS8_3/(VI:7<>5HK/4(AIGE^&XCN+=H&#3M.O$>EQE"01Q?[KC*2\$^#
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M%:TWZ5R'?E3'(GE:X6202$:OK-"-P!^E+CX:]Z8-\FJRW/F,,RM_N8F(XFM
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M3KR+HGU"QM;R6^];ZY&K788^A>16CK"GH>I')^\9V6ZCC6)E]*23_=F/T?\
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MV$7GV'UO)&OQ^F92=/N2(AN6(B8A1_K4IC=,8'SAJQW!EL-/E(/1:O=+0?\
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M+^9^3_M8;^4EF:SO;J=V:>ZU"\:16/PJ(9FMHU04'%?2@C/^OR?]K#O"K3A
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MIPR89LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV1WSP:6&G,:T35M-.PK6MY$O\
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M;  DW;&X;8?Y4N'F%'FN-)O+NH6\WPPW,7U9W\%G(B9NA^SSKALBE452:D
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M92/O&17\I5*?ECY70]5TVV7[HP,E%Q_O/+MR^!MAU.V03R-ZTGY&Z3RHLC:
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M?\X]6 DJ]?+/%@>I'U,BG;)]I,RS:59S)7C)!$ZUZT9 17!6;"+RB[&'5(V
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M%#TS4&,:&%@0R*P/4$ UQC6-DWVK>)N^Z*>GT86R^3?*$S,TNAZ?(S@AR]K
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M"HO+_@<$'SG^8HD4#\O[@Q$E>0U*PY @T!*E_L$ MRY?R?#\3<%H/.OG-O\
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M_'#S-FS9S?6K/\Z8+_5KW2;FSO()+Z$Z-ILXC18;*%!)/SE"AVDNV5K:-?\
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MFS9LV;-FS9LV;">7@/-UO5G]1]/GXIQ^ !9X:DO7[1Y"BTPXPFN55?..GN2
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MS9LV;-FS9LV;-FS9LV; DG"_MXIK.ZHBR!UDC(9'"$AD:G5?D?M8+S9LV;,
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E9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-F)W \<__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>exh103_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh103_1.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_X1@T17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    <    <@$R  (    4    CH=I  0    !    I    -  +<;    G
M$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S #(P,38Z,#@Z
M,#,@,38Z,34Z,S4      Z !  ,    !__\  * "  0    !   "P* #  0
M   !   #CP         & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $  !;^
M     $@    !    2     '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 #_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ H !\ P$B  (1 0,1 ?_=  0
M"/_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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MY[LU_P!*NDN9I#CE98F?_0?;]'^4ILS,:RJ'OMIL+F!HKNR+/:2TOU>QC?\
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MV2"P0T[7#Z%CFOLHWM8[Z3/524\^S,R?IC)#H : +6SN;K(:'[/H_O\ Z/\
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M_I1&W?\ =!__ (#_ .ED2D@O_HKJ=/IGT_\ -_16/<DIF[^?K_JN_P"^*/\
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M[8[SMA)3_]G_[1Q24&AO=&]S:&]P(#,N,  X0DE-!"4      !
M            .$))30/M       0 2P    !  $!+     $  3A"24T$)@
M    #@             _@   .$))300-       $    'CA"24T$&0
M!    !XX0DE- _,       D           $ .$))300*       !   X0DE-
M)Q        H  0         ".$))30/T       2 #4    ! "T    &
M   !.$))30/W       <  #_____________________________ ^@  #A"
M24T$"       $     $   )    "0      X0DE-!!X       0     .$))
M300:      -%    !@             #CP   L     ( &4 > !H #$ ,  S
M %\ ,0    $                          0             "P    X\
M                     0                         0     0
M &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   X\
M    4F=H=&QO;F<   +     !G-L:6-E<U9L3',    !3V)J8P    $
M  5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N
M97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M    #     $_\        #A"24T$$0       0$ .$))3004       $
M 3A"24T$#      7&@    $   !\    H    70  .B    6_@ 8  '_V/_@
M !!*1DE&  $"  !( $@  /_M  Q!9&]B95]#30 #_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ H !\ P$B  (1 0,1 ?_=  0 "/_$ 3\   $% 0$! 0$!
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MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
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MWIUFWW8V*7:\-V#^3ILN_P"J_L*QAX0J=ZKJJJK(+8J$Z?\ &;:O^H24G?\
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MX_0MC3^5NVI.S\=IAW3[QP?YII GCZ+DE-#['UD!S!<\-L'[U<@_R_TGT?\
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MV?U'Z?.M1@_8]LZ^G$_V4E/_T/54DDDE+<R"-$&K"QZGA[&F6B& N<YK0?\
M1UO<YE?[OZ-'224I,G224I))))2DDDDE*22224I))))2-W\^W^H_\K%'_M)_
MUO\ [ZB%@+M_YP! ^!_\Y0]COL?IP=WI[8[SMA)3_]DX0DE-!"$      %4
M   ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$
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M# P,# P,# P,# P,_\  "P@#CP+  0$1 /_=  0 6/_$ -(    ' 0$! 0$
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M'N8I0$#.H6>3ZNSP_'-'^Z^)VRM*\\^;YY=!665Y5FO'MM12)()'E'KPQK-
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M4N?^R/$'U?\ /A>GEOR^^Y'PZG<]!T.]J/M=LN+6_P \^+"7RMH?(TX$:M,
M/&H^JM7'OKOYW*HIY2T9VI\1&L2@5]@;,8F==_/.NWE/10/ ZM*3_P!0F4VN
M_GN?L^5-#'SU68_]BHQHUS\^R"3Y6T(4- #JD]3[BEMEKKGY\;\O*NAGPIJL
MP_[%CF.O?GN%)_PGHC$#H-6EW/TVN-.O_GR"1_A'16'8C5I0/QML4B\Q?G@
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M=RR\8N/'CQQ:U_+]X;=X%EACM9-3M=0;3XXJ6OIV\,<3QF/IRDDC^L\O]_\
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MF1(Y'B].)V]1,*XOS[UZ?3KRYAT*/E!= (ZB[FCCL3'<.;F3T87DDB7ZJO\
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MA#KNJ?D/Y@N)9M0N]/ENY8)[>:YB+13-%=1>C,&EC"O5H_AY<N2K]G"^"/\
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M+Y1LXK^<%H;-]<MA,X )JL?I<F%%)^'%)/.WYA13M#+Y2LHY4B,[Q/K< <1
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MXO?Z<C?EF\LU\T>;R9XP&OK4@\UW_P!QUN/')+]?L?\ EHB_X-?ZYOKUB?\
MCXB_X-?ZYOK]C_RT1?\ !K_7-]>LO^6B+_@U_KE_7K+_ ):(_P#@U_KF^N6?
M^_X_^#7^N;Z[9_[_ (_^#7^N5]?L>83ZQ%S()"\UK0;$TK[X_P"LVW7U4WZ?
M$,:EY9N6"3QL4(5@'4D$@$ []P<4]:$/PYKS'5:BOW9O4CK3D*CJ*C-ZL?\
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MX]^*4^<6-_Y67IW_ %8]?V%?^.1>_P#5/%8_S%TQXW=M)UR/@0.+:1?<C7P
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MJ>IR;_4R!SQZ:OE^+3K3S+Y<+R>5WT&Y6Y\Q"5(KF1X_CBYK(! J0\N*"/\
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MC^C-%#.H('H6M2I8*#]GIRHO^MB,%G^6=P^IHNG:6$TB9;;4)7MH$BCE:-)
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ML"ME:#UEE+&&61U^L00Q2"K#T2C/+Z\,B\E3@V8?G<D^HP2VL,9LVI'+9M/
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M;EZO+&7WE+SS;:AK%YHUT\$5]/=3>A#,B,_K26/&1!*CQ+.(;>Z5&?X5Y?\
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MA<6:*\Q6S'KR($X2-_H\L:_"C>G\/P_#R='Y=_.9)KB\3UH[V<NLD_UBRDE
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M]>II<#%/T+Y^_P"IFM?^X8/^RC,=%\_FG_.SVP_[=@_[*,WZ%\__ /4S6O\
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M9?6Y<6Y8_P#Y4WI2O>7$.J7D&H7L4D,UW'Z()5[U+Q24,9C:1#&(/49>;P?
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MW$2E642H4<#>GQ(Q7)<  *#H,V;-FPA\D.'\OA@2P-W?[FH_X_9O&AP^R/\
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MJ7DW](1W5_HJ2W]YIUY<I*LUFWISQM:7(DXR>E_=2V32KR^U"_\ =0NZ.LZ
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MV;-FS9LV;-FS9LV;-FS9LC_D)"GE6S4D,W*?DP'$%C<2%B![G?)!D:_,6O\
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M'M^F/:O_ "R?1BAUO\R: _X5L:GJ/TN=MO\ F#S#6OS)X@GRM85/4?I9MO\
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MT9FYJW"XA/%U_;XXIIU]YMU#4)M/@\]P+?1Q"Y-O)H;0,L-$8EA-,M2!+&6
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M_0&D%BH>GU2VKPKLWV/LU[XH/(/D%U!'ES2F4@$$65L01V_8R_\  'D2E/\
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MUV'R2F@W5Y:23C5;/4"K1O/"+>SF@D%MRDXRR_#;\$>;FZ1\8F]3T^> K/\
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MFE2(<%=DY<6D5GI^SCI/-7EN.:W@;4[8RW4[VL"K*C5FB0R21[$T9$6K<O\
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M0CQ6[1R.%=7B5EE/I./L^FDG[MY%=UQ.^\RSV$S/?^;_ #'%8(YBDOQ;:+Z
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M;BTA^N/PD<+%%]:N)&CDX2?Z/^\;[>,U+S3#87^I110>7;VUT^T]>RO(]+B
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MORE;PV\:3W#R2WS\(IF*QR&@2B.RMQ;[+<<0L/-?YDZG=VUO8:KY7D:[C,L
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MGS.2Q?SSJYJU5"PZ6H VV_WC/?*/D;S$:_\ .]:UO_Q7I?C7_EBRO\"^8O\
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M:S+<0P!FJP@22-?W>'V;-FS9LV$7G?\ Y1R;>G[^T_ZBXL/<V%&N?\=/R_\
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M%40O3DQYRF23XN*LL?P9(\V;-FS9LV;-FS9LV;([^8#E/+$A'4W=@O\ P5]
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1-FS9LV;-FS9LV;-FS9L__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>exh103_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh103_2.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_X1GJ17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    <    <@$R  (    4    CH=I  0    !    I    -  +<;    G
M$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S #(P,38Z,#@Z
M,#,@,38Z,34Z,C<      Z !  ,    !__\  * "  0    !   "P* #  0
M   !   #CP         & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $  !BT
M     $@    !    2     '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 #_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ H !\ P$B  (1 0,1 ?_=  0
M"/_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M<PY-8#@1(L:")[MU0<=V!0YSQF^KN 'Z6X/ C]V3[?Y22FEU?;AN:]F1;28
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M<T& [[3$B>?YW]U)3.C&L?=<?6> ?3(EE8/T?SIJ5:S[.Z^NQXR3;2+/2?\
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M=MI(,3VESO=L2=TV\N.VC!VR8FHDQ/Q_<24V\8.;;<USB\M+!N,"3M&OMAJ
MW"RFN)>XW'>YP>;[*Y!=O8PT5,]%OIM_1>W^<_ZXEC8.(;;FVX])<TLW$5M
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M30/M       0 2P    !  $!+     $  3A"24T$)@      #@
M   _@   .$))300-       $    'CA"24T$&0      !    !XX0DE- _,
M      D           $ .$))300*       !   X0DE-)Q        H  0
M       ".$))30/T       2 #4    ! "T    &       !.$))30/W
M   <  #_____________________________ ^@  #A"24T$"       $
M  $   )    "0      X0DE-!!X       0     .$))300:      -%
M!@             #CP   L     ( &4 > !H #$ ,  S %\ ,@    $
M                     0             "P    X\
M     0                         0     0       &YU;&P    "
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   X\     4F=H=&QO;F<
M  +     !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(
M   '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG
M:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y
M<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   ./     %)G:'1L;VYG   "P     -U<FQ415A4
M     0       &YU;&Q415A4     0       $US9V5415A4     0
M!F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC
M96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(
M;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC
M959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%
M4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M    "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M      MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     $_\
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MY?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$
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MU+KY#O<W<!H/LF7!,?RZ&?NN_P!;$YZKU8 CW$[1!^RY4;]'%NT8;_T6W?\
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M33M>QU3;&+364YC+*K?<YPKV$.;;:YIEWT"+'?F[?^FM5)2SOHGX(4?JD?\
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M &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@
M;P!P "  0P!3 #(    ! #A"24T$!@      !P $     0$ _^$Y(6AT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B
M(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T82!X
M;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB,RXQ+C$M,3$Q(CX*
M(" @/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY
M+S R+S(R+7)D9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&%P34T](FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B/@H@(" @(" @(" \>&%P34TZ
M1&]C=6UE;G1)1#YU=6ED.C V.$4P1#(U1# U.44V,3$X-3@S.3,R048P.3 Q
M,38P/"]X87!-33I$;V-U;65N=$E$/@H@(" @(" @(" \>&%P34TZ26YS=&%N
M8V5)1#YU=6ED.C W.$4P1#(U1# U.44V,3$X-3@S.3,R048P.3 Q,38P/"]X
M87!-33I);G-T86YC94E$/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @
M(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @
M>&UL;G,Z>&%P/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(CX*(" @
M(" @(" @/'AA<#I#<F5A=&5$871E/C(P,38M,#@M,#-4,38Z,3,Z,3(M,#<Z
M,# \+WAA<#I#<F5A=&5$871E/@H@(" @(" @(" \>&%P.DUO9&EF>41A=&4^
M,C Q-BTP."TP,U0Q-CHQ-3HR-RTP-SHP,#PO>&%P.DUO9&EF>41A=&4^"B @
M(" @(" @(#QX87 Z365T861A=&%$871E/C(P,38M,#@M,#-4,38Z,34Z,C<M
M,#<Z,# \+WAA<#I-971A9&%T841A=&4^"B @(" @(" @(#QX87 Z0W)E871O
M<E1O;VP^061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S/"]X87 Z0W)E871O
M<E1O;VP^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E
M<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SID8STB
M:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/@H@(" @(" @(" \
M9&,Z9F]R;6%T/FEM86=E+VIP96<\+V1C.F9O<FUA=#X*(" @(" @/"]R9&8Z
M1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T
M/2(B"B @(" @(" @(" @('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(^"B @(" @(" @(#QP:&]T;W-H;W Z
M0V]L;W)-;V1E/C$\+W!H;W1O<VAO<#I#;VQO<DUO9&4^"B @(" @(" @(#QP
M:&]T;W-H;W Z2&ES=&]R>2\^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @
M("!X;6QN<SIT:69F/2)H='1P.B\O;G,N861O8F4N8V]M+W1I9F8O,2XP+R(^
M"B @(" @(" @(#QT:69F.D]R:65N=&%T:6]N/C$\+W1I9F8Z3W)I96YT871I
M;VX^"B @(" @(" @(#QT:69F.EA297-O;'5T:6]N/C,P,# P,# O,3 P,# \
M+W1I9F8Z6%)E<V]L=71I;VX^"B @(" @(" @(#QT:69F.EE297-O;'5T:6]N
M/C,P,# P,# O,3 P,# \+W1I9F8Z65)E<V]L=71I;VX^"B @(" @(" @(#QT
M:69F.E)E<V]L=71I;VY5;FET/C(\+W1I9F8Z4F5S;VQU=&EO;E5N:70^"B @
M(" @(" @(#QT:69F.DYA=&EV941I9V5S=#XR-38L,C4W+#(U."PR-3DL,C8R
M+#(W-"PR-S<L,C@T+#4S,"PU,S$L,C@R+#(X,RPR.38L,S Q+#,Q."PS,3DL
M-3(Y+#4S,BPS,#8L,C<P+#(W,2PR-S(L,S U+#,Q-2PS,S0S,CLU0T0Y-C=$
M0SDR-39%03-&,S@Q-41"0S8Q.3$T1$,X03PO=&EF9CI.871I=F5$:6=E<W0^
M"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIE>&EF/2)H='1P
M.B\O;G,N861O8F4N8V]M+V5X:68O,2XP+R(^"B @(" @(" @(#QE>&EF.E!I
M>&5L6$1I;65N<VEO;CXW,#0\+V5X:68Z4&EX96Q81&EM96YS:6]N/@H@(" @
M(" @(" \97AI9CI0:7AE;%E$:6UE;G-I;VX^.3$Q/"]E>&EF.E!I>&5L641I
M;65N<VEO;CX*(" @(" @(" @/&5X:68Z0V]L;W)3<&%C93XM,3PO97AI9CI#
M;VQO<E-P86-E/@H@(" @(" @(" \97AI9CI.871I=F5$:6=E<W0^,S8X-C0L
M-# Y-C L-# Y-C$L,S<Q,C$L,S<Q,C(L-# Y-C(L-# Y-C,L,S<U,3 L-# Y
M-C0L,S8X-C<L,S8X-C@L,S,T,S0L,S,T,S<L,S0X-3 L,S0X-3(L,S0X-34L
M,S0X-38L,S<S-S<L,S<S-S@L,S<S-SDL,S<S.# L,S<S.#$L,S<S.#(L,S<S
M.#,L,S<S.#0L,S<S.#4L,S<S.#8L,S<S.38L-#$T.#,L-#$T.#0L-#$T.#8L
M-#$T.#<L-#$T.#@L-#$T.3(L-#$T.3,L-#$T.34L-#$W,C@L-#$W,CDL-#$W
M,S L-#$Y.#4L-#$Y.#8L-#$Y.#<L-#$Y.#@L-#$Y.#DL-#$Y.3 L-#$Y.3$L
M-#$Y.3(L-#$Y.3,L-#$Y.30L-#$Y.34L-#$Y.38L-#(P,38L,"PR+#0L-2PV
M+#<L."PY+#$P+#$Q+#$R+#$S+#$T+#$U+#$V+#$W+#$X+#(P+#(R+#(S+#(T
M+#(U+#(V+#(W+#(X+#,P.T1&0CA&-#0X1$$Y,SDQ.#-!.3=$-C8S-D4Y,3$T
M-T1"/"]E>&EF.DYA=&EV941I9V5S=#X*(" @(" @/"]R9&8Z1&5S8W)I<'1I
M;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_[@ .061O
M8F4 9       _]L 0P &! 0$!00&!04&"08%!@D+" 8&" L,"@H+"@H,$ P,
M# P,#! ,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  "P@#CP+  0$1
M /_=  0 6/_$ -(    ' 0$! 0$           0% P(& 0 '" D*"Q   @$#
M P($ @8' P0"!@)S 0(#$00 !2$2,4%1!A-A(G&!%#*1H0<5L4(CP5+1X3,6
M8O D<H+Q)4,T4Y*BLF-SPC5$)Y.CLS875&1TP]+B"":#"0H8&82414:DM%;3
M52@:\N/SQ-3D]&5UA96EM<75Y?5F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]SA(
M6&AXB)BHN,C8Z/@I.4E9:7F)F:FYR=GI^2HZ2EIJ>HJ:JKK*VNKZ_]H " $!
M   _ /5.;-FS9L:6^+@-FI6M#2E<=FS9LV;-FS9LV;-FS9LV;-C7>C!!L[ D
M&A(VIU^_'9LV;-FS9LV;-FS9LV;-FS8UW"E5_:>H78D5I7>F.%:;]<V;-FS9
MLV;-FS9LV;-FS9L:[A2H-:L:"@)WI7M\L<*T%=SW.;-FS9LV;-FS9LV;-FS9
MLV4[A ":[D#8$[DT[9:UIN:GQ&?_T/5.;&10I%SX5^-B[5);<]:5)I\L>0#U
M^>;-FS9LV;-FS9LV;-FS9LV,CACC:1EK65N;U)(KQ"[ GX=E&RX]@"*'IFS9
MLV;-FS9LV;-FS9LV;-C%A197E%><@56W)%%K2@K0?:[8\@$$'H<P%!3-FS9L
MV;-FS9LV;-FS9LV,$,8G:<5]1E"'XC2BDD?#7C^T=Z8\BHIF    Z#-FS9LV
M;-FS9LV;-FS9LV,,*&83;^H%*#<TH2#TZ=NN/S* !0=!FS93,J*68T4;DY__
MT?5.;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV
M;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS__TO5.;-FS9LV;
M-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9
MLV;-FS9LV;-FS9LV;-FS9LV;-FS9L ZA?R6MYID"*&6^N6@D)K50MO+-4>_*
M(#!V;-G_T_5.;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9L
MV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9L*-<_P".GY?_
M .8^3_J!N<-\V;/_U/5.;-FRBR@5)H/$Y1EB!H74'PJ,WK1?SK]XS>M%_.OW
MC*]:'^=?O&;UX/\ ?B[]/B&4;FW!H94!_P!891O+0=9XQ\V7^N,&I:<>EU"?
M^>B_UQS7MFI :>-2PJH+J*CQ&^4;ZR5BIN(@PZ@NM105\?#'-=VJ_:F1?FP'
M\<8=1T\=;J$?\]%_KC#J^E#K>P#_ )ZI_7-^F-(_Y;K?_D:G]<WZ9TC_ );K
M?_D:G]<K],Z/_P MUO\ \C4_KF.M:.!4W]N ._JI_7$SYB\OCKJ=H/G/'W_V
M6(GS?Y3'76K =_\ >J'_ )JQO^,_)_\ U?=/_P"DN#_FO-_C/R?_ -7W3_\
MI+@_YKS?XS\G_P#5]T__ *2X/^:\:?.WDP&AU_3@>M/K<'3_ (/&/Y^\BI7G
MYCTM:&AK>VXW';[>-/Y@^00O(^9=*"TK7Z[;4I_P>-/YB_E\!4^9])I_S'6W
M_->-_P"5D_EU_P!33H__ $GVO_53-_RLG\NO^IIT?_I/M?\ JIF_Y65^77_4
MU:/_ -)]K_U4QK?F;^6ZFC>:M''_ $?VW_53&G\TORS4T/FS1P?^8^V_YKS?
M\K2_+/;_ )VS1]]A_I]M_P UXP_FO^6 _P"FMT?_ *3K?_FO&G\W/RM J?-V
MCTZ?[W6__->5_P K=_*RE?\ %VCTZ?[VV_\ S7F'YN?E:>GFW2/^DV#_ )JR
M_P#E;?Y7?]39I/\ TFP?\U9O^5M_E=_U-FD_])L'_-6;_E;?Y7?]39I/_2;!
M_P U9O\ E;?Y7?\ 4V:3_P!)L'_-6-;\W?RM7KYLTGZ+R$_J;,?S?_*P-Q_Q
M9I5?^8N'_FK&_P#*XORKK0>:]+)\!=1G]1QC_G/^5*=?-6G'>E%G5C7Y"N,_
MY79^4] ?\4V%#T_>_1X8X?G1^51I3S-8FM*4<]^G;OF/YT?E6#0^9K(&M*%R
M-SVZ92_G5^5+$A/,]BQ!H0)*D'PV&6/SG_*P@%?,MDP8T!#DC[P,S?G1^5BK
MR/F6SX]*AF/ZEQ,_G=^50-/\16Y/LLI^^B9O^5W_ )55I_B*WZ5^S+_S1E-^
M>'Y4J:'S%;[^"S'M7LF,/YZ_E,IHWF.!:TI5)A6M* 5C^UO]G[6++^=7Y6%N
M(\QVM??U -Z]RM/V?\^2XX_G1^5H<)_B.UJ>]7ITKUXT[90_.K\K22!YBMB1
M7M)VZ_LY7_*Z_P K/^ICMOND_P":<:_YV_E:A(;7X@1L?W<Y'WB/,_YU_EBE
M.6LT!- ?JUW0D5V!]+?IB7_*^/RFJ1_B".HZCT+GM_SRS-^>WY4*W!M?0/\
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M*TL6/E/2B36I-I#W_P!CF_Y5%^5E:_X2TFO_ #!P?+^7%!^5/Y8#IY3TC?\
MY<;?_FC+_P"55_EC6O\ A/1ZC_EQMO&O\F6/RL_+(=/*>C]"/]X+;O\ [#'_
M /*LORV_ZE31_P#I M?^J>;_ )5E^6W_ %*FC_\ </M?^J>.'Y;?EV#4>5](
M'RL+;_JGB@_+[R$IJOEO2P>E196_3_@,>/(?D< #_#VF47I_H=OMV_DR_P#
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M+INNO9_X=NI+>.?3Y!<6BO)9W,R@SP:@MRY"JS)&R)P]->7J,;>3M9_,*_\
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M)N/(<OY>VUM:Z-+:Z[H^AW-K*AM)(Y+>XFMO0G@D;BOKR7$S5_=^MZS?O_\
M+R,Z5Y736]"\HII5RVB><_+'E^UDTF[N(I84BU"&2ES:W!955DF7DCQNWV']
M149.7(WT>&[MM?\ (>N^8;(0Z)!IUZEU81IZT>G:U=3M)ZLD"<F4.K20QS\&
M5/YUY\L,7O)M1_)3SKRT*'1;K5(M1%GHUOZCR3RRQF)9UA94=/K4@$B(L?\
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MAF62&\DM6X"2VN'$:O;S-]B5D7]K^7%?RX\[:AYKL-3?4=).CZAI&HW&EW<
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M,2SS23D_NI=BC0>F?19%56>)(UYKPP[LO(2V7G;6/-T&IS_7=9MX[6>V9(C
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M(-/WP@C+_P"5]GC@#S3^4=[=7\5WH>H&,O//=W?UR64M]<FBA@2ZC* @M%%
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M9JYU6U^LBX:CM"UQ,UN9Q$(#<F MZ/UEH5$;S<.3?ZV2/-FS9LV;*6-$+%0
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M2>IAW>^;_+-EHUOK5SJ,*:7=\?JEV&YI+S4NOI\.1?X%9_A_85W^RK83:_\
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M'#-)Z:?!Q:,D)\7J?S1X4Z/Y[\SV'F+5K+5+9[R"[U&*UMR+E/\ 1;B714U
M6T(]).</-)1ZK\>'-/AE^+#'R5^9GU_5-$\NO:RAKS2H+V.^O)@\TQ:VCG;B
MRQI#<,OJ<)O3=)4?]Y]76%U?*N/S@:'7K_2CI:\(7:#3[LW'[J:=;Z"PXR.(
MS%&OK72%_3DG>'BZ2QI-^ZP#YH_,#S7$+VTFL(;6&'0]4O;\65^&NHYK.X2
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MXH_3A>5/2GY\>'-7YIQ;(/K?FY]9L[2;6Q:I!J^@Z^]BD\)BO8HX[:"-A5G
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MJW.E-'^[/(\8IG3TN;?!AC'KWDO0OS=\V7][);6]R--TV-'$8]9Y^5RTT<9
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M-!3;;&MIFFL8BUI"3 H2$F-?@4$$*NWPK55-!_+C5T?25A,"V5N(&D$S1")
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MR\V;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FPEUK_CO>7O\
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M=,O1-$N+G\L-)L=4TJ9;70?+GI3V4UK-R>_U*;T77T>'J-+!;PR;HO)/K7+
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M:X?S!8+;I,ML\QN(^ F<$HA:M*N%;A_/^SAQI6JZ9JVGPZCI=U%>V%P"T%U
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M^>]Z?F1JU?>TTP]C_P NWCB9_+K\Q#3E^9FI[ #X;'31OW_W2<L?ESY^IO\
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M $#RZ.7$GS'HX7_I+4_J&''FKSEI/EF.U;4([F5KUI([:*TMY+AF>&%YV'P
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M=/WT$SJWIK+Z47"/U62\E^7[KS!^1UAH]M?R:=/=02QB]BW90;B0/5>CAEY
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MC8ZE:@^\T?\ S5F_3^@T)_25K0=3ZT>W_#8F?-/ED==7LAWWN(NA_P!EC?\
M%OE2E?TS8T\?K,/_ #5C#YS\GCKKNGC:O^]4'3_@\K_&GDZG+].Z=Q\?K<%/
M^)YO\:^3:5_3VG4/3_2X/^:\W^-?)O\ U?M._P"DN#_FO-_C;R;_ -7[3O\
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MGIW^'])CO;Z1(;:";2_28O-R])6$D*E/6]-C%SX^HO'C]M.0V[\J_D'::O\
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M].^FC6K%*GBJ*J_Y*Y-1^4WY7"M/*.C[]?\ 0;?Y_P F6?RI_+ ]?*6C[_\
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M<9(P54L 7^P*[FF^V8NH!)( '4D],RLK"JD,/$;Y OR@_P!Y_-W_ (%6L?\
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M/VI1ZY>:5:RV'Z1O]633X]7DEGFL3Z6D17BOZ1EI&\_]U'%#)&GVY.4LB_O
M^@_G'YCU'6M+2XLK&VTV]GTRVF@Y2M<J^IVT\@96)5.*RV]8_P!W^]AE3[&2
MS7+BGYJ>7;%[MU@O=)U7U; RL(I6CDM>+&*O$NJO+\=.7'EC_P L;^ZFL-:T
MV:5[B'0M8N],LKB0EW:VBX21*SFI<PB7ZN7;XV]'X_CY9,<V;(#^;W]SY/\
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MGW@812<662,\9(Y(V#QRQM^S)%(JR1M_,N8Z-I'UQ-2GM()-1A3B-0DBC]<
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MY?"W+!]G>6=[:Q7=G/'<VLRAX;B%UDC=3T974E6'RQ;-FS9LQR _D4Q;\L[
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MT<D,2_R<,%V_Y+W,NMB\:UTVTTZ[35G:*W+,UC+J,=ND#V2M"B\HFM/K#/\
MN/W]Q)Z:?#\8BQ_+/S;:SV>JK#I*W]D-/MFTI7E%A<Q6-O<VS7#D0AHYF6\Y
MQ1^E)Z7H)'ZK<N:!--_*;SS9MI:K/I/""+1%O)%]<,CZ,TR?Z../^[+>8?&[
M+Q=>'#@V#-._*_S9#8:.)1HT=_H5YIYMY+>.1%NK?3XIK=9;E^'J>LT<X98%
MY1(\?][^]^ ;YX_+;6]=\SW&IVD.FM9W$.E1NMTT@D9M,U#ZZQ8+#(O[Q/\
M1U^+X5_X#)/^7V@:EY?\MKI>H"W$L=U>31BT9FB$=U=27**.:1D>F)?3IQ_8
MR29LV;-FR"?DA7_E7%CN2/K>I\>7A^DKBE/\FGV<G>;-FS9LV;-FS9LV;(#^
M4'^\_F[_ ,"K6/\ D^,GV;-FS9LV;-FS9LV0%/\ R?4__@*Q?]U&3)]FS9LV
M;-FS9LV$FJ_\I1H7^K>?\FTP[S9L_]'U3FS9LV;-FS9L@7D'_P F!^9'_;3L
M/^Z5;9/<V;-FS9LV;-FS9L@/YO?W/D__ ,"K2?\ DZV'OFOS;)HDMG9V>GOJ
MFJWZW$EK9)(D/*.T023'U)/AY49%1?VW?]A.;K'-5_.*VL+:ZU!=(GNM*C.H
M1VEW%+%6:?2HVEND*$CTUXPW'I2<V]3T&^SSBYI'\X+N*XD@NO+5Q T-RUE)
M_I,#_OFT]M3@4<30B6W6CM55BE^']Y]K 4_YEZWJL^A)%9W&@O-J.D2RPL\$
MZW6GZK'.R*6"GTVYP,KJK*R\?M,C8_RS^;AEM]!MWL+JZ;5Y71[F>:!I86EO
M;B"))!;H(PJ&#ARD]%>/!4:>59>*NF?G3->R6EO)H#VE[JD5G+I,4UU'QD-[
M-+"%F=5/H>G]6E?9969?LKZG[O!UE^:MW<^8+/1AY=N@_*WAUF=9$DCL9KE&
M95:1 8I$4JJ,WJH_*3BD;LLBJWS)^;(\N^:'T75+"&WM_6LTAO9+LKZEO>)+
M_I'I^B:+#-;M!*O/X6>+XOCPDA_,OS-+YB%E'IK6U_?7FC6ES8W5VKPVL=]9
MW%V[0<+<.).$!63UN7*7[*\5^(=^3OGW6-6MK+1=9BDGNVL)=0@UB257:YC2
M^EMF]2-4C$3KQ0\5Y? W^Z_LXGJ/YG:SJEAI8TZ!='LO,-[:6NGZT9HIY5M[
MB6>-V-N5_<W'^CHD7J++!ZEU$K,TB/%A=YCU?S?:3:YI_E[5]1?5M)OM,2UB
MOTM)(I?K(=F@#1CE)%=1JOQ2)'- [?WG[&):E^8>L>9?,-A-H6JS:?Y5N]%U
M*XC,*())+RSAAE=S*R2%!;M<K"R?!^^BF5N62/\ *'4//VI6WZ3UYIVT:]TW
M3I[(WHMA<-=R0\KIXA:["T>J-'Z_[WER^%4SHV;-FR"_DBG'\M]/((*O<ZC(
MA%2.#ZC<,O7_ "3DZS9LV;-FS9LV;-FS9 ?R@_WG\W?^!5K'_)\9/LV;-FS9
MLV;-FS9L@*?^3ZG_ / 5B_[J,F3X$$D [CKFS9LV;-FS9LV$.K$_XMT =C'>
MGOV2/#[-FS__TO5.;-FS9LV;-FR!>0?_ "8'YD?]M.P_[I5MD]S9LV;-FS9L
MV;-FR _F]_<^3_;S5I-/^1K9)_,?E+R]YDAMXM9M!=+:R>K;MR>-T8J48!XV
M1^$B,T<L?+TY8_@D5EPNO?R[\CR#4)[G3U]*]2;ZX@EF2*DT82=DC5Q'"TT2
M!)WB5&E3X7Y?%D>U/RG^5YTRSO[>=+6?7YHCH>H37%W,LM[<6QM[:58S,/5?
MZL?37E_NKX/L8<:%^5WEK3]"TG3KR'ZY<Z5]4D6]$EQ&SSV,?IP2[RNX$:U]
M.(R/%'R?@OQ9</Y1_EW"(!%I"I]697@*S7 *LDS3HU?4J62621T8_9]23C\+
MME#\H/RZ]'T3I >(0+:HKSW+\(8YOK"+&6D)BX3?O4:/BR/]G$=5T;\J_+VK
MZ7?7UM:V>J6\(BTU5$C/Z-M6C^C'RYBW]1OW\D;>CZG]XO+!+3?EMYOU%8&:
MTU2_ET]9HT-2[Z=+-'*KK6G*%IXHFY+^VN$VJW'Y*3:G?W&H36TM]<7\<=[,
M7G?E?Z:K%(^2DJ)K=#)^Z3_=?/DO#ED@\K>3_(MF;37/+EO'Q>U,-E>03R2Q
MM:3/Z_%*NZ&-Y&]7;]KXL7A_+[R3#!J5O'HUJ(-7?U-1B,89)6Y&0?"U0M)&
M:50G'C*S2K^\^+$X/RY\EP)2/35#FXCO'G:29IGN(1QBE>9G,KM$OPQ<W;TU
M^QCKW\N_)5[+%+<:1"SP12V\)7D@2*X9FF10A4!9F=C*/]V?MX<:7I=AI6GP
M:=I\(M[&U01V\"DE40=%6I/PC]D8*S9LV03\C0@_*W11'O&/K00UKM]<FIOD
M[S9LV;-FS9LV;-FS9 ?R@_WG\W?^!5K'_)\9/LV;-FS9LV;-FS9L@<:'_E>]
MP^]!Y7@'385U"7O]&3RF;-FS9LV;-FS80:L?^=O\OBA_N[[?M]B/#_-FS__3
M]4YLV;-FS9LV;(%Y!_\ )@?F1_VT[#_NE6V3W-FS9LV;-FS9LV;(+^:PK_@X
M<>0_Q/IM5I7IZAK_ +$_%A=^=>M:S8V^CVFD7-S'<WCW?.WLBPGX1VC\;G]W
M^]:.TG:&5XPOIS?#'+\.$5I=><Y-2M%M4U^^TB2:>Z3548*CV%YHZ^C\,DBM
MZJWX,BQ>E_H\GPK\/%,+#IWYC7C^6TU72M9NKFRO- NH7]9?JRV]M&AOOK:&
M54:[%VLTCR2K)\'H^B_'EB>FVOYI&:WCO8/,2:=)J6G7%V!.WK" PW2WZ>HL
MS2LGK"V_NU@1O[RW@@PQT&+\UIK2T2>VUF/78M/1=.O+BXC2Q6:*UEAF74(B
MTGK2/<F.=&,<CR_N?WT2)-DK_+2Q\Y0Z%JINY-0AO+@JUBNO^G,8KCTZ2\8X
M)6<VWJ4;_>G]XW/T_23[2#67G'1O-=YK>K6KZPVJ:/#8+?:+$%-I<6TMQ(52
MWN)9'6.X$T;!^4J^M%^^XIPR)6'E;\QXKO0]02P=/-VEZ59VT][*D"6A:\FG
M6_AY6_&,BV%S!=(B)Z;/:_M8"TKRCYELSIVFVFD:M8PVOG"ZU1+](X'DCL9[
M.2V2XK(98VD>23E(K1NWVWXYW'RQY<TSRUH%CH6F*ZV&GQB*#U&+N14DLS'J
MS,2S89YLV;-FS9L@/Y#BGY3Z"/!;C_J+ER?9LV;-FS5&;-FS9LU1E<E\1D!_
M*"BVWFZI_P"FJUC<_P#&<9/N:?S#[\WJ(/VA]^;DN^XVW.745 KN>F;-7-4>
M.:H\<KDOB,W-/YA]^;FE*\A3I6N5ZL?\Z_>,<&!- =\@L K^>%XP)8#RS:C;
M[(K?W'AW-,G6;-FS9LV;-FS80ZL3_B[0!V,=\?N2/#[-E%5+!CU6M/IS_]3U
M3FS9LV;-FS9LY#I?DR37_P Q?/\ .GF'5]&]'4+*,PZ5<) C_P"XRV/*0/%)
MR;>GVLD _*6<"G^.?-7_ $GQ?]D^;_E4T_\ U//FK_I/A_[)\:?RBD+ASYY\
MU\@*#_<C&!X_9$''\,L_E),>OGGS5]&H1#]4&5_RJ&0FI\\>:S[?I%!^J 9O
M^50-M_SN_FN@[?I)?#_C#D:M_*=BWFT>6I/,/GJ!Y8YGM-0FU!A:W!M. G$;
M4,J\?57XY(HXY?\ =+ODD_Y4Y!U;SEYL)_[;$P[4Z*H&6/R<M@?^4O\ -9]O
MTS/_ $QP_)^S_P"IK\TG;_J\W/W]<W_*G['K_BKS34]?]S-U_7&#\E]+!5AY
MF\S@KNI_3-UM^.8?DQI("@^9/,S*A#*IUJ[IR H#LW;(Q^8'Y7:3:2^5:ZUK
MUR;C7K6W)GU:\<JLB2LQ3X_@D^'X9$XNO\V+>=/RN\@6[Z987PUK7=4U.Y*Z
M3ITNKWC\I8D,KREII2D,<"+SDE^U]E55W94Q.P\O_E>]K-^EM>U?0+ZTFDM+
MRQU#S'>1/'-$J.P1C<\)8_3DCD21/A]-U^S]G*G\I?E@VHO86.KZI>W]O?6E
MA=QGS%>0E#>!9%9#)<#UFX$/Z47)Y&^%/BP6WY?_ )-(D[OYEO$2"18;AF\P
MWBA978A$8FX^TSHP4?M,C?RXV_\ RJ\@-H"ZKH?Z9\P+.RI90V6MWK)*Q?T_
M[TS^FD<9#>H['X.#?M_!@72_RR\BZAY-?S):VVMQ3PQW#/ITVM7R.LUF[QRQ
M>JDTB;21.J2+\+?:R/0>6_):Z=8W6H:+KEF^LZ?+J6A_[G[V6.X]&W^MM;-(
MDO*&Y,'*15>)HVX/QE^'#/R%Y*_+OS3)<VTEGK-A=V]I9:CQ;7+Z=&MM2B:2
M \TF7C(OIOZD;I\/VOC1L,?\%?D+]5^M'S!.+<2&#U&UZ^ :0)ZO$5N/BK'\
M:\?MQ_&N!_,'D[\IM,NM#M[5KR_;6KNTMUX:]J *0WQ/HW"@3MZJOQ^!05YK
MR=?L-DM'Y%?EZ*5CU(_/5]3_ .RC+_Y47^71&\&H'W.K:IW[?[TY1_(?\M6-
M6L[XGQ.JZF3_ -1.-'Y#?EDK56SO585Z:KJ==Q0_\?.9?R$_+)2I6QO04-5(
MU34]B!04_P!)VVVQ@_YQ^_*P-R&G78;<<OTGJ5=Q0_\ 'QW&4?\ G'S\JB6)
MTRZ);9C^DM2J?G_I&.;_ )Q__*IY3++IES+(U.3R:EJ+DT]VN#X9#OR@_)?\
MN-:_+C1]2U+3))KRX6;U9!>7D8/"YE446.9478?LKDR'_./WY3@D_H:3?QOK
M\C;_ )[XH/R'_*L+Q&COQK4#Z[?4!\1^_P!LM/R'_*Q&++H[JQ%"PO;ZOSKZ
M_7-_RH?\JJ<?T*:=Q];O:'J=_P!]OUS'\A_RI/70Z_\ 1U>?]5LW_*AORG[Z
M$"/^8J\_ZK91_(7\IC2N@@T-16ZNS0CO_?9?_*AORH_ZL?\ T]7G_5;-_P J
M&_*C_JQ_]/5Y_P!5LW_*AORH_P"K'_T]7G_5;-_RH;\J/^K'_P!/5Y_U6RC^
M0OY3D4.A CP-U=G_ )G91_(3\I32N@J:=*W-V?\ F=E+^0/Y0J:CR]'7_C/=
M?]5<AOY:?DS^6>JP>93?Z(DYL_,6IVEM6:X7A##+QC3X9!]D=S\63 _\X^?D
MZ>OEN(_.>Z_ZJY3?\X]?DVU WEJ%@H(4&:Y- >H'[W'#_G'[\H!RIY=C',<7
MI<76Z^!_>[CVQQ_(/\I"RL= 4LE>#&YNZK78T/K;9?\ RH7\I]Z:%2O4BZO
M?^3V;_E0OY35J=!%?'ZS=_\ 5;*/Y!_E(=SH"GM_O3=]/^1V;_E07Y1UK_A]
M:^/UF[_ZJXT_\X_?E 34^78R?'ZQ=?\ 57&_]"]_DY_U+<7_ "/N?^JN8?\
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M6'76+$?.YA[?[+*/FWRH#0ZS8@^'UF'_ )JS#S;Y4)H-:L2?#ZS#_P U9O\
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MIACCMYE,FE^D95O':*$P^K$GJ\I8WC/#[#HW/CFMC_SCA?W5HMMY<TZ>2_\
MJWI2)H[<%^MRO;0<W] (G.>)X-S_ 'OPX?>4/)OY4>9-$AUBW\DZ;:Q3F14B
MN=.@1^*2,H;BT8^UU_X7]G"/\E/R[\@:A^5^AW5_Y;TN[NI$G$EQ/9V\DC<;
MF4#D[(6:@ &^38?E3^6 4+_A+1J#_EPMO^:,O_E5?Y8[_P#.I:-OU_W'VO\
MU3RQ^5OY9#IY2T;_ +A]K_U3RO\ E5OY:5'_ #J6BT[_ .X^U_ZIY?\ RJW\
MLO\ J4=%_P"X?:_]4\W_ "JW\LO^I1T7_N'VO_5/-_RJW\LO^I1T7_N'VO\
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MFR!:=_Y//7?_  '=,_ZC+W)[FS9LV;-FS9LV$5_(G^-M&CH?4-AJ+@]N(DM
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M+IEG>00,)[=KA0RL9';X@:49J\B,EW_*[_RA_P"INTO_ *2$_KF_Y7?^4/\
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M1P_IC?\ E?/Y.\BO^+=/J*_[L--O>F6/SX_)TR"/_%NG\CL#ZOP_\%3CBO\
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MR;;C&W^N5P-Y9\DR>8="L]9M?._FV"WO$+I#/=68D6C%2&X6[K6J_LNV&?\
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M\S%J4J)[0"OC3ZMF_P"53:S_ .7"\SU_XSVG_9-E#\IM9K_Y,/S/3_C/:?\
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MW^'?SP_ZG+2?^X,W_95CAY<_.NF_G32P?;16_P"RO+/ES\ZJ[>==+I[Z*?\
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MII&XIO\ N<IOR[_,4H%/YEZD #6HL-.!^D^CCA^7OYB $'\RM1-36OU#3?\
MJCF_Y5UY_P"0;_E96J<@2:?4M-H:FM*>AE-^7GGI(F+?F/JST!)'U330#MN/
M]YSMD8_*KR1YMO\ \M_+-Y:^>]4T^"33X#'906^GM%&..RJ9+=G('^6S-_E9
M*A^77G@<:_F1K! K7_1M-J?^G;+/Y<><^.WYCZT&KN3!IA%/E]5_CE'\N/.O
M;\R-9Z_\L^F]*?\ ,-E_\JX\YT_\F/K5?'T-,_[)<L?ESYPIO^8VMUKM^YTS
MI_TB8[_E7/FW_P N)KG_ "*TS_LDRO\ E7/FZH_Y"+KE._[G3/\ LDS?\JY\
MW5_\F+KE/#T=,_[),Q_+GS=44_,77..]1Z.F5]O^/3*/Y<^<=^/YC:V.E*P:
M8?G_ ,>HS'\N/./):?F-K84?;!@TPD_(_5=L:/RX\Z<M_P Q]:X^'U?3*_\
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M  W)).1W_E9'Y>4_Y2C2>E?][K;I_P 'E'\R_P NAU\TZ0.W^]UM_P UYO\
ME9?Y<_\ 4TZ1X_[W6W_->4/S-_+@[#S5I'_2=;=MOY\P_,[\MR.0\U:01X_7
M[;_FO-_RL[\M]_\ G:M(VZ_Z=;=O]GBMI^8?D&\NX;.T\R:7<7=PPC@MXKRW
M>1W8T"HJN69B>PR09LA/EHD_FIYVK3X;31E!VK3A='?Z3DVS9LV;-FS9LV;"
M%G3_ !Y&@/[P:6Y(IV-PM-_H.'V;-G__U/5.;-FS9LV;-FR$?ED*7OG>H*D^
M9;HT(H?]Y;7?Z>HR;YLV$/FS7;G3OT786''])ZW>+8VCR LD8$;SS3,H(Y>E
M!#(RK7XI."M\.1)/S(UUO+D/GH);?X4FODMET[TI/KGU22[%DEUZWJ</4]0B
M;ZMZ']S^[]3U/BP1>_G9Y?BTV>[MM-U*:58#<6<$ELT'UE4N5M)?2:0@?N9I
M(Q+7]EU=>>";;\S;&(ZDMRES?7%O>7R1V=I:,LT5MIZQ&=I%:1O4])I57U5X
M>NTB+#"V#-'_ #0\M:QK,.F6"74@N97@M[\PE;625+5;P*DC$%N=L_JH0O'C
M_L<"ZMJWY@IYQLM)MIM-M]/U)[DPJ8)I[F*UMH!6XDD]:*/XKJ2%/2]+[#_W
MG+#SR7YC;S#H$6H2PBWNTEGM+Z!354N;.9[><(3U3U(F,=?V..'F;-D&_,)5
M;S7^7H(K36YB.O4:7>4.P.#O,NO:O_BC2?*ND2)9W.HVUU?W.HRQ^L([>T:*
M/A'&2JM+))<1_:^%(U?]KCD;@_.8:?%?V>LZ7=WVI:0;]KZXTR)&@:VTR9(Y
MKD"2562D<T4CP5D96Y1HTC8)3\T4N]4AB99=-T^+6+NR-[PAF@N+:STY[QV=
M_4#P!U'K*ZQLW&/A^T_$4WYMV4?U>.70]26ZO9;..RM^-N3+'J*RFUFY^MZ:
M)(;>5&5WYQ/_ 'BJOQ882^8-1\Q>2K/7/+5[%HR72BXGN]0@]<V\$88S*T*.
MBM*KIZ;?ON"_&_)N/%MY(\VQ7FDZ/9:YJMF_FN^M%O7L$*03O%)61'%J7>11
MZ5.7VOLMD5U_S)Y\M#YQNK358S9^5KZU,D)M8V<Z=);PW=V0U=YH89I/1/'C
M^Z_>([/RR4Z;YBO'_P 3:_)=B[\N6/(:9!%&G(BT@YW+K(/[T/+RCC_XQMD<
ML?,GFN6U\JZI?:YZ+>;AR@TNUL5EAB$]JT\213\782VZ<9GDN3Z,WHS?#']G
M"!_S>\VI^6ER)A%'YZLV2.YF$8: 6TD:7*7ZQTH8WMIHXU'V?K;</LY(+/S!
MY\C_ # N-)@N9=7L+75(K2[B>TCCAAL9=/CN7G>[C5%]>.>14CB_W8C?W?\
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M MXVLLBW,JAQZT?I^NGU=0Z\7AE67G^R-U/6//-Q:PZUI.J10Q7NHK%HVD-
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M6":1>7%N#\'XM]G"W_E7GE^VDCB^M3KI OOTE;Z \D:V?UWF9PRCAZW#U_\
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MV_AR4>6-'\S6WDC0]/,\&DZG:6\4=V@MTF3X$X\>".B(_P!EGX,R\N6 _/\
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M@A/_ #OEV/\ M5V_;_EXG[X?YLV?_]3U3FS9LV;-FS9LA7Y8-4^;A2G'S)J
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M16W:C2PT5?YN+8$'FK\O RS+^7FK>HA01,/+<O*L(I'Q/I;>FJ_!_(OV<O\
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MIH^D1WWZ0CL;=+\)Z0NUB03>F  $]0#GPV'PUQNN$C1-0(%3]6FH/^>9R/\
MY1*%_*OR@HIMH]CT! _WG3QWP;9>>M O=>FT6!Y#<0O/%ZS(5A:6T"&XC5S^
MU")8^>W#XOA9OBP'9_F=Y5N9(5$DL,4ZU6XEB81"0VYO!"SCEQF:T'UE8_\
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M[ZA<'?)OFS9!_-/G_06;6_+<?K/=Q6EQ%+<I&3;I<&V:40/(/LR>E\>X]/\
M9Y\_AR.3>79;?\I- N_*OEC2]2UR33["L<]O "RO;KS?FR,.2GXFYAN2\OV^
M.'6O^6Y8_(IO=)\J:3+YI>",BQ^JPA!-+0,JEU('I%N59/A^#XL=I_EWGY$&
MHW7E+24\T"U:7]&&UAX&9:E8257[34X\E^#G_DY?Y>^5S>>6XY?-_E?2K+61
M(\<D$5K PXQGB'+! C>H07'!57AQR2_X+\G?]6'3O^D2#_FC-_@OR=_U8=._
MZ1(/^:,B/YK^5_*UEY&O+JVTFRM9HKBQ*3PVT*.G^G0"JL%!&='S9!_)U/\
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M7EKR[8QB*RTRUMH@DD02*%$7A-Q]1:  <9/33F/VN"_RX&MO(_DNUM;JTM=
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MFS9LV;-FS9LV;-E-]D_+(+^11!_*+RM3I]27V_:;)WFS9LV;-FS9LV;-G/\
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M -'68_F#YU'_ )3K6#\KK2_^RK-_RL+SK_Y;G6-_^7G2_P#LKRQ^8/G4BO\
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F;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9L_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>exh103_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh103_3.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_X1 117AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    <    <@$R  (    4    CH=I  0    !    I    -  +<;    G
M$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S #(P,38Z,#@Z
M,#,@,38Z,34Z-#0      Z !  ,    !__\  * "  0    !   "P* #  0
M   !   #CP         & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $   [;
M     $@    !    2     '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 #_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ H !\ P$B  (1 0,1 ?_=  0
M"/_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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MMY AQW$N=M>[W;5*BD-L:Z[+;<UI.]@H:V=#M]S/<U)3K)*G_DWG8/\ ,/\
MY%#(Z>+@?3&S8?\ !F)D?R4E.@DL>S&8Y[BS(:QAG:W[,TQ)W<[/S6^Q5G5Y
MCF;/0-<N+R]@QG.&C@VAN^K8^KZ+_4>RNUG_  B2GH4ES_V?(V:->#!(!9C2
M7#5M3MN,YK:[?H^M_@_\)5_A$>G":QP?9D6.!(<:?LU1:-9=7OKQ6O<S\S<D
MIV4RH>G@F]CAC^T,>#^A=$DUQ_@_)%VX!U^S_P#@#O\ TFDIMI*B^O >US6T
MFMS@0+&XYW-)_/;OI>S<W^4U5V8E8;M==<7AQ=O&,P':?HL_HNWV_O)*=9,A
M8C=M#1&T2Z!$0"3M]I^C[49)3__0]54+7%M3W-Y:TD?$!30[_P"8L_JN_(DI
MBZ_T\87.:7^UI(;$ZQK[BUOM0<;.-SH<Q_O,L&S:0PB1O_2/W?U_^$K]B>JY
M[\9K78MCFN8 6GTX((X(-JACV4LW?9L%S#62QVQM3(/M<X?SC?Y/T4E,NH9&
M13'H1.QSH+=^H=6T:>I1^_\ Z1 9FYEC2/4KI()FRVJ&&/S/;EEV_P#\@A=8
MO>6L+\>P- =)=Z) ]U7O=O\ M3?;_P 0J-3GSZSZ'NL?#6$-I>'.)+/>YF$V
MRO9ZO^OZ5)3LU/S+'@-R\:S\XM96XG;_ .Q)_P Y.[]H50ZVZNQDM$,K+'27
M5-Y=;:SW?I?_  -9-+<VZEIQJ;"T;@Y]5U=0U=OV,?\ 9ZWV-V.9_P!\6B_*
MS74QD8;JW"ZL-+7UN:6[Z]KM7L<W^JDI,,V\@'[%>)B035(F>8N_-VJ3\J]K
MB&XEKP.X-8[;OSK6_P!12^T7?]Q;?OJ_]+)?:+O^XMOWU_\ I9)3&F^VS(<U
M[36/3:X5NVD@ESVSN87M]VW]] NSLMM]E;&UUMK(#?6)!?(W>HST@_\ 1[O9
M^^IBZT9CW?9[#-3!$US]*S_A4]O4ZJ3MO8:7$2&OLJ:8XW:W)*8G+M/J-:]C
MXJ>\/8TC:YNW9NWE[?=O_P"@KE9)K:3J2 3]RI6Y[;:;&,K<XNK<0 ZO41S_
M #OFKE7\TS^J/R)*9I)))*?_T?54._\ F+/ZCOR(BA=K38/Y)_(DII^GEWX+
M:C54-S&Q^E?$@!S=VRNMWTOY7O5;!QLMKI(9:ZAY:9NR!#P-(^T>M^9;9O\
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M24DMR7FI_P"KV_1/[GA_QB-1_,5_U&_D5;[0QF+8+\JJQ\/.\0P1J6C;O?\
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M ^T      ! !+     $  0$L     0 !.$))300F       .
M #^    X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-! H       $  #A"24TG$       "@ !
M      (X0DE- _0      !( -0    $ +0    8       $X0DE- _<
M !P  /____________________________\#Z   .$))300(       0
M 0   D    )      #A"24T$'@      !      X0DE-!!H      T4    &
M              ./   "P     @ 90!X &@ ,0 P #, 7P S     0
M                   !              +    #CP
M   !                         !     !        ;G5L;     (    &
M8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M    3&5F=&QO;F<          $)T;VUL;VYG   #CP    !29VAT;&]N9P
M L     &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@
M  =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I
M;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP
M965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   X\     4F=H=&QO;F<   +      W5R;%1%6%0
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M;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M   *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M    "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     3_P
M    .$))3001       ! 0 X0DE-!!0       0    !.$))300,      [W
M     0   'P   "@   !=   Z(    [; !@  ?_8_^  $$I&248  0(  $@
M2   _^T #$%D;V)E7T--  /_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" "@ 'P# 2(
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M=^8K#KA7C>C87N LJ:S;1:S:S?6UK=SA9N?_ ,)N24H=+K:UK6X=,,C:/5?
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MT\"T>:2D](N&23<6FSTQ)8"&_2=^\7)WCJ&\['4[-\B0Z=D-]OTOYS=O]_\
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M))3_ /_9 #A"24T$(0      50    $!    #P!! &0 ;P!B &4 ( !0 &@
M;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O
M '  ( !# %, ,@    $ .$))300&       '  0    ! 0#_X3DA:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@
M:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM
M;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2(S+C$N,2TQ,3$B/@H@
M(" \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO
M,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N
M(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX87!-33TB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(^"B @(" @(" @(#QX87!-33I$
M;V-U;65N=$E$/G5U:60Z-#0S1#,X,#1$,#4Y138Q,3@U.#,Y,S)!1C Y,#$Q
M-C \+WAA<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX87!-33I);G-T86YC
M94E$/G5U:60Z,$(X13!$,C5$,#4Y138Q,3@U.#,Y,S)!1C Y,#$Q-C \+WAA
M<$U-.DEN<W1A;F-E240^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @
M(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X
M;6QN<SIX87 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B/@H@(" @
M(" @(" \>&%P.D-R96%T941A=&4^,C Q-BTP."TP,U0Q-CHQ,SHQ,BTP-SHP
M,#PO>&%P.D-R96%T941A=&4^"B @(" @(" @(#QX87 Z36]D:69Y1&%T93XR
M,#$V+3 X+3 S5#$V.C$U.C0T+3 W.C P/"]X87 Z36]D:69Y1&%T93X*(" @
M(" @(" @/'AA<#I-971A9&%T841A=&4^,C Q-BTP."TP,U0Q-CHQ-3HT-"TP
M-SHP,#PO>&%P.DUE=&%D871A1&%T93X*(" @(" @(" @/'AA<#I#<F5A=&]R
M5&]O;#Y!9&]B92!0:&]T;W-H;W @0U,R(%=I;F1O=W,\+WAA<#I#<F5A=&]R
M5&]O;#X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H
M='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD
M8SIF;W)M870^:6UA9V4O:G!E9SPO9&,Z9F]R;6%T/@H@(" @(" \+W)D9CI$
M97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70]
M(B(*(" @(" @(" @(" @>&UL;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O
M8F4N8V]M+W!H;W1O<VAO<"\Q+C O(CX*(" @(" @(" @/'!H;W1O<VAO<#I#
M;VQO<DUO9&4^,3PO<&AO=&]S:&]P.D-O;&]R36]D93X*(" @(" @(" @/'!H
M;W1O<VAO<#I(:7-T;W)Y+SX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @
M(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @
M('AM;&YS.G1I9F8](FAT=' Z+R]N<RYA9&]B92YC;VTO=&EF9B\Q+C O(CX*
M(" @(" @(" @/'1I9F8Z3W)I96YT871I;VX^,3PO=&EF9CI/<FEE;G1A=&EO
M;CX*(" @(" @(" @/'1I9F8Z6%)E<V]L=71I;VX^,S P,# P,"\Q,# P,#PO
M=&EF9CI84F5S;VQU=&EO;CX*(" @(" @(" @/'1I9F8Z65)E<V]L=71I;VX^
M,S P,# P,"\Q,# P,#PO=&EF9CI94F5S;VQU=&EO;CX*(" @(" @(" @/'1I
M9F8Z4F5S;VQU=&EO;E5N:70^,CPO=&EF9CI297-O;'5T:6]N56YI=#X*(" @
M(" @(" @/'1I9F8Z3F%T:79E1&EG97-T/C(U-BPR-3<L,C4X+#(U.2PR-C(L
M,C<T+#(W-RPR.#0L-3,P+#4S,2PR.#(L,C@S+#(Y-BPS,#$L,S$X+#,Q.2PU
M,CDL-3,R+#,P-BPR-S L,C<Q+#(W,BPS,#4L,S$U+#,S-#,R.S(S-#,P0CE&
M0C<T03 S0S1$-3,S-T(Q,D(Q-3,U,$5"/"]T:69F.DYA=&EV941I9V5S=#X*
M(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I
M;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.F5X:68](FAT=' Z
M+R]N<RYA9&]B92YC;VTO97AI9B\Q+C O(CX*(" @(" @(" @/&5X:68Z4&EX
M96Q81&EM96YS:6]N/C<P-#PO97AI9CI0:7AE;%A$:6UE;G-I;VX^"B @(" @
M(" @(#QE>&EF.E!I>&5L641I;65N<VEO;CXY,3$\+V5X:68Z4&EX96Q91&EM
M96YS:6]N/@H@(" @(" @(" \97AI9CI#;VQO<E-P86-E/BTQ/"]E>&EF.D-O
M;&]R4W!A8V4^"B @(" @(" @(#QE>&EF.DYA=&EV941I9V5S=#XS-C@V-"PT
M,#DV,"PT,#DV,2PS-S$R,2PS-S$R,BPT,#DV,BPT,#DV,RPS-S4Q,"PT,#DV
M-"PS-C@V-RPS-C@V."PS,S0S-"PS,S0S-RPS-#@U,"PS-#@U,BPS-#@U-2PS
M-#@U-BPS-S,W-RPS-S,W."PS-S,W.2PS-S,X,"PS-S,X,2PS-S,X,BPS-S,X
M,RPS-S,X-"PS-S,X-2PS-S,X-BPS-S,Y-BPT,30X,RPT,30X-"PT,30X-BPT
M,30X-RPT,30X."PT,30Y,BPT,30Y,RPT,30Y-2PT,3<R."PT,3<R.2PT,3<S
M,"PT,3DX-2PT,3DX-BPT,3DX-RPT,3DX."PT,3DX.2PT,3DY,"PT,3DY,2PT
M,3DY,BPT,3DY,RPT,3DY-"PT,3DY-2PT,3DY-BPT,C Q-BPP+#(L-"PU+#8L
M-RPX+#DL,3 L,3$L,3(L,3,L,30L,34L,38L,3<L,3@L,C L,C(L,C,L,C0L
M,C4L,C8L,C<L,C@L,S [1$9".$8T-#A$03DS.3$X,T$Y-T0V-C,V13DQ,30W
M1$(\+V5X:68Z3F%T:79E1&EG97-T/@H@(" @(" \+W)D9CI$97-C<FEP=&EO
M;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_N  Y!9&]B
M90!D      #_VP!#  8$! 0%! 8%!08)!@4&"0L(!@8("PP*"@L*"@P0# P,
M# P,$ P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  +" ./ L ! 1$
M_]T ! !8_\0 T@    <! 0$! 0          ! 4# @8!  <("0H+$  " 0,#
M @0"!@<#! (& G,! @,1!  %(1(Q05$&$V$B<8$4,I&A!Q6Q0B/!4M'A,Q9B
M\"1R@O$E0S13DJ*R8W/"-40GDZ.S-A=49'3#TN(()H,)"A@9A)1%1J2T5M-5
M*!KRX_/$U.3T976%E:6UQ=7E]69VAI:FML;6YO8W1U=G=X>7I[?'U^?W.$A8
M:'B(F*BXR-CH^"DY25EI>8F9J;G)V>GY*CI*6FIZBIJJNLK:ZOK_V@ ( 0$
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M_C;&?XP\I5I^F["OA]:A[_[+*/G+R>#0Z[IX(ZCZU!_S7F_QGY/_ .K[I_\
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MR+%SXKP]7#'2?-&O7^E?EOK$^K2S:XEQ8Q>8=+BU!H[F2VO><-O(U@!Z4J3
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MWQ R)+ZC/ZB2O_D\0VH_D]Y3O+O7IT:XLHO,EFFGZK9VABBMWBCV5@@C/&4
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M_AH!BB_F+I;"HTO6Z#_M4WX[T[Q9?_*P+#E3]$:W\_T5>4_Y-XC)^9-FAH-
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MZU^;'$?[C="#=_\ 3KRG_4)C'G_-[?A8^7QX5O+T_P#8MC/7_.3_ )8O+O\
MTEWW_9-CQ-^;W>T\O]?^6F]Z?\B,>9/S8XFD&@\NW[Z\I_R:S<OS8(KPT%3_
M "\[QOQXK^K&D?F[4T;R_3]G:]V^>^)</SF_W[Y<_P"1=]_S7FX?G-_OWRY_
MR+OO^JF;A^<W^_?+G_(N^_ZJ8HD?YOT'.?R^#WI#>G_F:,<L?YMU'*XT #O2
M"]K7_D=@'1-#_-/2K>>".]T.19[JYO"S6]W4/=SO.ZT$WV4:3BN&(@_-4@5O
MM"4FM?\ 1+PT\/\ CY%<QM?S5[:CH8'>MC=G_L;&)M9_FY^SJN@CPKI]X?\
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MF_NY)O@B^R8Z+YZT76-7?2K9+B.Z5+B5?7A:)'6SN?JEQP9OM>E-Q5O]=?\
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M;."]@DNW225+=9%,ACBD]*1PE>7!)?W;-3CS^'*?7=&7Z\3>0TTU>6H$.#Z
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MHDG";XE?/@\PWGDOS;:ZEIEN]H;65-)6T>6\N)R>0CYP>@GIR5],J(WF^/\
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MPE^8?_4]S?\ <-L?^:<K_"7YA_\ 4]S?]PVQ_P":<8?)WYAG_IO[@?+3=/\
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MLV;(5^:AI8^7#6G_ #LFC_\ 46N37-FS9LV;-FS9LV;"[S'_ ,H]JG_,)/\
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MQ:'IWF'2-+@L];N)K5)K&]GN)(WBM9;D$K);0+Q;T2GV\G>%_F+_ )1_4_\
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M2K= PDE5$CC;E<%8XSZ:>I;R1MA9::[YA%^OER34+R-W\PG3YKN\6!;I+/\
M1KWD?IR1+Z+_ %F2&L3!.<<3M"_&1<6\O:[K7FGR[87MWJLNDI#ID,NJ7=HB
M!Y)[AJ@QATD16:.)73BC_#=? O+AA1-YI\]6%NGZ1O&.HZ+9:1.\ 6-#>2:C
MJ<EK(DZ <?4^KI'$W#@D=T[.G[.2JRFUO5O,'G;2/TO/90V=S8+9W,:PF2WB
MDM8IIEBYH4JY+_'*LG'EAC^7+ZG-Y92]O[ZXOQ?3S7-A-=",2BR=S]6#>FD:
MGE"$E^Q_NS"C\Y/^.-Y>_P# FT/_ *CX\GV;-B-XQ6SG99EMV6-R+AP"D9"G
MXV!('%?M'?.&6VHZO)Y?N-.UN\N+C6K#S'HGUQ9)#-;.'UA52ZLY2%;T9^#+
MZ'%/1:'X4XMSDZ=YM_+7RYYIUC2]5U,2?6=)8- L94))217XS*5/JI173@WP
M<9I/V^#*IY\_+S0?.UG:6NKF5%LY3/!) 51PQ0K0L5:J<N$AC^Q(\4?J<T^'
M%?-OD/R_YJ\N+Y>U.)ETU&C:-;<B)D]+90C**QCC\!]/C\'P8;Z1IEMI6EVF
MFVPI;V<*01?"J_#&H6I"!4J:5/%5P7FR'>=1_P [=Y"/AJMU_P!TJ\R8X \P
M"N@ZD/&UG'_)-L(?RB%/RJ\GC_M2V'_4,F2W-FS9LV;-FS9LV;-G_]7U3FS9
MLV;-FS9LA?G[_E)/(7_;<?\ [I=[DTR$K^7U6N83.UNT&L2:_HFH14+PW%R'
M,T<B/4.G*6=&'V7@F^'A(G+ NM>1]834+'4["<W6M76K6]UJNI,L2+%:VUM/
M#$B0DCE%$9O[OF\K>K*_J8*B_+"VMP([75+F& Q:>LD7"%N4VFWC7B3$E-FE
MD=ED1?@XM\''X<:?RKL6LQ9MJ5P;>V!BTH$1EK:![N&\>+D0?5'J6T4:L_Q)
M O#[?[S#JP\L3Z?I6H65EJ<T,]]>7-\EYPB=H7NYS.R(CJ4:,,S*.8Y<?VN7
MQ8!G\DH]UHT*ORL[#4)=:O)W($L]ZRR!-D"JJ\YFD:G^^XX_VFQ^L?EWHNM7
MT]SJDLTZR7=M?0PJPB$4EK$8>*L@#M'-&SI.C-\:.R?9P*OY86,4LL]OJ=Y#
M<W$]_+<3+Z)+Q:HR274%#'01^I&CQ-_>Q,OVV7X<=8_EAHMAK=GJ-E=7-O:V
M%T;ZUTM#%]76=K,V+M5HS-1X/V/5X^I\?[6'6I>6-/U*\N;B\:207-A)IAB#
M<52&<UF*$#FKRT0,W+_=281:1^5NG:5J-MJ5OJ^I&]A@AL[F9G@'UFUMN/HQ
M3!(5'P<:>K%Z4\B_!+*Z8-\K_E[HGER_DO;.2>64P&S@$[*1#;>O)<^DO%4+
M 2S.0TOJ2<?AYY)\@7Y41R'\IM-CAG:VD$-T([A%5V0BXEHP5P48KX,,+?+7
MGGS!JT6A:3JEQ^C/,4IBENC!''Z-]97%K++'=6_K*]*.B+/&OQ6\W[M_W;Q.
MX3RUY[\SZK8?E]Z\US#/KTDJ:K=&W@2*8+93W ](E6"_O(4X\5_N^7+#/\K?
M,OG36OT?<:DTEWIEUI0N;N]EMEMUCOS-Q6&!E">M$T/)W^"3TV1?WW[S@K/^
M5J?HVRD=["]U,A]:N97=K:-HH-(OA!.E%*J5C21?0_;D1?C_ 'G+$;WSSKUO
MYQU=6CGEATV]73M,TBTXNMZ9-,%^S2_NGFC=!5D>/_)B9./.3#+6/S,OXM!U
M34],T5Y5TZVE:5KF5(3#=QV:WGHS1[O14D5*Q\V];X.*Q_OL5A\ZW<.N7>F>
MA)<:M<W<-I:6$TT:6ZN--6]E,<J1%UC"AN7/UG:;['&/[(6T_-^&[N+'T=(F
M%E=2:=%-</+&K0OJ<\UJBF(<BS17,#(_Q<>'[U&_98Q\T_F#<Z'K+:>FDM=P
MQ#3C-<B=(Z#5+M[*/BC*2S),J\MU^!OM?#Q<OA_-AI+"6[_1-#IL?K:Y")U+
M0H+V:Q8P? /K/%[6:7?T?W2_[];AA=JWYEWEOYGLM3XLOEL6FL1I DH8W4]C
M>VMDC.A0>C^_DD5/WC?NWY2*C?#AWI'F/6[_ ,[:=;7L,FG*VGZG]:TPNLD;
M2VMU:+#.& 5_CBF9D#JC\9/BCPIO?-FN7VH1P07;Z?;ZGYDET!;A0E;>WL8)
M9)"G,,OUB\GA>-7<-QC=."\UPXN]6U;RW?/I=O<G7KJ[2XOK."]E2%H+:SBB
M]:(S(C&1WDE5H><7[;^I)P3"37OS>O4TV\ETJQCBE-K:7>EF]:1&FBNI+5#(
M$$9C98_K923TII'AEB_?(GJQ\NH)RX+S #T'( U />A(%?NR\AVN_P#DT_*7
M_;.UG_B5CAWK'E/R_K%U#=:E:">>!>"L6=0R"191'(JE5EC]6-)/3E#IS7&7
MGD[RW>VEK:75DLMO9AA A9Q\,A!D1R&!DCD*J98Y.22\?WG+&2^2/*TM_/?R
M6"M<W+,\K%GX\WX"1U3EP1Y1#$LS(JM*J<9.2Y<ODORU+KIUV2T+:HSQR-,9
M9N):%>,9,7/TO@'V/W?P_:^UC8O(WE2+2K[28]/1=/U)/2O8.3_O(@.*Q<N7
M-847X(XE;TXT^!%5<,;G1]-N4LUN(!*-/E2>SYDL8Y8U**X)->05F&_\V#,*
M;[RIY?O[B^N+NT$TVI6RV-\S,_[RV1F98B P'$,[]/YV_FQ+3_)/E73H[F.R
MTZ.%;M)(KFA8ETE $BDDDT8*O_ XI_A'RX=,_1C62-9^HLQ5BS.94H%D,I)E
M,BA0O/GSX_#]G-=^4/+-Y8-I]SIT,EBTD<QMN-$$D*+'$P44X^FD:*E/L\%Q
MEOY+\JVXL1!I=O&--+-8@)M&6?U21XGU?WOQ?9D_>?;P4OE_1EFU&=;1!-JZ
MA=2?>LX5/37GOOQC^ ?Y.#+>WAMK>*W@01P0HL<4:B@5%%%4#P &07\Y/^.-
MY>_\";0_^H^/)]FS94D<<D;1R*'C<%71@""#L00>HSFOYCZ+Y6\J^38Y[*V@
MTJQ&N:/=7LJ 1H FIP,SN3_NM%K\/V(U^SQ7#O\ Y7%^5?\ U-6F?]),?]<W
M_*X?RL_ZFK3?^DA/ZYO^5P_E9_U-6F_])"?US?\ *X?RL_ZFK3?^DA/ZYC^<
M7Y6 $_XITW;_ )>$/\<8WYS_ )5*:'S3I]>FTRG]6$6H^??)OF;SMY(M= U>
MWU*X@U*ZFFBMVY,L8TR[0N=OL\F5:YU# .O?\<+4=B?]%FV'7^[;"'\H_P#R
M5?D__MC6'_4,F2S-FS9LV;-FS9LV;-G_UO5.;-FS9LV;-FR&>?A_SL?D,^&N
M/_W2[W)GFS9LV;-FS9LV;-FR#_E# DWY7:5 Q(22.YC8J2&HUQ*-F&X/OAA9
MZ;Y$NI=,TRUN(+F^\N(Z::$N/4NK91$;62CAC+_=OZ<E3]KAR^-5P3!Y$\M6
M]GI%G#;R1V^@LSZ2JW$X,#-&T1(;GR;]W(Z?O"_POAAH6A:9H.E6^DZ7$8-/
MM05MX2[R<%))XAI&=Z5.U6PIF_+CR?-%+%)9,T<R7T<B^O<"J:I()KT;2;>O
M(JLU/L_L<<3U?R3Y(NGD@U.WY2ZM=Q77)KB=)'N[:'TXWBD617CE6W3A^Y9.
M4?+[7Q8L?RZ\EFZN+G]%1"6[M197 !<(T B] #TPWIA_1_=>L%];TOW?J<<6
M;R1Y89:&S(;U(9EF$LPE66WB]"*1)>?J(ZPDQ\U;DR<N?+EF/D;RH2A&G(OI
MFT,81G55.GLSVM%5@/W+NS)_E-B^H>4_+^HWLE[>V8FN95MU>1G<5%G-]8M]
M@P7]U/\ O%V^U@=/(?E%&A9=,CY0/(\9JYJ99_K3AZM^\3ZS^_"2<D67XU7E
MC&_+WR2UY>7;Z-;//?K<+>%DY+(+OC]8!0_!^_X*9?A^-OB;XL$Z5Y/\M:2]
MH^G6$=L]C%+!:LG*JQSLKRBI)Y>HT:%V;DWP+B+>3-$E.JPW,*7.FZO,MU<V
M$JAD6Z4 --&?M(S\(WV^S*GJIQ=FQ2;R7Y6GMH[>;3898XI&F5G!:3U'7TW9
MI"?4<R1_NY.3?O(_W;\DS3>2_*DXO%ETNW=-00QW:,M5=2$!''[*U]*+EPX\
MO3C_ )%PY1$C1410J( JJ-@ -@!EY#M?:GYH^4-JEK'617P'^AG^&3'-FS9L
MV;-FS9LV;-D"_..GZ&\OU/\ TTNAT_Z3X\GN;-FRG1'%'4,/ BHRO1AV^!=N
MFPR^*^ S<5\!FXKX#-Q7P&;BO@,W%? 9> ]; .C7X(J/JTM1_L#D?_*3_P E
M9Y0_[8UA_P!0R9+,V;-FS9LV;-FS9L8T\*S)"S@2RAFC0]2$IR(^7(9__]?U
M3FS9LV;-FS9LAWGS_CO>1?\ MNM_W3+W)CFS9LV;-FS9LV;-FSGWY:VM[=_D
M[:VMC-]6O9[:]BM;C_?<KS3*C[?R,0V%ECHE_>Z1Y"T:VTRYTS4/+TD3:I<O
M&T*VT<%I);W"13TX3FZ=QP]%I%?^^DX\,#W$7YF0>6O4NFU"2?3[N#2[TVP:
M2YNK&V>3U=1AB1XV,ERSP,XB9)O1BD6/$I-*\_-;74AO]>::!M$BMB2L;212
M21+?R-'$&C]1849YN);TW:3'ZG!^8%G=:GIME^F+A+:>^-C>EVD5K:30PMM^
M\+#U)/TC&QH%9HYFY?!ZF)SVOFQ/+NHV5XU[)?27N@2Z)+>%I)3>$6TEUZ;.
M=DC>.9YE7C'&OK?L9V+-FS9LV;-FS9LV0WS""/S/\G,%!K::PI-.E5M36O\
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M[RRNW[?%J>IG]=SE'\DORV- =-G-.E=0U _KN,L?DI^6H_Z54G_2;??+_?\
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M<_ K_M<<$V>O^<_\<IHU]:Z<NES0W-TA@DF>[BMX76.%YJJ(N4[/]E3^R_\
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MS9LV;-FS9LV;(=^:I"^7M/)V US1*G_MZ6^3'-FS9LV;-FS9LV;$;W_>.?\
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M+<0PY=>-=Z?+&O/ G/G(JE%YN"14*/VC[85^6_,MMY@M&O+6VN(;0\&MIKA
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M7L]CI[1M=V=VUMZ_[MWL]7>[Y*&A9JRVDSKSF>23[47]UP13/4?RX\QW,5_
M;6UEAO3K$=J&F(^I27]Y]8MKZ,\/[Q%^VJ<98WCC])^/+!GEO\O]<TKSE#K!
MAMQ&U_K$U[=+)6:2WOA$;>M%6I]2(O)%]B-OB7EBI\BZXVO3W-Q;VMS%'?W]
M]'?-(?6N;:\M7B73YD92!&CNB_$SQ>E;PMP]3[,I\BZ/<Z-Y.T;2KJWAM;NR
MLX8+F*W(:+U8T"NRL%3ES8<Z\<*/-'_DRO(_^KJO_4-'DTS9LV;-FS9LV;-F
MS9!?SG-/)UL:5IK6B;?]O6VR=9LV;-FS9LV;-FS8RX%8)!XJP_#(;^2@I^4W
ME,>&FP#[ER:YLV;-FS9LV;-FS9L__]+U3FS9LV;-FS9L@OYGI74_(;5^SYE@
M-/&ME=C)UFS9LV;-FS9LV;-FR%?E$D@_+FPC1PKK+?(K?:"D7LX%17>GA7"'
M0/S+\P7GE)O,5RD-WZ>BSZK=:9'9SVWQI]@0W$TABFC^%UEX_P"NO\C Y///
MFZTM"US<K8V=GIUCJ\UQ%I\,H,-_,8O0](72FL?IMZ<J_P _[R/]W^\G-SY]
MT^ W3"QO9;6V:2,7T<2FW>6&X6VE02%P(_3F>C//Z47&.:3GZ<3MB.F_F-IF
MJ164FF6-Y?)=1Q2R^@B-]76>62",R_']DRP2AGC]1$1/5=O2^/!OECSGIWF-
M4:Q@N(PULES+ZZHIB+RR0^A(%=N,Z/!)S3]GC]K([!^:5G86B?7H+V^=GNI9
M;A(8(1#;PZF=//-/6/\ <NR?8YO+$OJ\>?*-3SS;Y[TSRO/:)?V\[Q73(OKQ
MA."^I/' H^-E:1^<RL8XE=_25Y/V< _F/J_F?1K2WU#2[R""WDO-.L3#)#ZK
M$WMZEO*_(LOV(Y5,:_S_ &\+=-\]ZGI?G#5-#\PS&\MHKBTM;6^@ACBBB::S
MENOWJ\S)\:PM]D2*K?R*V"[;\U(;OZJMIH&IS2W\Z0V2F.*)95DM6O%D6262
M-.(B1Q)ORCD7BWVDY)M^;NG\WACTF\DN_K5I:16ZM;\F>^:=(:L90B'U+21)
M5+?NN2<OV^"NG?FOI^I_5A8:3?SNX5;]%BY&SE>2:'A.4+(.$MM*DLBOP1>,
MGQ)]E"3\V(IETP:?IDSR:A+HQ99VC3T[?6A(R-\+-^\C$#JZ?S<6^)<4T#\P
M6N888H;2\U.8SSF]D?ZO&]O!^DIK%&*H55TC>&3['Q_5XO4D_>_"\\S9LA?F
MC_R97D?_ %=5_P"H:/)A-<VT)C6:5(VE;A$'8*68_LK7J<S7-NKF-I45UX\D
M+ $<R0FW^40>/\V4UW:K<+;--&+EQR2$L Y4=PM:D;8R/4M.DG%O'=0O<-S*
MPK(I<^FQ1Z*#7X'!5OY6RUO[%DG=;F(I;,4N6#J1&RBK*YK\! ._+*GU'3[<
M0FXNH81<$+ 9)%7U&:@ 2I'(FH^S@C$C=6HF: S()D3U7BY#D$K3F5K7C4?:
MQ&#6-)N+,7MO>P3V9<1BYBE1XRY8(%YJ2O(N0E/YL9'KNB26,M_'J%L]C 2L
M]VLT9B1EV(9P>*D5[G'W>KZ59P"XN[R&WMRC2B>614C]-!R9^3$+Q534ME#6
MM'*6D@OK<QZA3Z@XE0K/45'I&O[RH_DQTFK:5$+HRWL$8L5#WI:5!Z"D%@TM
M3^[!45^/*TW6-)U2)Y=,O;>^BC;A));2I,JM0-Q)0L W$@TR'?G7_P H5#_V
MV=%_[JEOD\S9LV$J>=O*#VMY=#6+,6VGN(KV8S(J1,30!F) ^)OA4_99N7\N
M&#:KIBZ;^E&NX1IOI^O]=]1/0](CEZGJ5X<*;\J\<1N?,6@VQM!<:A;P_7PI
MLN<B+ZH8J%*5/Q!BZ*/\IT7]M<$B^LC?&P$\?UU8A.;;D/4$3,4$G"O+@6!7
ME_-A8/.WD\WMS8#6[$WMD)#=VHN(O5B$/]Z73ER7T_VZ_9P0OF3R^^C_ *:3
M4;=M)[WPD7T=G].G.O&OJ?!3^?X?M899LV-FWB<#^4_JR&_DL*?E/Y5'AIT'
M_$<FF;-FS9LV;-FS9LV;/__3]4YLV;-FS9LV;(/^9J5U#R,W\OF6W/WV=T,G
M&<M\V>9M?CF\R7$-R]G;Z?JVDZ*9U;B+:QN_JLMY=BO)?4(NF3U67]RD:O\
MSXKJ^O:MY8\UWEEH[F^TQK/3Y)8+V>65+6[N]12S7]\_J2*)X97E](M_Q[\U
M^W\19J?GWS+<6VJ1ZC]3BAL](U9KBU@DGC%Q<6%WZ!EAN%=)HXS&NP3]Y&[2
M+S;CRPVUK\S]4T^+4+JWM[66TMFU>UB@=I!-%/I%N\XDN&K3T)Q%^RJM&LUL
MWJ2>K\,A\O\ F/4=0L->74)K.TNM*G: 747+T$1[2&ZCDE$C?[K%Q23XE5N'
M+X.60S3KG6M%\L/<SW4MWK&C:]9VLUZEU/<P:BE]);0R>FMP\IB5HKG_ 'F4
MLEM<Q?N<%^=9+N7\Q9=/@?U$?R^]U]4DU">PA$J77IB8&([R<&*[F/\ U\6_
MY61=-J7U'2)[6>V@G>QC@G]1[N54TAM1AO*\UY13,JHO[O\ >)\?J\_APLA_
M,F37YM'5ELI@;_074QM(1%)J5G+,PJDJ\VCE7X%?X>'VT9_BQ/0_S4UCZMY9
MAU&_L+HZBMDNJGAZ4@:_GG@ZF4*A1XD15C29N7J>OZ'[KF3^7_,.HR>0],TF
M_FAETZWM_+UW;W\3.LD$LFJ1P26]U([D23-P+CX8OA]1'3]MY]Y$\]:MYAU_
M4+6Y-BEM;_6%^I0R,;ZVEM[IH.%S'\0421A75G])F;^[1X_B6>9"/RE;C^75
MJ9I?3"W&I5E)7X5&H7%#4U7X5[G_ &6.A\@^6;+0H-);5KL:.+26PM+>2Z01
M"*XC,;<2%7U'](LJ,_/AR;CC;WR/Y-N[25;C4I6M;RPMM)8_6D"-!8R&6(*0
M*>HK,W-Q\3<L>GD#R??SZE+:WMQ(M]<+>206]Z[0V]SZRW!FAC#%(7EFB623
M;X_B_G?&6/Y<^5$ECN])NKB2YT]I(6'UV9X9)(YWN$AO%5_WJVUS*[K&_P :
M<F5L'>4K&ST'U++4KNQ7S-KD\NI7MO;-Z:R3. '^KQ2,93&B1]?VOWDOP\FQ
M*;\KO*DUI+:RK</%-%/!)6>2ICN;L7THJ#^U<#E7^7X/L8IYC\G>4/-6I2Q7
M\KR7]I;I!<PVUT\3K%),MQ"9$C8$?OK<21,?Y,-O,'ES3=>LH;+4/4,$%Q!=
MH(Y&C/JVT@EB)935@DBJ_$_:X_%@.Y\B^7KG5I=5EBD-Y-=07LK>JX5I;6%K
M>*J \> BD=62G%^7)\0TK\N/*VE2V,EE'<*=-F,UB)+NYE$58G@$2B21_P!P
MD4LB1P?W4?/X%Y9'-6_+'RM;7>BZ?I-U]0OA=VURD,]W</++::;)),8K=6D8
MKZ37+<67^Z5^/V6P]3R9Y L-;TM$C2VU58&CL;<7$J-<16[F9C+%Z@6[]*64
MR\YUEX22\_M/BEI^6/DRT0K!9R"K6C!FN;EF7]'LS6@1FD)C6#FZHJ<?W;>G
M]C'+^6GDQ9;65; B2TDEDB/K3T;UYS=2)* ])XOK+-,L,_J1))]A%R3YLV0W
MS./^0C>23[:H/^G9,(OS=\MZEJ4Y;3&2\U#4--GTBTTV6-W]&2XFC=;^.13Q
M@^K<><LC_P D?!O4X1R"-9M'GT+])W$,D]Q<Z_ICPL86:46]E?0Q+(5"\D!C
MBFN6;BO!9GQFI)'9_F'?^8=,CEU&[M[2:+5+:YLM[=HH$-L+*Z,*2TG<\'A2
M::*7U))?@:)\!WFD:';:[H&CBQF.LZ;+!=3ZTEE<RM+>-"Z(JW*H8UBY2-/=
ML\JQ>G^[_O)GX$FF:+J)\GZ] VGW*1Q^38M,U&WD@?G/K$:W//@I6LTJL_\
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M;;QR<YLV;-E<%#%Z#D0 6[D#I^O+RF56%& (\#[9>;-FS9LAOY-_^2M\L?\
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MGS(1X_HF<=?G3+'YHP,2!Y8\Q[=:Z7,/UG+_ .5GP_\ 4L>8_P#N&2_US?\
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M_P JS_+C_J5-'_[A]K_U3S?\JS_+C_J5-'_[A]K_ -4\W_*L_P N/^I4T?\
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ME%U)9QP" ^J6&HN4MI*+7]U)Q<B7['%'_EQUMYTT9;>.74[RTLVGNI[6WX7
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M;Y4_ZO5CTK_O3#T/^RRO\7^4_P#J]6'_ $E0_P#-6;_%_E+_ *O=A_TE0_\
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MZJH 8D4-0.N6MO K^HL:A]SS"BN_7?+:"!EXM&I6O*A (Y'O\\KZM;4 ])*
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M&9**_'"31?S>M+O0+'5KS3Y8$>VL;K561XV2S34G,=MR^+G)6G-^"_!'\?\
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M?](=E_8_=K\7Q_"*U;\U[_2]/FGN-,@>XLKB\BO8(KAW_=V<\,9>+]R#1DN
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ML+& 6^G%380B->$!52BF):4CXH2B\?V<C6D1_E9J>K_4--L+&>_L(4:/C9_
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MX;(V_E?S*="\V0I87$=YJ'F)-1T\0SQPRO:F2U$CI*DH].L4,U4=T9E^']O
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GFS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>exh102_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh102_1.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_X1/417AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    <    <@$R  (    4    CH=I  0    !    I    -  +<;    G
M$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S #(P,38Z,#@Z
M,#,@,38Z,30Z-3$      Z !  ,    !__\  * "  0    !   "P* #  0
M   !   #CP         & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $  !*>
M     $@    !    2     '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 #_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ H !\ P$B  (1 0,1 ?_=  0
M"/_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M?L]%0JH?>'.IR[FLX:'-<")'/Z7:YR2E\6O<"PXMK&M +776;G..OYWJ6O\
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M<PAP\0HS?K[&^7N/_D%-NZ/< #X S_!J2ETDDDE/_]+U50L8+&%A,!W?0_\
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M[_OZ2D3/7L:YK!OVS#VFUP'! +MGO=_;4W-R1MVM>)U(VVNC\[DU^_Z7Y_\
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MZ2&_/: 2+&DC2 ZKD1^]8W\W\U3^U5D _:ZNX)]L&=6?X1)2GWT@R<PM!EP
MV1M)V1K6?H.:D+:V/&_,)X<6G9J#_58'>Y+[2T  YE.XZ#CD3N]OJ)SF4$P,
MRF9;I+3\?\)^>Y)2G$F ,P@P!Q69('J%WT/SF>Y-ZC+'EK,Z'//M:/3)$G0-
MEBBW-K<Y[1F4^W5I]OT9.[BW^S^8I#(G7[70?D. 6@_X7S24N^ZK2,P-W:M^
MAJ"(';^2DRZMH:YV8UX$2?9#MS=S/H_R6^HQ(93/<[[906[@1QHWZ3F3ZOTM
MGYZ<WD SDT M)W2.!V'\][4E,\5[7!P&0,@B)(VZ?]M_O(ZK-R 1KDTNUDP.
MWT?]*?SU'U;2X-;DT;G: ;"23Y?ITE-M)18+ #ZA!,G;M!'M_-F2[W*22E))
M))*?_]?U5))))3C9+L/TY;B6,L<-@L-1L#?=_A&5V;OS=W_F"KU>C8^KU*;'
MB2+&U8KV-<7;-CG[K;K*6L_2.^G^D]5$/VE^2;&T&J]X>VRQHM:6^[=0]KOL
M[JK/HLW_ /@J'@X^:3M)K;8XGUV/QGNU,_I?5L^R5NVMVTN]-GI^FRM)25O3
M,HL#L:RM]5@EILJ+O^+<Q[,NG8S;_(5RFKJ(LW9+*+*8(V5U;7ET^QV^S(LK
MV;/IJ=.)FU/W?:&$&-S/2VB '?1VV^WW.^FK(%^DN9YZ'_R22G*'VFO)W6.<
M]@<UGIBB1'+H?6UV[=M?_A=E']C],7(MQK\9VW&M:UKFEVZFQA,ZZ-8&WO\
M^LHMW3/5LLL=MWVL-9(+FZ'U!^:=V[;=M]FQ#HZ.ZCJ%F?Z[K76  56$%E<#
M;^@]N^O?[_4_TGJV>HDI UF-N<,BAYFPEP8S)(.CF>W<T-V_U/T/^$3.;BF
M^AX!=)VC*&GT?I,9_P!4K1Z8^N78K_0M[/)WS)!<;-[-]GM;L_G$K</J-@GU
MJR^(WP]I (VGT]K]M=G_  B2E_V?A"6^A8!J-'OC7PVV>2@[$Z90 Y]=C!N!
M;'J'W?F[=FY#?CY.+Z=]VV\4F&>Z#M)]K7NM:[\[_#>I3_PBF[J-MKJ@,=V\
M/( ;8PD$M>V?=[?WOI)*2#/Z7O#!N#W& WT[!WV_N?O*Y3Z<$L:6^,@C_JE3
M9]J.UKL>X->/3<'65N   ;ZECI=9_F[_ /A*U<I%C6!MAW%H WDB7?RG;6L:
MU)21))))3__0]54?4K!(W"1R)"3GM:8(/R:3_P!2% OJ.I83_8=_Y%)3/>S]
MX?>EO9^\/O0]]!'T'1_Q;O\ R":<<_X,_P#;;O\ R"2DN]G[P^]+>S]X?>A3
MC_Z,_P#;;O\ R"0.-/\ -'3_ ()W_D$E)=[/WA]Z?<WQ"#^K1_-:?\6[_P @
MD?LQYJ)_ZTX_]\24FD)T#]6_T7_@;O\ R"F+*VZ!KAWT8[_R*2F3ZZ[&[;&A
M[>8<)&GQ0CA89$&BLCPV-_N\U/UV>#_\QW_D4_JM\'?YKO\ R*2F:29K@[43
M\P1^5.DI22222G__V?_M%_)0:&]T;W-H;W @,RXP #A"24T$)0      $
M                   X0DE- ^T      ! !+     $  0$L     0 !.$))
M300F       .             #^    X0DE-! T       0    >.$))3009
M       $    'CA"24T#\P      "0           0 X0DE-! H       $
M #A"24TG$       "@ !          (X0DE- _0      !( -0    $ +0
M  8       $X0DE- _<      !P  /____________________________\#
MZ   .$))300(       0     0   D    )      #A"24T$'@      !
M   X0DE-!!H      T4    &              ./   "P     @ 90!X &@
M,0 P #( 7P Q     0                         !              +
M   #CP                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   #CP    !29VAT;&]N9P   L     &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   X\     4F=H=&QO
M;F<   +      W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     3_P        .$))3001       ! 0 X0DE-!!0
M  0    !.$))300,     !*Z     0   'P   "@   !=   Z(   !*> !@
M ?_8_^  $$I&248  0(  $@ 2   _^T #$%D;V)E7T--  /_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1" "@ 'P# 2(  A$! Q$!_]T !  (_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
M @(! @0$ P0%!@<'!@4U 0 "$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1
M Q$ /P#U-C&5L;76T,8P!K&-$  :-:T!220;Z#<6Q;94&\BL@3Q]*6N24F47
M/8P N(:"8$F-2JO[/?!!R\@RT"=S09&WW^VL>[VJ-G2Q:US7Y5[FN_-)81_T
MJTE-LWTB9L:(U.HX4/MF)K^GK]LAWO;H1]*=57;TC&826/>PDD^S:V-PV>W8
MQNWZ*7[(I/TK;72-NI:>>_T/I)*;+LG&: 76L:#P2X"?Q_DIOM>)I^FKUF/<
M.W/=5G=&QW"/4L'806F >PW,<G=TC&),.>T$ET-( $_2@;?SDE-C[9B$2+ZX
M(D'>WC[TCFX8@&^L;OH^]NOPU0/V5CZ#?9M'#00!&GMT;^=M]R3NE8[@!NL$
M1!#B#I&W5L?1A)2?[9A\>O7//TV\1O\ ']WW)-S<-Y 9?6XD[0 ]IDG\WE _
M9.-!]UNXF=WJ.W<06[OW')?LN@1MLN8>Y;:\2--'0[^2DINI*J.G4@@^K>2-
MO-UGYH+?W_SMWO\ WTW[-IT_2Y&G_#V_^E$E-M))))3_ /_0]50LE]C*'OJV
M[P/;O.ULS^<_:_;_ )B*A9!(H>0XM,?2:TN(_JL;[DE.7^ULDG^>Q"V"9;:Y
MW]7C'^AN_P (HGJ>0[5M]0:),MW.D#6=OV7]W?\ GJS5?=2&MNO=8UP):6U$
M.))YW666>W^RK/JTD$_:QH-3->FL;OH^:2FFUW6B=75C^R\_^B&*+<O-+B#<
M=L3[<>UQX/YPJ:W]Q7;I+6&O,]/>06N/ID.!+6[62W\]SV*L>G9OO#;R),L)
M?88(.F@>W;^C<YGL_K_X-)2]'VZTS9<XL:2'!M+ZG'^KZ[_H_P KTU+(?Z;7
M"<DO+=-@W1,[7>P?R/SE.G#R*_=8_P!2P M#][F^TZ[2T^IN]WYZ#EU 7#<7
MMM>T,8]CJW.!)?[?UMNSW_1]K$E(7>YY(LZB&GAH:($\?F;_ /._ZXC41)#F
MYMFXM(]0EL3I_@W5?V]Z%4YHM+79=[6-F3OH['_1U5[_ '*QLJT<<V\M)VS(
MB1!U+:DE,KFBL BK(>YQ(:&6F9VN=^=>QOYBJUTOV@&C,(DDE][MT0W_ (?]
M_P"A_P!=5I[,>RL5>M<'M>*_4!=OW[8W?1V>YOY^ST5"JA]X<ZG+N:SAH<UP
M(D<_I=KG)*7Q:]P+#BVL:T M==9N<XZ_G>I:_P#SU>K:&,#0-H'8&55KPKF3
MOR#;/9X.GPV/:K-;"Q@:2#'A(_ZHO24S22224__1]54+6N?4YK3#B(!,_P#?
M5-"R3^@?+=XB"V2)!_XL/>DIKNP[7EN_80)@R^1)_-U_-W(OHWC^;-33+I_1
MG@GV#2QOYOTU0^RXA#@[&C1[AN?=J=/WF?G?^<(8JQ]6'";$B-SK3/TC/Z2E
MJ2G:  X "4A9--&$[U ,6H.V.V;=Q+P!$?1;O_.^BC-P*[*ZWMQJFN< ;&O#
MA!'[O_224WW/8WZ3@/B57L&+=>=[@88((?&A+IG8YOM4Z,/'J(>VIC+(()8.
MQ.XH.;36ZRM[JC=Z9:6U @ DO'N<VPMK=Z7\ZS=]#_!>])24TX@W;CH\$$.>
MXB"-L>YW[J48+;?5W,%G[VX3QM\?W52&+0'2.C5@ZB8HX(W'AWT7([,2FP$N
MP*JYY#PR3/N=_-ML:DIL_:<?_2L_S@D,G&/%K/\ .']Z:MCZF[*JJV,$D-:Z
M!J=SM!6I3?\ N-_SC_Y!)2WVG'F/59/]8*;7M>-S"'#Q"C-^OL;Y>X_^04V[
MH]P /@#/\&I*722224__TO55"Q@L86$P'=]#_P!4'-4U&P%U;F@D$@@$&#\B
MDIK#IU$@O)LCC>&'3W>S^;^A[D_[/ID&7#:(@0-.(^BJV\!@8++]S)+G'>YT
M$_G>S;_T$XR&"&S:2>"1=K_U*2F^*JFD%K&@C0$ :2IK-^U5<^\_V;?REWN0
M+#;O!J:]\DSOMR*@()W!K&>K]%GT/](DIV51ZD/87^O]FVM$VGAOO9^D=J/H
M?RE3;=EUL+#362PQ+K+["1+MVZU].[\WVJ#LK-)!972PN #R3>!V?[;#4U)3
M(/K<\C]KDN+@-K8T,G:P-ESO\]%I8VYX<SJ%MS!#BVL'4$O^DYF[;N=_Y[01
ME9Q#=VP;CR77M''Y[GL;L;_95RO*S&N_3V8P9&FQQ+I\_4<SVI*79CU,?O\
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M'2MI<_'PP&07RYOM)^CN_1I'&Z626?9L0N8=A:=NAY#3^B_D)*1BO)C:[IC
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M'ICZY=BO]"WL\G?,D%QLWLWV>UNS^<2MP^HV"?6K+XC?#VD C:?3VOVUV?\
M")*7_9^$);Z%@&HT>^-?#;9Y*#L3IE #GUV,&X%L>H?=^;MV;D-^/DXOIWW;
M;Q289[H.TGVM>ZUKOSO\-ZE/_"*;NHVVNJ QW;P\@!MC"02U[9]WM_>^DDI(
M,_I>\,&X/<8#?3L'?;^Y^\KE/IP2QI;XR"/^J5-GVH[6NQ[@UX]-P=96X  !
MOJ6.EUG^;O\ ^$K5RD6-8&V'<6@#>2)=_*=M:QK4E)$DDDE/_]#U51]2L$C<
M)'(D).>UI@@_)I/_ %(4"^HZEA/]AW_D4E,][/WA]Z6]G[P^]#WT$?0='_%N
M_P#()IQS_@S_ -MN_P#()*2[V?O#[TM[/WA]Z%./_HS_ -MN_P#() XT_P T
M=/\ @G?^024EWL_>'WI]S?$(/ZM'\UI_Q;O_ ""1^S'FHG_K3C_WQ)2:0G0/
MU;_1?^!N_P#(*8LK;H&N'?1CO_(I*9/KKL;ML:'MYAPD:?%".%AD0:*R/#8W
M^[S4_79X/_S'?^13^JWP=_FN_P#(I*9I)FN#M1/S!'Y4Z2E))))*?__9.$))
M300A      !5     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@
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MS9LV;-FRF:E.NYH* G[Z98K05-3W.;-FS9LV;-FS9LV;-FS9LV4S!1T)J:;
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MY(Y.#O\ 95EYI'\7'#7RAY!_P_8WMN]]ZLMW;P68NH(_0E2*VC:.-N;/.QE
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M1KP^'X&*Y?RJL9759-7OY;9XXOKD,S1R-<7,$;QQ7,LK)ZG->?)D4K$S1Q?
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MTT]['D&1^2\O4]8#E\/'T_C3-#^5TUM>-J5MK4D>IR&)Y7]%3;%[;@MM2W#
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M$6O[%02US$ #Q)+J*&M*=?;'"ZM2 1,A!K3XAVZ]\9)J.GQ(7DN8D04)9G4
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MS\?]YQ>Y^VZMG1[<S-!&TZA)RJF5%/)5<CX@&H*@'OCR:=<8TT*_:=5H*FI
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M(QZK8TZ[<YA&3M[/D@S9LV;-FS9LV;-FS9LV;-FS9LW)?$97-/YA]^5ZD?\
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M,EQ>^;+.ZNSI7U*2RGLII4!BCM6F=2 T1+,L\5ORD;DLD33M_=\%PPTZ\O\
M4K7R[J%+ZSENI/3GMT(>$1PI*QDEYC^[N/37A(?WG[R+[/Q9+LV;-FS9LV;-
MFS9LV;-FS9LC'YG@G\O/,0!H383T/6AX'?!\&D:TDKO+KL\RO6D1@ME"GMQ*
MQ\O^"+Y#UDGTCS;K%Q<:O=>E>7=O!(L,%M0.FG>LK2,R5 XQ,J\?M/Z:XW3?
M-D%_>Z592:_JFGWNM&1K:UE&F53TXUF5"1"W][%*O#CS;DK*S<ER]:\VV^CZ
MU/I5UK6L--!+#&[!+#CPGB:4RI2WY,D5(XY:CX7FA_GP'?\ FW4+2]B^M76J
M(T%);RW6>PX+;(+6L@*VU979KR/E$'3_ ';P?^ZP/8><Q+I,FH-J&LFSCFMX
MA(TMOZA>:$2<>7U6. A?4799G=F7[*_98=?:L8KG2;&^UG4[+4=9G:)%M[RU
MECB!'[EF86Y(2XDDBA6L/-'?_)^()I'F*]OH[6W>6_BU+4(^=O$^IKZ"@SW"
MCE.MNK!O]#;_ '2Z_O4B_P K!OESSKI>LR+:(NKP P3R)/+<$O(D$$3,Z<=N
M5963X^#+(JOQXS1M@6P\Q7.IWVGVEN+X/>F"Y=HM0N)UCM;J-'7U/2BY)*@?
MXT_N8OMM+P;!.I:L;:>]'KW*16$KVMNLVJ7$4\LAEBC:6:+B0MG']8]3ZPK,
M\<<?+_=F![;S3%>7L>BQP7QFN+@6T.H1ZI=/:M=H;E)H_7C/-45+;U8^2JLW
M+_?T+)A?9>:X'O+./44OXK*2UM[B2\MM3U-XT6>&XN%Y.2J<@+<Q<6^.:1N,
M?V.#&'EO4[/4;FP1)+BSNKFW1YK;4-6U.*87,KSHT$44K!G:)H.3QNJ2>E*C
M_!^T&GUE9;;3WN#]4:2TBNI[N36-32UA^L+<3"-V61"\AC@:CO\ M-_Q6D;!
M(_,_IW3GZG=V,,CQJEWJ&H:B88$>6UBD,O.Y".\0N&9][=H>'+XN;90UNXOS
M?M:Z?6ZMHX!9CZY>R&5[B2)&GCB-W!,\'!RZ<(^++Z?^DI\6&<GF&:QT+3]2
M329;B6ZM;^2]"S7LS6\UK*EO#6%I'DXF23C=1(S20_Y:QL^&'EH:3J&N26FI
M6,<5POKO$@EG]:WD,TD7HSLTS\Y9H4$T;J(_W:MP7@J-DKC\C^5HPPCLO3##
MB>$LR[4([/[X]/)GEM(Q']3Y*HH \LK]*_S.=]^N-_P-Y0Z?HFW_ . RW\D>
M4G4*VE6Y 41CX?V1VQ@\A>30I7]#VS*>H9.0ZD]#7N<</(WDX,7_ $-:<RO#
MD84)XU#4J1_,BG_8Y9\D^4#2NCVAHI05B0_">VX]\L>2O*  'Z%LF !'Q6\;
M;$4/53U&+6GE3RQ92+)9Z39VSI3@T-O%'Q*FH(XJ*4.('R1Y/+%CHMD26=B3
M!&?BD7BYZ?M+\/\ JXZ7R9Y1FX^KHUE)QH%Y01FE* =5]LS>2_*#*5;1;$JV
M[#ZO%O\ "%_E_E51_L<5M_*WEJV0QV^E6<2&M52", U->R^../EGRXS%FTNS
M+-]IC;Q$G;CN>/AMAEFS9LV;-FS9LV;-G__3]4YLV;-FS9LI6#*&7H=QV_7@
M74M(TK5(DAU*SAO8HV]1(YXUD57H5Y ,#0\688H;"Q,@D-O$9 H0/P7EP ("
MUI]FC,*?Y66;&R8H6MXR8U*1DHM51AQ*C;92!2F-?3M/D3A);1.@8R<612.;
M @M0C[1!-3BR11(6*(JESR<J *F@%33KL ,I88E9V50"YJ_N:4S06\$$8B@C
M6*,5(1%"J*FIV'OEB*)7+A%#M]I@!4_,Y95202 2IJI/8],I8HU9F5 K.:N0
M "Q I4^.PQU!FH,V;-FS9LV;-FS9LV;-FS9LV;"7SO'')Y.UM)5#(;&XJ&Z?
MW;87Z?Y;U6V\Z7>L2^F^GW E%O")I2T#.D(:0(R\6:Y,5)$^Q!Z,;0_%/<85
M:Y>-:^:+A(K=;B2XO;0"/]URYII]U*KCU2HJAA4[-SX+Q7(YY>O%MI-&TQ=)
ML8--NOT>]W=PP6\<*-/IL]VR!/AE5OK2^M'(O+TUD^'C\6+V^IKJ#V[7M[9I
M<R7:07?F!8K&5;8&T%PBPSD20N)Y;>%HO63UHD2)9%9VA?!.@1:#<Z_H<$T&
MG2R2:1-J%KI_H6X*W,,T*)=V\?#UH_K,0Y?WC?!%%P_N>6):=]0/E.WM%U5(
MK"XN[:6[OXH[>![.9K0W!1?W8BBDCGCA1/4B]2%'])OBXMAGIGZ/M_,FDZ;9
MO#;74MG'=:II5+:"%E>)V01P*@>2=KE/69T_NDC^+[2+A*]Y:3?EUKM[<W4-
MU%;VUM+];FAMR$N6"SW%IP$?I\%FI^XH[(\K+]O)5J4T=EYRTB:UDBG@NTCM
M[73XI3&\:2>H9;E8D4K-&46+FS'BGI+A/:R0VOEV6:&^GC::[MOTY=0H(EM9
M9IO3O!#*(T9*/&L<R?[I7@WP<L5>ZOI]4TB8S7'UVYMM,,4;(%^LV\L[K?&X
MC4&-N,#1LX;^X;BT?I\\4\KK)/9ZHNI->""UB2XNXD,D+174<]R9(X#$5:,>
MBD/[N!E7@R-_NYN;+*XN]/.CZ;JVH7MH)[*R:R6&$2M/=&=WN(7D:.7EPC:%
M"C\6]'U9N7PO)'T0PQ%U<HI=:\6(%17K0^^9XHG0HZ*R'JI (/T'+*J000*'
MK[YN"5!XBH% :;TR^*^&:@S9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV?_U/5.
M;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS84^;N7^%=9*TY"
MQN2M0&%1$Q%5.QPS@?G#&]*<E!H.FXKA!8649\ZZU+*!+_H^GRPA@"(W N8R
M4KT8KWP_]&+;X%VI38;4%!]V!SI&E&VEM#9P&UF8O-;^FGINQ()9DIQ9J@&I
MP4$04HH! H-NV,%M;!&C$2>FY+.G$4+$U)([FN*4%:TW\<P '04KN<U!4&FX
MZ'-09LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-F)H"?#*5@RAAT(J*[9>;-FS
M9L__U?5.;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS85>;$Y
M^5M82M.5C<BM"W6%NPZX,TQF?3;1V^TT,9:NVY481Z=>*GGCS EPZ1(MKIWI
M%B%+ _6">IWWPZEUC28C26]MXR!4AI4&WCN<23S#H+\N.HVQX'BW[U.OWXJ-
M8TDD@7MN2 "1ZJ=&W'?O7;$+GS/Y:M6*W.K64#+0,)+B)"*U(KR8=>)P.?.W
MDT+R.O:=Q\?K<%.M/Y\63S5Y8=>2:Q9,NYY"YB(VZ]&QA\X>4@I8ZW8!5IR/
MUJ&@J:"OQ=SMC#YV\FA/4.NZ?PY<.?UJ"G*@-*\^M#CYO.'E.!(Y)M:L8TEY
M>DS7,(#>G3GQ/+?CR7EB+>??(ZIZC>8-.$?\YNH:4.]:\NF9?/?DEBH37M/8
MO]GC=0FM03V;P&.;SQY,7[6NV W WN8>I%1^UX8D?S"\BB41#7[!I"*A%N(V
M--_Y2?Y3CD\^^3']3CK-J1%7F?4%!Q-&WZ;8P?F'Y&+^F-<LS)0'@)5+4--Z
M#>FXRE_,/R4REH]6AE514F+E(._\@;PQR>?O*+QEQJ*A1_,DJGK2E&4&I[8P
M?F'Y1(^&\<GX#P%M<EOWE OP^GRWY#MBG^._+)IQGGD!I0QVEVX^(5&ZQ'MB
M@\Z>7F8HLTQ<+S*"UN2W'D%K3TZ_:89<OF_18E9G%YQ3[3+87K#[UA.5%YRT
M25>4:WK+4BHT^^ZKL?\ =&,;SMH*L5(O@5-"/T=?_P#5#&+Y[T)V98XM1=E
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MC#49+M+:7](R1TEN%TR\]9HR%%&<0<BIHHZ_L_Y.*1:SY/\ 12VATV<P0/\
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M^/V!R.PARI?.^CQLRBWU&7@2&,>FWS $;'<0T/T9:^<K LX^H:HJH*\SIUX
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M\>+\_MLIJM[^9<7ER.2.WA.N&X *VT8:-8GLV?XD:1^7I71]/^]C]7@OV%?
M(U[\WKF.7T-*M;1T:7CZT;O793$F\T0/[8:53P;X?A^%N1UYBD\^>M.^AI&?
M6TND,,Q14AO?64%^?%F=O1=V1&'I,T*_SMAG*NJWOE25*RV^K/:,O*,B-Q<"
M/JAZ"LGV<A<P_./2M(9K!4U.5HX.$=T8WGC=8[02GD'C$OJ2-?<E/'AP7@WV
M.9EK#_FC;7VI75@([BPDDB6ULE2)Y8T]"#F\)>6%7)F^LJT<SI\/&1>7V6':
M!=?F!>:E"NL6T>GV5J91=,GIO]:?_=?I$2.R0<77XF5)6>)N2HGVB*QE_/%K
M:::ZBLHIDED]&W81/RB<2%2S)(O]R1$L:U7U>7[U_M<1=VOYIQZ9I$5L/7NT
MADDU"<FV1FG'+@DM7*HA!7: 2_'\#OZ?QX'\N#\Z$U/3?TT+:2RED5M58&(<
M5^JQJP148E?WZNXX%_C?_?6(<OSI:XFA5T2Y07DD#E;8V;(7D%LLE$$HDXB/
MTHTE^'[=U+^QF?2/S:U&*SMKZ\:$12VSW<D1MH1)"E&?B8P\BW#-RCN5#?5V
MCX_5_P!O%8=-_-^>_A6]O$CT]+ZVDD6!H8R8(FC9UKP=VAD19%D3]U/ZW[?U
M?'GR_P#F=%J#+:ZD\=C/J4L\S&:)^-G/>2NZKZL4LGJQVWU=;>-62%%]7]OA
M@[6]-_- ZLUQHNHP):-<S,+>Y"-&L(MHDMUHJ!^/K?6))?CY\O3X_N_APCN]
M$_.IX;N4:F/@A!L8E:V]?F$9:,WHK#ZU7;][Q6)OW7[OX,-TT3\QH=%O%CU%
MY-2FN+:2%GG1F6!$5'B5FB]-7^$/*WH\9F]3CPY_"$O?)7FM]"L+>8IJ5[#^
MDGFYW4L:I>7D_.UNU<CE_HJ%U1/A:'G^Y^SA>WY<?F19W!FTCS#Z=Q<7<D][
M<S32R<E*<8QZ97CP0M,WH@</4EY_L+QF?E/2O,VGZEK(U:\:\T^22 :29)?5
MD6..$1OR'!.)=E#MN_)V?_927-FS9LV; &O6NH7>D75MITPMKV5.,$Y)4(U1
MO503D5_P?YO?R]8V'Z:>&[M+V:ZDE6:9VEC9W:)))C21O3+JS)P6-N/I?9^+
M"VY_+?SF[QR1>8V]998Y&G=YRY6*2=XT-&HRQ+.D?_%OI<I&]1^>5>_EEYJ=
MH([77G6.-.:W$LMR\L-T;;TGGB5G=7::5GD_>M^X_P!T_%RP;Y<\B>9=,\QZ
M?JE[J":@EI:26[M-/<RS<IVC+*/4Y1LL(B/IR\4EE]1O4XY/\ :]I\^HZ/=6
M-O.;6:X3@DZE@5J>H*E6'^Q;(C%^7FMR:%I]E=:RZWNG2W,T$\;3L.<TG*%I
M"94:9H!R^W\/^3\.;3OR\URUL=7C?6#]<U*U6TBND,Q:%8V8@J9)';E+ZDCR
MM^S))\'P+A;=?E5YGN7EG;S)(DXMEM[0_OF,4GU9X)948NJQO.S)ZGIPK^[C
M^'XWQVJ?E+K5[9M"/,4I::(PW<4YGE@G3ZM%!$LBF8-^XD26X1D9/4DD7U_4
M^+DOI_Y7:U:ZI;7\VN->&"\-WZ,XF9%HSLOI#U:1O)SX3_;1HXX^*K\7+HV;
M-FS9LV;-FS9LV;-FS9LV?__4]4YLV;-FS9LV;,S!06)H!N3[9!;G\QO*9D@L
M=2T^:/ZZ4XI-#'+$;>93)'.[(TD:Q.@=_B/J+Q;G'@^+SAY"U*6Q"20W+WI2
MTM',#$5F#LL)9DHE?0?E&WV>*\OM)BT?G+R7%J:Z9%<(EVTBVZJL,@0R*Y@1
M!($],GFC(GQ?[K?^1LVB><O*6ISG3],/*/@\RTA,<3($BE9UJ%J&6Y0_9^)N
M?\N XOS3\D_H^WO+>=S:S20P@K"ZA'GG:W16J .?JH_[M?WO%>?#A\6+#\R_
M)P9N5P\<<3E9+AX9%B1"4"S,Y6BP2M(BQS?8? <GYQ>2([F-/K326DPA]"]A
M1Y(V:8R@BB@N%C]+]X]./)^/VE?BB?SF\L1P/+=6M] P?TXX/0YRN20(P$1F
M/*5?WB)_OO[?%F5<--8_,GRWI3*MR+AN<=M*#'"S'_2Q(T2E=G#\()9&7C\*
MI_-\.%DWYQ>74:)!:WBF9%F25H@8A"\A1)'>-GX>IPDX(W[Q63C*D38+TW\S
MM)U"UO[J*TG6.Q2U)C9H/4>2\D:.*,<9&B7XA'\;RJB^K\?#@^ +G\V#!I+Z
MH=%G-L]U+;6JF1 SI'9K=*[4Y*&E8M"J*7^SRYX/TK\S-*OO,,&B26\MM=74
MD\,0EX#C+;1(\D3<6;E)O)Q]/DG"/ERPNLOSETN_$+V6D7TD,EP;>:5_1C$=
M&<<]Y*NO")I/@#?#Q_:S6_YS:1<6EW>1Z9>FVL+B6"\:D9:-(WCC63@'+?&\
M\8]/[:?'S^SB>G_F]+,T@GT.<I"Q,LUM+'-&$^L>B C \9F"O&Y])F1OWG'[
M&,@_.4W6D1:C;:!<E''&0-)'Q25FF$:%DYUJ+9O4_:BYHC+SPUU?\Q?JNKZE
MH]IITEU>6)2,2(P9>311SLTBCXHU$<O[OE_?O')&O'&^5OS%FU_5$L;?2W2.
MC&6[>11P5 R_'$ 6CE:1#QA9O[EHYN?Q\,;I?YAW]_#=QC26COK;3FO@A=BK
M2I%&YCH$Y*CO+Z<;_;=X9_W?[O ]I^9>M_6](M+WR](&U6[$'UB*7]W%"Y95
ME=716Y\E^*#XO@_><_V<5?\ ,#S!:L([OR_*S/=2Q0R1F4(\*74L$9_NGXS2
M)&LJ(S>DZ-S]=/A7!L'GG4;B#5KJ/0[A;73;-;J%G]027,SQ>H((HA$7JIY1
MR'[:O_NO">Y_,OS.-/>9?+$]M,\+^BDWK.PN%,8(9(H'9HOWOPLOQ-Q^SQY.
M@C7_ #MYPTVY2*TT%KXV^GK=7**LP:6XD 58D*H\4:*_+FWJRR?\5>G^^P3Y
M>\X^:[[7+;3]1\O2V=I/#-.]\>85")']*(JR_:]-5]0U7]XWP+PPID_,WS?]
M58P^5Y#?PP(]U9,9^4<LC. U5A8F!55#]E9F]3X8?@?%;GSCY_O85-AHDMH_
MQ&96CE,B*BJVWK0I&[RT=8>/)4_W<GJ?!BFF><_/U_JUO:3>7GT^W_24L,TT
MB2M6SCI1@W'T@QKR,A=8W7^Y_>?!AC;ZYY\,&H++HZJRP73Z9,6Y,TL' 1++
M&.(I.9']+BRMQA;G]KEB&E>8?S"6]TNSU/1TDBG8M?ZA$'58XV X+P^*DJLW
M[P_W?' =[YM_,D/)##H/!Q?30),(9'0VRSHL<H/.GP0,TSEPJSM^ZA^)?B=9
M^:OS*N%C=_+[1M'>F.\@X*"+5'"EHY&E"3/*O)X_3^")>*RLTG+&Z=K_ .;$
MZ037>AQ6[R4BE4T*0TG9&E],2EY0\0614$J\,,5U[S^/+5S?W>CK::D6B>"R
MC3ZVT,+S&.166*<?69HHE];]TT*MZB(OV7Q*_P!>_,FV\JPW\6C1W.N7%VB?
MHU%%(+9A2LC>O0MS&[JW[M9/BC;TWDQ>_P!6_,:#199H-)@GU1-1:..%2OIO
M8%_W;U]7D).#*LC?LNDC>EZ?%L PZG^<'H.TFGZ<SOZ/H%EDCX<EK*)%624M
M^\/I*1P5>/JM\+? ]KS\VFD@#65KP+^LWIA$!!C5Q;RLTTA0*W.-IXEE]1N'
MP1)\>/T2Y_,Q]1T@ZY;QQ6J^HNHBV"E2U)5C<GD7^(F#X%C^#[;/^RNAU3\Q
M+76#%+:+=6-QJKP1%T5#'9NTA60.C'DD4,:OR=%9G=8?M8(O[G\RGU.:&Q@M
MHK.&<RI/(JD2PJ/@MU_><AZOVI+AD_=-^[2%^/J,%2Z_-5_+:O/;PQ:W];FY
MI L3*(%A9XE'J2\65[@)"TG]YZ3<_35OCS2V/YF"VTJ*"\ G GDU"5UAD7F)
MB\2M_=U#1-Z7[OX5^W^Q\2,4?YL7^G7PNQ!9W<6K1RZ>J.$#6,5',;LA<F-Y
M%56W61XVD^S]G D:?F^HDG#/1SZ<7JBU,H4*G"1X48Q(SR!DE6.23A!SE3][
MQ3#*&/\ -N[GDCO/T;8PI)^XN(6D=RI#H7X'DFW%9$63E_??$O*#XD=)N_S/
MDU/5]-N_M6]BIL[YX8X[8W$@58VC< ^K+\,[W*<?2B_<*GV\#7EC^<LD"VHO
MXP)!=!KN".V$BAH@( _,H%X/R99(D;X^/J)PP5!I_P":MC;1I%>17;/=/,1*
M48QI)/*RQ.[*K&V2$Q!N'.Y]3^Z;TUQ30-/_ #*M]:MCJ%QZVCS>K+>B22$S
MI+RCX!61./I_!)^ZC5/W4G]YZV ]<B_-<7UQ^BSRL7N;YKBIB!^K&W1;1;;D
M0ZR!QRY5X^MZGJ?#QQ#S#IGYI6VO-K>FR"YCM[..E@LKB*:X$)1HDBJ5'J7!
M%7DC_=Q?O?4YIPR0:Q9^?BY-G=<@MI;K^Y:"/E,)!]:8"6&2DK1C_1VY>@OQ
M>HGV<*[VQ_-R"T>XBOTN96=%%G +97$;71YE7EA">HMMZ:JSGA_>-PY<< 1Z
M#^<IU(<M4B2P98Y9B'4,TPDC:3C\$G'DH9>%/2X<N/#U,5U#3_S:TV"P>"_D
MU2YNKBV6\2+ZN%MRKLLIK)$E;0PT,O\ Q\--_=M&N=,S9LV;-FS9LV;-FS9L
MV;-FS9__U?5.;-FS9LV;-FQLCHD;._V%!+?("IR"V=Q^4BVT<_JVG'AZ\:7;
ML[I'0QT"3EF2-0K(D:CTU_>>FOV\&V7_ "K:6&"WL7M+A=/1=3B6%S*RK:,R
MI,S LS>DY<+ZA;XL 1:K^5FJ:##J=Q'#!8ZW<&WBEE!1WG$SM02QEN#>M([(
MZ2?M_:P;HMY^6IU"VMM(CM_KFHHZQ)'"P;TQ$0RR54>DK1P'X).'/A]G NBP
M?EQ/JVGVUGHBQ73VEQ]1N)[;@HC$TD<T*O)OZS,)G:,?O/2Y<^*-B^H7OY66
M.I"UN[>Q2_TT)'Z8M>30)(C(O+BA].(1JU6;]VB8Y_,_Y;Q6!N98H8K."615
M+V;+1K:/ZTSJGI\@BB;FDG'BSR_!\4J\B:#5/R7U*1[Z&SMY^"+IL<8M7X.L
MY67THX./#D7*J_[OGZB\&^SAI<^>/R]N;<K=VK2*K(T=O/82586X+K*B/']B
M#B[+)^QP;AAOHK^4-8%R;"RA80/(DC&V$8;U_B=T9E7U$GIR]1/AD_UL-+/1
M='LK06=I9006@3TA!'&BIZ8J>/$"G'<X)]&&B+P6D?\ =B@HM!04\-MLQ@@,
MJS&-?54$+)Q'(!NH!Z[TS)##&O%$5%%3Q4 "I-3T\2<<%5:\0!4U-/$YE55
M50 !T V&%VMZS;Z1;PRR1&3UYEAC16BC^)@SLQ:5HT 5$=C\61.+\V_+?KND
M%C<$MSDE=! :\50(S<9#O+R2/^>'_=_I8KIGYN:%J&L6FFI8WL/UV[EL[>ZF
MC18F:).7,4=F].1OW<;\?MXM:_F3;WNI26=AI\LJPI=R-*SHH86E5"JJEVYR
MR*Z\)/3:-%]1_P"\CY 8_P W[(6UK/<:1=1+>3I%;E7@=7A=Y4,X;FM%3T6Y
M(X23_??J8KJWYMZ9I_F#4]!73KBYO=,19)"AC1'4Q&9N+.RBJH/L_P _P_#C
M;;\W=,NKM+6#3+HRO"DU7:! &:,RLE#)ZAX*O]XJ>DS_  <^>(K^;;27#^AH
MTDUH[1"UE$T8)61E0M*-_2<-)'^Y;X^'QM]I,JT_-U]0^NG3=!N)UL6/J%Y%
M0E$6KE0JR?O%_9B/VU^+G^SAEK7YB)IVAZ=J<5M'.;V&2>2/UPJQ^C;^NZ%^
M)_>*.HX_"BR/^Q@34/S'O/T%=:A86UN'C>R$+W$H$'&\<HSM*3%&57B98W]1
M$DADA?[3\,=I_P":4,WEJ_U2?3YH[O2+>TEU*UXLH$EVB2*J;,U.$BR?$/@3
MCZO#XN(.W_-V[GO/13R]<$1V\L]S"&_?PLBQ&(2JRJBB<RTA]-IG?[;)&O/!
M=Y^9>J6MS+:MY>FFNH5D#0P/(Y9UE>).+>@$]*0JBB5V3XY/L>FC2X$;\V=4
MCO#%+Y>F$+<I(W8RJRPB)) 77TF)8<^4RK_=)^RS+C-._-N_O;ZTL8M',]S+
M(HGCMS*S)&YC"S,K1@QP<)XY!(WQ? W*./E@O2?S0O\ 4Y-2M(-#=-3TZ$/)
M8R2.L@E:X]%%<&*JQNE+A)%#?N?V%RF_,KS DUQ')Y9N%^KSW4*%1<2>M]62
MJ)'P@8*\_P!M&<^AZ?+][ZG[O D?YH>9&N4MUT"1KNYM?K5M:\;DL0$WXT@_
MN_4'VIO1;]B-'?#W5?-OF!/,1T:QT>5HDN+1'U$I*Z>A,T7JR"B+%15DD3^_
MY(T,C/%PX\D9?-7G..6_(T(S017#PV042H[+$=W>J/6.0?8>,?[%L;=^>/-,
M>E:--;>6KJ?4-3AD>Y@*2+';21T $K<2R!V-4Y#EPP&_GG\P;:ZAM;KRMS>6
M5T$\;3>DP3X5 *QS<6E/[Q6DX1JGPLV*W'FG\QENH+*/0HS<I,$GG E^K21N
MDM75R/W:0NL7+DWJ2\OW:9CYO_,=GL(%\K*DMVLAGE:1S% >"O'R(45XEBC[
MIS9?@P>WF'SE#HEW=3:0IO[>[,*VZ+(RO L082(%+/)ZLW[I& _=\^<J\8I,
M3N/,_GE="N[N+R^!J">B]O;,SM1)9720.J#E(\*(LC+%]KU5P&?-/YD7'Z32
M/R_]2^KIRL9)%]4S$PE@B<90*^IMZDG!5^P\7Q897&N>=[:PM"=(2YOI/K$=
MP( ?3]6-P+?[3@Q0S)S9I6+\./V?BPCNOS \\VINWDT&D=E"LC(\;H9C),J1
MK&_-D2:56XK;GFRO\;O^QAYKVH^>AJ5OI^EV2+!*D)N-0"AUC)?]^REW0?"@
MX)&T;-\?J_L>FP34-4_,RVN=9GL]/@O+6%N&F6S*$=QQE;U.?JCD!^Y1D(^-
MF^#T\?JNK?F0=*TU+#3(1JEY9R-=L/BC@NQ'5161X^"\OV667G]CX>/-D-.O
M?S5CU"WL+RVMY;8^C]9U+@*CDX>9@J2*@55+0Q)\;KQ21_4_:7OM<_,..YU6
MWMM'$T8N##I=V@C4&-T3A(XDEZ1,9#))QXM\"K']K UK?_F\]O%*;2R'I!!+
M%/#PFG(5S(1PNFCA/-4C3^\5N?K?#_=JC>:G^;MO/;>C803K/<Q+*O%"D432
M3<QR63GQX?5_WE/W?^7R;#+0K[\PGT36WU*U1=;5FDTB%D18"GU>.B#A(]:7
M F_O)59_A^*-'^!T-[Y[.C&XO+=8KZ2[A6WMHXUY+!Q7>;A).J^I+\,W&3]Q
M'^W\/JX&U,>?KK2[VTA>:*]>WLC'/%'#"5D^N.MUZ9]1EJ;5 W][^TG'A(W'
M!?DN_P#.#W+:9KL*K]0L[9I;D@F26:9>/%G!](NGHR22^GS7_2(5Y\HWYR[-
MFS9LV;-FS9LV;-FS9LV;-G__UO5.;-FS9LV;-FRF564JPJK"A'L<($\A>4(K
ME+K]'1^K#'Z2LS.5$8)8*5+<6XEFX\OL\G_F;'OY6\H)=&]:SMTE2WGM7)-$
M]":CSHR5X4:E6JOV<0;RAY%N;.VLC9VTMO;W#7=L@<DB=*%I.0;DS+\/*I_E
M_P G&V$/D..YL]5LYK9)KA5:SD$Y D#H%5Q&7XLWIR!5?ASX2?Y>#AI/E9IH
M9DBM_4M#)/"R,!Z9+L99 %.WQO+S?_+D7]ML0N]'\D7%Q<75S!9//?!+>ZE8
MI67DA9(VW^(M&[$#]I,0CC_+Z*#]'\[$1*'*I+(I)62 2R%'D)+#ZOP=BK?!
M"J?L+B%K!^5HF2^MVT@RQ@NMPLD#$5C#%N53OZ4?,M_*O/!EM-Y EB^O6TFE
MRQ+6W^M1M ZCX'<Q^H*@? TC%:_9YX7:%JOY<Z/<:N=-U&W28WA35 TPI%-&
MGV*,0(XXUZ</@P[LO-_EF]CN)+74H)([5D6X;F%">JW",GE3X9&_NW^R_P"S
MD?O_ #'H"7"R_P"-W2.[?E;VUN;"10C2K$.)^KR/Z:NZCU';_*Y?"V*:IJ&D
M6SBTN?.=S!.Z225C:RYJD'Q2,:6S*H7@Z_$OQ?$OV\3MY-(N[&ZOK7SQ?7%I
M9('N[B"2RD1%*\@3PMB/L[[8A=W/ERVC6XNO.^H)%/:Q744OK0!/J\S$13 I
M;A/BHQ!_D1W^Q&[+5IK7E47UN/\ %]^TT<_);2:1 )6%Q]7],KZ 9T>:BJJG
MDR?&G[MN6'%QYU_+Z_@,5QJ-E>6X+.R/25 T ]6K AE5@%YQ\OM_[KY8V;S+
MY#MWN;T- ;RQLI;Z>-(3]92V 265O3*B0$^I$SJ1S^-.6+'S7Y1CBN[N,AA8
M3)'.T<#\O5F<PJR'A^\5I \?JQ\H^22*S_ ^7I/G3R=J%Y;VMA=(;V_5I8X#
M$\<AHG(\PRKP=HQR7U/BDC7FG), 7?YE>1K6Q,\<C3QKR=8XK>45*2%&(+HB
M!N0D*U;E)Z4WI<_3?!3>>_*_*W=C(?7?TXI!;RD,PH&]-N'[T(7X2-%SX-\.
M)67YC^3[LJ]I)+*KBD9CMIB[D2F(JD83U7X2!@_%.*<<4_Y6)Y2_15_JL$[S
MV=A&MQ,\,,A,D3R-"LL(*CUHVDB=?4CY)\'+EPP--^:WDV*QDNXYII0$]6*%
M() \R?'5XPP4&,>C+RE)6->'V\VM_F)Y$TF]N[2]<O?:9-&\MO#;/-*LMQ&S
M*Z*BL>1CY\G'^K^UC3^9ODV.>2.-;A[AD6:XCBM9"X A]1O4 6H>&)?WB-\:
M?9_9P.GYI^3K2\EA6UNH1<3<Q/':/QGY(I^LG@*\'4<4D?XY%C;]B/!4WYJ^
M54M;Z:(W$[63RQF%('Y2F%E0M&6 0QO*Z1)(65&?!]WY[T2UU]-#G2X2[D*H
MLIB/H^HZ+((_4Z<^#JVWP_[+"?\ Y6[H4DBQVEA?W#. T=(E42(S!*Q%G',\
MN5%^'^[?[/P\G6OYE^3Y=2GDL;*YFN7(CN;V*UX\HX^(5V=BCO&'D6-?M,K?
ML+'\>&^I>8],T[RVWFFUM5F6[6U>J#C)*L[I%%R*+([</5V4*[?LIA3J/YIZ
M98:A<Z?+:NUS;06TC!20&GG=%>W4,JMZD"3P2R57EPD^)$XX_7OS&MM*T^:_
M2Q%R8[:VN> E569;J.>15!XM]GZN1_E<O\G$](_,:]U/6;;3$TEHN;2"ZD=I
MR8A&54DQ^@&CJS4_TCT/\GGB&O\ YFWVF7/H1Z;'/]9O7L;!EE=VY0SPP2M/
M%'&TJU:>L4<*S,ZJO+AZF&OF#SK=:)<003:8T[2V$^H&2.2BJMFG*Y4@KSJK
M20+%\/Q^JWV/2^((_P"8L2M?6T]JIN+'CS:VN!)#(6:V $<G%":?7(^?P?#_
M +-<#Z!^9S7_ ):U/5+G37M9]-@MYEM#ZO*9[N(/#&BO&LK<G985E2-XY7_N
MN;*Z+=O^9D\]E=:@NF@6UC 3/:F1EO9+E8ED>*W@>-3($;G#\123U4_N\!3_
M )OO%5?T8&F=(S! LCEF=K>:XDB?]W^[DMA''Z]?L_Z1_OGXW3_FM>:?-Z=Y
M8PWL'*1!?Z?*9+=A:%9;UP2#1;:U?E0MRDGBDB7_ "5;/\RM0OK+1G@MK6.\
MU*^GM;N%IN7U:&+FZ,P8Q-ZCQ+&W!N/'G^WA=!^;NIW(,<46GH\LDICN6F=X
MH(XOK!,-RJ@,+IA:?NT#+SY_L\.+U;_G+<?6;N:>SBDTZ&Y@B7T&K*MO(HDD
MN35C(RQP5GXM;0?!\/Q/B4/YN^9[F*\F31XK9[.V>8V4S#FTIEN(HXC(TD;+
M_O/^\:*VG7_C'DE\N><=9UG5X%^KI;Z9-)?PO'-%+'=QO8R)'Q:K&/=G(8CX
M?W?[OU$DYJ5:CY_\S:;;7+S_ %"1X;N_CAYQS0">/3U4K;1?O)>5[=LQ]'?[
M,;_N9<2\Y_FKJVB>8)M-M+6!HHK>)W-P51HY9D+J7K/&W!%4^I^Z6-?V[J/[
M.#_,_GKS'INCZ-=Z5:0ZI+J$<TMS+"GJ0HL04\R8YV5(OB_>2)+<</M(DN 4
M_,S59;566XL+:22^FMY;JXX-;VL4*3NJRK#<O-ZDWU?TT:86S<F^&!N/IY4/
MYC>9$BN)YH89I4U">!=.1 LZVELEXY8*)Y)C+*MHI3U8(>7[,7\J4_YDZ\[:
MA>0O!!:_58;C3+:9$#>C<,"EQ,C3)<G]PRRLB1*D?Q+)(OQ<32Z_,35K?2--
MOHM/-^)KRZ2\DM8Y71M/LYFB>[A5>9"N/2ECY.Z\/VV^%\/_ "A>>8+H:J=8
MD5_0OYK:S"0- /0B-$?XF?U/4!KR'PY(,V;-FS9LV;-FS9LV;-FS9LV;/__7
M]4YLV;-FS9LP(/0UIL<V4P#*5/0BA^6<P'Y*V$MA#%'K<LKQ*8Q(\:RQ"+UI
M)A$(V8CT_P!]\2.TG)XX9/\ =>&ME^6&BVESJ%^-4GDN=23T%G<Q'@*K0+\/
MQ,1'Z;M]N2/X6^+X\4T'\K]%T/4=-U!;Z>:?3E>&V]9DXDRJ5;:FS.6D9^'Q
M/\*_8C7"Z#\K_*E@M6UJ9"LT:@O) H$PC$03[->;?!1>7+X45/A^'!-AY$\F
M:-IFK:2-5],2V:V]\TDMNDL,3,S^HU%7CZK2?'Z@X28)B\D>49-$'E^*_#"6
M9-2F:.2'U93*!&7X@$+%,&X+P7BO+C%^SA/'^5'Y?3B%[+57,^GJT/-)X'0,
MH4?O(PO"L;,DG!?37FR\UX-PR_\  7D=+;3[?6=?2:XCO[J:8>O!;I=7LD86
MXC,0Z%50,T49Y)\7^ZWX8:-H?Y7W=HVD/=6\BZ^RR+%]:X2W)MY2P,15E=J.
MYC/I_;3]W]G ]WY6_*J.W^H2W4<)T(A7/UIO4@EG6, N2Q_>R>E&WQ#ER_UV
MP1;:+^75_#<Z%#J"WMV$6>]<7/J74B"Y74.;,#NIFE61N ^%955>"LF(6_EO
M\NM4LY[NSU1WT^6*&&]]*[*PRK&R>D7]ZC@K+Q^W)^W]@*WEC\K6TB/5+G4)
M)].G9XX[R6YD"22RHU)%X\5+I$S^E(J\4CP2FA?E:MCK]H;GU+2Z2UCU=C/*
MR!(E0VR+(II7XT:B,SMS5?L<%QKZ5^5%YI$5FMZALM/M["%)X[J7]W#$2+13
M-R_;%[PW;G(D_P 7[.5''^41U"UU2"59Y[NYB@@$#7,R272?Z7#RC3F.81O6
M1G''T?B_NUQTFA_E/I43Z!,"JVXY>C))=2<2NRQQR58>JGUH>G!&WJJLJ<8_
MLX+N;'\N=)B:>]:1#K5D]K.]S)>22RVP"1RR3>H6D0@-$DUS+P=?W?J2_9QH
MD_+GTY[)8YY4OKA86C2*^D]22RE,E(BJM6&*;FTKQ?N/4>3U6_>?$VSU?\K[
M.>WUJ"EM*RR1P7?HW,0DC@C7G(1P5'BBB9/](9?31&^&3$8=#_*>U%YJ"P$K
MI<YBO)6-Y(K3SR"-00Q9;MA+^ZB($WI-RCCX?%B'Z0_)U8)CP46G&21JQW?H
M*?2,TL:*1Z<<IC0R2P($D9N7).?+*$7Y.VUH]JMGQMU4Q)2&\8R)ZSR/) ]"
MTJK*KL\\3-_K\63#+4[O\N-/@M--ET\&RU6S,UN;6UE> VEL_P!9!]2)>*)'
M)-ZB+R7XY5X?:Q.XD_+Y=#BOI-!D>"TO(K$VRV3O<PW"R$1!XP#)Q+SU#?$C
M?6.7[>5>:M^5/Z0N;Z:.TGU6258;Q0@>;U5]6-5E4[(X$,_V^/V/]3#'4+SR
M#I&IWLUU##;WK1)'?.(3O%+'+(.0 *MS2WE!_FXK'_(N!=,N?RZLUO;B'3DL
M9HW2?4(Y[5XYD:X<*C.KKR'(R?#Q^RK?ZV(Z;YC_ "TNO+>I:U%90PZ8A]2^
M#VJ\I!=!)$<(@;U?K ,3KQY,S<>2^HN,UOS9^6]W'<:<]DFMR"ZCM)-/@MTD
M9YR(%C*^J8XV7A-#QF]3AQ7X7_=\<$76K>0[B/3H9-'2ZLM71?WOU6$Q0JTZ
MQHMPKD.E;F0)14?A+\4G#[67:ZGY&NIX%L-$2YBU*::UFNXK>W1$>U7FPFYL
MDO$QQK+$423FGINOVERD\^>5#Y*L]<@T]FT>YN!!!:*+0!9%D8J7/J_5H_CC
MJG*7EZOII_?.J8G<_F3Y&-Q<6D\/.:WOC:-&Z0$?6D:0 L6?C"U;9V3ZP87;
MX&3[2X#OO,'D+31<:A-Y9X6.B&YM[+4$M;;TG9/6%W';_$.'%X)$?U!%SY<T
MY1<WQEWY[\AOKVG)<Z(DFL74L1L[F0:>6$DA"(4N#-P>3]TO%8)))&6->/V/
MA,XO./DV.VO_ ##+ILEH_&QFN;E[>,S3074GHVEQRB9^<:MR^TWJ0K&W)%Q2
M/\S_ "O=W]K96J27=S>2:E;6RJ(ZO)III*B\G'(3\?W!'PR+\3<<)]4\R_EO
M9^7](UXZ+ VDP7<ITF3T[:W6-DA:>6:)96B4-RA9.'PN\T?^2K89/^:.B166
MKWJ6$YBTB9;69!Z22$AG!9E9E]"*/@S<IS'_ *N#F\Z>6OKVGS&V=KB^GET^
MWNQ&C<62:.(J9 :B.225./'[7V\6_P 40PVFK75SIQA&EWR61HT;&5I3&%D4
MBG$4N5KR^+[>%D?YF^6E\O7>HZ?;.;;3A9B6W(CA"-?S>BJ,*G@R,><@X_89
M6C]3GE:!YNT3S'.9ET,*#;)>22RI&TC?"60)13S^$_ W/[+_ &<;8>==&U/3
MY&M-#,ZW5TD-O9,L*--.T;S<I.?&)&"PM\7-_BQMYY\@TO6KI+K0?JZPO';W
M%ZLD)E/.P>]1>*BIXB%X6_><5;BR<T^R'U+\U-/TNY>'6=(:UU6W'!HPZ3+Z
MDGHF*%)PM.4Z7!]+EPYR120_:]/U#/S)^8<6B/=UL&EAMYQ91SF0('NC MR5
M*A7=8Q"W]Z%=O47AZ7[6#;[S5+8KI*W&GF6?5:>B;=C)")0OJ2+S9(W^&W$T
MZNT2<UA=./JLB,56?YD1S3)#<Z7Z-Q/8G4[<"5) ;5X7FAYDJK)*XBD1X^#>
MGQ^W(N-\N?FG8ZHFLN]H((-&MIKN3TG:0B."66)E<-'"JR'T&9/3:6/]GU%9
M,:_YCR#4FTXZ.(KF*WFN[V.24L%$,4=PJJ\,4T99XY?M2O$JNO'X^2XRY_-%
MK6%Y;G3 3#I9U=FB:X=. ]?X.9ME],TMV^.;TN?/C#ZN2;RAYD7S%HB:FL/H
M!Y9H@M6(;T)6B+KS6*0*Q3I+%%)_,F$5O^9]N-)_2=]ITT$"WQL)!$1*1PM3
M=23#9:PHJM_E?#RX_L9)=%\P:9K2W#Z>[2Q6T@ADEXE5+\0Q52>I7E\?\K89
M9LV;-FS9LV;-FS9LV;-FS9LV?__0]4YLV;-FS9LV;-D%G_+:2..=--O/J2/]
M8:.VA BA=I[QKJDRH/B54/H_ZN.M_P OIY/*VE:#<R);PV-PSW A<2&2&2WE
MA=580P*COZY/]U\*_MLWQ8#N_P O/,EU%^CTU&&PTVPU&75M*EA!GG:X:=IX
M%G69."PPM(5*Q,TC\5_>QX]OR^U=)]*EA-ERTVZ:XE=3-;RW(?F?WTL0Y-P,
MG]TW-)/BYM\65YA_+;4-4U?4[F.>TAM;R07,;^FXNO5,=M$\;RJ1Q@*V@?X/
MWGJ\/]]_&I>?EG<WEX\TE^D$<\$,-UZ2RO)*T#V[QN[RR/\ &GU=J2JJ2,KH
MLG/TL3E_*J6Y>"6YU3TI;(1)9&UB$:JL8@5U8%CSCGCM^$L3?9Y\HF1T7%]/
M_*U+.WN8CJLMR;J:6\D>:*,E;NXMI[>XECXA>"R^NK\#S;]U_>-S^%)?RNNR
M+!7U1%%M MI<LD,SO)#'=17<9CDGN)Y(Y5EA/Q,TJ<9/W<<?##9?)#VS7%SI
M]\8]0FU.35%DG5Y8 9%9#$T(D0<0CGXD:-N?%\#^3_RVL_+-W#<P7DD[I')$
MZ2<O2I(D(/HQEV2#XH*_ /C5_3?EZ<>:Y_+'2+JWB2YFDEF@6!8+@A Z"WO&
MN_@V^$N6](_Y'^5C8/RSLW\N6.@ZA<A[6PFCFC:RC:S9A' UN.;+)(_.C<S)
M&Z?%^S@:R_+#ZI"8[?4U 62VN;2X%N/52:T]+TRW&00O"1$W*)(8O[WX9/@3
M!3?EO;S&]-Q?RS+J36LMX[QQ^LTMIZ!4^HH HS6RLR</VF_9XX9Z5Y(T/2['
M2[6S0QC3)(YUE4*'FEBMFM TIIO^Z:FW']E5^#X< Z[^7^DZFTTFI7DBZ>MV
M-2]$%$1)%15DYNP),;*G^3PY/\7V. C5?*NG:S:1#3KYK&!+2YTRMF(GC-O.
MR"5 &#*&4P\58?W?QY5I^7_E:R;252*HTR6ZDM(Y"K!Y+LL\A<$?O"G)O3_:
M3 *_E'Y2-I':7"R7$%N'^J!U@1HFDX5E5XHHW>8&*)EGE9Y?W:_']OD)A_+[
MR_+^F/6N;B^CU>:![R.61&0/9S&5%HJ#D>?[N1I?4D:)(X6?A&N5JGY;^4+J
MXFN)(OJD]TAMA)"4CI$]O]7]! 5(X%0KA/\ ?J<L3G_+GRKZ!36)9=1T^%6B
MMK6^=6AMXI"Q*+Q5"1\>SS-)(GIQ<77AAG=:!HNIV]K%/=/<BVMI[99!*O-X
MY L<C,R ?&K(OQIQXR8VT\LZ+/HC6XNI+ZWOKF+49;]I$9YY8Y(Y8Y.<:K&5
M_<Q(."<?37"[6?(ODO\ T:>XF_1\]O*##<>I&26EFE;B1<++&_.:[DIR3[;+
MQP?K?EWRK=^O^E'59-2$,,DC3>D[F(.D/ @K1OWTG'A^TV D_+[R_)-ZESJ%
MW>W)F+7TDLZ<KHTC"1W"QK&K+'Z$7IJBQ\>/^7)R$P^1/)BVKV$-G$+&:6&X
MGL W*"5[6,0H9(B2CT5(^=1\;QQM)\2X7Q^0_P MT@@6W*0O"S0VEU%>.LT<
MD\T<RHD@DKR]2"/T4_85/3C^#FN";KROY)CGT6WFE:)K<O'I\(NI46=RRSD2
MA7 N)/5"SKZO-O5_>?:P7I_E_P D:/'";*&ULXFEXP!) J-/Z/U<\1RXM*T*
M\'_;;C\7Q82II?DG3O*DVG:W>B/3+6ZN77U[J1'5)FF5%Y!ED=9(6D"K\7J+
MRX\L-+C3/(MMI-O9FXBLK%+Q_JTD5TT!6\D60N%F1U<2E7E^'G]G$;[RAY"9
MY)+\AXM0DE989;J7T!))%(\YBCY^G&TL9FFF*CX_CD;+N#^75SJKW\M];IJ,
M'%7N%NV@;C%&) *K(@=%CD5F^TG\^:/3/RV@MKJT]2S,%T\(N8Y;GU*FV'K0
M1_O)&*)$H]2.%>,:+^QQQ+2=/_*JWLI-1TS]%M9:<( ]U')%+';?5O[GXN3"
M)DVX_99O\K!,LWY>O96MN[V4U@DUQ;0#DLD*2R6TDEPC&I5*VS2\^?[#_P"5
MA:\7Y27%M<VK7MF;6>2-YD%XZ1^I-5D9") J-+R:OI<?55OCY*V#;C1_RXBL
M'UB06\=BQ$2W<<SK&K1RQ@+#Z;A4?U;:)?W/%G>)4P<-5\D7EJZ?6[*:WO91
M))\:<9)4-0QWW8>AM_QB_P C )U[\M;25K<O80O<<9'0)'1EL 3%*_$$<8?0
M_<NW\B*G[.!J_E;J%U?6L3VS,MD9K\V\CQ1+:OU9FB94#4EKR_O%Y9E/Y4*L
MBI-9_OXXG,22MRX.I$;QH&K&>*O^\B56_O.7[>#$UG\N9K&"]!LVM;QQ"CF(
M&DD5F\@60<:Q&.R$G]YPXQ?#^W@'3=8_*>UC>UMY+%(9/WH,U'$H6-)ZAY>1
M?TUB3;]AX>"_%%\(B?6_RMNKT7]Q+8/=SS16AN9D 8W#U$43,ZCC*?2XJK?'
M\/'^7#6/S9Y2NXKB[CO8)UTJDDS@%FA+AHP5%.?)_CC7@/C^PN1XI^4[Z3/,
MMO;G2Q=*;J98Y(XUF,#2?$Y"_"L#LKQ@\$5VB=/B9,$-^8/Y716\\_UNV%O%
M#*LDBV[E3$7C]9!QC/,&2X3G&/M/S^'X).+;?4/RKT#1_K-M';6^FSR3V(EB
MMY)!*Q(69 51WDC/I(A;XHO@2/\ EQ5O-GY9MJ<".]M^D$BAMK<O;,KB*ZC]
M2&)"R#X)$/PHO^5_E8-\O^=?(VKWJV^A7D%U<W(FEK;1M0B-Z2L\@7B*N:_&
MW[S[:\L.9M%T:>V^JSV%O+;"03"!XD:/U%-0_$CCS'\V.TW2K#3898K*(1)-
M/-<R[DEIKB0RRN2235G8G!6;-FS9LV;-FS9LV;-FS9LV;-G_T?5.;-FS9LV;
M-FS'<;&GOD,;1?S%DXR2:O!'.$W,*@*TB2_N^0:,_NVB'.1!\7JNZ<_3X8II
M5C^9$FLQWFJ7UI!IOU=U_1\(]1A.PH"[F-.:J>)7CQ_X; ND^6_/R65Z-3U<
MRWC16\=HZ3&E89?4F9N,42K]8J4VCY)#QC^+AR9\?EW\P+>\TLPZQ%/:6TL!
MOO7'[V6%5;UD+)&I>C/^X^)/V/5:3XE9&?RS^8UUYAN)Y=>%MHKW/J0VUNY$
M@@%5X;Q#CRC/Q?O7_??O%Q.#RC^9 EN7G\S$AJ&V5:%5=>(5N(B2BT!YQ%I5
M?_(S:;Y&\[())KOS)-'<&998H(I9IH0 Q9PS2<&82-\7#CP1/W*_N_M.T[R5
MYWAMK,WOF*2[N[:2 REI)1',D4K22!U7@*R_NOV?A56BY<&Q]WY8\]:A?ZG(
MFNS:9:_6W_1*@+(R0M#_ 'S &CLL[N(H9?W?HI'S3U,4U'R5YJU/2[2WO=>I
M<)</->&%9HXF5F4QA DJ,?1X?"DQD@=I&]2+[. ;7\N/.$)5W\X73R&UN+:>
M5O4=F:9P\<B R<8G0@_$HY<?@P=:_E]JEO'KT/Z=N98]4D@>S>:2>62W6"3F
M$!>4_L_N^:<7?[3\L4M_(^O0Z8;;_$$DUPU]]<D>9)7B=/1,1B9!.LE'>ERX
M298O7^Q$L?P87Q?E3?V\=I%9^9KVU@MF5I88N024F%(IJ@2 H)2CR<$;A&\G
MP+RP%J?Y6>9=0U&:V_Q!<V^B>BZPRK<7+7#,TD;1Q%5DCXQ6Z1G@_J>J\C\W
M_EP\OOR\O;W5[.]G\PWPM;:U@MI+&)C&DSPFKR2$-\7K@\9%;E\/[67?_EM'
M>16-J^J7#6-I:?4I(9*NTD85T^UR"_&LG&8-')ZJQQ_9XX%L_P I]%L-6MKP
M7TOU6$1QKI[\?1D,;B55*D\/[Q?4 2/EZG-N7Q8^\_*?3KWS/>:]>:E=7'UR
MXMIWL'X&W"VH91$%X_8=7XO^TRX#B_)Z%;N"X&O7JQP/._&-F1W^L1B)F:0N
MU)."@<XPB_M</4^/!OEW\LUTA[R+Z\7L+JTE@^KQ+Z2>O=32RSS^F"44\9$C
MB _97 [?D_820V]O)K%Y/:VU&2&989 T@$2EI 4XO\%O&JKQ^'XW^)GQ[?E%
MY6N(Y(TN[GU0KP74T;QF1Q)5I$F;@>7-9/C#_:7AES?D_H3W/UE+RX]=8FB7
MU/3DCJURUT2T97BR/(Y$D7V)$P7<^0M,U'0-,\OMJ<IMM#EB,9@])9?3A0K'
M%(0&X_NSQ:@7FO[.(Q?E1HYD9[Z]N-0CEDBFNHKA+=EF>!PT?/\ =<@M%571
M&1)/V\6N_P J_+-V;0W+32BUM[6U9)/3D$L=D&$/J<T9NK<F6-HT=^+NOPX
ML/R8\J07LU^+J[N?K,,<8$DD;!1%0I(CA ZRCXOWJMR_>-B?E/\ *K3M/N%O
M;O5FO]0M9IU#6ZQ01)SB:!(RBAV5XX'H_&1/6D_>RHSX(E_)CR6\,40^L0K%
M-#./2D6/E]6%(T<*G%D6I[?M?:Q7_E6?ET:#8V&I7+&+3)I;V>5&$:NTK%VY
MM)ZCI&E%6-UD62-(T_>XM9?E[Y,L;:PTOEZCP2R7EJ)'C621RJ(\A5%17XH(
MUY\.7\S<VPFT3\J_*-TM_)+),[M=RQ$QS,!Z%N\T(B-2U5X2R12M_P #P=<.
M+?\ +CR;!H\FEQ2.MHUR=1KZJ\U:2$VYH]/L- S1<FY/Q;^\Y_%B-WY-\CVV
MBC0]8E5X;B[EN%4N\9=YRT*0K1F9@D,JVZ1<FY(N(ZE^4_D5[?TW<VTLBFVA
MFYQJ?691&A6@3]YR /&,IZC?:P4OY2^5YM(L[#4A+>/;337<DX=X?5N+E@\L
MC(C<?B=58#]GC_K\C6/R)Y;BMKR"*!X_K\B33RK(_/U89VN8I%-?@>.>1G7B
M/Y5;X5QMQY \LS:-;Z,UNPT^V:22.(2,3SEC>-F9F)9C25F_UL"7'Y6>39[/
MZG):R&'X.(]:0T"*$H 6*T*#B=OVFPTU'REI%[HUOH]);:RM989X!;RO'(K6
M\@E3C(#S'Q+V;E@-ORX\FM## VG@V\$3P+"9)"C(ZS+\8+?&5%W<\&;['K-Q
MQ*X_+'R9/([/8LJ/$(7@2:58B%4JC^F&X^K&K%8Y?MIC[3\M?)EK;7=I%IX%
MG>V_U.:V+N8A"3R=47E1#(_[R5D^*23XV^+$D_*[R7%<S75O9R6UU.J(UQ!<
M3Q2!47AQ1T=60.GPOP/Q8.D\B>4Y+%;%]/0VJ\/W?)]_3M?J2ACRJP^J_N?B
M^TN YORP\E2",KIXBEBB>&.5'?D%=>)K5B&/[7QAOC^+&6GY7>4X]/L;6^BE
MU6:RG-X+Z]D9IY;IJ5FF9/361_A7JG[.&R^4?+:)<I'8I&+Q52X,99"P1N:&
MJD$.C_&CK\:M\2MC5\F^6%TMM*&GQ'3W<R26YJ5=RGIEGJ27+)\+<OM8"D_+
M7R0]M]7;3%X4IS$DPD_8/]Z'$G^ZH_VOV<,U\M:$MO;VXLXQ!:R/-;Q[T625
MS([#?]IV+8!3\OO)27+W(TBW,S^C5F4M0VR<(2H8D*T:?"&7XL4TGR+Y2TBX
MMKC3M-BMYK-9$M74L?3$H ?B&)&ZJJ5_D^#[.'N;-FS9LV;-FS9LV;-FS9LV
M;-FS9__2]4YLV;-FS9LV;"V]\S^6[%G6]U2TMFB;A(LL\:%6I6A#,*&F^<IO
M/S"\V_7JC7M%6S2-'C875K&'N&AD?T=Y6D^&8K&T;+\4212^I\4JX\?F%YPE
M73DBUO2?K$QG^L1J]M,0D=F'BD(65:*TXF]<Q^IPX1\(O2YXS6_S$\S6MK?V
MUEYDTV>[6-5L+UGLHT8"8%I'1Y WUEX3]C@MMZ?[7K8:7_YAW47F&(0Z_8OI
MCSP&1%:$\458Q<*%8^JT?PW35C+R^LUM_NE9<*[OSAYJ,>LSZ7YABEN)Y'73
MX9!$T2PQM5'A<1%4<K6/C/\ M?WG\^#]8\_:S+>-'I>KP^@;"W29E4(T=^LP
M,_IB2"7[<+CXI5:-%5>$?J2?"5'S+YI2.2"+6TN'<@1O"9VC5Y"'>296MWG/
M%5_T5(W1/]_?L\M;^9/.<UQ<2/J\T$=83:E[>Y>-?23TYB$2U9G#.B-^]_;:
M1H_W?QX;:%YDUV*X]:[UN>YCB26W2T^J7LBGDKM$[R"PC,DZR"-?455C:/G^
M[PFTBZ_,2WTR3](:[>378D>)(5MKTB6W^)_@E-CRCN'8H@E^/TT^+C@EKG5K
M<6)CU34[<P:3;6[I'9:G+')=VH9)1(LMI*6CDY<B[*LSXZ'5/--KY8UFR74+
MHW$YMETN1;#5B;>.*.-;A5,5JGIJ>),/!/YN3X^>'SI*EW/;ZYJOUN:!X@GU
M+44B4R*X' &W98W'[BDZ(_#A))Z?.3X@M];>;?0BAGU#6+H7$D$>HP/:ZD8V
M'$1H8WCA4+3[<Z<8X+B3^_\ 3Y/B5U%YQ;3"EGJ?F/\ 2$T@]5VM+]5].D;N
M$9XF$'QB=E*Q._%TA^S\*'&E:UYDL-4@U2Y@UK4U5)(YK-K&]C%;B?\ O%#I
MQ'HVZP\D^SR25DXO)^\!7X\SWWFW5+R>7S"FD3D&QM+.UO83%(D92-_[U$(1
MRSNJGTIOW?),T,.N_HK4;<6^OKJ%W<->I=);3AN4=FUNM9)9BR.[@3<(OW<;
M<4BP7?6GG?4O+UE96SZW8:G;VB1&Z9."22>LDI:0K<F3DT49B=V^->?V4Y-'
MA-IFA^;[JRTJ5?TPL5L4F!0-20.M0P5KA8XV@IZ2I&D22Q,WJ_'AK)H/FV2Z
MBXWGF#T[<R"-/1B4&*2/[(;ZVM9%F]0\W_W5(D7^ZO4Q!M!\\1Z7IEC9V6HV
M@AN+^YU": I\+74RR1F!'O>4LD?[S@UR[I]OE%\:K@>?RKYLFU.VBCTS6HM*
MMV11Q>T]41"**.6+FU^.4=UPD^M.ZO-_=>C(K<VPZO\ 0_,EUYM36X-'U&"V
M6>"Z:U#VB-RB6%-F6_5"W"#TW]2-E^KS3)Q=\ ZC^7^K7/Z3DM=/O[6?599"
MTD2V*E;9V#B&4-> ,/4_>-P'Q-B_F?RSYMU);-+71KN95BM;>6&^EM6A].TE
M5F$H2]J\5PH9GCXR2-*L7[],+]/_ "_\T+)6[TV_D0&L#-<VQ:*:%5CCFXFZ
MX,5$?[AQ^]6)E67^[7+NO(OFJ V4FFZ)=2S+,MQJ/UFXL@KR)*94F51/)6>)
M6]&+>-$C_P"%':GY&U*[U"XNX-!O(9;FX>ZN93)I_)WE=R2M)MIH(W].WG?E
MZ2_L_$V"+'RQYLM'U?U=+GO)-5L38QW37%F#!'Z9CHL;L_%FXHSKR>.63XVX
M?80G@_*O5([#ZDNC3":>(Q7=T\]HT<D:JJ1PRH7=FCA]-I+9/C6%I?\ (XX9
MZYY%\Q:QKCWDVF20)<^@L\BSVI(2%X2R>J*3>FZVJ/Z:I\$LCLLF"-%\DZOI
MVJZAJKZ/))+?6]Q9/:_7(2GHS3O+4&BTKSW7^;D_P<N.1BV_*7S-%#>6\NDF
M>"6WAL[:3ZW9QRF&".&.DQ6&K(?JZ\8!)Z:?Y4KM)AFOY=>:)+OG-I)6.-WD
MM1'>VRE'EJ&DDD%N9II5#<5E<\U15C_F9EO^57ZW!JB:G#8*\T5\MU'&UW&_
M$Q%/2=7EA8HP,?[YH^#7*<4E7X%SHTVH>:U:D.C6\BT7XFO2IJ1\0IZ#?9;;
M_*QGZ1\YEA31+,+7XBVH-6E3T MC7&G4///(TT6P*=C^D9 ?I'U/^.8W_GFA
MIHVGUIL#J,O7_I#QYN?.Y1&73M-5C7G&U[.>/V:486OQ?MU^%?LK_-\-FY\[
M<&II^F\PPX@WL]"G<U^J[,/EB0N?/_(UT[2N/8_7KFO_ %"8^&X\\F0>M8:8
ML>]2E[<%O;K:C'1W/G5J<]/TZ/:I(O)WWVV_WF3_ "M\>)/-]9*V^GE:CTAZ
MT]:=^7[K*,OG(("+;3F?]I3/.H._9O1:G_ Y5K)YS9";NWTZ-Z_"(IYY!QH>
MI:*/?Z,4F;S3Z1$*V"S'[)=IBO4=@ <!._Y@LBF Z.Y%1)4W-.0.]*5QKS>?
MT>$2-HR"1^)!:Y!WJ0$K3DU!C;2_\WRV\K27FBB6"OK-$9I$C';G5T(Z-UP;
M-_B^2$-9S::2P!65TG92"%-0%<5K\=/B_DP*]UYND>\-O?Z.([<\3R2:0Q$&
MI$U)DH?3_P!7^;&2W7G**\CMWU#15DN%D-K:NDZ2R<17X:S'D%J.;+&V*O)Y
MXA]66YN-(AM8P&,K+<#BHW=FJZJ*#_*QLU[YD5K91JNCQO>LWU)7BE8SJ%Y#
MT_\ 2%Y'C\3<.?PX*,'G,,M+[3BM#SK:3@UIM3_23WP/<#\Q S?5VT@J''#U
M%N03'3<FC&C5Q>!/.IBC,\NFK+R/JJD<Y7A7;B2X/*GBN.>'SEP?A=Z<'HWI
M@VTY -/AJ1<=FZ_S?Y.!!;_F/RWOM'XU/2SNJT[?\?6*I;^?N7QW^E<*;TL[
MFM?^DK!$4/FT(OK7E@9*-S*6LP%?V: W!_V6&-FMZL-+R2.6;DU'B1HUXU^$
M<6>0U ZGEBV;-FS9LV;-FS9L_]/U3FS9LV;-FS9LB?F:3S/!<LUH;AX);FT6
MU-I!!*8T*N+CUUD^-H:A&=E*R?&L<?I_')B7FRX\X"[L9/+=ASC$,SWA<0*W
MJ2KZ=N!ZAW,,G[V559?@7]O[&,MI/,TUU8R :FMHL<HC^LBU1S/S'%KM$ZP%
M#\/'A)\+_!S]/"JTG_,.V@=DAU&?U;:2+A<FU>1-1FB4B2H"CZK#,I"D?NUY
MM^[]/CCK;2_S'N[J#],3SQVUO=6LL1LIUA,D;7=R9H[A8SR*Q6S6RGB_&3]V
MWPOZJ8E#!^;D,"+<F2X@W,RQO;+.J1P0JZ(P/QM</Z[PORYPRK\7[MX_3'+_
M (_?0= 6RMI4N+>ZDN=02ZN%2>6SAD810.S"?]]<Q.C\';X/3XR3IA.FA?F\
MQXW]W-/Z=JD=C-9W4< 6Z-&$UVK4YK"S.DBIZRSI&C^ER;BIQYKT?\P]4UNX
MM[658?+ET+2W4PW$D,\9BE6::Y/I-#)PD4O;^G#<)*W!/V&; LOD7SZZ7W_.
MQS.TDL5O LDLX5[8?51)-)Z,L922D-Q^[MOJS_OW_?\ Q8%/E'\RSIW#ZZPU
MAD$1O_KLWHK;?4A%Z(C7A67ZW^^^L</5X_[OY_#BVI>0O/1=EMM:DGA6 VR
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MJMZ<W[?"./XL%2:OY\&OZ)&+23ZBZ6PU0I&/2<S1N9GW7G!]7<1CB9_VO[K
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M.3_28?A<D@*?BV;8[8F?.ODT DZ]IP %23=P;#_@\=_C#RB>FMZ?_P!)4/\
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M.A-K'ZLZ$O;LI]")"[\?B1>7Q8Z7]#6<PCNO/%Y'/+ ;I%FN+)3]7*EQ(%]
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MT]?[WTN/[I&_=Q_R8677Y+:+=Z=;V%WJVH7$-B"NFES:UMD$\4Z(E(.,BQM
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M;N'7BIYK<VE*GCR6C2J?AJW_  .)-YB\U"O'RI<G84K=V0J:C_BW%XM9\RN
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MD#GG>TB$BM>!%G2,K)=JKR>F/[[ZLEM&J,W+FKYGTWS2(X(7U.[NY=4]3ZE
M!=VUR\5O*H#SQK"\<7$21>OSC19O4_=>C\'!;7[#2[V]1+;7V@NK^X>5[J W
M;P"6&)+!(Y9")4A0ZCZA1N<3?'RC=OVC?6;6Y6]U6WUK6HKN![S3;H6),_\
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MFS9JBM*[GH,__]#U3FS9LV;-FS9L!:AKFBZ=)%%J&H6UG)-4PI<31Q,_'[7
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MF QC?F/Y/4J/KDI+KR4+:W3&FWA$?YE_X+%8O/GEF0D+-<#B2"6L[M14>[1
M8QOS#\I+6MW+MUI:W1Z_*+&?\K(\GU ^MS;_ /+G=_\ 5+%O\>^6?BI-<$H*
ML!97E:5 Z>C4_:&('\R?* F2%KBY662G!#8WH)J*[5AQ\/YB^4IBJK<SJSGB
MJR6=Y&:[4%'A6E:_#_-^SEP_F%Y6F_NY;HFG+B;"^#<2 :\3"#2AQ0^>O+P
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MIL:J*'?*G\WV4-.=AJ9!%1PT^[D[$_L1MX8HGF:![<SQV&H, O(1FTE1ST-
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MB)8(?4#A>/!EE9_B_N42;_=GPCO+WYBOK6I16\>D3V]E-Q,=[(Z[K*)O28H
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MN:U\H><&O+*=GL['3+<R1W.@F:YO8I[>[/&Y$D\O"LBQJCP?N?3Y<X_A5V?
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MZE0TSI*BK(B0PB3T_5!]7G^PJ^ER7U65\DZ'YWTF;3=.U*]>;3K.S8W3LZ7
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MN<7[E?3Y8)M?*WG>2?3AJ&IDP6K0R3/'=S^HXCG$KPNJQQ1R@\5_?-Q=H_\
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M:JB?6T,4YG1FXAJ<@J*J5/J>K)ZL?'GZ<F'?FF\U"ST"[NM/K];A560B,S4
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M3#*+S#;75Q)9VBEKQ5NA&)!Q0O:.L3J2*G[<D?\ L&P#%YRYV7EJY_1\\O\
MB()3T*.MNSVYN/WA;B>/PLO+C_E8.@\S:;-Y@GT)/4-];H'D/#X "JM3D.GP
MNN[#BWV5;ERP3JNH-8QV[B/U!-<PV[-6@03.$Y'Z3Q7_ "V7]GXL#1>9M-?6
MY-'XS+=(YB$C1L(GD$*W#(LG0E8I%8_\#]I6QWF+S'IGE^Q%]J+,MN7$9914
MBH))I4;*%)QP\PZ:=4_1@9S<"7T">#</5] 7/#EX^BP?^7_98_6M4&FVL4[
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MX^@O)>-U&QX?Y7' ,7F0SO$;#7]?FC:]33?46+271I?C7E^\B7X)/2:3FG_
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M*EW/>)8VZW5TI2YG$:!Y%:@8.:?'7BM>6%S^0?)CZ8-,?1[9K$ *(B@.RLS
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M#Z<,62/(?91)Y9\Y)IENJQZ)YD^L7-M HH(-2B DG5 -A'=Q<[CC^S/#,_\
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MG10KR.L?I*TA%.96/X%Y?97$7\NZ&][%>M8PFZ@=Y8I> J))0 [_ .NU/M'
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M[R;(CN-7M^$85I)&8HBASQ4EF 45;;,_Y@^1XRPDUZQ0ILX:XC!%/$$[9O\
ME87D6O']/V'+P^L1U\?'%H?.WE&=N$&L6DK!2Y5)58\5%2=CTIB9\_>2%<HV
MO6"N#0J;B,$'PW;'2>>O)D1I)KEBA\#<1@[CEX^&^;_'/DSF(_TY8\R">/UB
M*M!U_:Q_^-/)^_\ N<L-J5_TF'OT_:Q[>;O*JHKMK-BJNO-";F(56I%15MQM
MCE\T^66G-N-6L_7!*F+UXN7)?M"G*M1WQI\W^4P:'6K 'WNH?^:LK_&/E&M/
MTWI]3T_TJ'_FK'1>;/*LI*Q:S8R,!R(6YA) \=FZ9?\ BKRQL?TQ94)H/])B
MW)W_ )L8?./E$4KKFGCET_TJ'>G^RQZ>:O*[DA-8L6(H"!<Q&E>G[6._Q-Y;
MV_W+6>]:?Z1%O3K^UF?S-Y;0T?5;-2"00;B(;@T(^UVRQYE\N$L!JMF2JAV'
MUB+9#T8_%]DUZY:>8O+[NJ)J=HSO]A5GC).U=@&WV.*Q:OI,H!BO8) 0""LJ
M&H/0['OEG5=,%*WD J*BLB;C[\L:GIQ"D74-'-$/J+N1V&^^4-5TLF@O("?#
MU$[?3EC4]-)H+N$FM*>HE:^'7+&HZ>>EU$:>$B]OIRUO[%EY+<Q,HW)#J1UI
MX^.*1SPR?W<BO_JD']6.Y+6E17P_#+S9LV;-FS9LV;-FS9LV;/_0]4YLV;-F
MS9LV;-FS9LV;-FS9LV;-FS9LV;-F--J_1FS9LV;-FS9LV;-C9?2X'U>/I_M<
MZ4^FN7\/MF^'VR]LKX.],WP>V5^[]LW[G_)_#*_<=^/X99]'OQ_#$U^I4^'T
MZ;]./TY9^J5W].O;ITQI^H4W]*E-Z\>F!/\ G6^7_'GRI_Q56F7_ ,Z]_P N
MG_)+&_\ .M>HO^\7J?L?W5?HQ!O\&?M_H[Z?0RS_ (-WK^CO>OH>.*C_  O1
M:?4:<?A_N?LT'3V^S@9/\"^H/3_1?J\MN/U?ER^C>N-B_P !;^E^BNU>/U?Z
M.F7)_@2B>K^BZ<?W?+ZO]FO[->V.7_!%(>/Z,IR/U>GU?[517A_E5X_9Q+_D
M'O/_ *5//M_O-7O_ &YA_P J]YK3]$\Z_!_O-6OMCE_P%5^/Z*K7XZ?5^OOC
MT_P/P;A^C.&W.GU>G7:O^RP;I_Z!]1OT=]5]2GQ_5_3K3WX8*'U7EMPY=J4K
C]K_FK_AL5S9LV;-FS9LV;-FS9LV4[A0"034@; GJ:=L__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>exh102_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh102_2.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_X1&-17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    <    <@$R  (    4    CH=I  0    !    I    -  +<;    G
M$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S #(P,38Z,#@Z
M,#,@,38Z,30Z-#,      Z !  ,    !__\  * "  0    !   "P* #  0
M   !   #CP         & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $  !!7
M     $@    !    2     '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 #_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ H !\ P$B  (1 0,1 ?_=  0
M"/_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M-=)'Z1OC4W?N_.24K$LM&X.MJ# ^UQ;!W;?4LW/W&S_I;$7(MJ=6S:]KIMK
M@@Z[V.C_ #4+&KM%,MIJW;KFN!)  ]2S:UI%?N8GS*[14 RBIP]5A'NC3=6W
M=_-N^E[M_P#(24VVV5N,-<''F 05)"II8P;O294\Z'9X?UMK$5)2DDDDE/\
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MR[]Y$ROYIO\ QE7_ )\8DI6)_-._XRW_ ,^/2ROYIO\ QE7_ )\8EB_S3O\
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M!!D       0    >.$))30/S       )           ! #A"24T$"@
M 0  .$))32<0       *  $          CA"24T#]       $@ U     0 M
M    !@       3A"24T#]P      '   ____________________________
M_P/H   X0DE-! @      !     !   "0    D      .$))300>       $
M     #A"24T$&@     #10    8              X\   +     " !E '@
M:  Q #  ,@!? #(    !                          $
M L    ./                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   ./     %)G:'1L;VYG   "P     9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   #CP    !29VAT
M;&]N9P   L     #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    !/_         X0DE-!!$       $! #A"24T$%
M    !     $X0DE-! P     $',    !    ?    *    %T  #H@   $%<
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M1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$
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M398ZIUCF!A#F1)+"!_9>6['_ -A$#0W1HC6=/$H8LN)8#20'$AQW-]L?1/\
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M ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "
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M(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_[@ .061O8F4 9
M    _]L 0P &! 0$!00&!04&"08%!@D+" 8&" L,"@H+"@H,$ P,# P,#! ,
M# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  "P@#CP+  0$1 /_=  0
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MLRM)\?H<OBXX8Z OY=ZIJYFTKT#J^F24X+(4G401?50_IA@S0^BXC5BOI/\
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MZK%<2V\UP@2KQ&2*Y5(6@XOR7][&W*9>.2#RWYSU/4]7U>WN6M5@L%D,$4?
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ML1<5./3\KO+"0O$)]6*R!0Y.L:F6^ U!#?6*K_E<?M8S_E5/E:E/K&L4Z_\
M':U7_LIR_P#E57E6E/6U;Y_IG5:_?]9S)^5GE= P$^K_ !KQ-=9U0[$@[5N=
MNF/'Y8>65MV@$^K>F[!V_P!S&I\J@4IR^L<N._V:\<9_RJORL"")M6! H/\
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M*_%X@8V+\H?RRB#"+RW91<]V*1\2?F01C_\ E4_Y<\2OZ!MJ,*'9J_?RP/\
M\J:_++_JPP_\'-_S7F;\F?RQ;[6@0'O]J7J/]GCA^3?Y8 4_PY:$>#*Q'6O=
ML67\J/RZ7IH-M](8_K.,;\H?RU9@W^'[5>))H@9!4]20K $GQ..MORF_+BV9
M6B\OVM4KQYJ9/M @UYEJ]<$K^6OY?J_,>7K#EL?]YXST)/0CQ8XN/(?DD!0-
M!T\!350+:( $]Z!<2F_+KR%.U9O+VGR?$KD-;1$%D-5)!6AH<P_+C\OA'Z7^
M&M+]+;]V;. KL"!\/"FP9O\ @L8/RR_+@4IY5T@<>G^@6VU?]ABL/Y>^0H8S
M%#Y;TN.,GD42RMU7D.] G7%;7R/Y,L[N&]M-"T^VN[<AH+B&UACD0A2M595#
M+\+,O^RP[S9LV;-FS9__T_5.;-FS9L@?YD>7_.6ISI-Y=N7B5+*:WE@$OI+*
MTT\'N.,L4:22Q2?S)Z/V)FPIF\O_ )IIJ+7]O,'$EV^JQ6S7+(J.8Y(19RJ&
M9'B,/H#X?W2S\IOM_'@[R=Y/U_1]=MI=0-Q>1V\ MTNY)(Y10(5+N[R^OR:G
M18G^U@:;R7YQNI8X#(T1:=CJ]_+<>HEVGUU9XGC@Y.H]*!7CX2)'_>>E\4:X
M;>9O+.MSS6<=DK3Q6]DMO8R1S?5EM+Q)%I=.BLI=. ^ROJ<>'I>GPF?"W2?R
MYU>+] &\:)C;O//J_,^MS<\!$"33UFXB3]Z_Q1\_APKC_*[S+)H4-J)$M]1,
MD\]Y/-Z,@9WMY8XPKQ@224>7X9Y_W\7V_C^S@W4O)/F;4Y;N(6QLY9I9))]2
M>X$BW%O,8VCMBH);_1J4H\?I?N?@Y>N^&$7D_7+/R]964ULFKK97UW-+IS3>
ME%/#,9?0,=1PB6+U$9;9N20_L.S1QXAY6\C^;-)U^TU._N5O:R&*[*.0_I_4
M8HEE:1OCG031,/0D^RS+<)\7/FG9>3O,,,*K=Z5;WIMYD>^YW1KJK+]8'K2*
M08EXF:*4+*O/FG#[,4.):?\ E7K,=S"U[<PW=E*LBZC9RR32*W^XU;. IR''
MDIYI*>/[Q$AE_O%RK;\K]<TZXTV_T^6U6XTV"QB6U4*B/)!;R1S.9_2,Z S2
M+*R(>-PBNLJ<WY94/D#S9826UO,(->L+8SBU1Y7M1'-=M!,UVP!=N<,\=S_=
M/SXW'[OC\:X+O?R]O+6[N+RQTVQOX[C5;B[DTR0K#$\-Q:K"CR$QL"\$HD?C
MQ;X)9.'QXOY8_+K5M'\QVFK7%ZMZ(TEBG!HC_%;PQK)S$?JSU:%^45Q,Z)ZB
MRQ_''QSH&;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-
MFS9LV;-FS9LV;-FS9LV;-FS9L__4]4YLV;-FR)^=]=UO3+NQBTP%O6@O)I$5
M8#5H%C]/D9Y8 (N4E'X-ZGV..7!YDOY]>MXXI$DL9M(&II;HGQR2,:!%=J-Q
M8'D%]/GA./-^N1Q6H^OP7$>JV]M.;Y8E$>GFYG$1Y@/\:'GP@]3XO5B?U7=?
MA7>9?,_F#1_1CMM234I8(;^:=H88.-;:2W""Z'J<DCB2<_67MQZG']YZ7[&&
M;:UKR:_>VYOK0:=:VC:K'<2<0AAF0I#&["E(X98I9I+CE\431+_-A;+KGFJ/
M1-0NGU1(KG30D\X>" AEDMR56*2-Y(WA>:CQLRI-Z?P29.=.CO([-$O)Q<SC
ME6=5"AEY'@:#:O#CRI^UG/)?-7G)K7S1/9S<HM*FO84GG6U2&-HI5$*1L&Y5
M6,MZ[7*<?LMRQFK><O,X1TL9I5UB#4+QY-*C6UGI:6MNC^C(0/L>I+ &E23G
M'Z_VOAQ?_&6H7&NS7-I?RC1));=(Y6^J&UCAN]/6>$[*;M9I)G'I/)_H_P#N
MO_)POM_./G&6U2VN+T1W-Y8V2:3-;BUDFNI)9P'OT0U3BT#?W+!4YQ2\5^*/
M#:W\VW^H1PI>ZPOEU[>T+S2.D!,MY!.\-S&XE#+PA].)GBB*2?Z2G[S[.(2>
M9=;EO_,5M%JX6XMFO8M)MHF@FEED6VDDC3T/2]2(VY3FLDDCK.WP,O[.,U37
M]2;2O,&IV/F1QING6]K-:W06W(+FT<-%ZACX&22=H)76C?%^Z54Y\</+R_DT
M_6_+.G7'F!G:[:X]0-]70W2 <H>0XUZE(ZQ</4PI?S)-#IFI:EJ6LW$&J1#4
M(Y=$B$7",PLRP<*Q-)&W P,DSOZ<S2K^RZ+@.77=<AT:STW4M4NK#4M-UFSM
MM0N96MDFGM)T$I,AC$L/V&8-Z1Y<8N6&6I>:FO=7L;G3M2D2R/I :?&5AN'+
M74D)F2*6-UO89>''A'+&T,2^LOQ2)DVL]4L[RYO;>W<O)I\HM[KX2 LK1I+Q
M#$4;X)$)X_9PH\^726OEN:4ZA)IDG.,0W$3!7+EQ\ JK\N2\OAXY'?-VKZW;
MZC*NEW%S-I_U?3V!MQS:.26X<+,I",9(I%18KI?CXK+'+^[7U'PS\NW4\^K-
M+>ZI=+JC7%U%<:*0I@2.-V$-$X5C41".1)_4_?\ /]KFJ+)M-U.SU*T%W9N9
M+=GDC#E63XHG:-Q1PK;.C#IA+YOTV2YDTYK9[I+R6\MX5>WN)XHXXDD]>=W2
M-UC:L,<B?O%;[2)@;3Y&E\SZC-8O<D1Q3HZW$DQ2>='  CA>D,44!_=I(O!I
M^;?;1/4>.6>KZ])Y/GE4.L[7%C^EK\R73%$E*+>@U$<D;6P'[T6RQ(B_8]%N
M3H=P7\D4_E":;U[26;U;6XLP]R\31"%^+NCUZRI"8I;C]ZJR<&;DS9K:</\
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MOD_2[I[34M;L;.ZC($EO/<11R*6 9:JS!A56!&./G+R@!4ZYI].G^]4/_-6
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M"9.)- >2E_3I_=_N_P!UQ3X<9Y3T_P [6VM:S+K]\MUILTO+28UX\EC'P?O
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M*V,$TUEJ,3,>0@E$$AI+$D=5D;X>#31_S8:>5M2EU+RYIM_,Z23W%O'),\=
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MT-Z-4C74H'F,<S6B-$(YX5B9?3#JQ<>FKK(TK?[[;E%\&)6/D2"QNK>6WO9
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MY-^SF3S%H;B^*WL1_1ID6^'+>(PJ'DY#K\"LO(XM!J^ESV:7L5W$UHX0K-R
M7]X 4!)I0L&6BGXL5DO;./TO4GC3UO[GDZCG6GV:GXNHZ8A;ZSIL_JA9T1X6
MD66.0A'7TI#$S%6H>'(?"_V6QYU;2Q#+.;R 00 &:7U$X(#TY-6BU]\=^DM.
MYQQ_6HO4F"M"G->3A_LE17X@W[-,2L];TB]N+FWM+R*:XLY&BN848%XW2G(,
MO7X>2UQ:UOK&[#FTN(K@1MQD,3J_%J5H>)-#3'27=K%-'#+,B32U]*-F 9Z=
M>(.[?1C!J6G&5H1=1&5.7*/FO(<*<ZBM?@J.7\N.L[ZROK=;BRN([FW?[,T+
MK(A^3*2,"ZMK^E:4(_KMPD<DKQI'#R'J-ZD@C!5*\F4,WQ<?LXJFK6$K7,5K
M/'=W-G7ZQ:P2(\J,*_ R\OA8TH.?'&0ZYI;Z9::E)<);6MZD<D#SLL5?57FJ
M_$?M<?V<;'Y@T636)M&6\B.JP(DDMGR E"R LI"G<_"I;;[./37-%>*YE2_M
MVBLV*W<@E0K$PV(D-:(?];+TK5[+5())[-Q)#'+) 9 05+1-Q8J02&7P.6FI
MVKW]Q9*P,EK&DD[<D(3U*T5@&YJW%>?Q)QXM\+8I:7]C>(9+2XBN4% 6B=7
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MBC1U9F2)@DC* =UC=@CG]EOAR[Z^LK.#U+NXCMHV/!7F=44L02 "Q&^V0_\
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M<7YA/V6^S_E?#E77G/3;763ILRD*HDY72LKHK10M<2*P4EU*QK7IR^S@"_\
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M+P-'<<DXOQ;*A\N:=#J-QJ$;7"W5U$()F^L3%?36O !"Q1?3Y/Z94?!S?^;
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M,<ER)'MW]2(EHX8_4>4Q!O56%3^[]0I_>\5_;CY5Y=\SV^M^IZ5O+;A8H+J
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MFS9LV;-FS9LV;-FS9LV$'YA 'R#YE!%0=*O@1_T;/AQ8(B6-LB *BQ(%4;
M*  ,7S9LB7YN!?\ E6/F<MT73KAS2E?A0MW!\,E<;AXU<=& .^W48[(9^3__
M "@-G_S%ZE_W4;C)GFS9LV;-FR(?EY/)/<>;6>E5\P748IX)# H_ 9+\V;-F
MS9LV;-FS9LV;-FS9LV;/_]+U3FS9LV;-FS9LV;(OY=B27S+YSCD'*.2]ME9#
MT(.FVX/WX-_P7Y=%K]66"10&B9)A//ZZ&!2L7"<OZR<%9U4(_'B\B_[L?%U\
MN:0MS8SA9?7TY"EH3<3_  J?M%EY\9"W[;2!V;]K'6?E[2;2\O+N%)#/??[U
M^I/-,C[ ;QR.\8HHXCBOV/A^S@;_  9Y=&G6FGQ6[V]O8ES:-;S30RQ^H29
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MI5#1CI-[0T!_X]W\</\ 3QQL+9:4I$@I_L1B^0W\H?\ E [3H?\ 2]2Z=/\
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M-#TZ0[%[6%C7WC![X.S9LC?YEBOY=>:!2O\ N)O=A_S#OXX?67^\<'_&-/\
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MGU-7= S\_A'IU-3RKQ''[66=8TKB2+N)_AF:BNK$K;,$GH!4GTG/"3^1OA;
M]OYC\MM:PW$.H6PMKA)IK=Q(BJ\=O_?,FXY+%_NRGV,M]>\MK<VX>_M5N;B(
M/;%I$#/$XY J2?LL!R'\V)P^:O*LD=U<0:G:.ELHDNY$E0A%.RLY![U^'&MY
MK\JO;BX;4;9H5MY+Y7+ T@MV"2RCVA<\9/\ ?;?:PW4QNJR"A4CDK==B.H.%
MUIYH\NW=D][;:E;R6L?'U)1(M%YGBG*IVYG['\_[.#+&_L;^V6ZL;B.ZMG+!
M9H761"5)5AR4D55@5;_*P)%YDT275Y='CNE.H0@F2*C  JJLRAR/3+JKHSQJ
M_-5;DRXC%YO\N2V<MY%>I);PND3,H<DO* 8PB <Y/5# Q>FK>K_NOEC[GS5Y
M>MH;*>:^C6'4.)LY!5E=6*J&JH/%.3HID?BBLZ+R^+!L6H6,MY/91W$;WELJ
M/<6ZL"Z+)7@67J U#QS7VI6%@D;WMQ';I-*D$)D8+SED-$1:]78_97 $WF[R
MO!917LVJ6T=I,SK%.TBA28FX2;D_[K?X9/Y&^WAOFS9LV;-FS9LV;-FS9LV;
M-FR.?F3_ .2Z\T_]LB__ .H63#3R_P#\<'3?^86'_DVN#\V;(K^:_+_E6/FS
MC]K]$7M*?\P[Y);/_>2#_C&O_$1BN1#\JT*^5[BM-]7UEA3P.JW)R7YLV;-F
MS9LB/D, :QYVI_U?C_W3K+)=FS9LV;-FS9LV;-FS9LV;-FS9_]#U3FS9LV;-
MFS9LV;(-H%M]9\X?F';JU&FEL8]QL"VFQ@>/C@/2_P O_,\,#6]_J$5S]<GL
MY[^YJ6<>ASNIPB2(R,LFH2,R1M\"VWP_LX+@\I>884TI"D$EQ9""V>]]=J-:
MVUR719[<Q^E,_H\?3X\&BN.;)(OPXKHWEK7=/UD:GZ88L=8+V[W1,2_6KM9[
M8(HC/'U0O[Y_]U_\686IY$\RW&C:':W(M+:^TJUOK<7$4SS"*:;T_0F0-%'S
M4\&2>)N'[J1TY-AK9>6?,%I.MFK0/IMQ)!+?R<E/)([6.VEMVBDAD+QMZ/[M
MDEAXK)\7V?C4_P +:D;2Y9(K2*\BOX[K3AR9D-O!(CQP.0BF-?@^'@)%B?X_
MCXX4ZIY!UV_EN;Q#:VFHW46H/%*KN\=M/=+!&D=.*&6*:*%OK1_=_O&]1%Y<
M&R?00-%9QP5JR1A*^)"TR#6/D[S(#I-Y<1VD5WHEM9VL5HLKRQ7'U<D2.[F-
M#&55C]6^!^#\N7VLFVG1S);?OX(;>9W>1XH#5 78FI8JG)S6KMQ^WA%>:#JF
MI:O>/?)$E@T$UKI[12,6C$\8629XRBAYI"2GV^,42?#_ 'LF K#1/-]II=P\
M<=I%JLD=G9QK'*QC6&U4H\R,\1XRNKOZ<;(ZQ_!S=\1O_*&KMI,%GI]O;VT<
MVG2Z5<VC3O(L"S2*?K"2F,-.ZJ'9U98_5?C\>'ZV>K#S<;WTH_T8;(6_K>L?
M4]02&2OH^GQIO3EZO^QQ7S%IUW>6UL]F$:ZLKF*[BBD)57],D,A8 \.2,W%N
M+?%D9O/*WF::QMU2*UCOG^O/+<Q7,L9MY+ZY,_IT])TNK8 J)8Y47U'CR=J*
M*!X#Y9LV;-FS9LV;-FS9LV;-FS9LCWYC G\O?-  Y$Z1? +X_P"C2;88^7&Y
M>7M+;^:T@/WQ+AAFS9%OS5Y_\JR\U\*<OT1>TY=/]YWZUR0Z<_/3[9^G*)#0
M&O50>N",B/Y6FOE>?_MK:S_W5+G)=FS9LV;-FR)>101K/G6O_5]K_P!RVRR6
MYLV;-FS9LV;-FS9LV;-FS9LV?__1]4YLV;-FS9LV;-FR'^5!3S[YX][C3S_T
MX1C)=(91Q]-0Q+ -4\:+W/0U/MCLV;-FS9LV;-FS9LV;-FS9LV;-FS92(B+Q
M04%2:>Y-3^.7FS9LV;-FS9L(/S *CR'YD+[*-+O>1'A]7>N#?+*E/+FE(>JV
M=N#]$2X99LV1O\R__)<^:=F/^XB^J$H6/^C/TKMAOHC*VC6#(.*&VA*J=R 4
M%!@W(C^5I!\KST_ZNVL_]U2YR79LV;-FS9LB7D9E.L^=>*\::[0]34_HVRJ=
M\EN;-FS9LV;-FS9LV;-FS9LV;-G_TO5.;-FS9LV;-FS9LA_E4_\ .^>>*_[_
M -/_ .H%,F%1FS9LU1FS9L0@O[&X@>>"YBE@C+*\J.K(I3[0+ T'']K%1+&0
MI#@A_L&H^*HKMX[8U[FWCFCA>5$FFKZ,3, S\15N*G=J#<TQ0D 5)H!U.5S2
MH'(5/05ZY@RGH0>OX=<O,2!2II7IC#/ )A"9%$S*66,D<BHV) ZTREN;=A(5
ME0B$D2D,/@(%2&_EI[Y3W=JBQN\R*LI B8L &+= IK\5<=Z\'K>AZB^OQY^E
M4<^-:<N/7C7OFCFAE+B.17,;%).)!XL-RIIT;?ICR0.IIE*RL*J00"0:>(V.
M(W;7;6LOU!HC=#:/UJF/D#N&X?%B^8@$$'H=CE(BHBHOV5 "U))H-NIRO5B]
M01<U]4CD$J.7$&E:=:8[-FS$TW/3*]1.(;D.)Z&NQKEU&5R6A-11>I\,RLK*
M&4@J=P1N",)//B,_D?S"BBK-IEXH'N;=Q@WR]_QP-,_YA(/^3:X/S9LCGYD@
M-^77FD$5!TB_J/\ HVDPS\NT_P /Z93I]4@I_P BUPPR'_E4:^5[C:G^YC6A
M_P!S6YR89LV;-FS9LAOD$M^F?.]*$?I]JDGI_N-LJ4R99LV;-FS9LV;-FS9L
MV;-FS9LV?__3]4YLV;-FS9LV;-FR":1<2Q>:OS$EMK7ZW<0M9&.U6E9I!IR,
MJ?$0OQ[)\1PF^H^8O+MK9Z4#.+&>ZL&9[65()9GE@F%Y;P^I)]LO!%.RKZ7]
M[)Z#>K@B";S<VMQ:<T][)J,5G;3+PN+?A 9+NXH;^*J\^5JD44C0I*KR+)QX
MR>G+DMTBWU$Z]J4]S-?K;"4K9V\_H_5O3X)5DX<I&Y2<RGJ%65?AXX;:;=RW
M=E%<S6LEE)("6M9N/J)N11N!=??9LCE[Y>DD\^VM\L,@TTPFZO&7B(WOX*0V
MK/OS)6WDGY?#P^"WY?W:XKY;AU>V75+V^&H2RK+<&TLKB2-U-N)7:!8J,1S9
M1]J1^?QJK_954'7T]]=:?I5RD-[:32W%K)<6L'H>K&KD%X[CF73TDK2X]%N?
MP_NFPXD ,; KS!!JOC[;YSBSTRZN-&O;J/0Y["1[S3IKG23#'%']5M9D9H84
M1B)W2,-ZC$+ZS?NT_=\5P2=*OX[#RKSTR:66TU6:\X(JL]I:R_6/31BSKP].
M.>&,HC/QX<>/%,%R:3Y@B_,-M12$3V=PT06X>.$I#:);NLB"4UN5F-P5:../
MC#P>3GR_8-_-VFRW]E:1F WEE'=Q2ZC8+Q/KVZAAP*L0KJDACF>,_P!XL7I_
M%RX9%M2\JW5RL(T;1%TU-%BNKW1%F].GUZ2>JK&%DK KHC?#\,:I<<67X.&*
M6'EKS ?--MJ?U+ZO8/JLU]<0S/%ZD/*Q>+U(O3:0%9WD6.:,%?WL*S?MLV2_
M03>&.^%TMTI%[<"$WAA),1>J&'T?^/>AI#ZO[[C_ 'F _-EH\OZ+N8+!KRZL
M[Z&6.2-8VDACK29E,A7CRBY(W$\FY84:OY<U6X\Z6UW8$I"+JVO+RXE@4E%A
MB:)HH;@R!^,R? T*PM\32/ZJ\^+$:>5=8M[;4C!9R2:=!]40VP@C@N+Y+34/
MK$P9?4<3N\'J1^I)Z/UCU/L?M8,O-'N4T?39H]-O(]2ADU*31H(8H)8K=KJ5
MGMDN4E#K".!C^)>*P<7C]1,,I-&U!_.,=R+-DG2]-T=5''@;-M/^K_5^5>;?
MZ5\?H$<?@];'^0=(N[$EI[%[&6.QM+2]+<0+B\@,AFG7B3ZG+U*^N?[SE_D9
MO.NE37E_')/I<FLV1M)8;2WA*!K>]8U6>KM'Z99/A2X5N=OQ^'^\P#H5GYGM
M-72U;ZXM;EVO9&$?U&2W:W'JS(X'/UWNPSQ_[L_G3T<TSZO^AM5AT"[ENH8-
M72.>X@9)+D6K00O<>DRJ_*82NW+X))/[SC\?'%)W\UF'3OK<NIB'T9*2Z?%#
MZ[7 F(C^LI*"H4P<.J)$S^HTOI?NTPUTJ+4[;S9JWUI[U[:\F6:Q6BM9K%]6
MA0U>G)'$T4O[OE^WRXMRY8_S?:3SRZ2TEH=0TF*Z9M3LT02L5,+K%(8R?WB1
MRE69*.WV9./[O"L6H@UWRH]AH]S:V\"7"3L8PQ@@N$/"&20,Y4>J$9HPS</A
MQ"VU'SB=5UQY(KZ&V^JW1@B$*S&*=) ML;?F(HIF>(M+Z:,R?9CDD]3$VU/S
M9_A^%^6I+<O=R(DJVG)Y(A!1"\1C6>UC:8U5I(I>+I^\_</DJ%QJ'Z8TN.07
M21RVDS740CA>W$H,5/6G #+**OZ2Q?NY?WO\B8MYD:%=!OFFL7U.,0L6T^(%
MGFI_NL*.O+O_ ,;9![O1K<^4;(26]T\D=Y/<P6D>G-);I<2)($B^ISQO)%:!
MWXQ/Z:<6_>L\7/#R">1?.6DS7>G31ZC<:5)%J%U#!*]LDK-#(L37 !CHI2?C
MR;_B:X3^7-.N[>*\&IZ;*+06,<6M1O 9OK.H>N[23I& 1=+P;F\BJW-/3C^/
MT^$<E\A6EQ:>68()XVC99KDQAHOJ]8VN)&C80#^X5D*LD/\ NM?Y<WYC*S_E
M]YG1?M-I-\%^9MGPP\ML6\NZ6Q!!:T@-#L16)<,<V;([^8__ )+SS1_VR+__
M *AI,,O+G_*/:7_S"0?\FEPPR'_E5_RB]QO7_<QK77_MJW.3#-FS9LV;-D0\
MA C6/.]0177B=Q3_ *5UEODOS9LV;-FS9LV;-FS9LV;-FS9L_]3U3FS9LV;-
MFS9LV;(CY6B*>>_.K%>/J3:>X-:U'U)%K[?9IC[7SYI]_:Q7$&G7-PLQ46*(
M;>0RW!Y$P B4I%/&B&219GB]-,2;\Q- 35+6'ZG*L]T(XY9V^KH\4DEPUMZ#
MH\BSR/'/&5D6!)N/PO\ 8;EDHBU"QFO+BRBG1[RT$;7-NK O&LH)C+KU7GQ;
MC_JXCJFK1:?]74PRW$UT[1P0P!2S,D3S'[;(OV(V_:^U@6R\W>7;TV:P7J%[
M^-)+5&JI82J7134461E5F]-OC^%OAQEYYT\M6FE7FJO>+)96"A[F2)6DHID,
M55"@\QZB.GP?M*V")_,-@B:>Z.K1ZC.((&<F/>C=.8%6JO$)]IL<OF+1&U8Z
M0+R/])*>)M:T?EZ?J\=_VO2_><?M>G\?V<"W7G3R[;6=Q=R7),5K+!#<!8Y&
M=6N9!'%5 O/B[M]OCP^U_+@MM<L_]QI2K)JC\+=F_=_[J:4$K)Q:I"?8IS_R
M?A;&7'F70K>]>QEO8UNXU9FBW)'%/4*["GJ>G^\]/^\X?'QXX_1_,&CZS$\N
MF72W,:<2Q6HVD4.C48 E'4\D?[#_ +.&&;-FS9LV;-FS$ ['$K:UMK6(0VT*
M01 DB.-0B@DU.RT&^*YLV;-FS9LV;-FPE\[*&\F:\IZ-IUV#],#XIY0F$WE/
M19A6DMA:N.1J?BA4[F@PVS9LCWYBBOY?>9Q_VJ;[_J&?#/0!QT+3EI2EK"*#
MI_=K@[(G^6'_ "B\O_;4U?M3_I:7.2S-FS9LV;-D4\FB4>8/.@<DC]+QE 2"
M*'3+/I0#\<E>;-FS9LV;-FS9LV;-FS9LV;-G_]7U3FS9LV;-FS9LV;(CY;DK
M^8/G&(MNHTQ@M-@&MW%?F2IPPM_*%M;:/::=;W<Z-I\JS6=V!")$=4,?Q!8U
MCD#(SH_-/B5OYN+8#;\O-*/J\KF=C<J1=.PB9W<SR7#2AO3K'(7F<<HN'%.'
M'["Y(8+26.^N;EKJ26*<1B.U81B.(H"&*%5$A]2OQ>H[_9^#CB>IZ4E\UM)Z
M\EM/:.TL$T7#DK/$\1VD5U/PR-U7"2P_+[2-.N[:6RD:.VM_0;ZL\<,M9+:,
M1(XDD1I(VX*O/TV7[/[/Q<J@_+_3EL-6LKBZEG35X_2N'5((#L782\8(XXVG
MY2?%*T?Q\4Y8MJ/E/4+^RLH)M=NO6L[E;LW0BM>4CQMRC4KZ7!43_)7DW[38
MI<>4+>?4A?M>3K(M_P#I)47@ '^HFP,8/'EP]-B]:^IZG[?'X<!V7Y=Z?:VN
MH0_7KF1]0%KRF(A#(]DYDAD7C& TA?XY6E]3U6^U@^_\MW5ZFG>KJUPL^G3&
MY69(X 9):,H+J8RO%4D=.*\?^"Q*X\G0S7L\WUZ=+:>9KOZF!&42Y:'T?45B
MI>E/C],MP]3_ "?@P9HOEV#2IY98KB6;U;>UMN,G"@6T1D5AQ53R?E\=?A_D
MXX:YLV;-FS9LV;-FS9LV;-FS9LV;-FPI\W$#RIK1/06%U_R9;$O(W_*$^7_^
MV;9_\F$P[S9LCWYB_P#DOO,__;)OO^H9\,]").AZ<3U-M#_R;&#LB?Y7L6\J
M,3U.IZOT-?\ I9W.2S-FS9LV;-D5\H,Q\R>= 3TU6"B\JT_W&6?;]FN2K-FS
M8V179**Y1JCX@ >AJ>OCCLV;-FS9LV;-FS9LV;-G_];U3FS9LV;-FS9LV;(E
MY<C(_,#SA)39ETQ0?=;=S_QMA#I=QYRT[R_%?VS2RI=FVADCO'N;F6!@TAN+
MEQ*IECY+Z4?H_'&K?O?A^+D:QZ[YLNG\O0QM# NI6LTE_=?5+B6)7C>(0\:F
M(QFX5W^"7[/Q?R?$).JZI:WGF6.RMFN);:&*72HC!/'&S+$5,8<_NI.#H/[G
M@WQ<?M?%A=<>:-?-DH^L*+.266--;^I3D2<8%=$%L&YH7E:2/U.7']UP7]Z^
M2ORP]TWEG26NA)];-G;_ %@2AA)ZGI+SYA_C#\J\N?Q9&+/S5K]Q8:M-,0AB
MT^6X'I6LP>RND##ZNW,M]9?]KX$_W6W[$D>'7D+D?*>GR/=3WDTL0>:>Y]82
MF0BCAEF)=:,/]7^5<*KHZ]<>?KB"SGFBMK2*TN6#/,(F0>H)H8XC']5E,H*!
MG:=986^/C\. K+SGYRET#5[^ZLK>WN[*SANK>W$<TCK-)R+021H26V55Y(_J
M*WVH_LX+\QRZU/:Z!$=7])+N_/UR:RMIXP]N(Y&1:K(9(E601(SL_P"]Y?['
M!3>9M5'FK]%A5HMRL7U 0R&0VAAY?7/K!81A1)MQXM]GTO[YL)V\S>??T.MY
M;^C=7<UQ<10VB6%Q58K>.YDB:0F1>+7?H0ITX1M,O#GR7%=6\[>9+#2;>5K4
M_I%#<-<1_5Y!'(L,_IQHB\FEYR(5;X!)\/)^6&,OF+7XO,:PA4GTY]2?35@6
M%U<*-.^N"8S<BG]\/0^QP^/[7J87MYL\S+HL]U%)'=7Y6W::T6RG3ZCZTWIS
M>HS-2;ZLE:I\$G[OU6XQ-\)I8>8-<?0]*N[H117%S?K:7!$%Q*)(&E>-'18J
M^BTJB-O4D9K>+XN3\<E><]\L7;?5[UM1N;U(S:PMK32M<5BU!IG218V%3$O$
M+R2#BB0^E)\'/G@G3[W5YO+%OIB7;#4M5N[FVM;Q&D?T[5979YHGEK*PCMQ2
M&23_ ':T7[/'!.IWK)YVTRST^YFDD,A.JVH>9RL'U<^FWIO_ *.(.?'U9/[W
MU>/#XN:XCY7\Q6UO:^;)I+J:]M],U*4P+(\DK^DT$16.,R5+!I_5CC5?V_@P
M/KLUW8:5I-KJ.H7-MK^HF9C<Q/*+:W>1TEE9^%4D6VJL%K"_]]]GCQ:5T&07
MM_\ XV>WDGN/7:[<?5*N;==-%D&27CO$*WE%]7^\]3G#]E<+;'5()?)VKPMK
M4R)9ZG)'^DIS<LT=N;P/&LDJE)A$8OW7K^HJK'\?J*F2[RI?27N@6MPXV/-(
MY 9&66.-V2.93*6E*S(JRKS9FXO]M_MX3#S%J5IJWF&VEN$O+NW9YM'T81<)
MY8ELHI$$;\OC1IA,G/A_>?!^SQP?Y6\Q3ZO-=QEHKB"V2W*WUNCQQ-+(K&6&
MCECSA*J6^+X?516^/EC-<G6#S7Y?*W$J-.\\$UNLDGHM&8'=6>):Q<O51 DC
MC_)5OBXL3Z;K-S%YKG]:\<Q0#5)-;BF9_3MX(9H_J+A&^"+E!R*LG'UU]21N
M?#X%KNYD/E*74-4U%[.YU*22\L%DN);)(P8RUM;M)$#(BB%%:9:-SF]3X&^Q
M@ZXU46WFG08);WC)?6<Z36I<^F[+Z;(X0C^\+<U5C^SS7$+C4XKC]/ZU>7\U
MEHFG12V$,L!((,6]U<(*,&D$E((3Q9D:&3C_ 'F$MW?-'Y:L?K.KW%OI<TUY
MRO([HM/$4C<VUL]V&9I)%<?SMZDJI!SE_P!VGNGZK=KK?E^*_N6CNK[2'>\L
MY"$'UA6@(;TJ?#)5YU_V/^3@+\O=8U>_U#4A>W+3HJ@LI(;TYOK-PA5E 'U:
M3T4AY6E9/3^URY-\<XPJ\V 'RMK )H/J-S4^'[EL1\C?\H3Y?_[9MG_R83#O
M-FR/?F+_ .2^\S_]LF^_ZAGPST&GZ#TZG3ZK#3O_ +K'A@[(A^5CJWEJZ"DE
M4UC646M.0 U2XV('3)?FS9LV;-FR&^26KYO\^CD6 U:VZ]O]Q5IMDRS9LV;-
MFS9LV;-FS9LV;-FS9L__U_5.;-FS9LV;-FS9LAWELU_,CSF/"/2O'_?$OT9,
M<V;-FS9LV;-FS9LV;-FS9152P8@%A4 ]Q7KEYB 10BHS9LV;-FS9BJD$$ @[
M$'OFS9@JJ*  #P&:@S9J#-A/YS_Y0_7?^V?=?\F'Q/R+_P H1Y>_[9EG_P!0
MZ8>9LV1[\QO_ "7OF?\ [9-]_P!0SX9>7]]!TVG_ "RP=>O]VN#\AOY75&E:
MVE253S!K*I4UH/K\II^.3+-FS9LV;-D/\F,3YN\^"M0NJ6M!X5TJTKDPS9LV
M;-FS9LV;-FS9LV;-FS9L_]#U3FS9LV;-FS9LV;(9Y:I_RLSSKX^EI)_Y(S9,
M\V;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS83^<_\ E#]=_P"V?=?\
MF'Q/R+_RA'E[_MF6?_4.F'AVS @@$=#TS9'OS%!/Y?>9P.ITF^ _Z1GPST)&
M30].1OM+;0AOF(P,'9%_R\2$:3J3Q  2:UJ[,1W;](S@G\,E&;-FS9LV;(;Y
M*4+YP\^T[ZK:D_,Z5:9,LV;-FS9LV;-FS9LV;-FS9LV;/__1]4YLV;-FS9LV
M;-FR"Z/<K:_F!Y]NG5F2"UTN0JE6=@EO.Q"A?BKX86:7J_G#2M):TU.::VD=
MK6XFU2X1KWZM!<QN9J%:@B.>+TT]7^Y299)>4:X&;7_-7Z+CM7N+B!E/JP.+
M.Y:6^+:A*DBQU)EMTA@2-T1N3>E+S;U($SJ<WIF"3FQ6/B>3*2"!3<@C<?1D
M M=8O(?)>CZA#J4R+'?+^E[RZ62=UB8NK"42%71 S15_D7!%WYMUL^9K:RMW
M1;">&%[9WA9?K"2J3+,A-6Y0_P"^N/\ QF95D1U;Y!\R^;-2U%8=9:.6WFM?
M6C>.UDM^#B*UF7D6=Z^H+R10O_+O_-ZF'/GK3S<:-+-";HWR*8+%+2XGM_WU
MRR1([>@Z<O38JWQ\E1>>2#^Y@WY2>FNY^T[<1[=6.0'3_/.L7&E:M<2201O$
MMK)87,L,BQ(+QV7C,8FF7]SQI(W/]TW]_P %R5^5=0O-1T&VN[QE>Y?U%DDC
M3TT?A(R!T7E)\+JH96#\7^VOPMA%?7^I?\K GBCNIGM['3%FM=+6-TBGN7,W
M-?6!"._!(?A=6]/DO'[> +?S)>:IY;UEKF[:>$VB26]S;P7%I)%>2AQ]44 ^
MJ\D4BQ_9_>?O/3EPR\Q:N+>S\M7TES)!2ZB>]<>HB^B87$OK*M%X<RE?4'PM
M_E8V?S/KQ\P/IT0@C<W;6L-BT4C3?5_J_-+WU0W#TO5^U^[X\?W?J>O\.%T/
MGGS/=:/?7HLUTOZI;6RI+J,3QQR7,TOIO(K!J")>+CC)PXMZ;22+&_+#?3_,
MVHS>7M'OYI88[B\ODM)V>WEXR*TSQ?NEA>8*7"J8YVD>W;[?V'^&69LV;-FS
M9LV;-FS9LV;-FS9L)_.?_*'Z[_VS[K_DP^)^1?\ E"/+W_;,L_\ J'3#S-FR
M/_F(2/R_\S$;D:3?&G_1L^&>B.7T:P=AQ9K:$E=]B4&V^#<BWY<S&;0[V4BA
M;6-8V!KTU*X'\,E.;-FS9LV;(SY3K^G_ #AM0?I6*C>/^XRSR39LV;-FS9LV
M;-FS9LV;-FS9LV?_TO5.;-FS9LV;-FS9LAWEN-A^9'G.6GPM%I2@U'589B=O
M]D,F.;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9L)_.7_*'Z[_ -L^
MZ_Y,/F\FH$\H:&@Z+I]J!3V@08<9LV1W\Q__ "7OFC_MDWW_ %#/AGH!!T+3
M2%XCZK#13V_=KM@_(E^651H-^"*,-:UFH_[>4_ADMS9LV;-FS9$_)<KR:]YU
MY<1PUE%  -:#3;.E:Y+,V;-FS9LV;-FS9LV;-FS9LV;/_]/U3FS9LV;-FS9L
MV;(EY=7_ )"!YO:O5=-%/E Y_CDMS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV
M;-FS9LV;-A-YT-/)VNFE::==[#K_ '#Y?DP >3]" %!^C[78_P#&!,.,V;(]
M^8II^7WF<^&DWW_4,^&>@L7T/3F/5K6$GZ8Q@[(G^6IKHVI^VMZP/^YC-DLS
M9LV;-FS9#O(I'^(O/*[<AK49.V]#IEG2IR8YLV;-FS9LV;-FS9LV;-FS9LV?
M_]3U3FS9LV;-FS9LV;(CY<"C\PO./3D5TPGIT^KN!^HY+LV;-FS9LV;-FS9L
MV;-FS9LV;-FS9LV;-FS9LV;-FS83^<O^40US_MGW7_)A\WDUBWE#0V/4Z?:D
M_3 N'&;-D=_,?_R7GFC_ +9%_P#]0TF&7EW_ )1_3/\ F$@_Y-KAAD5_+B,K
MH^I&M>>M:PWR_P!R,X[?+)5FS9LV;-FR&^1S_P [3Y\%*$:Q!OMWTNSR99LV
M;-FS9LV;-FS9LV;-FS9LV?_5]4YLV;-FS85V>O+<:M)I<EE<6MPD;3(\PBX/
M&D@CY*8Y)&'(FJ>HJ<E_V6&F;-FR'>7AP_,CSD:\JV^DOQ W_NYQ_P :X96?
MGCR_=Z0^JPR2FW29+;TVBD68S2%5C18B.;&0NOIT^%LJY\\:+;);/-'=HEQ#
M)<DFUGK#%"XCD:=>/*((S;\U_P K[.+Z?YMTJ^U2738UGBN(Y)H4::%XXY6M
MF"RB*0CB_ GQP5K6LVND6BW=TDC0F2.)C$A?CZC!0S?RH"?B;*N=;MX=4ATQ
M(IKBZD >7T5!2"-JA9)G)545F4JBCE(W[*<5=E$:CJ%KI]E->W3<((%Y.0"Q
M\  !NS,=E7"I?..F?5K2=XKF,75X-/>-HB6@N6;@$GXDJGQ\5Y<F5N2\?AP9
M<Z]:VVJ6^GSQ3HURPCAN?3)@:4JSB/F/VN*,?Y?\KEB;^8[4:=->QVUU/Z%P
MUK):PQ%Y_463T_L#]G]OE]GT_CP3I&JV^JZ?%?6Z2)%*7 292CJ8W*,&4^#*
M<&9L+]5U_2]*9%O)65Y$>14CBDF81QE0\A6)798T+IR=O@7E@HWMF&XF>,-4
MKQ+J#55YL*5ZJOQ'_)QBZGIK1R2K=PF.(\97$BE5('*C&NQIOB5QK5C"UA\1
MEBU&3TK>XB >+D49UY.#0!^-$/\ -@A[ZR2X%N]Q&MP4,@A9U#\%ZMQ)KQ'\
MV-AU'3YT=X;J&5(UYNR2*P5=_B)!V&QQQO;,*C&>,+)3TSS6C5( X[[[FF)Q
MZIITM]-I\=S&U[;A#/;AAS42 LE5_P I03CKG4+:WM+BZ),L=JK-,L*F5QP%
M2H1*L6I^R/BQ2VN(;FWBN(&YPS(LD3CH5<54_2#@&?S'I$.M1:*9N6IS)ZOU
M= 6*1[T=Z;(IXM3E@]9X'+JLBLT=.8!!*U'(5\*C?$M0U"TT^QGOKJ3A:VT;
MS3. 6HD:EF( J311VQ998V( 8$D<@*[T\:8G=7MI:(DEU,D".ZQ(TC!09)#Q
M117]ICL,4]6*JCFM7W05'Q;5V\<J::&"%YYG6.&)2\DCD*JJHJ68G8 #"J'S
MAY:F$9COD8R7"6:I1P_UB1/42,H1R5GC^-.0^)<$7/F#2+;5K?2)I^.HW2E[
M>WX.2RBM2&"E/AI\7Q?#_LLJP\Q:)J$L,=C>17+W$3W$'IGD'BBD])V!&WP2
M'@W\K8IJ^M:9I%J+K49Q!"6X!J,Q)H6-%0,QXJK.VWP(K.WP*V,?S!HZ:C!I
MQN5-W<H)(44,RE6!*_O #&I<*YC5FY2<']/EP; T7G#RY-^D/2N_4.EHTMXJ
M1RLPC0LK/& M9U5HY$Y0>I^\1H_MX;0S13PQS1,'BE4/&XZ%6%0?I&%7G+_E
M$-<_[9]U_P F'QOD@U\EZ =]]-M#O2O]PGAAUFS9'_S#7GY \S)_-I5\-MSO
M;/ACH'#] Z;Z9)3ZK#P)%"1Z:TJ-\'Y&/R]*'1KXH0R?IC5Z$&O_ $LI\D^;
M-FS9LV;(EY*M^'F3SO/RJ)M8B''PX:99CK[Y+<V;-C'GAC>-))%1Y25B5B 6
M(%2%!Z["N/P%<:YHML)&N+^WA6*00RF2:- LI7F$;D1Q<I\7$_%QQ8:A8EH%
M%S%RNARMEYK650*UCW^,4W^'%G=$1G=@J*"68F@ &Y).,BN;>6))8I4DBD_N
MY%8,K5_E(V./Y+RXU'*E>-=Z9G=$0N[!4459F- ![DY331+PY.H]0T2I Y$[
MT'CCLV;-FS9LQ-!7P\-\_];U3FS9LV;-@&WTJ*+5[O5"YDGNHX80"!2.*'D0
MJ_ZSR.[?\VX.S9LV0C2$FG_,#SS%;2?5[HVFEI%<D>H$9H;C@W \:\&;EQY?
M%@J/R']3M)+33[J,VTD%G ]M>Q-=QO\ 4^0^+U)*A9$*CBG'TVC5U;'KY%CE
M;2TOYTO;6P@GAG@E20^J9YHY@ WJ_P!S$8A&L,HG5H_A;$[#\NK"WU2\U&6;
MUI;^6]^MIQ8));7Q#&$@NP5T95_?1^FSI\#)@C4?)5LGEZYTCR\+?2S=2I-(
M\D;SH60J:E!)&>1]-/V\K4?)C7GF2UUKZS'%(BVWUND-9&-I(\B>A(7_ '*2
MF1H[A>,GJ1<4Y)]K!%YY,TAK*\BL(Q9W5TJTN1R?B\<@F0E2VZB50S+\/+ =
MWY4UV;3HHHM2MX[UM235+N5[=Y(RT<BR+%&JS1,J#@J%G=^6&%_Y>EOM=L=2
MGDA"Z=*TEHRPD7*J\1CDB];F?W<C'E(OI_%Q5?V>>;R_I.LV(U/Z[<V\K7MP
M]S 88W7TS(*%6YN_.G%:4XX.T32X]*TBSTY&]06D*1&0BA=E%&<BIW=JM@4^
M4_+YU:35_JG^Y&4DR3B20$EH_2/P\N/]W\/V<$:3H.E:2)180F(3%3)RDDD)
MXB@WD9L*?-GES5M7N+=[*Y@MECBDC$S)(+B!Y"/W\$T3HW)0N\#_ +J3X>?V
M>.!;SR?J/Z8GOX;F*6U:X:_,#Q$W#3MIWU!E60.D:!E"R5]/[7)?LY'[+R)K
M4/E/1X9+>W^M0QZ3;OIR6T82-+::*2=[E?6].X=>+KRC=/AY-&K<^.2&?RAJ
MD-A9V^G2VD;0ZE^DID:-XX11ZB*%(S\"T/Q,2WQ_%^W\(>^_+^>3S1-K,,L4
M@FG6\7ZP9RT<B6WU;@JHZJT; +]K]EI%].3X>)78_E-=6NGW5K'<6D1N(@#Z
M4+(K2#ZFX20!@6@Y6<D7#_?$O^MR%3_EM<W>DM;2_4X+F2SU2(D+)<+%=:FT
M;>K$TG$JJ&,NW%(^3M\*IAW;^6[FW\U7.MVXM774(8$N99$/UB-[>.1 8FI\
M0<.E>;?#Q;[7+X2[RWY.\PZ1!JLDMS;7.H:A;Q1<R&5'GC,I>:3BJ\?5,W]V
MB?N^'VVR2^7+._LM"L;*_,1N[6%()&@+&,B,<%8<P&^)0"?\K #>7K@^:I]8
M*6AAGMH[0MZ9^M!8_4-1)T^(R\:?R+A%I_Y?ZBNGFRU,6%S%QTBW*!)"LL.E
M2\B\W/[4LJ4XK3BG'@S2+@?4_P M]3NM'O;"EA<M=PW]M ]TKD6D=U=RW$3P
M *=T26.-X_@_N(N$G'#FP\K:C'YQDUN5+6*(B2LD1=Y9@\<<85TD6D++Z0J\
M,O&141?17#3S3H9UC38X42&2:WN;>[A2Y%8F:WE5^+$!RO-0R<@K?:PDUCR9
MJ&I7\-VT=BDIMK>#UB':2Q:&0N[V+<13U%;C_NG^[C9N:_N\D>OZ5^EM'NM/
M$@B:=*)(5#J'4AEY*?M+R Y+^TN$NO:-YGU+]'RHMB);'48+T1&25 T<,+*R
MF3TW)9I7;C^[7A'_ #M@F+3_ #*=7TJ\NC:SK:V]Q%>RJSQL7N)(V'IQ\&7B
MB1?M2+RPO\I>2]1T;4X+R>>'T4LYK>6UB#,/7>6,^NCL%IZL4*>M'Q_O?B5O
MB;#7S/I.J7ALKK2_0>\LGE*PW3,D3K-"\)JR+(RLG,.*)\2\HO@]3GA/;^2-
M1M;O3XHI89+"$V$EU,Y?UQ)IT)B41I0J5F^"K-*OI_O/AD]3%-(\L:[9),)#
M;.;6RET_3N+NOJK)*9!),>!]$A0B\$]7XN;<OV</O+5G>V/E_3[&]6-;JTMX
M[>3TG,B$Q*$#!F5#\07E]GX<1\Y?\HAKG_;/NO\ DP^;R9')%Y/T*.3^\33[
M57^8@0'#C-FR._F1M^7GFCO_ +B+_;_HVDPS\O\ '] Z;PKQ^JP<:]:>FM*X
M/R)?E@O'RY=C84UC6>@I_P!+2XR6YLV;-FS9LB_DZ2)]:\X^FW(+K*JVU*,-
M-LZC)1FS9LCGF^&=[C1);?2Y=0EM[])6EA$-8(P"'8M*\9 :H^QRY881ZA<W
ME[JNGQ0/;K9I&D5\_P!B26:,NP0;5$(,?)J_:?C^QD2\IZ#YFLO*US87MFDE
MW:VL2V+7*VY>341"R7$_*+9HGE96CDE_TEN4WJ?:7%=<\I3F[TBVTV"1FM$L
M(VNN$(ACBLKE9>0<L)8Y" W)(D;U%;AR3XGPTUUKOS#Y6UZRM;.2.57FLX!)
MQK+Z7$-*BM\)'+F(UD^"3A\7[M\([O2=17RKIY&F3W%ZNN0WZKPC%PD(U!;B
M21E!5(6:!6Y1QG_)^TS8/U70+^;SW87]BA"K-'<7URT('&*.WDB,27)8,4D+
MI6!(W^/XW=,,_,"WNHZ;Q73Y3';W\/UBTD],FXMH9E+.@#,K(P_>*C\6?AP9
M<C=]Y7U8V4$0L&G9;2ZATU>2?Z%/->*\#U+?NS%"4/./["P<%_85NBYLV;-F
MS9L__]?U3FS9LV;-FS9LV;(AH\8B\^><9HVI-);::VX^$!8IPI[5W!KA=H/G
MC6UTXOJD0ENYK2PN+"*51"T\EZ65U7ZL;O\ =JR_N_W7J?:YK_NS!L?YB-/:
M:3>VVFEK/44Y7%Q)-P2W/KB#BW%)#NW/@\HAC;AQYJ_PX8:1YQ.I:PUE'83)
M:&2ZABO"'IZEE)Z4@D#(J)R<-Z7&61V_;2/%/.6JZAIUE9O8R>G)<7D=N["!
MKIN#J_V8E*LQJ%.QPNL//%^=1M=+OM-?ZR!;Q:C-"'_=7%RH:,>F%D41<3^]
M=KC]TWP_O>#/@J'S%K=[8ZO)%I@MQ8?6X89VN$(EGMF9?A'IOQC:E0\B<N?-
M6AX<7D1_QG.NE:-+:6GURXU#33J;B>9+:D$4<32?$%9#,?76B )']KE)&N)2
M^=;^XU*RCLK5$TV34(+*>YED E8S6GUFBP<?LT:->8EY<N7[OT_CR2:MJ2Z=
M;1W#(71[BWMVH0O'ZQ,D(<D]E,G+(W?_ )@R6=N]RVEO)!;PZA<7CK,G[N/3
M+CZO)Q!%9#)]N.G^J_'%KGSM*NIB*&R8Z9#>RV-S?%E+>I;VLEQ(%AV?C\'!
M7_:;_=?#C)B-E^83W.D:AJ)TJ>,6-M'?)&:CUK>0$_ [HB^NBJW*,<H_[OC/
MQ?FLIL9[J:W$EU;FUF)-82ZR$"NWQ+\.XR+)YIUZ/S7+8W,41TC])#3HIEA=
M2H>R6Y1WF]5AS,S>@$]!>7P_&N"X/-$L&F33SPR3W3:G-I]K;_ M9/69(EY[
M(L84?WC?%_K2?#B47FG4]5O%L=,2*QN(DNS>/>(9D6:SE2$Q+Z;Q<A602-*&
M^%./P<W^ ;_B'5!K4&E)I3W0:&"XNM1AEC6VC24LK$<V$C$.GP(JMRC^+E^R
MZ-IYVBN8I?3TZY^LVUO+-=6@"-+$\4Y@6$A6-9)621HN'+DB?Y2<@_\ C+5)
MQHYLM+6234);J"ZMY)U1X7MD8E1\.Y+(?MJC+^TBY+,@K>;O,K6UU,ENCQPJ
MCI+'#)&/56]%N;?E,WIS>O&&XS1M^Y^TW+E'@Z^_,&TT_3%N[VT9)UFGAN;5
M)(V9!:FDLBU*^HB_#OQ_;7EPP;K'FM].N[R :9<74=A9_7[F>)H0HBXRE5 =
MU9I&:!UX\?\ *Y876?YE6-Q97MR^GW%JUH$].&9H09F>9H.,91W&TL;+O\3_
M .ZU;!5OYX2\M+673],NKNXN(IIWLU,*21I;R^A)4R.B,WJ_"BAOB_R,=)YY
ML%U"ZM5MY)4MO71IHVC-9K6+U9(RG(.OPAE61AZ;.O'E]CDVX\Z/P!M-.EE;
MZUI\#B1XX_W6H!")1\1_N^?!D^US7^3X\,[S59H-8TRR])A#?"8-)Q5E#QQ\
MPA/,,IXJQ_NW3_*7 T?FN!YYZV5S'IT'K\M6<1+:UM2RR@DR>HG%D9><D2(W
M[+8677G>6Y\OOJNE0^D]KJ%K9W=O=()&*3RPJX0PR\0_IW*.C\G7]EH\-M0\
MSV]EKMIH[VTSR7:JR7 ]-8AR<I2LCHSLM*NL:NRJR_S8<YLV;-A/YR_Y1#7/
M^V?=?\F&R_)\AE\I:)(05+V%JQ!-2"85.YPWS9LC_P"8<;2^0?,L2]9-*OE'
M;<VSC!_EI@WEW2F'0V=N1],2X8Y%/RSI_A^\ [:QK(/_ '$[C)7FS9LV;-FR
M'>0/^.QYX_[;[?\ =.LLF.;-FS9LV;-FS9LV;-FS9LV;-G__T/5.;-FS9LV;
M-FS9LAN@#U/S'\YQRD21FVTE?3;<<3'<56A\:Y(8O+GEZ&"6WATRTCMYRK30
MI!&J.4%%+*%H>('P_P N-/E?RT9;27]%6@DL?]XV$,8,0Y<Z)0?".9Y[?M_%
M]K!$>E:5'>O?QV<"7KU#W2QH)36@-7 Y;T&*W=C97B)'=V\=PD;K(B2HKA73
M[+@,#1E_9;$+C1-'N+^'4)[*&6^@IZ-RT:F1:5I1B*_#4\?Y<=%I&E112PQ6
M4$<4QK-&L:*KDDM5@!1OB);?$9_+?EZX@BMY]-M98(',L$3PHRH[?:90112>
M],4DT31I=0349+&W>_C 6.[:)#*H7=0'(Y"G;%[RRL[VUDM;R!+FVF'&6"50
MZ,/!E:H. _\ #/EST/J_Z+M/0]*6W,0AC">C.P::/C2G"5E5I%_;;[6.;R[H
M+:DNIMI]NVH+QXW1C4R H"JL&ILP4\>7VN/P_9P*GDORHEK<VBZ5;_5KO@+F
M$H"KK&_-%(/["N>2I]C#6UM;>TMX[:VC6*")0D4:B@51T P*-!T4:DVJ?4H?
MT@Q#&ZX#GR"A.5?YN X<OM<?AP+9>3O*]C:WEK::;##;WY#7D:KM(PW#-7]H
M'?EBL_ECR[<64%C-I\$EI;$M!$R@A2U>1'?XZGG_ +\_;QZZ!H:ZJ-46TB74
MA&L8N */Z: JJ[?LJ';C_+RP)9>4[!(-3CU$C4GU><7%\\T<:ABB)'$H5 /A
MB6).'[7+X^6+S>5O+TUA%I\EA$;2%S)%'0CB[5Y,&!#<GY-S;E\?+XL-%544
M*HHJBBCP P!_A[0Q8/IXL85L9)1<26RJ!&91()>94;<O44/_ *V!KOR;Y8NP
M!<:=$Z^I-,R[A6>Y;E/S ($BRN.;H_)&?XL6G\LZ#<7ES>364;W5Y!]5NI36
MLD'$KZ;[[KQ9A_LL0G\I^6/0F]2SCCB?XY75FCI1_5Y!E92A#_'R4K^U_,V:
MX\F>6+FUMK62PC-O:EVMT4L@'JMRD%5(+)(WQ2(WP2-]O%QY9T(:DVI"RC%X
MP*M)O0U3TR>%>'(Q_ 6X\N'PX&A\D^68+*ZLHK0I#>>E]8833>H3;T]$B7GZ
MJ-#Q7TF1U:/BG'[*X*'EW2@]H_IN7L0!:N992R\:]R]6)J0Y;[:_"_)<0E\H
M:!-/=320.QO%E6>(S3>B?7'&5EAY^E&[C[4D:*_^5B,GD7RU)92V4L$TEO/<
MI>SA[JY9I+B(*$D=S)S>GIILS<?@1OV<%S>6=&FU*/4986>ZB]/B3++P)AJ8
MV>+GZ4CQU^"21&=/V6PTS9LV;"?SDC/Y0UQ%^TVGW07>FY@?OF\F$'R?H1!J
M#I]H03W_ '"8<9LV$OG<!O)FO*>ATZ[!_P"1#XKY2*GRIHI444V%M0=:#T5P
MUR)_EI7]":B"*4UK6 *_]M&?)9FS9LV;-FR'^0B/TSYW %/]SQK3_MG663#-
MFS9LV;-FS9LV;-FS9LV;-FS_T?5.;-FS9LV;-FS9LAVA))_RL/SD(V"N]MI9
M1J5HQCN%!/CTP"-(\RG2>/U/41.);;]+PMJ"E[Q$YB<V;B7]QS=HY/M6?JQK
MZ7&'$)/+_G;E!<(UW];MK> VP>\#Q*QU!F:.5>2B>:*P;TY)9$=9/YY)/BR0
MZ1IUY9ZIJR36ER\-U//<1727 ]%DF5/@"&4.DH*<1^[54_9D^+"#]'><D\G6
M4,,&HC5Y"!?F>[66=)(H2B,A2YCC]*20+R_??\620N_+#2.U\R2:I92ZC'?-
MQBLVC>SN(X[>.11_I27,?-1)R?PCE_=_#%Z;8OY'TF\T<7NGW$%X:W-U.+V>
MX]>!TFNY9HA$K2R2(WIRCU/W<?V?VL$>;M/NYY=(O+>&ZN1873R3P6<PAE9)
M+>6*HY/"C\7=/A9_LX :S\U/YF,_&Z2W^L6[VKBX06B60A47$,\/)N=P9O5*
MN(V^U%QG1%;#OS1'?2Z+-%9"Y]>5HTY6;1K.JEUYLID:-=EKRHZR</[IO4XY
M%+^R\Y+Y=CAM8+V:>6ROX%C2Y"SI<-.C6,TDDL_)>,8?G^_D9?[MN>!1?Z_)
MJ?F&2&:\,%A>7*/<FXB-K!;)9++Z?I<O56;UI.<;>FW_ !F]+]WBND'S?=^7
MH+M!?^C<0V$MRCSP/=3%OCNGM'#E8T=&04+0_M^BD+_;&75EYJDL](B<ZFJ?
M7+GZVUM-;"X6Q99! D[,P#/7T?CBYS+\7[SGR;#"RTV^LO.%Y<2I?7-O=BW%
MM,L];9 D!CD,L1=0&Y1\JB-N32KQ_;XC_-^GW%_I*PQ0FZA6>&2\L5*@W%NC
M@R1?$54\AOP=N$O'TG^%\AFI>3+JZU16T?3IM#L8["Z@K#Z8]2.:5/5MU195
M$1GC#-#M^XD5)/W;88^7_+K6TELVHZ TU]%]0-G>\XO]'BB@CC:/GSYQ_5G6
M7G$G))^7+]YZC\3SSW?7ECY<>XLY'BN1<V:)Z;1H["2[BC=%,O[OD\;,HYX0
MSQ^9_P!'6222:O%$+N90T/HR7AL/1X#ZP:&/UFG^.-E_?)'_ )?J8+]#S2OF
MXLS7SP"X00L&A_1PL! .7J+42-<&;GVY\N'']Q@$0^=OT/?"U_20ULI +E[I
MK9K8N)E^LFR56#5:'U/1^*./['V)<UT?.J:-I\8FOC=L]RX]*W5245AZ$,[F
M2>2)R"?3G?G'_P M7^4:QS>86\\E>5Y^C!420/$J6R(( 1)'.O)9@TWP^F?3
MN$?XO[A?B-/.,4\WE;5(+>.6:XGMI(H(H461VD=2J+Q<,A4L1S]0>GP^W\&1
M'7W\^W5Q:R:5)?VD?Z/030I%"J"[_?@D^HCGEZB0*W$\/1?GB_E_5?,MYKLP
M$UU+#!J5S%?(Z0FTCM$A)X1L@,OKK<,@5';U>//X/2X-FTJZ\TGRS97%[<:J
MMQ)=>GJ0-K']:AMU$G Q1"%N?(_5_6DX3?[LX</V1 /GB6+2J3W2?I&)8;ES
M%;H]H8YO5^L2KQ<"6>UY1.G]VL_#C&G+ M[?>?.&IK'-<I?#ZPL5O%:AXHU%
MS&ML\$S1\'Y6S,TJOZS,W/X(?2P*=0_,2/3Q#*UTY^LK]:O&MPDJ1%) !$L$
M%QR031Q\V%O*WQ\N2Q.KJ;S7OFV*^CD+W,GHC2TEMXK8?5I/K5RT=W("4:7]
MU %=PLO[C[3?:RK*^U>QMM?CENM2N+^)[Z6UB-GZRQH\[&W:$K'&+CC'(G&#
MUV9D3AQY+AMY)NM7N='9]4:62=9G1)YHS"9$%*,L;Q6\BK7DH]2+E\/VI%XN
MQ_FS84^;?^44UG:O^@W.U:5_<MWQ+R+Q_P $^7N-0OZ,L^/+<T^KIU]\.\V;
M"3SPO+R7KZU(Y:;>"HI7>!^E<$^6@!Y<TH   6=N !T ])<,LB_Y<D'0[VG_
M %>-8Z_]M*XR49LV;-FS9LB/D0 :UYV"B@_3M3UW)TVRKUR79LV;,2 *G-FS
M9LV;-FS9LV;-FS9L_]+U3FS9LV;-FS9LV;(?H;.GYB><6IRXVNE%%\:)<;??
MFM/S*TFYMEND51:TTXRW)FC]*,ZC7X6<'CR@I^\7_*7'V_YA6]Q'ICP6$TWZ
M25G14D@V19O1Y(7=%GK_ 'G&$LWI?%_)R'V_FI9[R.*.TD^JW,EQ;6-X67A+
M<6O/G&5KR0-Z4OI.WV_3;[/[OFA%YS:;0K#4(-.DDO=1DEA@T[U(P0\ D:3E
M*3PH%@?XOVOAS)YVAFOK..WM6?3[E;;U;PL T4E\A>W0Q $M4!?4;G^[]2/[
M?Q\-_C-HOT@EWITD%Q9Q12QVXDC=W^L2M%!&Y4\(I975>*,[?"_V_M8K'YKE
M>RBN#8.D@OUTV_B,B_N)&F6$.II^]0LZ,O$+^[;]G[.+1^9K=O,LVA/Z44T:
MHT?J2A990R%R8XBOQ*E*,>?\W\N ;;SW;SV<MR+.0<UM)--7FE+F._E,-LP:
MM(RTB_&I_NTXO\6,NO/H@M;:5=.EEG,<]QJ-JLD?.VALYA!<OUI,4E/P*O'U
M$5V^'[.#)O-)376TV.S,MN)!:M>B1 !=M;FY6$H=^+0\?WO+[;\..!;/SE>*
MEU'JFE_5KZWFMK9+*UN$N6DFNE#+&'9;=%=%/.2OP+'\?/#[3+^6]@>26SGL
M9$D:-H;@)R/']I3&TB,C?LL&P7FS9LQ (H14>^;-FS9LV;&100Q<_2C6/U&+
MR<0!R8]6-.K;=<?FS9LV;-FS9L+/- <^6=6"4#_4KCB22!7TFI4C?[L#>1:_
MX(\O5Z_HRSK_ -(Z8>9LV$/G^3TO(GF.7_?>EWK>'2W<^!_5@WRY_P H]I?_
M #"0?\FEPQR)?EA(TGER[=@%8ZQK-0-AMJEP,EN;-FS9LV;(GY( _3/G2E?^
M.YW_ .V;99+,V;-FS9LV;-FS9LV;-FS9LV8D $DT W).?__3]4YLV;-FS9LV
M;-FR(:-&)/S!\WQU*\[32U++2HJER*BM=\'67DG3[.2-X;FXK&EA&0QC(9=.
M#K%4<.K^I^]9?Y5X>GB!\@VGU6WL?TA=G3XB/6M6,162D[W :H0-$_J2;R0E
M&:-$7]GE@BW\H)!J"7"W\YM8);BYLK(B+A!<77/U)5;AS>GK2^FDA9$]3_5X
MH1>1HH-"M-+MM4NXY;&>2XM=0(@:=3-S$BD"-8F5EFE7^[^'E_D+BD7D?38-
M0M;FWGFCMK=+97LJJ4E>R0I;.[$>IRC5MZ/Q?A'R^S\5V?DV*"SU*TGO[B[C
MU&;ZRTD@B61)@_-7$B(C.R4B5/4Y\$AC1?AQ\OE-FTQ;./49HYC=QW]S=\(F
M:6:.59MU92BIRC3X4"_#@BZT*>ZU>"[N+Z1[*V=)X-/X1A5G163GZ@'J%:-R
MX?S_ .3\&%MMY"M;?3C9+>SE8%M8]-<A*VR6,IFMP!3C)Q<_&SC]XGPXZZ\B
M6\T4(6^FBF$=Q!?3JL9:YAO)O7N$8%2$YR5XF/CPY-@O_"L UUM36YD6*2=;
MR6Q 01M=);BV64M3U/[E5_=\N/)>67=>5;::WN42YFAN9[U=22[7B7CG0*J\
M0P*E/3C$11E^*/EACIUI<6MN4N+I[R9W:1II JTY&H554 *B#X5'_!,V"LV;
M-FS9LV;-FS9LV;-FS9LV;-FPN\Q_\H_J>U?]$GVH6K^Z;L.N!O)-?\&:!44/
MZ.M*CI3]PF'6;-A!^8(KY#\R#_M5WOO_ ,>SX.\N?\H]I?\ S"0?\FEPQR)?
ME>"/+=T"*$:QK.W_ &]+C);FS9LV;-FR'^0G9M8\[U[:\0.VPTZRR89LV;-F
MS9LV;-FS9LV;-FS9LIT1T9'4,C AE(J"#U!&?__4]4YLV;-FS9LV;-FR$65S
M<Q^=_/#V<?JW<%CIIAB(J'D$5RR+0&NYH,*#YFU.WN[%[;6?KEBQM9+^[NU"
MQP3W"S1O%)Z:Q<4H/6,#\6MY(D]1XUEPXC\Q75YJ?E.Y-P(!>S7T-S#&["&>
M*..18I51OV))8XI(6/Q_O%3DW+XEYO-7U74/,R0,M_>6,"W%G8Q2%F<1H1*J
MQ\FWCDIZWI+R^-?@Y\>1???F!?VFBW5X9[*YDBO6MK>X@0BW>-+99VY&:XB"
MR58HO&5^7[$;MAA9>:M0E\R6L-U/;6FFZAIUE=6=O*#ZTL\YF$L<+\EYM'2W
MY_ W%6_9Y84Z?^96KW6G7MS+:6EM)'#!)&DDR,;9IYQ!(+N..224+;<O4F=D
MM_L.G%/MY)/)6K3:G::A++=P7IBO9(EN+5BT#*L<9'IU+%5^*O'F_%OVWR-Z
MYYSU/2_,M]<Q3R2Z) _U!XY! ;6.[^JM.#ZB\;A6:7ZO#P;FOQR-_J/M_P Q
M]6C=X+^VM0Z);&2[B=Q;Q">?TGEDY[B*.-HY/M?MKR95?DJ^H?F)/9Z=+=R?
M5$5;>^EMIF9O1N'LID4"%JCF)8GJ*?MJ_#U(TY88VWFN_D\R26#_ %0V'Z0?
M3(2CL9_42Q%[R8?8_F3TQ_QDY?L8SRQYDU.X\G3:EJ5YI\NJVUL\]PBDP10L
MJ,W&Y^*5H@&5N;<?A7]CX<E%I,9K6&9N!,B*Y,;<TJP!^%J#DO\ *U,B[:S?
M#\P%T\7WJ6KKP_1\:IRC @,IEF5D67@ST"7,<SP\F6V]'U/WF"?+GF&W>QUB
MXO=3CN+;3+J?E=LT8"6R ,&<QA5XK\?Q4_8P'Y^\R7NE1:6]K((K6Y>5[F?U
M(H>210F18EDF250\O["B/G)PX<H_BD43+-J8\TZ3';ZC<-;WJRW5Q821P"..
MVAA5 -HQ,KM<2Q-4R_SK]G"_RUYEU9M;U.#5IE-I86\DU_<!X6MX94E;B(VB
M^)(V@^(K<_OOW7V?Y]^8'FF^L+&PGTJX,:7,%U=+,OI*"(8!)&3ZZD,A9E+0
MI^_D7^[^R^&JZVZ><[?2WOHV2YT^2X-D?35EECDB *J0)OB1W/%RWV<*O*FN
M^8CKEQ8:P',,%DUQ?74C6_HQ7"SE>,1B-5ADB^-/7XR<(N3?$SXMYS\QSV\=
ME+IVI);6]Q97=[:W*"*2.YFA6)K: %PP=)_59N,7&23C^[DQ!_,>K#SM#:"[
M B-^FGR:4$3_ 'G?3#>_6B2/5Y"=3%RY>CP^#CZGQ9.,V;-FS9LV;-FS9L*/
M.!8>4M;*L586%T0PK4'T6WVQ/R+_ ,H3Y>_[9MG_ ,F$P[S9L(O/G_*#^8O^
MV9>?]0[X+\M,&\N:4PZ&SMR/IB7#+(G^617_  ]><>@UC6?'_JYW'CDLS9LV
M;-FS9#_(0XZUYX7K_N>Y5&XWTVRV^8[Y,,V;-FS9LV;-FS9LV;-FS9LV8$'I
M\L__U?5.;-FS9LV;-FS9LAOEK_R9?G04/]SI)J>G]S,-A]&3'BM"*"AZCQKE
MT&;BOA@33])T_3X6AM(N"/(9G+,TC-(U*LSN69FV W;[."N*U!H*CIF]--_A
M'Q?:VZ_/,B(BA44*JB@4"@ &;BO@,W%2*$"G3-P2@%!0=-NF4(H@:A%K7E6@
MK6E*_=F6&)>95%!DW>@'Q=M_''  "@Z#&>A#ZWK^FOK<>'JT'+C6O'EUXUWI
MB%WI>GWEI+:7-O'+;3 ":%E'%P#4!AW%<$2112*%D17 (8!@#N#4'?PR_3CY
M^IQ'.G'G3>E:TK@>ZTS3[JRGL9X$:TN0RW$-**X?[0:E*\OVL5FMK>8()HDE
M$;"2,.H;BZ]&%>C#L<:UE9M<+<M!&;E?LSE%+C8KLU.7V21FM[*SMHWBMX(X
M8Y&9Y$C155G<U=B !5F)JQ_:RS:6ICBC,*&. J8$XCBA392HI\/']FF;ZI:?
M6A=^C']:"&(7'$>H(R:E.=.7&N_'%<V;-FS9LV;-FS9L*?-Q<>5-:*4+_4+G
MB#TKZ+4KB7D4U\D>7C_VK+/_ *ATP[S9L(_/0KY)\P"@/^XV\V/3_>=^N"_+
M51Y<TJIJ?J=OO_SR7#'(I^6E?T#>DTI^F=8X@=A^D[C)7FS9LV;-FR(^0^/Z
M8\[4%/\ <\:_/]&V6^2[-FS9LV;-FS9LV;-FS9LV;-FS_];U3FS9LV;-FS9L
MV;(?Y<X_\K(\Y44U]+2JO78_N9MJ>W_&V2XR()%C->3 L-C2BT!WZ#[6.S9L
MV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;"OS4*^6-7%2M;*Y^)>H_<MN
M,0\BU_P3Y>KU_1EG7_I'3#O-FPD\\&GDW7>G']'7?(DTH/J[X*\M_P#*.Z7_
M ,P<'_)I<,<B?Y9LK>7KQE-5.L:S0C_MIW&2S-FS9LV;-D2\C C6?.M13_<Y
M4?+]&V7B!DMS9LV;-FS9LV;-FS9LV;-FS9L__]?U3FS9LV;-FS9LV;(CY<-?
MS"\X? !1=,_>>/[B3X?]C_QMDNS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-
MFS9LV;-A7YK;CY7UAO"QN3UI_NEN_;$?) IY+T ;[:;:#?8_W"8=9LV$'YA"
MOD'S*":5TJ^WZT_T9\'>7/\ E'M+_P"82#_DTN&.0[\J?^46N?\ MLZU_P!U
M6YR8YLV;-FS9LB7D9@VL^=:=M<H=J;C3;+);FS9LV;-FS9LV;-FS9LV;-FS9
M_]#U3FS9LV;-FS9LV;(GY<0CS]YO<G9AIH"]MK=MZ>]?^%R69LV;-FS9LV;-
MFS9LV;-FS9LV;-FS9LV;&QH4!'(M4EJMVJ:T^0[8[-FS9LV;"GS>ZQ^4]:=@
M"J6%TS ]"!"Q-:XGY(;EY+T!J4Y:;:&@KM6!/'#K-FP@_,%>7D+S(O\ -I5Z
M/'K;/@[RY_RCVE_\PD'_ ":7#'(=^5/_ "B]S_VV=:_[JMSDQS9LV;-FS9$?
M(H8:SYUY K_N=J.5=Q^C;*A%>V2[-FS9LV;-FS9LV;-FS9LV;-FS_]'U3FS9
MLV;-FS9LV;(AY:8_\K#\Y+S) &F'AV4FW<5&W>GCDOS9LV;-FS9LV;-FS9LV
M;-FS9LV;-FS9LV;-FS9LV;-A/YRI_A#7*]/T?=5_Y$/B?D7_ )0CR]_VS+/_
M *ATP\S9L(O/H)\C>8@#0_HR]H?^C=\&>6_^4>TO_F$@_P"32X8Y#_RJ5E\L
M708$'],ZUL?^VK<Y,,V;-FS9LV17R?([>8O.BE@RKJT7&E-JZ99U&2K-FS9L
MV;-FS9LV;-FS9LV;-FS_TO5.;-FS9LV]?;OFS9LV;(?Y;Y?\K%\YU8$<-+HG
M<?Z/)O\ [+_C7)AFS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;"?SG
M_P H?KO_ &S[K_DP^)^1?^4(\O?]LRS_ .H=,/,V;"#\P!7R'YD'CI=Z/^G=
M\'>7/^4>TO\ YA(/^32X8Y$_RO;EY7FZ;:KK V->FJ7/7WR69LV;-FS9LB7D
MV%4\S>=V  ,FK0$@5_ZMEGOX9+<V;-FS9LV;-FS9LV;-FS9LV;/_T_5.;-FS
M9LV;-FS9LAOEJO\ RLOSIOMZ6DT7P/HS;TR99LV;-FS9LV;-FS9LV;-FS9LV
M;-FS9LV;-FS9LV;-FPH\X_\ *(ZYT_XY]UUZ?W+8GY%_Y0CR]_VS+/\ ZATP
M[S9LCWYB,4_+_P S..JZ3?$?1;/ACY<_Y1[2_P#F$@_Y-+@\AB5H: '<>.V1
M+\K9EE\LW)!J5U?65?8#<:I<#MDNS9LV;-FS9%/)Y<^9_.U22@U6W"BFP/Z+
MLZT.2O-FS9LV;-FS9LV;-FS9LV;-FS__U/5.;-FS9LV;-FS9LBGEU$_QWYND
M ',_HY6--Z+;,1O_ ++)7FS9LV;-FS9LV;-FREY;\J==J>&7FS9LV;-FS9LI
MB0!0$[@;4[]]\O-FS8V1.:%>13H>2['8U[X[-FS9L)_.1(\H:X1L1I]U0_\
M/!\3\B_\H1Y>_P"V99_]0Z8>9LV1W\Q__)>>:/\ MD7_ /U#289>7/\ E'M+
M_P"82#_DTN&&0_\ *XI^A=6C10J0Z]K*"@(/_'0F;XO?XLF&;-FS9LV;(AY,
MY_XL\]!J<?TK;<:"G_2JM,E^;-FS9LV;-FS9LV;-FS9LV;,2:@4K7J?#/__5
M]4YLV;-FS9LV;-FR(^6)6D\^>=%-*12Z?& /^8-7W_X/)=FS9LV;-FS9LV;-
MFS9LV;-FS9LV;-FS9LV;-FS9LV;"?SG_ ,H?KO\ VS[K_DP^)^1?^4(\O?\
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M2JJJH5110* #H ,O(K^5YKY&TX^+7!^^YE.2K-FS9LV;-D/_ "U $'F.@/\
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MLV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-D+U&3\Q(A>SZ?
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:-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6749251040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jul. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOCRYST PHARMACEUTICALS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000882796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">bcrx<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,700,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6749762784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Current Period Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 8,661<span></span>
</td>
<td class="nump">$ 28,899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">4,426<span></span>
</td>
<td class="nump">1,612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investments</a></td>
<td class="nump">27,079<span></span>
</td>
<td class="nump">22,664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables from collaborations</a></td>
<td class="nump">2,234<span></span>
</td>
<td class="nump">6,243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">1,949<span></span>
</td>
<td class="nump">1,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,674<span></span>
</td>
<td class="nump">2,674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Deferred collaboration expense</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">46,112<span></span>
</td>
<td class="nump">63,794<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Investments</a></td>
<td class="nump">24,154<span></span>
</td>
<td class="nump">47,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">10,112<span></span>
</td>
<td class="nump">5,149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DeferredCollaborationExpenseAssets', window );">Deferred collaboration expense</a></td>
<td class="nump">229<span></span>
</td>
<td class="nump">265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,610<span></span>
</td>
<td class="nump">5,468<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">82,217<span></span>
</td>
<td class="nump">122,359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">5,051<span></span>
</td>
<td class="nump">9,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">11,783<span></span>
</td>
<td class="nump">16,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest payable</a></td>
<td class="nump">9,203<span></span>
</td>
<td class="nump">6,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred collaboration revenue</a></td>
<td class="nump">2,134<span></span>
</td>
<td class="nump">2,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Non-recourse notes payable</a></td>
<td class="nump">28,023<span></span>
</td>
<td class="nump">27,804<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">56,194<span></span>
</td>
<td class="nump">62,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred collaboration revenue</a></td>
<td class="nump">8,776<span></span>
</td>
<td class="nump">9,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
<td class="nump">297<span></span>
</td>
<td class="nump">329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Foreign currency derivative</a></td>
<td class="nump">974<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_LeaseFinancingObligationNetOfCurrent', window );">Lease financing obligation</a></td>
<td class="nump">2,589<span></span>
</td>
<td class="nump">2,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; shares authorized &#8212; 5,000; no shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value: shares authorized &#8212; 200,000; shares issued and outstanding &#8212; 73,701 in 2016 and 73,355 in 2015</a></td>
<td class="nump">737<span></span>
</td>
<td class="nump">734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">562,634<span></span>
</td>
<td class="nump">558,113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">46<span></span>
</td>
<td class="num">(206)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(550,030)<span></span>
</td>
<td class="num">(510,917)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">13,387<span></span>
</td>
<td class="nump">47,724<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 82,217<span></span>
</td>
<td class="nump">$ 122,359<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DeferredCollaborationExpenseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents deferred collaboration expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DeferredCollaborationExpenseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_LeaseFinancingObligationNetOfCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease Financing obligation as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_LeaseFinancingObligationNetOfCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt securities classified as available-for-sale, expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65884222&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of debt securities categorized neither as held-to-maturity nor trading which are intended be sold or mature more than one year from the balance sheet date or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65884222&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13495-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6749773360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">73,701,000<span></span>
</td>
<td class="nump">73,355,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">73,701,000<span></span>
</td>
<td class="nump">73,355,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6749690752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive (Loss) Income (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product sales, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenue</a></td>
<td class="nump">629<span></span>
</td>
<td class="nump">132<span></span>
</td>
<td class="nump">2,519<span></span>
</td>
<td class="nump">1,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAndOtherResearchAndDevelopment', window );">Collaborative and other research and development</a></td>
<td class="nump">4,158<span></span>
</td>
<td class="nump">25,710<span></span>
</td>
<td class="nump">7,088<span></span>
</td>
<td class="nump">30,481<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Total revenues</a></td>
<td class="nump">4,787<span></span>
</td>
<td class="nump">25,842<span></span>
</td>
<td class="nump">9,607<span></span>
</td>
<td class="nump">32,668<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of products sold</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">14,166<span></span>
</td>
<td class="nump">16,524<span></span>
</td>
<td class="nump">34,745<span></span>
</td>
<td class="nump">33,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,724<span></span>
</td>
<td class="nump">3,534<span></span>
</td>
<td class="nump">5,936<span></span>
</td>
<td class="nump">7,595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">442<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="nump">502<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">16,917<span></span>
</td>
<td class="nump">20,500<span></span>
</td>
<td class="nump">40,785<span></span>
</td>
<td class="nump">41,756<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">(Loss) income from operations</a></td>
<td class="num">(12,130)<span></span>
</td>
<td class="nump">5,342<span></span>
</td>
<td class="num">(31,178)<span></span>
</td>
<td class="num">(9,088)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="nump">586<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1,421)<span></span>
</td>
<td class="num">(1,306)<span></span>
</td>
<td class="num">(2,891)<span></span>
</td>
<td class="num">(2,621)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">(Loss) gain on foreign currency derivative</a></td>
<td class="num">(2,877)<span></span>
</td>
<td class="nump">749<span></span>
</td>
<td class="num">(5,630)<span></span>
</td>
<td class="nump">1,213<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (16,281)<span></span>
</td>
<td class="nump">$ 4,901<span></span>
</td>
<td class="num">$ (39,113)<span></span>
</td>
<td class="num">$ (10,263)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net (loss) income per common share (in dollars per share)</a></td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net (loss) income per common share (in dollars per share)</a></td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic (in shares)</a></td>
<td class="nump">73,695<span></span>
</td>
<td class="nump">72,642<span></span>
</td>
<td class="nump">73,648<span></span>
</td>
<td class="nump">72,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted (in shares)</a></td>
<td class="nump">73,695<span></span>
</td>
<td class="nump">76,760<span></span>
</td>
<td class="nump">73,648<span></span>
</td>
<td class="nump">72,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on available for sale investments</a></td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">$ (102)<span></span>
</td>
<td class="nump">$ 252<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive (loss) income</a></td>
<td class="num">$ (16,283)<span></span>
</td>
<td class="nump">$ 4,799<span></span>
</td>
<td class="num">$ (38,861)<span></span>
</td>
<td class="num">$ (10,225)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CollaborativeAndOtherResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative and other research and development during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CollaborativeAndOtherResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831223<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6742395872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToReportingEntityAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (39,113,000)<span></span>
</td>
<td class="num">$ (10,263,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">136,000<span></span>
</td>
<td class="nump">94,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">4,491,000<span></span>
</td>
<td class="nump">5,934,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of Debt Issuance Costs</a></td>
<td class="nump">220,000<span></span>
</td>
<td class="nump">220,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AmortizationOfDiscountAndPremiumOnInvestments', window );">Amortization of premium/discount on investments</a></td>
<td class="nump">302,000<span></span>
</td>
<td class="nump">266,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeAssets', window );">Change in fair value of foreign currency derivative</a></td>
<td class="nump">6,441,000<span></span>
</td>
<td class="nump">332,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Receivables</a></td>
<td class="nump">4,009,000<span></span>
</td>
<td class="nump">5,194,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(337,000)<span></span>
</td>
<td class="num">(625,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">503,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities', window );">Deferred collaboration expense</a></td>
<td class="nump">37,000<span></span>
</td>
<td class="num">(136,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(8,742,000)<span></span>
</td>
<td class="nump">8,612,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Interest payable</a></td>
<td class="nump">2,457,000<span></span>
</td>
<td class="num">(1,579,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(927,000)<span></span>
</td>
<td class="nump">5,820,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash (used in) provided by operating activities</a></td>
<td class="num">(30,026,000)<span></span>
</td>
<td class="nump">14,372,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Acquisitions of property and equipment</a></td>
<td class="num">(5,099,000)<span></span>
</td>
<td class="num">(934,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Change in restricted cash</a></td>
<td class="num">(2,814,000)<span></span>
</td>
<td class="num">(1,419,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(19,407,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Sales and maturities of investments</a></td>
<td class="nump">19,064,000<span></span>
</td>
<td class="nump">24,884,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash provided by investing activities</a></td>
<td class="nump">11,151,000<span></span>
</td>
<td class="nump">3,124,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Sale of common stock, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,175,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Net proceeds from common stock issued under stock-based compensation plans</a></td>
<td class="nump">33,000<span></span>
</td>
<td class="nump">3,570,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForHedgeFinancingActivities', window );">Payment of foreign currency derivative collateral</a></td>
<td class="num">(1,610,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Increase in lease financing obligation</a></td>
<td class="nump">214,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(1,363,000)<span></span>
</td>
<td class="nump">4,745,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">(Decrease) increase in cash and cash equivalents</a></td>
<td class="num">(20,238,000)<span></span>
</td>
<td class="nump">22,241,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">28,899,000<span></span>
</td>
<td class="nump">54,540,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 8,661,000<span></span>
</td>
<td class="nump">$ 76,781,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AmortizationOfDiscountAndPremiumOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to the discount and premium on investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AmortizationOfDiscountAndPremiumOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents deferred collaboration expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as assets that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToReportingEntityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToReportingEntityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForHedgeFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a financial contract that meets the hedge criteria as either cash flow hedge, fair value hedge or hedge of net investment in foreign operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 27<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3581-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForHedgeFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire debt securities classified as available-for-sale securities, because they are not classified as either held-to-maturity securities or trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26853-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale or maturity (principal being due) of securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26853-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6908039936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Note 1 &#x2014; Significant Accounting Policies</div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">The Company</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">BioCryst Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) is a biotechnology company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and align with its capabilities and expertise. The Company was incorporated in Delaware in 1986 and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred losses and negative cash flows from operations since inception.&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Based on its current operating plans, the Company expects it has sufficient liquidity, with its existing cash, restricted cash and investments of $64,320, to continue its planned operations through mid-2017. The Company&#x2019;s liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key development and regulatory events in the future. In order to continue its operations substantially beyond mid-2017 it will need to: (1)&nbsp;successfully secure or increase U.S. Government funding of its programs, including procurement contracts; (2)&nbsp;out-license rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; (3)&nbsp;raise additional capital through equity or debt financings or from other sources; (4)&nbsp;obtain additional product candidate regulatory approvals, which would generate revenue and cash flow; (5)&nbsp;reduce spending on one or more research and development programs; and/or (6)&nbsp;restructure operations. The Company may issue securities, including common stock, preferred stock, depositary shares, stock purchase contracts, warrants and units, through private placement transactions or registered public offerings pursuant to its registration statements on Form S-3 initially filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March 3, 2015 and November&nbsp;6, 2013. The Company will continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations.&nbsp;&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Basis of Presentation</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, JPR Royalty Sub LLC (&#x201c;Royalty Sub&#x201d;). Royalty Sub was formed in connection with a $30,000&nbsp;financing transaction the Company completed on March&nbsp;9, 2011. See Note 4, Royalty Monetization, for a further description of this transaction. All intercompany transactions and balances have been eliminated.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;) for interim financial reporting and the instructions to Form 10-Q and do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management&#x2019;s opinion, necessary to present fairly, in all material respects, the Company&#x2019;s consolidated financial position, results of operations, and cash flows. There were no adjustments other than normal recurring adjustments.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">These financial statements should be read in conjunction with the financial statements for the year ended December&nbsp;31, 2015 and the notes thereto included in the Company&#x2019;s 2015 Annual Report on Form 10-K. Interim operating results are not necessarily indicative of operating results for the full year. The balance sheet as of December&nbsp;31, 2015 has been derived from the audited consolidated financial statements included in the Company&#x2019;s most recent Annual Report on Form 10-K.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Reclassifications</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div>   <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">During the first quarter of 2016, the Company adopted Accounting Standards Update No. 2015-03, <div style="display: inline; font-style: italic;">Interest &#x2013; Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs</div>. Accordingly, debt issuance costs of $2,196 classified as other current assets as of December 31, 2015 have been reclassified and netted against non-recourse notes payable to conform to the 2016 presentation.</div>  <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Cash and Cash Equivalents</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of three months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.</div> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div>  <!-- Field: Page; Sequence: 6; Value: 3 -->   <!-- Field: /Page --> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Restricted Cash</div></div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Restricted cash as of June&nbsp;30, 2016 reflects $3,022 in royalty revenue paid by Shionogi&nbsp;&amp; Co., Ltd. (&#x201c;Shionogi&#x201d;) designated for interest on the PhaRMA Notes (defined in Note 4) and $1,404 the Company is required to maintain as collateral for a letter of credit associated with the lease execution and build-out of its new Birmingham research facilities.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Investments</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#x2019;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that may consist of U.S. Government and government agency securities, money market and mutual fund investments, municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&#x2019;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of three years and requires an average portfolio maturity of no more than 18 months. Some of the securities the Company invests in may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&#x2019;s investments are not collateralized. The Company has not realized any significant losses from its investments.</div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond three months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. At June 30, 2016, the Company believes that the costs of its investments are recoverable in all material respects.</div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The following tables summarize the fair value of the Company&#x2019;s investments by type. The estimated fair value of the Company&#x2019;s fixed income investments are classified as Level 2 in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. These fair values are obtained from independent pricing services which utilize Level 2 inputs.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">  <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June&nbsp;30, 2016</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amortized<br /> Cost</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accrued<br /> Interest</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br /> Unrealized<br /> Gains</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br /> Unrealized<br /> Losses</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Estimated<br /> Fair&nbsp;Value</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt">Obligations of the U.S. Government and its agencies</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">14,081</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">38</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">8</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">&#x2014;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">14,127</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Corporate debt securities</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">16,641</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">147</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">23</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(1</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">16,810</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt">Certificates of deposit</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">20,258</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">22</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">23</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(7</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">20,296</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">50,980</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">207</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">54</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(8</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">51,233</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">  <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31, 2015</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amortized<br /> Cost</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accrued<br /> Interest</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br /> Unrealized<br /> Gains</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br /> Unrealized<br /> Losses</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Estimated<br /> Fair&nbsp;Value</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt; width: 35%">Obligations of the U.S. Government and its agencies</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">26,557</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">88</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">&#x2014;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">(99</td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">26,546</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Corporate debt securities</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">21,820</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">184</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(41</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">21,963</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt">Certificates of deposit</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21,884</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(72</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21,838</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">70,261</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">293</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(212</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">70,347</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div>   <!-- Field: Page; Sequence: 7; Value: 3 -->   <!-- Field: /Page --> <div style=" font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0">The following table summarizes the scheduled maturity for the Company&#x2019;s investments at June&nbsp;30, 2016 and December&nbsp;31, 2015.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">  <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; font-size: 10pt; text-align: left">Maturing in one year or less</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">27,079</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">22,664</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Maturing after one year through two years</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">18,164</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">28,395</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Maturing after two years</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5,990</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">19,288</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">51,233</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">70,347</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Receivables from Collaborations</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables from Shionogi and Seqirus UK Limited (&#x201c;SUL&#x201d;), and product sales to SUL. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date. At June 30, 2016 and December&nbsp;31, 2015, the Company had the following receivables.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">  <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June&nbsp;30, 2016</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Billed</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Unbilled</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">723</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">1,273</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">1,996</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Shionogi&nbsp;&amp; Co. Ltd.</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">145</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">145</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Seqirus UK Limited</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">37</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">56</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">93</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total receivables</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">905</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">1,329</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">2,234</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">  <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31, 2015</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Billed</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Unbilled</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">&#x2014;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">5,536</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">5,536</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Shionogi&nbsp;&amp; Co. Ltd.</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">469</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">469</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Seqirus UK Limited</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">210</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">28</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">238</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total receivables</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">679</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5,564</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">6,243</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Monthly invoices are submitted to the U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&#x2019;s calculations of its indirect cost rates are subject to audit by the U.S. Government.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Receivables from Product Sales</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Receivables from product sales are recorded for amounts due to the Company related to sales of RAPIVAB. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Inventory</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">At June 30, 2016 and December 31, 2015, the Company&#x2019;s inventory consisted of RAPIVAB work in process. Inventory is stated at the lower of cost, determined under the first-in, first-out (&#x201c;FIFO&#x201d;) method, or market. The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company will capitalize subsequent costs related to the production of inventories.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">During 2014, in connection with the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) approval of RAPIVAB, the Company began capitalizing costs associated with the production of RAPIVAB inventories.</div> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div>  <!-- Field: Page; Sequence: 8; Value: 3 -->   <!-- Field: /Page --> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#x2019;s inventory consisted of the following at June&nbsp;30, 2016 and December&nbsp;31, 2015:</div> <div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">  <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; font-size: 10pt; text-align: left; padding-bottom: 1pt">Work in process</td> <td style="width: 1%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,949</td> <td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,612</td> <td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.25pt">Inventories</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">1,949</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">1,612</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Property and Equipment</div></div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of three years. Laboratory equipment, office equipment, and software are depreciated over a life of five years. Furniture and fixtures are depreciated over a life of seven years. Leasehold improvements are amortized over their estimated useful lives or the expected lease term, whichever is less. Property consists of a leased building which did not meet the sale-leaseback criteria and is recorded at its fair value, less depreciation. The building is being depreciated over a period equal to the expected term of the related lease.</div>  <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In accordance with U.S. GAAP, the Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Patents and Licenses</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Accrued Expenses</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company generally enters into contractual agreements with third-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include:</div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; width: 700px;">  <tr> <td style="width: 5%">&nbsp;</td> <td style="vertical-align: top; width: 2%"><div style="display: inline; font-size: 10pt">&#x2022;</div></td> <td style="vertical-align: top; width: 1%">&nbsp;</td> <td style="vertical-align: top; width: 92%"><div style="display: inline; font-size: 10pt">fees paid to Clinical Research Organizations (&#x201c;CROs&#x201d;) in connection with preclinical and toxicology studies and clinical trials;</div></td> </tr> <tr> <td>&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">&#x2022;</div></td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">fees paid to investigative sites in connection with clinical trials;</div></td> </tr> <tr> <td>&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">&#x2022;</div></td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">fees paid to contract manufacturers in connection with the production of our raw materials, drug substance and drug products;&nbsp;and</div></td> </tr> <tr> <td>&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">&#x2022;</div></td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">professional fees.</div></td> </tr>  </table> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&#x2019;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of June 30, 2016 and December 31, 2015, the carrying value of accrued expenses approximates their fair value due to their short-term settlement.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Income Taxes</div></div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The liability method is used in the Company&#x2019;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div>  <!-- Field: Page; Sequence: 9; Value: 3 -->   <!-- Field: /Page -->  <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Accumulated Other Comprehensive Income (Loss)</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div>   <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Accumulated other comprehensive income (loss) is comprised of unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&#x2019; equity. Amounts reclassified from accumulated other comprehensive income (loss) are recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. During the six months ended June 30, 2016, realized gains of $10 were reclassified out of accumulated other comprehensive income (loss). During the six months ended June 30, 2015, realized gains of $12 were reclassified out of accumulated other comprehensive income (loss).</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Revenue Recognition</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recognizes revenues from collaborative and other research and development arrangements, royalties and product sales when realized or realizable and earned. Revenue is realized or realizable and earned when all of the following criteria are met: (i)&nbsp;persuasive evidence of an arrangement exists; (ii)&nbsp;delivery has occurred or services have been rendered; (iii)&nbsp;the seller&#x2019;s price to the buyer is fixed or determinable; and (iv)&nbsp;collectability is reasonably assured.</div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-style: italic;">Collaborative and Other Research and Development Arrangements and Royalties</div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Revenue from license fees, royalty payments, event payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement. Fees received under licensing agreements that are related to future performance are deferred and recognized over an estimated period determined by management based on the terms of the agreement and the products licensed. Revisions to revenue or profit estimates as a result of changes in the estimated revenue period are recognized prospectively.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Under certain of the Company&#x2019;s license agreements, the Company receives royalty payments based upon its licensees&#x2019; net sales of covered products. The Company recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">For arrangements that involve the delivery of more than one element, each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting. This determination is based on whether the deliverable has &#x201c;stand-alone value&#x201d; to the customer. The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective evidence of fair value, (ii) third-party evidence of selling price (&#x201c;TPE&#x201d;) and (iii) best estimate of selling price (&#x201c;BESP&#x201d;). The BESP reflects our best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis. In most cases the Company expects to use TPE or BESP for allocating consideration to each deliverable. The consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In June 2015, the Company entered into a License Agreement (the &#x201c;SUL Agreement&#x201d;) granting SUL and its affiliates worldwide rights, excluding Israel, Japan, Korea and Taiwan, to develop, manufacture and commercialize RAPIVAB. The SUL Agreement provides for various types of payments, including a non-refundable upfront fee, milestone payments, and future royalties. Analysis of the SUL Agreement identified three deliverables: (i) license rights, (ii) inventory and (iii) regulatory support to obtain Canadian and European Union (&#x201c;EU&#x201d;) marketing approvals. The Company received an upfront payment of $33,740 from SUL, of which $7,000 was determined to be contingent upon EU marketing approval and will be deferred until that time. Approximately $21,777 of the upfront payment was allocated to the license rights and recognized as revenue in the second quarter. Approximately $3,740 of the upfront payment was allocated to the pending sale of inventory and was recognized during the third quarter, when the inventory transfer was completed. Approximately $1,223 of the revenue from the SUL Agreement will be recognized over the expected period of involvement in these regulatory support activities.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not reasonably assured at the inception of the agreement; and (ii) the fees are non-refundable. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <!-- Field: Page; Sequence: 10; Value: 3 -->   <!-- Field: /Page --> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Under the terms of the SUL Agreement, the Company may receive up to $12,000 in additional payments related to the successful achievement of regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Products and Food Branch of Health Canada (&#x201c;Health Canada&#x201d;) for an adult indication in Canada. The Company evaluated each event based payment under the provisions of ASU 2010-17, <div style="display: inline; font-style: italic;">Milestone Method of Revenue Recognition</div>, and determined that each event based payment met the criteria to be considered substantive and represents a milestone under the milestone method of accounting. No event based payments were achieved during the periods presented.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company&#x2019;s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (&#x201d;BARDA/HHS&#x201d;) and the National Institute of Allergy and Infectious Diseases (&#x201c;NIAID/HHS&#x201d;), revenue is recognized as reimbursable direct and indirect costs are incurred.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-style: italic;">Product Sales</div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recognizes revenue for sales of RAPIVAB when title and substantially all the risks and rewards of ownership have transferred to the customer, which generally occurs on the date of shipment from our specialty distributors, utilizing the Sell-Through revenue recognition methodology. Product sales are recognized when there is persuasive evidence that an arrangement exists, title has passed, the price is fixed and determinable, and collectability is reasonably assured. Product sales are recognized net of estimated allowances, discounts, sales returns, chargebacks and rebates. In the United States, and prior to the SUL Agreement, the Company sold RAPIVAB to specialty distributors, who in turn, sell to physician offices, hospitals and federal, state and commercial health care organizations.&nbsp;With the completion of the SUL worldwide license of RAPIVAB, SUL will be responsible for sales of RAPIVAB, other than U.S. Government stockpiling sales. With the completion of the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&#x2019;s partners, except for U.S. Government stockpiling sales, and the Company will be reliant on these partners to generate sales.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Sales deductions consist of statutory rebates to state Medicaid, Medicare and other government agencies and sales discounts (including trade discounts and distribution service fees). These deductions are recorded as reductions from revenue from RAPIVAB in the same period as the related sales with estimates of future utilization derived from historical experience adjusted to reflect known changes in the factors that impact such reserves.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company utilizes data from external sources to help it estimate gross-to-net sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. Externally sourced data includes, but is not limited to, information obtained from specialty distributors with respect to their inventory levels and their sell-through to customers, as well as information from third-party suppliers of market research data to the pharmaceutical industry.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company accounts for these sales deductions in accordance with authoritative guidance on revenue recognition when consideration is given by a vendor to a customer.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company has categorized and described more fully the following significant sales deductions, all of which involve estimates and judgments, which the Company considers to be critical accounting estimates, and require it to use information from external sources.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt"><div style="display: inline; font-style: italic;">Rebates and Chargebacks</div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 13.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Statutory rebates to state Medicaid agencies and Medicare are based on statutory discounts to RAPIVAB&#x2019;s selling price.&nbsp;As it can take up to nine months or more for information to be received on actual usage of RAPIVAB in Medicaid and other governmental programs, the Company maintains reserves for amounts payable under these programs relating to RAPIVAB sales.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Chargebacks claimed by specialty distributors are based on the differentials between product acquisition prices paid by the specialty distributors and lower government contract pricing paid by eligible customers covered under federally qualified programs.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">The amount of the reserve for rebates and chargebacks is based on multiple qualitative and quantitative factors, including the historical and projected utilization levels, historical payment experience, changes in statutory laws and interpretations as well as contractual terms, product pricing (both normal selling prices and statutory or negotiated prices), changes in prescription demand patterns and utilization of the Company&#x2019;s product through public benefit plans, and the levels of RAPIVAB inventory in the distribution channel. The Company acquires prescription utilization data from third-party suppliers of market research data to the pharmaceutical industry. The Company updates its estimates and assumptions each period and records any necessary adjustments to its reserves. Settlements of rebates and chargebacks typically occur within nine months from point of sale. To the extent actual rebates and chargebacks differ from the Company&#x2019;s estimates, additional reserves may be required or reserves may need to be reversed, either of which would impact current period product revenue.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div>  <!-- Field: Page; Sequence: 11; Value: 3 -->   <!-- Field: /Page --> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Discounts and Sales Incentives</div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Discounts and other sales incentives primarily consist of Inventory Management Agreement (&#x201c;IMA&#x201d;) Fees. Per contractual agreements with the Company&#x2019;s specialty distributors, the Company provides an IMA fee based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth in individual contracts. The Company tracks sales to these distributors each period and accrues a liability relating to the unpaid portion of these fees by applying the contractual rates to such product sales.&nbsp;With the completion of the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&#x2019;s partners, except for U.S. Government stockpiling sales, and the Company will be reliant on these partners to generate sales and to provide for discounts and sales incentives.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Product Returns</div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company does not record a product return allowance as it does not offer the ability to return goods once a bonafide shipment has been accepted by a specialty distributor.&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recorded the following revenues for the three and six months ended June&nbsp;30, 2016 and 2015:</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">  <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; font-size: 10pt; text-align: left">Product sales, net</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">&#x2014;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">&#x2014;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">&#x2014;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">537</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Royalty revenue</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">629</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">132</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">2,519</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,650</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Collaborative and other research and development revenues:</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 20pt">U.S. Department of Health and Human Services</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">3,709</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">3,731</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">6,033</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">8,206</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Shionogi (Japan)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">296</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">296</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">592</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">592</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Seqirus UK Limited</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">153</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21,683</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">463</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21,683</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total collaborative and other research and development revenues</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,158</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">25,710</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7,088</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">30,481</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total revenues</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">4,787</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">25,842</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">9,607</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">32,668</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Advertising</div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company engages in very limited distribution and direct-response advertising when promoting RAPIVAB. Advertising and promotional costs are expensed as the costs are incurred.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Research and Development Expenses</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#x2019;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&#x2019;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&#x2019;s manufacturing and clinical and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&#x2019;s on-going review of the level of services actually performed.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Additionally, the Company has license agreements with third parties, such as Albert Einstein College of Medicine of Yeshiva University (&#x201c;AECOM&#x201d;), Industrial Research, Ltd. (&#x201c;IRL&#x201d;), and the University of Alabama at Birmingham (&#x201c;UAB&#x201d;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Deferred collaboration expenses represent sub-license payments, paid to the Company&#x2019;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to our academic partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt of such payments or modifications from the Company&#x2019;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <!-- Field: Page; Sequence: 12; Value: 3 -->   <!-- Field: /Page --> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Stock-Based Compensation</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&#x2019;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which no compensation expense is recognized until &#x201c;performance&#x201d; is deemed to have occurred.</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Interest Expense and Deferred Financing Costs</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Interest expense for the three months ended June&nbsp;30, 2016 and 2015 was $1,338 and $1,306, respectively, and for the six months ended June 30, 2016 and 2015 was $2,677 and $2,621, respectively, and relates to the issuance of the PhaRMA Notes (defined in Note 4). Costs directly associated with the issuance of the PhaRMA Notes have been capitalized and are netted against the non-recourse notes payable on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the term of the PhaRMA Notes using the effective interest rate method. Amortization of deferred financing costs included in interest expense was $110 for each of the three months ended June&nbsp;30, 2016 and 2015, and $220 for each of the six months ended June 30, 2016 and 2015.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Lease Financing Obligation</div></div></div> <div style=" font-size: 10pt; text-indent: 0.25in; margin: 0pt 0 0pt 12pt">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Based on the terms of the lease agreement for the new research facility in Birmingham, Alabama, the Company had construction period risks during the construction period and the Company was deemed the owner of the building (for accounting purposes only) during the construction period. Accordingly, the Company recorded an asset of $1,589, representing the Company&#x2019;s leased portion of the building and recorded a corresponding liability. Upon completion of leasehold improvement construction, the Company did not meet the sale-leaseback criteria for de-recognition of the building asset and liability. Therefore, the lease is accounted for as a financing obligation. The asset will be depreciated over the expected duration of the lease of 20.5 years, and rental payments will be treated as principal and interest payments on the lease financing obligation liability. The underlying accounting for this transaction has no impact on cash flows associated with the underlying lease or construction in process. Interest expense for the three and six months ended June 30, 2016 includes $83 and $214, respectively, related to the lease financing obligation.</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">At June 30, 2016, the lease financing obligation balance was $2,589 and was recorded as a long term liability on the consolidated balance sheets. The remaining future minimum payments under the lease financing obligation are $4,839.</div> <div style=" font-size: 10pt; text-indent: 24.5pt; margin: 0pt 0 0pt 12pt">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Currency Hedge Agreement</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore, mark-to-market adjustments are recognized in the Company&#x2019;s Consolidated Statements of Comprehensive Loss. Cumulative mark-to-market adjustments for the six months ended June&nbsp;30, 2016 and 2015 resulted in losses of $6,441 and $332, respectively. Mark-to-market adjustments are determined by a third party pricing model that uses quoted prices in markets that are not actively traded and for which significant inputs are observable directly or indirectly, representing Level 2 in the fair value hierarchy as defined by U.S. GAAP. The Company is also required to post collateral in connection with the mark-to-market adjustments based on thresholds defined in the Currency Hedge Agreement. In addition, the Company realized currency exchange gains of $811 and $1,545 during the first six months of 2016 and 2015, respectively, associated with the exercise of a U.S. dollar/Japanese yen currency option under the Currency Hedge Agreement. As of June&nbsp;30, 2016, $1,610 of hedge collateral was posted under the agreement. No hedge collateral was posted as of December 31, 2015.</div>  <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Net Loss Per Share</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein, except for the three months ended June 30, 2015 for which diluted income per share is $0.06 and basic income per share is $0.07 per share, because common equivalent shares from unexercised stock options and common shares expected to be issued under the Company&#x2019;s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the three months ended June&nbsp;30, 2016 does not include 885 of such potential common shares, as their impact would be anti-dilutive. The calculation of diluted earnings per share for the six months ended June&nbsp;30, 2016 and 2015 does not include 1,091 and 4,038, respectively, of such potential common shares, as their impact would be anti-dilutive.</div>   <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.</div> <div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div>  <!-- Field: Page; Sequence: 13; Value: 3 -->   <!-- Field: /Page --> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Significant Customers and Other Risks</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Significant Customers</div></div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Prior to the SUL Agreement, the Company relied primarily on three specialty distributors to purchase and supply the majority of RAPIVAB. These three pharmaceutical specialty distributors accounted for greater than 90% of all RAPIVAB product sales to date and accounted for predominantly all of the Company&#x2019;s outstanding receivables from product sales. The loss of one or more of these specialty distributors as a customer could negatively impact the commercialization of RAPIVAB. However, the Company will utilize these specialty distributors on a limited basis subsequent to the SUL collaboration as SUL, and other peramivir collaboration partners, will be responsible for commercial sales on a worldwide basis. In addition, in connection with the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&#x2019;s partners and the Company will be reliant on these partners to generate sales and remit cash to satisfy receivables.</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">The Company&#x2019;s primary source of revenue that has an underlying cash flow stream is the reimbursement of RAPIVAB and BCX4430 development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its RAPIVAB and BCX4430 programs. Accordingly, reimbursement of these expenses represents a significant portion of the Company&#x2019;s collaborative and other research and development revenues. The completion (as with the June 30, 2014 BARDA/HHS peramivir development contract) or termination of the NIAID/HHS and BARDA/HHS BCX4430 contracts could negatively impact the Company&#x2019;s future Consolidated Statements of Comprehensive Loss and Cash Flows. In addition, the Company also recognizes royalty revenue from the net sales of RAPIACTA by Shionogi; however, the underlying cash flow from these royalty payments goes directly to pay the interest, and then the principal, on the Company&#x2019;s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. Further, the Company&#x2019;s drug development activities are performed by a limited group of third party vendors. If any of these vendors were unable to perform their services, this could significantly impact the Company&#x2019;s ability to complete its drug development activities.</div>  <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Risks from Third Party Manufacturing and Distribution Concentration</div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 22.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">The Company relies on single source manufacturers for active pharmaceutical ingredient and finished drug product manufacturing of RAPIVAB, as well as for its other product candidates in development. Delays in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling of RAPIVAB or the Company&#x2019;s product candidates in development.</div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Credit Risk</div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 22.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately 18 months or less. Other than product sale and collaborative partner receivables discussed above, the majority of the Company&#x2019;s receivables from collaborations are due from the U.S. Government, for which there is no assumed credit risk.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Recent Accounting Pronouncements</div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In March 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update No. 2016-09: <div style="display: inline; font-style: italic;">Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</div> (&#x201c;ASU 2016-09&#x201d;). The amendments in this update simplify several aspects of the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures and statutory tax withholding requirements, as well as classification in the statement of cash flows. ASU 2016-09 will be effective for the Company in fiscal year 2017, but early adoption is permitted. The Company is currently evaluating the impact of this update on its consolidated financial statements.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In February 2016, the FASB issued Accounting Standards Update No. 2016-02: <div style="display: inline; font-style: italic;">Leases (Topic 842)</div> (&#x201c;ASU 2016-02&#x201d;). The amendments in this update require lessees, among other things, to recognize lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous authoritative guidance. This update also introduces new disclosure requirements for leasing arrangements. ASU 2016-02 will be effective for the Company in fiscal year 2019, but early adoption is permitted. The Company is currently evaluating the impact of this update on its consolidated financial statements.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In January 2016, the FASB issued Accounting Standards Update No. 2016-01: <div style="display: inline; font-style: italic;">Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</div> (&#x201c;ASU 2016-01&#x201d;). The amendments in this update address certain aspects of recognition, measurement, presentation and disclosure of financial instruments. In particular, the amendments in this update supersede, for public business entities, the requirement to disclose the methods and significant assumptions used in calculating the fair value of financial instruments required to be disclosed for financial instruments measured at amortized cost on the balance sheet. ASU 2016-01 will be effective for the Company in fiscal year 2018, but early adoption is permitted. The Company does not expect this standard to have a material impact on its consolidated financial statements.</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</div>  <!-- Field: Page; Sequence: 14; Value: 3 -->   <!-- Field: /Page -->   <div style=" font-size: 10pt; text-indent: 22.3pt; margin: 0pt 0">In November 2015, the FASB issued Accounting Standards Update No. 2015-17, <div style="display: inline; font-style: italic;">Balance Sheet Classification of Deferred Taxes</div>, requiring all deferred tax assets and liabilities, and any related valuation allowance, to be classified as noncurrent on the balance sheet. The classification change for all deferred taxes as noncurrent simplifies entities&#x2019; processes as it eliminates the need to separately identify the net current and net noncurrent deferred tax asset or liability in each jurisdiction and allocate valuation allowances. We elected to prospectively adopt the accounting standard in the beginning of our fourth quarter of fiscal 2015. Adoption of this standard had no impact on the Company&#x2019;s consolidated financial statements.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In July 2015, the FASB issued Accounting Standards Update No. 2015-11: <div style="display: inline; font-style: italic;">Inventory (Topic 330): Simplifying the Measurement of Inventory</div> (&#x201c;ASU 2015-11&#x201d;), which changes the measurement principle for inventory from the lower of cost or market to the lower of cost and net realizable value. ASU 2015-11 defines net realizable value as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The update does not apply to inventory that is measured using last-in, first-out or the retail inventory method. The update applies to all other inventory, which includes inventory that is measured using first-in, first-out or average cost methods. The amendments in ASU 2015-11 will be effective for the Company for fiscal years, and the interim periods within those years, beginning after December 15, 2016. The amendments must be applied prospectively and early adoption is permitted. The Company does not expect this standard to have a material impact on its consolidated financial statements.</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In April 2015, the FASB issued Accounting Standards Update No. 2015-03: <div style="display: inline; font-style: italic;">Interest &#x2013; Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs</div> (&#x201c;ASU 2015-03&#x201d;). This standard amends existing guidance to require the presentation of debt issuance costs in the balance sheet as a deduction from the carrying amount of the related debt liability instead of a deferred charge. It is effective for annual reporting periods beginning after December 15, 2015 and requires retrospective application for all periods presented. The Company adopted ASU 2015-03 in the first quarter of 2016. Adoption did not have a material impact on its consolidated financial statements.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In August 2014, the FASB issued Accounting Standards Update No. 2014-15: <div style="display: inline; font-style: italic;">Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern</div> (&#x201c;ASU 2014-15&#x201d;) <div style="display: inline; font-style: italic;">,</div> which defines management&#x2019;s responsibility to evaluate, at each annual and interim reporting period, whether there are conditions or events that raise substantial doubt about an entity&#x2019;s ability to continue as a going concern within one year after the date the financial statements are issued and to provide related footnote disclosures in certain circumstances. In connection with each annual and interim period, management must assess if there is substantial doubt about the company&#x2019;s ability to continue as a going concern within one year after the issuance date.&nbsp;Disclosures are required if conditions give rise to substantial doubt.&nbsp;ASU 2014-15 is effective for all companies in the first annual period ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The Company is currently evaluating the impact this standard will have on its financial statements and disclosures.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In May 2014, the FASB issued Standards Update No. 2014-09: <div style="display: inline; font-style: italic;">Revenue from Contracts with Customers (Topic 606) </div>(&#x201c;ASU 2014-09&#x201d;), which provides a single, comprehensive revenue recognition model for all contracts with customers. The core principal of this ASU is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. In July 2015, the FASB finalized a one year delay in the effective date of this standard, which will now be effective January 1, 2018; however, early adoption is permitted any time after the original effective date, January 1, 2017. Companies can transition to the new standard under the full retrospective method or the modified retrospective method. The Company is currently evaluating the impact this standard will have on its consolidated financial statements.&nbsp;</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18861-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18743-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18854-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6619182576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Note 2 &#x2014; Stock-Based Compensation</div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div>   <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As of June&nbsp;30, 2016, the Company had two stock-based employee compensation plans, the Stock Incentive Plan (&#x201c;Incentive Plan&#x201d;) and the Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;). The Incentive Plan was amended and restated in April 2016 and approved by the Company&#x2019;s stockholders in May 2016. The ESPP was amended and restated in March 2014 and approved by the Company&#x2019;s stockholders in May 2014. Stock-based compensation expense of $4,491 ($4,402 of expense related to the Incentive Plan and $89 of expense related to the ESPP) was recognized during the first six months of 2016, while $5,934 ($5,840 of expense related to the Incentive Plan and $94 of expense related to the ESPP) was recognized during the first six months of 2015.</div>  <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">There was approximately $18,417 of total unrecognized compensation cost related to non-vested stock option awards and restricted stock unit awards granted by the Company as of June&nbsp;30, 2016. That cost is expected to be recognized as follows: $3,782 during the remainder of 2016, $6,966 in 2017, $4,703 in 2018, $2,586 in 2019 and $380 in 2020. In addition, the Company has outstanding performance-based stock options for which no compensation expense is recognized until &#x201c;performance&#x201d; has occurred and the award vests. At the time of vesting, compensation expense will be recognized.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div>  <!-- Field: Page; Sequence: 15; Value: 3 -->   <!-- Field: /Page --> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Stock Incentive Plan</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company grants stock option awards and restricted stock unit awards to its employees, directors, and consultants under the Incentive Plan. Under the Incentive Plan, stock option awards are granted with an exercise price equal to the market price of the Company&#x2019;s stock at the date of grant. Since March&nbsp;1, 2011, stock option awards granted to employees generally vest 25% each year until fully vested after four years. In January 2013, the Company made retention grants of stock option awards and restricted stock units. These awards vest 50% each year until fully vested after two years. In August 2013 and December 2014, the Company issued 1,032 and 1,250 performance-based stock options, respectively. These awards vest upon successful completion of specific development milestones. As of June 30, 2016, 75% of the August 2013 grants have vested based upon achievement of three milestones: (1) successful completion of the OPuS-1 clinical trial, for which vesting occurred in the second quarter of 2014, (2) FDA approval of RAPIVAB for which vesting occurred in the fourth quarter of 2014, and (3) initiation of a Phase 1 clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally-administered BCX7353 in healthy volunteers, for which vesting occurred in the second quarter of 2015. Thus, as of June 30, 2016, 25% of the August 2013 performance-based grants and 100% of the December 2014 performance-based grants remain unvested and no compensation expense has been recognized for these portions of the previously issued performance-based grants. Stock option awards granted to non-employee directors of the Company generally vest monthly over one year. All stock option awards have contractual terms of 5 to 10&nbsp;years. The vesting exercise provisions of all awards granted under the Incentive Plan are subject to acceleration in the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Incentive Plan.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Related activity under the Incentive Plan is as follows:</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">  <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Awards<br /> Available</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options<br /> Outstanding</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted<br /> Average<br /> Exercise<br /> Price</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%; font-size: 10pt">Balance December&nbsp;31, 2015</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 10%; font-size: 10pt; text-align: right">16</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 10%; font-size: 10pt; text-align: right">10,671</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">7.50</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Plan amendment</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">3,800</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Restricted stock unit awards granted</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(21</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Restricted stock unit awards cancelled</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">15</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Stock option awards granted</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(2,120</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">2,120</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">3.21</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Stock option awards exercised</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(79</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">2.32</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Stock option awards cancelled</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">499</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(499</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">11.24</td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.25pt">Balance June&nbsp;30, 2016</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">2,189</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">12,213</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">$</td> <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: right">6.63</td> <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">For stock option awards granted under the Incentive Plan during the first six months of 2016 and 2015, the fair value was estimated on the date of grant using a Black-Scholes option pricing model and the assumptions noted in the table below. The weighted average grant date fair value per share of the awards granted during the first six months of 2016 and 2015 was $2.18 and $8.21, respectively. The fair value of the stock option awards is amortized to expense over the vesting periods using a straight-line expense attribution method. The following table summarizes the key assumptions used by the Company to value the stock option awards granted during the first six months of 2016 and 2015. The expected life is based on the average of the assumption that all outstanding stock option awards will be exercised at full vesting and the assumption that all outstanding stock option awards will be exercised at the midpoint of the current date (if already vested) or at full vesting (if not yet vested) and the full contractual term. The expected volatility represents the historical volatility on the Company&#x2019;s publicly traded common stock. The Company has assumed no expected dividend yield, as dividends have never been paid to stock or option holders and will not be paid for the foreseeable future. The weighted average risk-free interest rate is the implied yield currently available on zero-coupon government issues with a remaining term equal to the expected term.</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-size: 10pt; text-align: center; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Weighted Average Assumptions for Stock Option Awards Granted to</div></div> <div style=" font-size: 10pt; text-align: center; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Employees and Directors under the Incentive Plan</div></div> <div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">  <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; font-size: 10pt; text-align: left">Expected Life in Years</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 10%; font-size: 10pt; text-align: right">5.6</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 10%; font-size: 10pt; text-align: right">5.5</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Expected Volatility</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">82</td> <td style="font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">83</td> <td style="font-size: 10pt; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Expected Dividend Yield</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">0.0</td> <td style="font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">0.0</td> <td style="font-size: 10pt; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Risk-Free Interest Rate</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1.4</td> <td style="font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1.5</td> <td style="font-size: 10pt; text-align: left">%</td> </tr>  </table> </div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Employee Stock Purchase Plan</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company has reserved a total of 1,475 shares of common stock to be purchased under the ESPP, of which 463 shares remain available for purchase at June&nbsp;30, 2016. Eligible employees may authorize up to 15% of their salary to purchase common stock at the lower of 85% of the beginning or 85% of the ending price during six-month purchase intervals. No more than 3 shares may be purchased by any one employee at the six-month purchase dates and no employee may purchase stock having a fair market value at the commencement date of $25 or more in any one calendar year. The Company issued 34 shares during the first six months of 2016 under the ESPP. Compensation expense for shares purchased under the ESPP related to the purchase discount and the &#x201c;look-back&#x201d; option were determined using a Black-Scholes option pricing model.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65895303&amp;loc=d3e17540-113929<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6686121840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Collaborative and Other Research and Development Contracts<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Arrangement Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Note 3 &#x2014; Collaborative and Other Research and Development Contracts</div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">U.S.&nbsp;Department of Health and Human Services (&#x201c;BARDA/HHS&#x201d;).</div> On March 31, 2015, the Company announced that BARDA/HHS had awarded the Company a contract for the continued development of BCX4430 as a potential treatment for diseases caused by RNA pathogens, including filoviruses.&nbsp;This BARDA/HHS contract includes a base contract of $16,265 to support BCX4430 drug manufacturing, as well as $22,855 in additional development options that can be exercised by the government, bringing the potential value of the contract to $39,120. As of June 30, 2016, a total of $20,574 has been awarded under exercised options within this contract.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div>  <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">National Institute of Allergy and Infectious Diseases (&#x201c;NIAID/HHS&#x201d;).</div> In September 2013, NIAID/HHS contracted with the Company for the development of BCX4430 as a treatment for Marburg virus disease. NIAID/HHS, part of the National Institutes of Health, made an initial award of $5,000 to the Company. The goals of this contract, including amendments, are to file IND applications for intravenous (&#x201c;i.v.&#x201d;) and intramuscular (&#x201c;i.m.&#x201d;) BCX4430 for the treatment of Marburg virus disease and other hemorrhagic fever virus diseases, to study BCX4430 as a treatment for Ebola virus disease and to conduct an initial Phase 1 human clinical trial. BCX4430 is the lead compound in the Company&#x2019;s BSAV research program. On June 30, 2016, NIAID/HHS granted an additional $5,475 to BioCryst for the development of BCX4430 as a treatment for hemorrhagic fever viruses. As of June 30, 2016, the total NIAID/HHS contract amount to advance the program through the completion of the Phase I clinical program could be up to $39,477, if all contract options are exercised. As of June 30, 2016, a total of $35,350 has been awarded under the exercised options within this contract.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The contracts with BARDA/HHS and NIAID/HHS are cost-plus-fixed-fee contracts. That is, the Company is entitled to receive reimbursement for all costs incurred in accordance with the contract provisions that are related to the development of BCX4430 plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make periodic assessments of progress and the continuation of the contract is based on the Company&#x2019;s performance, the timeliness and quality of deliverables, and other factors. The government has rights under certain contract clauses to terminate these contracts. These contracts are terminable by the government at any time for breach or without cause.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Seqirus UK Limited (&#x201c;SUL&#x201d;).</div> On June 16, 2015, the Company and Seqirus UK Limited (&#x201c;SUL&#x201d;), a limited company organized under the laws of the United Kingdom and a subsidiary of CSL Limited, a company organized under the laws of Australia, entered into a License Agreement (the &#x201c;SUL Agreement&#x201d;) granting SUL and its affiliates worldwide rights to develop, manufacture and commercialize RAPIVAB (peramivir injection) for the treatment of influenza except for the rights to conduct such activities in Israel, Japan, Korea and Taiwan (the permitted geographies together constituting the &#x201c;Territory&#x201d;). RAPIVAB is an intravenous treatment for acute uncomplicated influenza and is currently licensed for use in the United States, Japan and Korea. RAPIVAB is the first and only intravenous influenza treatment in the world and was approved by the FDA in December 2014 for the treatment of acute uncomplicated influenza in patients 18 years and older who have been symptomatic for no more than two days. The Company retains all rights and associated economics to procure pandemic stockpiling orders for RAPIVAB from the U.S. Government, while SUL has the right to pursue government stockpiling outside the U.S.</div>  <div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Pursuant to the SUL Agreement, RAPIVAB will be commercialized by CSL's subsidiary, SUL, which specializes in influenza prevention through the supply of seasonal and pandemic vaccine to global markets. SUL will manufacture, commercialize and exercise decision-making authority with respect to the development and commercialization of RAPIVAB within the Territory and be responsible for all related costs, including sales and promotion.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In December 2013, the Company submitted an NDA for RAPIVAB to the FDA. Under the terms of the SUL Agreement, the Company is responsible for fulfilling all post-marketing approval commitments in connection with the FDA's approval of the NDA, and upon fulfillment will transfer ownership of and financial responsibility for the NDA to SUL. Pursuant to potential rights to sell RAPIVAB in Canada and the EU, the Company is also responsible for regulatory filings and interactions with the Health Canada and the European Medicines Agency (&quot;EMA&quot;) until marketing approval for RAPIVAB is obtained and assigned to SUL. In January 2016, the Company submitted a New Drug Submission (&#x201c;NDS&#x201d;) for RAPIVAB in Canada, seeking approval for treatment of acute uncomplicated influenza in adult patients. In accordance with the SUL Agreement, the Company and SUL formed a joint steering committee, composed of an equal number of representatives from each party, to oversee, review and coordinate the conduct and progress of the commercialization of RAPIVAB in the Territory and any additional development.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Under the terms of the SUL Agreement, the Company received an upfront payment of $33,740, and may receive up to $12,000 in additional milestone payments related to the successful achievement of regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Canada for an adult indication in Canada. The Company is also entitled under the SUL Agreement to receive tiered royalties at a percentage rate beginning in the mid-teens contingent upon meeting minimum thresholds of net sales, as well as a low-thirties percentage of the gross profit from government stockpiling purchases made outside the U.S. Specifically, the Company receives tiered royalties at a percentage rate in the mid-teens to low-forties on net sales in the U.S. during a Contract Year (defined as July 1 - June 30) and tiered royalties at a percentage rate in the mid-teens to mid-twenties on net sales in the Territory, other than in the U.S., during a Calendar Year, each subject to certain downward adjustments for circumstance or events impacting the overall market opportunity. SUL's royalty payment obligations commence on the date of the SUL Agreement and expire, on a country-by-country basis, upon the later of (i) the expiration of legal exclusivity in such country and (ii) ten years from the date of the SUL Agreement. The Company developed RAPIVAB under a license from UAB and will owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from SUL.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div>  <!-- Field: Page; Sequence: 17; Value: 3 -->   <!-- Field: /Page --> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Shionogi&nbsp;&amp; Co., Ltd. (&#x201c;Shionogi&#x201d;).</div> In February 2007, the Company entered into an exclusive license agreement with Shionogi to develop and commercialize peramivir in Japan for the treatment of seasonal and potentially life-threatening human influenza. Under the terms of the agreement, Shionogi obtained rights to injectable formulations of peramivir in Japan. The Company developed peramivir under a license from UAB and will owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from Shionogi. In October 2008, the Company and Shionogi amended the license agreement to expand the territory covered by the agreement to include Taiwan. Shionogi has commercially launched peramivir under the commercial name RAPIACTA in Japan. Shionogi submitted an NDA to the Taiwan FDA in late 2013.</div> <div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Green Cross Corporation (&#x201c;Green Cross&#x201d;).</div> In June 2006, the Company entered into an agreement with Green Cross to develop and commercialize peramivir in Korea. Under the terms of the agreement, Green Cross will be responsible for all development, regulatory, and commercialization costs in Korea. The Company received a one-time license fee of $250. The license also provides that the Company will share in profits resulting from the sale of peramivir in Korea, including the sale of peramivir to the Korean government for stockpiling purposes. Furthermore, Green Cross will pay the Company a premium over its cost to supply peramivir for development and any future marketing of peramivir products in Korea.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">&nbsp;</div></div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Mundipharma International Holdings Limited (&#x201c;Mundipharma&#x201d;).</div> In February 2006, the Company entered into an exclusive, royalty bearing right and license agreement with Mundipharma for the development and commercialization of forodesine, a Purine Nucleoside Phosphorylase (&#x201c;PNP&#x201d;) inhibitor, for use in oncology. Under the terms of the license agreement, as amended, Mundipharma obtained rights to forodesine in markets across Europe, Asia, and Australasia in exchange for a $10,000 up-front payment.</div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. (&#x201c;AECOM&#x201d; and &#x201c;IRL&#x201d; respectively).</div> In June 2000, the Company licensed a series of potent inhibitors of PNP from AECOM and IRL, (collectively, the &#x201c;Licensors&#x201d;). The lead product candidates from this collaboration are forodesine and ulodesine. The Company has obtained worldwide exclusive rights to develop and ultimately distribute these, or any other, product candidates that might arise from research on these inhibitors. The Company has the option to expand the Agreement to include other inventions in the field made by the investigators or employees of the Licensors. The Company agreed to use commercially reasonable efforts to develop these drugs. In addition, the Company has agreed to pay certain milestone payments for each licensed product (which range in the aggregate from $1,400 to almost $4,000&nbsp;per indication) for future development of these inhibitors, single digit royalties on net sales of any resulting product made by the Company, and to share approximately one quarter of future payments received from other third-party partners, if any. In addition, the Company has agreed to pay annual license fees, which can range from $150 to $500, that are creditable against actual royalties and other payments due to the Licensors. This agreement may be terminated by the Company at any time by giving 60&nbsp;days advance notice or in the event of material uncured breach by the Licensors.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In May 2010, the Company amended the licensee agreement through which the Company obtained worldwide exclusive rights to develop and ultimately distribute any product candidates that might arise from research on a series of PNP inhibitors, including forodesine and ulodesine. Under the terms of the amendment, the Licensors agreed to accept a reduction of one-half in the percentage of future payments received from third-party sub licensees of the licensed PNP inhibitors that must be paid to the Licensors. This reduction does not apply to (i)&nbsp;any milestone payments the Company may receive in the future under its license agreement dated February&nbsp;1, 2006 with Mundipharma and (ii)&nbsp;royalties received from its sub licensees in connection with the sale of licensed products, for which the original payment rate will remain in effect. The rate of royalty payments to the Licensors based on net sales of any resulting product made by the Company remains unchanged.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On November&nbsp;17, 2011, the Company further amended its agreements with the Licensors whereby the Licensors agreed to accept a reduction of one-half in the percentage of Net Proceeds (as defined) received by the Company under its Amended and Restated Agreement with Mundipharma that will be paid to AECOM/IRL.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On June 19, 2012, the Company further amended its agreements with AECOM/IRL whereby the parties clarified the definition of the field with respect to PNP inhibition and AECOM/IRL agreed to exclusive worldwide license of BCX4430 to BioCryst for any antiviral use.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">At its sole option and subject to certain agreed upon conditions, any future non-royalty payments due to be paid by the Company to AECOM/IRL under the license agreement may be made either in cash, in shares of the Company&#x2019;s common stock, or in a combination of cash and shares.</div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div>  <!-- Field: Page; Sequence: 18; Value: 3 -->   <!-- Field: /Page --> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On January 6, 2014, the Carbohydrate Chemistry Research Team from Callaghan Innovation Research Limited, formerly Industrial Research Limited, transferred to Victoria University of Wellington (&#x201c;VUW&#x201d;) to establish the Ferrier Research Institute. The intellectual property rights relating to this research team, and the contracts relating to that intellectual property were transferred to a wholly owned subsidiary of VUW, including the contracts to which BioCryst is a party. The parties executed novation agreements in order to effectuate the transfer. Except for a substitution of parties, the terms and conditions of the contracts are substantially the same.</div> <div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">The University of Alabama at Birmingham (&#x201c;UAB&#x201d;).</div> The Company currently has agreements with UAB for influenza neuraminidase and complement inhibitors. Under the terms of these agreements, UAB performed specific research for the Company in return for research payments and license fees. UAB has granted the Company certain rights to any discoveries in these areas resulting from research developed by UAB or jointly developed with the Company. The Company has agreed to pay single digit royalties on sales of any resulting product and to share in future payments received from other third-party partners. The Company has completed the research under the UAB agreements. These two agreements have initial 25-year terms, are automatically renewable for five-year terms throughout the life of the last patent and are terminable by the Company upon three months&#x2019; notice and by UAB under certain circumstances. Upon termination both parties shall cease using the other parties&#x2019; proprietary and confidential information and materials, the parties shall jointly own joint inventions and UAB shall resume full ownership of all UAB licensed products. There is currently no activity between the Company and UAB on these agreements, but when the Company licenses this technology, such as in the case of the Shionogi, Green Cross and SUL agreements, or commercializes products related to these programs, the Company will owe sublicense fees or royalties on amounts it receives.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6686111952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Royalty Monetization<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationTextBlock', window );">Royalty Monetization [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Note 4 &#x2014; Royalty Monetization</div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Overview</div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On March&nbsp;9, 2011, the Company completed a $30,000&nbsp;financing transaction to monetize certain future royalty and milestone payments under the Shionogi Agreement, pursuant to which Shionogi licensed from the Company the rights to market RAPIACTA in Japan and, if approved for commercial sale, Taiwan. The Company received net proceeds of $22,691&nbsp;from the transaction after transaction costs of $4,309&nbsp;and the establishment of a $3,000&nbsp;interest reserve account by Royalty Sub, available to help cover interest shortfalls in the future. All of the interest reserve account has been fully utilized with the September 2012 interest payment.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As part of the transaction, the Company entered into a purchase and sale agreement dated as of March&nbsp;9, 2011 with Royalty Sub, whereby the Company transferred to Royalty Sub, among other things, (i)&nbsp;its rights to receive certain royalty and milestone payments from Shionogi arising under the Shionogi Agreement, and (ii)&nbsp;the right to receive payments under a Japanese yen/US dollar foreign currency hedge arrangement (as further described below, the &#x201c;Currency Hedge Agreement&#x201d;) put into place by the Company in connection with the transaction. Royalty payments will be paid by Shionogi in Japanese yen and milestone payments will paid in U.S. dollars. The Company&#x2019;s collaboration with Shionogi was not impacted as a result of this transaction.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Non-Recourse Notes Payable</div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On March&nbsp;9, 2011, Royalty Sub completed a private placement to institutional investors of $30,000 in aggregate principal amount of its PhaRMA Senior Secured 14.0% Notes due 2020 (the &#x201c;PhaRMA Notes&#x201d;). The PhaRMA Notes were issued by Royalty Sub under an Indenture, dated as of March&nbsp;9, 2011 (the &#x201c;Indenture&#x201d;), by and between Royalty Sub and U.S. Bank National Association, as Trustee. Principal and interest on the PhaRMA Notes issued are payable from, and are secured by, the rights to royalty and milestone payments under the Shionogi Agreement transferred by the Company to Royalty Sub and payments, if any, made to Royalty Sub under the Currency Hedge Agreement. The PhaRMA Notes bear interest at 14%&nbsp;per annum, payable annually in arrears on September&nbsp;1st of each year. The Company remains entitled to receive any royalties and milestone payments related to sales of peramivir by Shionogi following repayment of the PhaRMA Notes.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Royalty Sub&#x2019;s obligations to pay principal and interest on the PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person, including the Company, except to the extent of the Company&#x2019;s pledge of its equity interests in Royalty Sub in support of the PhaRMA Notes. The Company may, but is not obligated to, make capital contributions to a capital account that may be used to redeem, or on up to one occasion pay any interest shortfall on, the PhaRMA Notes.</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On September 1, 2014, Royalty Sub was unable to pay the full amount of interest payable to avoid an event of default. Accordingly, the PhaRMA Notes and related accrued interest have been classified as current liabilities on the balance sheet. As a result of the event of default under the PhaRMA Notes, the holders of the PhaRMA Notes may pursue acceleration of the PhaRMA Notes, may foreclose on the collateral securing the PhaRMA Notes and the equity interest in Royalty Sub and exercise other remedies available to them under the Indenture in respect of the PhaRMA Notes. In such event, the Company may not realize the benefit of future royalty payments that might otherwise accrue to it following repayment of the PhaRMA Notes and it might otherwise be adversely affected. Due to the non-recourse nature of the PhaRMA Notes, in the event of any potential acceleration or foreclosure, the primary impact to the Company would be the loss of future royalty payments from Shionogi and legal costs associated with retiring the PhaRMA Notes. In addition, the Company may incur costs associated with liquidating the related Currency Hedge Agreement, which would no longer be required in the event of foreclosure, or if the PhaRMA Notes cease to be outstanding. As the PhaRMA Notes are the obligation of Royalty Sub and non-recourse to the Company, the event of default of the PhaRMA Notes is not expected to have a significant impact on the Company&#x2019;s future results of operations or cash flows. As of June 30, 2016, the PhaRMA Notes remain in default.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0"></div> <!-- Field: Page; Sequence: 19; Value: 3 --> <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-size: 10pt; width: 700px;">  <tr style="vertical-align: top; text-align: left"> <td style="width: 100%; text-align: center"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19 <!-- Field: /Sequence --></td> </tr>  </table> </div> <div style="page-break-before: always; margin-top: 6pt">  &nbsp; </div> <!-- Field: /Page --> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">As of June 30, 2016, the aggregate fair value of the PhaRMA Notes was estimated to be approximately 50% of its carrying value of $30,000. The estimated fair value of the PhaRMA Notes is classified as Level 2 in the fair value hierarchy as defined in U.S. GAAP.&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The PhaRMA Notes are redeemable at the option of Royalty Sub at any time at a redemption price equal to the outstanding principal balance of the PhaRMA Notes being redeemed plus accrued and unpaid interest through the redemption date on the PhaRMA Notes being redeemed.</div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">&nbsp;</div></div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Foreign Currency Hedge</div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. Under the Currency Hedge Agreement, the Company has the right to purchase dollars and sell yen at a rate of 100 yen per dollar for which the Company may be required to pay a premium in each year from 2017 through 2020, provided the Currency Hedge Agreement remains in effect. A payment of $1,950&nbsp;will be required if, on May&nbsp;18 of the relevant year, the U.S. dollar is worth 100 yen or less as determined in accordance with the Currency Hedge Agreement.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore, mark-to-market adjustments are recognized in the Company&#x2019;s Consolidated Statement of Comprehensive Loss. Cumulative mark-to-market adjustments for the six months ended June&nbsp;30, 2016 and 2015 resulted in losses of $6,441 and $332, respectively. The Company is also required to post collateral in connection with the mark-to-market adjustments based on defined thresholds. As of June 30, 2016, $1,610 of hedge collateral was posted under the Currency Hedge Agreement. The Company will not be required to post collateral exceeding the maximum premium payments remaining payable under the Currency Hedge Agreement. As of June 30, 2016, the maximum amount of hedge collateral the Company may be required to post is $7,800.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyMonetizationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty monetization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyMonetizationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6686123712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Note 5 &#x2014; Stockholders&#x2019; Equity</div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On March 3, 2015, the Company filed a $150,000 shelf registration statement on Form S-3 with the SEC. This shelf registration statement, as amended by a post-effective amendment filed on February 26, 2016 and declared effective on April 18, 2016, allows the Company to sell securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants and units, from time to time at prices and on terms to be determined at the time of sale.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">On November&nbsp;6, 2013, the Company filed a $125,000 shelf registration statement on Form S-3 with the SEC. This shelf registration statement was declared effective in November 2013 and allows the Company to sell securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants and units, from time to time at prices and on terms to be determined at the time of sale. The Company has $10,000 remaining under this shelf registration statement.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74567-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6738397968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DescriptionOfCompanyPolicyTextBlock', window );">Description of Company [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">The Company</div></div></div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">BioCryst Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) is a biotechnology company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and align with its capabilities and expertise. The Company was incorporated in Delaware in 1986 and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred losses and negative cash flows from operations since inception.&nbsp;</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Based on its current operating plans, the Company expects it has sufficient liquidity, with its existing cash, restricted cash and investments of $64,320, to continue its planned operations through mid-2017. The Company&#x2019;s liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key development and regulatory events in the future. In order to continue its operations substantially beyond mid-2017 it will need to: (1)&nbsp;successfully secure or increase U.S. Government funding of its programs, including procurement contracts; (2)&nbsp;out-license rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; (3)&nbsp;raise additional capital through equity or debt financings or from other sources; (4)&nbsp;obtain additional product candidate regulatory approvals, which would generate revenue and cash flow; (5)&nbsp;reduce spending on one or more research and development programs; and/or (6)&nbsp;restructure operations. The Company may issue securities, including common stock, preferred stock, depositary shares, stock purchase contracts, warrants and units, through private placement transactions or registered public offerings pursuant to its registration statements on Form S-3 initially filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March 3, 2015 and November&nbsp;6, 2013. The Company will continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations.&nbsp;&nbsp;</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Basis of Presentation</div></div></div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, JPR Royalty Sub LLC (&#x201c;Royalty Sub&#x201d;). Royalty Sub was formed in connection with a $30,000&nbsp;financing transaction the Company completed on March&nbsp;9, 2011. See Note 4, Royalty Monetization, for a further description of this transaction. All intercompany transactions and balances have been eliminated.</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;) for interim financial reporting and the instructions to Form 10-Q and do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management&#x2019;s opinion, necessary to present fairly, in all material respects, the Company&#x2019;s consolidated financial position, results of operations, and cash flows. There were no adjustments other than normal recurring adjustments.</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">These financial statements should be read in conjunction with the financial statements for the year ended December&nbsp;31, 2015 and the notes thereto included in the Company&#x2019;s 2015 Annual Report on Form 10-K. Interim operating results are not necessarily indicative of operating results for the full year. The balance sheet as of December&nbsp;31, 2015 has been derived from the audited consolidated financial statements included in the Company&#x2019;s most recent Annual Report on Form 10-K.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Reclassifications</div></div></div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">During the first quarter of 2016, the Company adopted Accounting Standards Update No. 2015-03, <div style="display: inline; font-style: italic;">Interest &#x2013; Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs</div>. Accordingly, debt issuance costs of $2,196 classified as other current assets as of December 31, 2015 have been reclassified and netted against non-recourse notes payable to conform to the 2016 presentation.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Cash and Cash Equivalents</div></div></div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of three months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Restricted Cash</div></div></div><div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Restricted cash as of June&nbsp;30, 2016 reflects $3,022 in royalty revenue paid by Shionogi&nbsp;&amp; Co., Ltd. (&#x201c;Shionogi&#x201d;) designated for interest on the PhaRMA Notes (defined in Note 4) and $1,404 the Company is required to maintain as collateral for a letter of credit associated with the lease execution and build-out of its new Birmingham research facilities.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investment, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Investments</div></div></div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#x2019;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that may consist of U.S. Government and government agency securities, money market and mutual fund investments, municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&#x2019;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of three years and requires an average portfolio maturity of no more than 18 months. Some of the securities the Company invests in may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&#x2019;s investments are not collateralized. The Company has not realized any significant losses from its investments.</div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond three months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. At June 30, 2016, the Company believes that the costs of its investments are recoverable in all material respects.</div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The following tables summarize the fair value of the Company&#x2019;s investments by type. The estimated fair value of the Company&#x2019;s fixed income investments are classified as Level 2 in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. These fair values are obtained from independent pricing services which utilize Level 2 inputs.</div><div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div><div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June&nbsp;30, 2016</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amortized<br /> Cost</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accrued<br /> Interest</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br /> Unrealized<br /> Gains</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br /> Unrealized<br /> Losses</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Estimated<br /> Fair&nbsp;Value</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt">Obligations of the U.S. Government and its agencies</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">14,081</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">38</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">8</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">&#x2014;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">14,127</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Corporate debt securities</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">16,641</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">147</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">23</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(1</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">16,810</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt">Certificates of deposit</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">20,258</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">22</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">23</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(7</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">20,296</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">50,980</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">207</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">54</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(8</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">51,233</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div><div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31, 2015</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amortized<br /> Cost</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accrued<br /> Interest</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br /> Unrealized<br /> Gains</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br /> Unrealized<br /> Losses</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Estimated<br /> Fair&nbsp;Value</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt; width: 35%">Obligations of the U.S. Government and its agencies</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">26,557</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">88</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">&#x2014;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">(99</td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">26,546</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Corporate debt securities</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">21,820</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">184</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(41</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">21,963</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt">Certificates of deposit</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21,884</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(72</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21,838</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">70,261</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">293</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(212</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">70,347</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div><div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-align: justify; text-indent: 27pt; margin: 0pt 0">The following table summarizes the scheduled maturity for the Company&#x2019;s investments at June&nbsp;30, 2016 and December&nbsp;31, 2015.</div><div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div><div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; font-size: 10pt; text-align: left">Maturing in one year or less</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">27,079</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">22,664</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Maturing after one year through two years</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">18,164</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">28,395</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Maturing after two years</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5,990</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">19,288</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">51,233</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">70,347</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Receivables, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Receivables from Collaborations</div></div></div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables from Shionogi and Seqirus UK Limited (&#x201c;SUL&#x201d;), and product sales to SUL. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date. At June 30, 2016 and December&nbsp;31, 2015, the Company had the following receivables.</div><div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div><div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June&nbsp;30, 2016</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Billed</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Unbilled</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">723</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">1,273</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">1,996</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Shionogi&nbsp;&amp; Co. Ltd.</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">145</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">145</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Seqirus UK Limited</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">37</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">56</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">93</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total receivables</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">905</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">1,329</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">2,234</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div><div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div><div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31, 2015</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Billed</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Unbilled</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">&#x2014;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">5,536</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">5,536</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Shionogi&nbsp;&amp; Co. Ltd.</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">469</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">469</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Seqirus UK Limited</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">210</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">28</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">238</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total receivables</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">679</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5,564</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">6,243</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Monthly invoices are submitted to the U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&#x2019;s calculations of its indirect cost rates are subject to audit by the U.S. Government.</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Receivables from Product Sales</div></div></div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Receivables from product sales are recorded for amounts due to the Company related to sales of RAPIVAB. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Inventory</div></div></div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">At June 30, 2016 and December 31, 2015, the Company&#x2019;s inventory consisted of RAPIVAB work in process. Inventory is stated at the lower of cost, determined under the first-in, first-out (&#x201c;FIFO&#x201d;) method, or market. The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company will capitalize subsequent costs related to the production of inventories.</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">During 2014, in connection with the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) approval of RAPIVAB, the Company began capitalizing costs associated with the production of RAPIVAB inventories.</div><div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#x2019;s inventory consisted of the following at June&nbsp;30, 2016 and December&nbsp;31, 2015:</div><div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div><div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; font-size: 10pt; text-align: left; padding-bottom: 1pt">Work in process</td> <td style="width: 1%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,949</td> <td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,612</td> <td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.25pt">Inventories</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">1,949</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">1,612</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Property and Equipment</div></div></div><div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of three years. Laboratory equipment, office equipment, and software are depreciated over a life of five years. Furniture and fixtures are depreciated over a life of seven years. Leasehold improvements are amortized over their estimated useful lives or the expected lease term, whichever is less. Property consists of a leased building which did not meet the sale-leaseback criteria and is recorded at its fair value, less depreciation. The building is being depreciated over a period equal to the expected term of the related lease.</div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In accordance with U.S. GAAP, the Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Patents and Licenses</div></div></div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AccruedExpensesPolicyTextBlock', window );">Accrued Expenses [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Accrued Expenses</div></div></div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company generally enters into contractual agreements with third-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include:</div><div style=" font-size: 10pt; text-indent: 23pt; margin: 0pt 0">&nbsp;</div><table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; width: 700px;"> <tr> <td style="width: 5%">&nbsp;</td> <td style="vertical-align: top; width: 2%"><div style="display: inline; font-size: 10pt">&#x2022;</div></td> <td style="vertical-align: top; width: 1%">&nbsp;</td> <td style="vertical-align: top; width: 92%"><div style="display: inline; font-size: 10pt">fees paid to Clinical Research Organizations (&#x201c;CROs&#x201d;) in connection with preclinical and toxicology studies and clinical trials;</div></td> </tr> <tr> <td>&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">&#x2022;</div></td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">fees paid to investigative sites in connection with clinical trials;</div></td> </tr> <tr> <td>&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">&#x2022;</div></td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">fees paid to contract manufacturers in connection with the production of our raw materials, drug substance and drug products;&nbsp;and</div></td> </tr> <tr> <td>&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top">&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">&#x2022;</div></td> <td style="vertical-align: top">&nbsp;</td> <td style="vertical-align: top"><div style="display: inline; font-size: 10pt">professional fees.</div></td> </tr> </table><div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&#x2019;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of June 30, 2016 and December 31, 2015, the carrying value of accrued expenses approximates their fair value due to their short-term settlement.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Income Taxes</div></div></div><div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The liability method is used in the Company&#x2019;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Accumulated Other Comprehensive Income (Loss)</div></div></div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Accumulated other comprehensive income (loss) is comprised of unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&#x2019; equity. Amounts reclassified from accumulated other comprehensive income (loss) are recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. During the six months ended June 30, 2016, realized gains of $10 were reclassified out of accumulated other comprehensive income (loss). During the six months ended June 30, 2015, realized gains of $12 were reclassified out of accumulated other comprehensive income (loss).</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Revenue Recognition</div></div></div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recognizes revenues from collaborative and other research and development arrangements, royalties and product sales when realized or realizable and earned. Revenue is realized or realizable and earned when all of the following criteria are met: (i)&nbsp;persuasive evidence of an arrangement exists; (ii)&nbsp;delivery has occurred or services have been rendered; (iii)&nbsp;the seller&#x2019;s price to the buyer is fixed or determinable; and (iv)&nbsp;collectability is reasonably assured.</div><div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-style: italic;">Collaborative and Other Research and Development Arrangements and Royalties</div></div><div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Revenue from license fees, royalty payments, event payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement. Fees received under licensing agreements that are related to future performance are deferred and recognized over an estimated period determined by management based on the terms of the agreement and the products licensed. Revisions to revenue or profit estimates as a result of changes in the estimated revenue period are recognized prospectively.&nbsp;</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Under certain of the Company&#x2019;s license agreements, the Company receives royalty payments based upon its licensees&#x2019; net sales of covered products. The Company recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured.&nbsp;</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">For arrangements that involve the delivery of more than one element, each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting. This determination is based on whether the deliverable has &#x201c;stand-alone value&#x201d; to the customer. The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective evidence of fair value, (ii) third-party evidence of selling price (&#x201c;TPE&#x201d;) and (iii) best estimate of selling price (&#x201c;BESP&#x201d;). The BESP reflects our best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis. In most cases the Company expects to use TPE or BESP for allocating consideration to each deliverable. The consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation.</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In June 2015, the Company entered into a License Agreement (the &#x201c;SUL Agreement&#x201d;) granting SUL and its affiliates worldwide rights, excluding Israel, Japan, Korea and Taiwan, to develop, manufacture and commercialize RAPIVAB. The SUL Agreement provides for various types of payments, including a non-refundable upfront fee, milestone payments, and future royalties. Analysis of the SUL Agreement identified three deliverables: (i) license rights, (ii) inventory and (iii) regulatory support to obtain Canadian and European Union (&#x201c;EU&#x201d;) marketing approvals. The Company received an upfront payment of $33,740 from SUL, of which $7,000 was determined to be contingent upon EU marketing approval and will be deferred until that time. Approximately $21,777 of the upfront payment was allocated to the license rights and recognized as revenue in the second quarter. Approximately $3,740 of the upfront payment was allocated to the pending sale of inventory and was recognized during the third quarter, when the inventory transfer was completed. Approximately $1,223 of the revenue from the SUL Agreement will be recognized over the expected period of involvement in these regulatory support activities.</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not reasonably assured at the inception of the agreement; and (ii) the fees are non-refundable. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Under the terms of the SUL Agreement, the Company may receive up to $12,000 in additional payments related to the successful achievement of regulatory milestones, including marketing approval (i) by the FDA for a pediatric indication, (ii) by the EMA for an adult indication in the EU and (iii) by Health Products and Food Branch of Health Canada (&#x201c;Health Canada&#x201d;) for an adult indication in Canada. The Company evaluated each event based payment under the provisions of ASU 2010-17, <div style="display: inline; font-style: italic;">Milestone Method of Revenue Recognition</div>, and determined that each event based payment met the criteria to be considered substantive and represents a milestone under the milestone method of accounting. No event based payments were achieved during the periods presented.&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company&#x2019;s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (&#x201d;BARDA/HHS&#x201d;) and the National Institute of Allergy and Infectious Diseases (&#x201c;NIAID/HHS&#x201d;), revenue is recognized as reimbursable direct and indirect costs are incurred.</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-style: italic;">Product Sales</div></div><div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 11.5pt">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recognizes revenue for sales of RAPIVAB when title and substantially all the risks and rewards of ownership have transferred to the customer, which generally occurs on the date of shipment from our specialty distributors, utilizing the Sell-Through revenue recognition methodology. Product sales are recognized when there is persuasive evidence that an arrangement exists, title has passed, the price is fixed and determinable, and collectability is reasonably assured. Product sales are recognized net of estimated allowances, discounts, sales returns, chargebacks and rebates. In the United States, and prior to the SUL Agreement, the Company sold RAPIVAB to specialty distributors, who in turn, sell to physician offices, hospitals and federal, state and commercial health care organizations.&nbsp;With the completion of the SUL worldwide license of RAPIVAB, SUL will be responsible for sales of RAPIVAB, other than U.S. Government stockpiling sales. With the completion of the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&#x2019;s partners, except for U.S. Government stockpiling sales, and the Company will be reliant on these partners to generate sales.</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Sales deductions consist of statutory rebates to state Medicaid, Medicare and other government agencies and sales discounts (including trade discounts and distribution service fees). These deductions are recorded as reductions from revenue from RAPIVAB in the same period as the related sales with estimates of future utilization derived from historical experience adjusted to reflect known changes in the factors that impact such reserves.</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company utilizes data from external sources to help it estimate gross-to-net sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. Externally sourced data includes, but is not limited to, information obtained from specialty distributors with respect to their inventory levels and their sell-through to customers, as well as information from third-party suppliers of market research data to the pharmaceutical industry.</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company accounts for these sales deductions in accordance with authoritative guidance on revenue recognition when consideration is given by a vendor to a customer.&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company has categorized and described more fully the following significant sales deductions, all of which involve estimates and judgments, which the Company considers to be critical accounting estimates, and require it to use information from external sources.&nbsp;</div><div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</div><div style=" font-size: 10pt; margin: 0pt 0 0pt 13.5pt"><div style="display: inline; font-style: italic;">Rebates and Chargebacks</div></div><div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 13.5pt">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Statutory rebates to state Medicaid agencies and Medicare are based on statutory discounts to RAPIVAB&#x2019;s selling price.&nbsp;As it can take up to nine months or more for information to be received on actual usage of RAPIVAB in Medicaid and other governmental programs, the Company maintains reserves for amounts payable under these programs relating to RAPIVAB sales.&nbsp;</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Chargebacks claimed by specialty distributors are based on the differentials between product acquisition prices paid by the specialty distributors and lower government contract pricing paid by eligible customers covered under federally qualified programs.&nbsp;</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">The amount of the reserve for rebates and chargebacks is based on multiple qualitative and quantitative factors, including the historical and projected utilization levels, historical payment experience, changes in statutory laws and interpretations as well as contractual terms, product pricing (both normal selling prices and statutory or negotiated prices), changes in prescription demand patterns and utilization of the Company&#x2019;s product through public benefit plans, and the levels of RAPIVAB inventory in the distribution channel. The Company acquires prescription utilization data from third-party suppliers of market research data to the pharmaceutical industry. The Company updates its estimates and assumptions each period and records any necessary adjustments to its reserves. Settlements of rebates and chargebacks typically occur within nine months from point of sale. To the extent actual rebates and chargebacks differ from the Company&#x2019;s estimates, additional reserves may be required or reserves may need to be reversed, either of which would impact current period product revenue.&nbsp;</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Discounts and Sales Incentives</div></div><div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Discounts and other sales incentives primarily consist of Inventory Management Agreement (&#x201c;IMA&#x201d;) Fees. Per contractual agreements with the Company&#x2019;s specialty distributors, the Company provides an IMA fee based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth in individual contracts. The Company tracks sales to these distributors each period and accrues a liability relating to the unpaid portion of these fees by applying the contractual rates to such product sales.&nbsp;With the completion of the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&#x2019;s partners, except for U.S. Government stockpiling sales, and the Company will be reliant on these partners to generate sales and to provide for discounts and sales incentives.</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Product Returns</div></div><div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 0.25in">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company does not record a product return allowance as it does not offer the ability to return goods once a bonafide shipment has been accepted by a specialty distributor.&nbsp;</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company recorded the following revenues for the three and six months ended June&nbsp;30, 2016 and 2015:</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; font-size: 10pt; text-align: left">Product sales, net</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">&#x2014;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">&#x2014;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">&#x2014;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">537</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Royalty revenue</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">629</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">132</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">2,519</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,650</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Collaborative and other research and development revenues:</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 20pt">U.S. Department of Health and Human Services</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">3,709</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">3,731</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">6,033</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">8,206</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Shionogi (Japan)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">296</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">296</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">592</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">592</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Seqirus UK Limited</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">153</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21,683</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">463</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21,683</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total collaborative and other research and development revenues</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,158</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">25,710</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7,088</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">30,481</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total revenues</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">4,787</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">25,842</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">9,607</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">32,668</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-style: italic;">Advertising</div></div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company engages in very limited distribution and direct-response advertising when promoting RAPIVAB. Advertising and promotional costs are expensed as the costs are incurred.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Research and Development Expenses</div></div></div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The Company&#x2019;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&#x2019;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&#x2019;s manufacturing and clinical and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&#x2019;s on-going review of the level of services actually performed.&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Additionally, the Company has license agreements with third parties, such as Albert Einstein College of Medicine of Yeshiva University (&#x201c;AECOM&#x201d;), Industrial Research, Ltd. (&#x201c;IRL&#x201d;), and the University of Alabama at Birmingham (&#x201c;UAB&#x201d;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Deferred collaboration expenses represent sub-license payments, paid to the Company&#x2019;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to our academic partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt of such payments or modifications from the Company&#x2019;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Stock-Based Compensation</div></div></div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&#x2019;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which no compensation expense is recognized until &#x201c;performance&#x201d; is deemed to have occurred.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock', window );">Interest Expense and Deferred Financing Costs [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Interest Expense and Deferred Financing Costs</div></div></div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Interest expense for the three months ended June&nbsp;30, 2016 and 2015 was $1,338 and $1,306, respectively, and for the six months ended June 30, 2016 and 2015 was $2,677 and $2,621, respectively, and relates to the issuance of the PhaRMA Notes (defined in Note 4). Costs directly associated with the issuance of the PhaRMA Notes have been capitalized and are netted against the non-recourse notes payable on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the term of the PhaRMA Notes using the effective interest rate method. Amortization of deferred financing costs included in interest expense was $110 for each of the three months ended June&nbsp;30, 2016 and 2015, and $220 for each of the six months ended June 30, 2016 and 2015.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasePolicyTextBlock', window );">Lease, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Lease Financing Obligation</div></div></div><div style=" font-size: 10pt; text-indent: 0.25in; margin: 0pt 0 0pt 12pt">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Based on the terms of the lease agreement for the new research facility in Birmingham, Alabama, the Company had construction period risks during the construction period and the Company was deemed the owner of the building (for accounting purposes only) during the construction period. Accordingly, the Company recorded an asset of $1,589, representing the Company&#x2019;s leased portion of the building and recorded a corresponding liability. Upon completion of leasehold improvement construction, the Company did not meet the sale-leaseback criteria for de-recognition of the building asset and liability. Therefore, the lease is accounted for as a financing obligation. The asset will be depreciated over the expected duration of the lease of 20.5 years, and rental payments will be treated as principal and interest payments on the lease financing obligation liability. The underlying accounting for this transaction has no impact on cash flows associated with the underlying lease or construction in process. Interest expense for the three and six months ended June 30, 2016 includes $83 and $214, respectively, related to the lease financing obligation.</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">At June 30, 2016, the lease financing obligation balance was $2,589 and was recorded as a long term liability on the consolidated balance sheets. The remaining future minimum payments under the lease financing obligation are $4,839.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CurrencyHedgeAgreementPolicyTextBlock', window );">Currency Hedge Agreement [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Currency Hedge Agreement</div></div></div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore, mark-to-market adjustments are recognized in the Company&#x2019;s Consolidated Statements of Comprehensive Loss. Cumulative mark-to-market adjustments for the six months ended June&nbsp;30, 2016 and 2015 resulted in losses of $6,441 and $332, respectively. Mark-to-market adjustments are determined by a third party pricing model that uses quoted prices in markets that are not actively traded and for which significant inputs are observable directly or indirectly, representing Level 2 in the fair value hierarchy as defined by U.S. GAAP. The Company is also required to post collateral in connection with the mark-to-market adjustments based on thresholds defined in the Currency Hedge Agreement. In addition, the Company realized currency exchange gains of $811 and $1,545 during the first six months of 2016 and 2015, respectively, associated with the exercise of a U.S. dollar/Japanese yen currency option under the Currency Hedge Agreement. As of June&nbsp;30, 2016, $1,610 of hedge collateral was posted under the agreement. No hedge collateral was posted as of December 31, 2015.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Net Loss Per Share</div></div></div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein, except for the three months ended June 30, 2015 for which diluted income per share is $0.06 and basic income per share is $0.07 per share, because common equivalent shares from unexercised stock options and common shares expected to be issued under the Company&#x2019;s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the three months ended June&nbsp;30, 2016 does not include 885 of such potential common shares, as their impact would be anti-dilutive. The calculation of diluted earnings per share for the six months ended June&nbsp;30, 2016 and 2015 does not include 1,091 and 4,038, respectively, of such potential common shares, as their impact would be anti-dilutive.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div></div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ConcentrationOfMarketRiskPolicyTextBlock', window );">Concentration of Market Risk [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Significant Customers and Other Risks</div></div></div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Significant Customers</div></div><div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">Prior to the SUL Agreement, the Company relied primarily on three specialty distributors to purchase and supply the majority of RAPIVAB. These three pharmaceutical specialty distributors accounted for greater than 90% of all RAPIVAB product sales to date and accounted for predominantly all of the Company&#x2019;s outstanding receivables from product sales. The loss of one or more of these specialty distributors as a customer could negatively impact the commercialization of RAPIVAB. However, the Company will utilize these specialty distributors on a limited basis subsequent to the SUL collaboration as SUL, and other peramivir collaboration partners, will be responsible for commercial sales on a worldwide basis. In addition, in connection with the SUL collaboration, all peramivir sales (i.e., RAPIVAB, RAPIACTA, and PERAMIFLU) will be made by the Company&#x2019;s partners and the Company will be reliant on these partners to generate sales and remit cash to satisfy receivables.</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">The Company&#x2019;s primary source of revenue that has an underlying cash flow stream is the reimbursement of RAPIVAB and BCX4430 development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its RAPIVAB and BCX4430 programs. Accordingly, reimbursement of these expenses represents a significant portion of the Company&#x2019;s collaborative and other research and development revenues. The completion (as with the June 30, 2014 BARDA/HHS peramivir development contract) or termination of the NIAID/HHS and BARDA/HHS BCX4430 contracts could negatively impact the Company&#x2019;s future Consolidated Statements of Comprehensive Loss and Cash Flows. In addition, the Company also recognizes royalty revenue from the net sales of RAPIACTA by Shionogi; however, the underlying cash flow from these royalty payments goes directly to pay the interest, and then the principal, on the Company&#x2019;s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. Further, the Company&#x2019;s drug development activities are performed by a limited group of third party vendors. If any of these vendors were unable to perform their services, this could significantly impact the Company&#x2019;s ability to complete its drug development activities.</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Risks from Third Party Manufacturing and Distribution Concentration</div></div><div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 22.5pt">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27.35pt; margin: 0pt 0">The Company relies on single source manufacturers for active pharmaceutical ingredient and finished drug product manufacturing of RAPIVAB, as well as for its other product candidates in development. Delays in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling of RAPIVAB or the Company&#x2019;s product candidates in development.</div><div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Credit Risk</div></div><div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0 0pt 22.5pt">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately 18 months or less. Other than product sale and collaborative partner receivables discussed above, the majority of the Company&#x2019;s receivables from collaborations are due from the U.S. Government, for which there is no assumed credit risk.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Recent Accounting Pronouncements</div></div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In March 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update No. 2016-09: <div style="display: inline; font-style: italic;">Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</div> (&#x201c;ASU 2016-09&#x201d;). The amendments in this update simplify several aspects of the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures and statutory tax withholding requirements, as well as classification in the statement of cash flows. ASU 2016-09 will be effective for the Company in fiscal year 2017, but early adoption is permitted. The Company is currently evaluating the impact of this update on its consolidated financial statements.</div><div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In February 2016, the FASB issued Accounting Standards Update No. 2016-02: <div style="display: inline; font-style: italic;">Leases (Topic 842)</div> (&#x201c;ASU 2016-02&#x201d;). The amendments in this update require lessees, among other things, to recognize lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous authoritative guidance. This update also introduces new disclosure requirements for leasing arrangements. ASU 2016-02 will be effective for the Company in fiscal year 2019, but early adoption is permitted. The Company is currently evaluating the impact of this update on its consolidated financial statements.</div><div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In January 2016, the FASB issued Accounting Standards Update No. 2016-01: <div style="display: inline; font-style: italic;">Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</div> (&#x201c;ASU 2016-01&#x201d;). The amendments in this update address certain aspects of recognition, measurement, presentation and disclosure of financial instruments. In particular, the amendments in this update supersede, for public business entities, the requirement to disclose the methods and significant assumptions used in calculating the fair value of financial instruments required to be disclosed for financial instruments measured at amortized cost on the balance sheet. ASU 2016-01 will be effective for the Company in fiscal year 2018, but early adoption is permitted. The Company does not expect this standard to have a material impact on its consolidated financial statements.</div><div style=" font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 22.3pt; margin: 0pt 0">In November 2015, the FASB issued Accounting Standards Update No. 2015-17, <div style="display: inline; font-style: italic;">Balance Sheet Classification of Deferred Taxes</div>, requiring all deferred tax assets and liabilities, and any related valuation allowance, to be classified as noncurrent on the balance sheet. The classification change for all deferred taxes as noncurrent simplifies entities&#x2019; processes as it eliminates the need to separately identify the net current and net noncurrent deferred tax asset or liability in each jurisdiction and allocate valuation allowances. We elected to prospectively adopt the accounting standard in the beginning of our fourth quarter of fiscal 2015. Adoption of this standard had no impact on the Company&#x2019;s consolidated financial statements.</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In July 2015, the FASB issued Accounting Standards Update No. 2015-11: <div style="display: inline; font-style: italic;">Inventory (Topic 330): Simplifying the Measurement of Inventory</div> (&#x201c;ASU 2015-11&#x201d;), which changes the measurement principle for inventory from the lower of cost or market to the lower of cost and net realizable value. ASU 2015-11 defines net realizable value as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The update does not apply to inventory that is measured using last-in, first-out or the retail inventory method. The update applies to all other inventory, which includes inventory that is measured using first-in, first-out or average cost methods. The amendments in ASU 2015-11 will be effective for the Company for fiscal years, and the interim periods within those years, beginning after December 15, 2016. The amendments must be applied prospectively and early adoption is permitted. The Company does not expect this standard to have a material impact on its consolidated financial statements.</div><div style=" font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In April 2015, the FASB issued Accounting Standards Update No. 2015-03: <div style="display: inline; font-style: italic;">Interest &#x2013; Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs</div> (&#x201c;ASU 2015-03&#x201d;). This standard amends existing guidance to require the presentation of debt issuance costs in the balance sheet as a deduction from the carrying amount of the related debt liability instead of a deferred charge. It is effective for annual reporting periods beginning after December 15, 2015 and requires retrospective application for all periods presented. The Company adopted ASU 2015-03 in the first quarter of 2016. Adoption did not have a material impact on its consolidated financial statements.</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In August 2014, the FASB issued Accounting Standards Update No. 2014-15: <div style="display: inline; font-style: italic;">Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern</div> (&#x201c;ASU 2014-15&#x201d;) <div style="display: inline; font-style: italic;">,</div> which defines management&#x2019;s responsibility to evaluate, at each annual and interim reporting period, whether there are conditions or events that raise substantial doubt about an entity&#x2019;s ability to continue as a going concern within one year after the date the financial statements are issued and to provide related footnote disclosures in certain circumstances. In connection with each annual and interim period, management must assess if there is substantial doubt about the company&#x2019;s ability to continue as a going concern within one year after the issuance date.&nbsp;Disclosures are required if conditions give rise to substantial doubt.&nbsp;ASU 2014-15 is effective for all companies in the first annual period ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The Company is currently evaluating the impact this standard will have on its financial statements and disclosures.&nbsp;</div><div style=" font-size: 10pt; text-indent: 22.5pt; margin: 0pt 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">In May 2014, the FASB issued Standards Update No. 2014-09: <div style="display: inline; font-style: italic;">Revenue from Contracts with Customers (Topic 606) </div>(&#x201c;ASU 2014-09&#x201d;), which provides a single, comprehensive revenue recognition model for all contracts with customers. The core principal of this ASU is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. In July 2015, the FASB finalized a one year delay in the effective date of this standard, which will now be effective January 1, 2018; however, early adoption is permitted any time after the original effective date, January 1, 2017. Companies can transition to the new standard under the full retrospective method or the modified retrospective method. The Company is currently evaluating the impact this standard will have on its consolidated financial statements.&nbsp;</div></div></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AccruedExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents accrued expenses policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AccruedExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ConcentrationOfMarketRiskPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents concentration of market risk policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ConcentrationOfMarketRiskPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CurrencyHedgeAgreementPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents currency hedge agreement policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CurrencyHedgeAgreementPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DescriptionOfCompanyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of company policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DescriptionOfCompanyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents interest expense and deferred financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4492-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4556-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investments in financial assets, including marketable securities (debt and equity securities with readily determinable fair values), investments accounted for under the equity method and cost method, securities borrowed and loaned, and repurchase and resale agreements. For marketable securities, the disclosure may include the entity's accounting treatment for transfers between investment categories and how the fair values for such securities are determined. Also, for all investments, an entity may describe its policy for assessing, recognizing and measuring impairment of the investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2,12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.M)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877573&amp;loc=d3e87990-122713<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6872867&amp;loc=d3e40691-111596<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangements (both lessor and lessee). This disclosure may address (1) lease classification (that is, operating versus capital), (2) how the term of a lease is determined (for example, the circumstances in which a renewal option is considered part of the lease term), (3) how rental revenue or expense is recognized for a lease that contains rent escalations, (4) an entity's accounting treatment for deferred rent, including that which arises from lease incentives, rent abatements, rent holidays, or tenant allowances (5) an entity's accounting treatment for contingent rental payments and (6) an entity's policy for reviewing, at least annually, the residual values of sales-type and direct-finance leases. The disclosure also may indicate how the entity accounts for its capital leases, leveraged leases or sale-leaseback transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6453394&amp;loc=d3e39740-112701<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65670824&amp;loc=d3e14754-158437<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6456037&amp;loc=d3e48589-112741<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for trade and other accounts receivable, and finance, loan and lease receivables, including those classified as held for investment and held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the valuation allowance for receivables is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions (8) the nature and amount of any guarantees to repurchase receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65890831&amp;loc=d3e10133-111534<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66008989&amp;loc=d3e4975-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6908066384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Available-for-sale Securities [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June&nbsp;30, 2016</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amortized<br /> Cost</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accrued<br /> Interest</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br /> Unrealized<br /> Gains</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br /> Unrealized<br /> Losses</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Estimated<br /> Fair&nbsp;Value</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt">Obligations of the U.S. Government and its agencies</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">14,081</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">38</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">8</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">&#x2014;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">14,127</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Corporate debt securities</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">16,641</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">147</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">23</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(1</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">16,810</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt">Certificates of deposit</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">20,258</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">22</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">23</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(7</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">20,296</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">50,980</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">207</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">54</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(8</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">51,233</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="19" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31, 2015</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amortized<br /> Cost</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accrued<br /> Interest</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br /> Unrealized<br /> Gains</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<br /> Unrealized<br /> Losses</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Estimated<br /> Fair&nbsp;Value</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt; width: 35%">Obligations of the U.S. Government and its agencies</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">26,557</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">88</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">&#x2014;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">(99</td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">26,546</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Corporate debt securities</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">21,820</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">184</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(41</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">21,963</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt">Certificates of deposit</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21,884</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(72</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21,838</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">70,261</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">293</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(212</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">70,347</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock', window );">Available For Sale Securities Debt Maturities Fair Value [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; font-size: 10pt; text-align: left">Maturing in one year or less</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">27,079</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">22,664</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Maturing after one year through two years</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">18,164</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">28,395</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Maturing after two years</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5,990</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">19,288</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">51,233</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">70,347</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock', window );">Schedule of Receivables from Collaborations [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June&nbsp;30, 2016</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Billed</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Unbilled</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">723</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">1,273</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">1,996</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Shionogi&nbsp;&amp; Co. Ltd.</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">145</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">145</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Seqirus UK Limited</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">37</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">56</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">93</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total receivables</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">905</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">1,329</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">2,234</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31, 2015</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Billed</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Unbilled</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%; font-size: 10pt; text-align: left">U.S. Department of Health and Human Services</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">&#x2014;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">5,536</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">5,536</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Shionogi&nbsp;&amp; Co. Ltd.</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">469</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">469</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Seqirus UK Limited</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">210</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">28</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">238</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total receivables</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">679</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">5,564</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">6,243</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; font-size: 10pt; text-align: left; padding-bottom: 1pt">Work in process</td> <td style="width: 1%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,949</td> <td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,612</td> <td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.25pt">Inventories</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">1,949</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">1,612</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock', window );">Schedule of Revenues from Collaborations [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; font-size: 10pt; text-align: left">Product sales, net</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">&#x2014;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">&#x2014;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">&#x2014;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">537</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Royalty revenue</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">629</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">132</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">2,519</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,650</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Collaborative and other research and development revenues:</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 20pt">U.S. Department of Health and Human Services</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">3,709</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">3,731</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">6,033</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">8,206</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Shionogi (Japan)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">296</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">296</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">592</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">592</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Seqirus UK Limited</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">153</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21,683</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">463</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21,683</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total collaborative and other research and development revenues</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,158</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">25,710</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7,088</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">30,481</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total revenues</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">4,787</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">25,842</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">9,607</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">32,668</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available for sale securities debt maturities fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure representing receivables from collaborations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of schedule of revenues from collaborations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62557-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27198-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27357-111563<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6910147600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of Share-based Compensation, Activity [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Awards<br /> Available</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options<br /> Outstanding</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted<br /> Average<br /> Exercise<br /> Price</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%; font-size: 10pt">Balance December&nbsp;31, 2015</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 10%; font-size: 10pt; text-align: right">16</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 10%; font-size: 10pt; text-align: right">10,671</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">7.50</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Plan amendment</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">3,800</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Restricted stock unit awards granted</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(21</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Restricted stock unit awards cancelled</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">15</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Stock option awards granted</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(2,120</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">2,120</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">3.21</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Stock option awards exercised</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&#x2014;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(79</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">2.32</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Stock option awards cancelled</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">499</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(499</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">11.24</td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.25pt">Balance June&nbsp;30, 2016</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">2,189</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">12,213</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">$</td> <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: right">6.63</td> <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; font-size: 10pt; text-align: left">Expected Life in Years</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 10%; font-size: 10pt; text-align: right">5.6</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 10%; font-size: 10pt; text-align: right">5.5</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Expected Volatility</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">82</td> <td style="font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">83</td> <td style="font-size: 10pt; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Expected Dividend Yield</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">0.0</td> <td style="font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">0.0</td> <td style="font-size: 10pt; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Risk-Free Interest Rate</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1.4</td> <td style="font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1.5</td> <td style="font-size: 10pt; text-align: left">%</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based compensation plans that may be presented in a single table for outstanding, vested and expected to vest, and exercisable awards. The information that may be disclosed in this table may include, but is not limited to, number of shares, weighted average exercise price, weighted average remaining contractual life, and aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6754609424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies (Details Textual)<br> $ / shares in Units, shares in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 09, 2011 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember', window );">Currency Hedge Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollateralAlreadyPostedAggregateFairValue', window );">Collateral Already Posted, Aggregate Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,610,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,610,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueAdditions', window );">Deferred Revenue, Additions</a></td>
<td class="nump">$ 3,740,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLossOnDerivative', window );">Derivative, Loss on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,441,000<span></span>
</td>
<td class="nump">$ 332,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Derivative, Gain on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 811,000<span></span>
</td>
<td class="nump">1,545,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Sales Revenue, Product Line [Member] | RAPIVAB [Member] | Three Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Sales Revenue, Product Line [Member] | RAPIVAB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_NumberOfMajorCustomers', window );">Number of Major Customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=bcrx_RAPIVABMember', window );">RAPIVAB [Member] | Agreement [Member] | CSL [Member] | Contingent upon EU Marketing Approval [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Proceeds from License Fees Received</a></td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=bcrx_RAPIVABMember', window );">RAPIVAB [Member] | Agreement [Member] | CSL [Member] | Regulatory Support Revenue for Canadian and EU Marketing Approvals, Portion Recognized Ratably Over Expected Period of Involvement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueAdditions', window );">Deferred Revenue, Additions</a></td>
<td class="nump">1,223,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=bcrx_RAPIVABMember', window );">RAPIVAB [Member] | Agreement [Member] | CSL [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Proceeds from License Fees Received</a></td>
<td class="nump">33,740,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">21,777,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MilestonePaymentMaximum', window );">Milestone Payment Maximum</a></td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember', window );">JPR Royalty Sub LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized', window );">Revenue Recognition Royalty and Milestone Revenue Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementEarlyAdoptionAxis=bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember', window );">Debt Issuance Costs Reclassifed from Other Current Assets [Member] | December 31, 2015 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustment', window );">Prior Period Reclassification Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,196,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_RoyaltyReceivableMember', window );">Royalty Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted Cash and Cash Equivalents, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,022,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,022,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_CollateralForCreditMember', window );">Collateral for Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted Cash and Cash Equivalents, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,404,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,404,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaturityPeriodOfHighQualityMarketablesecurities', window );">Maturity Period of High Quality Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities', window );">Average Maturity Period of High Quality Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaturityperiodOfShortTermInvestment', window );">Maturity Period of Short Term Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AveragematurityForPortfolioInvestments', window );">Average Maturity for Portfolio Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaturityperiodOfShortTermInvestment', window );">Maturity Period of Short Term Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_LongtermInvestmentMaturityMinimum', window );">Long-term Investment Maturity, Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember', window );">Laboratory Equipment, Office Equipment and Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member] | Birmingham Research Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years 182 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,589,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,589,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_LeaseFinancingObligationNetOfCurrent', window );">Lease Financing Obligation, Net of Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,589,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,589,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bcrx_PhaRMANotesMember', window );">PhaRMA Notes Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,338,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,306,000<span></span>
</td>
<td class="nump">2,677,000<span></span>
</td>
<td class="nump">2,621,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=bcrx_BirminghamResearchFacilityMember', window );">Birmingham Research Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue', window );">Capital Leases, Future Minimum Payments Due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,839,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,839,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossOnSaleOfInvestments', window );">Loss on Sale of Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of Debt Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
<td class="nump">220,000<span></span>
</td>
<td class="nump">220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Investments and Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaturityOfInvestments', window );">Maturity of Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted Cash and Cash Equivalents, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,426,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,426,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,612,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,787,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,842,000<span></span>
</td>
<td class="nump">9,607,000<span></span>
</td>
<td class="nump">32,668,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,421,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,306,000<span></span>
</td>
<td class="nump">2,891,000<span></span>
</td>
<td class="nump">$ 2,621,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_LeaseFinancingObligationNetOfCurrent', window );">Lease Financing Obligation, Net of Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,589,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,589,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings Per Share, Diluted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings Per Share, Basic | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,091<span></span>
</td>
<td class="nump">4,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AveragematurityForPortfolioInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average maturity for portfolio investments during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AveragematurityForPortfolioInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average maturity period of high quality marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AveragematurityPeriodOfHighQualityMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_LeaseFinancingObligationNetOfCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease Financing obligation as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_LeaseFinancingObligationNetOfCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_LongtermInvestmentMaturityMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents long term investment maturity minimum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_LongtermInvestmentMaturityMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaturityOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents maturity of investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaturityOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaturityPeriodOfHighQualityMarketablesecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents maturity period of high quality marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaturityPeriodOfHighQualityMarketablesecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaturityperiodOfShortTermInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maturity period of short term investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaturityperiodOfShortTermInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MilestonePaymentMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents milestone payment maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MilestonePaymentMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_NumberOfMajorCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of major customers accounting for 10% or more of the specified concentration risk benchmark, which includes, but not limited to, sales revenue, accounts receivable, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_NumberOfMajorCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition royalty and milestone revenue recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAlreadyPostedAggregateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4H<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAlreadyPostedAggregateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6351-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13531-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6404-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a),(c),(d),(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLossOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5618551-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a),(c),(d),(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLossOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying value and the sale price of an investment.  A loss would be recognized when the sale price of the investment is less than the carrying value of the investment. This element refers to the Loss included in earnings and not to the cash proceeds of the sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a reclassification adjustment made to prior period financial statement amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=bcrx_RAPIVABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=bcrx_RAPIVABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=bcrx_ThreeCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=bcrx_ThreeCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=bcrx_CSLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=bcrx_CSLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=bcrx_ContingentUponEuMarketingApprovalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=bcrx_ContingentUponEuMarketingApprovalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_RegulatorySupportRevenueForCanadianAndEUMarketingApprovalsPortionRecognizedRatablyOverExpectedPeriodOfInvolvementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementEarlyAdoptionAxis=bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementEarlyAdoptionAxis=bcrx_DebtIssuanceCostsReclassifedFromOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreationDateAxis=bcrx_December312015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreationDateAxis=bcrx_December312015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_RoyaltyReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_RoyaltyReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_CollateralForCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_CollateralForCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=bcrx_BirminghamResearchFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=bcrx_BirminghamResearchFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bcrx_PhaRMANotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bcrx_PhaRMANotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6742391200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Fair Value of the Company's Investments by Type (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Agencies Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">$ 14,081<span></span>
</td>
<td class="nump">$ 26,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">8<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(99)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">14,127<span></span>
</td>
<td class="nump">26,546<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">16,641<span></span>
</td>
<td class="nump">21,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">23<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">16,810<span></span>
</td>
<td class="nump">21,963<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">20,258<span></span>
</td>
<td class="nump">21,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(72)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">20,296<span></span>
</td>
<td class="nump">21,838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">50,980<span></span>
</td>
<td class="nump">70,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
<td class="nump">207<span></span>
</td>
<td class="nump">293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(212)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 51,233<span></span>
</td>
<td class="nump">$ 70,347<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AvailableForSaleSecuritiesAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents available for sale securities accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AvailableForSaleSecuritiesAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65884222&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6910525760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Scheduled Maturity for the Company's Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturing in one year or less</a></td>
<td class="nump">$ 27,079<span></span>
</td>
<td class="nump">$ 22,664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue', window );">Maturing after one year through two years</a></td>
<td class="nump">18,164<span></span>
</td>
<td class="nump">28,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears', window );">Maturing after two years</a></td>
<td class="nump">5,990<span></span>
</td>
<td class="nump">19,288<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Total investments</a></td>
<td class="nump">$ 51,233<span></span>
</td>
<td class="nump">$ 70,347<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents available for sale securities debt maturities after one through two years fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents debt maturities after two years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65884222&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of available-for-sale debt securities maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6739062800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Summary of Receivables (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">US Department of Health and Human Services [Member] | Billed Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">$ 723<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">US Department of Health and Human Services [Member] | Unbilled Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">1,273<span></span>
</td>
<td class="nump">5,536<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">US Department of Health and Human Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">1,996<span></span>
</td>
<td class="nump">5,536<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_ShionogiAndCoLtdMember', window );">Shionogi and Co. Ltd [Member] | Billed Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">469<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_ShionogiAndCoLtdMember', window );">Shionogi and Co. Ltd [Member] | Unbilled Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_ShionogiAndCoLtdMember', window );">Shionogi and Co. Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">469<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_SeqirusUKLimitedMember', window );">Seqirus UK Limited [Member] | Billed Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_SeqirusUKLimitedMember', window );">Seqirus UK Limited [Member] | Unbilled Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_SeqirusUKLimitedMember', window );">Seqirus UK Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">93<span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember', window );">Billed Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">905<span></span>
</td>
<td class="nump">679<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember', window );">Unbilled Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">1,329<span></span>
</td>
<td class="nump">5,564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">$ 2,234<span></span>
</td>
<td class="nump">$ 6,243<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e604059-122996<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_ShionogiAndCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_ShionogiAndCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_SeqirusUKLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_SeqirusUKLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6910209744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">$ 1,949<span></span>
</td>
<td class="nump">$ 1,612<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">$ 1,949<span></span>
</td>
<td class="nump">$ 1,612<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6749250816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Summary of Revenues (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">US Department of Health and Human Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues', window );">Collaborative and other research and development revenues</a></td>
<td class="nump">$ 3,709<span></span>
</td>
<td class="nump">$ 3,731<span></span>
</td>
<td class="nump">$ 6,033<span></span>
</td>
<td class="nump">$ 8,206<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=bcrx_ShionogiAndCoLtdMember', window );">Shionogi and Co. Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues', window );">Collaborative and other research and development revenues</a></td>
<td class="nump">296<span></span>
</td>
<td class="nump">296<span></span>
</td>
<td class="nump">592<span></span>
</td>
<td class="nump">592<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=bcrx_SeqirusUKLimitedMember', window );">Seqirus UK Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues', window );">Collaborative and other research and development revenues</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">21,683<span></span>
</td>
<td class="nump">463<span></span>
</td>
<td class="nump">21,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product sales, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenue</a></td>
<td class="nump">629<span></span>
</td>
<td class="nump">132<span></span>
</td>
<td class="nump">2,519<span></span>
</td>
<td class="nump">1,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues', window );">Collaborative and other research and development revenues</a></td>
<td class="nump">4,158<span></span>
</td>
<td class="nump">25,710<span></span>
</td>
<td class="nump">7,088<span></span>
</td>
<td class="nump">30,481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 4,787<span></span>
</td>
<td class="nump">$ 25,842<span></span>
</td>
<td class="nump">$ 9,607<span></span>
</td>
<td class="nump">$ 32,668<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents collaborative and other research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=bcrx_ShionogiAndCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=bcrx_ShionogiAndCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=bcrx_SeqirusUKLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=bcrx_SeqirusUKLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6750054992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Stock-based Compensation (Details Textual)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2013 </div>
<div>shares</div>
</th>
<th class="th"><div>Jan. 31, 2013</div></th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Employee Stock Option [Member] | Vest 25% Each Year Until Fully Vested [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Employee Stock Option [Member] | Non-employee Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate', window );">Share-based Compensation Arrangement by Share-based Payment Award, First Vesting Period After Grant Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Employee Stock Option [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Employee Stock Option [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Stock Options and Restricted Stock [Member] | Vest 50% Each Year Until Fully Vested [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Performance Shares [Member] | Vest Upon Successful Completion of Specific Development Milestones [Member] | August 2013 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_NumberOfMilestonesAchieved', window );">Number of Milestones Achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage', window );">Share-based Compensation Arrangement by Shar-based Payment Award, Awards Unvested, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Performance Shares [Member] | Vest Upon Successful Completion of Specific Development Milestones [Member] | December 2014 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage', window );">Share-based Compensation Arrangement by Shar-based Payment Award, Awards Unvested, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Performance Shares [Member] | Vest Upon Successful Completion of Specific Development Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">1,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,402<span></span>
</td>
<td class="nump">$ 5,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.18<span></span>
</td>
<td class="nump">$ 8.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum', window );">Percentage of Salary to Purchase Common Stock, Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PercentageOfCommonStockSharesBeginning', window );">Percentage of Common Stock Shares, Beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PercentageOfCommonStockSharesEnding', window );">Percentage of Common Stock Shares, Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount', window );">Shar-based Compensation Arrangement by Shar-based Payment Award, Maximum Number of Shares Per Employee, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Stock Issued During Period, Shares, Employee Stock Purchase Plans | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_NumberOfStockbasedCompensationPlans', window );">Number of Stock-based Compensation Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,491<span></span>
</td>
<td class="nump">$ 5,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear', window );">Employee Service Share-based Compensation Nonvested Awards Compensation Cost Expected to be Recognized For Remainder of Fiscal Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards compensation cost expected to be recognized for remainder of fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards compensation cost expected to be recognized year five.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards compensation cost expected to be recognized year four.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards compensation cost expected to be recognized year three.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards compensation cost expected to be recognized year two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_NumberOfMilestonesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of milestones achieved.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_NumberOfMilestonesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_NumberOfStockbasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of stock based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_NumberOfStockbasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PercentageOfCommonStockSharesBeginning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of common stock shares beginning.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PercentageOfCommonStockSharesBeginning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PercentageOfCommonStockSharesEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of common stock shares ending.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PercentageOfCommonStockSharesEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of salary to purchase common stock maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents share-based compensation arrangement by share-based payment award maximum value per employee amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ShareBasedCompensationArrangementBySharbasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award first vesting period after grant date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of performance awards that remain unvested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_SharebasedCompensationArrangementBySharbasedPaymentAwardAwardsUnvestedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=bcrx_Vest25PercentEachYearUntilFullyVestedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=bcrx_Vest25PercentEachYearUntilFullyVestedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=bcrx_NonEmployeeDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=bcrx_NonEmployeeDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bcrx_StockOptionsAndRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bcrx_StockOptionsAndRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=bcrx_Vest50PercentEachYearUntilFullyVestedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=bcrx_Vest50PercentEachYearUntilFullyVestedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=bcrx_August2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=bcrx_August2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=bcrx_December2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=bcrx_December2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6750717808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Stock Incentive Plan Activities (Details) - Incentive Plan [Member]<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2016 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock unit awards granted (in shares)</a></td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Restricted stock unit awards cancelled (in shares)</a></td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Awards Available (in shares)</a></td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding (in shares)</a></td>
<td class="nump">10,671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 7.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Plan amendment (in shares)</a></td>
<td class="nump">3,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable', window );">Stock option awards granted (in shares)</a></td>
<td class="num">(2,120)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock option awards granted (in shares)</a></td>
<td class="nump">2,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Stock option awards granted (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option awards exercised (in shares)</a></td>
<td class="num">(79)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Stock option awards exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable', window );">Stock option awards cancelled (in shares)</a></td>
<td class="nump">499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Stock option awards cancelled (in shares)</a></td>
<td class="num">(499)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Stock option awards cancelled (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 11.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Awards Available (in shares)</a></td>
<td class="nump">2,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding (in shares)</a></td>
<td class="nump">12,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.63<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents share based compensation arrangement by share based payment award options grants in period awards available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options forfeitures in period awards available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under an established share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6633166144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Weighted Average Assumptions (Details) - Incentive Plan [Member]<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Life in Years</a></td>
<td class="text">5 years 219 days<span></span>
</td>
<td class="text">5 years 182 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility</a></td>
<td class="nump">82.00%<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected Dividend Yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-Free Interest Rate</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6749693152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Collaborative and Other Research and Development Contracts (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">34 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 16, 2015</div></th>
<th class="th"><div>Sep. 30, 2013</div></th>
<th class="th"><div>Jun. 30, 2006</div></th>
<th class="th"><div>Feb. 28, 2006</div></th>
<th class="th"><div>Jun. 30, 2000</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_BaseContractMember', window );">Base Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GovernmentContractReceivable', window );">Government Contract Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,265,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_AdditionalDevelopmentOptionsMember', window );">Additional Development Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GovernmentContractReceivable', window );">Government Contract Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,855,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_ASPRBARDAContractMember', window );">ASPRBARDA Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GovernmentContractReceivable', window );">Government Contract Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,120,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts', window );">Proceeds from awards for Research and Development Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,574,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_GreenCrossCorporationMember', window );">Green Cross Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Proceeds from License Fees Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_MundipharmaMember', window );">Mundipharma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_UpfrontPaymentsReceivableAmount', window );">Upfront Payments Receivable Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember', window );">AECOM and IRL [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MilestonePaymentMaximum', window );">Milestone Payment Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MilestonePaymentMinimum', window );">Milestone Payment Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AnnualLicenseFeeMinimum', window );">Annual License Fee Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AnnualLicenseFeeMaximum', window );">Annual License Fee Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AdvanceNoticePeriodForTerminationOfAgreement', window );">Advance Notice Period for Termination of Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember', window );">National Institute of Allergy and Infectious Diseases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts', window );">Proceeds from awards for Research and Development Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts', window );">Expected Receivable From Awards for Research and Development Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,477,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborationAgreementAdditionalPaymentsReceived', window );">Collaboration Agreement Additional Payments Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,350<span></span>
</td>
<td class="nump">$ 35,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_UABMember', window );">UAB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PeriodOfAgreement', window );">Period of Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">25 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RenewablePeriodOfAgreement', window );">Renewable Period of Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=bcrx_CSLLimitedMember', window );">CSL Limited [Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Proceeds from License Fees Received</a></td>
<td class="nump">$ 33,740,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MilestonePaymentMaximum', window );">Milestone Payment Maximum</a></td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyTerm', window );">Royalty Term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AdvanceNoticePeriodForTerminationOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents advance notice period for termination of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AdvanceNoticePeriodForTerminationOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AnnualLicenseFeeMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents annual maximum license fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AnnualLicenseFeeMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AnnualLicenseFeeMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent minimum annual license fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AnnualLicenseFeeMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CollaborationAgreementAdditionalPaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents collaboration agreement additional payments received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CollaborationAgreementAdditionalPaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents expected receivable from awards for research and development contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MilestonePaymentMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents milestone payment maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MilestonePaymentMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MilestonePaymentMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents milestone payment minimum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MilestonePaymentMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PeriodOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents period of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PeriodOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents proceeds from awards for research and development contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RenewablePeriodOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents renewable period of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RenewablePeriodOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between the date of the Agreement and its expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_UpfrontPaymentsReceivableAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents upfront payments receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_UpfrontPaymentsReceivableAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentContractReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of receivables that are derived from government contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68054760&amp;loc=d3e55295-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentContractReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_BaseContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_BaseContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_AdditionalDevelopmentOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_AdditionalDevelopmentOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_ASPRBARDAContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_ASPRBARDAContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_GreenCrossCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_GreenCrossCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_MundipharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_MundipharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_UABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_UABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=bcrx_CSLLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=bcrx_CSLLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6751705328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Royalty Monetization (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 18, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 09, 2011 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 18, 2016 </div>
<div>JPY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_JPRRoyaltySubLLCMember', window );">JPR Royalty Sub LLC [Member] | Royalty Monetization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized', window );">Revenue Recognition Royalty and Milestone Revenue Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet', window );">Revenue Recognition Royalty And Milestone Revenue Recognized, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,691,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_TransactionCosts', window );">Transaction Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,309,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_Interestreserve', window );">Interest Reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_JPRRoyaltySubLLCMember', window );">JPR Royalty Sub LLC [Member] | PhaRMA Notes Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes Payable, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_JPRRoyaltySubLLCMember', window );">JPR Royalty Sub LLC [Member] | PhaRMA Notes Member] | Currency Hedge Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollateralAlreadyPostedAggregateFairValue', window );">Collateral Already Posted, Aggregate Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,610,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaximumAmountOfCollateralRequiredToPost', window );">Maximum Amount of Collateral Required to Post</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_JPRRoyaltySubLLCMember', window );">JPR Royalty Sub LLC [Member] | PhaRMA Notes Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PrivatePlacementOfSeniorSecuredNotes', window );">Private Placement of Senior Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember', window );">PhaRMA Notes Member] | JPR Royalty Sub LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PercentageOfCarryingAmountInExcessOfFairValue1', window );">Percentage of Carrying Amount in Excess of Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember', window );">PhaRMA Notes Member] | Japan, Yen [Member] | Currency Hedge Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeForwardExchangeRate1', window );">Derivative, Forward Exchange Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember', window );">PhaRMA Notes Member] | Currency Hedge Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities', window );">Payments for (Proceeds from) Hedge, Investing Activities</a></td>
<td class="nump">$ 1,950,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RequiredForeignCurrencyHedgePerDollar', window );">Required Foreign Currency Hedge Per Dollar | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember', window );">JPR Royalty Sub LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized', window );">Revenue Recognition Royalty and Milestone Revenue Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember', window );">Currency Hedge Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollateralAlreadyPostedAggregateFairValue', window );">Collateral Already Posted, Aggregate Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,610,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLossOnDerivative', window );">Derivative, Loss on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,441,000<span></span>
</td>
<td class="nump">$ 332,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_Interestreserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents interest reserve established as part of the royalty monetization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_Interestreserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaximumAmountOfCollateralRequiredToPost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents maximum amount of collateral required to post.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaximumAmountOfCollateralRequiredToPost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PercentageOfCarryingAmountInExcessOfFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of carrying amount in excess of fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PercentageOfCarryingAmountInExcessOfFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PrivatePlacementOfSeniorSecuredNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents private placement of senior secured notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PrivatePlacementOfSeniorSecuredNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RequiredForeignCurrencyHedgePerDollar">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Company is required to maintain a foreign currency hedge per dollar under the agreements governing the PhaRMA Notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RequiredForeignCurrencyHedgePerDollar</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents revenue recognition royalty and milestone revenue recognized, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition royalty and milestone revenue recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RevenuerecognitionRoyaltyAndMilestoneRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_TransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents transaction costs associated with royalty monetization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_TransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAlreadyPostedAggregateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4H<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAlreadyPostedAggregateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeForwardExchangeRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual rate at which a foreign currency can be purchased or sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeForwardExchangeRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLossOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5618551-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a),(c),(d),(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLossOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow or inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 27<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3581-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3098-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3095-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromHedgeInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_JPRRoyaltySubLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_JPRRoyaltySubLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=bcrx_RoyaltyMonetizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=bcrx_RoyaltyMonetizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=bcrx_JapanYenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=bcrx_JapanYenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6910852896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 5 - Stockholders' Equity (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 03, 2015</div></th>
<th class="th"><div>Nov. 06, 2013</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaximumAggregateOfferingPrice', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RemainingAggregateOfferingPrice', window );">Remaining Aggregate Offering Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaximumAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum aggregate offering price of common stock, preferred stock, depository shares, stock purchase contracts, warrants and units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaximumAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RemainingAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the remaining aggregate offering price of common stock, preferred stock, depository shares, stock purchase contracts, warrants and units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RemainingAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>47
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M>@"%,;X[)9J4@B,WHX*[O]C\ E!+ P04    "  G?0A)>Q>T)50!  !8$
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MKP$[4$2/ =$]  8WD;''C^WQO3T&>VSLB6M^H-B"(GT,2)R Q-BS>T!G%"D
M0+%:X2Q?0$F=E!1BS"P#%/EC0.8$9) &SDRQ!"M9D"HK)V(%?F>N6(25+$B6
MW(G(P1_/(*PD>8Q H9-AAE6$= 8R:K(%%.2FV+J<^^2C9@D%NRE0G"C_.GUW
M5I-%61@F,5[ BMPLJ&0\EV*C9D&.(7>](RAG/)=EHV9!FB%WT2.H:1S/E/VH
M"=&"JD?NLD=0U=CY_Y58CM4LH;AK'T%EXVQNSZQF]8D2W)Q*+>5G<UH+[\ N
MG81#:1J=;@0;<VX&'_*RZ,F9_B+\7'?"VS.ISD9SA)T8DU3APR>UV$K=6:9.
M0T]2/V9Z%^ 4AXYD_7@IF6Y&Y7]02P,$%     @ )WT(2;6,C@,7!   /A0
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MB%5@G.VUS4!-<V$5X]PF,H7_7'/^+VD#[_MC]F]NM<9^1Q6K!/_=''1M9$F
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MNEC'*Q43B\/R0-976OX'4$L#!!0    ( "=]"$EY %:PI@$  +$#   9
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MWDC1145ES@WC*(4N*CIFC!2"4K)1QMR=(\'K8S1=>S36'A,(M4*02N7$A/0
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MY-]'RL2TC>)HGGCI#YVV$[ JX=G7])P.JA<#D+3=1M_B39U9A1/\[NFD+OK
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M[#@&HY!?BC\#$(0 )0$2_A1 (3$ 4#Z7 L#@@#Q"_A1 $ ,T"Y#PYP *"0*
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MV]6E#?&],O]E/D_5^'DU?TE##*,#  -@"@!W@,0 R0U0&*"F *&< 1$&1%.
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M0IUS.]+8"\E.XX0VC8GU?U!+ P04    "  G?0A)!HZT!O$!  ";!0  &0
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M"[6=T/W[]05H4J7M"YZQSSESQF:J49M7VP,X]"Z%LEO<.S=L"+'['B2S-WH
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M\_GHU2-TQ$:92!]0+N:/MD ZA_X#BX<^,;IJE[ND 96CZ96>'ZJ[; UR=D#
MG'LI!!/W^@!R]*Q>LF:S@GO7%4GH_G-=#PSOU8"0/*] 0,*R;WGX30+[TEF0
M#X\<PA_R,D>S!R_+5INB)+.J1V3I6O3/ ?61C(R)(=$N9"%LDQ0QN:E7"1,]
MP*\IWSAXX8 V)6^]!JLX <J_>K2$_OV[?"?,?>#5+[*F6"+1A)?1@5_*04,R
M?R0W>%FL6SQ:O]H#_P(SO<$G9I]AF<% [)[W-%G0).XY]H]ZRDK&?L]S/I5U
MGJV9KZV#/<D^9\4:E3+<'3J+,/%!;3[B-?=MT'T<"ZV-U^OJMNEG4!TMVI%W
MM@1BZ54-D6!P.%V5X_M6)I/LJ@054M#F8):EW(#?XF<R@=H&!HL+T_/&CCKW
M,H>U6!:L!-,)WJ!)_].PBCB"#2?U>8/'Y5Y#Y,P\"]?L9;[8D;5.&@0RH>Y4
MHUM@=)NBW7RS OL6[0+<[OOV]B8KKW'WDZNL4%D*CWG"J>5'--$*DH5#"V1T
MJ,YJ&D/Q";9?O_D4&T*\.P]8/\:XZ+=GE$CVA$KV409\+D >)HN[7I+IMY/O
MO^9L"8ID0VIR(W*FQ]H<WKSZ?E/]?0MB*<-%A&??0PV7*)7IG9MLU]:L]]Y_
MBUL@NRS%(Z;\VIE8P]?@>/#]RT")ZE$:<!0P@&6>KYS'P=^B:EH+:DS-7_4=
MRBTHZETRS.[(X7/_F6#C>(=BO;O]RYIL2MBF]:.-RP?H[NH1B[?W,N<W$[-V
M8U@^UOTSZ"=*LEVRR*^+LJ0Y7*% !%/F2??G>)B'[GQ7[?)D"J+A$I:[ %,.
M?<YRO/&5[T'$+/O$ ?D;@+4+;8&2Y&50A[;N?W;R[Q_S+[ODQ1J()?:(][L2
M9-1H(S_T[(\W.6GP67F7O"BJ\_H.U*GW(,4W\,R6S;\4U?EQL@<<#Y[Y-[G\
MEY__#ML)2Y@L"GC?\J:LUM7U'1$R/FUW XN[RAL8 #RAVNZ*#2@ C55)FZ2L
MX$/2;++U.ME4ZWS9PC%;U>UUP_<O<-+)#_D=;--/0/[(VS]7Z\\L)G% VPQ,
MIFO08YN"& 1(&Z2O9AQ,[0J]JLA!^*8=T.!.#U.-6I7>AH^]O2E =6[,RK7E
M!D[!)E_A>L"IQ[.=?RE$107-!L[B;;&[20J@J66V#4UUY/@@&9L\'--MUI#N
M4F\K]MO#JU_FZ^P6QP.?IZ<G[-3 A][DV>K'-JOA8*.M!ZK#TMW3UC?9)DW>
M@?B] >6FAKTML_!=!6C*U_B6AN:/(KG8PF7,5&$#<>O29(G;#WM1P;7;&_B"
MIER@PP3C4&@=L"# 30:EKX9-6^5KI"B@=1+TGU$J^BV.]W8;DA:,IJ[:ZQO>
M2F2;H!%QC !6!UX')DY;YZ/KEO@-4H;0U-B3ZPTO9$O2$W4J6?<ROQ:6B,?^
MBA2^R/2 749]!O_:XA?P5.+&J*K@5HJ'Q M7XLPI#5?7%K<7#;&"1]*T5^CR
M85<BL!K0+F$A'740V>"3<%!I+"YYO[V,P]UY=G20SF=@W<(2@_8(-X-BA(_"
ML6 0Q4Q'EW-3K$9@#!\'5/#+S_^[\6-B,DZ9@HE>[_ -V6I5XR; J4*_*5]S
M6\ >KC'0M+X#A@M; 'L/YB*+ %R,IEW2WJ&(QJ&)<;U$(V%%=(?OP8-LS%'Z
MKLZOT5=6 66AXK-K]&1?M;CU8V ^256CN(SG;[>Q7:!!L@-&2R.\JU!SD$7
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MP20,^GXZ.P9J4HT[M@3@"!T=3.&ZXV0V3_:FR3Y^=3*=).?];A&833H[/$G
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MQ,$4^ESK/0<@%,*/4R^?&_7R+^'!8=%Z<$K_'H%&?&&(,_XM0"IXI;4C23^
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MG])L(#4^P6@&03';_0#MJ7AW.).""Z$5HYGYK7TZKH6V2%PQ2*#H5U)'[K!
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M2Z3)$/X-%L&A5";.;[(#.JWYC!GGBFM&S$#8/-:D:_=&;OGH<M^Y/HZ1W%
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M8:=](051H&3DO>T\'GZ0:V%J&FK6@ZU!0DL2^&E29[<N_@NGG:IVI4)SR78
M?:7"D:KR:!38'BRG&C),?LMCZEAPA?:N\=MB#/)H7LH& N(V9&):H1"+N,*^
M7_)D8LRF:"[J[KM!O6]KW94VI9$3DV'#-<'*=_;CVI6^D<;.)F9>$C-W9\LV
MU;$]'CJRJ<RO@;]($<%G%'020)&-M9O, ]/,$=SEMB3S2Q&1I*+E?8AVVPQ(
M28[RXIRD=:ZJZ;SXOJM?7M:5=/3$I OIYN@XL,A,;3,1+)DI;%7;I6Y-0)EH
M)ZK2=F2PT^1W%;THDJ7FW\6C%;&Z(QB<[&""\?2B^%3\5!B6:-[,VT-A:OH2
M&Q;O3-3X';"!16Z"43J7'N<5\SGEF'4KT*N2;M<+O'.?_[-;#M 5#[8*@ V(
MWEJ HK;5 #Y5IT?#I_2,C]F7IRCS_B[1/U5INE.W"JJ]37^]CJG*XPQ\>M8.
MG^7ATBC=DUVN*ZWSA4N</84Y5$91BY*<//Q3@76Y.5FY"H ]6+D'CV>FARL_
M\!Y)J-J )4_HU=Z[E)>,<XZ/J5T1_CJ[-6D<D67I(-&\8F,''-^!10^@/W?+
M.(+$+]Z;I^PF6!2,#99K0_B^)R9[F%*VG]BK6=\/TQME/_?6=+5XXK !VHK-
M_'OS*+NIEV&XGQTZ*\:#R@54OL$X&&7<8??84GA<$T% <;7]&/,T6NE?YG.0
MZ+1G3YI9Z(9L[DG=J[XB=6]L*\KN!V-+DVA)"51OPN60P2RE<N1)\WS\0 [[
M!S+[M0;2S6C@&J /'+EX>@U?Y_:./4@!D<97M\>)$9]SL]N#@1S3,<*E*R@S
M"0.*Q ;<(A+0 /4A9J!XD -97:)5H6,GY^8#5_-#396Q#Q]X1RFQM-US:M>!
MEF";T0;DJ-J+W,S*H/4%0:L@)@7VV4!8&N!-;(]52['>K$GD3<<:*0=^_E:Z
M^+*6N%[G-6.K$\"I>%,7[1U[B3F7D) RQ,,(DV15=J_XO$][ GS2^!EK;FR_
MP#+OAGCUV*:\R,XQN_M@=^ZEV;DSLW/TXP>W>;H%1!*NBVAN$U)\=P%V.OK_
M<V'% +F0=1 ED6>."+VHP.UEQ GU#S2^&EPUJ-!0=C7] OA E?%6/;*Y:77G
M =ZSTM&KS(T^JAJVI?2 A*]S:Q#P];R$)(N]HNT$I[$\M ^E>3M+?]$2>&W=
MRCD?D+,V11,-875\H7MH2/=/P2VO Y'13DMT-HM&*_]UTQAC!B.O7C6.&J)$
M<+-^O*[6D<<=408\UD)KLOYDH&YB[:O3LBY2W5U?YPY .*\+!8!-H\R<A&O0
M))*<HKGUQP[QU;":T_O2EEG)$6<\OBY*P*:-B&^NR'K,J7^-&1+V($MS-W*F
ML=*E[ L&[TN8,-<O7PM@(UL;/*'463X"<..P>C$D(9HC1MC[\S=@DJP=*&)L
MH<3@%!D$I!$!*:JRN )708#%AE/TJ68^) CPW/[R\]\((7J4K7%29"Q@CUWA
MLDLP8D#.2E&_UIYD BJ2[089,)5*BG01B#2LG*06U\-3"0^8 T\65[P( '6"
MF:G$V></WI 4 >JO5]6]!/3IY7 _QUY8"+(K?.1J)'P-J96)-I(H#:>\-]U>
M&(X5G50?W[_B1(/2M;-'Y=&&Q+HWO7AU^=YW$<+_^2)I] 5U'G&K ;WP6:XQ
M@,#?VT6[)5F#N1O8[K'!2'#42(?+/PQ!N=(/QF)8DA$5^ ,$M4V.",P=28G&
M?R7Y2^*>CJBO&J""\+(N^?50G02"O4"UD=GKJEHU@<+",H5>BQ[[M63TZ9'I
M/21<QT:ORS571L25F0'&I\IL??>3DJ-5JZSSW=[CZS!-Z//[=G7M$P8ZY"]X
MO6$T@E@17>/FFJ(<XA87M9,/RLVDOHHRG[+2M='ID?Q$ &00=!-3\Q":70*
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M)[!=P?">3<83)DT>VM UQ_ZK%/0][MXL2V2F**M%;E,8C5!Q[(C1^A>_O#$
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M;*\QKUR)J%2&:59#6\N:'OC95?=V35WQ#KO4(OW45#=8E)&( 3BAF/S8E,4
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M:RYX;6PN<F5L<U!+ 0(4 Q0    ( "=]"$G!"0'RCP(  &L(   0
M      "  4($  !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ )WT(27:-
M)S ^ 0  :0,  !$              ( !_P8  &1O8U!R;W!S+V-O<F4N>&UL
M4$L! A0#%     @ )WT(29E<G",0!@  G"<  !,              ( !; @
M 'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  G?0A)90DEIU<"  #2
M"@  #0              @ &M#@  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    (
M "=]"$G#",#_0 ,  +()   /              "  2\1  !X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    "  G?0A)J6(77W8"   E"0  &
M@ &<%   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ )WT(
M2;6,C@,7!   /A0  !@              ( !2!<  'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+ 0(4 Q0    ( "=]"$E];X#5%P(  $H'   8
M      "  94;  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M"  G?0A)TQ/F-(D$  #C%0  &               @ 'B'0  >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L! A0#%     @ )WT(26\ 5TLR!   5A0  !@
M             ( !H2(  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4
M Q0    ( "=]"$F>_A+7I0$  +$#   8              "  0DG  !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  G?0A)ZF+(%J4!  "Q
M P  &               @ 'D*   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L! A0#%     @ )WT(2=&/'%RF 0  L0,  !@              ( !ORH
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( "=]"$GHB/<Z
MI@$  +$#   8              "  9LL  !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"% ,4    "  G?0A)>0!6L*8!  "Q P  &0
M@ %W+@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( "=]
M"$FFG6>BR0(  ),,   9              "  50P  !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L! A0#%     @ )WT(22ZS6Y7< 0  104  !D
M         ( !5#,  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M    "  G?0A)J%YR#K$!   6!   &0              @ %G-0  >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( "=]"$E_MU]$V 4  -XA
M   9              "  4\W  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L! A0#%     @ )WT(2='TS9<B P  I0X  !D              ( !7CT
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    "  G?0A)7RR9
MG^$!   8!0  &0              @ &W0   >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;%!+ 0(4 Q0    ( "=]"$D<IC?UQ (  $P,   9
M  "  <]"  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @
M)WT(296MR1>D 0  ^P,  !D              ( !RD4  'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"% ,4    "  G?0A)4F+!J]4"  #V"@  &0
M            @ &E1P  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4
M Q0    ( "=]"$D\$&YN2 0  !06   9              "  ;%*  !X;"]W
M;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ )WT(25W.'.63 @
M,@H  !D              ( !,$\  'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"% ,4    "  G?0A)!HZT!O$!  ";!0  &0              @ 'Z
M40  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( "=]"$E.
MN]G7/0,  '$/   9              "  2)4  !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&UL4$L! A0#%     @ )WT(29K82&87 P  ' X  !D
M     ( !EE<  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
M"  G?0A)>ZPY$Z$!  #5 P  &0              @ 'D6@  >&PO=V]R:W-H
M965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( "=]"$GLJGBB\H$  .C< 0 4
M              "  ;Q<  !X;"]S:&%R9613=')I;F=S+GAM;%!+!08
..(@ B " )  #@W@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.5.0.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>121</ContextCount>
  <ElementCount>233</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>61</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="bcrx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160630/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bcrx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets (Current Period Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160630/role/statement-consolidated-balance-sheets-current-period-unaudited</Role>
      <ShortName>Consolidated Balance Sheets (Current Period Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bcrx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bcrx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Comprehensive (Loss) Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160630/role/statement-consolidated-statements-of-comprehensive-loss-income-unaudited</Role>
      <ShortName>Consolidated Statements of Comprehensive (Loss) Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bcrx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160630/role/statement-consolidated-statements-of-cash-flows-unaudited</Role>
      <ShortName>Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bcrx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Disclosure - Note 1 - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160630/role/statement-note-1-significant-accounting-policies</Role>
      <ShortName>Note 1 - Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bcrx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Note 2 - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160630/role/statement-note-2-stockbased-compensation</Role>
      <ShortName>Note 2 - Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bcrx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Note 3 - Collaborative and Other Research and Development Contracts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160630/role/statement-note-3-collaborative-and-other-research-and-development-contracts</Role>
      <ShortName>Note 3 - Collaborative and Other Research and Development Contracts</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bcrx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Note 4 - Royalty Monetization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160630/role/statement-note-4-royalty-monetization</Role>
      <ShortName>Note 4 - Royalty Monetization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bcrx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note 5 - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160630/role/statement-note-5-stockholders-equity</Role>
      <ShortName>Note 5 - Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bcrx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160630/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.biocryst.com/20160630/role/statement-note-1-significant-accounting-policies</ParentRole>
      <Position>11</Position>
    </Report>
    <Report instance="bcrx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Note 1 - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160630/role/statement-note-1-significant-accounting-policies-tables</Role>
      <ShortName>Note 1 - Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biocryst.com/20160630/role/statement-note-1-significant-accounting-policies</ParentRole>
      <Position>12</Position>
    </Report>
    <Report instance="bcrx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note 2 - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160630/role/statement-note-2-stockbased-compensation-tables</Role>
      <ShortName>Note 2 - Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biocryst.com/20160630/role/statement-note-2-stockbased-compensation</ParentRole>
      <Position>13</Position>
    </Report>
    <Report instance="bcrx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Note 1 - Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160630/role/statement-note-1-significant-accounting-policies-details-textual</Role>
      <ShortName>Note 1 - Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20160630/role/statement-note-1-significant-accounting-policies-tables</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="bcrx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Note 1 - Fair Value of the Company's Investments by Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160630/role/statement-note-1-fair-value-of-the-companys-investments-by-type-details</Role>
      <ShortName>Note 1 - Fair Value of the Company's Investments by Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bcrx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Note 1 - Scheduled Maturity for the Company's Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160630/role/statement-note-1-scheduled-maturity-for-the-companys-investments-details</Role>
      <ShortName>Note 1 - Scheduled Maturity for the Company's Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bcrx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Note 1 - Summary of Receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160630/role/statement-note-1-summary-of-receivables-details</Role>
      <ShortName>Note 1 - Summary of Receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bcrx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Note 1 - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160630/role/statement-note-1-inventory-details</Role>
      <ShortName>Note 1 - Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="bcrx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Note 1 - Summary of Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160630/role/statement-note-1-summary-of-revenues-details</Role>
      <ShortName>Note 1 - Summary of Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="bcrx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Note 2 - Stock-based Compensation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160630/role/statement-note-2-stockbased-compensation-details-textual</Role>
      <ShortName>Note 2 - Stock-based Compensation (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20160630/role/statement-note-2-stockbased-compensation-tables</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="bcrx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Note 2 - Stock Incentive Plan Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160630/role/statement-note-2-stock-incentive-plan-activities-details</Role>
      <ShortName>Note 2 - Stock Incentive Plan Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="bcrx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Note 2 - Weighted Average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160630/role/statement-note-2-weighted-average-assumptions-details</Role>
      <ShortName>Note 2 - Weighted Average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="bcrx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Note 3 - Collaborative and Other Research and Development Contracts (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-details-textual</Role>
      <ShortName>Note 3 - Collaborative and Other Research and Development Contracts (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20160630/role/statement-note-3-collaborative-and-other-research-and-development-contracts</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="bcrx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Note 4 - Royalty Monetization (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160630/role/statement-note-4-royalty-monetization-details-textual</Role>
      <ShortName>Note 4 - Royalty Monetization (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20160630/role/statement-note-4-royalty-monetization</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="bcrx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Note 5 - Stockholders' Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20160630/role/statement-note-5-stockholders-equity-details-textual</Role>
      <ShortName>Note 5 - Stockholders' Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20160630/role/statement-note-5-stockholders-equity</ParentRole>
      <Position>25</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>bcrx-20160630.xml</File>
    <File>bcrx-20160630.xsd</File>
    <File>bcrx-20160630_cal.xml</File>
    <File>bcrx-20160630_def.xml</File>
    <File>bcrx-20160630_lab.xml</File>
    <File>bcrx-20160630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>53
<FILENAME>0001171843-16-011576-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001171843-16-011576-xbrl.zip
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M,XP\8'\51L[]42P'+,PZ!8)/8(\!?]L IPV/(:09L3(,BQPVM;_!CX(\+.;
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M&8-WHL@.QO36X+L7UP<?3B\_#0+W_/KB$Y%5Q 2ZW5Z_V;!>_'+5:9Q)V#<
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MB)?4 [!M2F.;V('1;_Q$M\E]7TX@ZZ<8L8VEV@ Z*CZ'D!7'F47,#?%R=)
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MD@4#BXEBJDN( S)1LG^*?@"J#Q_$:43 B%+P!#%5&I20%.$;HJRZI3J29((
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M%#%W -SEQNI/IV&<?*"3C[E?PO?L.G,. P]<,XP]@JB^''T$#<?VL9K1+KZ
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MB^+D-Q9COV:8P O=P2AAT3_AQ>0,.X>O<5'Y#QKIRWQ60=/+&0+"J5DD_7F
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MDLHY)0'\2D+2'#Q$-V'3,(HF]MASC!$L3U1\$J.(('^2U)TO6ZX/<!K;%7/
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M06 1D*II4_VDV!7T=* JUDBDDG*-5C@8^Q]YB09TDU?0&N14*3\/S/.I!\8
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M=*TEH#7;[3V =IDFJ!ZZ_/;<IJ1K[T(Z9>I=@%Q)Q,XN1%P'R&V;2?3TC0*
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M;6)'-%O:CF6-]H+K9#>X-C$9]*WY6HUN;W$9=Z37VKS5[&CA,KOMS@9P%7W
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MU'8N[JJ@Z4=73[PEEQ!LAR(A: ^CQ2',QP2IE'=-@H'XD#7L!$$-S?$1O)/
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M(U]'I8I6D"8*37&1&AJ:# Q<&FA4L[BFS@\Y3:>PMH?M^A$%4R?!A^;,,=B
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MS3DWJVF[V^FWC[GGJP"<,X%"?J]SZU^TJ\]MT&HMB>'\NUN!M 56^Q>=:L4
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MK*VP5SG%%!_&"B1#L821'".H"^#8"U_HGRF)BY(?L,R4+#75Z6M]F93-+XD
MSOP%SX!#$CIP MS(L>BRAPXM[#=P "IE\6X75[8MO%LHVP-3)_[JS#':M<?5
MB\K:S_9%L[U09[G\Q1U 6G_YHK+0LMV_:'9W!PEG\M(D7L.EJ,+8?]7)Q+3
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MFK=UI% (WQQ(,<*4PR/CY0DL#KP]4A<A<( (=0XXLSXZ0[2CL0U"]KX-3XW
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MXL58#E].G3F1RY#%!C84 1\%)0:>$;9G4F'5[*^J^0 <O1X(AO?B%*'CDVF
MM\3TO"8>+F-<]@*>2_TDN^Y%TXAB41 E3)L '>TXY7MGLY"O(=%-+**F6Z&O
MRM&."A?*A-$&)&L"%Z<H3*1J1Z=VM*KS B/)-GZFI>\BO&856%YXIV]%%9@]
MYR&3>XL'G+6EFU%7.N1H$MUXTYNYL=BH9Q' R.R"1XQ*76"H@9;O'RPJO)E)
MMJ$A]YV$X$>4K!O8<!NY EKE9'_3;D!N][?/7_SZM?.?#7:5P_=P&\JU8/;7
M+Z0"LW_B'!^E_DHVVX?-]A[+9C.53+>Q6"&7[.D"]M0_A3T]H%MK^+$]0$>[
M^9_61?O='C@Q+KWA)(LUQ1_;W*![(ZGW%\;+T]A D>\+3UT9U^7%![V7]_WF
M'?8.3)AG?A>.GTQ@N=]3<&=46+\D2E ,W526U?S:7[@_68J_AT7Q]V#X.)!<
M'3IN]T\(R_>$C>IY;H.% IH3I+GCL_7-!*R^<"QQ9'/X,2E))RW@<\4,G]ZI
MH_,^6+@*H3D*!U4W$U<&BQ^2$;<EDD%EU=HC())[X#GQEXS2^/L_*U.X"^BL
MO.C0Z9\Z-N^%Y;;%9V6I2>^$-,(1]EV9HQF<D%VP.5>NV&EEGF?0/'D!5,XR
M*S9;?1&MTQX<=[<KH*HT0]OMA>M9AX-*Y=8>@Q+8QK@UL%IESA["=C@8]AZ+
MJS2H-&9[O<ZQ5,$.6+X7;("D>!S8>"2NTJ#Z[D;W_%AB^5&Q\%I7:=#<J5+Y
M(1EQ:R*IM$4? 9&<G*LT:%;7@"ZTJSA!=)Z@KP3F\HJF=R>#SR/LN]*H;G=.
M:.,'<)8&S4I+_;Q_\B)H2V=I4#UXO=<[/[);L@*J2D/TO-W=QS??L[H/L%57
M]SV;ZCZ#;G37:=_GC/E3O\ZYM'6WL/5BY1_UO*9*D=CR4J$+L'0UDJZYHBH8
M.1VF44SW#2.5O.:VZ-AT-)RIV^I8=I85[%"14^[.88$*.W3T(KETEO;I;* X
M:I:*T!5WH"U1>DNI/^O[/RVE (L#'&Z^?USH#(YOS?C>%E6Y4>]K>(RJU&)1
M^!YB1\]:H'U[JL!)8 =]Q@GVPA86=POG^6^ZT?>0*B!A)1E/N#B'A@OD<QFH
M6[]UF5C_2&'%3I,;X!.$^FIH3AOZCFBQ0@RGN]%=W1"_+FD\=0;_O<]EIJ$6
M^+.:OR5\?X9]P(,Q-># ?\<SQ]7_5J ,D?JB!E'F+ 9X]$^OK3OI)9-?K'ZS
M.?O!O,S+1_K=6X$S2!U?L]XP3))P:CSIZ2=+15=Q,XFW_KTRX62I33;XZ_#@
M)NO#+@$9P=]?8*.J+3YF2AI7H$7XVE(HU-]_XV/1)D!A43MK@@5IS* F16R+
M</V<1$\4RYW[0#(;J$]^F]HX??(;_1:"&;$/C\!78-5Q!$K50PD71K]8T7CX
MLMWLVN!PV>U>[U49'RG!=][ZVY+15=R,+T:,M6VT:_6YJ>^6?'9C5JY>H@+R
MG]:OU5RW6(2'3:OUVYT#PK;?AA\+SEIVNU]C;7NL#09+"O0H6-M7XOQ[ I;Q
M!NJZ C!M<1L XD_X?V"(GED?$^]L8U6PNTFP,ZEM>I[=W@- <[KXR!VG[D.
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M!RVQ$4B#$)_29J4+WY)HFX$#=NG=DDDW<^8\Z@\-S'$8>C2&+=;^'0TANY,
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M:V$=1A?^&G \0IZ/*9*]M.@=QV873^!.5TW*T1*9W9&I@'G?"*1&'/K+2<L
M*=R@/CAT"5+M*@">BQ/*M\2%-S#:BS JQ@*T(+D1_"-5SXDA;BZ)-BDTK*"4
MXF/+)%I"F20-37MH.65ON@R%]+T-8I[G)&FV*F4DC/.S831&'4\Z0ED;Q@ZP
MUB%P_/G_-,F:'@ZLCY2%3FKA'9V"8[ 1B;"[/U)OS$*-7; %%IDZ&*5'VR6W
MKEB T3/97FTT(TCPA5&F&+4,#%@,VE1W&[#W66ZX[>/&/$ R"ZB5)D@MCX>B
MSD24),%*>NNCPLAE9KR]Q*=-!KWY_C'_<Y'CQW"V1'_X#)76H+(>C4!%DQ%W
M%T:^=P=GSD> MOX/7;1Q%4>.\&WK'P[ 95O_!(7FT!K?''F'OZ'#),/?+.40
MRAC0V2# 3*'TVBJ B[H0I1EGO70R+9G/V'C)?8Z\F,0!2@\:('G \B9*2V?@
MQ;#G 8!(H-<$Y4+17]%U.=J34VP HD-;:D6X%!](\A;@EP5^8$FNB56CCN0T
MV /P8@A&0"YM\T(6*D<)(^*T<$AVXELPW3V)E [/OT^C<";@']\#9)>"''[_
MO7BV0%1_"CI<2G*!LEBV[=A%@?4TCA12<,\_=3IVO]M4$]J^?[199&/.^J>^
MW6PV21@;:@Y@'HHE$?/^>PDDM!E=)Y7Y-B@+?96QDU.<HX:/_R!] =+^IW;+
M[O?[^CP6049H"K*62D4*9[#H/1E^I_)+8O@C/ ,&4Y2@7;(  6-D&P!FH,Y5
MB9/@"SGF^;,ZR^#QN/R'/#,JZ%!PV+E;G+^? ._&@#E:)/-=ET!NV>UV1X,<
MF6[],E'K$RDK.& MF3N8O!>T;9D?"#RZ-[%$S'E-VR.3PI^6A$5)Y")W[35V
MLZ(FT'F8A=8<E9=-95(H1B/G)=EOPI!-DJI/T(HARP^0"Z:XEITE*Q??OG-8
MVR_[5Y8RN$!:BAEIW$7?7X<)%4A9M*8H4U$ZSDMD:2Y3P)3#$ O>KTED/)HK
MNHYS&C0K5@KQU^P2#XD7)1NJLNZG34#?RX-%!:XKJG<TBQ02@8X0@3^UVB1M
M@0B<K#;,Q'BAXA7<;HR6C5)_D48,QLS)SU2<)6(:*5/9UQ_>7;(Y# ( ]!&F
M.ZD0EZL_E'93S[[_I)Y%D#$ E#^H!2VH!</=F.L[DU]UQ G_^ 'L7NL-B#E0
M.?FU2E*(3E'W%?Y45(,KX.#'%^JD,F>:+%8.;;+?J.5\'@$DXR36MQ\O;[ZC
MO=9LM/JVM6LP.A<YG\#19CF[)O=DJQAKKH@G^HY9&?A3P3(@X[E,;Y/3@/ZM
M(7I88ZK**0P>Y$R?XR'_W30#VHPI? [+( 'S4D29*"MH/UUHJK[[B*O2KLT;
MN89\1+)45>QAFC3"46,6NL!^9KV:44ZXMMS>%)H+-LU;.%ELD$.KX4QR70DY
ML@JWPZR/81SCC5V.[Y!S13%<Y$C%,AJZ,RL7;17E7KHB.*NA>B/#*1:=@EQ1
MY?3>BAQ+"H048: 0WU<[ :LWVT.\\:7KEZ9 >'-Y_>[RY]]_OUD.?> 7/CM*
MOEX%<2*3E ,5EYAY&[/)=A6,,!Z#;L@["<#'Q2^XKS]?75Z]6_J"G9_*HJM?
MN E>=LTA/^6\2/.T<\Q'R=-M?-'Y%#-MNZ39N7)_X7ZR<@7PZK^ZP*"$-=6_
M8W:;#'T9_ZG=G3LG\FB%\ ZK+B=RQBEG[4!$1N1(!61U:36X<5C'!@M3YCK6
ML5-/AP5A,<[JH4.!03ZR<2E/X.'E"#E,P>( ,R,%UTYF0:4;X?N-;Y,H3,>3
M4H.0]0A=YCC+;K@7[WDK!M*>442<59:IYS1;6:[>5GC$X/4,(TF>K?0ZQB&S
MX+.I7I%)[<WS&:MAQT0,AH^SR')V=QQ  _R1!L5R?H>#;. "!'@%AJY68<\B
M?<1#OJ5T52(F]7AT98ZO,3\IHJHI#:WWBN.\FX2D7@ @F\*W^/!L,H^EB[&*
M<#3BV-TDC.G.$@,Z$AB5]&V,SR:+@2!KPA+<122%T=@!'''.U5#^_];*1#F\
MA@N#N\KC5=KQSQG'YB<R%S>>H<6#,K>,S6Q5RT)Z<*%'!8 /NGHF?>W8 ^K7
M %:H2;>)38%4G2GXQ?K;+^69.+/S[^,/EV^_7?(!?GU_??GIZL/'[Z^R+4P=
MV&<Q^KU0'9(5FHL?Z._11M?N);^AH8DBQYD/AYLH(4#%\ZJ0&PZ?104F_IS]
MYM0_A)5&*@5X7%DZV9TODG% JRFY38K/B"^(@.D.C2-!:O!/D5D%-<YQ[ !R
M7%WHQ*>=<3><>^:!@43VA/$G$CR:[Y"B=$(0W?)7>6%_!O:R)9C]B21T(?ZC
MV5R'OIQIGH4O)B!431:2>)[@QRP4!TU9MK-;!0S.]BU^80*P@Q&'%A\:CI$D
M>:POA+%E2PDBZ\\ E--BD0 &C,-()U*!%E&.IG3CA[IM/#8J,[4]XPP)P4D<
MQA8L 02#-_Q D;I,9Q/ASRRCKL(:1V"D-Y*PD2?Q&9_911ZZC\0GE]^=R#4K
M10)R\T(3 0K^,^N] H%R:PB$Q_"I>YT@&X 0=3(ISSIA%(%R+OR%(5?F\J[*
M-0@3$PIAU1,(P 1)F$<WZ8Y?K$41"DDT&1)E,L +VE1!>86>)(@HNL64PZ&"
MG'E>5-WUC(AV.=J1NU:T3QVT!04[=5R14K- -,3QJMO\$9.;\L8YC<+".UZ4
M>1A@<E%V4.J,#LA17A@GRL>IY+_1K:=EHXU,L6+R$4AE#*\&J*<<E=NF%E!Y
M[O^Q>O8F>JE\#!AN#,CZ7V8QQBZ0.T9[L=9CE")7%8L 8G#)Z )5D"P=AZTK
M5=D2UW4D1H$5?$/G6&-ML)MJ6Y]$K",\<)!\HSC/.V?+Z:H]ODHILS*3)89:
ME%('.;]*/ZQYUH:_'-@5[>SMBEXK2P!Q]C:WQH_ME';NJ_SS9KW-4S1J<OLG
M$GF936XZY38-+*1T3M%8+=2 &$1U&>L:L\3Y4\?$ RQPHJ9WZAYBQ-K,I%8F
M^BS@AI48=$L<R-H9FXX!"KY\5R7V&X;;HW ,YGJ\&*R7 >JZ.+-("HW'9LZ<
M$] Z5!:+;"%5?H1&7Y@K83:='T,-7.7R!CM8KN](U6N@P@PHD M%%N1H)+ ]
M%75H&(KD#@OC]>4 QP7Y%*M;SA%W>,!34UY0U4?@3$'B%FUR':"D=8CPU$+@
MY(S)+<PLC*Q&D@]2>;$@S75=G9<=ZR,_/-1I3+UYQI@;VXWH5D4N]<P8A%D?
M.$W]1((#S+A)\IIZ^#<VK.1?*,O>S#[AQPQ_05T)^8-SSJ:'P9:A;3ZL4QNY
MDV&;OD0NAGSG+E:Q5=!BLT@DJJK;,"$U8:"HH*R=G9&?)I670Q 18 .#J/&+
M@DNY>-D' 6L!6 4)7QWF1UX5@,,4!VCFF?*>IK1Q)T$ERXN9>U_9PT8!J6WD
M&;4OT.U4+%!L@>';*_NZ( 6U[2TU*QJ>)T(<"+^8+"-VQ+*OPB8*[F#FW1S4
M$"] D<ZH20_5+A7-(XS"36=\PEQ9J]Q;50:"<5%<(1"8,W6P*,/PI;#:+<E%
M^YEU(Y+$SY,G5>R0S&<(K0Z:Z@2&J;.X?64H55V 0Y6#H:JS2 3W 4JI/7CY
M-UA,KKER;QIW>>8X4U6J D^W9.%[4\;? I$5]:"U'U%X5$A2CIE=RL6:RCEW
MN;.@1K.FR"QW?Y*R<;71N:.!^*X0P^'PTE6 8P6Q;O_(=N+^1O-F#3<*>V2C
MB;T8F>T411Z\*?VY&5*[RD3-I_QBBE'!6&@@\^FRF*K[0!U;OJIK/EI2+S?$
MJ6"*JHBV:==E18=@=5YA+8,PK!0L@(AP?\J*Y/#$#)RA"24#%UK)9@L8K9 %
MA6(3].HHRP<?PSUD.=.B?,/? <LS:EDPQJ)HX2P*-V[HA-E;O);!"0K3X*3R
MM8 L'MUF@W>B;GF1NPXR6I?M%% =90Y!FE]66+)=ZX!X(2"N.I1ITE+Y?Y.!
M%EGG=*)-1Y&0.C%VS5FMIR$23;;U0J'+\-#20+F1Z4/<LM$HVB$?-WLA)-U.
M97F*=RE23B^INP#TEC4$A3Y":LKRL!B(HJO$( & P-GW<LJ%WE[Z^/2OK%,.
MI!AORZ^OJ^N?7+I-W"=_:.,,+V%[5'Z?@]MITC#L<WH6B_)_N6?NQ!_KV>D;
M3C_+)D#W[V4"-!$138O89H;/X]SL#?!)^5;KN?![(1:ERW/89.\Y;/)YGN0]
M3KWO7FP\*KM0@65CS57UX3S^0>.YP],]))#[[;Q&7HV\&GDKQ^IU^O>"L_L:
M<5L!V'6QA\C&6G)W8_#8LTS/VT><[_X(\='JM&M\F .M[5ZKII "A=CGO173
M[A]:PAUD\&]%7[DU[1%U>.J7)W#*#PK4PT-0HZ5&R^- R\-9A(MA<7T4VTS4
M?0*'W+'[S=I"6,!(IU5CI##HN]E9,>C[&6($C+/F-E'6QVA%5@G(FXD,@W L
MK9?4>^O5$SC.]N"(AUGCX]'CHS>HPPKWAH_3,PEOQ%\R2F/K^S^MCWSK<(O=
M[Y1-*Q905&3"#AG#WNM+1G2EM\).N+_=/.]#:+?L\XOZ'![\'+KG]2$\^"$\
M-#.<B"E?=>;?PH1*OW>,%==45\'Z=JMW<0K[>=['T.[9_=:*;$]]#O=S#GV[
M>5&SPX,?0Z=I=R]6A#9/71=NZMD]/8>[SE#5:*G1\@C0<J+F?ONLW2M8_ <P
MX(TU=]9AO(;EA2G-B-R[]G'OCY@F?/]B157DX;9S$+OEB1\&&/(7W14QY_HT
M[O,T!O9YLV:-$SF,3ML^/]_6N3KP:9A:[V>Z(IK_\\E>(;_T2*WC[)5%8)[2
M9681C!W5+(BF1^J^FX7^/-PJ%MO%-U1K8VRTFN&'>S/.HG :4@^(K$.%@4/=
M<PD?H4XQ>=]YU?8_:PR[04?Z;7[^OS^G<6/L.+-?U*@+8]+%5_!\W?DW0-H;
M/W3__/7__7\LZ_\N/,Y-F^"1:S$"^ODO7DYK-,\;S5;V8Z?YW[?8:T%$U(+H
MLS,5ES]DW'A[\_&3F Y%]%]U3^Q+I&K+Z,\*3^J1;_.9^#(RQC_3,UGC$G[J
MA>4)5TX=/_[[BZO/'UY8TOO["[??OQ@T.X,7-/R/P)1QV&VW^HTT]E[\"C_T
M^\UF<PD3\:8;AMUVU8;/><,F((U.#L?%H!J.+IA<>X'1R\'HK0.CVZQ$1P^,
MC7W1T=H4'=U6%1P#4+/[HJ.U,3K:56!TVJ!@-H&#K]>\9V[=BT;Z[6I:74!)
MX:/; ;0%M?0[E=327:25/2#:@F[ZG4JZ:36[A\31IB34[U224*^Y-8[TV*&]
MR*C9K8+HO#TH@TA]=3N(MJ&C9J_RU#JE.-H)HFWHJ'E>+0=;!T72QH34[%<B
MZ;S7W!@D:GRF_O(;=J[Y+)+-Z,D I8KOK1_Q+X'T__XBB5+QXN==OEQ&-\:7
MJ_C[ %\NHP_CRU5\?)@];TX&G4IYTBEJ@;)O5T.W,1E4 =:J%'1+%LS"=[<$
M:AO)TJK$UK(]LQ]4VTB75J4$7K)N]D;5QH35JA3"R[;.:JC<B?!2'\SRK*G@
M6^Y"^0V]X,QOV((#&ZW!BU\W\DE'SE3Z\$N<5AM;@;BSP'MR@HI;Z!@4.$SS
MIF?2O:GNUG+ 33YDMY9^=Y/6!=68_'<8_<F]DD-LU%M]7*LZ)>Q3:&"L>Y@4
M_8;=(PY5%&P/NBNNF!U\=_LVW'C61W7>6I%FN<>CJFM%3CG-7:/E=++_*_)=
MVBB5=:)_9_549S/O]S!6*J"'2V:6)XPV]?^JO,:;B1.)-]C;'=-M(HBI(?FE
MF\A;F<QW]R';K=J'?#8^Y"6-6,9/#R/K9X+C\M:1/I'N4]_\%QZP4MC]ES3!
MH=2>SLP_Y?W_FQ;A&ZG&\8O(&8O"[][_P$''<?&77W$DT .ZYN=531/?.#[U
MIG\G7$IKYQCOM*@7^HI&O@_1CW&;1;=HS+@J./1D>ED>"W=-^[R_XK;#D\'?
M87N!]L]6]<=[$LU J^[Y?P698SE3$7A83_,$?-Z.?=$\8K/#1X@16FIMF^ :
M,4\I0+(I^U\+K&BDB8\TA8E2A)9#UK4UCIQ@F\8?IWO2+]M[=S=["CV?:DGP
MJ"7!X;7_2O9WT1OQ_2<A +8:@E+3>XV8DQ8$Q^UU2((@Y,G"3] 2L%OMO?V#
MIV ,' 013XKY.V?[FXF/2?N7<;I0(=.GP.NUEJL2@OV]VU\_"0EX=LS1*8].
MR6]O[S^S7D+=P;8U$W5#IX,?PLM[.(7-A=M^R"]Y]Y 8WWYYPV%NG;6[]PQY
M7?^XEZ53US_6:#D9M)Q:6:@NKB@?,K^'O'^PXL1[^5HA7'!1EXR>VJFTVG:[
MM6VKYT=S+.6O'Z!&9*>%C>% 9ZO:G.\']:&+=+<IMUU?LOO5F5,7%O08R8=4
MM8C_<OR4%X[C=,J_VZ.4MUV7\CZ;4M[Z.N@13:2MKH/2 MB?A!+"'^4(FTU9
M_Q%.M-,%T.-5_QVI>K)W5I>>[H&\G<J33S9(L(X]_A7ZH/!\T*%/P".\V#L.
M_K>G@(6]!SXN8>$DD@!%PGT'AI\G L_ZCQ3^4TCS-<_V3F,_!>H]!AH>6-A>
MR_C/QH=(".L*+2T1)]:UDVQ^P>MT#ZMUMB*X_GQHMK7*:#@ S>[B)N_NXBZX
MS^!4@E?RFPA$Y/B7@7?I366 '61IY-1A6D96-G5J]]O%AHB;@7.8+6S3PJM=
MV8JOT^L\W!:VZ??5KFS=UQMTSA_R%#;N#M:^J-I"OS?H[;^%TB#4?EB_J,1Z
MMSMH%4$N_?QN(&Z#U8M*K )A= \$HM$<^<V\7(S1?_X%ZA/.[:N(9.BU-L']
M?^D];,%,79??3V=^.!?"$(JZD;/O!%E_YZL XR) "?A;]8#Z-OT=?V[W  Q\
M[+WC3C# \!W>\#^DOC_'/PM/-W;..CFWFX,7OW[M_F<=QG;#QGWBN9/CF7[L
MM!;P;"H=8*^\1I_^L"O*>\VM4=YJ <K;IXWR]W^EX()?!8"C%'\9?\$ICM\F
M3J P^"&,1@*[MU\%_.4=*'_A"+X#2\?7-]\W/(KJ_M,]LZ?FCV'DRT:,NXQ?
M_-KJ;2 >CH*?^SJ8W["F/#[!4^D.*D^EO8E>.3QR#G0D'QP9H14K# M6AP5T
M5 #]JXW.8AO\%IOR=RYZ2PB>I9%X\>LA4+OI)A\<I\N&Q%8X+9!L?UF0/$F,
MYD'7H]!I :?GRV) X?3LHGUDM!;W>0*(/2BQ-JL1VWDJB,70%4:N=.#J^/3:
M[U2BM=GJ'@FO9=M\<*P>E%B[*[#:>WQ8_>3\D--T^CG%7:NP5PQ6AG;NMJ?1
M@EOX-8W<"7QSO9TU:/<N*NVLSF',K'6;/1!.]?J7GB=YD!-_Z3)-)F$D_R<V
MLV[WL%C/JS&)G=T/@LSUNSPP.E<B41Z!'E=X8]W^@?RQJLT=!W>Z)1XX>>11
M'!V%RSI(H[![?B"F7K/%AT)DK]%J8RQG#RZN1E[K_$GC;G\)>+ZLIG.?_6+P
MF+#W15NL=!$7/Z#[':H6A[JK(34R/ PR"PXZ8+,B)].8B:A1Q"Z6PAX M=MM
M^K"85A&P%,\T\,!3D!&ML%UL:@_:K=8[W<&!2'?3K=XS9C>F[(-'H0#M%;.#
M2HB<+L/=XRG<'^WO$(3=(]Q=;::V6^T#F:G'#*"6KOU;%,8E<R@[C>9%GN:Y
M6$[SP-NC,)KBK216*+MF=K[/PN F=7%.RRCU<4N^0#A!4<W@)$;2?2=NA1_.
M:&*J].&5,-"?J[;E6BO,D>;"W+XC8/0!CJR+)AP?65=9<X_LR*JMH%:[=TP&
M._J1+8A$^N,[)Q%9^.3(28MVMZ+4ID1=M,]:%\="]%H\G-@A[!F+6SR$S0W3
MB[-VZXD<@M';G5V0HWB?*V1'\[Q_H,1GU8[N'6$',-N7LYBYL 7M^4@1MIVS
MN0O=+=CA6PA6[--]%)P>T.".-W-QQ6GX0!63?DN56F>;K.=!T7#@(U@IS.\5
M_[V*&L82_'>VTV>'P\$FR.=%P9DM;#_^&OK2G6]Q\_>B?=[OMLZ/=?OWV:^X
M?/MNZD1C&?QBP3^LYN9 %"[%;OX:_1%^ESA &*_S3F0-HBC+)"FS8'_5SRMW
M9]X8^",%'VPT7^B(UCSKR: 4#<5;#EM],6NWUB]'\:7O6\37C2'M>\;\&=N
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M>['<*7*YCND192**D.AY_Q@6PYB0;<8[B5I=>%@R8N-T-$(U J_Y\B\X!ID
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MDW0IYH"84] JI4@% P'<PH2^[WA(*?Q[<OT!QVA;P#$&#@<<BV<6SD I(RL
M3X*9BU8%['/&TI0J'_PY+4#^IX,H(TS%Y-[8U34>%<1 M@M]$-9(?19*N1JT
MBS8;6TY@2]WA?X*PL#\V*&&7 ?P%L(U@H6]&!Y@_]W2X+BZG#3 #R?P=HM7J
M:!G[1QH80I8\IK)WD?+PCW.P=BTPA;%?,U!"T6SJM RK"I]F6D;\"[:7D %6
MU_S0^Y=!D,+WKX6R@C*&^N<9=]R54\/NTA3BT-DG&8E*'T,Q&$4B4RPG(.,=
MO2_TVVAS;/,I^0PH$R+!X B\O&*_Z+J3N ('4V*XC#P9TJE@JR?<(F S3;P:
M.U,L\$%7#(//U4@Z>5)^<(/P6KB^ Q[#B*@##N=4C4'K0'+A71KI>K:1C("*
M5'P3*1MS-\6PE..%I#F-!,<-%G=1\=KW&3G:G\,SB]/"X$SM>@Y9_^R<SCNO
MK2N,=SK:P,J>>0E68@*:R+4N.KU&I_GJ%^M&@C8$+.N]F?8],^TPL:YB=$%=
MW%Z<%$[ZC'88H3^-^HMB$E(_C=5T'$1KVZW!N:4IAJOJ6*WH(!_\1: (*D@*
MRQ 0VJ")A+D,N8H)8MH9.VA%@  +&ECY!FZSEI\S9T[3@3ARA18#_HB[Q8/3
M2MCAB&J!=FK6+R&YMSI42C]@Q\-;QT<1?*HBX.#FN&$CHUZ2'J8YR)@2.3:0
MQH9LK=*?)L)7-L-TBKEFSE*X?Y(9I3Q'FR*/+%0YV:&B4#9HKD!@3"OZ$Q5J
MYFE&A8"U#!0+Y@THV2X!BU('?LATQM;[L&(RH25\C!F#$4O))CDE5:^C7*S/
M72>*2$9DY;E9P'QIWQ0U_$%5P+%9T^MQU(?BU!-0N0V,7EN!PT$\,NBQ<!7T
M^;:VY.;* /_U?QH-ZP..R/C%^@JV^FOP7_]*!0BL7ZSSUQ;5Q_QB=:Q&P] ?
MQCL_XTOZKZ?/K7GA(_'K 7ET%3OR?\_:\)?C<^;U8AJ'B+Q\(*CVXF+KIX[=
M;+>192(5L]#A[)DCR6^\F8!&",=R(62(_P>2X,RV/B;>V4+ U'PE<X,Y!\BF
MJ_:(41^K8,O7B7/]Z9)"*.!6>V)$*1T C(,JKXC-?FK9W6:W8&1(P\T%QL(R
M%0[OQSS0+D$9I6(O/FI),E9<>%R2P@U!""5F>-BG3(OX >Y=YE(/4^E[C3!-
M=#($BTO>2,P[C2?.- _@CQQ7I9%K\WD#LRT3VL]':[*F(BTU 41J2@1#FM*>
M"XIL,5HEZ=?Z$6M&5P-T8HJN+2"3*5; <CX E1/U(9B+*K4*-(Q9!E9JX? /
M#)#>BH6 ;=%E7/HF?@R^(8(8%1>I,V<D$H[SDC$9W6;V,[^-C)\&E.<%A2PP
M@!1G_$JICRP?7$QD3-%]SL(TFMU5J,K$+2678I7DIAPPO468*T-V[D*CK2"3
M5(6%3.N$EJ:D&>YLG.=>00$&6*N%QY0EA3'\RB:$,T7C1,L+]6'Q \Y!9Y++
MSE8?Z(*$TY8[(Y)#;&@#T>_)V,FS>QR*P[P?F64QP;"8."[;R[R0(BR:6IC"
M3K'HCX[0I%)X,@W@K&;P-RXS4<4QRN\@\1G2L1MHG3DS571"/H_*A"9C *2!
M@Y8P-V   \C$!!8Z2_&*@H)E*E6T0J41&&K464NDAH8F P.7!AI5OF#*Y9<4
M [J5'J) V9'SW(K$F(^^MJ8^Z, !<^VDA:&5$< 3%MX,0D[^4DRQ=:$LT3/K
M)IQFO%@XU5(9@N=,?J$ZJ4C&?R*&@&BFP@ET8-92.4Y)P7#L[88,E^E@+C,B
MFG'26$D,CH;CL6:DS.'F#,F T9&/"6AX'3Y:$#FHEP&6(BG':B)1O"#(E@UT
M ML-$01/\8?0,]YR4:!J0I))"@B_#:6G/7A57@''@1>Y\#!,VHAD&.E4<G8D
M'FVBX,F;H'LAUI2&";@SO@0;21?;.'F@6G,W<ZJ!6L*$Y<!_$3X*ZRWL'YA3
M>U,KPMPFPG2<,C=R\));41XB?/A,)/BO%IV!422GDLVE$.VC!SM;.22'5[)9
M="36B9)%>L.3TRT.&V =-F)PW,ZL[T&&*PJE$$\K+(7!T@$4KZ"ZA>ND^)9M
MI0'[E0'\E"V-?T*QKOUFIE7PDXTL WB *$<C3HBP@G<=Q9ME:TVP)HH6JJH%
MX6N86,3GDYTOQ=TR(Z*E7 8&WOWAZD, QW!H@1V $>G.*-\#18S= 1($EA6J
M,BK,.)$ HK==&;GI%(ND2%MS<%TPRR>FGYT+'I2FI"A01C$7$O)1P@[]A2I-
MQ:&Q$E>9W%[ &B7(=/*I9)\@)J8<_^<X?\Z[!=Y6&SNSKBLIATF%7"ZFE&P%
M?(BQC66E4Y''[;>YM$QZ-"K4PN47CV-UL<O"409)%JL&]9!,0NWWF*EEQ&OD
M<;;; 164)#Y7[%# E@X9[9<%V1U&<DQ5IX80=]0[1B1%%\05HB],,DCA4PZ$
M.$D6D6'UV-:/9CF18G*%/H,H*(9756"U!%PG%_P*HEV_X8-I0E$<4!X).=R6
M]K.+&L0@2TWH.C:\))VB GE7ID0?I9 &4PA$!I$G;@XK)J?(:,I3*5Z WT@7
M8N'G?*:D0'[Y?L.51O('<:7BO^(I%,_Z(Y59M;.RT/P#$PE'!20^Q\>,Z$66
M=B?@@/YO]:!%7C^[P!\.R64B@QX,2#=1A;CJ'S*8I6ALYT+IKS3$3=(-?^ZD
M *:7[T2V-4P3KA4@A@=Q;Q=BH>16DL?'-B.)Y^)J%*#1;^.?U=J+Z^@%=/:?
M/LN+Z_T:'13H":Z^U-E-I!<LBE1F&97AJ*X!L1()*4ZT -K(<8^8V(?R=PP"
MY$,\Z91<\&!G6$0:C/_^HOF"_AW/'%?_6\$R)-^P06;:+ : ]$^O+3V^OMF<
M_>"(B+71+-H-1L[N/LIT.<9CJ5TV^.OPX";KPS8!&\'?7[0&+[;YF!G#P0RU
MB%Y;"H?Z^]1* Z&P2$<2+.6!SD6XMIGX^[BPW+D/)%^BCXXF#GY]&%D_$RB8
M#WWZ6W?=*%W8N$XI/_G-4__3PM9S/ZGPZ]_0\JW1H7_]D<S_)X^/]]KB*FP>
M[]GG0%)&<1]Q7#: /1H/7[:;7;O=N;#;O=ZK,I&ME&RG][>E>\#+,[=S=.._
M2HV'1B;XOPSA167**?NR+,R*MKV.%5>3@@*SM0SEQDJF>HF*X>(_K5^KN6XQ
M8]IYUVY>M X(WGY[?BQHZUS4*-L2937&ML68V7N@1M[V@JW5[M\+VO95B/^>
MR$1LX+A4 /8VR]TMY!0W-F%V]XAV)K!-3_'</N^N4$]' ^B$4=)=0=7/$!_M
M3HT. QTO]^:65T\ "R W+EK-XP%T'S[0$HQ53N7;\L+;+7:_D[M:#)56N)J'
M-$KV^I(A,)J \A76Z/UMZ)F?0_L4-O/,SV"%\JS/X'[.X.4*>^XPF]E<HS\S
MU*,J&"SEF^YO0_?E.3X],_=!@7IX"&JTU&BIT?*(T?(@#F1UXDQKN/99NZ>.
MYEN8T!6+XFV?W8P(8]F=M3NO87EA.O3% 6+*>W\D)YA>TQY<K(@V'&X_![&F
MG_AIM)O;&M3U41R+,;KU29S&2;S<-N"UTU[V<32?^ 'T6J"KMXVV')@=M-&A
M_H$%L?G?=KN!7%:DNZHJ5R^?8Z NRSVYLMSJ=E?[F+&/"]-U:6Y=FOOPM:AU
M:6[AUW5I[L.7YFX155A=CIOI[$[O;W5I;HD?>V[W>O=3P?:4T'91%YK6A:;W
MB+R7@\$!85OA03]^5*%$ZZY(M]8UN8\A/=)NV1?M(];6/4*4M"Y6!#J?(3XV
M4RC/$#$O]R]F?PKEN2!"!N='K-NNRW,?<4T6J)=5XK0N2[RO<SB%S3SO,UB*
MM]='</_5N4<O4Z_+<U>H@E4WK>ORW%,U\.K*PAHM-5IJM#Q6M)Q8(JTNS]VG
M]*K?M-OGVWHS=27BL<IS!P]<!5<?Q:[N97T0QZK.;;>V]3+K^MR#*XG.JLXJ
MCZ<^=[D@=^N9DROFC/4//F?,1%+Y_)\M^E+G;:FYD;R>7>'EG</UW-?UPQJ2
MJDE<6(94721;=SD^DF?Q.*OYREH:/\5-[E4<OF>CT'YWXYJ13R0':(Z.%09J
MK+6:6U!]3$^@^*9O-_N'+%5Z'N5=[;9]?KXB'?ET:I8RQG!&-&]1\T8R@:^,
M)U9R%_+(K"<00VI=V*U5I_H,PVKM"[LS6.$1/C1U'RFDIG7I O5O3^S/+#?7
MLP>#;:^\U^GI@Q]#:V"W5U6\URG24Y6W=7:GSN[4V9VG<;&^/HTG&D9=&99\
M>K/=KX4KY"W/]Z-);V\Q(#@,U6!2<S=5/Y\D8C>*)B]MWBUL/AOO2%,V,8C,
M@TYCRTMI>+ Y-3(2/@TSI&'&<CI,HY@"LSBW% <.4@39P]EXX8PNMO)0R6R&
M)=U[?2=F3L3#C\.1];MP_(1?_#V=.H%UHR;NV584SN%O^-6%'=Q, /)P+.FM
M&_&7C-+8^OY/ZR,./ ?P7N;!;_?US?>/^3^]UZ]L-14^]%(7[$4'5X7]P&-Z
M2J#Y/<2.X#&)O.]LK*DE1Q;C!&<$"HRU.1BS5T,ZP]3W<# L:#I82<83'-J8
M6,(!+$4"IW"C5Z;F/"^,ZEP3B"].\IPX'L]_S#(&!OQUS/Y(]N+!P]FM5CV9
M\(DD#=Y(W^<F!T]ZF]^#X?/8*'DM#^%L*<EWOGD4?AL%NTOP_[&D-_JK.L#7
M*:'RF)O=[M=8VQYK@U6MUI].'DT;W0: ^!/^']BB9];'Q#M[ H&Z5O>(R:)'
MB(_ZSOM#$,J)AG*U<;;L<^\1.GS2B:S.T:>@U,G$M:'T!QR%4I\!?VKKVQ%U
M,O<$=%R=S*W1<EIH.5'#:"G';<3@]U )3SRK.FC65[5.Y"A:=J>]HHJZ/HS[
M/(PVB*<''C%R G>VU.HY NI\XLGE$^N1"G5.L<XIUCG%YY!3W"P27J?)*NY5
M]#KWDR:KL7;*,;+GG5SLGJ_PL9YKQ*A.+MXSH9QH#*U.+F[?2+2^JOCPA_"
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M6#(97G$V@_[(&Z4=&=] GL1=+60HXA3EB:370KVC*BSELLTV?J:E[R*LB A
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M(DY]0_"4$=M54XBA((=)/(@)$D(#5EA45,!.^!&"HS& ]S)O0&/1+@8*_U7
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MV=MCY#C%-;E5I$^ 9180@$'O$*/8)\QTY9\0:FNL(.[TO 67Y?D[1CA<AG\
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ME62WZ#]OB3"U=W;+1A$ODGH+ROI,6^YB=$OI9.8;L+02%?+ 0:W:P<G[<F'
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M6E [\?K"\$*2[L_O+.XO4>E-DO2;'8'3:NW._S-(LO3^GY<\VV>S=5'1%E6
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M;I'"9$O2HRP0S+!O-*6W]AWHYM+SHR*:"94;DN;8NDW?\K4BE"?] KR<-Z\
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MZ<30!MQH)[GX'/#XWN$#/$RC#(^E;=Z60"G()_+NH+G@MJVJ!*_P!,6*+Z
M4CT)W3)5UDS:]P&I<H91+DK%M$@GT,2BQ!-<L.<3T:J1B4YHM:IA4DS/<:!<
M(1KR )8B$RL'7Y"$NH(3NK6BJ-Q$88\!H91;Z6Q(9LV$;.(+5(#5W,,GG^HZ
M>QL9U7LL$*?(JB9),:%X(G&[LZN"R_Q!URJ^$ U503=TJU1=;XR"G]]"N3 E
M,T(!;$!Q;]\A?38UC:);\0(Q9VS!C[']W14_1E-1?/B10F,\\"-IN5OB!]@Z
M'P4_1&L!X?A98=P!U0?(YA,$\:/NRE6.'WEWH4[XL9LL3X ?+9[P</R\,I?R
MCQ]K.VLI?GS=>3'P8S=C5C1KIJE^R790\I1=1L6W?GF9DCG_09L/7A0IS  W
M1R6RZB)H:HH[69Y00.@,"!+X^2]TQD0(Y?MSUZ":VP[SSZ\/(#.F?BW_4OR!
M$STALQ?\_U\FUUN W[Y]>_404C]9I]DKGRZ+ EYO?GS_YG4!,]W,T2BF&1F]
M&['[K?_U@2VM8,1:K]BB+4Z)#5EEA3!N(1UM!BJJ?NF.4\)+PR6[;&T0U@"L
M6C^;,L.(2DH8^TD<D."EM#+:,>XRUC:?YVG&?O^^MF"DM(U.83;!YS=IK^PO
M'\0$B%L9(.&2S2-=$S+EO+ZK+I=<V1;3 ^QB@+CK0MMA:K"<($DS T2PJ]<&
M\468$)\-5%]0%=C: $D%YV\+"P>_'.Y4Y.(/8N)T^AD@\S<V_KL?[DCB%S8=
M?_$'\9(O;*:BJSR*UOS/@D<BFG8W1/0/;UH1K=G=$-$\=G6:^SY)TUD>\9RH
MB/"9OIU-2Z^#?\%4S(B6&5)AQ+K06/"@I-E!=0":*6$Y_N8E@>+1\]HV#DF5
M%LH5M.H)N>ZK^18$'5Y*ZHBN#UIQ\P[O[>Q\3^V9$)[V'1158:8++R%G7#.Z
M\]:%C5!5D=C0J"[9T>MGB9\I3;?JMZV4[>U#&![>Z^05&I+,:++D!9^*]2<O
MUJ]H[8!\IG(?>JP.::YIXHY0^<,^M8UZ0:S[,W9X<.@[?7!H>+@"U<,56RUN
M7\_;]R>?K8\TO4+WW2G <0#:@;K\U, XS4\AD+SA59'A51'AJR)A%A&>GA:$
MCV&0>Y'L51%96P2D_QYFB^+BS VIBW!U3^LBEU6@8*-\)W#=[U[<W,F3+L5B
M6=/"&9E2WM>VZ0&I.D+0I0O99%$VX>47G5=<H(=1J)<-95I-+?]KY@=1%DWK
MF=)RT-H%9W!E2<SUZ)96IQ<EJFTU1KE2Z^>3NK@T ?F#KTZ34$-!MR+J513:
MUO6/4K+K9N5XTGIU G6]H34,5T'')[68-PH6L;M!(9 '+?\7.NZHI<!@G T0
M/;[R99* ''3'ER@>AX*"1E&>4O7LKYN?7IU4JIE21=<" >$KL@8PHJ);5DUM
MI%0S^A;E I1/F&QFFYA6@2S 5P+M5-X':?T"Q? ^2(>ST_KU%GSUV? 5<?ZN
MBAH/-84T=Q+\2'15YIX@LFV$Q<^6KE0S_,AU;)?XT>AY \V>C4,Z^I".7H]/
M,QW=:"K/CAEV\M3?CWS^?F7Q@E?X2$9>'(PH?]1ZE%0E=8M?!3MKY\BO:N!L
M9QV8RF[B4]:RW<T1VRXA_O+\]A,[H*\G!Z_W/,N(%S4RD,DZGMY-SL:3BW']
M$QW/R) W-4%,$!13[$5[UO?*(26A"]S+ (E\C:M9)6YE@(3SZ<U-N RE:=&B
M-@8^_S$A)#Y/:)J>TV1%R]I(8DH S0T0]2EG&N"*;<)+3TR*L)&)J@5>*8*\
MX%B8Y1FO.A=%))FO^<*-9X17C\M3=I;P:CRR@@9M!C( Y,OX3$S<T1\=9!8W
M*]1WF'O<IMS?R<-U'QQ\OG\X[U%?H[H)(#<8P05,<1W2(SRJQPR'+'%M&-KU
M70_3 IO5ASU)B.XWC<TC(6R'V],$]];^MKHGK>):KFARRY7^]+@,Y!$;#([=
M*]8<EPLTQQI1*<*!-7MCNU]80\(QJH3C(>US2/L4)A.N)07/#U,&96U/(!<,
M@ ^=;;KM:_8JRQ/*B /Y1+EZT+XW<ZYK $47K]V: 1#+M-UI-QF 9_[J@6[;
M,WN'H.9LJ2CW2[,284;45/<5NYN.P>6G-KPA7$VZ9BD*\ANA7 S&WW+JR6.K
M;0]-L&,.B-Q01H8%Y H_(!"OH4A]&^J1/'X G3[<C3(@\%W:7==#>/D07JZ%
M%3_&[_ MQ:[L%?B1X[YYF-W]A@#B(8"X'I]F ''C4!3;P<(?1@E=>U&V'BUI
M3++PSR8O6LD'L1;@"R&C5>CN>9XD)/;KJS)*6IB( -7\=!N?I8($_@S][D"7
M!*0"VAL@ZQ]WDTDY[=/\X>;F7$R0O*4)4KR5%_]!)*&Q]2T,?/INX4T^C3^S
M92 )-!4V,D! Q=E/>RM/3(BR<3<$B0((P>V;.G=3XK^:T\?7 0GY%O:!_\!)
M_K#GSF6_^E==XEI%H^C/B$@R%2<!)>V&S+VH)*#&Y2UIX2"FMWS4,BW6W@WU
MBFI;5V'LQ7X8SR?$)^$CU_*8RKQ',T\^VEV7%.%J77S"07AL=6C(PF)KFC@(
MAR4/V>ZI<0FYXH:NB58&@JJ:]Q: ^X@NR/OS1V"@3];W& BFF=E)#G\'7KK$
MU5V&@/V&,*Z\,/G-BW)RMM[^^&M($FXZ8B?9(Y$]<Z#7V2&XZWB59VE!T3MI
M7@^@AT,8GXC'Q:>P?AXS7+HK-!KC.X#J?D>\H@D)Y_'ED[_@=BQI+JQ6'_M0
MN"V"%],@*2.NK*LBWCSDC3$0+Y4R5?/> G"_(O8N4*5C:/\2)<6DT?/$8+F?
MM<\T#BI9$B32 UK:)[MP>9W3Y3+,2J^B>,>2-75/N%2"Y(U[2;Q[B1^RN(8L
MKB&+RW 65T]2H;JS!Z-SSNLH553#&8@RF*Z3>:4&5+G>9MNHM29T$J_0EJB>
MGQ6EG$MG13)[)YF1HG(BH1-0I>N(PF(24(JF9#:$<X8KV<2 :"K]ZVAD4A@Z
MT5M=0,9["@W,L)OD8W S;.+402.,[=P==5Q0.8)026[#.:S#W=QY8C?=RV1B
MJC#T!8U\R\)@*2 *$J6TUO*=:@3> E'A>]$$'MJ 1@*UXF4.)U$=K(Q20$'3
M5#NMT! <=!DGT.EMX)$&8OT+NM4*\5BC6Z=*/_4>0*5C#N7J5$R+= (-K,F_
MHI/3(9'9Z>8JS?O4O%OB!6)NTO!C;+_#X,>HH83C!X/ BX.?29:,!/@985*]
M[P/:-N9U_/C:>;;,JDE#Q8.AXH%@%<(J'FCFSNY@VJEO\,,HS1@1"QHQ]J4C
M\I^<G8@;DH#E#:1C6*MN * "5MQ@R"X:(B2'",DA0K*[",FNB-UM?Y?%[L<O
M3_#GH;3[GT 0Z&!HPW\=<&2?&JX$PY6@VR)H#3=<BU<$;@-EZ\CWV,]>:9$+
MX_EH1:/0#TFZ_0%^8= =T<;UH1E-[1XY]GTF@\'E$W\ZFZ1W_ MK:?DE6 \3
M9<QHS/;1K"Q^?3O[Y"5?26%, Q"IV[>SJFL06G4Z&B#T@J1^$JY*SO!'T[UX
M#2!3HYL!(J^Y#9RD625F1>G1&6&,VMG>B\?= 82W',I9#2I&UUVUX!47=G4'
M^R#.O#1,;V<'I"D$K5EG!\6OO)17P^7_X^?EHQ=QLR\,FU9?+- F;/TDH9^1
M0$:^%F*](1TP@FUQ"5GP>P'WYK!SF^B(L&YW^P OO21F2RN](\ETX24$A@O8
MRSZ<DL?WWA,,AZJY"P"9%\]#=GL:IRG)TBNN5I(;)CZ!='F!^[F ],B6,DV
M:T;5W V -%,K<N#V+FJ%>"EP;<N:.J@"0K[M*0 )C=F/?AD@H+,1-QW&/N #
M0A1*GZ*U _*3D";L6 AI,"%^Y*5I<9<MC"#!O_-R6>S=(D2X&@[C C!=D21;
MWT7LPLX4&*Z\K.![A6YW^P#WHIM@D-0=7("H>[VBN@Q*#U:-GBY@L;,R)XSC
M=%Z:GZ!3!.S78__H"4! X.+EVCU_LCC@5QDF\J4MK=ASBR<ZN8&-*9E\^Y+?
M_UJ,-'BV!\\V(L_VEY3<SB[3+%PR>D0,KF\T^*@''_7@HQY\U(9]U*!;(#K_
MM(KJX^IH2M\&.HP PFE3UQHZ886!;>/> 4(V5!'*..1V5@T@>(L/7&N!;^#R
M B*V^+"U <1-7%Y 1EA\\5J+$4"#.!"EH;(;QE%"[5Y F(;J%70RF6K_#!"D
MH63W#G;J)F99(.B?D(+6]"%"]0^4VI9. !L4*%9-"^;EAJ+$JEPUB[6 HL:J
M56E:\J%PL:I4VMX8*&"LJE-KLSF4 =BT*G-1FU .8%6XU $94(38M*VFD<]0
MO%@5+:WP.:C- YN:!?&$0+%ATZQ:I!= (6-5L]I%4EG,%BK2\-\JTVFRXL*^
MH1)88T!W6&ME!YH1UBYYZ-$+(S[H%4VF7D2FQ,\3!HFDO.;+)R^K_K6MYU/X
M7>3916:&-)"!,O47),@CMH/M67>NV/(YIQ&CD):+/U5#:C6082#%C:$U"KU1
M'"30"(5(%1VET;/'P44G  %!?-1V06S-HJ4^FTD74]/N0R34$ F%*!(*)./Z
MDCQ$0@V14$,DU! )U0"2;+-!%QPD():VT$3139L8H_F;'KKH( 5X W="=#%!
M:IENIO.B"P72F-LF-V7;AK)W9;W*!^YI&OE[KJ9F!C+H<-8,8WH$V2S-.5SH
M<5[HZSVO8S\+'WF9=KWK?9/!<("_\]9%7>]O7A(4)<)*WW/*3^,21)KFRY7:
M@-CM1P;+R& 9&2PC@V5DL(P,EI'!,G+ZEA$3JA6ZF6P&VY3RA"\V(R"9%T;I
MB&\)N;==T<:"- 3C(XK6D%+8+FRC_M749V$8LH=56T4CC!])XLW)LK3OK:]H
M<D>3;,90TUVNT*%>VJ"G>5++[+W;V:_A?/$_;$;8K\K +[ZP=M9+ .F:(QF
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M%2\0<\86_!C;WUWQ8S05Q8<?*33& S^2EKLE?H"M\U'P0[06$(Z?%<8=4'V
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M#X].<]34CR&)50C7G^8=H'E.'#J]40^[;LP2.L51#ZXJ9 *=JMA8$P:$:._
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MIA2S%<0#,T>KR(M'WM:/VE#5UQ[7V@6@(66M_(;7FV_QN(Q/S\1GWSTF:6;
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M?EVE&E$%J(-GCHZ2UM I>$GZXV'A@5C1]U:H5XFG6V,?@O7WZN/Q5S'P^BN
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M9G5(+$XNV3Y*RSVG_C[AOFC),EHU:L\T^R^'3'K"W>U@*'I9<7'0$%<I?B2
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M;;Y=]AB*V+?K#\V&X:Z_#CRL-_\SV_0/Q"(J26_^_N+/?&OIPE_L[=>COWA
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M1&S%Y3GMR+'7TQ+T5O90&YG=&!Q[_#_3_)$9E,^=M?_7HXD(%W!(O)X3ZD*
M;/4(ER_A W-TH!4V;>YA;[YFUQ%95*5=4^3HU:T*80XS,8:&GRE*!J/2JK5
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M/<T2EHL3>+H4@>Y'XZ[]'>H)A4+_KC5#&8C^4PLGW*$2DPL@I$$"!_@2"ZG
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MA$J\\V;>UN'.<E0& 4YN+$YMYFA@_/I4#TD).42OLB6WV<M=E(Y45!QMB_2
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M%PFNYAMD;VKT-*/LK6C%\0+4%>XU_XG_LOX5_S\@R7_S_P-02P,$%     @
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MS\RCYP_*1[S9.&RO'+DK['O[V8N0K%6,$J*BR- 7]QH6D4 2V1YO _/2STP
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M:K..HPC%$3UT<8PF5'P\X?("SS/!TI8N91("UXQLN!D&HEBNGX+'FVCYX43
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M0,@6: #\DJK165NV&!A&=2)PMM39J2%5S]T#QJSCS</4,*L0 P4#U?'66CJ
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M_895NJ>)#.-%C,+/=&+,^FG4P$7]9?HA.=NHY%\O4TJ^YBK*4>"Y2&A\AUX
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M,1B[<[[CJGC#MX=WG'NN,G4VH)8,=-RVD!JGS2?7V'+F2%4Q+<%06P2/XP<
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M)W:O[G1Q:$SWKHQDM2?H+3!<.;.[,<-,4#/*':2EPI%:;S'KR>*FGVFZF*,
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M]@F]0H\QRT<.$TF5$G^@::+W1@V[X2U50PM-SD',B!Y@4HB>4RDM%I8--\%
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M):[4$I7.,\M5X9;0VRA*V%T([%J^0YX CROH/+,L,1EB]\([,1.CW73!%S
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MT=D;)]A%(WS,81AYK'&D?S@"Y+WR]+RGG=9Y.FFMUTE/Z%G([60F@HL8A=,
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M)+/56)WKDB1+<471A#@!RW*YP8$3N#A8SHZD7NPN<%K3P?;!))($6G0]MM.
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MI/LY_<W_!U!+ 0(4 Q0    ( "=]"$FZTM4!I0H! "H""0 1
M  "  0    !B8W)X+3(P,38P-C,P+GAM;%!+ 0(4 Q0    ( "=]"$FR9WJC
M#Q$  -"P   1              "  =0* 0!B8W)X+3(P,38P-C,P+GAS9%!+
M 0(4 Q0    ( "=]"$F-XITF, H  &2*   5              "  1(< 0!B
M8W)X+3(P,38P-C,P7V-A;"YX;6Q02P$"% ,4    "  G?0A)6/\/MJ!$  "
M$04 %0              @ %U)@$ 8F-R>"TR,#$V,#8S,%]D968N>&UL4$L!
M A0#%     @ )WT(2>.PGI(06   E]T$ !4              ( !2&L! &)C
M<G@M,C Q-C V,S!?;&%B+GAM;%!+ 0(4 Q0    ( "=]"$GF%KY=,4,  ,$:
M!0 5              "  8O# 0!B8W)X+3(P,38P-C,P7W!R92YX;6Q02P4&
2      8 !@"* 0  [P8"

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
